-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Fblvb0YAKbLYGTg86hxAfSZqxN0Xc/DH2e83BbESmRwPZF6KFL4n4K9eLhLGhXLX
 LhBGedpXxgNip23m/TPE0A==

<SEC-DOCUMENT>0000950123-10-050308.txt : 20100517
<SEC-HEADER>0000950123-10-050308.hdr.sgml : 20100517
<ACCEPTANCE-DATETIME>20100517151322
ACCESSION NUMBER:		0000950123-10-050308
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20100331
FILED AS OF DATE:		20100517
DATE AS OF CHANGE:		20100517

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		10838045

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>g23297e10vq.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
<TITLE>e10vq</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 10-Q</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(Mark One)
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 6pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#254;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>


<!-- xbrl,dc -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 12%"><B>For the quarterly period ended March&nbsp;31, 2010</B></DIV>
<!-- /xbrl,dc -->

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>or</B></DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 6pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#111;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 12%"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>
Commission File Number: 001-33637</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Cumberland Pharmaceuticals Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">
(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Tennessee</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>62-1765329</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction <BR>
of incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer Identification No.)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>2525 West End Avenue, Suite&nbsp;950, Nashville, Tennessee</B><BR>
(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>37203</B><BR>
(Zipcode)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(615)&nbsp;255-0068</B><BR>
(Registrant&#146;s telephone number, including area code)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the Registrant (1)&nbsp;has filed all reports required to be filed by
Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for
such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
subject to such filing requirements for the past 90&nbsp;days. Yes <FONT style="font-family: Wingdings">&#254;</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant has submitted electronically and posted on its Web
site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405
of Regulation&nbsp;S-T (&#167;232.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter
period that the registrant was required to submit and post such
files.) Yes <FONT style="font-family: Wingdings">&#111;</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No
<FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated
filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><FONT style="white-space: nowrap">Large accelerated filer <FONT style="font-family: Wingdings">&#111;</FONT></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="white-space: nowrap">Accelerated filer <FONT style="font-family: Wingdings">&#111;</FONT></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Non-accelerated filer <FONT style="font-family: Wingdings">&#254;</FONT>
</TD>
    <TD>&nbsp;</TD>

<TD align="center" valign="top"><FONT style="white-space: nowrap">Smaller reporting company <FONT style="font-family: Wingdings">&#111;</FONT></FONT></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="white-space: nowrap">(Do not check if a smaller reporting company)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether registrant is a shell company (as defined in Rule&nbsp;12b-2 of the
Exchange Act).Yes <FONT style="font-family: Wingdings">&#111;</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No <FONT style="font-family: Wingdings">&#254;</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate the number of shares outstanding of each of the issuer&#146;s classes of common stock, as of
the latest practicable date.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Class
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Outstanding at May&nbsp;7, 2010</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Common stock, no par value
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">20,437,176</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">







<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CUMBERLAND PHARMACEUTICALS INC.<BR>
INDEX</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#101">Part I &#151; Financial Information</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#102">Item&nbsp;1: Financial Statements</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px"><A href="#103">Condensed Consolidated Balance Sheets</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px"><A href="#104">Condensed Consolidated Statements of Income</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px"><A href="#105">Condensed Consolidated Statements of Cash Flows</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px"><A href="#106">Condensed Consolidated Statements of Equity and Comprehensive Income</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#107">Item&nbsp;2. Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#108">Item&nbsp;3: Quantitative and Qualitative Disclosure about Market Risk</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#109">Item&nbsp;4T: Controls and Procedures</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#110">Part II &#151; Other Financial Information</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#111">Item&nbsp;1a: Risk Factors</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#112">Item&nbsp;2: Unregistered Sales of Equity Securities and Use of Proceeds</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#113">Item&nbsp;6: Exhibits</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#114">Signatures</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g23297exv4w6w1.htm">EX-4.6.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g23297exv4w6w2.htm">EX-4.6.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g23297exv4w7.htm">EX-4.7</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g23297exv10w9w4.htm">EX-10.9.4</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g23297exv10w19.htm">EX-10.19</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g23297exv10w21w2.htm">EX-10.21.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g23297exv31w1.htm">EX-31.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g23297exv31w2.htm">EX-31.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="g23297exv32w1.htm">EX-32.1</A></FONT></TD></TR>
</TABLE>
</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left">
<A name="101"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PART I &#151; FINANCIAL INFORMATION</B>
</DIV>

<DIV align="left">
<A name="102"></A>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;1:</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Financial Statements</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</B>
</DIV>

<DIV align="left">
<A name="103"></A>
</DIV>
<!-- xbrl,bs -->
<DIV align="Center" style="font-size: 10pt; margin-top: 0pt"><B>Condensed Consolidated Balance Sheets</B>
</DIV>
<!-- xbrl,body -->
<DIV align="Center" style="font-size: 10pt; margin-top: 0pt"><B>(Unaudited)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>March 31,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>ASSETS</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">73,752,814</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">78,701,682</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts receivable, net of allowances</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,814,947</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,176,585</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Inventories</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,406,402</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,822,873</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,369,809</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,472,455</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">88,343,972</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">93,173,595</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property and equipment, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">948,580</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">918,412</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Intangible assets, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,818,394</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,956,009</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,578,723</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,676,304</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">98,689,669</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">103,724,320</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>LIABILITIES AND EQUITY</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current liabilities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Current portion of long-term debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9,061,973</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Current portion of other long-term obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">88,739</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">144,828</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,813,974</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,632,796</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other accrued liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,556,585</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,784,777</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,459,298</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18,624,374</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revolving line of credit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,825,951</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,825,951</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Long-term debt, excluding current portion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,438,027</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,938,027</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other long-term obligations, excluding current portion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">181,455</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">184,632</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,904,731</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,572,984</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Commitments and contingencies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Redeemable common stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,930,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Equity:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Shareholders&#146; equity:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Common stock &#151; no par value;
100,000,000 shares authorized;
20,413,605<SUP style="FONT-size: 85%; vertical-align: text-top">(1)</SUP>
and
20,180,486<SUP style="FONT-size: 85%; vertical-align: text-top">(1)</SUP>
shares issued and
outstanding
as of March&nbsp;31, 2010 and
December&nbsp;31, 2009,
respectively</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68,861,850</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">67,711,746</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Retained earnings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,865,704</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,542,126</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:75px; text-indent:-15px">Total shareholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73,727,554</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72,253,872</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Noncontrolling interests</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(42,616</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(32,536</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73,684,938</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72,221,336</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Total liabilities and equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">98,689,669</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">103,724,320</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<!-- /xbrl,bs -->



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>Number of shares issued and outstanding represent total shares of common stock
regardless of classification on the consolidated balance sheet. The number of shares of
redeemable common stock at March&nbsp;31, 2010 and December&nbsp;31, 2009 was 9,497 and 142,016,
respectively.</TD>
</TR>

</TABLE>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">See accompanying notes to unaudited condensed consolidated financial statements.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</B>
</DIV>

<DIV align="left">
<A name="104"></A>
</DIV>
<!-- xbrl,in -->
<DIV align="Center" style="font-size: 10pt; margin-top: 0pt"><B>Condensed Consolidated Statements of Income</B>
</DIV>
<!-- xbrl,body -->
<DIV align="Center" style="font-size: 10pt; margin-top: 0pt"><B>(Unaudited)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Three Months Ended March 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10,130,652</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9,404,599</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Costs and expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cost of products sold</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">859,288</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">733,218</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Selling and marketing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,607,512</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,140,187</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">773,868</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">770,117</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,881,203</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,444,863</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Amortization of product license right</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">171,726</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">171,726</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26,547</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27,463</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total costs and expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,320,144</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,287,574</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">810,508</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,117,025</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">60,679</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,596</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(345,952</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(97,711</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Income before income tax expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">525,235</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,036,910</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Income tax expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(211,737</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(831,059</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">313,498</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,205,851</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss attributable to noncontrolling interests</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,080</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,239</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net income attributable to common shareholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">323,578</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,218,090</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Earnings per share attributable to common shareholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">- Basic</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.02</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">- Diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.02</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.08</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted-average shares outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">- Basic</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,233,267</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,321,175</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">- Diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,395,419</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,127,240</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">See accompanying notes to unaudited condensed consolidated financial statements.
</DIV>
<!-- /xbrl,in -->


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</B>
</DIV>

<DIV align="left">
<A name="105"></A>
</DIV>
<!-- xbrl,cf -->
<DIV align="Center" style="font-size: 10pt; margin-top: 0pt"><B>Condensed Consolidated Statements of Cash Flows</B>
</DIV>
<!-- xbrl,body -->
<DIV align="Center" style="font-size: 10pt; margin-top: 0pt"><B>(Unaudited)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Three Months Ended March 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash flows from operating activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">313,498</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,205,851</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Adjustments to reconcile net income to net cash flows from operating activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Depreciation and amortization expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">231,332</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">196,059</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Nonemployee equity compensation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,972</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37,760</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Stock-based compensation &#151; employee stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">130,915</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">143,902</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Excess tax benefit derived from exercise of stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(206,418</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,842,825</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Noncash interest expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">67,380</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,256</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Net changes in assets and liabilities affecting operating activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Accounts receivable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,361,638</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(267,892</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Inventory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,583,529</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">415,948</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Other current assets and other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">132,847</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">955,169</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Accounts payable and other accrued liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">127,104</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,187,558</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Other long-term obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(59,266</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(405,801</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Net cash provided by (used in) operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">519,473</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,735,131</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash flows from investing activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Additions to property and equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(64,085</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(15,601</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Additions to patents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(16,345</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Net cash used in investment activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(64,085</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(31,946</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash flows from financing activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Costs of initial public offering</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(114,428</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Principal payments on note payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,561,973</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Costs of financing for long-term debt and credit facility</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(27,500</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(15,475</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Proceeds from exercise of stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">807,496</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,296</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Excess tax benefit derived from exercise of stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">206,418</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,842,825</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Payments made in connection with repurchase of common shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,828,697</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,707,419</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Net cash (used in) provided by financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5,404,256</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,799</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Net decrease in cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,948,868</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,757,278</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents at beginning of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">78,701,682</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,829,551</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents at end of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">73,752,814</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10,072,273</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Supplemental disclosure of cash flow information:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash paid during the year for:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">276,288</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">33,517</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,376</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">80,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Non-cash investing and financing activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Increase in accounts payable and accrued expenses of initial public offering</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,311</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">See accompanying notes to unaudited condensed consolidated financial statements.
</DIV>
<!-- /xbrl,cf -->


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</B>
</DIV>

<DIV align="left">
<A name="106"></A>
</DIV>
<!-- xbrl,ci -->
<DIV align="Center" style="font-size: 10pt; margin-top: 0pt"><B>Condensed Consolidated Statements of Equity and Comprehensive Income</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 0pt"><B>(Unaudited)</B>
</DIV>
<!-- xbrl,body -->
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Non-</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Common stock</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>Retained</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>controlling</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>Total</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Amount</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>earnings</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>interests</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>equity</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance, December&nbsp;31, 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,180,486</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">67,711,746</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,542,126</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(32,536</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">72,221,336</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stock-based compensation -
nonemployees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,972</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,972</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise of options and
related tax benefit, net
of mature shares
redeemed for the
exercise price</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">386,662</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,013,914</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,013,914</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stock-based compensation -
employees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">130,915</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">130,915</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Repurchase of shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(153,543</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,828,697</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,828,697</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Reclass of redeemable
common stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,830,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,830,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net and
comprehensive income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">323,578</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(10,080</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">313,498</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance, March&nbsp;31, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,413,605</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">68,861,850</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,865,704</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(42,616</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">73,684,938</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">See accompanying notes to unaudited condensed consolidated financial statements.
</DIV>
<!-- /xbrl,ci -->



<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</B>
</DIV>

<!-- xbrl,ns -->


<DIV align="center" style="font-size: 10pt"><B>Notes to condensed consolidated financial statements</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(unaudited)</B></DIV>


<!-- xbrl,n -->
<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left"><B>(1)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>BASIS OF PRESENTATION</B></TD>
</TR>
<!-- xbrl,body -->

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the opinion of management, the accompanying unaudited condensed consolidated financial
statements (&#147;condensed consolidated financial statements&#148;) of Cumberland Pharmaceuticals Inc.
and its subsidiaries (collectively, the &#147;Company&#148; or &#147;Cumberland&#148;) have been prepared on a
basis consistent with the December&nbsp;31, 2009 audited consolidated financial statements and
include all adjustments, consisting of only normal recurring adjustments, necessary to fairly
present the information set forth herein. All significant intercompany accounts and
transactions have been eliminated in consolidation. The condensed consolidated financial
statements have been prepared in accordance with the regulations of the Securities and Exchange
Commission, or SEC, and omit certain information and footnote disclosure necessary to present
the statements in accordance with U.S. generally accepted accounting principles. These
condensed consolidated financial statements should be read in conjunction with the audited
consolidated financial statements and notes thereto included in our Annual Report on Form 10-K
for the year ended December&nbsp;31, 2009. The results of operations for the first three months of
2010 are not necessarily indicative of the results to be expected for the entire fiscal year or
any future period.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Total comprehensive income was comprised solely of net income for the three months ended March
31, 2010 and 2009.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B><I>Accounting Policies:</I></B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In preparing the condensed consolidated financial statements in conformity with U.S. generally
accepted accounting principles, management must make decisions that impact the reported amounts
and the related disclosures. Such decisions include the selection of the appropriate accounting
principles to be applied and the assumptions on which to base accounting estimates. In reaching
such decisions, management applies judgments based on its understanding and analysis of the
relevant circumstances, historical experience, and other available information. Actual amounts
could differ from those estimated at the time the condensed consolidated financial statements
are prepared.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company has evaluated events occurring subsequent to March&nbsp;31, 2010 for accounting and
disclosure implications.</TD>
</TR>

</TABLE>
</DIV>

<!-- xbrl,n -->
<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left"><B>(2)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>EARNINGS PER SHARE</B></TD>
</TR>
<!-- xbrl,body -->

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The following table reconciles the numerator and denominator used to calculate diluted earnings
per share for the three months ended March&nbsp;31, 2010 and 2009:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="97%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Three Months Ended March 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Numerator:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net income attributable to common shareholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">323,578</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,218,090</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Denominator:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD><DIV style="margin-left:30px; text-indent:-15px">Weighted-average shares outstanding &#151; basic</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,233,267</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,321,175</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Convertible preferred stock shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#150;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,625,498</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Dilutive effect of other securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,162,152</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,180,567</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">

<TD><DIV style="margin-left:30px; text-indent:-15px">Weighted-average shares outstanding &#151; diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,395,419</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,127,240</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As of March&nbsp;31, 2010 and 2009, options to purchase 541,522 and 344,587 shares of common stock,
respectively, were outstanding but were not included in the computation of diluted EPS because
the effect would be antidilutive.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES<BR>
Notes to condensed consolidated financial statements &#151; continued<BR>
(unaudited)</B>
</DIV>


<!-- xbrl,n -->
<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left"><B>(3)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>SEGMENT REPORTING</B></TD>
</TR>
<!-- xbrl,body -->

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We operate in one segment, specialty pharmaceutical products. Management has chosen to organize
the Company based on the type of products sold. All of the Company&#146;s assets are located in the
United States. The Company had sales of less than $0.1&nbsp;million to non-U.S. customers during the
three months ended March&nbsp;31, 2010 and $0.7&nbsp;million during the three month period ended March
31, 2009.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company&#146;s net revenues consisted of the following for the three months ended March&nbsp;31, 2010
and 2009:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="97%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Three Months Ended March 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Products:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Acetadote</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">7,723,273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">7,133,430</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Kristalose</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,309,982</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,228,615</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Caldolor</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19,305</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#150;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">78,092</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42,554</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total net revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10,130,652</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9,404,599</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left"><B>(4)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>SHAREHOLDERS&#146; EQUITY</B></TD>
</TR>
<!-- xbrl,body -->

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In February&nbsp;2010, the Company repurchased 153,543 shares of common stock totaling $1.8&nbsp;million
for the settlement of tax liabilities associated with the exercise of certain options in 2009. As
of December&nbsp;31, 2009, this amount was included in redeemable common stock in the condensed
consolidated balance sheet. The repurchase amount was based on the fair-market value of common
stock on the date of settlement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the first quarter of 2010, options to purchase 394,456 shares of common stock were
exercised. In connection with an exercise, 7,794 shares of mature stock was tendered as
consideration for the exercise price. The exercise of these options created a tax deduction of
approximately $3.6&nbsp;million, of which approximately $0.5&nbsp;million was used to offset the
estimated tax liability resulting from the results of operations for the three months ended
March&nbsp;31, 2010. As of March&nbsp;31, 2010, the Company has unrecognized tax deductions of
approximately $68.6&nbsp;million that will be recognized when the deduction reduces income taxes
payable.</TD>
</TR>

</TABLE>
</DIV>

<!-- xbrl,n -->
<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left"><B>(5)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>COLLABORATIVE AGREEMENTS</B></TD>
</TR>
<!-- xbrl,body -->
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company is a party to several collaborative arrangements with certain research institutions
to identify and pursue promising pre-clinical pharmaceutical product candidates. The Company
has determined these collaborative agreements do not meet the criteria for accounting under
Accounting Standards Codification 808, <I>Collaborative Agreements</I>. The agreements do not
specifically designate each party&#146;s rights and obligations to each other under the
collaborative arrangements. Except for patent defense costs, expenses incurred by one party are
not required to be reimbursed by the other party. The funding for these programs is generally
provided through private sector investments or federal Small Business (SBIR/STTR) grant
programs. Expenses incurred under these collaborative agreements are included in research and
development expenses in the condensed consolidated statements of income. Funding received from
private sector investments and grants are recorded as net revenues in the condensed
consolidated statements of income.</TD>
</TR>

</TABLE>
</DIV>

<!-- xbrl,n -->
<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left"><B>(6)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>SUBSEQUENT EVENTS</B></TD>
</TR>
<!-- xbrl,body -->
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In May&nbsp;2010, the Board of Directors authorized the repurchase of up to $10&nbsp;million of common
stock. Repurchases will be made from time to time on the open market over a number of months
and will be funded through excess cash flow.</TD>
</TR>

</TABLE>
</DIV>
<!-- /xbrl,ns -->





<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">



<DIV align="left">
<A name="107"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;2. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following discussion contains certain forward-looking statements which reflect management&#146;s
current views of future events and operations. These statements involve certain risks and
uncertainties, and actual results may differ materially from them. Forward-looking statements are
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. We caution you that our actual results may differ significantly from the results we discuss
in these forward looking statements. Some important factors which may cause results to differ from
expectations include: availability of additional debt and equity capital required to finance the
business model; market conditions at the time additional capital is required; significant leverage
and debt service requirements of the Company; our ability to continue to acquire branded products;
product sales; and management of our growth and integration of our acquisitions. Other important
factors that may cause actual results to differ materially from forward-looking statements are
discussed in &#147;Risk Factors&#148; on pages 20 through 32 and &#147;Special note regarding forward-looking
statements&#148; on page 32 of our Annual Report on Form 10-K for the year ended December&nbsp;31, 2009. The
Company does not undertake to publicly update or revise any of its forward-looking statements, even
in the event that experience or future changes indicate that the anticipated results will not be
realized. The following presentation of management&#146;s discussion and analysis of financial condition
and results of operations should be read in conjunction with the Company&#146;s unaudited condensed
consolidated financial statements and related notes thereto included in this Form 10-Q.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>OVERVIEW</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Our Business</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We are a profitable and growing specialty pharmaceutical company focused on the acquisition,
development and commercialization of branded prescription products. Our primary target markets are
hospital acute care and gastroenterology, which are characterized by relatively concentrated
physician bases that we believe can be penetrated effectively by relatively small, targeted sales
forces. Cumberland is dedicated to providing innovative products which improve quality of care for
patients.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Our product portfolio includes Acetadote<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (<I>acetylcysteine</I>) Injection for the treatment
of acetaminophen poisoning, Caldolor<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (<I>ibuprofen</I>) Injection, the first injectable
treatment for pain and fever available in the United States, and Kristalose<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (<I>lactulose</I>)
for Oral Solution, a prescription laxative. We market and sell our products through our dedicated
hospital and gastroenterology sales forces in the United States, and are working with partners to
reach international markets.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We have both product development and commercialization capabilities, and believe we can leverage
our existing infrastructure to support our expected growth. Our management team consists of
pharmaceutical industry veterans experienced in business development, product development, sales
and marketing and finance and accounting. Our internal product development and regulatory
executives develop proprietary product formulations, design and manage our clinical trials, prepare
all regulatory submissions and manage our medical call center. Cumberland&#146;s operations and quality
affairs professionals play an active role in the manufacture of our products by our manufacturing
partners. All aspects of commercialization are handled by our sales and marketing professionals,
and we work closely with our distribution partner to make our products available across the United
States.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We have been profitable since 2004, and have generated sufficient cash flows to fund our
development and marketing programs. In 2009, we completed an initial public offering of our common
stock to help facilitate further growth. Our strategy includes maximizing the potential of our
existing products and continuing to build a portfolio of new, differentiated products. Our current
products are approved for sale in the United States, and we are working to bring them to select
international markets. We also look for opportunities to expand into additional patient populations
through new product indications, whether through our own resources or by supporting
investigator-initiated studies at research institutions. We actively pursue opportunities to
acquire additional late-stage development product candidates as well as marketed products in our
target medical specialties. Further, we are supplementing the aforementioned growth strategies
through the early-stage drug development activities of Cumberland Emerging Technologies (CET), our
majority-owned subsidiary. CET partners with university research centers to
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">identify and cost-effectively develop promising, early-stage product candidates that Cumberland
Pharmaceuticals has the opportunity to commercialize.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We were incorporated in 1999 and have been headquartered in Nashville, Tennessee since inception.
Our website address is www.cumberlandpharma.com. We make available through our website our annual
reports on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K and any
amendments, as well as other documents, as soon as reasonably practicable after their filing with
the SEC. These filings are also available to the public through the Internet of the SEC, at
www.sec.gov.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Recent Developments</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Acetadote</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></B></SUP>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Supplemental New Drug Application</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In March&nbsp;2010, we submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug
Administration (FDA)&nbsp;for the use of Acetadote in patients with non-acetaminophen acute liver
failure. The sNDA includes data from a clinical trial led by investigators at the University of
Texas Southwestern Medical Center indicating that acute liver failure patients treated with
Acetadote have a significantly improved chance of survival without a transplant. These patients can
also survive a significant number of days longer without transplant, providing patients requiring
transplant increased time for a donor organ to become available.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Acute liver failure is associated with a high mortality rate and frequent need for liver
transplantation. Approximately half of acute liver failure cases are caused by acetaminophen
poisoning while the other half result from a variety of causes including hepatitis and alcohol.
Currently, transplantation of the liver is the only treatment for patients with liver failure not
caused by acetaminophen overdose.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In May&nbsp;2010, the FDA officially accepted the sNDA and granted a priority review. In addition to
expanded labeling for Acetadote, we have requested additional exclusivity for the product. If
approved, we expect to begin marketing Acetadote with the new indication in 2011.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Australian Regulatory Approval</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In April&nbsp;2010, the Therapeutic Goods Administration approved Acetadote for marketing in Australia.
We previously granted an exclusive license to Phebra Pty Ltd., an Australian-based specialty
pharmaceutical company, to commercialize Acetadote in Australia. Phebra is now preparing for the
Australian launch of the product, which it expects to commence this year.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Under our agreement, Phebra is responsible for ongoing regulatory requirements, marketing,
distribution and sales of Acetadote in Australia while we maintain responsibility for product
formulation, development and manufacturing. In exchange for the product license, Cumberland
receives upfront and milestone payments, a transfer price and royalties on future sales.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Caldolor</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></B></SUP>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>License Agreement for Canada</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In April&nbsp;2010, we entered into an exclusive agreement with Alveda Pharmaceuticals Inc., a
Toronto-based specialty pharmaceutical company, for the commercialization of Caldolor in Canada.
Under the agreement, Alveda will seek Canadian regulatory approval for Caldolor and, upon approval,
will handle ongoing regulatory requirements as well as product marketing, distribution and sales
throughout Canada. Cumberland will maintain responsibility for product formulation, development and
manufacturing. In exchange for the license to the product, Cumberland will receive royalties on
future sales of Caldolor in addition to upfront and milestone payments as well as a transfer price.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Compassionate Use in Australia</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In December&nbsp;2009, we entered into an exclusive agreement with Phebra Pty Ltd. for distribution of
Caldolor in Australia and New Zealand. As of April&nbsp;2010, Phebra has made the product available in
Australia on a limited, compassionate use basis. The Therapeutics Goods Administration (TGA), which
regulates drugs and medical devices in Australia, operates compassionate use programs that allow
patients with critical clinical need to access products not yet approved through their medical
practitioner. Phebra is also planning to submit an application to the TGA for regulatory approval
of Caldolor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>RECENT LEGISLATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On March&nbsp;23, 2010, President Obama signed into law the Patient Protection and Affordable Care Act,
or PPACA. On March&nbsp;30, 2010, the Health Care and Education Reconciliation Act of 2010, or HCERA,
was enacted into law, which modified the revenue provisions of the PPACA. The PPACA as amended by
the HCERA constitutes the healthcare reform legislation. The following highlights certain
provisions of the legislation that may affect us in the future.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Pharmaceutical Industry Fee</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Beginning in calendar-year 2011, an annual fee will be imposed on pharmaceutical manufacturers and
importers that sell branded prescription drugs to specified government programs (e.g., Medicare
Part&nbsp;D, Medicare Part&nbsp;B, Medicaid, Department of Veterans Affairs programs, Department of Defense
programs and TRICARE). The annual fee will be allocated to companies based on their previous
calendar-year market share using sales data that the government agencies that purchase the
pharmaceuticals will provide to the Treasury Department. We participate in minimal governmental
programs that would subject us to this fee. The first $5.0&nbsp;million of sales to government programs
is exempted from the fee. Our current sales volume to government programs is estimated to be less
than $5.0&nbsp;million and, thus, we do not anticipate being impacted by this fee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Medicaid Rebate Rate</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We currently provide rebates for Kristalose sold to Medicaid beneficiaries. Effective January&nbsp;1,
2010, the rebate increased from 11&nbsp;percent to 13&nbsp;percent of the average manufacturer price, or AMP.
We do not have a significant volume of Kristalose sales to Medicaid beneficiaries and, thus, the
impact on our results of operations for the three months ended March&nbsp;31, 2010 was not material. We
do not expect this aspect of the legislation will have a material impact on our results of
operations in the future.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Therapeutic Discovery Project Credit</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The legislation established a 50&nbsp;percent nonrefundable investment tax credit for qualified
investments in qualifying therapeutic discovery projects. The provision allocates $1&nbsp;billion
during the two-year period (2009-2010) for the program. The credit is available only to companies
with 250 or fewer employees. The qualified investment for any tax year is the aggregate amount of
the costs paid or incurred in that year for expenses necessary for and directly related to the
conduct of the qualifying therapeutic discovery project. We are currently evaluating our projects
to position ourselves to apply for these credits when the United States Treasury issues guidance on
how taxpayers may apply for the credits, which is expected to occur by May&nbsp;21, 2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Please see a discussion of our critical accounting policies and significant judgments and estimates
on pages 39 through 42 in &#147;Management&#146;s discussion and analysis&#148; of our Annual Report on Form 10-K
for the year ended December&nbsp;31, 2009.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Accounting Estimates and Judgments</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The preparation of consolidated financial statements in conformity with U.S. generally accepted
accounting principles requires management to make estimates, judgments and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date
of the financial statements and the reported amounts of revenues and expenses during the period. We
base our estimates on past experience and on other factors we deem reasonable given the
circumstances. Past results help form the basis of our judgments about the carrying value of assets
and liabilities that are not determined from other sources. Actual results could differ from these
estimates. These estimates, judgments and assumptions are most critical with respect to our
accounting for revenue recognition, provision for income taxes, stock-based compensation, research
and development accounting and intangible assets.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>RECENTLY ISSUED ACCOUNTING STANDARDS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In March&nbsp;2010, the Financial Accounting Standards Board, or FASB, issued guidance providing for the
recognition of revenue using the milestone method. Under this new guidance, an entity can
recognize revenue associated with milestones if the milestones are substantive and there is
substantive uncertainty about whether the milestone will be achieved. To meet the definition of a
substantive milestone, the consideration earned by achieving the milestone (1)&nbsp;would have to be
commensurate with either the level of effort required to achieve the milestone or the enhancement
in the value of the item delivered, (2)&nbsp;would have to relate solely to past performance and (3)
should be reasonable relative to all deliverables and payment terms in the arrangement. The new
guidance is effective for our third quarter ended September&nbsp;30, 2010. Early adoption is permitted.
The adoption of this guidance is not expected to have a material impact on our consolidated
financial position or results of operations.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In October&nbsp;2009, the FASB issued guidance setting forth requirements that must be met for an entity
to recognize revenue from the sale of a delivered item that is part of a multiple-element
arrangement when other items have not yet been delivered. The overall arrangement fee will be
allocated to each element based on their relative selling prices. If an entity does not have a
selling price for an element, then management must estimate the selling price. This guidance is
effective for us for all revenue arrangements entered into or materially modified after January&nbsp;1,
2011. Early adoption is permitted. The future impact of adopting this standard will depend on the
nature and extent of transactions covered by this standard.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>RESULTS OF OPERATIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Three months ended March&nbsp;31, 2010 compared to the three months ended March&nbsp;31, 2009</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Net revenues. </I>Net revenues for the three months ended March&nbsp;31, 2010 totaled approximately $10.1
million, representing an increase of approximately $0.7&nbsp;million, or 8%, over the same period in
2009, of which $0.6&nbsp;million was attributable to Acetadote, with sales volume for Acetadote and
Kristalose remaining consistent for the three months ended March&nbsp;31, 2010 as compared to the same
period in 2009. Also impacting our net revenues was an increase in our gross-to-net revenue
adjustments for Acetadote and Kristalose primarily due to additional fee-for-service agreements in
2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">During the second quarter of 2009, we expanded our hospital sales force in connection with the
commercial launch of Caldolor. In addition to the expansion of our hospital sales force, we
realigned our field sales force to enable them to also promote Caldolor in the surgery-center
market. The sales forces have been working diligently in the continued launch of Caldolor while
maintaining a consistent level of focus on our existing products, which is evidenced by consistent
sales volume of Acetadote and Kristalose.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Cost of products sold</I>. Cost of products sold as a percentage of net revenues increased slightly
from 7.8% for the three months ended March&nbsp;31, 2009 to 8.5% for the same period in 2010. The
increase in cost of products sold as a percentage of net revenues was primarily due to (1)&nbsp;the
weakening of the U.S. dollar and (2)&nbsp;an increase in our gross-to-net revenue adjustments discussed
above.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Selling and marketing</I>. Selling and marketing expense for the three months ended March&nbsp;31, 2010
totaled approximately $5.6&nbsp;million, representing an increase of approximately $1.5&nbsp;million, or 35%,
over the same period in 2009. The increase was primarily due to the expansion of our hospital sales
force in the second quarter of 2009, and the resulting increases in payroll and related taxes,
travel, meals and promotional activities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>General and administrative. </I>General and administrative expense for the three months ended March&nbsp;31,
2010 totaled approximately $1.9&nbsp;million, representing an increase of approximately $0.4&nbsp;million, or
30%, over the same period in 2009. The increase is primarily due to additional expenses associated
with being an SEC registrant, including legal and accounting-related costs and insurance. In
addition, we incurred additional foreign currency expense associated with our products bought from
overseas suppliers.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Interest expense. </I>Interest expense for the three months ended March&nbsp;31, 2010 totaled approximately
$0.3&nbsp;million, representing an increase of approximately $0.2&nbsp;million as compared to the same period
in 2009. The increase is directly attributable to the increase in our term debt balance of $8.4
million as of March&nbsp;31, 2010 as compared to March&nbsp;31, 2009.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Income tax expense</I>. Income tax expense for the three months ended March&nbsp;31, 2010 totaled
approximately $0.2&nbsp;million, representing a decrease of approximately $0.6&nbsp;million, or 75%, over the
same period in 2009. As a percentage of income before income taxes, income tax expense decreased
slightly from 40.8% for the three months ended March&nbsp;31, 2009 to 40.3% for the three months ended
March&nbsp;31, 2010. The decrease, in dollars, was primarily due to lower earnings in the first quarter
of 2010 as compared to the same period in 2009.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>LIQUIDITY AND CAPITAL RESOURCES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Working Capital</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Our primary sources of liquidity are cash flows provided by our operations, our borrowings and the
cash proceeds from our initial public offering of common stock that was completed in August&nbsp;2009.
We believe that our internally generated cash flows, amounts available under our credit facilities
and cash on hand will be adequate to service existing debt, finance internal growth and fund
capital expenditures. As of March&nbsp;31, 2010 and December&nbsp;31, 2009, cash and cash equivalents was
$73.8&nbsp;million and $78.7&nbsp;million, respectively, working capital (current assets minus current
liabilities) was $72.9&nbsp;million and $74.5&nbsp;million, respectively, and our current ratio (current
assets to current liabilities) was 5.7x and 5.0x, respectively. As of March&nbsp;31 2010, we had an
additional $2.2&nbsp;million available to us on our line of credit.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following table summarizes our net changes in cash and cash equivalents for the three months
ended March&nbsp;31, 2010 and 2009:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>March 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000">&nbsp;</TD>

    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">(in thousands)</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net cash provided by (used in):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">519</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1,735</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Investing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(64</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(32</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5,404</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net decrease in cash and cash equivalents <SUP style="FONT-size: 85%; vertical-align: text-top">(1)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(4,949</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1,757</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>The sum of the individual amounts may not agree due to rounding.</TD>
</TR>

</TABLE>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The net decrease in cash and cash equivalents of $4.9&nbsp;million for the three months ended March&nbsp;31,
2010 was primarily due to cash used in financing activities, which included (1)&nbsp;principal payments
on our term debt of approximately $4.6&nbsp;million, (2)&nbsp;the repurchase of common stock of approximately
$1.8&nbsp;million, (3)&nbsp;proceeds from the exercise of stock options of approximately $0.8&nbsp;million and (4)
the excess tax benefit derived from the exercise of nonqualified options of approximately $0.2
million.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>OFF-BALANCE SHEET ARRANGEMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">During the three months ended March&nbsp;31, 2010, the Company did not engage in any off-balance sheet
arrangements.
</DIV>

<DIV align="left">
<A name="108"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;3: Quantitative and Qualitative Disclosure about Market Risk</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Interest Rate Risk</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We are exposed to market risk related to changes in interest rates on our revolving credit facility
and our term note payable. We do not utilize derivative financial instruments or other market
risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our
cash investment activities is to preserve principal while maximizing interest income through
low-risk investments.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The interest rate related to borrowings under our revolving credit facility and term debt is a
variable rate of LIBOR plus an applicable margin, as defined in the debt agreement (5.75% at March
31, 2010). As of March&nbsp;31, 2010, we had outstanding borrowings of approximately $15.3&nbsp;million under
our revolving credit facility and term debt combined. If interest rates increased by 1.0%, our
annual interest expense on our borrowings would increase by approximately $0.2&nbsp;million.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Exchange Rate Risk</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">While we operate primarily in the U.S., we are exposed to foreign currency risk. Acetadote is
manufactured by a supplier that denominates supply prices in Canadian dollars. One of our supply
agreements for Caldolor is denominated in Australian dollars. Additionally, some of our research
and development is performed abroad. As of March&nbsp;31, 2010, our outstanding payables denominated in
a foreign currency totaled $1.1&nbsp;million.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Currently, we do not utilize financial instruments to hedge exposure to foreign currency
fluctuations. We believe our exposure to foreign currency fluctuation is minimal as our purchases
in foreign currency have a maximum exposure of 90&nbsp;days based on invoice terms, with much of the
exposure being limited to 30&nbsp;days based on the due date of the invoice. Foreign currency exchange
gains and losses were not significant for the three months ended March&nbsp;31, 2010. Neither a 10%
increase nor decrease from current exchange rates would have a significant effect on our operating
results or financial condition.
</DIV>

<DIV align="left">
<A name="109"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;4T: Controls and Procedures</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#146;s Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness
of the design and operation of the Company&#146;s disclosure controls and procedures as of March&nbsp;31,
2010. Based on that evaluation, they have concluded that the Company&#146;s disclosure controls and
procedures are effective to ensure that material information relating to the Company and the
Company&#146;s consolidated subsidiaries is made known to officers within these entities in order to
allow for timely decisions regarding required disclosure.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">During the Company&#146;s first quarter of 2010, there have been no changes in the Company&#146;s internal
control over financial reporting (as defined in Rule&nbsp;13a-15(f) or 15d-15(f)).
</DIV>

<DIV align="left">
<A name="110"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PART II &#150; OTHER FINANCIAL INFORMATION</B>
</DIV>

<DIV align="left">
<A name="111"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;1a: Risk Factors</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Information regarding risk factors appears on pages 20 through 32 in our Annual Report on Form 10-K
for the year ended December&nbsp;31, 2009 under the sections titled &#147;Risk Factors.&#148; There have been no
material changes from the risk factors previously discussed therein.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">



<DIV align="left">
<A name="112"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;2: Unregistered Sales of Equity Securities and Use of Proceeds</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Use of Proceeds</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On August&nbsp;10, 2009, our Registration Statement on Form S-1 (File No.&nbsp;333-142535) for 5,000,000
shares of common stock was declared effective for the Company&#146;s initial public offering. As of
March&nbsp;31, 2010, we have used approximately $4.2&nbsp;million of the net proceeds to pay off the existing
term debt with Bank of America, approximately $5.5&nbsp;million for the commercialization of Caldolor,
approximately $3.6&nbsp;million for the expansion of our sales force and approximately $1.4&nbsp;million for
ongoing clinical work, product development and other costs related to Caldolor. The remaining
proceeds have been invested in money market accounts. There have been no material changes in the
planned expected use of the net proceeds from the offering.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Purchases of Equity Securities</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following table summarizes the purchase of equity securities by the Company during the three
months ended March&nbsp;31, 2010:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Total Number</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>of Shares (or</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Price Paid</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Units)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>per Share</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>Period</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Purchased</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(or Unit)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="9" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">January 1 &#150; January 31</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#150;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#150;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">February 1 &#150; February 28</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">161,337</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">11.89</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">March 1 &#150; March 31</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#150;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#150;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">161,337</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The purchase of 153,543 shares of common stock was made pursuant to a put right held by an
executive to provide for the settlement of the remaining tax liability associated with the exercise
of stock options in 2009. In addition, a shareholder tendered 7,794 existing shares held as
consideration for the exercise price of options exercised. The purchase price of these
transactions was the then-current fair market value of common stock on the date of the transaction.
</DIV>

<DIV align="left">
<A name="113"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;6: Exhibits</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.6.1#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Incentive Stock Option Agreement under 2007 Long-Term Incentive Compensation Plan of
Cumberland Pharmaceuticals Inc.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.6.2#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Nonstatutory Stock Option Agreement under 2007 Long-Term Incentive Compensation Plan
of Cumberland Pharmaceuticals Inc.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.7#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Nonstatutory Stock Option Agreement under 2007 Directors&#146; Compensation Plan of
Cumberland Pharmaceuticals Inc.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.6.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fifth Amendment to Service Agreement, dated April&nbsp;1, 2010, by and between Ventiv Commercial
Services, LLC and Cumberland Pharmaceuticals Inc., incorporated herein by reference from
Exhibit&nbsp;10.1 of the Registrant&#146;s Current Report on Form&nbsp;8-K (File No.&nbsp;001-33637) as filed with
the SEC on April&nbsp;6, 2010</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.9.4&#134;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fourth Amendment to Kristalose Agreement, effective January&nbsp;1, 2010, by and between Inalco
S.p.A., Inalco Biochemicals, Inc., and Cumberland Pharmaceuticals Inc.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.11#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employment Agreement effective as of January&nbsp;1, 2010 by and between A.J. Kazimi and
Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit
to the Registrant&#146;s Current Report of Form&nbsp;8-K (File No.&nbsp;001-33637) as filed with the SEC on
March&nbsp;29, 2010.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.12#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employment Agreement effective as of January&nbsp;1, 2010 by and between Jean W. Marstiller and
Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit
to the Registrant&#146;s Current Report of Form&nbsp;8-K (File No.&nbsp;001-33637) as filed with the SEC on
March&nbsp;29, 2010.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.13#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employment Agreement effective as of January&nbsp;1, 2010 by and between Leo Pavliv and
Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit
to the Registrant&#146;s Current Report of Form&nbsp;8-K (File No.&nbsp;001-33637) as filed with the SEC on
March&nbsp;29, 2010.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.15#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employment Agreement effective as of January&nbsp;1, 2010 by and between David L. Lowrance and
Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit
to the Registrant&#146;s Current Report of Form&nbsp;8-K (File No.&nbsp;001-33637) as filed with the SEC on
March&nbsp;29, 2010.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.19#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2007 Directors&#146; Incentive Plan of Cumberland Pharmaceuticals Inc.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.21.2&#134;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Second Amendment to Office Lease Agreement, dated March&nbsp;2, 2010, by and between 2525 West
End, LLC (successor in interest to Nashville Hines Development LLC) and Cumberland
Pharmaceuticals Inc.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.26#
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employment Agreement effective as of January&nbsp;1, 2010 by and between Martin E. Cearnal and
Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit
to the Registrant&#146;s Current Report of Form&nbsp;8-K (File No.&nbsp;001-33637) as filed with the SEC on
March&nbsp;29, 2010.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">31.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of Chief Executive Officer Pursuant to Rule&nbsp;13-14(a) of the Securities Exchange
Act of 1934 as Adopted Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">31.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of Chief Financial Officer Pursuant to Rule&nbsp;13-14(a) of the Securities Exchange
Act of 1934 as Adopted Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">32.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C.
Section&nbsp;1350, as Adopted Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">#</TD>
    <TD>&nbsp;</TD>
    <TD>Indicates a management contract or compensatory plan.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">&#134;</TD>
    <TD>&nbsp;</TD>
    <TD>Confidential treatment has been requested for portions of this
exhibit. These portions have been omitted from the Quarterly Report
and submitted separately to the Securities and Exchange Commission.</TD>
</TR>

</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">





<DIV align="left">
<A name="114"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned thereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Cumberland Pharmaceuticals Inc.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Dated: May 17, 2010&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ A. J. Kazimi&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">A. J. Kazimi&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Dated: May 17, 2010&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/
David L. Lowrance&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">David L. Lowrance&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" nowrap>Vice President and
Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6.1
<SEQUENCE>2
<FILENAME>g23297exv4w6w1.htm
<DESCRIPTION>EX-4.6.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w6w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">EXHIBIT 4.6.1
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC.<BR>
2007 LONG-TERM INCENTIVE COMPENSATION PLAN<BR>
INCENTIVE STOCK OPTION AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Grant of Option.</U> Cumberland Pharmaceuticals Inc. (the &#147;Company&#148;), a Tennessee
corporation, hereby grants to the Participant an option (the &#147;Option&#148;) to purchase from the Company
up to the number of shares of common stock (the &#147;Shares&#148;) described in the attached Notice of Stock
Option Grant (the &#147;Notice&#148;). This grant is made subject to the terms of the Cumberland
Pharmaceuticals Inc. 2007 Long-Term Incentive Compensation Plan (the &#147;Plan&#148;) and the number of
shares granted is subject to adjustment as described in the Plan. Unless otherwise defined in this
Incentive Stock Option Agreement (the &#147;Option Agreement&#148;), capitalized terms used in this Option
Agreement shall have the same meaning as those capitalized terms in the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Exercise Price.</U> If the Option is exercised, the purchase price per Share shall be
as shown in the attached Notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Method of Exercise.</U> The Option granted under this Option Agreement shall be
exercisable from time to time, in whole or in part, by written notice as described in Section&nbsp;9
hereof, accompanied by payment of the purchase price for the Shares which the Participant elects to
purchase by cash, check, or such other instrument as the Company may accept. The Company shall make
prompt delivery of such Shares, and in no event shall delivery of such shares be made more than 30
days after cash, check or other instrument is accepted by the Company in payment for the Shares,
except that if any law or regulation requires the Company to take any action with respect to the
Shares specified in such notice before issuance thereof, then the date of delivery of such Shares
shall be extended for the period necessary for the Company to take such action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Vesting.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Option shall vest in accordance with the schedule set forth in the Notice. Employment
for only a portion of the vesting period, even if a substantial portion, will not entitle the
Participant to any proportionate vesting or avoid or mitigate a termination of rights and benefits
upon or following a termination of employment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Upon the Participant&#146;s Employment Termination, the Option, to the extent unvested, shall
lapse and be cancelled, and be of no further force and effect, as of midnight of such date, unless
the Board resolves (under Section 4(b) of the Plan) to cancel or cause the forfeiture of the Option
at an earlier time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Upon an Acquisition Event and/or a Change in Control Event, the Option will vest to the
extent provided in the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Termination of Option; Restrictions on Exercise.</U> Except as otherwise stated in this
Agreement, this Option, to the extent not previously exercised, shall expire on the expiration date
set forth in the attached Notice (the &#147;Expiration Date&#148;). The following additional provisions shall
apply to the exercise of this Option:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <I>Termination of Employment. </I>Except as otherwise provided in this Option Agreement or in the
Plan, if Participant&#146;s employment with the Company and its Related Entities is terminated by the
Participant or the Company, the right to exercise this Option (to the extent that it is vested in
accordance with the applicable provisions of Section&nbsp;4 hereof) shall end on the <U>earlier</U> of
the following dates: (i)&nbsp;ninety (90)&nbsp;days after such termination or (ii)&nbsp;the expiration date of
this Option shown in the Notice. Except as expressly set forth otherwise herein, this Option shall
terminate in all other respects upon such termination of employment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <I>Death of Participant. </I>If the Participant&#146;s employment with the Company is terminated due
to his/her death during the term of this Option, the Participant&#146;s legal representative, or the
person so entitled under the Participant&#146;s last will and testament, or under applicable intestate
laws, shall have the right to exercise this Option for the number of Shares vested under Section&nbsp;4
hereof as of the time of Participant&#146;s death, and such right shall expire and this Option shall
terminate on the Expiration Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Provisions of Plan.</U> The terms and provisions of the Plan (including any written
amendments made to the Plan from time to time) are hereby incorporated herein by reference. In the
event of a conflict between the terms or provisions contained herein and the terms or provisions of
the Plan, the applicable terms and provisions of the Plan will govern and prevail; however, in the
event of a conflict regarding specific terms and provisions addressing the duration of this Option
after termination of employment, the terms and provisions of this Option will govern.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Tax Treatment of Option.</U> The Participant is responsible for any federal, state,
local, or foreign tax, including income tax, social security tax, payroll tax, payment on account,
or other tax-related withholding with respect to this Option (including the grant, vesting and
exercise of the Option and the receipt of Shares and sale of Shares). The Company does not
guarantee any particular tax treatment or results in connection with the grant, vesting or exercise
of the Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Code Section&nbsp;409A.</U> This Option Agreement is intended to be exempt from
the requirements of Internal Revenue Code Section&nbsp;409A (&#147;Section&nbsp;409A&#148;) and regulations or other
authority under Section&nbsp;409A, and not intended to provide for any deferral of compensation that
fails to satisfy the requirements of Section&nbsp;409A. Notwithstanding any other provision of Option
Agreement to the contrary, it is intended that any payment or benefit provided for in this Option
Agreement that constitutes &#147;nonqualified deferred compensation,&#148; as that term is defined in Code
Section&nbsp;409A, shall be provided and issued in a manner, and at such time and in such form, as
complies with the applicable requirements of Section&nbsp;409A. Any provision in this Option Agreement
that would result in the imposition of excise taxes or any other taxes upon Participant under
Section&nbsp;409A shall be void and without effect. To the extent permitted under Section&nbsp;409A, the
parties shall reform the provision, provided such reformation shall not subject Participant to
additional tax or interest and shall not require the Company to incur any additional compensation
costs as a result of the reformation. In addition, any provision that is required to appear in this
Option Agreement for purposes of Section&nbsp;409A compliance and that is not expressly set forth shall
be deemed to be set forth herein, and this Option Agreement shall be administered in all respects
as if such provision were expressly set forth. References in this
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Option Agreement to Section&nbsp;409A include rules, regulations, and guidance of general
application issued by the Department of the Treasury under Section&nbsp;409A.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Notices.</U> Any notice, request, instruction or other document given under this Option
Agreement shall be in writing and shall be addressed and delivered in the case of the Company, to
the Secretary of the Company at the principal office of the Company and, in the case of the
Participant, at the Participant&#146;s address as set forth in the attached Notice or to such other
address as the Participant may provide in a written notice to the Company, a copy of which shall be
on file with the Secretary of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Governing Law.</U> This Option Agreement shall be construed in accordance with and
governed by the law of the State of Tennessee, without giving effect to the conflict of law
provisions thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Relation to Other Benefits.</U> Unless otherwise provided, the benefits received by
the Participant under this Option Agreement will not be taken into account or treated as normal
salary or compensation in determining any benefits to which the Participant may be entitled under
any profit sharing, retirement, bonus, long service, or other benefit or compensation plan
maintained by the Company, including the amount of any life insurance coverage available to any
beneficiary of the Participant under any life insurance plan covering employees of the Company, or
as part of the calculation of any severance, resignation, termination, redundancy or end of service
payments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Miscellaneous</U>. The grant of this Option does not create any contractual or other
right to receive future grants of Options, or benefits in lieu of Options, even if the Participant
has a history of receiving Options or other stock awards.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Headings.</U> The headings of the Sections hereof are provided for convenience only
and are not to serve as a basis for interpretation or construction, and shall not constitute a part
of this Option Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<U>Signature.</U> This Option Agreement shall be deemed executed by the Company and the
Participant upon execution by such parties of the attached Notice.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"># # # #
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">FOR FUTURE USE
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>NOTICE OF EXERCISE</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cumberland Pharmaceuticals Inc.:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to exercise the purchase rights granted in the attached Option
Agreement # &#95;&#95;&#95; and associated Notice of Stock Option Grant. In accordance with the terms thereof,
the undersigned elects to purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares of Common Stock of Cumberland Pharmaceuticals
Inc. and tenders herewith payment of the purchase price for such shares in full.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please issue said shares of Common Stock in the name of the undersigned.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">PARTICIPANT
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="51%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="white-space: nowrap">Signature:</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="white-space: nowrap">Print Name:</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="white-space: nowrap">Address:</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="white-space: nowrap">City, State, Zip:</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="white-space: nowrap">Social Security Number:</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="white-space: nowrap">Phone Number:</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">$ <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Payment Attached

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6.2
<SEQUENCE>3
<FILENAME>g23297exv4w6w2.htm
<DESCRIPTION>EX-4.6.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w6w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">EXHIBIT 4.6.2
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC.<BR>
2007 LONG-TERM INCENTIVE COMPENSATION PLAN<BR>
NON-STATUTORY STOCK OPTION AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Grant of Option.</U> Cumberland Pharmaceuticals Inc. (the &#147;Company&#148;), a Tennessee
corporation, hereby grants to the Participant an option (the &#147;Option&#148;) to purchase from the Company
up to the number of shares of common stock (the &#147;Shares&#148;) described in the attached Notice of Stock
Option Grant (the &#147;Notice&#148;). This grant is made subject to the terms of the Cumberland
Pharmaceuticals Inc. 2007 Long-Term Incentive Compensation Plan (the &#147;Plan&#148;) and the number of
shares granted is subject to adjustment as described in the Plan. Unless otherwise defined in this
Non-Statutory Stock Option Agreement (the &#147;Option Agreement&#148;), capitalized terms used in this
Option Agreement shall have the same meaning as those capitalized terms in the Plan. This Option is
<I>not </I>intended to qualify as an incentive stock option within the meaning of Section&nbsp;422 of the
Internal Revenue Code of 1986, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Exercise Price.</U> If the Option is exercised, the purchase price per Share shall be
as shown in the attached Notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Method of Exercise.</U> The Option granted under this Option Agreement shall be
exercisable from time to time, in whole or in part, by written notice as described in Section&nbsp;9
hereof, accompanied by payment of the purchase price for the Shares which the Participant elects to
purchase by cash, check, or such other instrument as the Company may accept. The Company shall make
prompt delivery of such Shares, and in no event shall delivery of such shares be made more than 30
days after cash, check or other instrument is accepted by the Company in payment for the Shares,
except that if any law or regulation requires the Company to take any action with respect to the
Shares specified in such notice before issuance thereof, then the date of delivery of such Shares
shall be extended for the period necessary for the Company to take such action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Vesting.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Option shall vest in accordance with the schedule set forth in the attached Notice.
Employment (or consulting) for only a portion of the vesting period, even if a substantial portion,
will not entitle the Participant to any proportionate vesting or avoid or mitigate a termination of
rights and benefits upon or following a termination of employment (or consulting engagement).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Upon the Participant&#146;s Employment Termination (or termination of the consulting
engagement), the Option, to the extent unvested, shall lapse and be cancelled, and be of no further
force and effect, as of midnight of such date, unless the Board resolves (under Section 4(b) of the
Plan) to cancel or cause the forfeiture of the Option at an earlier time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Upon an Acquisition Event and/or a Change in Control Event, the Option will vest to the
extent provided in the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Termination of Option; Restrictions on Exercise.</U> Except as otherwise stated in this
Agreement, this Option, to the extent not previously exercised, shall expire on the expiration date
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">set forth in the attached Notice (the &#147;Expiration Date&#148;). The following additional provisions
shall apply to the exercise of this Option:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <I>Termination of Employment (or Consulting Engagement). </I>Except as otherwise provided in this
Option Agreement or in the Plan, if Participant&#146;s employment with the Company and its Related
Entities is terminated by the Participant or the Company (or if the Participant&#146;s consulting
engagement is terminated), the right to exercise this Option (to the extent that it is vested in
accordance with the applicable provisions of Section&nbsp;4 hereof) shall end on the <U>earlier</U> of
the following dates: (i)&nbsp;ninety (90)&nbsp;days after such termination or (ii)&nbsp;the expiration date of
this Option shown in the attached Notice. Except as expressly set forth otherwise herein, this
Option shall terminate in all other respects upon such termination of employment (or consulting
engagement).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <I>Death of Participant. </I>If the Participant&#146;s employment (or consulting engagement) with the
Company is terminated due to his/her death during the term of this Option, the Participant&#146;s legal
representative, or the person so entitled under the Participant&#146;s last will and testament, or under
applicable intestate laws, shall have the right to exercise this Option for the number of Shares
vested under Section&nbsp;4 hereof as of the time of Participant&#146;s death, and such right shall expire
and this Option shall terminate on the Expiration Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Provisions of Plan.</U> The terms and provisions of the Plan (including any written
amendments made to the Plan from time to time) are hereby incorporated herein by reference. In the
event of a conflict between the terms or provisions contained herein and the terms or provisions of
the Plan, the applicable terms and provisions of the Plan will govern and prevail; however, in the
event of a conflict regarding specific terms and provisions addressing the duration of this Option
after termination of employment (or consulting engagement), the terms and provisions of this Option
will govern.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Tax Treatment of Option.</U> The Participant is responsible for any federal, state,
local, or foreign tax, including income tax, social security tax, payroll tax, payment on account,
or other tax-related withholding with respect to this Option (including the grant, vesting and
exercise of the Option and the receipt of Shares and sale of Shares). The Company does not
guarantee any particular tax treatment or results in connection with the grant, vesting or exercise
of the Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Code Section&nbsp;409A.</U> This Option Agreement is intended to be exempt from
the requirements of Internal Revenue Code Section&nbsp;409A (&#147;Section&nbsp;409A&#148;) and regulations or other
authority under Section&nbsp;409A, and not intended to provide for any deferral of compensation that
fails to satisfy the requirements of Section&nbsp;409A. Notwithstanding any other provision of Option
Agreement to the contrary, it is intended that any payment or benefit provided for in this Option
Agreement that constitutes &#147;nonqualified deferred compensation,&#148; as that term is defined in Code
Section&nbsp;409A, shall be provided and issued in a manner, and at such time and in such form, as
complies with the applicable requirements of Section&nbsp;409A. Any provision in this Option Agreement
that would result in the imposition of excise taxes or any other taxes upon Participant under
Section&nbsp;409A shall be void and without effect. To the extent permitted under Section&nbsp;409A, the
parties shall reform the provision, provided such reformation shall not subject Participant to
additional tax or interest and shall not require the Company to incur any additional compensation
costs as a result of the reformation. In addition, any provision that is required to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">appear in this Option Agreement for purposes of Section&nbsp;409A compliance and that is not
expressly set forth shall be deemed to be set forth herein, and this Option Agreement shall be
administered in all respects as if such provision were expressly set forth. References in this
Option Agreement to Section&nbsp;409A include rules, regulations, and guidance of general application
issued by the Department of the Treasury under Section&nbsp;409A.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Notices.</U> Any notice, request, instruction or other document given under this Option
Agreement shall be in writing and shall be addressed and delivered in the case of the Company, to
the Secretary of the Company at the principal office of the Company and, in the case of the
Participant, at the Participant&#146;s address as set forth in the attached Notice or to such other
address as the Participant may provide in a written notice to the Company, a copy of which shall be
on file with the Secretary of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Governing Law.</U> This Option Agreement shall be construed in accordance with and
governed by the law of the State of Tennessee, without giving effect to the conflict of law
provisions thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Relation to Other Benefits.</U> Unless otherwise provided, the benefits received by
the Participant under this Option Agreement will not be taken into account or treated as normal
salary or compensation in determining any benefits to which the Participant may be entitled under
any profit sharing, retirement, bonus, long service, or other benefit or compensation plan
maintained by the Company, including the amount of any life insurance coverage available to any
beneficiary of the Participant under any life insurance plan covering employees of the Company, or
as part of the calculation of any severance, resignation, termination, redundancy or end of service
payments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Miscellaneous</U>. The grant of this Option does not create any contractual or other
right to receive future grants of Options, or benefits in lieu of Options, even if the Participant
has a history of receiving Options or other stock awards.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Headings.</U> The headings of the Sections hereof are provided for convenience only
and are not to serve as a basis for interpretation or construction, and shall not constitute a part
of this Option Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<U>Signature.</U> This Option Agreement shall be deemed executed by the Company and the
Participant upon execution by such parties of the attached Notice.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"># # # #
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">FOR FUTURE USE
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>NOTICE OF EXERCISE</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cumberland Pharmaceuticals Inc.:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to exercise the purchase rights granted in the attached Option
Agreement # &#95;&#95;&#95; and associated Notice of Stock Option Grant (Non-Statutory Stock Option). In
accordance with the terms thereof, the undersigned elects to purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;shares of Common
Stock of Cumberland Pharmaceuticals Inc. and tenders herewith payment of the purchase price for
such shares in full.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please issue said shares of Common Stock in the name of the undersigned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="51%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">PARTICIPANT
</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">Signature:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"  style="font-size: 1px">

<TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">Print Name:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"  style="font-size: 1px">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"  style="font-size: 1px">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">City, State, Zip:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"  style="font-size: 1px">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="white-space: nowrap">Social Security Number:</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">Phone Number:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"  style="font-size: 1px">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">$ <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Payment Attached

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>4
<FILENAME>g23297exv4w7.htm
<DESCRIPTION>EX-4.7
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w7</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">EXHIBIT 4.7
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC.<BR>
2007 DIRECTORS&#146; INCENTIVE PLAN<BR>
NON-STATUTORY STOCK OPTION AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Grant of Option.</U> Cumberland Pharmaceuticals Inc. (the &#147;Company&#148;), a Tennessee
corporation, hereby grants to the Participant an option (the &#147;Option&#148;) to purchase from the Company
up to the number of shares of common stock in the Company (the &#147;Shares&#148;) described in the attached
Notice of Stock Option Grant (the &#147;Notice&#148;). This grant is made subject to the terms of the
Cumberland Pharmaceuticals Inc. 2007 Directors&#146; Incentive Plan (the &#147;Plan&#148;) and the number of
shares granted is subject to adjustment as described in the Plan. Unless otherwise defined in this
Non-Statutory Stock Option Agreement (the &#147;Option Agreement&#148;), capitalized terms used in this
Option Agreement shall have the same meaning as those capitalized terms in the Plan. This Option is
<I>not </I>intended to qualify as an incentive stock option within the meaning of Section&nbsp;422 of the
Internal Revenue Code of 1986, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Exercise Price.</U> If the Option is exercised, the purchase price per Share shall be
as shown in the attached Notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Method of Exercise.</U> The Option shall be exercisable from time to time, in whole or
in part, by written notice as described in Section&nbsp;9 hereof, accompanied by payment of the purchase
price for the Shares which the Participant elects to purchase by cash, check, or such other
instrument as the Company may accept under the terms of the Plan. The Company shall make prompt
delivery of such Shares, and in no event shall delivery of such shares be made more than 30&nbsp;days
after cash, check or other instrument is accepted by the Company in payment for the Shares, except
that if any law or regulation requires the Company to take any action with respect to the Shares
specified in such notice before issuance thereof, then the date of delivery of such Shares shall be
extended for the period necessary for the Company to take such action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Vesting.</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Option shall vest in accordance with the schedule set forth in the Notice. Service as
a member of the Company&#146;s Board of Directors (a &#147;Director&#148;) for only a portion of the vesting
period, even if a substantial portion, will not entitle the Participant to any proportionate
vesting or avoid or mitigate a termination of rights and benefits upon or following a termination
of service as Director.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Upon termination of Participant&#146;s service as Director, the Option, to the extent unvested,
shall lapse and be cancelled, and be of no further force and effect, as of midnight of such date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Upon a Change of Control Event, the Option will vest to the extent provided in Section&nbsp;9.2
of the Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Termination of Option; Restrictions on Exercise.</U> Except as otherwise stated in this
Agreement, this Option, to the extent not previously exercised, shall expire on the expiration
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">date set forth in the attached Notice (the &#147;Expiration Date&#148;). The following additional
provisions shall apply to the exercise of this Option:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<I>Termination of Service as Director. </I>If Participant&#146;s service as Director is terminated for
any reason, the right to exercise this Option (to the extent that it is vested in accordance with
the applicable provisions of Section&nbsp;4 hereof) shall end on the <U>earlier</U> of the following
dates: (i)&nbsp;two (2)&nbsp;years after the date of such termination or (ii)&nbsp;the Expiration Date. Except as
expressly set forth otherwise herein, this Option shall terminate in all other respects upon such
termination of Participant&#146;s service as Director.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<I>Death of Participant. </I>If the Participant&#146;s service as Director is terminated due to
his/her death during the term of this Option, the Participant&#146;s legal representative, or the person
so entitled under the Participant&#146;s last will and testament, or under applicable intestate laws,
shall have the right to exercise this Option for the number of Shares vested under Section&nbsp;4 hereof
as of the time of Participant&#146;s death, and such right shall expire and this Option shall terminate
on the Expiration Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Provisions of Plan.</U> The terms and provisions of the Plan (including any written
amendments made to the Plan from time to time) are hereby incorporated herein by reference. In the
event of a conflict between the terms or provisions contained herein and the terms or provisions of
the Plan, the applicable terms and provisions of the Plan will govern and prevail; however, in the
event of a conflict regarding specific terms and provisions addressing the duration of this Option
after termination of Participant&#146;s service as Director, the terms and provisions of this Option
will govern. Participant is advised to consult his or her tax adviser concerning tax issues
regarding the Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Tax Treatment of Option.</U> The Participant is responsible for any federal, state,
local, or foreign tax, including income tax, social security tax, payroll tax, payment on account,
or other tax-related withholding with respect to this Option (including the grant, vesting and
exercise of the Option and the receipt of Shares and sale of Shares). The Company does not
guarantee any particular tax treatment or results in connection with the grant, vesting or exercise
of the Option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Code Section&nbsp;409A.</U> This Option Agreement is intended to be exempt from the
requirements of Internal Revenue Code Section&nbsp;409A (&#147;Section&nbsp;409A&#148;) and regulations or other
authority under Section&nbsp;409A, and not intended to provide for any deferral of compensation that
fails to satisfy the requirements of Section&nbsp;409A. Notwithstanding any other provision of Option
Agreement to the contrary, it is intended that any payment or benefit provided for in this Option
Agreement that constitutes &#147;nonqualified deferred compensation,&#148; as that term is defined in Code
Section&nbsp;409A, shall be provided and issued in a manner, and at such time and in such form, as
complies with the applicable requirements of Section&nbsp;409A. Any provision in this Option Agreement
that would result in the imposition of excise taxes or any other taxes upon Participant under
Section&nbsp;409A shall be void and without effect. To the extent permitted under Section&nbsp;409A, the
parties shall reform the provision, provided such reformation shall not subject Participant to
additional tax or interest and shall not require the Company to incur any additional compensation
costs as a result of the reformation. In addition, any provision that is required to appear in this
Option Agreement for purposes of Section&nbsp;409A compliance and that is not
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">expressly set forth shall be deemed to be set forth herein, and this Option Agreement shall be
administered in all respects as if such provision were expressly set forth. References in this
Option Agreement to Section&nbsp;409A include rules, regulations, and guidance of general application
issued by the Department of the Treasury under Section&nbsp;409A.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Notices.</U> Any notice, request, instruction or other document given under this Option
Agreement shall be in writing and shall be addressed and delivered in the case of the Company, to
the Secretary of the Company at the principal office of the Company and, in the case of the
Participant, at the Participant&#146;s address as set forth in the attached Notice or to such other
address as the Participant may provide in a written notice to the Company, a copy of which shall be
on file with the Secretary of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Governing Law.</U> This Option Agreement shall be construed in accordance with and
governed by the law of the State of Tennessee, without giving effect to the conflict of law
provisions thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Miscellaneous</U>. The grant of this Option does not create any contractual or other
right to receive future grants of Options, or benefits in lieu of Options, even if the Participant
has a history of receiving Options or other stock awards. The granting of this Option and the
vesting schedule set forth in the Notice do not constitute a promise, either express or implied, of
continued engagement as a Director and shall not interfere with the Company&#146;s right or the
Participant&#146;s right to terminate Participant&#146;s directorship at any time, with or without cause.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Headings.</U> The headings of the Sections hereof are provided for convenience only
and are not to serve as a basis for interpretation or construction, and shall not constitute a part
of this Option Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Signature.</U> This Option Agreement shall be deemed executed by the Company and the
Participant upon execution by such parties of the attached Notice.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">FOR FUTURE USE
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>NOTICE OF EXERCISE</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cumberland Pharmaceuticals Inc.:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to exercise the purchase rights granted in the attached Option
Agreement # &#95;&#95;&#95; and associated Notice of Stock Option Grant. In accordance with the terms
thereof, the undersigned elects to purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;shares of common stock of Cumberland
Pharmaceuticals Inc. and tenders herewith payment of the purchase price for such shares in full.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please issue said shares of common stock in the name of the undersigned.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="bottom" align="left">PARTICIPANT:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">Signature:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">Print Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><FONT style="white-space: nowrap">Social Security No.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">Phone Number:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px"><u>Delivery Information:</u>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">City, State, Zip:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">$ <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Payment Attached

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9.4
<SEQUENCE>5
<FILENAME>g23297exv10w9w4.htm
<DESCRIPTION>EX-10.9.4
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w9w4</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.9.4</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">*Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FOURTH AMENDMENT TO<BR>
KRISTALOSE AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Fourth Amendment to Kristalose Agreement (the &#147;Fourth Amendment&#148;) is effective this
1<SUP style="FONT-size: 85%; vertical-align: text-top">st</SUP> day of January, 2010 by and between Inalco S.P.A. (&#147;Inalco Italy&#148;), Inalco
Biochemicals, Inc. (&#147;Inalco U.S.&#148;) and Cumberland Pharmaceuticals Inc. (&#147;Cumberland&#148;). Inalco
Italy and Inalco U.S. are hereinafter collectively referred to as &#147;Inalco.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>Inalco and Cumberland entered into a certain Kristalose Agreement in April&nbsp;2006 (the
&#147;Original Agreement&#148;) and subsequently entered into a certain Amendment to the Kristalose Agreement
on April&nbsp;3, 2008 (&#147;First Amendment&#148;), a certain Second Amendment to the Kristalose Agreement on
July&nbsp;1, 2008 (&#147;Second Amendment&#148;), and a certain Third Amendment to the Kristalose Agreement on
April&nbsp;6, 2009 (&#147;Third Amendment&#148;) (The Original Agreement, First Amendment, Second Amendment, and
Third Amendment as amended hereby, are collectively referred to herein as the &#147;Kristalose
Agreement&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>Inalco and Cumberland desire to further amend the Kristalose Agreement in certain
respects as set forth herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW, THEREFORE, </B>for and in consideration of the mutual covenants and agreements hereinafter
set forth, and for other good and valuable consideration, the parties hereto agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U><B>Amendment of Section&nbsp;4.3</B></U>. Effective the date of this Amendment, Section&nbsp;4.3
(Payment for Product) of the Kristalose Agreement is hereby further amended to reflect a one-time
price increase by deleting &#147;&#091;***&#093;&#148; and substituting in lieu thereof &#147;&#091;***&#093;&#148; and by deleting &#147;&#091;***&#093;&#148;
and substituting in lieu thereof &#147;&#091;***&#093;&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;Capitalized terms not defined in this Fourth Amendment shall have the meaning set forth in
the Kristalose Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;It is mutually agreed that all covenants, conditions and agreements set forth in the
Kristalose Agreement (as amended hereby) shall remain binding upon the parties and inure to the
benefit of the parties hereto and their respective successors and assigns.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN WITNESS WHEREOF, </B>the parties hereto have caused this Fourth Amendment to be executed by
their duly authorized representatives effective as of the day and year first written above.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>INALCO S.P.A</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Giovanni Cipolletti
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Givanni Cipolletti&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Its:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal Representative&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>INALCO BIOCHEMICALS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ E. Lowe
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">E. Lowe&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Its:&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>CUMBERLAND PHARMACEUTICALS INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ A.J. Kazimi
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">A.J. Kazimi&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Its:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>6
<FILENAME>g23297exv10w19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w19</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">EXHIBIT 10.19
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="g23297g2329700.gif" alt="(CUMBERLAND LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>2007 DIRECTORS&#146; INCENTIVE PLAN</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CONFIDENTIAL</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC.<BR>
2007 DIRECTORS&#146; INCENTIVE PLAN</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Table of Contents</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>1. Purpose of the Plan</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>2. Definitions</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>3. Shares of Stock Subject to the Plan</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>4. Administration of the Plan</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>5. Terms and Conditions of Options</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>6. Terms and Conditions of Restricted Stock Grants</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>7. Terms and Conditions of Stock Grant</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>8. Adjustment Provisions</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>9. Change of Control</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>10. General Provisions</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>11. Amendments, Discontinuance or Termination of the Plan</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>12. Governing Law</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>13. Additional Requirements</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>14. &#147;Lockup&#148; Agreement</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>15. Limitation of Liability</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>16. Unfunded Status of Incentives</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>17. Nonexclusivity of the Plan</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>18. Successors and Assigns</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>19. No Fractional Shares</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>20. Severability</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>21. Effective Date of Plan</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CUMBERLAND PHARMACEUTICALS INC.<BR>
2007 DIRECTORS&#146; INCENTIVE PLAN</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>1. Purpose of the Plan</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the Cumberland Pharmaceuticals Inc. 2007 Directors&#146; Incentive Plan is to
promote the interests of the Company and its shareholders by strengthening the Company&#146;s ability to
attract, motivate and retain Directors of experience and ability, and to encourage the highest
level of performance by providing Directors with a proprietary interest in the Company&#146;s financial
success and growth. The Plan supersedes and replaces all provisions pertaining to grants of stock
options to Directors contained in the Cumberland Pharmaceuticals Inc. 1999 Stock Option Plan (the
&#147;Original Incentive Plan&#148;) but does not impair the vesting or exercise of any option granted under
the Original Incentive Plan prior to the date that this Plan became effective.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>2. Definitions</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 &#147;Affiliate&#148; shall have the meaning assigned to the term pursuant to Rule&nbsp;12b-2 as
promulgated under the Exchange Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 &#147;Award&#148; means an award under the Plan of Options, Restricted Stock , or a Stock Grant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 &#147;Board&#148; means the Board of Directors of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 &#147;Committee&#148; means the Compensation Committee of the Board or a subcommittee thereof. The
Committee shall consist of not fewer than two members of the Board, each of whom shall (a)&nbsp;qualify
as a &#147;non-employee director&#148; under Rule&nbsp;16b-3 promulgated under the Securities Exchange Act of
1934, or any successor rule, and (b)&nbsp;qualify as an &#147;outside director&#148; under Section 162(m) of the
Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), and the regulations promulgated thereunder
(collectively, &#147;Section&nbsp;162(m)&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 &#147;Company&#148; means Cumberland Pharmaceuticals Inc.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 &#147;Director&#148; means a member of the Board who is not employed by the Company or any of its
Affiliates or a joint venture of the company or one of its Affiliates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7 &#147;Exchange Act&#148; shall mean the Securities Exchange Act of 1934, as amended.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8 &#147;Fair Market Value&#148; means: (i)&nbsp;if the Stock or other security is listed on an established
stock exchange or any automated quotation system that provides sale quotations, the closing sale
price for a share thereof on such exchange or quotation system on the applicable date, and if
shares are not traded on such day, on the next preceding trading date, (ii)&nbsp;if the Stock or other
security is not listed on any exchange or quotation system, but bid and asked prices are quoted and
published, the mean between the quoted bid and asked prices on the applicable date,
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and if bid and asked prices are not available on such day, on the next preceding day on which
such prices were available, and (iii)&nbsp;if the Stock or other security is not regularly quoted, the
fair market value of a share thereof on the applicable date as established by the Committee in good
faith. For purposes of Awards effective as of the effective date of the Company&#146;s initial public
offering, Fair Market Value of the Stock shall be the price at which such stock is offered to the
public in the Company&#146;s initial public offering.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9 &#147;Option&#148; means a stock option that does not satisfy the requirements of Section&nbsp;422 of
the Code to be an incentive stock option.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10 &#147;Participant&#148; means each Director (as defined in Section&nbsp;2.6).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11 &#147;Plan&#148; means the Cumberland Pharmaceuticals Inc. 2007 Directors&#146; Incentive Plan as set
forth herein and as amended, restated, supplemented or otherwise modified from time to time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12 &#147;Restriction Period&#148; means the period of time, established by the Committee in
connection with an award of Restricted Stock, during which the shares of Restricted Stock are
subject to a Risk of Forfeiture described in the applicable award agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.13 &#147;Risk of Forfeiture&#148; means a limitation on the right of the Participant to retain
Restricted Stock, including a right in the Company to reacquire shares of Restricted Stock at less
than their then Fair Market Value, arising because of the occurrence or non-occurrence of specified
events or conditions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.14 &#147;Restricted Stock&#148; shall mean Stock of the Company awarded to a Director under this Plan
from time to time in the sole discretion of the Committee subject to various restrictions, vesting
schedules and such other conditions on ownership as the Committee shall determine.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15 &#147;Stock&#148; shall mean common stock of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.16 &#147;Stock Grant&#148; shall mean an award of Stock of the Company granted in full and
unrestricted ownership from time to time in the sole discretion of the Committee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>3. Shares of Stock Subject to the Plan</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 The Company may issue up to 125,000 shares of Stock, subject to the adjustment provisions
of Section&nbsp;8, in Awards granted hereunder. Such shares may be either authorized but unissued
shares or shares issued and thereafter acquired by the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 To the extent any shares of Stock: (i)&nbsp;subject to an Option are not issued because the
Option is forfeited or cancelled or (ii)&nbsp;subject to a Restricted Stock Grant are redeemed,
forfeited, cancelled, repurchased or otherwise retained by the Company, such shares shall again be
available for grant pursuant to the Plan. If the exercise price of any Option granted under this
Plan is satisfied by tendering shares of Stock to the Company (by either actual delivery or by
attestation), only the number of shares of Stock issued net of the shares of Stock tendered shall
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">be deemed delivered for purposes of determining the maximum number of shares of Stock available for
delivery under the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>4. Administration of the Plan</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 The Plan shall be administered by the Committee, which shall have the power to interpret
the Plan and, subject to its provisions, to prescribe, amend and rescind Plan rules and to make all
other determinations necessary for the Plan&#146;s administration.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 All action taken by the Committee in the administration and interpretation of the Plan
shall be final and binding upon all parties. No member of the Committee will be liable for any
action or determination made in good faith by the Committee with respect to the Plan or any Option.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 The Committee may grant Options or make Restricted Stock Grants or Stock Grants in its
sole discretion. No member of the Committee may vote on an Award to himself or herself.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>5. Terms and Conditions of Options</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 Unless exercisability is accelerated as provided in Section&nbsp;9.2 hereof, each Option shall
become exercisable on the date it vests.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 Unless terminated earlier as provided in Section&nbsp;5.5, the Options shall expire in up to
ten years following the date of grant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 The exercise price of each Option granted to Directors shall be equal to the Fair Market
Value, as defined herein, of a share of Stock on the date of grant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 The Committee shall determine the vesting period for Options granted under this Plan and
shall specify such vesting period in writing in making an award of an Option under this Plan.
However, should the Committee award Options under this Plan without specifying a vesting period,
then the vesting period shall be five years, with 20% of the Options to vest on each anniversary of
the date of grant until all Options granted hereunder are vested.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5 If a Director ceases to serve on the Board for any reason, the Options granted hereunder
must be exercised, to the extent otherwise exercisable at the time of termination of his or her
Board service, within two years from the date of termination of Board service. Any Options awarded
to a Director and not yet vested at the time of termination of his or her Board service shall, be
forfeited, automatically cancelled and of no further force and effect. Such forfeiture and
automatic cancellation shall take effect at midnight on the date that the Director&#146;s Board service
is terminated.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6 An Option may be exercised by giving written notice , specifying the number of shares of
Stock to be purchased. The procedure for exercise of each Option awarded under this
Plan will be set forth in the granting document for such Option. The Committee may, from time to
time, amend the exercise procedures, in which case Participants will be notified of such
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">revised procedures. The exercise notice shall be accompanied by tender of the full purchase price for such
shares, which may be paid or satisfied by (a)&nbsp;cash; (b)&nbsp;check; (c)&nbsp;delivery of shares of Stock,
which shares shall be valued for this purpose at the Fair Market Value on the business day
immediately preceding the date such Option is exercised and, unless otherwise determined by the
Committee, shall have been held by the optionee for at least six months; or (d)&nbsp;in such other
manner as may be authorized from time to time by the Committee. All such payments shall be made or
denominated in United States dollars. In the case of delivery of an uncertified check, no shares
shall be issued until the check has been paid in full. Prior to the issuance of shares of Stock
upon the exercise of an Option, a Participant shall have no rights as a shareholder with respect to
such Option.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7 Except for adjustments pursuant to Section&nbsp;8 or actions permitted to be taken by the
Board under Section&nbsp;9 in the event of a Change of Control, unless approved by the shareholders of
the Company, (a)&nbsp;the exercise price for any outstanding Option granted under this Plan may not be
decreased after the date of grant and (b)&nbsp;an outstanding Option that has been granted under this
Plan may not, as of any date that such Option has a per share exercise price that is less than the
then current Fair Market Value of a share of Stock, be surrendered to the Company as consideration
for the grant of a new Option with a lower exercise price or any payment of cash or Stock. No
Option or other Award made under this Plan may ever under any circumstances be backdated.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8 Upon approval of the Committee, the Company may repurchase all or a portion of a
previously granted Option from a Participant by mutual agreement before such option has been
exercised by payment to the Participant of cash or Stock or a combination thereof with a value
equal to the amount per share by which: (a)&nbsp;the Fair Market Value of the Stock subject to the
Option on the business day immediately preceding the date of purchase exceeds (b)&nbsp;the exercise
price.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.9 Any person who receives a grant of Options under this Plan may be required, at the time
the Options are awarded, to sign a consent allowing the Board, in its discretion, to cancel the
Options if the Fair Market Value of the Stock decreases such that the exercise price of the Options
is significantly above the Fair Market Value of the Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>6. Terms and Conditions of Restricted Stock Grants</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Committee may award Restricted Stock to a Director. All shares of Restricted Stock
granted shall be subject to a Risk of Forfeiture as determined by the Committee, and shall
additionally be subject to the following terms and conditions and such other terms and conditions
as the Committee may prescribe.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <U><I>Requirement of Board Service</I></U>. A grantee of Restricted Stock must remain on the
Board during the Restriction Period in order to retain the shares of Restricted Stock. If the
Director leaves the Board prior to the end of the Restriction Period, the Restricted Stock award
shall terminate and the shares of Restricted Stock shall be returned immediately to the Company,
effective at midnight on the date the Director&#146;s Board service ends.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <U><I>Restrictions on Transfer and Legend on Stock Certificates</I></U>. During the
Restriction Period, the Director may not sell, assign, transfer, pledge, or otherwise dispose of
the shares of Restricted Stock except as expressly permitted in this Plan. Each certificate for
shares of Restricted Stock issued hereunder shall contain a legend giving appropriate notice of the
restrictions in the grant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <U><I>Escrow Agreement</I></U>. The Committee may require the grantee to enter into an escrow
agreement providing that the certificates representing the Restricted Stock award will remain in
the physical custody of an escrow holder until all restrictions are removed or expire.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <U><I>Lapse of Restrictions</I></U>. In the document granting Restricted Stock, the Committee
will specify the Restriction Period. If no Restriction Period is specified in a document granting
Restricted Stock, then twenty percent (20%) of the Restricted Stock awarded under that granting
document will become free of restriction on each anniversary date of the grant for five (5)&nbsp;years.
All restrictions imposed on the Restricted Stock shall lapse upon the expiration of the Restriction
Period if the conditions of the grant have been met. The Director shall then be entitled to have
the legend removed from the certificates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <U><I>Dividends and Voting</I></U>. Dividends declared on the Stock during the Restriction
Period will be accumulated by the Company and paid to the Director if he becomes owner of the such
stock without restriction. If the Restricted Stock reverts to the Company, then the Company will
become the owner of all dividends accumulated in accordance with the preceding sentence. The
Director will be entitled to vote all shares of Restricted Stock during the Restriction Period.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>7. Terms and Conditions of Stock Grant</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Committee may make a Stock Grant to a Director under this Plan on such terms and
conditions as it sees fit, subject to the provisions of all applicable laws and regulations.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>8. Adjustment Provisions</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any recapitalization, reclassification, stock dividend, stock split,
combination of shares or other change in the Stock, the Committee shall equitably adjust all
limitations on numbers of shares of Stock provided in this Plan, and the number of shares subject
to outstanding Awards, with such adjustments made in proportion to the change in outstanding shares
of Stock. In addition, in the event of any such change in the Stock, the Committee shall make any
other adjustment that it determines to be equitable, including without limitation adjustments to
the exercise price of any Option in order to provide Participants with the same relative rights
before and after such adjustment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>9. Change of Control</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 &#147;Change of Control Event&#148; shall mean:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;any merger or consolidation that results in the voting securities of the Company
outstanding immediately prior thereto representing (either by remaining outstanding or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">by being
converted into voting securities of the surviving or acquiring entity) less than 50% of the
combined voting power of the voting securities of the Company or such surviving or acquiring entity
outstanding immediately after such merger or consolidation; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;the acquisition by an individual, entity or group (within the meaning of Section&nbsp;13(d)(3)
or 14(d)(2) of the Exchange Act) (a &#147;Person&#148;) of beneficial ownership of any capital stock of the
Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule&nbsp;13d-3
promulgated under the Exchange Act) 51% or more of either (A)&nbsp;the then-outstanding shares of Stock
of the Company (the &#147;Outstanding Company Stock&#148;), or (B)&nbsp;the combined voting power of the
then-outstanding voting securities of the Company entitled to vote generally in the election of
Directors (the &#147;Outstanding Company Voting Securities&#148;). However, for purposes of this subsection
(b), the following acquisitions shall not give rise to a Change of Control event: (A)&nbsp;any
acquisition directly from the Company, (B)&nbsp;any acquisition by the Company, (C)&nbsp;any acquisition by
any employee benefit plan (or related trust) sponsored or maintained by the Company or an
Affiliate, or (D)&nbsp;any acquisition by any Person pursuant to a transaction that results in all or
substantially all of the individuals and entities who were the beneficial owners of 50&nbsp;percent or
more of the Outstanding Company Stock and Outstanding Company Voting Securities immediately prior
to such transaction beneficially owning, directly or indirectly, more than 50% of the
then-outstanding shares of Stock and the combined voting power of the then-outstanding voting
securities entitled to vote generally in the election of directors, respectively, of the resulting
or acquiring Person in such transaction (which shall include, without limitation, a Person that as
a result of such transaction owns the Company or substantially all of the Company&#146;s assets either
directly or through one or more subsidiaries) in substantially the same proportions as their
ownership, immediately prior to such transaction, of the Outstanding Company Stock and Outstanding
Company Voting Securities, respectively;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;any sale of all or substantially all of the assets of the Company; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;the complete liquidation of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 <U><I>Effect on Options</I></U>. Upon the occurrence of a Change in Control Event, each
outstanding Option shall vest in full and shall become immediately exercisable. Any agreement with
respect to a Change in Control Event must provide that all outstanding Options shall be assumed, or
equivalent options shall be substituted, by the acquiring or succeeding corporation (or an
Affiliate thereof), if applicable. For purposes of this section, an Option shall be considered to
be assumed if, following consummation of the Change in Control Event, the Option confers the right
to purchase, for each share of Stock subject to the Option immediately prior to the consummation of
the Change in Control Event, the consideration (whether cash, securities or other property)
received as a result of the Change in Control Event by holders of Stock for each share of Stock
held immediately prior to the consummation of the Change in Control Event (and if holders were
offered a choice of consideration, the type of consideration chosen by the holders of a majority of
the outstanding shares of Stock). However, if the consideration received as a
result of the Change in Control Event is not solely Stock of the acquiring or succeeding
entity (or an Affiliate thereof), the Company may, with the consent of the acquiring or
succeedingentity, provide for the consideration to be received upon the exercise of Options to
consist solely of Stock of the acquiring or succeeding entity (or an Affiliate thereof) equivalent
in Fair Market
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Value to the per share consideration received by holders of outstanding shares of
Stock as a result of the Change in Control Event. Notwithstanding the foregoing, if the acquiring
or succeeding entity (or an Affiliate thereof), does not agree to assume such Options, or
substitute equivalent options for such Options, then the Board shall, upon written notice to the
Option holders, provide that all then unexercised Options will become exercisable in full as of a
specified time prior to the Change in Control Event and will terminate immediately prior to the
consummation of such Change in Control Event, except to the extent exercised by the Option holders
before the consummation of such Change in Control Event. However, in the event of an Change in
Control Event under the terms of which holders of Stock will receive upon consummation thereof a
cash payment for each share of Stock surrendered pursuant to such Change in Control Event (the
&#147;Acquisition Price&#148;), then the Board may instead provide that all outstanding Options shall
terminate upon consummation of such Change&nbsp;in Control Event and that each Option holder
shall receive, in exchange therefor, a cash payment equal to the amount (if any) by which (A)&nbsp;the
Acquisition Price multiplied by the number of shares of Stock subject to such outstanding Options
(whether or not then exercisable), exceeds (B)&nbsp;the aggregate exercise price of such Options.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3 <U><I>Effect on Restricted Stock.</I></U> Upon the occurrence of a Change in Control Event, all
restrictions and conditions on all Restricted Stock awards then outstanding shall automatically be
deemed terminated or satisfied and all such Restricted Stock shall be fully vested.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>10. General Provisions</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 Nothing in the Plan or in any instrument executed pursuant to the Plan will confer upon
any Participant any right to continue as a Director.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 No shares of Stock will be issued or transferred pursuant to an Option unless and until
all then-applicable requirements imposed by federal and state securities and other laws, rules and
regulations and by any regulatory agencies having jurisdiction, and by any stock exchanges upon
which the Stock may be listed, have been fully met. As a condition precedent to the issuance of
shares pursuant to the exercise of an Option, the Company may require the Participant to take any
reasonable action to meet such requirements.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3 No Participant and no Person claiming under or through such Participant will have any
right, title or interest in or to any shares of Stock allocated or reserved under the Plan or
subject to any Option except as to such shares of Stock, if any, that have been issued or
transferred to such Participant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4 No Options or Restricted Stock awards granted hereunder may be transferred, pledged,
assigned or otherwise encumbered by Director except:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;by will;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;by the laws of descent and distribution; or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;if permitted by the Committee and so provided in the stock option agreement or an
amendment thereto, (i)&nbsp;to Immediate Family Members (as defined below), (ii)&nbsp;to a partnership in
which the Participant and/or the Participant&#146;s Immediate Family Members, or entities in which the
Participant and/or the Participant&#146;s Immediate Family Members are the owners, members or
beneficiaries, as appropriate, are the sole partners, (iii)&nbsp;to a limited liability company in which
the Participant and/or the Participant&#146;s Immediate Family Members, or entities in which the
Participant and/or the Participant&#146;s Immediate Family Members are the sole owners, members or
beneficiaries, as appropriate, are the sole members, or (iv)&nbsp;to a trust for the benefit solely of
the Participant and/or the Participant&#146;s Immediate Family Members. &#147;Immediate Family Members&#148; means
the spouses and natural or adopted children or grandchildren of the Participants, the spouses of
such children and grandchildren, and the siblings and parents of the Participants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any attempted assignment, transfer, pledge, hypothecation or other disposition of an Option or
Restricted Stock grant or levy of attachment, or similar process upon an Option or Restricted Stock
award not specifically permitted herein, shall be null and void and without effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.5 Each Award made under this Plan will be set forth in a written agreement that includes
terms and conditions consistent with the Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.6 Anything in the Plan to the contrary notwithstanding: (a)&nbsp;the Company may, if it shall
determine it necessary or desirable for any reason, at the time of grant of any Award or the
issuance of any shares of Stock pursuant to any Option, require the recipient of the Award, as a
condition to the receipt thereof or to the receipt of shares of Stock issued pursuant thereto, to
deliver to the Company a written representation of present intention to acquire the Award or the
shares of Stock issued pursuant thereto for his or her own account for investment and not for
distribution; and (b)&nbsp;if at any time the Company further determines, in its sole discretion, that
the listing, registration or qualification (or any updating of any such document) of any Award or
the shares of Stock issuable pursuant thereto is necessary on any securities exchange or under any
federal or state securities or blue sky law, or that the consent or approval of any governmental
regulatory body is necessary or desirable as a condition of, or in connection with the grant of any
Award, the issuance of shares of Stock pursuant thereto, or the removal of any restrictions imposed
on such shares, such Award shall not be granted or such shares of Stock shall not be issued or such
restrictions shall not be removed, as the case may be, in whole or in part, unless such listing,
registration, qualification, consent or approval shall have been effected or obtained free of any
conditions not acceptable to the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.7 Any definition set forth in this Plan of the singular form of a term shall also apply to
the plural form of that term, and any definition of the plural form of a term shall also apply to
the singular form of the term. Any reference in this Plan to one gender shall also include the
other gender.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>11. Amendments, Discontinuance or Termination of the Plan</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.1 The Board may amend or discontinue the Plan at any time; provided, however, that no such
amendment may:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;without the approval of the shareholders, (i)&nbsp;increase, subject to adjustments permitted
herein, the maximum number of shares of Stock that may be issued through the Plan, (ii)&nbsp;materially
increase the benefits accruing to Participants under the Plan, (iii)&nbsp;materially expand the classes
of persons eligible to participate in the Plan, or (iv)&nbsp;amend Section&nbsp;5.7 to permit repricing of
Options; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;materially impair, without the consent of the recipient, an Option previously granted or a
Restricted Stock grant previously made, except that the Company retains all rights under Section&nbsp;8
hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.2
The Plan shall automatically terminate on the <U>earlier</U> of the following dates:
(1)&nbsp;ten years from the date that the Plan becomes effective, or (2)&nbsp;at such time as no shares of
Stock remain available for issuance through the Plan. No termination of the Plan will affect the
terms of any outstanding Options or shares of Restricted Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>12. Governing Law</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this Plan and all awards made under this Plan shall be governed by and
interpreted in accordance with the law of the State of Tennessee, without regard to applicable
conflicts of law principles.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>13. Additional Requirements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anything in the Plan to the contrary notwithstanding: (a)&nbsp;the Company may, if it shall
determine it necessary or desirable for any reason, at the time of grant of any Incentive or the
issuance of any shares of Stock pursuant to any Option, require the recipient of the Incentive, as
a condition to the receipt thereof or to the receipt of shares of Stock issued pursuant thereto, to
deliver to the Company a written representation of present intention to acquire the Incentive or
the shares of Stock issued pursuant thereto for his or her own account for investment and not for
distribution; and (b)&nbsp;if at any time the Company further determines, in its sole discretion, that
the listing, registration or qualification (or any updating of any such document) of any Incentive
or the shares of Stock issuable pursuant thereto is necessary on any securities exchange or under
any federal or state securities or blue sky law, or that the consent or approval of any
governmental regulatory body is necessary or desirable as a condition of, or in connection with the
grant of any Incentive, the issuance of shares of Stock pursuant thereto, or the removal of any
restrictions imposed on such shares, such Incentive shall not be granted or such shares of Stock
shall not be issued or such restrictions shall not be removed, as the case may be, in whole or in
part, unless such listing, registration, qualification, consent or approval shall have been
effected or obtained free of any conditions not acceptable to the Company.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>14. &#147;Lockup&#148; Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Committee may in its discretion require that upon request of the Company or the
underwriters managing any underwritten offering of the Company&#146;s securities, the Participant shall
agree in writing that for a period of time (not to exceed 180&nbsp;days) from the effective date of any
registration of securities of the Company, the Participant will not sell, make any short sale of,
loan, grant any option for the purchase of, or otherwise dispose of any shares of Stock issued or
issuable pursuant to the exercise of such Incentive, without the prior written consent of the
Company or such underwriters, as the case may be.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>15. Limitation of Liability</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each member of the Committee shall be entitled to, in good faith, rely or act upon any report
or other information furnished to him or her by any officer or other employee of the Company or any
Affiliate, the Company&#146;s independent certified public accountants, or other professional retained
by the Company to assist in the administration of the Plan. No member of the Committee, nor any
officer, director or employee of the Company acting on behalf of the Committee, shall be personally
liable for any action, determination, or interpretation taken or made in good faith with respect to
the Plan, and all members of the Committee and any officer, director or employee of the Company
acting on behalf of the Committee shall, to the extent permitted by law, be fully indemnified and
protected by the Company with respect to any such action, determination, or interpretation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>16. Unfunded Status of Incentives</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Plan is intended to constitute an &#147;unfunded&#148; plan for incentive compensation. With
respect to any payments not yet made to a Participant pursuant to an Incentive, nothing contained
in the Plan or any Incentive shall give any such Participant any rights that are greater than those
of a general creditor of the Company; <U>provided</U>, <U>however</U><I>, </I>that the Committee may
authorize the creation of trusts or make other arrangements to meet the Company&#146;s obligations under
the Plan to deliver cash, shares of Stock, other Incentives, or other property pursuant to any
Incentive, which trusts or other arrangements shall be consistent with the &#147;unfunded&#148; status of the
Plan unless the Committee otherwise determines with the consent of each affected Participant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>17. Nonexclusivity of the Plan</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the adoption of the Plan by the Board nor its submission to the stockholders of the
Company for approval shall be construed as creating any limitations on the power of the Board to
adopt such other incentive arrangements as it may deem desirable, including, without limitation,
arrangements granting incentives otherwise than under the Plan, and such
arrangements may be either applicable generally or only in specific cases.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>18. Successors and Assigns</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Plan shall be binding on all successors and assigns of the Company and a Participant,
including, without limitation, the estate of such Participant and the executor, administrator or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">trustee of such estate, and any receiver or trustee in bankruptcy or representative of the
Participant&#146;s creditors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>19. No Fractional Shares</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No fractional shares of Stock shall be issued or delivered pursuant to the Plan or any
Incentive, including on account of any action under Section 6(d) of the Plan. In lieu of such
fractional shares, the Committee shall determine, in its discretion, whether cash, other
Incentives, scrip certificates (which shall be in a form and have such terms and conditions as the
Committee in its discretion shall prescribe) or other property shall be issued or paid in lieu of
such fractional shares or whether such fractional shares or any rights thereto shall be forfeited
or otherwise eliminated.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>20. Severability</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any provision of the Plan is or becomes or is deemed invalid, illegal or unenforceable in
any jurisdiction, or would disqualify the Plan or any Incentive under any law deemed applicable by
the Committee, such provision shall be construed or deemed amended to conform to applicable laws or
if it cannot be construed or deemed amended without, in the determination of the Committee,
materially altering the intent of the Plan, it shall be stricken and the remainder of the Plan
shall remain in full force and effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>21. Effective Date of Plan</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Plan shall become effective upon adoption by the Board, subject to approval by the holders
of a majority of the shares of Stock and the Company&#146;s Series&nbsp;A Preferred Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned Corporate Secretary of Cumberland Pharmaceuticals Inc.
hereby certifies that the foregoing Cumberland Pharmaceuticals Inc. 2007 Directors&#146; Incentive Plan
was (i)&nbsp;approved by the Board in a Unanimous Consent of Directors dated as of January&nbsp;16, 2007, and
(ii)&nbsp;approved by majority of the holders of all of the Company&#146;s outstanding common and preferred
stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dated: April&nbsp;18, 2007 (Section&nbsp;5.2 amended, effective March&nbsp;22, 2010)
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>

    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>

    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>

    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Jean W. Marstiller
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>

    <TD colspan="3" align="left">Jean W. Marstiller&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>

    <TD colspan="3" align="left" nowrap>Senior Vice President, Administrative Services<br>
and Corporate Secretary&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21.2
<SEQUENCE>7
<FILENAME>g23297exv10w21w2.htm
<DESCRIPTION>EX-10.21.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w21w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.21.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">*Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>SECOND AMENDMENT TO OFFICE LEASE AGREEMENT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS SECOND AMENDMENT TO OFFICE LEASE AGREEMENT (this &#147;<B><I>Amendment</I></B>&#148;) is entered into between
<B>2525 WEST END, LLC</B>, a Delaware limited liability company (&#147;<B><I>Landlord</I></B>&#148;), and <B>CUMBERLAND
PHARMACEUTICALS INC.</B>, a Tennessee corporation (&#147;<B><I>Tenant</I></B>&#148;), with reference to the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;Nashville Hines Development, LLC (predecessor-in-interest to Landlord) and Tenant entered
into that certain Office Lease Agreement dated September&nbsp;10, 2005; Landlord and Tenant entered into
that certain First Amendment to Office Lease Agreement dated April&nbsp;25, 2008 (as amended, the
&#147;<B><I>Lease</I></B>&#148;) currently covering approximately 9,291 RSF on the ninth (9th) floor (the &#147;<B><I>Original
Premises</I></B>&#148;) of 2525 West End Avenue, Nashville, Tennessee (the &#147;<B><I>Building</I></B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;Landlord and Tenant now desire to further amend the Lease as set forth below. Unless
otherwise expressly provided in this Amendment, capitalized terms used in this Amendment shall have
the same meanings as in the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOR GOOD AND VALUABLE CONSIDERATION, the receipt and sufficiency of which are acknowledged,
the parties agree as follows:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1. Expansion Space</B>. Landlord leases to Tenant and Tenant leases from Landlord: (a)&nbsp;approximately
14,477 additional RSF located on the ninth (9th) floor of the Building (the &#147;<B><I>Second Expansion
Space</I></B>&#148;) as shown on the attached <U><B>Exhibit &#147;A&#148;</B></U>, which is incorporated into this Amendment for
all purposes, and (b)&nbsp;approximately 1,755 additional RSF located on the ninth (9th) floor of the
Building (the &#147;<B><I>Third Expansion Space</I></B>&#148;) as shown on the attached <U><B>Exhibit &#147;A&#148;</B></U>. The term
&#147;<B><I>Premises</I></B>&#148; as used in the Lease means and includes approximately 25,523 RSF, being the sum of the
RSF of the Original Premises (9,291 RSF), the Second Expansion Space and the Third Expansion Space.
The lease of the Second Expansion Space and Third Expansion Space is subject to all of the terms
and conditions of the Lease currently in effect, except as modified in this Amendment. Tenant
acknowledges that it has no further expansion or preferential rights or options under the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2. Second Extension Period</B>. The Term of the Lease for the entire Premises shall be extended until
October&nbsp;31, 2016. Tenant acknowledges that it has no further extension or renewal rights or options
under the Lease except as set forth in <U><B>Rider 1</B></U> attached to this Amendment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3. Base Rental</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Commencing on April&nbsp;1, 2010, and continuing through the Second Extension Period, Tenant
shall, at the time and place and in the manner provided in the Lease, pay to Landlord as Base
Rental for the Third Expansion Space the amounts set forth in the following rent schedule, plus any
applicable tax thereon:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>PERIOD</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Rate</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Monthly Base Rental</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">April&nbsp;1, 2010 through May&nbsp;31, 2010
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">June&nbsp;1, 2010 through October&nbsp;31, 2010
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">(b)</TD>
    <TD>&nbsp;</TD>
    <TD>Notwithstanding anything in the Lease to the contrary, commencing on November&nbsp;1, 2010, and
continuing through the Second Extension Period, Tenant shall, at the time and place and in the
manner provided in the Lease, pay to Landlord as Base Rental for the Original Premises, the Second
Expansion Space and the Third Expansion Space the amounts set forth in the following rent schedule,
plus any applicable tax thereon:</TD>
</TR>

</TABLE>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>PERIOD</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Rate</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Monthly Base Rental</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">November&nbsp;1, 2010 through December&nbsp;31, 2011
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">January&nbsp;1, 2012 through December&nbsp;31, 2012
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">January&nbsp;1, 2013 through December&nbsp;31, 2013
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">January&nbsp;1, 2014 through December&nbsp;31, 2014
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">January&nbsp;1, 2015 through December&nbsp;31, 2015
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">January&nbsp;1, 2016 through October&nbsp;31, 2016
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$ &#091;***&#093;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4. Additional Rent</B>. Commencing on April&nbsp;1, 2010 and continuing through the Second Extension
Period, Tenant&#146;s Additional Rental payable under Section&nbsp;2.3 of the Lease shall be increased to
take the Third Expansion Space into account, and commencing November&nbsp;1, 2010 and continuing through
the Second Extension Period, Tenant&#146;s Additional Rental shall be increased to take the Second
Expansion Space into account. Commencing on November&nbsp;1, 2010, the Expense Stop for the entire
Premises, refers to Landlord absorbing and being responsible for paying Operating Expenses (as
defined in the Lease) during any calendar year to the extent such Operating Expenses are less than
Nine and 45/100 Dollars ($9.45) per square foot of space in the Building leased to rent paying
tenants as such term is used in Section&nbsp;2.3(c) of the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5. Condition of the Second Expansion Space and Third Expansion Space</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Tenant accepts the Second Expansion Space in its &#147;as-is&#148; condition. Tenant acknowledges
that Landlord has not undertaken to perform any modification, alteration or improvement to the
Second Expansion Space. <FONT style="FONT-variant: SMALL-CAPS"><B>By taking possession of the Second Expansion Space, Tenant waives</B>
</FONT><B>(i)</B><FONT style="FONT-variant: SMALL-CAPS"><B> any claims due to defects in the Second Expansion Space; </B><U><B>and</B></U></FONT> <B>(ii) </B><FONT style="FONT-variant: SMALL-CAPS"><B>all
express and implied warranties of suitability, habitability and fitness for any particular
purpose</B></FONT><B>. </B>Tenant waives the right to terminate the Lease due to the condition of the Second
Expansion Space.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Tenant accepts the Third Expansion Space in its &#147;as-is&#148; condition. Tenant acknowledges
that Landlord has not undertaken to perform any modification, alteration or
improvement to the Third Expansion Space. <FONT style="FONT-variant: SMALL-CAPS"><B>By taking possession of the Third Expansion
Space, Tenant waives </B></FONT><B>(i)</B><FONT style="FONT-variant: SMALL-CAPS"><B> any claims due to defects in the Third Expansion Space;</B>
<U><B>and</B></U></FONT> <B>(ii) </B><FONT style="FONT-variant: SMALL-CAPS"><B>all express and implied warranties of suitability, habitability and
fitness for any particular purpose</B></FONT><B>. </B>Tenant waives the right to terminate the Lease due to the
condition of the Third Expansion Space.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6. Parking</B>. In connection with the Second Expansion Space, Landlord hereby agrees to make
available, or to cause the Garage Operator to make available, to Tenant (so long as Tenant shall
continue to lease the Second Expansion Space) up to 58 permits (&#147;<B><I>Second Expansion Space Permits</I></B>&#148;)
to park in the Kensington Parking Facility upon the terms and conditions set forth in Section&nbsp;3.4
of the Lease. In connection with the Third Expansion Space, Landlord hereby agrees to make
available, or to cause the Garage Operator to make available, to Tenant (so long as Tenant shall
continue to lease the Third Expansion Space) up to 7 permits (&#147;<B><I>Third Expansion Space Permits</I></B>&#148;) to
park in the Kensington Parking Facility upon the terms and conditions set forth in Section&nbsp;3.4 of
the Lease. Tenant shall pay as rental for the Second Expansion Space Permits and the Third
Expansion Space Permits at the rate charged from time to time by Landlord (or the Garage Operator),
in its sole and absolute discretion, plus any applicable taxes thereon. The current charge to
Tenant for each Second Expansion Space Permit and Third Expansion Space Permit is $45.00 per month,
plus any applicable taxes thereon.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7. Second Amendment Improvement Allowance</B>. Tenant shall receive an improvement allowance in the
amount of $&#091;***&#093; per RSF in the Original Premises and the Second Expansion Space (i.e., $&#091;***&#093;, the
&#147;<B><I>Second Amendment Improvement Allowance</I></B>&#148;) to be paid to Tenant within thirty (30)&nbsp;days after Tenant
pays to Landlord the monthly Base Rental payment for November&nbsp;1, 2010, provided that Tenant is not
then in default under the Lease. The Second Amendment Improvement Allowance may be used for any
costs relating to the Premises. However, Tenant shall not install any improvements which are not
compatible with Landlord&#146;s plans and specifications for the Building or which have not received
prior written approval by Landlord or Landlord&#146;s architect. Tenant agrees to comply with the terms
of Section&nbsp;5.1 of the Lease with respect to any Tenant work that is performed in the Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8. Consent</B>. This Amendment is subject to, and conditioned upon, any required consent or approval
being unconditionally granted by Landlord&#146;s mortgagee(s). If any such consent shall be denied, or
granted subject to an unacceptable condition, this Amendment shall be null and void and the Lease
shall remain unchanged and in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>9. No Broker</B>. Tenant represents and warrants that it has not been represented by any broker or
agent in connection with the execution of this Amendment. Tenant shall indemnify and hold harmless
Landlord and its designated property management, construction and marketing firms, and their
respective partners, members, affiliates and subsidiaries, and all of their respective officers,
directors, shareholders, employees, servants, partners, members, representatives, insurers and
agents from and against all claims (including costs of defense and investigation) of any broker or
agent or similar party claiming by, through or under Tenant in connection with this Amendment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>10. Time of the Essence</B>. Time is of the essence with respect to Tenant&#146;s execution and delivery to
Landlord of this Amendment. If Tenant fails to execute and deliver a signed copy of
this Amendment to Landlord by 5:00 p.m. (in the city in which the Premises is located) on
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2010, this Amendment shall be deemed null and void and shall have no force or effect,
unless otherwise agreed in writing by Landlord. Landlord&#146;s acceptance, execution and return of
this Amendment shall constitute Landlord&#146;s agreement to waive Tenant&#146;s failure to meet such
deadline.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>11. Miscellaneous</B>. This Amendment shall become effective only upon full execution and delivery of
this Amendment by Landlord and Tenant. This Amendment contains the parties&#146; entire agreement
regarding the subject matter covered by this Amendment, and supersedes all prior correspondence,
negotiations, and agreements, if any, whether oral or written, between the parties concerning such
subject matter. There are no contemporaneous oral agreements, and there are no representations or
warranties between the parties not contained in this Amendment. Except as modified by this
Amendment, the terms and provisions of the Lease shall remain in full force and effect, and the
Lease, as modified by this Amendment, shall be binding upon and shall inure to the benefit of the
parties hereto, their successors and permitted assigns.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signatures to follow&#093;
</DIV>






<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LANDLORD AND TENANT enter into this Amendment as of the Effective Date (below).
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><B>LANDLORD:</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left"><B>2525 WEST END, LLC</B>, a Delaware limited liability company</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">Cash Flow Asset Management, L.P.,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">a Texas limited partnership, its sole manager</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CFAM GP, L.L.C.,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">a Texas limited liability company, its sole general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel D. Dubrowski
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Daniel D. Dubrowski
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Effective Date: March&nbsp;2, 2010</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><B>TENANT:</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left"><B>CUMBERLAND PHARMACEUTICALS INC., </B>a Tennessee corporation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">/s/ A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">Name: A.J. Kazimi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">Title: Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT &#147;A&#148;</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>SECOND EXPANSION SPACE AND</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>THIRD EXPANSION SPACE</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><IMG src="g23297g2329701.gif" alt="(GRAPHIC)">
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->A-i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Rider One</B></U>
</div>
<DIV align="center" style="font-size: 10pt; margin-top: 6pt">
<B>OPTION TO EXTEND</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U><B>Renewal Period</B></U>. Tenant may, at its option, extend the Second Extension Period
(this &#147;<B><I>Option to Extend</I></B>&#148;) for one renewal period of six years (the &#147;<B><I>Renewal Period</I></B>&#148;) by written
notice to Landlord (the &#147;<B><I>Renewal Notice</I></B>&#148;) given no earlier than 18&nbsp;months nor later than 12&nbsp;months
prior to the expiration of the Second Extension Period, provided that at the time of such notice
and at the commencement of such Renewal Period, (i)&nbsp;Tenant remains in occupancy of the entire
Premises, and (ii)&nbsp;no uncured event of default exists under the Lease. The Base Rental payable
during the Renewal Period shall be the Market Rental Rate (defined below) for the Premises.
However, in no event shall the Base Rental for the Renewal Period be less than the Base Rental
during the last year of the Second Extension Period. Except as provided in this <U><B>Rider One</B></U>
all terms and conditions of the Lease shall continue to apply during the Renewal Period, except
that Tenant shall have no further option to extend the Term.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U><B>Acceptance</B></U>. Within 30&nbsp;days of the Renewal Notice, Landlord shall notify Tenant of
the Base Rental for such Renewal Period (the &#147;<B><I>Rental Notice</I></B>&#148;). Tenant may accept the terms set
forth in the Rental Notice by written notice (the &#147;<B><I>Acceptance Notice</I></B>&#148;) to Landlord given within 15
days after receipt of the Rental Notice. If Tenant timely delivers its Acceptance Notice, Tenant
shall, within 15&nbsp;days after receipt, execute a lease amendment confirming the Base Rental and other
terms applicable during the Renewal Period. If Tenant fails timely to deliver its Acceptance
Notice, then this Option to Extend shall automatically expire and be of no further force or effect.
In addition, this Option to Extend is personal to Cumberland Pharmaceuticals Inc. and shall not be
assignable to any other person or entity. Any assignment of the Lease or the subletting by Tenant
of all or any portion of the Premises shall terminate this Option to Extend. Any assignment in
violation of this paragraph is void and of no force or effect. Furthermore, this Option to Extend
shall be voidable at Landlord&#146;s election if (i)&nbsp;Tenant fails timely to execute and return the
required lease amendment, or (ii)&nbsp;an uncured event of default exists under the Lease or Tenant
fails to occupy the entire Premises at the commencement of the Renewal Period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U><B>Market Rental Rate</B></U>. The &#147;<B><I>Market Rental Rate</I></B>&#148; is the rate (or rates) a willing
tenant would pay and a willing landlord would accept for a comparable transaction (e.g., renewal,
expansion, relocation, etc., as applicable, in comparable space and in a comparable building) as of
the commencement date of the applicable term, neither being under any compulsion to lease and both
having reasonable knowledge of the relevant facts, considering the highest and most profitable use
if offered for lease in the open market with a reasonable period of time in which to consummate a
transaction. In calculating the Market Rental Rate, all relevant factors will be taken into
account, including the location and quality of the Building, lease term, amenities of the Building,
condition of the space and any concessions and allowances commonly being offered by Landlord for
comparable transactions in the Building. The parties agree that the best evidence of the Market
Rental Rate will be the rate then charged for comparable transactions in the Building.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->R-1-i<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>g23297exv31w1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv31w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;31.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER<BR>
PURSUANT TO SECTION 302 OF<BR>
THE SARBANES-OXLEY ACT OF 2002</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">I, A.J. Kazimi, certify that:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and
15d-15(e)) for the registrant and have:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such disclosure controls and procedures, or caused such disclosure controls
and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being
prepared;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such
evaluation; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Disclosed in this report any change in the registrant&#146;s internal control over financial
reporting that occurred during the registrant&#146;s most recent fiscal quarter (the
registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant&#146;s internal control
over financial reporting; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the
audit committee of the registrant&#146;s board of directors (or persons performing the equivalent
functions):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect
the registrant&#146;s ability to record, process, summarize and report financial information;
and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant&#146;s internal control over financial reporting.</TD>
</TR>

</TABLE>
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">May 17, 2010&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left"><I>/s/ A.J. Kazimi</I>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">A.J. Kazimi&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>g23297exv31w2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv31w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: Helvetica,Arial,sans-serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;31.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER<BR>
PURSUANT TO SECTION 302 OF<BR>
THE SARBANES-OXLEY ACT OF 2002</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">I, David L. Lowrance, certify that:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and
15d-15(e)) for the registrant and have:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such disclosure controls and procedures, or caused such disclosure controls
and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being
prepared;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such
evaluation; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Disclosed in this report any change in the registrant&#146;s internal control over financial
reporting that occurred during the registrant&#146;s most recent fiscal quarter (the
registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant&#146;s internal control
over financial reporting; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the
audit committee of the registrant&#146;s board of directors (or persons performing the equivalent
functions):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect
the registrant&#146;s ability to record, process, summarize and report financial information;
and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant&#146;s internal control over financial reporting.</TD>
</TR>

</TABLE>
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">May 17, 2010&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left"><I>/s/ David L. Lowrance</I>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">David L. Lowrance&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Vice President and Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>g23297exv32w1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv32w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: Helvetica,Arial,sans-serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;32.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND<BR>
CHIEF FINANCIAL OFFICER<BR>
PURSUANT TO 18 U.S.C. SECTION 1350,<BR>
AS ADOPTED PURSUANT TO SECTION 906<BR>
OF THE SARBANES-OXLEY ACT OF 2002</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In connection with the Quarterly Report on Form 10-Q for the fiscal quarter ended September&nbsp;30,
2009 of Cumberland Pharmaceuticals Inc. (the &#147;Company&#148;), as filed with the Securities and Exchange
Commission on the date hereof (the &#147;Report&#148;), I, A.J. Kazimi, Chief Executive Officer, and David L.
Lowrance, Vice President and Chief Financial Officer, of the Company, certify, pursuant to
Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.</TD>
</TR>

</TABLE>
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">     <I>/s/ A.J. Kazimi</I>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">A.J. Kazimi&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">May 17, 2010&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">     <I>/s/ David L. Lowrance</I>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">David L. Lowrance&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Vice President and Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">May 17, 2010&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g23297g2329700.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23297g2329700.gif
M1TE&.#EABP'-`.8``+Z^O>WM[;"PL/'R\6-C8_7V]41$0\W-S30S,ZNKJY"0
MD&MJ:HN+BU-34H&!@>'AX=S<W'Q[>UQ;6^GJZ24D)-C9V$Q+2^7EY=76U7)Q
M<186%=+2TKFZN<7&Q;6UM2PK*_S]_,'!P3P[.YZ>G::EI<G*R9F9F9:5E1L;
M&H6%A0L+"G9U=?CY^**BHM[?WJ"@H/K[^OGZ^??X]_KZ^>?HYQ$1$//S\QD8
M&*"?GR$@(,/$PU%14#$Q,!\>'F]N;A<7%BDI*/#P\-_@WUE96#DX.$%`0$].
M3J2DHTE)2,?'QYB8F/3T]'!P<+"PKR<F)F%@8.3DY,S,S-O;VY.3DK2TM*BH
MJ%=75G-S<J^OKHB'AYR<FV=F9B\N+M/3T^OKZWAW>(^/CK^_OZ*BH>CHZ)24
ME-34U)R;G'=W=]S<VX2$A'1T='EY>+"OL,_/S^SL[+.SLJ"@G[.RLVEH:$=&
M1K>WMPX.#9>7E]W=W3\^/E]>7N/CXS8V-<C(R,O+RP<'!OO\^R'Y!```````
M+`````"+`<T```?_@"!_@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR1@IV@
MH:*CI*6FIZBIH9^JK:ZOL+&RL[2&K+6XN;J[O+VEM[[!PI(RP\;'G,#(R\AE
MS,_0C<K1U+A!5-79U-/:W:T>`M[BQMSCYJ(6X>?KN>7L[Y8Z?NKP]:[N]OF,
M05;S^O^F\`$<..B*'W\$$VX2J#`?DX,(&TJDQ'#BN1@A#$",:+&C-(__2DC8
M>)`>R).'*J*$5N&*$Y(03:Y<J7*FL`MT&.0!H@+F1IDV0=8,FJL`'P42N/A<
M"I2HQ:%.8[$`8*'&TJLEHYZ$JE45`"M6L8IMVC4AU[*DA#`@(K9M5K03_\_"
M[50A@MN['.<2E*L7TP,C/?&Z)=O7'M_"DR"LJ2,8+V'$[PY#=@2#!(_&@A]/
M/B=YLZ()>S`WUNQ97.?2A08HT"!Z-&K#KS=-(!"XM>/8\$ZCIJ'4MFO<['1[
MUH'"-V;2P*,)GUPEA_'CR=<M1^RA^//?T<=-[]NA]O7;V;6'=Z2#\7?LX[5M
MARL%R'D_=7+L,="``),(*10H>?%"@'\!$AA@P`[UK9"""1Y$,4%ZR*Q75A`[
M^%8#%T;(D0(6#TBB$58];*&%#D$PZ(N#72V`60\+C!#"!9EL>!<7>22PA(CM
MT&A(%.:)=<,<$30A!0N=N"C8#SN0(04,-L9"HO]3!82&U0U#D'%``:,(B1D%
M6\1!99*M+$G4"%>I,(0.J%C96@T.>,%E*E[:Y$)8&ZF`A!8AIF*F;35800>2
M:Y+2YDQ9P(1$%76J<J=O=3"!09^C_(G2`Q]L1$$"L1QJ7!T1%,KH0DDR`)$&
M"LP@BZ7/_6#'ILDDB<=!/!Q`"ZG7->`,JI@X"I(+!XFPY2RP7G=#"[1>8JM'
M*_AAA*BU]/H=$T`&.\FP'8E@!`VY*/M=$8LZZPF-+/30AB[6?B=""=I"`NU$
M+IBP2[C?Y3!KN8R<*Y$.,X+[WETU;`!OO#0.P`N[YVD0Q;Z*R!LLP`&C03`B
M!@<K0P`0!W`'!`=TP,'_$2G(@<0>.>1X71'(+DQ(PR(G$@0&`)"0Q186?."=
M8$/P63+))3<2PP,`F,`$$CT(I@)RJ-)<LR0/C(`$G%BIP.+,0U-30!(I.(>5
M%34+#=`&,@-D0PAJ4'`5-B);_4\;'4PT@@@^66!#V#0NP4.]$K6!`$POL$TC
M%U?L*A$'16R$A]TBYE&#`A[1$$%@*I!+L-C_<'"0`R!5<,-!0RS,^#_N^3&$
MWA*-@;8&EB?YT$$&`.#1`TCXX>J^E^L3!M),J&G1`SFLL7B2,!!`D@II:*H0
M'SS<GF02/MV0AY82+5`,O*WK`T,>2ZE@A!(5*"2$'JRO2</+,%'@0`59YQ-^
M_[#-_Z/%72A8D((+30?79PQ]"T8!$DR<P($4R[=?3?DA]6R;"G@XPPFPH`,I
M^$Y_PN#?/^AP+S^H``5<P`,2ZN.#*T3``5G`@09QP#X$PD*!_U!"`\'CP7N@
MB@4F&F%;@%;"3H`0($]0X5AV$0,H9"]8*92A3UB(BB/XBWG.&D`:=+A#74P`
M`<)S%@FX)T,>EB(&<C!"$IU5`J\1\2VU&.(;IN@L*4#OBDX4Q0S6H`(5!("+
MS@I"%I`VPC""H@`KZ`D10K>P`,1/A6[DA`NLZ`<&T%%D<8A4&V5!1HCT(']`
MK)D7LB"U]^3Q$@&P@R`AH@;`U8P%$?#?=QY)"2B<@/\U),E!MM!8L@((P$G/
MX20D9F`&`S#1#UE@F@=C```?\+$UJF1$!4;PA%O"Q`D+LJ0'(4"&'8`2.J#P
M`@<8,(1&8@4+56NA(0H0!5NBQQ(LP``))/`2P5`MFM)$Q`-R0@`\6.<J/)2!
M'J)`!RTX@`!(X$EK>/!#6893$4O8@`=,L(8M-*`(>Z!`#S2@@1'<X:`4JQ@`
MWI``'"@@#2O8P@Z*\(%C&N<'9!K:"[.#L/,HH7T;C4Y'K^-'D-X3$R,USAJ:
MU;20)B>EMI$#2UMZTDO`%#,JB$`)70J<FPH&!0D8GT9K:@F?WB4'IFLA3W%C
MU+;LX8S27&ILFHJ5$\!-J43_K015T[:Z>TKU-5O=2`^R<-5P?A4U876@`PYH
MUJQ28JLYB,`8W#J(LY:FJ4"(0!?H.C*^1L*G(B!#R/QJ5\^DE`LC$()?4[+8
M1P",`D,`0Q^$NMC";D99*)C#%[[5V$58=C*6JH,!<)"ASCKBLY`QDP86X`&V
MFK9@KUV$E9X0AMA*`K6(<5$/0F#;9_46$1O:0SU_^PC<%D8C/*`6<;>U7$*X
MDE+--5=T!V&`/%!VNHR=K@'H@-WB8G<'KNVN+;`+3?%^9+IW,.]YHWM=]=;5
MO?`=;WSG:]SYHJ:^]O4,?O,[F?WR%S'^_6]?`BS@N1"XP&@Y,(*[HN`%1Z7!
M#B8*_X0C;),)4Y@F%UZNA3,L%`[_=L,>?DJ(;0OB$3>DQ"8VRR)L<(&#NOC%
M,+[#&,IJLA</UQ$T>#&-"Q$$%P?3$BYP,503(8,'Q/C(1Z8!YXB,Y"8?60\Q
M0,02G.SD"2!2$3UVL1M2,087*Y<26;Y#>!GQ8MDM8LI4%O*8:R5.*YQ3,$X@
MZR):\!-)-&`C24W$"PRYXT<`8".04\0=?.DS'H!-T,]Y*B+^W)HZX*&VB]@S
M1`)M"A;P$06<G82D_9"#3$=B(U=H!*/QHH(<&&`!96N$&R30LQH80''9+807
MG"F:/,RYSI&X,T3RC(A-:ZZ]BJ#!)/U`:40,^CDC6,0=$O\]Y$*,^DSOZC6@
M46&7C6RA$KX&PL`D`6I1^X8(..CS'ZJ8A2X$@`8)V`,9&'8($CQ'!=M&!)UC
M8F<\1YHDW)4$#(8X;4$3&C-[^/(AEFT<11_BV:UAPKTG?8H!:/(@&AAE)'SM
M!R!(@=L0"34C$"Z:*_RX$`'@@0D$@`1_IH`.7)#X>PUA@>OX0!'SQN(C='T0
M7A^"XBJX>"3>X#%B*YN/*B"HT(=.])[[H0F(+GBS"?'LH!/]Z18]2!VBK.=^
MET(-/D$")2CNAQKH_!'=WOC'QD<").(@U$OP0Q#60(!8$P).>XA$`#:R`YCC
M&A(T]X/-#<'U!H@;$7,C2;$'SL?_!D#B#FB#R*D207#2=>+9;6^$#-A`DJ47
MPM>##X4>:@,FB$3[$5SW`PKBW8BP+^+9F2>$#"90`0`HX#(D6<`ATF!K'.R!
M"49`X@@,X/9!;"3ND)@[1'B?B)CGI1%YW_OE/P61-$"BV@YDN+\A8GA(!`HB
MA&/\1HB_"<A#@BT0L3PA,&\*@QS$`C!`Y1YFZHA-JR!'0%`^(DRO"-0_H@``
MF`-),DH(!A@>!SL`!A3@+W:@=?)5"+\G=]MG=_26:_:F")O6#P=1`YZF""X0
M&#4P2:E'",=V$-7W"`JP$=EG;`O("=XW<QLA?H-`?J30!1"A`OI">1"1;Y#@
M:S$$$:/G_PCTEPCVMTI?Q"IZPP&'='9_\`0FP`)/8#L'2`@)&'PE*&]WAX*[
MMG!^<`4ND@-+9@@RP$=;P$<;.`@=Z`<?Z`@AB'U)YW@FN!&1YPAYIX)_P(*C
MH#L'L88M=Q!SL&9\MQ%=D'@3R%N,L(.+9G6/``.K`A'E-0@Q(`%#<`#<%0`I
MX``(0&/*T(2/$`,OMC10V(!X]X!5=Q!7(`5P0@#MY2D'00$7<$Y?^`=A.(:-
M4(8',05GZ`?<IPDGR(8I"(&""`IQ`">I]@=8D".P6(-Z^`"!)W6:`8@'EXN.
MT!T0(7L@EP<&8`<>0`+PU`?L9@B4V`G&YT3)1X6AQF\'`6F(T/\%8:$"A'-,
MJ;B*D0".?D`"L3B+F5"+R'>+G?@XI$!S#4!U?V`#$N@'"'!E5*@Z?]`>&Y$#
MCX&,AM"#D@![?D`$2R<#)+``#9`'8#!7UXB`$`%\H+"-]3:%N.B)@T!S-:!8
MA[`$$7(06Q!EZ/AS$($$:790&)``YY0#U:-]$%$$$9.3.8F'SJ:&D&`$]"AM
MTA<*5+`1*M<!&Z%3H+<1JQ,$Q>A`T#5_&>=M0QD)6_""?NA;V)B1HL"1#NB1
M]:AQ4H!*=7<(#@`1'[`T*SE]OJ$"1Z!L@J&1CB"/BS``SN2&<-@),=`;?O`$
MB'"5$/=Q`=E5#W"2!Z$"'R65("EV56G_?1OACA1Q"-G("5ZYB6`IE%5("&_P
M@LE6"!.@232XEHSW;W>A`4:`!?I(@G@AEU29*PKPFK`9F[#)`'4($>*6EYP0
M!R^87H?@@I2TE!#157_P`'?D0%6@F)G)F/8X"5.P$2=0"9/(E:%0F5)8<]Y8
M",4"<189DA`A`84@FL9&FG>!!/H"EZL9"1R'&7,0D*E8"3+02*Q8"$`)$=C3
M"+XFG'\0!.`'$<>YE8MY>LKH".=CAI'IGW[`FIM`G;9XF3<WE810`)/T`<BR
MF0?A!%<%GH0'$75``1S:H1[ZH211-['H5.CY'/*W@@&*"9M6`YAX"&-0&[9F
MGTQY""PPGX<9_TL8^9_UEZ*,X(I^D)A:F:,'VI51N*#6^9')20AHL)(N(#4U
M8',8:@CJ^`A"<$=.H'*%T'BR^'B^D0,XBJ0^UPDTP(?.J`@C`1%9":;X.0@T
M\(,.E`8R@Y`]V9B/`'U^T)]!RH32N9%%.H\,FH<Z.@BDZ$`Z<`;->`A1FJ6%
M%PDFL!'J8I-HV'V_YP"46JFU*7I70*D,<`18VJ!TB@G->9@,``"D6JJF"@!G
M"1%/D(7+%YR)0`,VZD`FP"=RRG0\N@@WZ$`GRB\&BJ"+8(DNUJ*&H*!^>J1A
MB0A#`!$U$!@&<$")RH&+"@F.`Q$K\(Y<"A%K6`C)"A'',G&W.@DST/]-K0&9
M:JH(-4H2#(`DM3H("AD)F>,''U!:>>I[>^H(PA>IAT"LC-"-2*IQAB`$OJ0"
M:_H'SPJ&T>IG<JJE\(@)=#D(`2"'!X$'PLJ>G3`ZMK$'`-FJ!S&PA,`"/E`;
M*G`&?_`##@J@G\H(G3>'EA"=!^&KBG"O6UI\?;JOG(B9_FH(18F0!:N*!SN7
M"?N$M.B3B$`#^@<1>"!P%+L)`?!FK:$%@\D(,[``M5$'"2"N-\N#WWH(0?"N
M?H`#*RN9]=H(,+NPA*"OB\"OQYH($.L$@_6=)VNPU!<)#%2R`P>T\2BTB+"U
M&R$"2%N/8:H)AGJ8`C*XA%NX@UN0&8NBK@K_M7;Z`PQYM8'XMGE;G#^P9=`)
MMBVK@,.WHYI8G7Y@C?VJ"#)P&37P>6Z[G*,9MY#@HY#+@7;+L'B+"`,P;`C0
MJ8"*NIAP@<TG"7*P$2**F0+9"#`PJ"31N@F9M8-0`"9`:YRD#,<4?Z<:O:::
MLQZH",0#$2D@O=I+JL5INXJ;I(AP``WPG(JPLV'HDB\9D^+J!TJIFKGRDD>V
M8PU[(PSI!SS@O=_K!P2PO=L+:X4`F*+'DX4P!G""`C8$O!Q["#!P.#!AO',Z
MA_S[!F*0!1)`:_J;FO/Z!WEG&QF@"&/P'2KP=YOFP(]@ON(I&,`"J;ZA?/-[
M(V^6`WVKL:V!H'VP_Q%E&@D0ZP<IX+<)C`@,O*Y_D)Z8(45L9@AP<!VF6PCU
M:QM_<YV78,+/403AI:6VP<*QJPAMX!TY\'6>>K&&D#LXV,-8=DSN@L"2($)`
M+,2DI@")RUR%8`/[*1J8P@@A\'"B00$=%+I/++EAV!I(4),J7,61J[+D0;(0
M$7]^*QJLF0`YTIZ+L`8;X9=='+R14`6U0<+LVAHJ0`1I4)^9,`T/$`%S``0W
M`'6FW`,?L`-'L#:,H`,^(`(48,JF_`,44`094(&(0`)"U[Z5$,L$55*)X`((
M(,O$3`%[,`0GX(:#X`+$W,Q#EZ:$$`)#=\.,4`4H,'1$T*FZ[,S$7`2&(/\!
M0G<#@#P)7<`%0I<#O%D(VTQ0N.P(2E#*&L#+B2#-W*P!%/`!>)`'*2``RIS!
M*497*/;/`!'0`JT/!%W0L('0?'70"AT9#0W0#^U6#!W1YC#1%&T:%UU3%IW1
MZI$(=B";.,`'[!=L"A"5AE`&"K!7Q$`&"F"YD?``LJD`.-`!;7P((Z``CYH(
M4O":O5C)"B"OE(#2$HD$5K`"1V!FK1C3L(F'`:``')`("6`',5P(.ZW4L=G3
MB=`!"D!ZCC`!";`"0V`!#;`%"H"_BA`#9&`"@HEC6VT)'!`!8=T`&4`"-7U:
MB:`!-;`'>DT!*E`#$I#$AW``,9NO?O"[TGH00`K_"7\F'WO=UPU0GHU@15Q=
M"%_DR(>P`:R1K2^]`CVP(W)P!=SD!R+PU#IX`WI]VJ<]L75[;<"E`6(<!JB]
M!Y.#`*B=TXIPEB/8"#-@`FA#!$^0`0M0!*46`:RJ"+KI!\$8"8*=VY`@`TQ0
M`SF0!U?P!#PQ!`*<"-R@`;-H`RG@!US@R8H@V&3[!W1FV(Y@`RAP`SQ``>/L
ML[E=`&``'SP9RW[@!$*%!G[`&I9M"$6``AH!`9-`!S>@`EF@-S`0!BB`DSJH
MV9&P;*Q]"`;@VI*@._ULEG[`W(I0`&PQ!R1)"#2`!!H`NH^P!!J0`T20`W\7
MOA=.">?#!'`C`U.PJW:-_PC:?0BI0Z[A/=C#6MB2$-]5$`9^0,W>AN$FX@&.
M0`$(<)9-T3>0O-_13&P8X`??='C7[+\@!VQ,R."'YP</;@@1+L:'0.&2@-N/
MH'\.D(4V4.&&$()O<`1^(`>2L-R4T#=F7:"(NK"I@Z<Y/M[E'0ENX`1<$&4[
M4`-@WI,8WKNDS0C&/`8:\`$N/0CRL`58\+?G30$_D"%V08..$"'`?`GZ:PD.
MG@A?/N%^H.:%0.:-X#ASD.*0@`%UP`,R8`,-4`-`W0AR/@E`&0>K<->S&`1D
MX-UYO.<R:]Z,8")L,`AT(%HEFML#<`+Y/=]Q%]_DF[QXH`(/(`"4W@A@\J@T
M4/\'2"#`,J`"R:4)GUX)H=[:A5X(8AX)J,X(5YGHF``#)@*Z?_9RD'#KDH#M
M-Z``4WVY-+ZA'-H#/0$$*LT(@NUT3V<5Q.[!<E(()L)_WG8#'9H#/?$!!QS9
M<1<#.1"OA%`%F8GM3M[M&K`KNI/<9.8'WDGN"#_-CG#N$"[A.%SJ8[[BD>T'
MJDT)'J`"L]@/6+T(^"X)6C`Y%?<%98#!=FX(&@`$L'D"57``1I\(@LT#_S'U
M`I`!/$X9&@'OKIX#-[:C#?":R2H!=5X(QCP([M;!?P`%>]`#_@+RE6CU2$<(
M04`!.8#4BB`$FK,)?C`'5.\?A>[R7@[SD+#ND-#NBQ#_*;5>"828+X50`=(C
MP#\O"4O0`6!0P15GTD?_G>/M".(][(]`/$[``:>:.F_IWH-P`3F@`7P0"67_
M!S,@`BC`(IX2:&Y/'BB``J)OJG=6K8U0`*]^\]RFY8\`^(4PZC%OZH1@^(J@
M.YIN"2'@!W@0O5R@`E[+^32/"17@`#=0`V,/6S2^^;:NXX70Y[W/ES[!!8D?
MB",H!'7P`:Q."*WOBRK@=RB`1(-0^XUPJ3"A`OT."'^"?PU^:8.(B8J+?@2+
MCXH!?B*/"!00D(\$?@&9BPY^"IZ"(7Y[!:.>,BA^K:ZO0#.I!Z&IM@I^4[:/
M((\:!KN*M,"++7XOJ29^0P'-_\[-8'XKJ0"U@SA^<[L4>X,R3RH6?B.#`GX.
MLWX6S\_82*DT%#5QCP5TMHW!BD9^48H5RV+HV]0I&"A1J23XN8)J$0<9HT;X
MB<#.F0\_7](AU/=(HA:.B'HM^@52T+!'QI!YDL*EQH5Z3FY(&55MHZ`MYVQQ
M0U2BU8X@Y7)Z*L!#P[U%-O#XT9$J#((Z*RK`&%2`@P$_`%+E*_F'CPH180;%
M2.)$!0>.!/4=M#5`@HHY5!H*JK"@S@)/0G[4T?.H`A`-8T;1LLEV`0\`$`71
M*2J$ZQ^1BDB6/%GLV*@K?NY"8N#'"$UK@R9\P)IJ)Z*+9X.B\Y0@<Z92"):D
M"B"GAO^?#SX<;.GAQTD(?*^"KQZEY88?+FO.\/"CP0/(M`9!IQK!A;F$"&=$
M^/G!9-09H8]P21`<_-4!UAK\`,FP9CF%#8X?/PIQOF00`/4570#PTE,'`+)!
M,H`.80B4B1L`/*#(&``P-4H')202P&^(,'C'*%$`X(4G(0#@QB[VJ&&``19D
MT48P`*2HXHH7VA($%A*,F$<5<NF#`6+ZW)&@/C!@P(`1(\K!@0VC%,`'CI`L
MD:*!D-RWXHI`#17'%D'J4&-)D,6GY99<=NGEEV"&*>:89)9I2Y9FIJGFFFRV
MZ>:;<(*)9IQTUFGGG7CFJ:=\>_;IYY^`!BKH8R`4:NBAB"8>JNBBC#;JZ*.0
71BKII)16:NFEF&:JZ::<=NKII($``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g23297g2329701.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g23297g2329701.gif
M1TE&.#EA!@*?`N8``):9ETY23(:)A^SM[./EY-W>W=/5U75X=L/%Q,W.S;N]
MO+*TLZNMK&5I9?O[]Z.EI+[#PX=76_?[]KW#O2LM*9RAFZVRK,[3TZZRLL3$
MO>/DWEI?5O/T[\[3SJ6JI)ZBHD1(0-/5SHR1BWV#@\;+Q=_CX[6ZM-_CWJ*D
MG8Z2D[*TK6%D7=;;UGN!>K:ZNN_S\VER:::JJL;+R]O<UN_S[KR^Q.OLY]?;
MV\O-QH.$@/?[^Y*4D+J\M:JLIN?KZ^?KYG)T;ZF7EL>[N%QD8>3>V6UR<-;-
MRGLS.-[?XSQ`.79,39R>GOOW]Z^NJO/O[D)'1ZRNLFX]0L?'Q\W/U,.^P8R.
MCG)L:.CGXY"-B=C7TWE]?J.>G[:VMKNUM*2FJ\W&Q*REH^_O[]?7U_;W^[RV
MN]//T;.NLN?GYY:0E./?X'MO<:JFJVMM;/3O\V1>7UA;6MS7V^OGZ\S'RX!\
M??O[^S@[./?W]_O_____^_/S\_O_^_/W]O?W\_W]_?[^_O___R'Y!```````
M+``````&`I\"``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-
MSL_0T=+3U-76U]C-?MO<W=[?X.'BX^3EYN"'Y^KBV>WN[XWK\O/T]>'I]NOP
M^_SP^?\``W;#)W!<OX,(J15<R/`<P8;E$DJ<2`RBQ8O;'F)$1[&C1UT;0Q;4
M>+&/R9-]_'Q<R3*6R)?_2%I$>5)ERYLX3\'<24\F1)HF;<;STT<'T41XDBI=
MBN<DG:0FZ4A%N=2D4D$F"1EM*LB/#CHF'4APT,=!4Z`U,_YAFE0H(;!]__`L
M2EJHZ%2;;/&X5404Z+U!?=&&0ZNCL.'":!,?1IPXG>"^4L&"<T"YLN7+:"]7
MSIOX;R'/A`0["HS2,=!'B5.K7LVQ4>=OD6,[R/-BP!D"!0H@$1.B3(<9>_H\
MTI''CAW(J_M,A4HU+V?-=/Y(=4!G&_,_V_I(X,`GKIT\B0)+39<7L'*P@II*
MU?%9+Z&SY-E:.A^;CG$[>_+KWY]_@/___OD@X(`^E&#@@244<,."#-[`PH,&
M7"#A!0E4:&$"4F2HH1077KBAA@A0(>*(5$Q@XHDF\J#BBCRHX.*+*E@@XXPR
M/F#CC0^@H....B[AXX]`!KG#D$0."<"12`)0)/^123;I)`!!^O@DE%%.N>25
M6&;)9)1+:.GEEUFB(>:8:#SYXQ8V>N%%#`PTT0,`%5Q@!VJ%$7`!`@@HX`(9
M?/9IQI^`_KG&H&LP8"B.#ZCYP!:,-KK%E$DN\8$`'-34QPL)/&`D`&5FF4(*
M581:A0"DEEJJJ*B2FL,((\PQAQ:PQ@HK$$`48:NM;+#1P*X-N.'KK\"NT*NP
M;JQ@[+'()JOLL;PVF^NSNK)QZ[0'5&OM`5JPJBVKIIXJPK?@BH"DCQ]\\$`,
MZ*:KKKH,0.'NNU`LL``7]-*K``3XY@L!BB<B0,*_`)/0P<`$=\#""0@G?,(/
M##?\PP!A1"QQ&/55'!O_:)DT9HC&GS'T&D_9/<8-4#A8<(-PCMC1AP\?[)KK
MK;32:JVK--><P\U5D"DFE4&6BX*-8*SQ0*'O>O&&#2F9I`,2`H#`1@6&,D"&
MO%3+6R\75&/@PM9<NU!#B&!3@<"'&28P11D&&""&&#>4D`8!<,,=1QS_27S?
MW6-8G-S>*8V,TE2$+?95X(?1(;C@?-,$3F3)2>#XXY!'KAEE:#F7.#@?@WQ.
MXIQCSOGGK(D3U724AV`!"R@WLH<.-^30@`)S'D(=XZ.?))=50BEWTB"5^174
M"VQ<D;14!0@0``#".\`$'GH'U4WBM*=$!V5P;0.X7GX87KT@>B]>,>CG45^?
M__/>'*Z#:HL1!GA4AZ-E<738.978Y&0!1?_DB1]"7VR)O>___^NC2?.`TKUO
M@&\U`U3<YOPB$^>%I@]\X$,(,'`#]J2L#P48P0JD4!UTB"XYU>/&6"X#%^IX
M90A(BXH?"%"%`.R``-1+'2&(8D"1#21^YQ%.R+)B'O+MD&__<,IT`GA`Q9@/
M<4IKGPUK.!7]908S[WLB9I;HM[TUA(H_3(LYBI@:S_EE@8H;3=]&=CZQ3+""
MP^E#"5PGA=1@1SR1N<Q]^&.<_.2!-C2@`7>H,SJ5&(4-*2P+'4H@@N/]P"IC
M],8;^^C%TN"0B-'S(6D228[,5?$U7?D;>C;VN><%[O^+];!D=LA"RK)@493R
M<"(H-><03@R&;YYH)$IT0!D\A``*!K!@(U2VQ@9(01P8PA.(."1,#5%!`0J@
M@K[P=$RQF4`!&2B`'20C&:_XH0'"(XI42I""-RSAD'&A)#=Z*,/15#(MX6F-
M)@*CEAG24)4H>:4X81-"=IBS8]]PCCK)&<]]1@)CF`#H&[]1BIAT(B)8F5X?
MSEA.19ROEU)X(UL>L(0C+6$+%5W"`SX0)"A95%(;Y:B/'E"!"CP@!%$)2ENN
M&0<=FH0``'A#!7[0%*[D9!K.*<]-#Q(8`V#```U-Q/D((`!?<H,M;NI!U!A@
M(P9@H`DQ>$`3N&`B!OSL7`S_B$$3GLHF!LAH!MEC@F16BLV^F<0',04`3<.Y
M4VGD5#YMY4=/?QI41!2E!$7]I768XH$8]"!=?8UJ#%R0@!L4(`092``+LJ"`
M!5C``QYHDZ%4T(,>-$$,9U$I]AH0R&V$80EO4&M-ZTJ+MS(EKH4P[5)0NX^Y
M`O417L&K&_3J![9`]K:W_8`%$&"""1"@`R7]V01"0`(<),`"YE(J`RK+@"RD
M-"5D19I4MO$"%(3V"J/EA6JOPMI(;)<NW66&:TEKB-A6X0T(."I3EGO;RGK`
M`C,8P`S\U8$0]#8$(<"!`7Y``!)8X`'O5:IE69`=&D;W/'_HPQX><-WL[N*[
M<@GO_R,@+.%EC!>V.D#K!M*[UZ5X($<`_K`'$'""$,R@`SW`6@4\L``%3*"^
M!M!`R1Y06>9B=A#0W:SPIJO@!QP/NVQ]\'<K[`@*$QD9%W:$20;P@0VJ=RDH
M*"F-/5`!$Q"`!B0`@`4Z0-(>4-D$)*`R`N1K`@_T``7+[4$(R%(]LI[A/%YY
MP0=^7-,(Z\+(1U8$GO-<D9/X]+5*UL$`'C`$!%A&L_^-@;FJ_""!=<`$<-K!
MSY3D`1*$H`,D.,,)%K`#!=PV!/4\RQBP63^B+/BZIH0?GY,QSF*T6AD9J8YT
M>E$_!]SR`N2MBZ`);>C>Y=@")I4R#D[PZ![LH`4BX,&#B/]K`0`(0`0>.$,"
M?N#B$*M9,A(UR1B"5^H^V('!.TB><E8-ZW8.X]6L5DE*9LV+6IL.U\,1M!<*
M?>@<>\!<'YX`PTA0@1YTX`0WZ(`+3-!;',R``!EX@`E8X)\50Y8!J,N(=;3-
M!@UTVP[615ZJVZ'(A-B$G17Y.`^1W)?LT#HL6<``O!U1F`%X8</UKBT></L`
M'%P!!PO``&6/A-7EDA0%9N[M#^R@@B5X&>+K?F."BU($BP>E*.`6MZJO$4^)
MB#PH(4]HKG^A375O/1:UGH$%5MZ(PH3!`QN`0,R3XN4H5Z`#!<#!!*CL`2X(
M[&"XZ8`"3/!?%Q4`RV:.;,15DA'_I16!"`Z@H>$8K'$VMP-P>^$'RK*WR7,7
MGCK+H)QT(G\+RCE@!AB8PM<%8?:7J]W7,N]!CE9\,!XP8`(L^($-3L`"%?!@
M`@);&`'LVUL-3(`!D.T!4)..E:(<`/%0F9X'WA#NC6>#<9R'!\K*0A97K]O;
M#EB&<80CZW:34NRBCW<87CZ!M>/!JEY^P`0RP(,,(&`"CK6`"KQJ@>5:8`'/
M5)$)W@]TR((:Z\6G`\=G%F>A`\O7>..6#;,S<@<!/]0W>K90<M*Q!]FG#/F1
M$A78;BKS>:$'@6:W?.6'>FSW`69F4AYP56Y74F46(\'E=C_75[?5`6DQ/#J@
M!3-`@$2A_P,QX$+B!H'+X&WH=!!)XP>:=VY/IV#'05"]\`W%476[0#T<.`6Z
MQ`B%\0([&(*48V\A5@$_LR,E55(]0``*AW,?EB,?YG!>!ED=4$4YJ`,C<(-M
M81(]P(.F9&?8D`?/E1#C-AY]MG1^8!S^A`L[Y`=YD'C"07RY8!F@%WXLIP-6
M&`"GEX4R]UAF%F(?<%4@9@(_L&+P]V$Z\EA`!V"/Y6]L6!1N"(=Z81([V'QD
M88?7@(>ZXX/3L(=3%PQ'$12`J(2\,(B%>(O11PNS$X4>Z(A7:'X3L%&J!W1?
M6%)'P@`DL'[`ME$50((HL`2050&CN(8%EC2%\88X*(=TN#OM`/^+<*&'T<&'
M1NB'N=AQN\A.O7B(OS@+P;B(P_B(D5AJ2?%?D14#$S`#)X`;!7`"!3`#9S``
M5W8&_C@#N4$`M'<"_$9WVL@-<`$6`H"*?3&'S2>.V4".#"AYYUB+P'"+*;&.
M-]2.-?&."1:/LE!K1(`!,@"!8T",;S`!(X2/>,!<-/8;)(``.&`P'6`B"&![
M&>!H.+"3N'<".#"-7)@`B321.E"1W]@'<R@"3M>1UL"1LB@-M&A]ZIB$[+@+
MO&B(*>E]95$`+@F3CL@`,UF3FC5_JK=E/SD!)E`!`(`"*N`O_])8'G`D'J`B
M,X!E*/`!)B6#'S>1?0"5<2B5;T"5]0/_DM6`E>8H'8[I"R+YAUY9DF#ICF*)
MB+C@>2=@`2_Y"#%IA6LI@GB@`@\`?!60`320<!.@`B@``"*P`U!2`4P"`!CP
M>RQ``\`G8A%I/>R#F*FHF(RI'NX`F0BQE7V(BY>);B"AF;[("V-1%B=PEJAQ
M*0OP!@I03=XPE[>E`"<P`&$&9@,S`0H0(RHP`3B07Q^6`#8P`,#F93$@@V:5
M=#J0`FM6%MK$`!L@`L(33@+E$]K%`:142SH%#?>@'$2H,O,$87EQ/Y/SH/AC
M%4JAH/;A`-N'B,SA2'61&&QQ.?)`'SI@!X,S,F2Q!]-E"@%*%`YP!1@``2KY
M0"^0G=LY3YX6_U6Z)3`AP`(34%(O5E\LT`$X\"85@`"7-@`%H&5>YF_.`X#W
MF9^&2`?\Z9^(%*#E%8BU@`<$2GT$"%<(ZD'5L7V<)T67X:`?6CE#EDG243^<
MV0CX4Q6I03_>H$"-Q!C2,TWZN70%%8C#Z:(P>ITSJIW<V0T+X'"019Y%^9H?
M!B=T26.X9VE(&9ONQ:1FI1)Z00?X24K[V9_)TQ0-X1-62@GA@`>P6#_.T8X+
MD30*%AQVQ4"<M$J7M!I\\44F<8'DXX<Q6@DR=Z9<"A=Q4:%"!!8O\`+G4QU_
M$S)[JHNAT1=78`%_JF38*:CS5*BX56D+\P,3L%NXYX\=@``,L``XP/]P-,`#
M`!!\9D:?!?9&=```4+JI5`J@#`&J6*JKX$"J84&A7IH+(&H.'=0'=S1/'T2G
M!9$<(R,9)I$'>^`-&PJPX^!``P5&'@JL0#&LYX,2E(%#N1I0@0A=?="L$`"!
M)A&H-0H.WEF))$@"2"FD%K!_)N)B"I``.(`#-M`!U\A>E#H02;,$[:H<4WH%
MM31/G:.L_*0:&0M;:/$'R&D(9KJT3,NK![0X)_&O'!,:":1)]<$9[F,Q7Q%`
M;.JOL'@267A`M)1TL0@4$NIK1D1+AC$;%&@X(SH=])&5DR!0'.NQ(!NM(_L-
M)9N&#V`!)I:MN`=LKT<"KJ<`F&8!=HD"%K#_I.@Z3BEQ!SJKJ3S+J55:0T`D
MM)ED10=UM$F;6DW[N4O+14`;M:6J&>I0M:`C2V!+'961!QP@&Y31%Q`:NS4T
M28DSNY91&!)P-[2Q!Q)`2[V#H<%A;J$@4$_1%'8+J#0ZJ-S``R9%@KCU>BQ0
M`"R@`22`9BA+;`HPBI$E(XRK4H6W#1^PLU+:GQI0%IYJN5:$N3A$L)M[&IW[
M'J`[O]\ENH-!%OAQ/Q:#H7=C',/ZOP`<P+4!(`%"(`,2-P@<-R6`!`IB6+DQ
M`RPP`V*0!0RR-@^2!0:`7QW0(1T2LQX<LPD@I'B")P%3PA`PPB.,(CQ`<"QL
M`@OP(C32!(9B`7IR_UNA^``N,`!ZFJQ?.0C'V['."H%$D0=<(*CA,`']%V*0
M16-&2C`*@``=8``XX&DTEH;,969EX$,IV0=+4`:2VP=JB07G"Z\[M`<W8``<
M(@4ORR$5@@`00`#]1+S<<P-RT,9L+`-XD@`RD`!G(*!7^@T#P`50T"YL\@!2
ML`"&<@--A&-_8!9Q$;;AI!=GD7B9916:RJ*DL5+84UM[%3(C0Q020'UGL`!+
M<%7!9E*20BXA]2-4PHSCL@3,",N1XLI.4E$[\"FA8BJHD@(`4`4B4`6@D@(B
MT"VD4@6L<C,CL"HCH"HCD"U:<``MH`4M`,W2/,W1_,PR4RLQ4P30P@8'4/\$
MM`(#,!`SX[PKS"+.,-``Z)S.ZJS.ZSP$#;`!\BS/`2#/0U#/`?`&^1P`_+P!
MT[P!_,S/;]``!W`&]=3#DI`=\$-#7)ITU;1T)F$#00P)?K`'"F#$X*``0-<$
M51QXP=<$]\?"E&4CN%5CP.=O]:-TEPH`"2"Y?F`!&R``8VQ3.Q3("B`%8X,!
M2U`A>ZP``$`%_90(>4#*-I("&B4I.U`%&54&JE0/!E`$!_`&^NP&Q[,K;K"=
M8*%0XS8YCB,6E!'*7#I"(P1!8A$7-:D9U(<'I!3*M40_>\`'!,H".]```0T"
M`9`$27#73U`'3_`$_/P$25`'?(W7(%#8AIT$AFW_V'5`V""`V(8=T`%@UXG=
MV'D-V?QLU_6\`2LPSY%]V9UMU_.\`E+=S_',!L9"UQM`V8\=`#`0``W`!K5R
MSP&P`J8-V^%<V)&-V2#@SRL``]`,!"T0`$/0`L0-S3G0`JTMV9@]!-^R`P*0
M`\W=`,A&F\=V)`?`SRMPUXX-`@T@``=0B%J$F8`1HATD%3Z``.3"``F`A],5
M';%H`R_J@Q5]T=L9#CSP,TP5>#66?CHBF%RHQ/L=-3&P97:`>>';!RSMTC`M
MTZTX>8%!``QP,BH3R"]0%B]@T6T4A(?P`A@0`QC`!0!@!ER@-0]0!68`!5Z0
M`$U]=32A/PG`!N?5`$`0_]D"P`8YP`8]D`!E8%P5LN,5@@-2T),P6Y0@'$S%
M%;,[^2]`#C`O)@7J*049D`%!_B\XC2?N!^7KA\+0I,91S@,(L,)S5P$"`-"7
MO=OY[#+Z_`9NP`9I'BWW/`354@2IO0)%``/9[<YS?@!`<``R_LV8+="1[<_'
M7>?3_`8@``//)@(YH`4YT-I#`-`;H,^S32K?4BWWW`(`<`!'L@,BL.=O``/(
M?0"MO0$[L`%'4E(YP,\M4`$YD`)25DBSK=F;'0`'@`+(IB-F%@!`H+BVZ0$J
MX`$M`-#F+-H'8`$F8F:W-P'$_8P3P`-]F0$`(,_(-IO17BLI<``OL#U=<4X$
M^_]QV^``!:``#*!1%,4`"'`#!5[1"087\/VQ%&W1&/T--A"05_"/#*D!5W`%
M9_`#5T``9Y#O^;[O_0XW^LXP_WYE9<$$6)<T":Z?*;'@,^W@)T$`.Z!V=!`<
M`Y`#`P#>:>.K<CP(+Z``!D```Y##$#,`"/`!$9,`8K#BF2NP(U,&S`<$7$``
M7+`#2V#C\FPL;R`LLF[:1;`"0-``PB(L1,\LD?[:IYTK1:_/FRW5&T#T2K\!
MIJW9`'W:FQWI4"_/\=P`4NWSPO(&\BS.'C`#"=``"5``:6``7J`%#%``+J#G
M;&,Z2;`"'C!<`K`"*I`;$P```VE?(V`""#,#"Q`"M'?_ZC!+`B8P`CUP,">P
MPA$<GPA3`(]6E"J@^!XP,/<M`(:/,&?VF@9P`BC@CW&W6RV@B2A``CW0`AZ`
M`T`PO;0'?Q-@``7``#(`</TU`O5%7'VYGC.``CP`P0*I`AU`!#*F`CB@`430
M`;8W`\Y/`CL0307@>QF@`;F1!3W@CR5F`</&`@#0`#R@`2=@`S8`!!X`XVSP
M9D>X/_(4.D.88`Q``&'P`@ZP!V$P`&7P]G,"'N\-"!@0?7^%AH>(?WY["F\*
M='Z1DI%X#@Y]EIE]FYE[$I>6GYFC#A)\#GATD)MX?7Y]2PF@KWX6&P(:EZV%
MD9M]/CLI/GL.+WU<5'FJ%V*^_ZY^B89A"@27"IMT=@D/='T&!M&^D;R3Y>8)
M;#MO$'9V&E@K6&\@`0$;]?=O&V_U`6_\__H)]+<A7SV``>B!N"=P7[][]/#Q
MZQ>P'KV"$>UML(#"0X<"#NP\6/`B`9P!7ES<F(-!RH%I*_@)F,`#AH`3GW`(
M^&2'P`(6.G3L<7$BCYT9)"PXT"&!P`<20>W@F#!`AXT?$RSU)%%@3Y@]!B;L
MT?&B`P`?V>QP\3"`AAT.;'4X.&%B1@LM%@3D.-""!8T-'((.D'%CK`X(!(+V
M*0'`SJ<?"F9X"M.#Q`M+>Q"(NI)AQB4^';+DL51@R8E,"3I@"MF$`Z8S/#1\
MLI5#0/^#!@#>F$C'AH"J5=CH6(IFKOBD;I#^#$"@:D""!#;\V%%PP\&?/7;Z
M=.MC0Q"A:.`7-7IDO!*H3.9+B1)%:I2$]YG\=/OC"Y*?6+-<V<+%ZGNO300L
MP4`,-UQ&1QY02)$'$]\X,PYX+U#3#15TT+='`EY8D@`XB8@S"7C1E+$"``TH
MD$`#?!64!$4)@1!1$BZZ:)%%&ZQP4$+]Q!@1"$G`J%"+.`*YP8HY_CB/0$2V
M2`\)/ZB@`!^N%0!`#DN<L0<!#U2AP`!V8`!`1P>`T(`6-O9``P=2:1&8`V%P
M90=V$Y0PUAXL,!"4`SY8T$%0.EQ`P@!]C(5`4%<B<(,.=NC_8(`"+Y#%P@<$
M8/>""PL8I@,&@.X!60$'O`$$#/4<P,(/#8S51TDWM&,'!&CUH8.4[;Q0P@2%
MD65"!R]DYP`"!A+0P6F6A#!#=G[,\`"@EV21!2@O<(&)'3^0D(L-'JQP6P!)
M-+!1.D40X*$Y((9K2"]^.""?`F+XL,`'E#*`P!YB)!!&'O5MTMT@XB(BGB/V
MF6.),_T!W%Y[$K3SKRNNT(=-)/AA0LM^N?2QBR*O`,A`&3>8D<8K>Q3`!01T
M;.@@-.`Q4H`K"=AAW0ME<"&<&#<0)PDV`-<,L!AO;.%&$;DIY.(!*E0P(@D9
M9)`#"&PD0`()7*`P008D`$!1$T``_X$"#@K@@$(%4J``!``D2C'!"AO@AL/9
M``!A`0DJ6.%/!CC`O<35./0`A*<AX&!"``V8@(,'+6P`!`M\S&"!6':<\<$!
M#0S0\1)%(&#''WE(`<0$+1"91!T[D-`!"RK`T($!%\C`@`M3E+Z$B3*87D4-
ML&,@P!(NN*#`$BE@P`4&LB_`^P>S8W`Z``+L[F41'\0@_`A:Q.`\!FPDCP(`
M(WBP@8P)O0&`"`%4L,02U,\.-AL"I%"%``(,(4`558R`XOI5#%'$"`<<8-L(
M^!?10!%:\/]/$6P8`JB&\(8&#*$@0R!@`Y)`P#?$1!\$M,@3_/&$(31@!T#P
M#<)4L8EQV/_L@R"$Q!ZDLX,;Q&`!91B`#PH`!08D@`%I>,$?D&,O[^3K$/LB
M3W$N$3!.9.(]\/G@#^'S+SQ43#N1^(`L'*:?6VB@/^3PQ0`>$+,$`,!9D0@#
M%Z"0`#%LYQD@"L.4SM>`*NQ@?3E@0PIV4`4(A.L5OXGC;U1%QY"5D0TH<$,`
M1+""'*P`!"C@`0HR```/S,`&-.B`"/A@@Q/8``4"*%H3.H`"%3B@"0H(02!I
M0(,KF```,\C"#`:0`2SPH9(DX`$1KM`##TP@!Q88`!%HP(,'T,`&'=``V`1Y
MMAT<L@4#8($%0D"#'[#`(\(TBP#RT(,'E&0)-_"=`7:P`P(8@P7_[FM!"T30
M@@#PK`<5:$$#//"!#^`.`,Z+014^@`'E48]W&(!""I8`!0RX``"Y<P'L`$`I
M%T`!G370YP<`$%`90&$$M7,!!#Z0`A>T#@(ID`$$2&""'5A@""!HP0CXUH##
M#8$$K9/!`AS:.B_4@#`RJ($`;G"!&\C@`Q"X`4NA4(,;K-`',2C!#0AP`1/(
MP`<E\$'K;"I4#P35FA>X0!@:-8`)^.`%>R@!!'ZPASQP804?N%TWV6"!(BSA
M``080!@&,(`7O"`/V!E8)N3(UM]@`CL#^(,#YI```:1!$9LP``#$L`0DO"([
MV[G7=VZHB%6YX1K/,,<>EO,FJ.J@#XG:_P,#9#C"?T$B4<[0`0<DL!H',`$2
M1J2/#CZ``W,E5@4;R,$),('#(YX!ALKH`P`PH`JTNJ`("CCB@Z*QJA*X"@%C
M")2B'I`H9LC,..7`@W*5ZXL$K*`"#9@`"A("`#9$1`0_D``'*C"!8CK@!FQ8
M``""<H$#:&$8=B`G`%QU`[V,Q0'3?(,+"."'"U!@`4MI[P%<D(?'+@$!"//"
M$'(@`T0M0`L%>*P?&O"$F/7A1%+`Q`NT\(8E#,`!9[C%#/-0A3IP`Q(/>(`#
MA%,`&-1!?SVZB0/V$((<O``:>4C`R3"A`+2HH@`/0.(`7*@=;\BA*IAP@1WH
MH`.IWL`5.KA!;O_OH(,9`.`'ON`!`_A@'@]8XE5<*,$!`@"$`TRP`05Z`L+"
M(`4Q0,,/"#A#<@H@@!';80!<:,8KN$@,^@R"R&<PU';*D`"$E4;-0TY`&4Z5
M'0;,L`]G@$`!(&&!-[0@!_UH0`]P`P0D\*E"A"4L+69X'2J(`0$YB'`?J)""
M-)1A2Y3#ZRM>@('<9MI"5'!$!\U!%B@$H`IG<)4._-"H$CP!S`X`5#8BX0,3
M/(`!Q_8``'!`Y58\([1X&&UI:1$)U*J6M>-R+0.\>.$!Y(`0F+A4#71+LFCX
M@`$GLX-8-K$'&2QA$TD]+G(EL5SF8B($\=@`"3RPHA;$I`%`6`(-+H'_@"*8
MX%GJH.^IP&<J']3!`,9P`&,ND"@_C``#QGC!"9[@`D3I0`H`B'"B2"``7K_@
M`D]@PYOV$(,A&."Q0GW#'R9'!RD(0.$(8$,9I/.'#=3`.GU`@!M:<(89SK40
M+!9``/A"#Q[0X-XMP,2II'#D2"A`S9]-P[N[<88'2*$;?BB#%,)0"#IT'$`*
M,$`W=""&!2!92E>P!!X4T`,.E((##_A$'P@`@0$H70M:F.`0$C"`-XQ!A"$H
M0,444(`ATZ$`.5@%G,T,609(X<6%.'L?"D`=':B"SX_M@];/,`X^0P,37H`&
M'98#$@?$X`VUT58`V,"#!@@`""4(_6!?+:Z$_U7(&P8(`P]$;@`O8NS-,Z3%
MJ5I=[GRQ>SRS+L>N=8"E#1S`"V=HE"M>L+<Y;%N&@1+#`U)0W1&0OP.H<#8E
MH!%MTII6$M9>K75(]I\^#``*1[X$'<ZPAI!D1PP&P$-@!!XZH``L`%50,09C
M80`/\%C%)V_SY@?UYFP.D`4-4`&7PSU<Q@\@```+P``L<'4G(`*;8`%+\`!+
M\`)24`7.XP(^8`<OX`-5`(.'4@(?`#-+4`&Y<RA:0``>@'%!\5()X`,=X`-2
M,`*OL`,0X#LE$&(),`(($`9!P0!+\'A?QP54Q``"L``"@`!^P`:W`S*!L@<3
M@`$)(`4$4``-4``SL/\#_E`$15`/.\`">]`''0`$G$4Y,D8R-68(:;`#A8!H
M7B`%D1`R"``HD)5;D7`&:;<);+<`TY<%`)`+[\$%/4!EEF!ET58`&"`&;/`$
MYO4&OW8#`Q``=>@'>6``B^8*U/`=!)`#(Q9L7!"`F,`%"D(??Z``J+`8AO)8
M3/`<>U`A?P9'4B`%YE(,#)`=]A=3TO$`2R<`-D(V0"`XN*=[O'=#R8%ITZ`,
M>R!7P:@!9B`&;")7RL=JKD98W<`(_))8DS"&BN(!%[`$#;`$!5!6?J`#.6``
M#,`_"1",NJ8#%G`!B\4'4M=!?Q!:,^0%TW9:MR!_BA!%FP`,,1!Q=4@%&)#_
M'7;P#>0&(LV28(<Q!H]5$@VH#1RB+Q%(;_7F"SC0`#L"(__@(AY``Q/P-03`
M`3_`91AP*B;`,\U@!UGE."]``$"P`Y*C`QT@`%H``6.Q`$LP!%)8&E50`F85
MCT4@`^W0`?5P!CIP;B/`*&0!`!/0*'M`!460`]9$!U[P!C%@"2^0`F[@103@
M!0L0!N7R`DL`!&60'6$P!W@A`!G532!0`461!QW0`F'0#@.``V*0!WG0D6$P
M5E;T`F15`&L0A6(E!1"0!F0U`"9P!IYI`+;H`Z)Y`1@@FF<0`A4P`U=P!6=@
MB05P`@5```!P!050`!<0`S*P9543`$^@!5WT!K69_P8W``%24)L$P$4W4)L)
M4`4%<`,S8`!KH&C)Z06S6`"JR`4W4`9B(%(0`(!BP`4F8`!EL"A5(`7/D0!<
MP`7/89X`<(92@``/8(M2L`0K``3^QF4'\09%D'M@=XWY`G9@YP<NP``^$!+R
M40!>$(6N<(H(8X[-)R[=,!WR%7WMN`=C<0$/P`(WP`!#$`-?@2AS,`4W0)86
MYG%$%@,=$%R8P%D50Q\>I)#O%PD+L`(WP5K^<40#$`,`4`9G,&3*X$(O5@:#
MYB$@HA8R4`)(@`$$4`*P"0$`H%,((`80.&\3R`DAT`#\<`\P0&E\8P($@``S
MH0%\<`8[``)BD"AD^@`^H/\#85``;71D/O!5A=$3#_`!A;%Y6L`KO.8#Q_:"
M9Z`\);!4-S`$(Y!@404`2@F#"+`$,O`5-^`&I>8`/B$`F'()3GHR>0`!<X``
M]/("7!B%>4``._`!2$$\>\$&#!`"!I``)G``\2)V)W2>JT,%$(``4"``"I"K
M7#`[5*!0`\4%+D`&/+`#)@"L,;`##V`"&+`N(^`[&.`U%?``3=`#`M`"'H`"
M*-`$*]`$*#!0R*,%;-`_*Z!&WU,'X+,%2[`^X`,Y[+,#Q/,&;,0^8\)&;ED$
M`G!&.\`&59`#6)`#*)(#<^"O,$`_!U`$3P`$<,@&^V`MXUH';.`&U^(&UM(`
M`3#_L2L0)A3K3?R9,/X)(O+A"L+A"OJH:`60!F*``0^0!B'+H*O&?)EV6;&&
M6,7!)V$@`SF0`B)0!2Z0?6Q*`'/`/BQX`BHC%'80!@P@`R\0!IPE@*>7,'T0
M`PLI"3/*'T`'D?;G+E!P=0Z0!WYP`US`J>+)M`]Z""_@!>PD.RY@`3^X!%S%
M`!^``%.*7%5Z;_O#!B)@`1H0`BQP`A;0`V'!`/NV`!UP.BP``+CB!^?F`J6S
MI"=4`A[`!3)`(`3`!0M@`1\`<7N752]08`2@``XE/,*SJE!@`!"``0EF!X,+
M`3(V``O5.DJ$#`803_#I@FRB`%4@!A"@BI;'>1@@`UZ`_P$(<#H+X`$&P`@5
MP``M,%L68+EOX#L+T`3SE)ZV:T]DH``/<`"YJ@!<D`,`D*M2@(*V`P$0\%\(
M@`!<L`06(`,((%*=(P-2L+TF`#4@MVPX(`5'V0$@9;L)D%07D#L7D!H7$``7
MH)T)L`!I)YYO.YZ+D@,`R&</@"YE@*#H4@(%4`(64`!PD`8)(`@EX)GB2P`@
MG`!+8`!A=0;/X0./B2"2F0=YE@:,V0<9H``V8`H<D`/.Z$TG8(T=&Q[/X%9V
MD`8*4$]K``6'N!W680?EZ++H*%<0X`@4XR]L"I]J=`$TNP<7```K8&&NH@I^
M4+,)@``?8`(D,`&G@0FJ$(@)X_\'#!"U,DJC3U2U%.,+.%4`3(!"S:`*G2L%
M5#"DLP8B0Y$J>P`!(&FA%^`!W2!3<5L>*;D)6;`"(@`$"\`#/7``)(!A%<`S
M"5`P#``$'H`)[74!C6(`(J`%`)!K=K`]'L"F"C`"#P`!B"(&N`E5#@``4$!<
M=J!?7CF^C;,'+S"^I.@`"J`%!R"01:8%`5`"^\<%<T"/;[:%UB1Z9`(H<9D#
M.Y`&]L>7!C!U"[`HN+(`%\"8.H!-83!B)[>*?7!UVO%XC8$)<"8+([:J8=`-
MP!P5?"<&H5<`)C!],U`!<5<*"J`"I_`>/5`*>5`""T`O9+$#,G`JB!(`<M$'
M->M%PM'_BI%P`@*@"K5;'=GA`@E@##,W`1W$=T!1+C)``MWX!S?P`3[@"T+:
M04_K"P3@`HI7BSSP`U`B`0>``O_CD9NPP^'1M`@S9%)G"?),+$S4LN=X0ZZP
M*QO@`LA%+P1@`A?`)4&A?9,B`Q>F?Z'G`Q,``1.@`!"@`&2L,CU&+K2``95<
MUGXPHZK%0_1W1`1`(/:'GE_W"F%0!C$`8$0*(29PNDI)*.Y67!>0R%1J1!(8
M`FQP%W6#`DLP`7S``A4``#LP`1S`2,$[`!)`&,JJ4P\`-D"AK%B8>WMP`[93
M5C)0AC6V!P+B`C'HN2[PMJ_,T1]7`!W@`A.P*@"`@LW)+ABP_P3R<2$]D``$
M<`-D!@`!:$X?8P>PW$+9S,M4(``^@`#>["4='0/-\%@74`2[M@@&<`.KT(K:
M00!M]@H[!F#E\FEDIQTNH&L^8"*A9T*/]2J3B`ES5W>8<$J?4&1SZ8@PQ2=[
M$`"'AXH8TPNMJ`H^,`<5`V?9_`H*<'G0,,\``@%``6\%1A]I\`"Y!@D:B1QK
MN0EA8"B^D`&'R%DXW0/_<RC;X=,RHS"&D`T+0S,)`W2^D`=*?$.OX``RL`)<
M0&WE$"B<N*;MQJB-4A((<)YG"!*\.`Q",0;L,6*4$%JNL``9``K/,*,M4,:#
M57\[5ATWM@-,4#%V@`!?M]?1,"D>^?\N.C`&+T`"%=`HQJ7BA5!O'=``9.,!
M`L!)L5!1=%$!(6!W'$`"'\`"`I`X;HN"+.`"RB,`5HD!N#86LFD!+E!"I8&>
M#^`'SJ,`'R!6_V0E29956I`J-L@%7E!C\S0[0C$'"_Y@5+@`,.BV#-``:5`:
M7G*FMGJ810LVQ=,Q#]#1"]`,KG("6A",=``67$X'"%`-V7`&*?`;-"YJ=$``
M8W=H4"$8"$!Q07&<NG8"*/#&N\(%=E<*5K84,1T&NC:('O<"`=!CH^W=VH$`
M/@!'?B=%Z.(+YJD,T``5FS`8A^(*+K5K#I`&4#``%7,#S1"+7#!B=%"S<*!_
MY:NT?<`'+:#_T_K)`N(`YTI=,V/KHB)D3QG/PPX@!3K.XY,@%`D`5GUP`RDP
ME$C[`LK&`.OT`195%040`PQ@AKD71-2F7*>WUE,N=6U\Y3R4;5*$;CP4YA!`
M+P<R!6I'YHGP`@R@`!?`@%/0.B\D`!V0`!QM\0>I7`YPI3;2`#S``618`1[A
M`#20`>A&`+=DKSL@%`8P`CO0`46[`$6P`%P"#"K!RPJ`/D+6!Q!0!6S0>%?,
M3T)1`K63>R]PO5H@A3X``0=`$HHRRB_W<6\+*%J'O9<1IP'``,$F!0`[&@1`
M!E%H!RS,!CG0>':`Z`J0`NXB42[0`.Y;O@S0`^4[GU];OBYP`.]9_[Y5L`3O
M^;[=BYE2\`%20`)2<#L>4/PRL/=?+`4J(`!^0P((4`&37?M:(/W2C:OO"0$"
MT,J[_P3&_YY-D-=B3COEBP`*P`:_O_J#6/X/4/O#3P)RD``3\`#I*P6F\P&M
M(P4N``A5"@@)"0P,"5**50F$"$M0.(H5#QD()`DK.P$!;`9]H'Y_HZ2EIJ>H
MJ7^@K*&H?7YT?GL8+J*JIGY]#E(K7+I^P<)^.CHR.2]V"TL&`!\^>1<D!CL)
M92Y>)7TO-QA5*2D+/QP.?7A_NGAXHK`+&>7EP0LK+2?E?:3!K#Y++GMT??YQ
MD>*`C@,#90"&NH4J3XP8+A14<;$@XH<#$_\4Q)""JZ,I=7@<A&BP(@`0#Q+V
MV%#@@44>"3\F`"#Q`D<%#Q5>[+FQ0\0"'SH*Q`!@0(>=`10)V%&00@"&/3H@
M[*@BQ8X.`A%?&/6!X8,!'P\P>#&P9X!$KSKV&'BP9(!1*0P4T$GPD$$:!P4^
M-'WA8$\"#&(*$L`@Y468'5P^//`1A@&4&BD8()`!00&;1(HP0%$DI1\"10H.
M-)*"H,H2TE*X`%`@!8*4#YQ=`/"B2(;$!*Y5".!"0DH&%``RD";1`@<"!%P$
MD890)08$&9_??%:T0#(AS\<5%#DNA4J*!ZB7/.`NI8)KVQ]B])82H\)ZB2ZH
M2#$4(X&<0HSF4UG_PD!29Q09")=``P!PX@DK#'FDH"JM(/A*++/4DF!'NO#B
M"S##!%/,!3N8H!<"=CA3@!UA%`!`#A@4@```/M"Q(00&6"`"&PIPL`LL?JC#
MCA_NP(/C//7<DX\NH.3!E@)QW+B'&5P,L$<9GR`X82EVN)#``&;Y,(`//I"P
M1!@#)&#`@AZ!Y,"`,*RP0`\5%$`##22@8((%)(1!0@]LVL#'#3%@X($!W3!P
M@PYG3,"``2[H$(84`&#`!0L7?,"`%UP0X(.D.O0Q``(8+`#!#3ZP]`$"?90`
MA0(N6%#"(UR\4*H)`$Q`A1UG,"#``S?LT1D42R"PAPLQO+!*K1&500`7_S'T
M&D:H'SB3P`M<&.!B'P1H84<P=MQ0`$`.($``+'WX(``=`+T@F4($2!&&+G],
M8)0=H2:0J0,E,-"'#G2<X($&#O0KA0DT.""!!"@Y<)4)0/7U@0Q&&?7&&++L
M=`.Y=%#Q[2YGS$&NIEPD`!`=\_$%BKN@^`#!!9GJ8(`,>X`B%`'<6A.*`QC<
MLZD!\"`PP0]\2,!'#B@8&"4H9!9]2H;"/!BQA&16V,LO.&98S`L0I+"#`CI)
M4<`>+U@PQ`()I!#`&QC84<X+"41TP!,M=.`C.CJNPN,[-\I#CSU$CZ(/*+5*
M48L/?1A$`!4NG&D`D3BJTK481F%=C%]+;'B!T?^J@"3!#"69=,4$&W0@`0TS
M4&+#'GFXL(()Y.PA@P`?%#,`!$W:84<'3\B@E0\F%*%`,9=Z<,.U!##@@ENA
M5H$!4"]4T4`)?G"SQ`@W]%'BH7GH,```0Z1!1QY4!`!``7WD(<8."`AKAQ15
M..F``@WD`+X/`+!![AX$`-#`!PG8`5CX.MQ0!"Q_>%+T=`&!B_EA`!H+Q@L>
M()=8J"@,J_B#"^ZE`Q^X@&&!*X`'6'&")9Q@%WB80!,")K`'W.-89\B4'9:@
M`-D5(P!A`$@>`*4/!6@@<)HZ`)$&`#9P?28,.)J@+BS8`7!=``$Z0`<!'O`M
M71C@<+!P``/L@(XP4`'_9\'(`!>N((%^Y6`)8SN0*RA'.:0%0VD1LD73=O$T
M#&7H7ML00P'<H@.MV.$%`1!`,F[`@`6DL!@Z0``;GK"=$^1A%PX@4MS:0;=X
M\.AN0M(;XL(`A1L,X`%E^(.K\E``VHA!6E)2Q1X6P+@]*``J:4D``#)U@<F1
M\10@Z4,(WL`)$'S.`P\8!PY@``"7T``X,>B9HA3`@`&X#``LTP$7&A"#8HA!
M`$MHDC-'`(%UT>$,2]`)`01P@`6\8`!^V@$#B&&'"R!3*\98PJ!\,`(@*,`/
M!.A'QQ*YE"440)-[8*`=XED%\(0A.0^`0A^.@H0':,%V,8A>II!P`(7800P3
M_P.%%,Y@MG#E(!XOB($"RD&'-"``@G20H(OV8$&&%4,H!M/!"5!@CRXBAP^(
M[($YPJ4`H`P4`%)(BU$"8`>`[`&B%+,8N'PPAUW080#S)-=DPE`0.D``7P[P
MP02F`#&5D:!E5\'``/3Q28/007\]I<.B`@,*'&3@"GSHF0`\\(8WP`!E8WRE
M7!D$(5JH<4%.NU#4AC'0$BSFCEY:`!T?<`9=W#&%+BK`$D0``"X,JB]F0]PB
MY^8CNP4I;^B89`P"8P`&8""DR>CL$A+0BC.F0@<N8$$Q(+"',:3E`DNPBAC$
M,-=2Q#(+*Z!E`";PIINHX`,3X($)%+`#'IS`!`]PR_\`PF"(!]B.3QI)T0-B
M<`$H0.`,&&```=(B@QATE[0N6$*?%'"!5#W@`Z":KJO4PH4%*(``+\BN!Y9`
M@@+L8`$Q6(!:&""%/%R3F&@`@`/XI!D7G$$,,9A4`I8(`8.%"P,(\`$#9("E
M,US@``0XPQD(4(@,8\4`!2``AP^0A@*4F#\%2#%<RG`#;7F@`"U.0%A:?`,9
M`.`&@$+`#C*0A2R$P`(/Z("/LR"`&83``)V10BL3(`!$7"`!%WB##,I0A@2T
MMQ!E\,Q\V#>:JJ&`.TOX\G0J@``%*,`$*:A`1B#0K,HH``,Y@(*C%+`$>7+!
M!7-X\P*@8!HN^'D'.^B!!2S_H(`5"("6#4!9IJ94V]K"8FEW51`@9=``+BP$
M:<S50AT1,((8:($!6@G(#@@I@#3\P0%V^(<=0$'%@;&B7_H(!D!ZM`M]<`&2
M.)0D*QHS(E!0@0%_6/5`[RP+I*'"`0\X0`YRL((Y'``(16A``.;`A@,H8*["
M:`5>V@>$`'C.#R7X0`[@*(,4#"I3"GB":L-@RB4`10<7>,(##.,'%PRA!'7L
M`P2@`+@^W.`-$_"#V4@PA`>D#`(TD9X?&/"$._KA`D!(@,!UL`0M%"!3?V"#
M%K;JASR<"B!^J((.9Q'O-^@@&`-`RPO\T`\*/N`-0QA"`]@P!#84X0E:.$`1
M#L"&_P8<0-D-&('0M:"%)XA``%48@<^;(@!N(CT%50""`$0`Z!:T``!4!T`1
M*@"`GK`!T(#.00MV@(*;`*T)'D!!"SS```N8X.IN-\$$`J``MRN@!Q[("'%Y
M@(.^(^``),!!"$CP@06P8`8%,($)"O`#`IQ@`02(0QP*<,'E#D`&-?!!RS3`
MA0*00P(AR`(\'+"`74@@##@0_<!P0`(.A,0!'1H;#-S6KTQ)B=%-,^,>#&M[
M6"RZ&$3"EJ-PCXI)#\'2>Q4&7U:WAS`\`-0*``#SHCR1!U0A!Q[[PPT68(!K
M)4#9`^A7X-:!H5DWTM:XEH6N03$`+XA!4XE\P/L+TH<RB/_!C(Q6!@1@W(0"
M;)@`4H$$!(``8R)7V=8*"=!M&^`!.X`#+_`!_`$`;D$U*6``+W`X9[`#2/`"
M"R``X24#D=(,'P!$80(`+_`"6N(%6O!)'X`!(R`#?A`#C,``$&!,=F!])7!Y
M.H`$5>!O56`!]?$"*0`)(Z`-1\$`,<!<"2`&`.`M:\4%0-!B(B`%,L``)_=P
M*3`!`Y`">[`$*:`E';,'@M(\*G,`*<-)2'!PVP4+9R``6&4N3W4O9R`#[^8'
M&2`!NT``"I``_0(3)G!(?:`!/6`/ZH``*D`#YL`!'D`#>"`!5\`#:,4'>_`!
M))!J#D`#;_`2#L`!H=<O>S`!9R#_,#2@`2/0+YLX`3A`.C3`>GI2#DC$!$>!
M`"@#$"LS!J-P`A:`-WC``BQ@B@[0!!S`!WA``\+!!PZ`!R0P`5S4!Q*0`QX@
M>[3G8+>';6:4;Q14#%911P<H?+]`)I-6:9<V#%!Q`55@`%Z0`[^3`C6E`QL`
M`=="![H2+'T@!N63!R]`(Q.P`R&1![(#+K+6![262+IP:Y>%#^NW#0S0:W\`
M$&QP?PXP0X=C1JA`!PI0`*@&(JOP)$OP#P9`6P:X-Z#@`"RP`@<@`#Q``F\`
M!(FR1#N`/)=2!*#V`B6P`DL@`(K"`@(`!&+@%C>F0*'!0M=2`",P!!&I!0^0
M`O!"``?P_P$GV#\C\`3K$@884`=:,"A2H`5#<$K$``0"]P=A`$8[\#MB\`8;
M4`8!$0;1=@&TD@(2:`=Y,`!5\`8^T#RJ=``-,`%[D%#$T`<%4`2`]`(7<&Y1
MT41^X`-F:!0+)$1]@`0U2`Q^H`"(]`,\P(?EH"_&A!<`8`_'R`,/0`[,6`'F
MX``:@`'\LHD5H``OD59O$##ATP$A@&IV,`&:Z0`_<`!=Q`$T8`$3T$42P(KW
M8`+]P@=78`(D8(R@AY<"<P5-\$']TG=I=8P]((P2,``90)D<$"`:0$(MT`/0
M:(J]%S74B#13LU5AL"[%@",#M1#ZTXT+8GS(5XV:@@$-T`!0</^"`&`")_@&
MPI('JU``#Z`]"0`')`(`X\('P(B'"((CY@</Z)<#'X0'!IE9K/`"`,!$;IE(
M!J``:;!J4()_J$`+(^)4#C`*=M`,M.B1KW2`(<D"&S`"+6`">^`!*_!4^V0!
M_%9'UB<OA8D]A6$4X54"5G$#0^`K>U`",Y(K+T``.6`!-Y`,/A``,L!N/G`!
M7@`!+Y`')0``2:@5"C`$(M"D.B`&\G='2+`B9[`'=@`!FJ`4\30'OK(*JH$\
MYN0!9^J?U<!=.3`1SX(!N6(52*`%NQ<0@&)[$U`"#N8#6G`O7!,75F$'9>H6
M4,$#>X!J*T$"7>0`!&`!-L('&N`!!"#_,-VB`L'8+SU@BH_X`YX(7.30%PU`
M0GPP`RR0$GN0`2<PJ;29`Q)@!QQ@`RI0B7W!>N'7%[LI,#&!`\8HDB1``UUT
M!5PPFST6DK]XJ3:``)[C+Q/@)ILH`-SI5M'XG4GSD>()+R608@4`I'L`%=<B
M)>M)?*?PC>^)-*[B`-P`*"40!JE&*PT`1*!`!P6@`*%8`%P``0"P`M'C`#*%
M2.CYCP'9H$3`"D.R:PRP!`MP`Z@&$`@PL7:PA!YZ"AYGD4YU+7YP$`"P:D\4
MGMHVDO.)EXUW&@;@+1B``26`7(<`.&RF`%Y0/EP#`;Y3`*V4`@;F(6_6LOC#
M`!9:0?+'8070_UG[9P&'<#R&HB(I(CO;ES;/$J=E,"J.,0&40@758!`Z$`->
M<`%:LRDF``&0(`.GH0"%AP$[(`5@\2PG:`!%H"5;4@ATZP*@X@,6=@`;Y@.=
M!+,$4`(9:@`GL&&Y*&*=90(GL+@=T"8$,`,X<!I9<`(%H`(>,`.+VT&(-P,=
MP``AP`(&P`(^$0(SP+F=PP(A$`+!Q8L&H!Y'U@$3<`!9T`$=$"<84`@=,&@X
M0+L)T`.!EP`3@`(>0`*!9[D(D`$XH!H\0!H(T`1-H`C"(0`=0!H*@`)-H#,(
M4'8\<+P94`0"T)VU5UJFE:)F!)@8,!1:B@$=`$0MDYXXLJ[>6`PR</]\X2@,
MX]D!(D!T7@`4[/8&H2A^?&1,`\!LWB,*?&`!NY`'$.J/L0"0YS>0Z7<+(!E?
MS5!,PO*0U^`#-_!^$GD*?<`:)I8BY7H#7`MC"("B9*2BH"`&&\`)*"`!'/`"
M4E`$X5!!7+`#.8`R;W8,:0$!.8!OQ7"^`O!.-\`&#\$UR08`':`#R)8HQ:``
M(\``WQ.F7C`"'X!O'U`%;)`,'.AN3SQU1:$##%`%3;@']L4&"V`V"=`6FA0&
M,;`!&Z<#6:H[4.$#0%"51Q%],9`#6HJ$#[`!,?``7B#%._``AJP%`+`$78<]
M`,"6.Z!Q7-<4!_`-C7P`70=H!]`"%;`#6+?_`@"`=0+0`%.'R6PP=8RE"3TA
M`(8F`#F@RIDL`CD@`DD@=BV0`T```\O&;+G<`EH``BUP`#FW`3ZW<QNP`<^6
MR4,`!%9PR[+'!D#0PC`P<RN0!&3Y!BNP`6_@!MB\`G5P`->\`2`0`"11$AN0
M6^*<!"7!K=XIONSJ$?@'6Q@@L!.+``+@*]=B%>HY?/%K#."8?`HT4-_W!FP@
MS%P`%'L@`"20GG9PM3'D`&?`!0@P``#!!S;01=!:?@[,H!!\60!QD"]026Z<
M`&=@5.#T&1%I;*>03[-Q$5VW!#C<`"Y=!0A@LJ_6`3;7`")P`A(0%%D,Q);A
M!7_4;4A4I`H``4"1_[&E?&XQP`8NH!7A1J=HR@(C<`%A4$$?`,AH*H9:D#][
M<`)O4$WWHD$34-5&^E[R.@"$E`:[P+41718/L&!UU*4FB)#8=Z]0``4EH!5>
M4&U#4`1$-P)%)W1YJG.LK#Q(AW0`\`:7_,A:`(&+9<D54&<Y\``54`$H$,L,
MP'8H``2"EBQ`<!,>T`.L_``]T`0J<``6H`(FT`-+J@*IG0,5X'9Q\08+8`(1
M0;09D;VH*`-FU39]EP`H8`&N60#"=7B+6P,$D`8$<`,N4$!84@9TJ"4LT*P]
MPP%9,`/]\A+`F0=O*7C]\@-RAW@G\`.<#+[2>&GAF2%<``EDG`+H!0$NL/]=
M@)3/["EI\MO/^/=0(B`#5N$'9P``%I!"*&@0N_!-7M7`C^8``',C((<XJ#4!
M]T`DM^:@"&J0(-D8[X<4=F%4/I``'P`!_IS?$$8`!6`7_\<<(@8!9=#!J/"M
MF84XNX`Y0Y!;0%"K\1Q>U`H%7.`%)L!N&0MYQS(`'K*$"T`9]8D`$)%?5:V'
MZA0#"%``"S""Q(0-Z@(!,:`:ZE)!R'%Y,E`"%A!-&"`#,H!>?O``$+`,%.L`
M:2`I+G`H^_$7?"H#+H`H$#8;J(0`A,8H%S!*@Z(5!:!IC]-B!X=O`#'`@+0'
M%@#BQ5`"1GV>$V`VM'F2LH.I/;"J)_``LXD<GNG_`![0AP3``S9@B@]P53XC
M`6^PJGS``J+7+[)IBK7IB;F)`%W$!\`*#W$8+E9R<GW0LH$:/-A=#K1KBA(0
MG>6P*3B`:@IPQU@`;3D@S@$@S-%(?PN!GO@POD>3L)<&"Y]X`U=<1U2X!PA0
M35;A*CCB`$S2SJ5`00-2>A%:"D:1`%I0/4QL!UQ@;B\`+-7A&/S5T/;(W7FP
M![EY#PL\"J&@`S7``^*G"W0PX3H]HA8^28*":F'P`1/$415#*OB'-,H0/143
M4N12!CM`+D_$XJ4`XP\/XW@!`[0$`R`@`BUH/2L"`"X0!B7@`2XPEX'T``"P
M`/T3L:,%%1/P`#LP(C9V__/T@P%8ES]B7*%*X>&3PM\30%T-$P.<K)8F`@3E
M,Q<!]5D\-%H]E0!SH`5<P%0&@'3XYGR(7!2/`)E&<0%-!P![+B@45`)L$`IJ
M$3WWH@`G8'N(2D$O8/.@(,=&30P4:0==]`,J@`"F>.F7>@)M(GX9(*JFB`("
M(P&/]P.YR@%?-JF3"D.>B+J7JO>F:`.VV2\TD/AFTYLD@*K]4@/XT@</S3"T
MR%H+*8@6">RTUP<&"E.7*`7'/NQO8`7VPPEO(`#&O`(X,#"HEE*+]FH.WR`1
MJA"Q<`^LH'XA<`$?1E(0("]\`L0@&PRD%VD>H>X-P.[%UP<7,`*N\BX6D`(E
M0/\+GG4BAY``,90&-=ET.3`'G%S]``0(?WV#.A`\#@Y]?GUT)BLM)Q(.BW]_
M?HN#85X0!08%"`QEG@4W7%**EZFJJG887`EE7E)2"0@/.5*@4JN\J8QT#G1T
MJ)>#Q@8P;P$`&QLC"R\Z=BX"+M$%7@M[.A=:50DZ.@D".07A`TL"=G9[-S$R
M+W8(6@(W=CH*11_Q+PD`&-'Z&`!P(QP#`0#$Z+CQ(4<,`GM>R&!3IH^#,UP>
MV$N0(P>#`7W.'!#`0EJ")4LNZ.A#8(D4'?T`5!&1H-4-12P/K.RSQT#!00A*
MA--!0$N?E2]B*-A)`,$`/SKH*)#DX(<)$H@D$.A!]83_AQ.)'"!80"/K`SZ(
M")CXX<`.#10D^.QQ(&%(678%6&3-0,".!`D_!%"E,:&#'40=.MB@*P&!!"95
M"_MU((;$BSX2KO"X$C8+"\P.^*C@@]8&B0ZA&6PX`&!%`!`-FC0`P"8!'ZK2
M)-S#:9&.'V'&&!FSP^0PG77'\T3T8V?)C3,(+NSQ<4'H"P`&=JIRL,"%GTK@
MPXL7%"Y!@P6#QO\)=P-`S7,",(3A>5C*`T2#Z!2H`N2`_R)S`&!,,+X08@A^
MF/#0`"224&())GV\L,0<*52Q@TP"5*&AA0A,T@LO=G"180IS:"B``'.PT9$`
M$/02G#'"(!+,(`4:DT4#(+QA_P$,/=RPQ!GG0.&<`02P``!(2[B0P$<,+0&`
M-=N\\($"+Y30CDLR5+%`-3Z\(``"'YBP!SLR?$""#S(,P`4`?I3P``$*Q.!#
M#"X)8,(`8?CAPA(1E;''`ERT%(,4.2!`P`X*/+#$/>RXP``!+G2B10D0I)!`
M`E7($`8&%X3Q0AA%#?#"IP88@&<8"MS@@P]GW"```27XP!`&)91`0`<8$'E"
M"1:<4,`,(3!@P@DAL$#"#L"&@,`.),R0119-5"!%!PET(,"E)"BPPP0DD(!`
M%1YXV^T;W2*```8,>)L!`#P@,($")A3QK@)<[(`"O"Y<:($)&)BP@PDJJ&"!
M"`"HT/^$"@`(8('!`!RPA`<//(`%%B@L40$*#7@````[')`#P5H$L`(0`93\
M!A`;M#:!KP6<X#(!/N"Y!P%GG$'`S00,D,<+`[!:L\T%G&$'SWN$84,8/M`1
M1@YGE,!%-&,.8D<5*H6S77??J:?>4>*<E]YX2,F0P@X9"B"G#MM(@\`2POTV
M=!AA#"#W`";@%YPO.LC`A=V**+`@6(ED74Q^!B10:AFD&""&&#<P#M*'O/0Q
M0`&DW$"YY3,P?D,:+[CXXN?$##Z(`S,T\%H1&]"0]P/@Z#"``@@)=4$*0,3P
M`@$7Q/"`#*PN`,493PVP@!8+H"U%"BD@8`=&,AFPAYL?`+G_QP5.0N`#/D6,
MX(,=2$BQQ`)"&0#%`EWV(84`*1C@P``/',#`'GXD\(`64$S'```0W#.`"R/<
M:<<X`)!!T5P`@!AH`0`,2&`,GK``#&!@`4YRX)8\T$`,0&$%%E0`!KQA`BZX
MP`,"8(`+N."O"2Q`8`33(!<8<(`)8,`"'IA##WC`A07L``O[XH("M-!!$S`@
M!RHPP0),@!`3\$`!/`B`!>#%`P_<RX@`6``/A&@!>2E``2H0`0HF8,0*5,"(
M)I@``";``QX@K`)DS$`/T)@!>F&!"PA0`"@\X*X,2&$'"9A`&Y>`@@P<*P`J
M<DT`E-$`$:S`*3\XFMQ>$)$HY>&1_YY2CAUV-JH7*&=G<]D9,`YCASY,PP`O
MH-Q1(J*#`C"@!)<)'7>\H[6ME<=K?5"/-"+4B6J9:E32B$H">F"W&0EC&'V@
M@04DT`<\X,$8W_F-#J:@@AG1R&\M(((D%%$)T7G2-WEPP!]2B0H:06X5B/@.
MC?"#"$'XQG.?6T4UK>D`%@@R`'7XP1T&(`4/F$,'_&M`36[0``%\8!M[2(`%
M[.&`$BPA!0IYP6P^@#8%C*`(,0B#ZSXP!!]$"$X/Z$,>+K`#-B#@,DOPPAO,
ML8<!+/$>1!%!%;;!!0`9H`\G2`$;%L#)&P1@"W/Q@;8*8`=TC(`+\RG``1HP
M`4].(%(?X/]$"6Z0`#;4J@2?0,"N",`I6YV!!5J`E:R6@(&:^<``7%`5S;C`
MJA_,``,3L,$5KL""#_Q@K2%`019LH%8>],H&B:S`6G_``@:<`*\_J``/$CD`
M&S3@!&'XP:UP8(/"FH`%5Z`K"UI`V!-88`(#H`$-S*4!S;[`!#3@``U.P`,2
MA)8#(<`L!SA0@![,8+42Z``._N(`#HRF-'*4A`7>4`0LK"`)`6C``40@@B*0
MX"^2H(,.'(`V'2P".#@!)C)5`0SHIL(28?!$%-<!57G`PPY0N1HK6RD>KID'
M/;$<SU%HZ8(8O",,ZQB`!S0T`B!@00#DR\\O8X2#MB0")WBPA'+_+]!,WSQ3
MN`7`#WA$AX@$[*`([@%&@1[TS0(APC=_",;_JG"`*D@!?A6^[GAJ9!$Q#"$`
M.3@`"%AP`Q*@:@D:7((,(#`E!ER``#%P@45?`($'T,M6+H"".SAA"Q/20L:,
MQ,@'?/!1'RR``0J``A<PL`0$0"&B%WC`/0NP@`5,($T%@`(#,*"1)4F!`0L`
MZRD1L397)*`?4#@7!DSY`3*+00$`>,FE7H"!FUBD!#H91$]^TH>@[,0'(UCO
M"SRPE*-0RJ+WX`%5?K"`#M%%`Q[H"@H*,+H,J"`/%G&`![)R`A6P10(<6,($
M]B`).VR``XC@``M"(*.53;H%:'$`#1:`_Q5$=&LQB'!!)T/B`ADX5R`0V(,Q
M->#:1.#A4L7$`Q^&V0<.7`$!M'8`#U@S`8WU0`!8:,$&4+RQ':0``!7@F`C&
MQC&.66A#54#>AD:T`RE,`CB8L(0./T`Y!23)`*F*QB+$FS7R@L>\L%1/)^UP
M`0$LX<K/N-Y";G`#Q2VN+WW83Q&*<``VK&`%.R#G?Y,Y#`('+CT3$"X1%+Q.
M&-F!`5"00@:TD(98>E(1P@BQ*@8DB)!H,`$*6,`->J&U8EQBG1"R2`8V``(8
M""``&V@`*E]@I`]8:0\(8`,&P.N##XA@`*XKP`<>(-$73"``IK(#DP4`CRIA
MYS!A@,`;$C"FKO\+0`&B*D$!+5KH9WCR#"ZH@@$ZZ8,J%($`%I%"$1XP@/4%
M.0W'*8"YI>>!!BRA2V>X0`[ZTH\/S`(>,;C)2DK`AI4PAP6<'@0$A+)<'VA!
MN3!Y`!=0^FA,3$!&/U"!I1UP@@=TI0()9K,*.$`5%.!!$E=8"R+XL,6YS.4-
MQ'?`'IQ5:P(PA@8M6/YGC_N7;H%$`GR`P!CL0`<?%'L,PS!`LC-\!17,`"U]
M"`&M<ZT"">#!`6'``6JT/8>U$.`'`[`#.R`"PG4B)^(?%B*`YG8A`)`#;_"`
M0!!O#"B``+`$AO<`G?,;./$=#C`0')<"+F`+(@`/X0!BJ;!*!6=PZV'_$@FG
M'GYP`SF@`'8@"`10!`A`!]M4"=<$#)90`"+@'S#0`/55`1SP"^G!&PO1!`Y@
M3'BP"'X#!#.0']T4'#K@*T,S"0E`7J+S(=34<W\P29"7"+!"="-&ADGG`"KP
M!DFP`0(``JYQ`V-0)6P@`)RV$@F0`E#1!W'W3^*@!=HS)A^P,7Z0)WL@!2X`
M/W9`>A#@7`@0`.BA`V+`!@<`!;AT`Y.R"'9@`%I@;.@P!'[6#3G@`?`#B1]0
M$,YE)D]A!PW0`/90`CN0`Z4($SI09YVD`XV8`IW"``I!>%HP%Z1Q`C.0!\0D
M!02`%IF!!7L`:@,@0N#E``0@!7PG#P$Q`!``_PY0<0)0$%Z6!1:2T`%I%1H<
M,$R)0$]/\1L,(`.3@'\'`&KK0`#VP`1]D``0$4LV4`4S$@92<!/`4'%A@(-T
M8!F#,``DH!),L`<%``Z#T!1@@1DS,`/_)0$*<'P28`,=D`6:Q0,YP%AHP0$5
M\(,!X`8@8#(E\QHA"0(@\`1UD`0I^1I)\`0NF00@`),BB0)\$!Q,:$QT<`-8
M\`1OP`:`=`/`\8668`F,P`5<D%XJN()C<%Y?(QYTD`<&4`5)$PQYD"AG$`83
MTA%:Z04%,"H`Q1YX\'U,<$PVAPE)N(3&Y(0-`(52:$V"1@#QH(=GH(40XB+#
M<`G5Y0!YD&!_0`<T0_^&XO$AU?0B)K`!,#`",+`!,R`E-R`#(P!TN'@)7S4"
M!9`#[9`H,9`"M+`#!`0!!#!?,!$-+O``4$`U-_``I0(`.K`$'R`VK/(`^Q`.
MU',#@F<'!0``".`%%B!VZ2``:*.9$6$^'F`!+@`257".;%`J51`#>98'$/`0
MD_`"*<``RQD&@#8"`)`]%X(\3[`$"M@"<T"!*C*!(&"!.U`%#5`$3M*`#5`%
MZPEAK"E3K'%N5?`&'X`\`O`&+;`Q2]!Q%[(#2_`&WIDP*R``YH:>6H`&,O$`
M=5"!&Y-BXNF>&K(#`4"!*2!<Y]DQ'58%:)`".;`$"MHP!X0&Z7``#P``6-#_
M43D@@.F0`QQS(6_PHAJ*;C"0!"8J`"T@`BTP2&\@`"*`!3HZ;E;P,2*0`^TY
M$W.P`FXP,E60,")P0UC0``\8`$1H-S<98'TY`%=I!V&@3=G$'$/Y7$:)E"H8
M#F-P`2TX'AU8!7B)@V)0!0F6*&L0`VBV`'@W""UF`#(0%`@P`S<Y#()@EC>@
MA$RHEFS9-DDG:$@#B0%P`70Y7;Q07CCX`C<P`'209;L0J66HJ6?(!:^A#'70
M`7M``D.@!3H`-_9Q!M%`J770(CIP!AB0`A+5!PK00O"S!QZ@!?,1#@M0FZ7$
M!D^@`[&2GQ"Q$A;P$I<@`Q2P%#`A!@>P`,QU!BD@_P,]M0AS&"%[$`,'\!(2
M!0!OX`-^D'D!4`5#$2>I>`=:`C4E8"H3X&>2XYM4<06(APB,)2,VL`,\D8Q<
M``'X,0!O)@A_H!*)$`;1T5POX!T)N0`:4$P.$`)2L%HU:0%XP`$])05/40FA
M0`<O,`QO8&!^R6G#8"C'80=QD`/!T!8(\%*)4'%[0",0D!_F)P/Y`0<(H`-]
M20`K8Q%\\"RA01<F\!=XL%G]%08]\`8;D`-)0`$@,&Y)D`3*`%PF&9/*X(84
M(#)*6@<K*8F`!`1<.VXE0Y-6>I/!H!['$4LXF$Q%>91)60E#@:;HM34.<`,[
MP&E^T!8`>@9/F1],0`?^>O\]YL<`%K``(G!B33`?OR!.@DJH:4FK:QF%B/HB
MX:!!S"E1C^I-J_`B>.D`+R`%8L8`(7!.ZK2IH9NH"[`!(],",(!X+W`!=GH&
MWG)'T+@V")!C/I``,?`!#`!*=E!/RF,]$&!CU.A>']`I-/8!4#`T_AH#!?",
M2[($"2`#N[,$$,`S>_(!+D``K@,%'D``8@`!K_,`W1L#"^`%)."O'V"!V9$'
M!.!!)V`XSVDHUNM`!M!6"+`'N:L#>5!*1;!<M14"63!-?"$C5V`4B[`'7L`%
MP$$`&3``0OFRY^`")+!>!/`!X)5Q6A9J8T$#N08`?]$'.F5]C.`%,GAT*["Q
M=-#_#F(`#`Z@`#4G#`,P!\.@EW&&<U*`=^#QLL(0!B$X#'1P9\[E`#;``U%X
M?XF!'WS0`QP@;32``_W5!U?0`Q:@`2'0`2&P+08P`V$@Q7S``1K@:5<`?GP@
M`"K+!T+0!"$`$H5P!MG4L!@9`$M0D\9PI3C72;_Q2UM(E'0PIFN[@MR0IN&A
MN01`!0;P2W;`F?V(")TD""6P`/<D#90Z`D.``#80:C02J(0PJ&C9A(Q[J'>9
MJ$>Q`T#@AR6@3:VTA9&S7]*5!NW385(`NJK@@F88'`Y@`@LB`ONR`W#)#5IP
M;HOH`P#`!4L0#F'`!K!Y`P1PHO?T`E`6S'O@4(G":240_P,6``4^,`9/TK)[
MX`(I@+NJB@````0LP$A))05>8`<0,`*Q*0XRY0*N@P%`L`0O-0X8<`#4"@$Y
M`'9$L038>0%J,@+QP1XCH`4Y\&9<<`&)0!0CD$H<\"S3),2T-0!&X4EYP`!4
M0",$X+U]^0<NP#7"LX@)R5`\\9D.F0@DP`6PA@A+<&&`EV"_\0`U\%]]X`85
M;)M#MPA44`!WZ0,'$,-Y4&DSD@!4`!*#H`"_$`8FH#S"`'`M>Q%"/#I4+",2
MT`0UB7\D(`54D0`XT'C@)P)9$$YGD`#(%0)?D6LMD`"=I@*3K'H^,-6RU89O
M'+9,Z+$;6$TYAV%BJK9KNQ(Z8/\`;'"49'IPZY`&8N`#!)`&!%``EJJ^:;"\
M:9`&"=!5GJ1V#G8`HSP(NE')2(C)A;K)CMO)D!L&!;`J.?/7@5F7GG,)8SM)
MK`(J>`N8X2&81#D@)J"?(H#6+1!1$>("0_``<]$'&-``'Q`AFZN>.P8!.L9(
M"A``,@`59_`!;\"L?>`%;)`_+^`#K-BRKE<$4K"J(B``8.<`$#"',B@/*;$'
M)54$`D!*'3`2)<`3&R0GUX-'8)<4;U`%0'(&V5D^9[`#(U"-R_AFHP)HF44#
M`R!_87"1,Z!9HS4'<#,`Q\P%>)('-Z``!+`S/<TS`U`"(K1(/@(W15(!'3`W
M"A#%D87_#FKU5:$0,S;P)*S"*@&0!JQ"`)<R-PM0!C\C!D7P,U3%PLL;1YMS
M,Q9``!K@CN)KV&=P9B5@,PD0+BRC1QK0,B>``BY#+(`RY3S0!#B0%QJ0`QE0
M`+:"`\/B*QF``ATP`P6PY0I0`C-`!%W0`UFP*R4`!1=0`$0P`R9@`BT``A5`
M3'%\D\*A@\3P-7:=MJ3=2GK-UWZM<,X8B$Y"@5`P`/;;I.VV,2<`$PGP`57P
M)JX#?R-GR4>AV8O[A)T]A<80#B5P*7->Z`MFVI?;%G3`!'+C&W9``(63`#=@
M@J\LNKE^AK.]GQZ0X!C@`F=@`!_P`3'P9C?P0E[0WIJ[-E)0_RLWL`!2$`8)
M``5BIJK4LP,,<$]A\&1G8)!BER924.RA1S=0X`4Q,#3]L`D^$"MB\`&>``6P
M6;_'_``.Q'H+8`%B\`(43D>4FF,>P`5GD"A>\`'S,0;)[G"PPV@NP"]O@`!&
MR0,1<T1XI@(ZI``]T-=7Q`4Y4`4C%&4[@`%7A&<*X`(3P`7G1B^.<@`08`(?
M%(I'9$.VS`4JP`,M@$5<4)H,8)0<K^TU1`4!T`06M``GVF4+D`,/\&0,8`8-
M``6N@`$&^F10<)Y>,&90(`(,``9-$`,9P@!-`$'X909F\`#[V0--8`$;8S!G
M#P0JT`,>X`$WU`,/T`,WY`$]@`(]L/\"K"F^*```,*0Q!X`"$",;R_D`'H`%
M.8`""C0"2\``;J^CKE&E?<Z$H;9S>#E=>*S'>7T4?/VVXP$,!%#U"30^<;:Q
M8E`JIZ^GM-('8N`&/7J>(Y`#%G`7R)39BDN6H@XCBZ#77-,.%R`&"7`&JHYT
MD-,'<EL%*$)3(6TY5QDZ(E;:Q2_;&_`&,%`$HH@/%B(%=G`#0C("'Z6)'1(.
M)T`VVI`42R`"*C$[!<]3>R(&S&6+!S4!.D`"(^$%GD)`38J])SH`]P`(!!\`
M,3=V"0!`2SIV#P``"G8#'SLW.GT(2P):>P0Q.P"&9Q\Y7B5]"Q\ZESH*``P"
M`!A<%E!O"US_N"@5/#RN%EP*"B9`5`H("E5+"!!2"DL*4M(?"`@DKM00R",)
M"%(\.RHD4@@>`!,DZ3DX4MT?$`9E!BD8!@9B!0$W8@8W"0H%;A2`DB!-"0)B
M#J0Y,R`-%`4^(LJ`<&)`F`$N+(9)LP#"BSQY"K@(8\?!E0PS'*C,DL6!!`D.
M3.!1&2:!E#Y]'(20,B"/RPHS^OBA0R`$3@<SFA"0P$<"@"E'0V2P@5.'#!]^
M<EIH\.9-!1H.A/K!@\>/V3]HL_I!^R<K3CIMA?:APX5+'[9X\[)E=:$(!J%Z
MV]()(\7`'CJ(Z62UT];/JDX`=8S:L2-%%0%8+'#(B0<Q3K<Z;O1P_T`6SUP7
M*V"P"-O93I]5L.V\,!`#0`X6.@+K#MS'0`XM10[8I9.GC(L%2Q(XV)W7K//G
M9G$>7;`A`(@`""3HD*)E1XE5%ZH`^/[BPP,9=G0,B"%`P0`=&$:DP&W'!8`'
M>_;X@%#/]04!;!B@0P%5#.%%>F$L<``"8>A`@``8D$?,`B_8\:`67*SBPR87
MV&%'`0Q@0,`>`P#P!@22+,!&%02`-T)&>]CA`026A`%!`GLL8(D==/APP!XY
M25!`4#EE<()*$M"@14Y][(&!`G3@-``"`ZQ%!P15O>`"`K!-\IH.5W`1E$H)
M\`"62P_`U,<95!3P!QUVQ$#%86$U$$9.=/^<(49T"/@PEQ\#'!!6'W9$$Z4#
M8DCQPE!T*)"3;"9`$"51"^QAE@T3M`13"$:IY,!H-#GC:0A4:)!'3CN((1T!
M"9B&E`<$.,`''B(@(!0=92APQ5PZN$#`42B\$4```(#51VG,[3:48"YP`5>R
M>[W6UU]KZ374`*XL<\8>#KC6K6.OV>%#`C[H0(<#+]P@@QQA<,"!2M)%*==K
MHI%&UEP*-*`::WDFD-X`)Z2G`P0"+!'#=]`RU\=&!!20A@]_])&'%#E4`848
MST(+W<;2Y63"$,)NX`$'+V``02H%Z+`';5(08,`9-W@APPL(+*!`#%R<#($+
M&##RP@48)$#`#03_0+#$/C;+\,``=;GPP0+O^8#!$A<8D$`)$S`01@D,W.S"
M#1Z8#("`?I1@P@)AL'!#"0L`($4,/']@P`4,(.#"!'NH?,$2#!CP@0\+>)"`
M"U6@"(4EE_C`AK=\#'D4`K&J1`,;@]KA!0:*^>$#%7Z^.4%6Z.:\RL(`7.+`
M#RJ,V0<./(2!9)IA;5X`Z#$H\,*C;%2)D\MB04!`E'^$(6B4>1S#F`,&2!%&
MQ(7.Q408HN?$T1A_.&"#`JMMV@%.,_7`1TYAX)"!IP8HD,:I>8P]E(/*J52`
M!P5X"H"M0[%^AF-VU%#"N7UDL$,1`=C!`(2"K(0U!RY#:5;&H,47OP`F_S`.
MZ)&*!-"U&X1!,3>XP=PZP(*Y-4@'!G"!(];P`!7\*BSR^DQ5"C":TN!+7ZLY
M%AV0,`(Q$*`#[EE%,C``N=P8,#!^N&&LPL``'N4A`<I(P!GNDK"-0:=C#N#!
M&U;0@AR@P`1+0%$)H,"%`GA(##'X@`+`8QX&$&``4M!$A_9@`A>\0`>S^0`U
MPA`&5SR`)R^`P`,^,(`])$`$+CB#A1CP@0HDP`]QJL([[(```!BL7`EX`)?$
M90$`>.$".BC!;\9C!P@P8`<)<-`"7%"`O)%``(I4#Q=0^0$9.,D`47(0$$KB
MDA,0R0$DN(*G:``$%#H@!@O(W)1\<"A;.0".6__2059*-#H"B"DG#BB3ZV2%
M`@G,90`9*$!BFH"`%T1I#VSPTUP0$D$Z0"XL?QC`'."51QDXP`\.*$`"7`=/
M1W4+>I*"$P%<<`DFV``EW7(`2_C@DI@0U'KC4(D=<E4`GPP`!3CZB#Q?\((P
MA.`!(;`!#6R`@AKX8`#8[$(!!D```M3``"3]IPH$\(8E&*N`/TP+`NF@P!\V
MD%JZH0.W"/``"*3!!2LJ@1V*(``1'``&`HC%#?I0@A$P0"!Z4H!FCA)!%>($
M"2V\5Z,:`(24R+``#5!:`Y;P1AW$`&0;*%U,]=*'&SQ@"8-XPZ\(T(1AM70`
M!G3B<SI6GP"T8`<H^`'_"]HS0#MTX!UPU`0#7O."`[Q"-I*!1H-\<($4^&$/
MW(%&C(Q6!!?DS0YBX",C2H"!&!2@#PG8P08^^(`8U(X19\``U/I(``!`03\>
M2,$',(F`'"QA!"1X#0%V(`,XGN`""_#7`T;P``&(BP%+2,$(/N""'!`"`R%Z
M`P94H`L`T*()`GB`!2S0`P^\H0<Q@`(#@*`%,X0H!CEH+0-B,`(O/."^!]#"
M!Y;PB#?$(`4`V`$0L%`!1PK@`)39004"L(0=""`'#=!"%7(`X2+,X<$[2,*$
MM3"'`S1@#EIHP1N`<(`#4#@`<P`"$-CP!C<<@`TL#L`*&E`$('0%QL(*0`/<
M_]"`!CR!#6YXPP:NPY45A,S(*Z@#&S;0E6$U8`5!WD"/5U"$),"8#5I@\8MA
M'`#V'J`%.A[!`0[\X1&,`$!:0$,.L%#%!H!@!V>":4R7E4!GV51:#JQ67A1#
M!R80H&X*.,`*O#``!\P!`BS`P`=8((,%($$'8H!"&J+$!(GUP)J#D@MH2I!5
MTS2*#5WE5WE@=C7IJ$L&"3CM6O.RIB5(80$-J`)C]I`&"&0@U8QIHEZC(QT'
MN"``0Q"!!VRPAQ(\8$!5,(`)O'`#`"Q`#`_X3EUH`P4/A68))?"!"710!3/&
M``,G\(("5GF!1LYN%=4M`0(P<(,J/,`%`M@9`%#K@?\P=&`)=\KD"!#`!0!L
M30L#Z,`#SJ``%UQ@?@3PP@X0>8@E!%Q1PB`83PY@-``00`9`(&H#QIP"`>S@
M"1T7P0Y:@&#,`,'C#A9``,53A16P`0#B^5\54D`9QSX"`#5^1&7\&XL='``+
M`0;`@V_^@`TXPI'=\<)^.<RW!]C""PQHK2.@$`-80!T*"_#""NK"!0:D8`E-
M\\(2<$$%H[F`#,9X!`2H0`4NI&#M5#`!"K@Y`04T0052($$&2`#*#$"`/VN0
M@S0PX(4;M:,*&)""'`R``#-<(`'_```50M"!$!!B"@D0@]T7?P\,R*``!I@!
M#WJ0@S<42R5R_B&=:6IG`][_]('-R8,?\D"%(F@!["CM,Q#*Y4G]*,`0!H!`
MH27V!SXL(">55HE:I,-I>WEZ`C`(M0S/L(24T<%G.DA`U+U`H57CQ0\OH$)#
MRN`#QM2D+LM8CJYW#443K&`#,!#!'FB@`RX,PHT^2,8'"-!P$<2@0C<0`YBT
M!WFT`UK@$26@"1CP'GOS`1&%``^P)TR%`0%V`7$D1GT$"R)P1@.P``OP':T0
M8%*@`WF``(YE`"]P!BZP`Q_8"5/S+S'`!CG@)PDX`E?1!P4@`LFF,F?#`F"W
M-C=P`6P@$"=P`CB``"=0``7`!:EF2UF0`THX-$[7,$/#!?B0!@40(060A#%@
M`0=1_P(&(`(^<!`=T`0X0`!%R&\S<`57,%QL6(4)$`<@E5X<>`9L$`<7L1%E
MD`=A$'X%$`8@00`'T$<DDC,58@<W@`/OH1+\Q`1V@$\ZT"T<X4U],``DT!+=
M$@)9<!02T`0N(3'=$"5^<`-4(AT/D`!SD2=E$!UIX`$W0!I]@`(NX!JH!1&I
MV"=OT@<L,`$J=WK.YWVK5U.NAV<X!4%ID`-`X`(&D`87!#ILT"(R8`&2@0$L
M0`<W``$7E!@.P`6;X0!,((KSPE2=-A?0%VJP&(WED@>P@0E0(%M<H'[>]P<T
M4P5IX``Q@A-A0`5+T%I4DE>[YA9'80)O``.J-0'TEP"Q]O]&A7)FEE!L<I0>
M>Q!:7*(##)`(/1,&`9`"QU8A!\<%"((`1>`##N`##S`$5?`>S38$7%`A8>`"
M;X`$%34`4#`25I$";\``CA$?-K@*'0@%[W$0`-``Q58;58`;4O`!5=!-57("
M([`(.G`!'<(`F*0ABX,3C7-+V<0!,,%+88%(#.`"GS$E`W`H8+D*)3.+ES``
M.^`:=G`%"X")#H!#TR0!U20E"F``86$'LY`'WU0$8XD3:9``DT(&)T0<!X`3
M'L(%5.`:="`&I0@7D8`8T*,`0$('(+('$8--+4%0+-$',.$`*(!"$P,E<U$`
M5!`K30(`JI(5K/(H!+`&)\`9'27_';ER!HGA`N*D$Z=$+#3`/60!C#,EC`G#
M"F)0!`QP"4"D'@2P**DX`!!0?EZ0BCC1"6&@.2W7`%)`BUT0%N6$%V_A`Z-Q
M+&71!Q,`:E[5&6$@`#)Y`!/P'G8@!0(@9@RP*$Z45^/R,R1P6F.01UJ@!2)@
M`B\0CVG!:])!'3#P`2AP179P-`I`#[+P`@GP`=]A%EP@@`\0!LUF'EQP`A1I
M`55@000#`:M``!B@:!9`4BFPH$OS'P"P6R50`1Z`%8P``#*0"R7C;IST-!ZP
M!'F0!MUV%%0@`%Z0;'^0`!0$H*,0"UX$<X`"*(JV`",@HAZ`24(1!D4`)(02
M$-)!$5W"_P9Q80<,L`",T2.<\R9V,!Q]\`)ANAPCN0/+\P<$H"-N408K^28.
ML`1PL294`$M_L`=>X%F'T0="R22L0AH.@`"Z9$V3(QAV0`8W\0=,D`8\$3%]
M@(V,-4K*5#8Q8`?@AT9XJ1AB@#%WX0`8D`<1XT=@.137B)H.T`1&$26!*2_&
M]CMA\0`F`(M9,`&ZY!(3$"NFT0%_!`(`<#M,%(_+UP?C!H\,]!K%>9S%^GU/
MA!,RD`*8Y`!3<@!%$`IQ824Y$3%XX`1,(AUL\9WA219948[G20<6<0-%<`M+
M53:]6@#WHU>N9P`D\`(/4`5UL%0OX`,(<`%GI&?`2*`X@0`Z!O\`'D`#`D`!
M*+@F.S!&;_0?-[`H9A4`7K0*CM`@%3($"^`89V"D(#@``K"22UD'QPDD/@`W
M%8*O#)(5$%`'*;`*=B`#58!)+^``6B``U1,&!3`'/7`N=N`;93`7?P`%`1`C
M/F``56`!E9A]EA4&>Q`&`+`!]F`'$^!%.:$#`A`;,,,(?7`!Y8(3+U`%?)8'
MBEE5?K0\0H&*W%(\4G`H>0`%CT(8K\@C\N0Z-^L"(,&'!L!_BF$,=V*/+,('
M',`'-C`#[L(''6`#W&D#(N`A<)(`96`'CC@`<$`2?X`'")`5*G,,C-`)FVL6
M/E`&&`,G]^`A'J(`>?`"2%``4A!(!*#_;LE5`%D`!SO`!?'`>$RH>%R0`UTC
M!4$*`"K0`POP`(#E`1Y@`0)0`0DJ="W0K@!0)0*[:L>:K'<&:<:)G'K!`>EA
M;9=0J3L@(.E#`0'P!G6P`MH$)Z6$%G=R!:[2,6=!KJPQGNB*>DU2&T]@70B0
M'QFD-BM)KTW$@?+Q!A8(1R]``#[0AP+:&`")$USP!HX%*S#P!!>0-WO`;^5R
M60;3J6_P=J]Q!@"P`ICD&'Z@!71T67:C'AO"!@A@!WMP`DG0,ZO@!PK``%CA
M!V+0`$OD!Q\P!`&2IC;I1J_1!W60`&CA`&50!3<Q`&_`!JIKJK&P!&:Q'4L@
M`U\B`!R:?2<G_X,IT``>%V`?4`<W!P#2=7-%D`-%=1EU@$H35KY5,`<4]@8Y
MB\8-D`-P/`<M]ALEE@0"$!P'T&(E)FAOT`!L0&5)\&0M]@3E6[Y--BQL0`$Y
M-BS7`0)OD`3640<4``(4D`040`%U\,F<W,FBC,FC+,JF[,F=3,JD?,J8#,I)
M@,E/$,NQ+,END,E=T61&Y@8K$`"Z7,CE6P2V5\A?I@405F(Y\&4-,`3$0JP+
M7+WO>+W-JKUY,5IRYP$/4`$5(`(M8$&6$0=P4CP?D`8?P@#:-`E8L`1-`*[E
ME#F4VB/E2K\P9+]^I`5O]X>K(`-(J4B64I\)\QH*0$$04`'E,@`34/\%!KT`
M$".@SM$Q?2!%$%P$%F`43W(&C``T3F,)->,"F^J<&``%#E@",=`G'K(W#``%
M+[`'"N`%%F!&!:``$V`!#^"O,>`1KA&A'\`%`^`#A$`U87`&\^4!).`#4/<=
M??@`)=K"!F!?S)8'GE21!K`?%3!&`Z+1T::F66<!9T``ZG5PR?5X!C`$56,/
M=C,W!@`%_YI!"0`$_7`#97`?_*!!#)``^P`B8B`0H?4``J%!.9`&`I$`4``!
M2G@#"G`X5`@`!7`0+4TN(!4B2$!'/C`'?PA2,Y```V`#!#T#8<`'-*`!+;"W
MV"(%>>#":?`%<?"->X`B,:(EE!FU-\`%8W#_";-A`#S"!*'J(0Y0/"Y,!S^#
M`(/BNI'C`%U0!D`+,Y.B`680/_(8`WCC$CNA2WRP!SCP`Y@6`B0``,N\"LT\
M+]8[C-CKK!`D`03PTN/%`#T```?``C10!/$#)PLC!5[4#0.@)0*P!QS0!#GA
M$WFZ%M(Q`.]\KOHR)O<B`G9%F:N`UH(M%AMC0(2R`+7C`0<S!B1U`QU@`$B0
MT,9*L-L8`!NP`4E``C1@!Z2%T*L``6P0;8_(``1LP1!0"7N0!R4@`ERPG"]0
M`#G`!>5"D@"0`">]!ZI%T6@D`"3P+PO0`B,!XAKV'7MP`^UAP0M`C;=C`%1V
M`R2B`#EP6W"R`$!0_P9PI&T'8`@0>@#N438T=P-C@%JA1!#=^P)7>DQV<`)B
M`!L4(3"!\HU-@@$N4&EIRA-#@:SEY"0>B1ACNQR:0R/2H7EW,A=+\!9G0`:"
M.10,,)_GX@"#R"0:H!PY`1!\('MVP`9`HA(V<RB"'0=-TBBLL`=<Q`INQ9PO
M(`=E4%7V((I,@`'$2C/!%#&"'3\YT0-?@">Q:A8%4'U'`0#;EA-9D`%+E*:]
M&A9Y@`,>P%+#>A8*K=W/S-W1_*QL45#V2`,P(0$A(`!90`,P\`.(!#X0(`9[
M<`;<YP5:H`#5\P!=&4$1H]]2TM_D2<@LX)G'H@,&8P$=X44@G@`L(`8]`__`
MT)*F7/``H";L*G,#"U``,E#!S8SA`CG(`70%`T`T35X"`N]:D",#4MDW></4
M%I``+U,`U(418.?@,C!N%B`W;U0";Q.[LR&`!0`!M?,.%W"*,6`"%)U],2`%
M_D"B`,`"(*)>&"`&95#27L`%XIP'8I=Y$YL`%G`!,K#S7ZG5C]XW5J'CI_B]
M>=``M/@A`H(37"JVE!,E8(H!G*JNS\DH5)`5.L4`SD(\`L"=V`)+42(&7.`Z
M.+$$\8XMC4Y3L@Y/=#`')0`OE:Y0"O`KR7?VAQ$,)6&9"N#-F(D>A/("F'H)
M?V8I.E`38F"/UKA40K&-6/H",@"6;^*Z&J`2?-#_!*T>%@0@W'.1!@]`JW_@
M@9<`6AD0*\AT)*9A`3DVK-(,C-*NK,E"G-EK[6@A`7OPF<[/`D//X_9T+@.1
M!O#T`$;V`%:9`3[Q3M$A[Y5([Q/08_=N37B`TK%V`S[`?]M1!5HP`F!/\,F"
M+DOP!D,0G[9C6".P`],%"`1_@X2%AH=_?HI]C'T./2"1("(`%AY[9PP`51\#
M`UX,2WXZ!%IB.G8O+EI:,G9]FBDZI#$-"R\Z+$L%N#H+2P][.@E:*0R\>RE`
M-SH#,3$E?78F(P(+/GT7*3DN>9]H#PD.!FP8/G0O!`(""&%[2T4""CH%554`
M.GLR7F%24CH8+LR:Q>85_ZH2S'3X05!B%IT]!^C0<82!BQU%>:0,\-/G#P2.
M=O8PX-)H3Y4_=AR$@2#&P<0;"L(T\B*1S@`JXAPXX,)E@(,\87(,8!*R@(%\
M=JB(<6?'1I$!>?*HHB(UC!@%:<(,>+%`JX\S,:!X\G&#P1D?`TH@D.+C*P($
M!.*F>5"@0(D"$##$)9#`A0$-:=(`$!(XC0$$:>HF6"+E1N('%NK>H&)&BH'+
M'B`DN"%&!(@`;P`,V.,`D6E$'#GV4<"E]&E#`UD48:`049^')VY(OM%AP@`[
M+";8>>B@`)<SM_O$S>,2#Q]&JJ'_:30`C`,_>!8I:-`@BZ,^>.Q(><:@91\=
M%_]RL-%24)%[]Z\+G5>``<F-&+A>&#@PI,B#,_'%YUXCCJ@0P($;\`##$!?L
ML<<)`E0A1A][&#`"%ZC8D<`'">SQP@4``,!+'Q`<\,`+YY6``08EI.("!C?8
M,4PY8=A1`@`'8##`>3)\<)0.!BP1`S,W:@$!+B7D4(08$YUP3P'HW/"`"P/\
MD485(MRPQP`NW),`B@0`@$`?+\"$P0,/0+!##!,HH(`4`2"@P`00+!`#!!!(
M`<`"$-")0`,(0/!6%3N\]=82+O@CQ0=2)"`%`CL`D,!:"!P@A0)R+L'`HQ#$
M`,";:^4@J!14"/D6!"DLL0`5:S7`1:`*0/$`%9@"P(#_FPJ0T0!K9+@0*4\*
M,+##`KDJ`(`+7)B`@3T+<&&G/!8L(.P.4#`P+0,Q,+#``5PP`$4,*8R`+11+
M5(%"#P^8`<0.V(:R`P;9?G#`$FMXX040(\3PP0,`"+#$!Q_$T`(`2VRQA`@'
M%!&`:-<%^%IJC+#FFL.QS5;;(7XX<.,Z(V@QP@A5-*3#"Q,Y8,<`":31QWON
MX>&RRX2L/!TCU3G@LFK;-3"#`^#A\8(%L@K@0D-T@-@O`'NP#)_#TG@@@P\O
M5.!"'P-<L$X54/C@\&D#-K+3&V\<``,`/.1U%P!08#"T#ME@<$(?7"!D`A0*
M(#K!`@9P@8$!&``0QL@^Q!#0_P(WC(>$`1Y<P,4#%UC@YI0AV6%`#`7`Z(,+
M#%P`K[$D+,"H`BD,(-$`SN;Y@A@?O)E#FUP4OC<)2QS5!PM0)+`B`5+LL`0"
M*3R@0)\0!*"`"[_#BR<">^*)YPJ!!EI%"@BPBL`2H$Z?IQ1J[O!HH)92(84+
MFG+J!0#>2R$'._Z4NJFCOZZ5@*L)Q!^L/XLID(`,\3<0?QD;>L%_&1!X@!3X
M)P8O&.`"]P.`CPX(J1O<@`6V:YT#B5<`!YX```0H@'VXX(6Z%$`*4)!"703#
M`P*D@0!E4,`93)B`'23`A`-8@@7B<H8$<,$`7SE#0+XR`!*H0`0+DXD?MF::
MU'!$8O]$K!AMAH@Q.XA!"_]*014>D((#G,(.%[F-`VY2@)4I[64P&X3,J&.=
MFT6,.S,@T`L>L(0=>&$M,D)`#!#P`5<H31%;.\\2,,``#`PA!1Z"0`[.Y((7
M$!$UB_":`C:P`1AL0`5[Z$,,=O`!#/J`"PJ0T8>.)8`SZ*`#`DB!`EZPAQ@\
MCP5V.,,!&."A,CW@27LPE@@20`\`Y`L7$```$H2A@Q(5X02DP$"^/#D!`6@!
M`WZP0]\(P#,"?&`.7'!0`@#0@!WHP`=0$,`."C"R!9@C%3YX'@)>\`(2N`(#
MM&3;`-B`BY24@`4#88@.'#"R`_`,BR-APD16LJ-70$`G=,C_0T5>\1,!,,(F
M+.$('0PPRI(]8")4<T$"#HH!L:S,`3GHXD102`>.0``)$_%#'HJP!SK,TP40
M8$1Q$""ZE,P#%2]0VT#.<(E1O&"`///#90[J`"@TXJ8NX%D?"J"`&;R"#V#`
M02/XXI(^G&`7(9W2&!@A!BH0X#Q[<,$-&M$!$^P@-'_KR"$-8<35M":)LY#-
M$E&C@QM4P0<ZF,(4QI&"&SB```X4@UX3`(4;W!$[8(S9$,EHL^PP8@)L@$$:
M">2"",F@+FR[@9R&IY`[YM$7MGO``63@H1MX@`0(^-)8R9I(E?*`D6\``0OV
MP`<#[&`$6K*#YA"`#0(4800?F,6-_U(@!AE=@!/`#$.0I$#.`2Q`"Q^`:P)&
M`(0NTJ,*M]#!&1:@U;]!H`$"*,&6N%`$*+Q@%!\00#JOU+H^A.$!0%A`2`A0
MA5WM`3@1@NL+2F`"$S3D#`(`@`%"(@,$E#*=?3A#`]@VBQ/\2`<(X*9"PL"&
MB=#!#C%8`!T&$08J5*DT5+@-.B+,LX#F8!`V48`!")$W%&7L`QWQ`^FDL+(^
M\#$,"M4"<C::@`FO!DJ,",,*7F%28DV8'A#8",\4<)Z100%#;`M<TD8VP(G\
MP0!E4*D=&-#4%R#`!73(3@&H4`">.0`,"5@$4U>6AB5L-1$/,,$8IB.&&ER5
M0EI51-$4\/]5O[%MM(4H*Q*WIL2+P09(.SC#&*9P@3Y,00!:VD$1#L!H+>2@
M"@;X*QCQ(-B94:V,ANW#!&"@6/`T(A4H0L4L9/"`;"VALDK;FDG/X*!TC"$?
M;M7=`@"$YT%T3:5<6$$U15`!5$I7`56X@1<HIX!96V`"!=A4`0S8@3V2TP>5
M>\$2!N"#OH&%10KP`N8V4X61O6``$%@"!!@P`:O9#P`^(,`##-`!'RU!``+1
M3PYD8(`'#&!18DB``@K`1BD,,DP6V8H,3."#M12\"@HX`&<F$`,O:"&37.#L
M+'P`A+_-(H,RLD."28D)+4B$0F2@0DH"RI::(&`X?HBI`EQBDR7_T$$G][[!
MRQT@69F\7+VWN7=O&4&%!?33#QF=^1EZJQ.&Z.1D6I#1R"!`@E<H1P8P5LC)
M8?H[@_A@`;.P0QC*T!*=.%"+="!)2O8PA7^ZY(,$8`+/FF"$E]/!!P:XC1W2
MX(4TV"$/?H`"!,8@([33LY<$^'APZCP`'4RXUHGPHEDG%J`^,]$0TKB!CG00
MAK^=(<AM-8`8.&,`*6"@`)(.K!@'2S-,JP:Q.B-02$I0@@L\]CPW,$`)TGT1
MRU)L%L+(_7MOH%4"^&`/B$]$:1W!A2$`H0(5(`$*O/`;`G!!!$L0PPO"`.P3
MT<,"*>`".7G_)6D(,K>D8(#0SG"R&!1!_PI)0T`5D*!;*&#M#*<#0`Y*X(<]
M@&@$";##?9)[G@N(0`LU-@`9``0BDDKEDC4:<`9+8!%D$@-`P%O-X`)#@"'Z
MYP$Y$"(84`Q08"<,\`0+,&R>L@,>(#@"$##6P@!O8"^R<@!S8"W/D`.:4BU5
MX"UG<@"#]`!0X`5L("L/\$PS.&S;\`'6`@4'X`75\@#:M`9IDP,M\``,\`!<
M$``X:"T?@`9K0()"&`-KP``!4"WPD@,"@"V>`D4Q@(-A6%$Q\#$,`#0/H`5<
MX`%H4@5H4"W78BT+P`9VLB(IH`7>A`'E(H0]P`5`@`8]``KEPH%+T`!+\"T*
M@"\+<&1;(``X*/\X(["($58!.]`"`5`!*")6M:9G9\5G:64QCU<(*7$&"D``
M$D`'!#`!)/`#>4`:8$<U^^9%+#-IE4989K0::$0@>P`!;Q``3_`&,9!D>I$/
MJ,8R>30[#/`!5=`"UN0#+/``X_0*P7=KCH```=``*%`!-!`"$.`"(^,";*!?
MI%%)IR8CA^$!!E$"'W`#O\$G`C`*);`$JP17RE&&/N`.4O(W!0"&&.!))>`!
M#7`!HQ`&-R`M[W4YT'!-(Q``XN`,6@``$"`1/H`F!.`@-^("4+,$`(`!$'`R
M`@`%0Y"19<(`;A@D>!-[%]``+.!`-R`#$%`7*I(`=H$0!U``)\1OE!/_&,91
M!B=$`%`0E/S&`":4!C>0`AED&$T``4N)`#"R%P\0E&+P*D$)!5`@!B9T!CE@
M`'MQ&*Q'`!A0!G)Q`T5`DP40+32I.+)G%PM0`@1P%WT$ETAP`4O`>@5P%1!0
M&&^Q%\X4%QOD!4A0%U*P``EP`FEP!61C0BB4BB60!BV4,@7@`XL8EG+`!4"I
M00R0`'=1`@K0`R+P!A405M>H>'MV>[E`BHA@!Q+``@#``@[P`TL`&A-``REQ
M3]<Q`#RP57>$BZ-G:36SBSGC'3VC`TN@!550+IG4![%7>-_U5Y<UFTE0!W70
M`F.P!\8A,IZ(9]CH`";`2#FP`R>P!V'@!2<@_P4C(`,>20#A=@$?\#>D5`(,
MP!`&4#4SA`!><`9<L`,O8"P@@@&]X$RT1$MLE&S'@"9AL$?^-A!MY0$%D``7
MX`,'H``WH`4&(`,YX`!P("+=LA%^4`!SL`!]\`$%(`,I$`8L$`.7=PVI$E/6
MM%[4N`<8(''-``3"(",(06`))B-D<@`$U5-<$%)Y0%O2\`=$Y@AV@$E>9@<I
MH!J7%'<=Q5`DPP@QD&(#8#^,P`1'MB,B)0!7U5$^<`$0Y90']0)LP$LZ@"DF
M10HR4'@R0F2S$%/BR`B!<Q%,9@`AM5-^\'(8L#+H(`-8Q@AI,)->U@-1)A%\
M,1Q]D`8DR@A_,"5LT_\'8D"FJ.`"2)"E'4!G"\.EI:D=H8B:-\`&%L`V=Y0/
M%B(,H",#PG0#KZ8#?V`R?_!@VWD(+],(>-!BC$``UM$S1]0`0+`SR>$`KR@!
M?.``>\`!#F`#!=!5&7`=2D,@>/0'DY9I!H`+>W`'43<`"'`!$\`,!-((1/2M
MC3`!*[`";+`"/4!/%X!;!.`BCR809Z`%#T`F*A8#`B`#LY``0%`%9\`1%G``
M^.$`UY8'K^`##[E581`#0Y!;J0`!(U!(>X``;'`!U]%66N`%/I`*`@`$!B`,
M[W.OY`D%.[!?Y/0`3S`!#N(";]``GD0B6E!(%\$`(3-JZ!<#'<LV##9/+E'_
M`A/""%+`3"]7`B/`F@[`!QY@$<7Z`Q/P`Q(@`7W@`I%$)B:@`%'[`BFP,L%D
M`'F0KUP@$X[P`<FT17[A$@!Q"Z_@!P=P#LU4:(RP`-R$(G8P8''J`C*`M87#
MI4_K".0)DG^G(G8:!@@0=XP`H8HP"[218V[247X`$S'"$0;D9#644\LF<[&Z
M@)&J;Y[$-OM6>R%03"```#3`""_#G1.VI\AR>*`JJJ2J-&,P!B!"`'*J`S>2
M?WU@`4\``G5``10P!V)0BH90JZ*+JWU0`KMJ1MOQJQW6!]](`S8P`"'``AQ0
MK!S0`A0``!UP1]#*1-.J"'>5$N=19!YB`0$@`%TD_Z[A*JY[H`(;T``KL(DT
ML`<)$`!O]0IVL`,G@@MA`#!V@!8?,+*X```BL"ONX0(?8*SSI4#Y\%L`\`!M
M-0)%``"]4```6WF+^P0W$(O;T9`&(`!/(`JX8`)L(+A[\(B:M+$`H&(,<`"P
M-1`>,`'ND#0Q<`"XH`"NX`6%I@@E4!!(&GM"1:$-$P8DQ3,O@`(J(`$Z<0(F
MH(IM:U-A<"ND>@8B\)Q75[[9T+58BV(<\:3G<5X`>I`'$`WTU'KSU$O(L3($
MT`!C(!%9)04IT58)\!L3$9(K$TMR3`\8D#0J%KBH4"$_(@PBJDF.,@M]@`0O
M='=V\`!S-1%PIT7)5@!J1_\':?)>%0(!GL0S;3H+?H`#)````8`"-'`=HSM:
M>YH(='"ZX:H#8V``#>!3?W4>!."1^'(4H715`.P"5-`KF(DBIP&\GA8=)9"N
MC="KR!NL`Z#)'4`"T"L!)-``(G`%L(F]P:R]D[:G(7$!-,P%'Y`2%Q``F^6U
MYKN,XKI(#=`"(I`!%?`.`R`#6A`CTQ<#L2,#*3>U@<,`,K`GQ'(&-Y!;&=O$
M]TH"87`CUK($>/4!)K`G!*``.7`!6'1U1XNO)S`D".`!5ZI`2Q"A6F`!A:L-
M^M:Q,KL`L_1;'O`B0[4+YR%M`#`!H4,#'3`P.X`#',`#(<`',GT"(H"L?,`!
M1$#_!#+-!QEP!47K!$2`!>>!11#@"C*",G_S8!I!2E;F7_0$%KC@!R7@%_DA
M`ZE8>7E@`>09!CX``3?0%H%CJ25`;47PU6T1DRM$``LP!;K1>A9Z&0;P`5!@
M`(16`^A$:/<A`_C3(P]@3E;M0J$U`7+=7PA0+1#@)B0P;PI07YAH`BX@V"*X
M`,=6!!7``%M8+MWB*6R@*6NP`"L@K_]2!0<0(O?0`,_S/`@#`Y_K$X!%::)<
MNJ4<I*<L6ZMLBRPS,GL0)@]``/EP!H47!@WP&]'A1;OL,M^J&CJ`!,!,(,<+
MK!-!`SS```/@52S0M#3``<S+!S0`S=`AS6"D4+*G`R?0_P&A-@#P%Q*1^JWG
M^ZVEO`%L(`(FL`<[4`?[);MU5&0?\`;HAPHIP`;S<#(A$DE[@`1:\'NH`(SH
M1TH",`+L5W\-@`$$1F<"07D?,`*B%@-/<`#",+P5D'^&ER/>I@!U`,%85`4K
M,.%]H`Q8M!I%\)[YP``-@`L24``[<``"X*MOL`%`4`0[7@<'8`4-8`5NL`%6
M4.0!`.3E:@4!L`)#L+))\`1-_@9#,(Q@<R`'`C9/\`3M"S9)L.5O\`2@8>6@
ML0+N70=LX`;<,8Q#T`!L<"`-P!\'0`$)LVAL,`2,-@)OP`I:L.!UL.`@\^9M
M9$M%D`(AL@0Y\`%+`,OR^@S'"?\%`6.O'XF5&+@B+@`$+^(")E`!GT(G94C#
M$#H")@#74L`%>5DXL:,!!<!>$Y!#4F`"!1`&+V`'E+S'%1``C+0$R-HSKCU6
MHVRZLBV*=M`!0V`!W<TR'+<52M<,PN`#;+`CCO!Q\<'+T,$(;=4$0M4(S9V\
M>]`!(8``+=`"&4`#$O`#5W`"$S`!,\#=Q"VMT_QR,;!O5<`&^-H'/O`T\5/&
MZ@W.!.*=Z^NK-)```C`!WX8[J;@E'E`$+Z4*#U=XO?1YL3X`'QGK-^!^LT8`
M!E`%K9`T7/&.U.8#]`&[!?!N\'2111!L+V`RQ.,#K"<##8"O`X`!;K`#)2!<
M.\"'!)#_!\PI`-6J\K^0`&<@`P(@`@)/`-.#(]1C*X$BDT6@UWI=`R[@>IHC
M`S>P\E50`"M4`E#@`F>1;@B`!&/-);#^;5,;$B\0;2AR!E2=#X#J`\:Z!Q;`
MHP57`A.A`R'4B2]P`'^ST`K6!T_C=F$@`(8W,C0\$#?P):KQ#W$Z`0C`-C8"
M`:B0QPFA?][:MN?!!P/0`0E@Q`[``B1P`BF1![VF$P$6:;=:.<C!,V*2<7U!
M?GD@`:[.,Q+@`1L0C+BNZ[M^2+T>VZC;>+/0`0]>[.\!)`%T8`2&"SGB&#MY
M!HQ'J\9MJ\A]`];^K=D>K`K0`4J"`RSPR3\P`]Y^`#:@[M&Z_[W24`"?T$F%
MU`PQZ2_1\,U,(ZX.P`/!^!G1"Q"!P@`ED!<*8`$(4!81"@@+7#<8$`,Z.A=<
M%U((?0L+"3$3!`H,#``&!@\R.GXO,A\,"P8^7`\+,1<W#PH8+@,='P4O=B\Q
M&*)]'2(0&!@O"@]02PA(`%YV?8D/&`QB+Q`/#!\L/C$N,5`O+S6=&`9T=CIG
M6G1[+SXW-WOM$#?<+R5:>\MA,0HZ?0YG"#[Z?2`LVQ-F`01]?@@L\=2'`(,"
M.FHEX!(&T9X'B,BYN)'1"X0]B%XT>#$0B0&$$$KHH.-G`!L[=.B\P.#(CPX#
M4L+TH:/#Q4H=8;A,T+?GAD]]/A1P7/]FX`)`'0P02?"!`(&#/G8Z3#A1+P\`
M%C'[7$G0QT\?.$W.]-FW8P),!U*XG'%@Q\Z@M79(>``2H`(?!W[P"/Y#N+#A
MPX;]T/FCV`67Q8@C_]&7J`&&M7XR:[:)@`V0!(B6Z<AC9\\)-@)2[-A198$/
MR80%XUF[%H_993=4`*;=1T$#(#.NTMF'0,2*5@AH[+%38$<.`GDV:^:=.;9L
MP7X<\),"),89!B]TV"GA(L4%9;S7PD:<?JT#%P'>;%C!08*=&T#8D*BK@,T'
M=C=HP4`*RQ20R0OM+`!``R[TD8<`(QP5Q@,[+)7`@7T,`$$#*1PR@`=%)%`:
M$D\4<<@+$P#_@$1(*0A@@#((!&#B``,L,<11%UTP`#H8!#!"12]\(`!'X0'P
MP1FU()#`'EZ$,UP)+UET@P$@[5%#"6,@XL,!.T7D!1<9$0"!#SS1<=!:P1R$
M5`KU-!3##:(A``PB=GR@PW)G;%2:'0]`@*`^`9"$R`D=`*2`2OJ$`01`>W`A
M!5X&R'`((F?J,(`+4M!)'IUY<H3(!1<,AX@%M+U``@(\Z:`55W=FLH]89935
MAQ@Q$*"=`U7LYX`.";AP!AW:N7""=GMT0$(.`0#`P56RK0>;8HS1X1ADSA*6
MT04-+("9=)]$A,YPVH5FAP-((*#``BXH8$!TL,G&FVUKZ9#;;K3Y_P;<6L/E
M<8(')H1`@@%\V$'#`A^0$`(!F6&6GF9_]'$==MK)L,02!;B0@$W!?(#`#63B
M&V\?C/E!6'7LM=<'#RL<(`(0)'"0R`<`F!!&"0LLX04M\BZQ`$$EW`!%`@@6
MMX0,?1C@Q0<NJ-1'`0M@4(`/!""PA$\W>`'`T`-<$`,`#XA1F@PQR&#'``8H
MD'0P'AA9PAX83.S3V,(0<$8C`GP01@%>3&Q`G@\\X($!-IWA!08^^&#Q3$LY
MX,,(XXPQ'@NE[8%`">/L40+C5^W!@$^[4N5#.PXH,,[8+B!P)T$/M&/Y`NQ$
MA``7GQ.TQ`LT%L"%`0,4[@$&!(1QQADKW/]P!@$^7(```<B#0T`))AU00@D%
MW.`!%T@44``$MUM?``8G0&\`+MK+\(#U-XB_\3HNF-`4J#NL+_X'"4A!`@,>
M*""%%#((*`4.4KC```Y548$([(<`$FCA`0B```*VI@`$3``!.^""`R?@@;T$
M8`<TT$YF;%.8A%5'/80!6<.@U9C'5*LP&4E`MK8E';SL@R7IH4,)AI<&ZR%O
M#R*3C+MH8YO,Z``)37"`;,S2GWL)D2<F6,$&WO`$`&20;!V0`0Y>(YR=.`!<
MLOH#M0P3DPNXP!DVPY@!Q&"`&U0$/1F!X7!N$QF3O6<#!]B!!0"@@!<`8'D`
MR",7HN$!1-F!`7W_^D#Q```%$T!A;0R0`0!>$`8%`,!3>R#!$@2`@3"\(`40
M`(!/2B```0``:'DK07CZT+?Z^6!`'O""2F0@@`@NK0KYB`@4<B""%-S``5=+
MP5`(D`(@+&%M#]`"`9;Q`@0`8`=QK(`6=K"$#RRA`F_X0`4J@((=8"&/%9@#
M%K"P&BRX0015$($(BM""'8A@!P(`0BN/J8445*%%;#@``*J`SA54800`$$`#
M<B"`=VI!G2E0S1O>*0(!%"$UJBG"`5(PSQ0\X9T,'4$.JE`%`*@S-1`:*$5%
M$,^`IN"?J?%G'@'0RX724P!L(&D5##J"@(I@!)ZLZ`Y2&M(#:(&B]]1"_S\K
M.@0!G!,+.<@!:SI9!"P4E*,M$.<.6J`R<P)@F<>LP#F+T)=E\3"'#=N)>ZZB
MQ9UHD26+*>$6G97"%9:%6V:!"7K2HX.:/>!J,(."#T08F1W61C,_#"*\UE+$
M&>P##\#"00X.T(`1**`B!7BK5,]S%>U<[T57]"I=$],'!@C@GS:MQQDJL(,/
MQ(`%&;F3I3AVQ<A.MC!NY,(;6B``%60!""F8TPEV\$@$84^4Y!A"#A80$47F
MH`/+N4`5+F.:!5B`<I;2)PDB(H4B`"`D$!```^9Z2@8LQP\+Z"E'"I""`X@-
M$0]X`T1>4!X9@.0&#1@"`L;Q@@,<X`01B0$;'O\P@`Q!X0/UM<,%1H":5AY`
MJ``X9[)HZYQRKN8`6/"I-3?@TT["H`4!1N=!5R,"+8"S14"`,$-WT(!Y+J$*
M1=AP/K4`5_G&X&A+&,$2&!"#&%B8`1;`10`P(`@7?`!I)E#`#C:G`%<T0`$0
MF,`$.DL"_,7@`PJ0`0*D`#\9)$!JG'"R-)H2OU88@`4W:"#SEK<$`CS-*&,:
M0!AD``$"("@,2S"`=OB@@0XLRP$SL(`&^-`'/@``!W^1``D4\`,)^)D$!+"/
M`XR%K"5D\*J%4<852P.9-?[!#M&*UK1.:"U$=*`!7&#A9K2*%<6$9A\ZD((@
M(JB`(Q?@M(:QJ\/P"D3_(?*FKW\5QPNBQ@46X$X')=B<#-HWK@&<(0RBED)]
M%1/6R`"K;'F4@0*64X)FG`NT=_)!>-XJ%\7L9*PA;(\=3/"&(HC``CB0YQ[%
M(P8&C(D<4H"">(RY!&`T,H\=V)$=2OV"/*1#V24PQ9<6H!)B>,`IZ&`!OV9-
M"`R,`PJ0<,$+I#`Q#)Q!/"\@!B(($`H9A`$#>4P!1+BPA#Z%)`%>,)T,"&""
M*IRA!"LFF#]B@`!+AH$%0`B#)7V@B1?0(!B4:P<!1E`?"7S(!'SPLP9(<`4)
M[$$"$-@54.R7$1\\8!E^*($'3HT(.;W@*G:(094(X`*(+(,!+5^.'=A@`QWL
M_ZH$H*T+`GY@=@?\8`1[V!4'%+!<II`@OWUP2Z*2K`\9YJ,L2?'439Q"F0\L
MHP\^@`!9L/+DBCBH"FKV\Q5((`'M9*$'!/@+'K!`^<J3P`29U\X""N``/^/@
M6%753FU&Y@=;&(`!2T`&`H:]&):04%HFI+1HL)7ILTIG.%A!SZZ4O@SF/-(!
M!(#"#;"*&%7WT"9(Z,%5:*,#6!\Q[B]@00%.%9XP>,"?)]A');B0`#$DX`8P
M%)D#C*T=4(P\!K4X`Q0*.CXZ->460":`.*[=1FUS.P`-8$XDL`<?(#;<H#43
MP0(OP``)4`)5<`+7@`\"L``7X`4<H0R.Q`)`LX#T,_\D>X`/,E`%`V`"(W`>
MXR`U&!`#!1`&WN48.D``GH4T!5`%)D`2RP!+$V$'*?(`*6``,P@_;(`$";`#
M8B`>.B`Q)O`??2``::,BC20#,P$:^E``;&!V#G(#I+</$U`"X3(`6E!Y$D`#
M,6`"RX%\:U=ZO9$1(V@ZR^`#`'!XS08YRP`!VT`4LZ,#$G`")C`#D5,_>=`'
M1C<$83`NX]$!MT()=)$A!R`!^_`")C`!5R$!6O$#?1!W![$KET(TN.$"]>`'
MA@,G:P$JO/$!:?4##S0NQ3(!/X"*.Q`"I2<!!$!YI3<#'G`"?^$`.6`5GJ<"
M15=Z%L`"KTAHJ7<5@<$8>''_(<QT3%4@%V$Q0F&%>]@&&[N':6@U'0703$/5
M20M07S>P`!-5!6^U!`/`?(?A?*P61+Q1?9[A5T>D#^,`%-(V#@G0-P;7![4@
M!A2R`[``$XK!58@!+&6!"/VP)R6@`%X`A49X*4^5`PR0!EI%,H=A,MOV!@W0
M`AM@`3;@!]OC`K:@7S!%)6?0`&R0#[.&"5(0'A?P2741<46``8B`!#LP`E!H
M!SZP!.*5(3;&AJ'#!AB@$BZ07@/`#24``#%P""4`!2Z`!#9!A0=@`(BW!&Q@
M7;X3`QM`-,743"\P!@.``6]P6`[P`D!P`%-`$`F0`'F``81'!P3`!G46AEF0
M!4'G_P`9H`&EYP`#D`,_X7U<4!>6@P!G4!?O(1H#P`5))Y!+,#I,4P#*$&HN
MH!-8D0Q]P`$=P`4=@#P_4#\<0`,2P`$!,"Y^1@`=X&=\@(CC\@,'$'=A:`((
M<(L&<'=M>289TD"440#+Y@F!9W;ZY92AH6XZP`<T@`-XYF<L,`%SIAT>8(@.
MP`=7@)P<<`)<H`&9R0$H$)HTP`$X`'I^)@$(,"R>QP,Y\`85\&9E@0=_`%AT
MT#_"UH@W($%SI4&W-VFZ]RG46(U782!E,$::8`!I8`=AX!PW0`!ED()4LGXZ
M)!COPFK2AR\\87V`I0/JD`>AA0ACX')V0!J5&`=B(`9GL/\'81$3DA$3B2AV
M-H$5/A"4%A$>Q:,)!(`>;%0RZ2$!)@!'^;0#'(`.V_,1T1`#`D`1QK1K4D*4
M0?D"PN43!5`$"I!F=<(U*:`2/D";.R`>>[`)H,%D$S`"$(!F4C"/=)*2"C<E
M[D02!>@"&)$`'K`$(G`#MK`X;+`'`V!K"]`)%S`-(V``+[`#,8`"`J`!>A9@
MOP$$0-`#`]`"$C`<>U!#`%%F+_0"6G`G=,$%HL,3/I``_[`3`H$(@^D(:W$"
M=H(5!.`TX]`'O3*I+^`!AY`%`B`?*]``!U`$0(`#-O`#/P`#E:D!H#D!,S`#
M!=`#)-`!"6`LLFHLQH0"))`!$_#_`!7PB#T&`$'F"B*@233V`!/(8CK:;@LP
M(%5P-!_P``UP8]/4`A!V3$S%3T(5`"V0`]X*!`T@`(,%!&_@7AD6`!N`KC"P
M`2"P`D4``T"P`:KZ&PW0`&\0`$L@GL5H1:/WA\`"+`5`!699B9GQC/!Y0M/(
M!=78>GX@!E5P=<,1$_7@`$U`>L!2HC"!:H5ACC[4:M<&+#RPCK%&#LK60(HI
M&N(2$P00`T$U!P!0!F&1&00:D4NC9*;S`C:A(>NU!R4J'F=@``F@%M$25N28
M;>GA`#&JJBV@`IK4<BEY"3TI!AA@-?\``3%0`I5("%[P$'L@!E"@``58+&]E
M`0;`=5PP_P![P@6:M!P)<&-0<`%1"C,?\4='4HGS.#7JD()+L$<#P`!54(!Y
M4@5+8@<S"P`,H(`$\``V`X6.9"1GH(<JD*LP$``@T+D@<)$KT`,QP`#W190M
M)@!>,+9'U@`MEH*ID8)0X`77"@6Q6S?3`*W2]0$Q)B"CNP0YX%E0$`.LX5D,
M@`$',+H[P+D!P+D4&0`B4$$J$``>P``]L``H```68`$JP(39:P$]T`#9>PDB
M4`$+H`)<($TTI@(6H(_IPP"T90*0\'UFXS\[\`#IX@)>T`H]Y@*MP0,FH`*<
MQ0-"-DT68`(\P`,M@`(*P`,9H`(H,`'$V@18H`(*D`$*D`,``/_!%`0`/)"\
MRPL"RKN\R^M$MS*P#L`$"D`%@,1B:_``CKH`!*!%#2MIN0>Q\GD9U8@5-Y`"
M80"B@*%Z`]!59N$`..0L&S0;++0T"4I]OG$`[`A\_(D\T7,(/E"ML0L`6A0&
MY@)D>X,9D&8':$5,N1.")B(O']"V!*`)IQ.I4S*.0\P2K$<;FT8;/!`?R[L!
M`=!3'S`$;S`$7O"7=I``!]1Z>^!(3KD'2,!0_Z`#$!``;!BE.P`!I1$4,2!M
M2Q--,%$C;+``87`5"]``BDD'9Q`#<X`P>P`%#?`1,J&J</N"7K`#$!$&%P#+
MMGD``G`(=@```5`%8/L"!:`%:,H'-J#_`AFV`LK;N>U*KCDP`O_$!EJ@!0=`
MD470`$7`!B7"!FS0`'F<S?ZZO/[*1/'QKW60!.`<`'7P!`'P!.J\SNB<SN;\
M!$F@SB"LO$\``O5L`MUC``T@/+^3`!#P.V>``6+@`[]#A0!-``LP`863-1!P
M`KFSE30R`"7P"@MM`#T0#[9S`6%`(U.P@=S``$'Y`R<P`3PP`#3PFSS``C]`
M`P,``!UPTGQP`CC``7S``0(W`YK)`0`P@*4QB1:`QR"0!$D`PM`4@$XD`7]H
M%C!D+C^3!C54`&E0#&GV!WL0:6)%:9-QPR!T&#U<!@)`>MIA&`/P!DE0!Q1P
MUA10!`:`U7*L_QDG('WN0@<*D#+!L1-X4!<^8!;+L18^4`1H30&0M@<K.#QE
M1-4P%#+<8@L`@2`V\7H=4`5:P`9L0A"[L@1I304O<!@)TQ[`<BM<``/R@<?C
MG%'+RP9#\0EHEAGH<`-%^0*3-`(3$`;7@`1:`+264@)G'!$ZL&.^0S$Q4`9[
M(`6M\0!JY@/\<`"/E@<#4+=T@`%SX(W`O09<,))8<0BB,!XOP`7`K"$P$P,Z
MP`(;P0!@<G4RD`1^8`,A8`,\L$3+.\[T.F#11`S"B\$WQ@55X`)0P`5%P`!`
M@$#-9#544$928%EXTPI+D`8#$`,)`(,$D`!LX!#`8`MG<&,^P#MN6/\"?F#.
M\;R\18`LYE4/#<!V@W(!D74H>;!^8<`&VD$'%U=']7`#PL88?\`%>T`:`[``
MHK,2!:!U>9`'9_"FM>``"6!Q,A<&@E2BY.$:69D`&-`!$.@#`B`I)CT#$W`%
M!+"<(D!TPMP"_%8"7/=O)C`$`2``(7"9`8`"=0`$'5`!5^``&WVY8A`].Y`&
MO",.6O2!8G"SD`88#EO#U7(MEK'5FIT'Z)<'8?4J?C`'YA(##W`#"U0`;*UI
M;RU$!BK7OU'7=(`'=[(V=H!E(;$V`_$'OA->*_`&<W`#%OH';ER-&3$&:!(>
M!I`#;%`%#U&?6D"15%``B^$@''H;"AH/11[_!GE``B1P3CU0`10P`OR%QR.`
M`5"0$G9P<@<P`5H@;2:P&A_@Y=.T!!,@I"E@<2\`X\ZT`S)P`X:T8@-0!@`P
M!P^`/)FD9G]P!E2PS`K@`#?P`2)`W'NP:R.P`WY@``!PD@1!``MR1Z-<4`*`
M!`XA`DO0`3X@!0#@#_*"``WPO`/P`Q40ENETZ^)5`#3@`5"`)`B2`!,S3#+@
M3@`P5P2P&F4P-@M`!FD0PV>P!B/@&GT`\8Y;.\=D9A..`33"#0N@!4G#R/24
M`3!`2\9<3B#``QIP`ARP`BSP\^7#2.3%,2!!``V@.A4."]PP!4DS!NT`"T'9
MJ<"P!V.`!-LP]B9`_P+2YGYFCR`6D`YC@P`U`*%_4#8E,(BY3#3:<09F&7<%
ML`4%D`<-LP,94'D.\'E78`*<"\+S;`(-``/96YW$:&U_4`8(L`8)L.MT4`8/
M4`8I(`:$CT-]'HV2D1'Z?!DB6U\)\`8,X,-E$1,-$,00\/J#">FZIS!E,>EQ
M;2]U[3"\`@0GH0@OTBTR@3M:U."OL2TO`!EH51?0'Q&`<SI:TC,/=_(%@%4D
ML]D*2AN=77J5*0`!``,HL+G\5-I2$*<%T`YAX`=U@`#Q<`%00!L7T)41,6M%
M8&9WXDAB``A^?@,!'WY_?@4Y50Y_?U)09WUT?104.B\Z8EH+>R]]$%HW`_]^
M=F\Q>WU[&`U0>SHZ.P*"+P4'(W9^.B5+!CJ"*0(.$GP`24D@(`$!*QH.#F=+
M2PYA=@0C'R]G=BD->PX#?S<"4G9_+U5>88<O;%P.?09%;&5Y=(,YCM8?J((0
M;R9>(4DBH,,&96\"`&GQ9@(?/C0$%!@#R\<-6'L@^'CQ8L^`$7M"OJ@A8\RK
M`C(&]-'1I^2>,2\@0`BIPT<-'6/Z^$!PPT['&Q=UV-&A0$>U/%,2.+"SYT9*
M.XV\B.ECQ\X`,8?H%#!S)H\=.FND/',0`H$-+LL";%"[H0*(!A5$$.CSS$Z?
M0W_")"``Q%(="D5\G&$@Z4\N.HCHN.""V)'CQY#_8>DPT``#2\B.Z`[0.*G/
M77A]@!"P`R=!GP%2YF)>C<C/7<]^D/1P@*?V)`4-@,R0X!F/CAL?.B#8\6"N
M4)8$7-R@XX`2'>:J"'`QX,>!H.O7^RB0)4#`B`$Z]@S=(P7`$A^8[++,CMVU
M9]C9W[L0T:)("Q@@GAP`\.1)`P`R&/"``COMD,`#$!BP@!<+>)#`"V$0$`,#
M!$PP&0,R^*!`#"XP(`4$4!C@P@-GA$''``<J0(4!7`"@0'D#O/"!`A#$0((%
M'MP04@DV7H"!#S%`<0,$7'0`A1<U*K"$%A#`0H`"4"2`P`4"QG`#`%),```/
M%@@`Q%K)+%,!"B$HI^0-_R3$(`,$"T#PP)1+=,+<#2[PP$`">4A!10(0+%$`
M`A,R<$,!"Y3Q%1T:H($!!@;<L$`,&'S@PAD*,#`A`>-L`"8(&ZR0A`@]H&`!
M"#T$N<`256``Q0("3#@A%`%8&D,,<PB`@1=0`)`#/T$*P,4"7&!0ZP(,+/#!
M`<$N@$(.`*C0@P4`[/!L$Q84X2P#:PB0`Q38HB'``PPPP,5_/6S1Q`-8F-%$
M$TL``88*371A10Y->`!M#BCL`,0!*UB16PL-*!,``!Q`Y5YU?SB@P`!+5075
M'GNFTH@?B%&\6&.L04;19`U8<!EF\-"1AV?0N5;*`PQ358H/(V<,F2#OW24;
M;?^VT8$;$%GPU@<>+_@P04@#J"=9>$A(L<=S=.V11W-]O/"<=>VYM]%XD@WE
MV0T($&@42T[#3`E>CK@7\R1/<_$&"'4@$\`3;!S07P!%2(%)D$O`TD<.([A"
MU!)B".6`"P(L44T"@7-Q1G@``/$@454<354,;,3P@A]A='/#2A`TP$8'>_BP
MA`@#F#3&"!M<X(`/#!RP0]\O`-#`PK\54<(D8>S0P`Z7^Y`#&Z9QT$$++51P
M4%H@K'""ZTWV,<X(1>G`2@Q"[5&%%)_0(481!Z115>KY0"6%1).DD0("5='Q
MPAMU,^4!&PM4U8?M2*S400`"+X-,!C30(`$,/X!V!E;_KC'+,_K@A!8XP"MY
MR$`"[,"'/ISA`B]XAA^D0!<'O.!%`SR#"RHX`!+LYADSF,%8^L"#"H8!!V*A
M1`&D$`?0Q$`,#N"#`ZZ0A;$0H0E7X(,$'(`"A^@P!!FX`C$X@`-G2(`#*H#!
M!MX``!J(YST4<X0",/"-D?DD`81Q3<6V>#&7:0P6E/%8'U;CF1<8H%$%`,J@
MCC8`2KRF@ACS8F8ZXX<2S*8V>)C$!'*3L][TH02^6(G='.")70!@`:4(0Q^\
M0K$G)BQJ@I#,"V[@`XID@BE"&8!3@B89DVF1$JMISWL4MI8A;`!X;QA!%;0P
M@@,0)A,*8$/=/',!`'F$`$1"_P\=;A"`!6("-RY0#Y1NP!$":.%!=M#+$J#0
MQ@'$0`!G,%]&#F"`GIVA31WQ`0"*0("0N(")/GC%`#XP@3"$X09+>`!Z7@"%
M_ZC$!S(`0D_V$`8>[*`";'A#IT#P!B#\(`1LT)$.""```!`S/"Y00`GL<(,#
MB2$/>3!`%>9@@*H0H`$H.UH8:!0&<"PA!0G8PQFDP(8/E*!G75I`"5Y!`"],
MX`4#X`$,5J`I9FBJ`Q(@1@-L,!8-A&`L/'#&,YS0@+%P@`=?&,L,OL#39_!@
M+`-0`0]DZ``BJ`"J&0A!`QV0A1J^IPGPD(`-,C`!#NPP"R8X@0SY4`$<]-2M
M($0!$?]V6(RGTB4!"LBA4W/V#!9,0`0@V($-)/"<K]WE#V7XP%X*0``"E"$&
M$)C<703!1<;(T3$;,P`;Q+B:I8AA$4L`@&@!0)@QYN&1[[GL8\3F&0+,Q@\U
MFP`;8.!5S^C`!1B`D`&V83>6,)0Z=!DC%`_[AWM$S3-[2(`(%$!,5:S$)P("
M`!)8DHI#N,>+V!FE`C1U`"!,@`8&P`!05K6`!2#!`!YPP0<*()DSQ``!$Y#!
M&1"@D1LPP``,(%`"+(`!![U"!PB`P@46T`$'+``!!5!`$Q3P*S%0@0$N.,]*
M'%``R$[@!F<@IQC*>X$'7*``#WA`#$QPAN84@`$0<`$`?!#_XH9"`0(,P``2
M&#"C*BB%G@@0`0`$0)P=Y$`$*GA`FA!```280%4%R,0+I*``!#"@#`%&``(6
M4(`T+"`!"?""`EP0@S#80SHO4@`!#!"#!'!A"6?H0'KS2X(/4"@30((`!GIH
M@1^WP`,H0($0'4`#&`B5#T3XZ3,4D`:J.L$*'!BJ"C(PEA!0X0I`'0L-I$K5
M&<SF&3;8$P?N^M,*]F"K-"!!!BJM`+7&D$PRE(`&<%!IN<:P&"[8H0/*4&H:
MZ-`$@N9#!^PY,!K`(VH)2P,5N,`%!1@;3_=P#L4HVT752D8,0.`L9B91@!28
MR(WP4:T7#_N>`<QF9WAPS01@`(,9_\3,$R7820H,QQ*[90**8%,M7=`)`Q&,
MP`/H$<I0?'#D,-@M%]IV3'9=L`%3!L`"$K##!`3P`1D,I0,?8-(>2N`B'WBF
M!"*H@B^<EX(<+-`.H8V!)+"8@&H0900-(``="*"K!]@C#PC(P7D<((4E4$&1
M>:#"`<Q@CP%L<PO-.4$54K"`%TC("R6`Q0M$\`9?9'@(.6"O#Q:0@Q_I(!H0
M`(\=%+"?$^A@`#LX``G$D^&"OL`.6$QR,G=0!(?W01$",,W*H5`%'=$!`5Q(
MPR0DR@8&?.4&BZ"+#@I0A2KXH"HRL))0",`&+<PEN6Q`F;@V@HD#W"`,$"I`
M!\Q)`P6(`?_S$3K`&08@&`LHX`P_.`->,9SZ!:1>`R=>``%*<((.GX``&@@O
M!$K`^QK4H+%(X`4!D'"#$"R@!VJL5(!8P`(!F*`#(0C!!!@0@@YT0`$BF$`'
M2!`"9DU!!C)@P!(4`/X.5,`%'<`!"7I0@1:`@&"_OHYCQ@;OX\*,P8UP-BR@
M+6W(7,WPK#59`9<QW.89W@8/M2%N;-``(O0>(H4!(K`#`/``%Z$\"2`&!G`!
M\#:`*U$`';(`+N`"Z.$`=F-;2X$1\:9:V*$P#=`I,%`!"4<"10``&^<#+I`#
M,G!V8H!;+S`&';`#2V`!HW$J`D`^1A$#'W`XOX$!+@!3JF(!P83_3FX63F=@
M`#M&!8."`5M@!G!0!F```&BP!@E`!EAP``)@`&4079(S218`!1PA8EU2`F<`
M!3L`4A7Q`6AF1E>2#8/A`0\@`Q3F`1^0`T'#4-&R$24`*`607$SX`0:0!^BT
M!!@037.'`!2F)XH%<QA`;#[@`$ZV!,@T``*R``^T94O034N07WY2`'$"`!CP
M`%H@`%7`8T^@2BD0#%J0<2E0!$-WBP#P!K>8`@!P`%H@6J@R`N8A#=B`AP#`
M2GB(AP?@!1_P`3N6`DCH!;>X*)!2!"[@!;-2!2,@*P"0`K@"!:RP3)OH`0#@
M`JL"BQ`&@EJ0`BX`@M3H`C)!`NLH`Q,P_P$>T'Z]9A?8,7_T-UGVYQKXIVW/
M%FT?@QE[(`8K]FL;.(!D=`C=]FT)J!T-T`"UY1EAX`(-\`9#``!)IP-><`#S
M4`01J6VJX`,7`![_!0L^@5P=535C-(#9-0%#H!`Z9B$>0&P"4`)+\0+3AP0:
M:`<TB#HN(`4[8`(U\B1+4`HU$0.]<`$^D```@``AY@,^D`(7X`)KH"$#\@&R
M^`9L,%$[@`5S@`5HB09J,"]J,`=ST`!H@`8=%P/Y>`%7P@7S80![T"HR\`!A
M4!XC60`,=P,@D0"IP@`[4&054`+E10`'4`6*U`<$\`$D(`-<4`(QQB-)!RU4
M$`,&D``[@`"48/\'!4"#`,`%++8#"O``!>")+F``7E``99`#1A,>!"!B59`-
M'P"%58`)A?<`*U9SK)0".U`%`#`PPOA1R"B,R&B,'S`$T_@!7C`"K>*-`)`.
M4#`K*8`!"X`!,3!T\XA;`A""N%4!7E`#QC8K:P(!,B``4R`3-?(!WR<#"P(!
M4W`!%S`"+B`&0"$#-5``!O`GH,A[2+`$+C![1>8"2!`C`\"@GO`"'?!7`S-8
M!`DV`WFAV75_[X"0^Z>0-?DRIIE;H)&2$OD8!7@:%AEN&*F1H.$;DP0!`"`"
M,O!?#[`[;W``)GI9YH,`RM&#_[4'M32=12=(GB&1V;5=<%$!(3"!DI/_82XP
MDCJ`A#%`2S'P`%S`$0D0GA<@'L8&'H/7'1@P`.0A`@)0HWZ``.D4396Y!-,X
M(5X@G$U@!NIB!F1PIUU@!EUPIUQPI[E2!;$$('D0"B.0@SKQ.0MT!@\`BAR!
M`%JPFYA``@=P`"\U=6ZZB`8@``J0"7N`!"EP;Q:1G0_`D0Q0!0_@$Y"`3'3@
M!=I"``Z0!@PP!PH`#P1`AX;3!^!24;"P`$`P`C/QGD5`/LH3#!!`$0AP`"[P
M"DU3!*&S(QLW!C*P4J_@`UKP"C!!$B'1%!GR7S-A$B-1K#N2K!4A`UT*1AOW
M"I;Q$B_P?3I`!YJP>^KA!;[@K@1P`>TZ>#&`_P3,00<?T"2P,`5B!I,F4`#/
M-:$B,#!!<Z$"!TD,.UG:T:'ZIPD@NAI?D0`YH`!'@VV"<*+31I$&N*(&F9$;
M^0(E8!GHQ`4L``LND``EP`(6EVT!MQ(E@$XF$#J?L`N+H0!X>796DX*7E:1#
MH#I-5'LQ8!?DX07VN@<+H``?X`E[H`4A)AZ[L`0_HQ/HU#1B8(:NN0H/4(2%
M="`)0`=[0``)8`"3L`U+L3//X1I,LTB^=1<Z(`/8X`$,@`![<&;F(0DZT2$P
MI9\(`G8,!P03!P#4J4ZZ95`#T)(DH`5AL!.XXIKVB0``4%TH\@!BP%!8Y`)A
M(`9O$BXQ(0#$HG+FD_\`'T``8A`#!`""9G25EC(`'A!?.:`#08D`55`"N.5F
M_C84!]"L8^`4L#`&-9!T+[$'1<"I[.0"8V`2!I`AO^L".#$&SN2\.($$5%01
M$&"O_XJ]L(`*+($:R4,'(G(#(^,`]'D/E#D%H,$+!&L=Z\@2?7`!`4L7*/M<
MTK<#`Y-H"ALV#`M)#GN0$<M_"_D8=L&*88LT,,NQ\^>Q*HJ`+#IN;&!N[_%U
METL"DH@`F.`%+D"FEW/`\F8'T'N5?(D19)L`RD%Y4NNS<K2"&;`"*]`#(K`'
M-("K#V``O2"5!?"*B?@`SL-<^46"=I!A$-2$05*9,5`"PBD+`KH$%S$X'J?_
M)!!0!M20!QU!![E00;!!-OL:!G^@'<`HBJ$UPS>@!56J"JQ()#*@`R8P@0"0
M``.`K++@`Y5YQD.QN`R0`GT0!FX6`SE0`@0`83%P`78`!2DP"&(K!3$0IV$0
M!S/\)J<C`+&*``-P91!5%4H2=W1`.'J,L:F[FP2@`Q/(02[0`K[:FV'`!TS!
M!C_P$`Z@`0664Q-`!#IT1&R0:GS`!1/P#'PP`SC05'S`:,1@`RHPJ\]P`BH@
M0QQP!AF0,TR`=H+F&6#5!WQ@`Z)&55F@`#.0:'R``@7V#%>@53)$!"BP&S)T
M?M9!!X[&4W:0!SP@0L\0`EW"1+Z6OZRQO_T+L9>5_Y#]AZ)+D089&S,;B\`)
MO,4?R\#B1FX-B%POD`!+H*D*D`"PT`%BD`H$R\&7M1)7`C=L,`(7(:23.+,M
M.30AJFTKB!O]=``2\`KH)(^DIV*.:`<^P`4[\`%!4P`A,A23L03\>74,(`!>
ML!&Y604(<':&;*]^L!-5L#HEPAQ>L:\&[![/$4%4@1A]8`)#L$`O0+L6(!X.
M:;9&H0`KH`5)1P"[Z'"[T'%]DUP-]PHOX`5`$$@7<`L.QU"I>'BH\P%080UH
M,`=48!TN<`"GN,5BL`-<`!6U^B-+H3L'`!4#8`('`)BP8`NYI0/'$P-\Q@$L
M<#LG("Z^E@<#T`(GP`$/H?\!1L`!'.`$R6P#I4T$0'`%-N`$5]`$*G`%LHT#
M/)`%&B#;*D`$&J`!60`&/:#;1(`#%3`#1)`%"6`&M3T#6=`%71`"794%6-!5
M(8`#[)=^.*`"%:`"))!^!Z`".(`#&:`"*)`!Y-T#.2!5/,`#.8`%PS8B.]`$
M7`#?6-`#7*`"*I`#+5BA\??/\]RP')I_/WLUKF1<P'8T#;D$!S`',4`*,`/0
M^ML:(H,"4/,>LN6B$5P3"@``$Y!D5'$!*2$%.=`>+@,?[O$,Y^0%4]*2Z6P#
MN\$!-C``,D0Q1XH9^QL?GK%=:3$!$O`;`J`%=DT46A!UF/`"%Y`"G]`47B`W
M`);_.`Q`.0W`TYEP=1^0`H<W22/``D5M`@V0`@)%";U5?U`$2C6I`Q!P<$IG
ME5Y7`A<0``A01TCX)CIP`5[@BBKQ=B.P!$.!!!OBT#[`8UKP"8K9<=1%<>QU
M!@5@`;\YMN'B`8L8`RV"%>@A!54@@C>@(!B@2%@48GT0<U`P`A_W&Q\0/PQP
MH`O@`#,@`!EP3P]`4VZ@$$GP!FZP`FZP1"VX`@'0`"O`!BL0,&S`!D50!!O0
M`%JP+T7PU2/`2AEMG2,P#][1'4Q4>!,U!Z.5`P*P!=+P`'UG[0O=V'B(!0(P
M)L\"`P`0)$V0+]3"`P\P!VO`!53``W,P/A"0`%#P`7N2_P`7,",)4`8%8+_T
MLP.<%)`94^/7X;\J^'8'T`0$WA[6D0<U4`5<(`53M@/EX."A1,42SJ*>4>&=
M!AL%\`'6*0*.^$004`0-<`(J29`5!`]*0P=G`%*$=`+I!V0R=!=T4!NA5.,Q
MXP`3<#;+T(\O\`!2@#K&.:;`X0N34R,Q@&\7L`0QL"&CH21U]R0[T`%1W@'2
MJ$X^X(A2Z0,E(#<9RK"AQ`5B+!?[5U#,,P".C,&8MTU<^0(,H`6<-`"1,N^5
M[@%*X@L*P$I-,@!9\U\^,(L`X!I<,`(/D`)F>P,I<$QY4`)5\)1.8V4`L-=+
M9BFG"'-`4!P#M006#&=5T``EX/\'+`<$.5!##I`!1=`$*H$'88`%<T%(!##1
MH#`7SV$'.5`]&3$%K\#R5.FN$T0R8>">&S.'8V`756DHS.&?!R0>C#'[%X``
M`OTG)0;-/8`#50$-G48':8"ZO0&")`.PAQ,2`8HT)]`#.Q"2X`'@)QJ0!%_1
M!H_P8&^:*2`%US8`Z=1&%/\R%D\;8C-N%@X(?7UV+S(3!@P/+'Y^$%I2?BE_
MDY25EA(2#@Z"='1V-P(?-WU>&'V;!2LB/WR;IWAXEI.,M+6,@K@*`3`5%3\5
M21,^?3H0"R][9P8`-WXZC4,*+SI[,3D&=HQ:#`-V9S<B!"_3``(E?LAO`,Y[
M.CJX\'W_MK2R?WXR6B\Q`C[N+`T(GNG0(N"%'SLE4J28]N+&`78^JKRQXR[!
M$PMA"`U\X0"="``OY#T(L,,'(S$%^_CP(:-*`70#U_VQ0X6-%#N:)";H0R=/
M'B_N_"Q3P.B&E@`+PO@1TP``!TUA`/2@D2F,EJ>;-"2@<PI"&CJ37K#I2(P+
M!#]_'!200N!4'Q?4=+Q@P$4'Q0(?]L@;0*4,V#\)$ORAX\<!!@=A:T#!58`*
M`0=X.'@@P=.!!AR0^Y0`\!*R![@X;]0HP76/BY=_F'10`(#D`$;U8M>K]4<!
M%\2R9<DK<*`)UWEHZ1@H*6@F@2HW]@S.S9P2[,$.4$#V@RL#_XP&65QQ';`D
M"04*.0I0N]$AI(_FE#!IXL35S@<!(VIX64"L`!`4(;(\%00YEBS@M<2CP!LP
M6&#!+T_<()`!2\!%C0@Q.!/&`0(`$!<40)1`D0/'O4/,!0H,X@,`(RQPC@]O
M?."..\C$(PB`]>R1P`@$[.$%%WZ$L8(6;%SPC!8;(&&'23Y\P(`."/@@``/.
M&)`#&S$X8`<&%);PS!X*Y/.)`A4.($,*"5@8A@XQ-)"#079!\,$98:3@!Q!A
M.)#`#F8L<8,=:<Q1!!=GS/(`4!=8\($6$.CP@8\"[.%'`Q5@44$F#BR@`@VM
M.`#$#)WX<<96@R"0!DY_#,#&'@Z\D/\'!@K@,<@-4IS'U034[#&E@WT0$"$C
M+TAA`"5EE.$'5X;9,4D>5"S`51\%*)!&'@[P84$'OUJ&0R:UVMG''WAX$(,.
M?_1A`!EM#>("$G=,LEIK``S@#GJRT68;;NSN=@`#FP#G`!UBI'`&'0XP04<!
M.8@!%KSL_D?/*=+A09T@$,#`!@O:L3,.12N6@,$#'SQ0,"SV\-3)B@W),`4A
M0]XPP!EGT+`>8M<:#.#"_"'0P`8ML-'#!'TPH$`_.A#`!0`IB#&`%%[(\($!
M>QCPP0(?*%```U),XT<!%E3Q0!AA2,$``UXDIZ8+2YPAPP-2J.N.B_(`5X\.
M$[RA@`X&/)#_P@X(A'$#%!CD4$("1G;CC34?%)!'#!D_X$,87'!AP3$7`("`
M7GT@D`(`&+QP!@1>/$!`STLLL`0$)2`00P%VR",%`%6P\`(!DQ]-QPU<+,#`
M5PEP44`8?X3AP@@`7/`)`R*X,$T"(AR0Q0!76*#`%33TP`4-3_$!Q`^GT$%`
M&3@YX+0=>5"S0AYVV!$&&53LL4<>!2!P^P!YF/!#&`.<$`,&-OQ`0`B^G'#"
M#1.H7T#Z"""``&WE@P*4X`8N&!T!TH``*"1@!@4@P`-X@(0"S"`!/,A"%M8"
M@!J4H0`A`,"A#%`&,C```1=(P!0^`($$Z,H".\B!.M35LH)9PEVW_['AM7A#
MK[39(BT2'$7X^K```+2%.C:<S8NZ%9WIX`(!16@`Q#A!C!<,(`PK>4'X"E"%
M(HQ``!N;Q:_XI0,?E*`$XRC!%*C1ASS(``,9L($KR#*;E\'L%!-H``QV,(0>
MD`HO.Y/2#7+@`@(08@0!P`!%7N`D!%#D!DN0PAGZ\(($Y$`8.AA`#%)@@'?H
M8`=U*,`>&`FFC'@H'C"2Q0L@``0?B"\!5?C`X1H2`!=T`P%:J%PF7:"%G>F@
M!%400`$&H)(EC,!'O^2,%F_P`"WX3@<%$(`%SK!(+2S`D#XP0>"F40`M,$,'
M>0#%#3(BHSD`(`]]&(`"N$$''T"@"C&P$O^6!"`#\^D``P*8`0?RT`&I$$`!
M/<C""2)X`"D4X`8%2``$;G`#,7BAA5-((1O*$!@Y;,$+"9!#`LC@!05(@0JG
MFX!(72""'4Q@`2:P@!9.JH)-PC,&,=A!%3+GA1@4@0$?V((QBY"Q#U1!"SM8
M0@4\P(8<````.Q#``790TA&\80X"V`$6-M```6A!"T!HP`$.`(2C`.$`;-#"
M$-[0@`"DBRM)O"$]WE4P)/*P7L"A9$-QX0`$R"`,/*EA6F>Q1)XD#&89``(;
M9H`+3[R`-4L(:@(\N0=(,B",L%!5)UXP!2\\%($IT`0=!O"`'&`@#J[H@ZKJ
M^#)X.&`"*P"""4;_H`(<Z.`&!,``!DJ`"!-`@0L^N,`.<&HEN7#A`1<H@-AB
M(`T7`$`&4#@-`K86@^2\X`3KE`$:;V"")*'-AS_4C0O>$`,"&.T!2UB">`90
M``!8@``&8";H+J:`!W27`3%8`@#$(!>?X98%M!6``@BP``4HX&@E<`$7;DM-
M/TB0"Q=(KPF\T($+-%<*,;B`T<#&A1O<BP!42``!$#``+C"@#"[X``)<L``0
MQ6"Y"7C!F`Q0`1Z0@`<A>``*RH&"'CS``F]``=>@X%/X0D$`2V#``C#`@#<D
MS@Q<$``:NM`%,JP!#6:@0N(ZN``(U*`**8``!!#`)1G8%0$/>``"I*`U_R@8
M(`$&&`X)*1H#`*39`,M%0'YF4`$5'%0,)##!#/8L!S0L]`8S0($%5E("*7#!
M`&<@@`]<<`,?$&``)(#A&W9`3+VF%8<$8XY;YP576Q#&#NS+E#Q>A-:]BO%%
MU*&#=&XA"`1D=0;:&1(`W/"&-Q0!`E4<P`LZ<(."R4-ADG7'HD>@A11X(05C
M\$0?I+`D8F[B6*0%D&E)L((&F*`"&2CH$@9``!%:;4P,P$`*!#&G.[WC`A6H
M@O#"(+LJ^&$/!%B"-$NP!QET=Q`ZN$`5`#`F,7R`OCHX%C&>H399V"$!18CO
M$@)RAFV8K0]'=<$>-I.")<B@C`(00`[0X8(=Q/\IF9LL0!\NT(`J!`19J(O!
M2D8@RQ4M00M5T!`$1"``!$Q#`5PE3;Q=X(KC6&U?4#A`"JQDA]WE``)VD`$`
MI#"(J<WA`-/B@PEL9H-6T.``&AB$2@PP:BH4@#!M+()>-*$`!``K#5*(0[?^
M4"B]O``#$A>V%UJ4AP2$@&5B$(-;_,`%PM!A#X;V6!JX(`9F.0L!I[!,!Q)_
MAB7H71.*2_8>&B,>.K"M+7B@P[G,.B9+)]$64A96$I%P@!AD`SB=*``7$N`*
M4SL''C#+5%J60):%N1H[N,`#-=9"W`3TM@0RN,$%>ATOT5+'`1*PPQC&,07Y
MI,`%=K`\'<X@!;V[A5__F<X-+4R+@!7`P`2KV`$;='F&+W;2#@3(P1+LH@,+
MQ*"3*MG'!4:I@&BT0P=G>``7S.9?-/;A!BD0.(0@!2S@#K\Q<*ED"3HP(]$D
M`-BP.A\P6SH0!E`P`@$Q(@VP`QHB/H0T#@E`.!>`10MP`.*U@",H`Q2Q!Q5H
M`B]00!\`!<14`@L@`#%P!I6D<08P#78P!2)P`WG@`U+@0'C5;7/``'%P!@M0
M!1Z@(+_D!4O@.S+X`1V@%QG@`3L@!33`7P?P`#:0"1(P!UFW"9O""1#P&()@
M!VQ0.I"G`)U0*U0P`,OQ-L20!U"P`)XT`!_@#)0D!:S7+0G@%[A`+]21!W)@
M_P:XX#-(TRPJD`&<0``)(`&"<`9H\'A\T`0,,`;UX2D#MP#BD18A8`$5H`XV
M\`RN)T:,P&6B9T.D9WHPTDX)4`";4(K=@DJ%11B#`0"UUVI%L`+9D5=^X`,X
MEP,"D`(^@@PMT0`6X&MIDWC*APPMB`070'12DFA*X1:)UU:LQA_4M@(6(``F
MX&(+D`!(L``U=4WA`R)`(0,&<`%<$'QT(06,-@$/T`&R4SH39P*@`P$D<`$8
MH&@>D`#_!0$3((%G(P@ZT!$%IX`R,`((@0']!0$^8``8T%T`X`*(4&48L%Q)
M43JKX9`?8#$8]480$&)2T#1O)`7N$`8)D)$,4``O8/\"=J)?,L``%N`"8B8Z
MXE$1=+$$!E``&(!F/VD`"@`%B2`%$S`Z=D$`)+``%H`!$;D`$R!@$Y`%)M`#
M'L`%%=`$`[`)$I`#5[`P9U`&G!!`I1-V3'!\'H4+9R`'E=8'"J`)#L`!<&<'
MF/`#4<('$E!WV",()`1V?6`*\K`')20/U@,!I(,)/(`#E7$%(4`MC:<@?<`'
M0S8&U+$6!/!W>S`!);`>(7!MZG`&I%B*M8"*:;6*IS</>;4'QX(6KG==K/DK
MW4)[U&%[,+`"=Y=7/8,!O:,`"W`"=O$"`#`$(R`8Q6=\IV`'HS1*+6@EGM`3
M+E`%"Z`R\&!#VT=7U!8`![#_`A5``SH@`TOP'@C%`+`2/@1`@\)4")/S`%:"
M`%4P`BAX`B/P-G)Q`VWF@'L@.SM0*#Y@`2,0-*:T(BN2@)70""-`#26P!$`0
M`]-``.\A`&&P!PC`!D60'#<```E0.D.2`[U$"("3@Q$Q`E&S@$:T(A<P.260
M3L*X!%K$1?$Y#2%F)5HD`W/P`.`C!3'$`+(R``!P)@X`C'/G#G:@`.,W#KRA
M!03``1)P`N9T`K^E`1P0!C9@/#XP``/`*MP66Q^4!FE0`(.U9V+@`4TP`V(P
M`U+0`[H2`F6``CB``R%``@!0`3A``C@P`2(0IR2``!^P!E(P9C%PDS6``#D@
M!?Y%_P8/H%^VL4DQP`4JP`,YL`-0``4]@`([T`0]T`,?P`8`\"=-D`,M\`!O
MN@-S@`5'!0`'(`(?L`,[V@('8%;]X'F?1PND.7JE=YJV8(UCQ)JMJ5FX4!A^
M=XNY&#FU>9M<(1<D(`.%$$#$P%D8\*"^MA[':453(`,R``'-]P)W0`US@@4*
M$"?:\1?H49TQ,S-#$``JT`[9)``/0!&(D``980<,X$73D!!5L%@Z@`16A33%
M$`,I-DH+``0IH&M.,J&GL!E+0``9,7`%*:"4@"0-D(-G``!0T@X_T0`>D!&V
MH@4*@B6B,('@4'/CP`5"QX3Z9JP],S\I9@<&4`5+X`,<\O\!0``!8[)*(L!A
MC15D9[`'`_"<"G`#E50%0``%.(&R/+E9%Z`S->*3ZM8-%W``57`"3T$#*C"/
M/;`#/*``/"`%*V`"+J``$(`!+,0%SPEW+N`"5/`&`J:H414[)N`!`G"5)L`%
M(E"I:]L".6`@)H`"!Z`"/6`!#+!OLF,&0+,&F8,AGO.=*0`$8>:I1H4"2^`!
M0("N0E4.%0``2X`&;K!O2X`"3U<!J(H%%#*JC\NY`-`"0[`")-&JLCB:"I"*
M!6.:,(*0"R.+LSAJX8-^`V"+>2";HP:LMOEL?3!*-T!;*6`B[E`"#X`![U0P
MR`<I$O"D/G`#2#`%4U`"->!*R'G_`C-`%9#AK*X:&^!Z"C*C"@(@`B<@*P30
M.%L;84)V!BY@`C>```!0`A`0`\95*"7C!7_)4&"C#Z)@%B7``-(E`NP'A(Y#
M,0!*</.P-AW0`!V%`8>V!%VS!!A0`!.0`N*3#```!5QV`31X`VS`4"8PJ@:P
M``^@:V7D`5H0$08@!B9@:$O0`1,@`%P0.#?`):XT<;)E`7R"`#MP!BD@`^@%
M!:C:DU``BZ<P``HA"EGS'A;X3^#UD2R0`TUPQ%F@`BVP!%F@`2=@`UK@*0)T
M`1!)`&=P:(J6:&Q``#]@/XMZ!E=P!5G``S-@`W)L`E=``#9P`AYP(&F,/S]P
M!2<S9E0Z_P`)(`.Z%@9SD0=71'U0\*"3QP-",P`TP`4D0`CDE0`T0`-Y@`0`
M4`;,0@,&0@,XL18%D`F'U0'9@V.U!@#[TKW8>(JK6YJS"B/7LG>R>"_`\KP*
MM7H^H!QV@(NSJ8N\Z+MRP0+\!5PP^@*A0R+-N@EXX`"8C,PUD`(U(!IK!&HG
M\,9P#(FCYA_?FHVGT`$P\`8KP(TBP``EH&LL`#3U=`88(%^&?`8XU5SNQ`#E
MX0Z#Y''HYU.SU8(NH%_3@*>;DTX0(`8X<4I!D9"5X`!28(%#D`+BP4RQ1#HO
MT#GM\`((,`(Y\#@)D`('$(*_M`-%<*$^T+>WPSG69,@.D=$M*/\YZS=*LF6#
M<","0'`!*H8!F&H0]?9\')$&#``%E^D':;`"2X!78;`##;#(960"!Q`0.D`"
M'O"63Y%M%6`#?="\`G`"U>.(G.!U><`O8=``*B,!>V`"$P"7&_8#S2L!(?(.
MI^("9\B@ZT&(%\H3%,4$E4$OFY`K#%`Z=)`&<)P]5_LK=J`5E=)M>O<'$F`!
M'D`J#I`%3J,)8VUAL.`!`?`&(!`.[Y"ZL/K*LLJ*J#?+9,'*Z%$]9P@_`Y`&
M6RDL#J"[MI=569![33("!]`!ZV@7=K"TG.%K;=C,-!`&8^`#QO0E7F`ES<L!
M=-8$<E0OHM7*W+<";Q``(-`!+`"VW#3_`N-'$?N@(L(F!4L@*RP1.+\K.0+P
M2#]EA^_`H!B@+B5`-17]`"9@@*-VT`DL"PLX!%"0.?*)%S'7!PD@!C&P`.(#
M7@_@`GG@`F9BWB]0`&%V!B<@E.)%$<0F`K+2.*$P#<^[!."#WE7@2C*P`%Q0
M@^679"S[NP90Q'9`40L`!8<S+_-C*P`0`U6`=&64+Z43MX+&!SA@A<BM"5V9
M=80QACPQ`9?)'T7`$>##!66M"00P`3_0+`Y0`WR]!PZ\"0[`'7E527[1+;T"
M#U#0$3TA!U!P+&=`!;!6U9)\+WVP*6;-2=B74E1.P5B-"29P`G@I`2$D`F\@
M`OV`JZ:FNJRK_VF"T$WI>EWRT#'V`"!^>>B[NG;"<@K4@7[41*6=T`E+(%D+
M(P5`L`)BP`B$\0Z5)`9[@#4>L@0'X+7**`BJ<B_(J1A3@`1(8!">D`?E@`U4
MI#"M?$<R$P`;0!(X^P$$4`(CT#E+^%\RX`4$P`B91#BB`Y`J)T'_=``C_7Y-
M(Q=[X`/Q]#1^\`"+#`$.&'`"9WD*.PE](`.L"@$6:J"Y9`!#,``78"<GH.)X
ML0`Y4&(!H"!C(D$3H`#&*L$^,`)5H,D*T#@7<`$8A6\)<``$<&O_&XX,H#IN
M)F12G@^,$*0(<`,64`(CHE!GPL%5<``&L)\K>S8?D`+PNV%58`(Y\/\`LC,,
M@[`#+\$3:2`&FB4%:8"0=G``]V<'$"`%L@)O"5!I=L#4#I`'_D4Q/@`%9T,#
M(7!W>R`!+/!XF\"&>1#J8L!S8D@"3=XL"$`94N+&'-`*9U`!!F!X)O#>E4GS
M#J`#8R#D.-$'++``'C!IDX2KD<7-S0$+C(`'&2!Q;54?6O`!9>DBT48;A<$R
M+0,LI6,#9&"3);QAGL)(Q/0K2\#I'8/IFD[YA.`"!Q!%&_``4B,#H(D!&U/W
M"A,^8?!0%V!K!NM*8K`$92`&@G.`HNV]M%!7>G0`C))\%5IS<B$#I;HYY0D`
M%?T",W@!!P$!PI@`SG`!16`*:L$`+C"E+5C_!&S@FV'```>PV$/D(N'^!_76
M`.I220!0*':1`NL>/C+`!FP`FBV8`])`$4#0#$-B`.9'#1_0`!.0(]W&!@@`
M"'XZ!BD=.B\Z,F\7B"4?!PF'/BD`!7U^"$L$.@,^56\,.GX^6B-^=GL%520Z
M.GT)``1^B`=#>X<&!QAV"P<"`E4``555E#D'*54[13G$54M/5;]5#6PIUR,-
M.==510#)52ML`,$[0TO)(@=``#L[6D`B\CMO[0`B0`$[\@)``NX[@&A1UJZ%
MO1UN=MS;P:8!@%\Y_.T#T.`9FBH16R39,>"/1X]X0N+Y2++DQY`@,YC(8[*E
M1S]]=!30\L%.GYLX_V^V],.S)\^7?DI>^CB@`(`;?_SL.3.@20,N>?IX7,*3
M3M(^4H"L$%,UZ0`%#QA@<''A5I@S!JRY;"E29-47-TJX&+''P$T[!?+X2&,G
MJ1TZ4M>N]=F'1(`-#=YX.'$G5Y$;8<(D8A,IS`L&#UPA6:(%P)D]4M@4,2`(
M[P,?.NP0V/$`$0,%52;H\!&C2)4^J'+B].FSY8L$0R"\V`-ZB0RX`-X<0,6E
MP8,%+V81`"+#SJPW"`1Q$0O!CHX1&Q8,$%1"A)87B%ZD,)#ZB8DD/OH42*$E
MQ8`^Z(WSU+'@L1\9"G000P&#I'#`!3'M08`(#.SA'08/$-`'`B.XP-$>"/\`
M<8`",F!0PAXW+7&#`TS0,8`8@+U"@!T.Y&%'%:VT@H`,KLQBP`LQO7*+C%+$
M=$@,,/F1!PLL.(!>""'8(8$##I@@01][T)"`!3C90,()3_*!0P=,2J`!ETQJ
M`$`6$BRI0`RB])&&%!+V,88"!=R!1Q\LJ(!"`"F<04=0((DD6$DH_8&'2BS]
M^1%,,M%DDVXZF<1;3R`F18<#=%2:H@-[A%"%#%3T.$`8@*F&XU1=P9355EU9
MI]0%,AAP`XY^0"!`$0D8>E);>/#D@`\7,)2`'5388<<+)5"AD`%,^+&GK3OU
MY``.&VP@`@P\>!#&`R[(H(4+Z/EA```&R,!3#`S_E&`"%S?$``47%O"ZQ!X\
MO>""`!@D0``!,2#P@05G]/&!"1Y\4``"`,C@`*.7/*HP3XI\``$"94FA!6<W
M]`$``&"],(`7%I3@QQE(".!"$755@1D4!-SP@`(`+,!""D58<H@)+B"P``$7
M`(!`"@3X4,((`'Q@0!@+0.=="4NPUB`$5<2P`X%B`.`"`Q>$H6A,/CS@`0"M
M83!6"CKLP8`6OPSR0`X,A,'3'D]?=489+R%0@%5]Y-'`HCIPX8)W=I0``6K>
M*0`K?QB`>`A5N-$00@=E[I$`ETONT0,-#DC``0D/=$F`"R'0(`$-$R`04A\$
MX+"D`S_LD`63>/"`IK(:_R"0QDUCN'!#4'1TP$`%>/;+IZ!^,AOHH"LQ>U6B
M-2$<6$D+WT18BGU4ZL`-#*3@0@%,2K&$[66<81,=5"E[U:E<B=_*+3$94)9W
M!G2@L?&XYGK34NAI?)\#82#0F0)2'`P8IL8[E+-(L((-\$`$5GH"MW00AM<(
M2P<L&,(#!B"*#S1``:UXP0($<(-;W*`!9\B#*PH@``NTP@X"^$`)4J.#B_GH
M!F5!F,*4EX@#;4`+*WR!`@X``</51D(Z.,,'P-6*&[Q!!F&0SP@.X(,P$"<'
MG@E;"9A(!TYHH0$(\,X%-O`!'1BI!"U[@1W"X($1?$@'/\L!<>P@L5<YJ`!%
MP/^`VO;P`"\@0@<(.```5CB``[QA$X=@026\4X`1\,P[+Q"``0[6A[=-B@Y4
M$`.3`,.&6P0.`HPDP-]P@L$$,6`!BQH``"[Q`AK@@`0L<L#BA%4Y"YSN<B@H
MDP0(H``6Y,$!'`@=DQQ`@`0P\@H`*-*23("F/CB@`%08D9ML5Y406(!W>1I*
MGP)EJ^$1RGB(FDGR$-:L1]T$,'N*WB5VXP,"E`%"MZ34#:"`@##D80]_")]5
M3*65\ED%1ZTP)@N]<P,I)&`!\,,53(S9`1DD``,38``=AG6#'4```F+XPZ3&
M&4"@\*0P#5B!!03P.0!XX`9V\($"+'`CD5X,-6&PP`C_8G`"]'Q+<';XB@=*
M4$XN'``*)2B!&+R@!21RP@`/*,`9?-!$$#%JA@C300**P(41[$`&/DA`,U*0
M`&.*4@&6><$9,+``'Q@@!Q;0@A@(@``!5.@,J0E##.QUAA<\``-G"$,"'I""
M"*WF`<%$S0MV5H("E/,#7"A`"3!`#`2<X0).BT6,$L`%>]V@A3=(60PN=C,7
M?``*`FM%UH(ZUAAH8E@#V,%CA96&!!`G#P$:`"H&T(`FOH!H+A@`>@H`IS!T
M`JNV]8%8/A6&&Z3`,F$@ZP1^8(,?("`#/R#N#QZ0W`$08`(52.X96,"`*YWA
M!"I0P;T(T`$%:$`#!,C"#G!`_X`3G*`'FLBI',R0@)PBP0,RN%<:,H#7WDD3
M>-0TE#6+QZQL7HV;CE(8DZ"4LLA^CPGJ5,`"&OM(2]T2-WZ0Y_CJV968>(>%
M,>H#!)*QA("V15ETV`,4EJ@%*$;EF$OXP`?*$#U&.J"B21D@#%8@@`.4R0X*
MP(#-Q"`%;%D`KHB]P`(4L#D3^$!8`UB`%*0`@3ZXP`-2\`(4SB`#!JA+L%R`
M0!+[`%0(N(`$B)"A-Y.:`%"4X`(?J,`''@N!H^"H``_8UXU*P(`E+`$!.E"9
M"*#@LY7=T0`+:-F1ZVP!*-S`!Q"(P0,,8(<;?""+#+Q`G+E``!$KV@6S"=JC
MPP`!#/^(08R)>,!3X;*##]Q9JRY(0;OZ8($8=#"F)@A&AT8`!0@H((_YNO4"
MMJ"`&E`!``S@`@*HX((WN,`%"G"!"':0;!=@```60+8"=J`W!<1:`%S@@H*U
M,(%CFZ`"&#,!#])L@G+SH`43H%F@M6""HC%`!"BP@`I,L.PFJ&`!/0"`"NS=
M`R#$NPE-:($66NW9*CP`"C'`P`@^L``&K`$`.1``"';@@]_A=R3"PSCQ"F4K
M_WY@#Y7"B2L"0QCGI6B,MJ4#`3:8@QX0P`$#I8,!T.6%S-DA#R["U(#!5RJL
M4%A9,$F1*QS@'9B<@6`7\+!;ONE%'[0U#0>S@P&(\8`03#+_*#!?F-8':DP2
M)`8&#2#`DL[P`(?<0ELC(%`?=B@`1(1A`A"@8!]^M@$NI(8!S@F;#L!R`4("
M(`%_EH8/'*0\KO<A##YP;AK.P,@7R&`(%S@$`JH`G4-`8`2OL@,$`E`$[T55
M"PH8O!\N<``#4%#2PAEC`C:%G@M400OL82``4+8'VPJ@`+?PP0=&4!:9Z+$$
M13<.`5Y``'+\R@Y"K`*!OB*`T#O(!\Q.CP(T$40I"&!`+A`-$("0@@"0K1D1
MB7@5?`$,`0B#')0XP,0T+8`4QR`&`M`:PLWZ?@S$0!=B84`[3&"!:E4@VR8P
M`3E``A,P`0K@`0+0`5M"`AXP`41"_UV+40`ST`$(<`4_,``S,%XV(`%AT`0>
M,`![D`=P(#<7!@$KLB<A@`$]\`8[H"<8=W$!%3<\P'&&@B@_\W$Y<@FNT!<3
M]4TA5RG#4@!B(`8W\1L0D`",YX,&4`8W8`,$0`<O4`8((`7\HS92(6$PD0`'
MX`9V(5&&IQNND`#)I@!*%Q)!%RH$4`!X,4EI0`Z+1G3?E#!;-V8WX0!>MP+G
MA@(LL'<8P`4?H``'Y6Q=Y1T^4&X$(`-B``$?0`(W@`$/A2Z)EF-<@$ABX`(0
M<`,RX#>G@0#YDFB_@C"6$CT#0`6W1@4(L`-P\P=8T0`QT!UYA@$?@&8)(`/O
MMQT)D``>P/\`P78!7"`"P(=&R&8`"M!I7)!D]1)HZD(""&`!?<=`"/``$+``
M>Y`N2P`+,G`!7L,`4'`!;?8K.D!+#.`%)@AH,M!C"@!HK.$"!\4`8H!DB@@%
M$V`':/8!T'@#!Y5"1]8*.V`7T?,VE$('4C`B@.$'*W!'>Z<`WM$'`X``]R$(
M$!`C>[!@"?D"2R`*.J`X.-`E2-(E=L``C6-*`+!+`\`#'<`!3$(""K!+W&5,
M$A!:J[,D$_`!WT16!-(*"T`@JL@"'M`#`2`"3[@\;8%-&H>2-/@G-KAPAG-"
M=R%1X320F-)BQI1.QD0`8J`G=0@88L`%"]`I=2,&"*``"E`&>6#_%?'4<UK(
MA5(13HSB`#%R`^-Q!F68*Q>E@_!"*4QR`UQ`!3KV`@?SCW.(5'6(``W0`#P`
M`!,@`I:%>U*0`O1B6TL``6=P"C[P#0/B`PN`#K&E5,"@AK``!3$R`'3%!98Q
M?3OP*R\0`]"A/#\XBK?8+SF@`.%T`4505J9E!R<`<550%GLP`EH0"7O@!=*2
M0W7V0%MU4V=0`!_0?CE$$9&G`Q?``"?@'0/``-Z@6=(0"GEF((RP!S%@1JGA
M>*!W"R1T``O@1`,@`"FP!^B1<)*Q!^?Y!I'@!UPP!``09EJ8`JB!&^LQD[^R
M)PC0CD/A!O<1$\CF"M_X-R.G`#X2D5R`_SXO``#6<9$A0`)[4#D;63D2T`-+
MPH$D`*%$]P,F@`.48P<$V)>EPR)X<`58L#J5DP!=Q"1I(#>5H@,NP!ZJF`7M
MT),2\CM!V5]#J0!%*1@W@48C\"[X`3)(\$#S)$Z3`H?1DP:E=0.6H!HW$%D@
M1RE]<`,*X`7"AAN5B``)(`;OQ"18^`I;V(5JJ1MLR9:\B)IQ.5`#ID__:`=I
M8`"E!7C^`W1_R1LYX0`(P`9#L%$G``,CX`44]`(8\)K#0@*M.'(/0!,4Q`([
M<``@-2Q+4`6HL9!+\(O<R6VUQP+L(!G?"!EBEB(8LAU0(`7@$J$7``0%X#4@
M=1GC\"&^)0#9D?^E=K:')7`#2R`>L\$`(P!7NM<`2W!D'P.-J5$"'K!6"N("
M$R-&`]"=[90:F1!?.B`%'^`!WA,&+`.9:'0,6`43M,$(/J`O#&``>W`"R2DX
MNB4`7M`!QJ1[GG%A`(`@-^%56(H`Z.H'E-(``[IW#]D*9$5!HJ"@%G9L$PD`
M(J0#?#`#"&"2>]`!BX2A*L`D=L`!'?``'*`D/^"`E",!"#`!QL0'!!`"'&"2
M-K`#(9`E".`!7H074E"38Z"O7D0'$W``1?`&(G`",'<K^664/QJD:U&'/[,$
M.%("KH(`*_079ZAR2V8`4:%Y!L``$"`%PR(&!M`I]Z&*T]-PC7678;'_9*I%
MIF9YIFGYA4S7"B5P)F28<1_&=&S9"ORZ4+<Y!P!`A"`W%'O*ISAAAQL0``>P
M`17@`8G6>^7*`#*0+?^T`+'"!56V`!.P!,'V-[FG/3=PB01078AF`E*``9&U
M,MNQ(H>P9;H!8BU6`%*``"X@!5!;*2\P!1N``3Y`BU[F!995,R/P,`^`9X<@
M`W^X:'06`Y8)`3/'!?8G`RL3F:,P%AT`!0E0N.>2``@@`LCY,!80L-/(`.GF
M`MR:FQPC`]IV4%4+!9TT"%P`!8Y(BU2C;:^J$&31:3>"1PXE!:V2`_7B3PA0
M+[?X`0P`IF#Z!K=&`FT&`+86C5(SC*H:LF!Y_PW-9@)%,%+&BP(BL``6H'\[
MP``]\``]4`0+\``H(,%L4`$B#`!:L&P[L`0'<```@050]`L[L`$"(`)8``!`
MX!#$<`S_<#&^<*F3&@`K@"=/2!(]VG%!:SQ#=X,X,@`&4``%8!DMIBJD$Z8^
M@',.8`!+$`-IH(8B-6QL8E3R40`&8'\.<'0N0`6[RY>`4:9GB:9HZR.XP8D/
M(`!O&CW[,7)&)2P&$+-V4"+1\P=YL+<EAQ->][<@```T,"$<]$`(D`.T@GA`
ML`/VP4M+(``3(%O]FT22H0!:P`"R)6G;\!DE(`!LP`I&@9\,1+HYH8IUZ`?!
M10!GD`95J8I*U0`R4/][-B4`*[0@P2%Y;(`F8;-#T.$@2\`&2R`9Q9<#D>`#
M/$2P1J$%T@@:*?09$;D!W`(75,5")4`V)8`(,G``$]1(2[`"'S`<2)`#KX(?
M-V!^FZ!##QP&PY*<:05H%`0!;#`".5`?`1!Q<_`+!R`-:'``S;`#SY`$OY`,
M15`$R6#0R7#"G0')-'P`IK8$90<%7`-N`K`[>`5M%;P`W.8!%N`!%7``\\9_
M^L8#`0AN$Y`!7]D$**D`$S`'PC:%*)`""%#37!`#6::[',(_@08`TM(O0!D\
M1`P21&G$583$I",#-X``ZQQT`^4#95`&`R`]C:8!Q`<E8C`%0C66,#$]2\#_
M!=W3(E*P8*TXU?RJQF;KA<HSI`.0+D4PQY12&M]DEP-0!CVV-]\#<H#<$SDA
M`02T`3W0`!X@`=_H;"MTK:]7RR_0#6`#)8[&+7VSI8^E`QC@KBBE4@QP1Q>@
M!1T@+&L;>JJ%,']\40,`!:56<Z_Y8M?:`&7Q`A!0'VJH`V+`!JW!"=H3"0/0
MBQ7P6'3PJ'NDMMKF(&*`N%-)#A]P>N1PV&)3!=OL.`#`!=$!`0)-(P[`!3FP
MJ:U@`!\@O+-!BZ1AF91P'+QP?<;:0)CV`C/W`#*P,P$II2)S`V)@CW#"Q,(F
M!EE,`&RPQ`6P3H86%S=@.R7@R@L@I26`!+J84WWE_QD]<P(DP`,6^`,X@`-A
M0`.180$<$!D_T*$#0`-Y\%P%<+)[@`,I&29@X@`V(`)6UP<@ZP%C4"EGD`#8
MTPH("A@%T`,>L`%5L*,^^X(U6,3,H@-'O7"(,)T?X"&WH(I,<`D.(`7!,`!]
M609HD#0N`"4^4*52O2<P$0:TQ7!8;0#E)-4X@=9HJ=:,DD_RD0,-@!1NZQ;*
M,DX&&CV`\0*Z5P4W$'*4$F-[W:=W.`'FYP'$-P!,8X]>,`%B\`%(8(GIDAFX
ML1D/@`3^;0%VL%8E,`'K@1ES51T.4@+JO=\#8`)!A2.,`DXWD60W60`:D`,+
M,*0=4`\OC@$`(@!BX$$0,O]8<%$!(7N37*`%DWF3"M`@PM)`#["[+-`982``
M%U`"-4U+G58)6+-Z7]J(".!H89H#9`'K\U(Q(>72!3`@%\`&#&`"*G0#"Q"-
M2R`&'H!5HG`&,:`%%&*/&'#%:!432U`DT7,"5743K,N7E[`":.4=VI9/@!X?
M#ND@(<8%)G!AZI%$.L`!!H!*3-(!M4ET#W#('+`')"`"2F('H,,")NG73F),
M#'XZ88`%5A<54K`#0#[&T>X`8\`?*V1,SJ0"PZ"\.RZ41`VD1OVM]7EX9R*[
M81.'QO3?[(3&9X"U7HX;_20#,O"O<\=87C#B`V.*L=[52V!,#H`'3((#@9OB
M<:K_&TZ9!BY@:-WTEW`>BG9.!V<`<0QP`U$1='((R+HA!3/&`P)P`B*0`M#A
M`]BZ/:C!!<$P'+K7,4CO`;F)"%(`5D/>9FN&%XZ+3R7P#*BQ50L`U`B3=9<!
M!2^`]LTG486Q+?]0'8#N`022!V%`#@@9D460@-U]`(8:4EQP%*AP`UH`"8W&
M&<(Q&]TI1]%*TRQDW<7Z`JYW``B`"`V5=K-A`CB5&N=)K`0@5WK$L^B]`SGP
ML&=0`3M@`T'_>BY`'!/@#VT2!K'H/QJ0D5W7`6%P,!P`0D.J-T,G4D"D84:U
M!UPU<@-0!=$1-N&R@P:53Y$."#I]#G8(50Z$`PIB=G0._QU-?71])U)YDWDY
M!GV2"1]]?G177P4ZDQ,W#HXA/0P!6`2@>+-^M7Y_N+FZNWY]>+TX/#2[Q+J"
M.B4"`"]^83<,*3=AMY*Y>3?8`WUA"V<86@P..CX%,@9V+R\Z?C(/30`8=+9T
M]'9Y#G\HB`Z##C@'&T+P&V2KX"U<_0[R,EBKF$-FN/P,>.&`R2U'\HHQ-,BI
M(XX-*TSLH)$D18H].@;L8(-`A[H+*9#4TF%@A[H"#PZX0/GA0A4=ZR@].&<G
MS`@39]@U>*`@'8,/-SI*!46USXT&`02\J7(FSY\P%PZ,6P)AG8X;128T*[(`
M@!\?*11P8;!N0)@G)_J\(%#3P/\+$0S:%2CQQJ0=H#XF?/"[)XR`6F>T5"EB
M0(>"&$L>#'CK9TF*O3<0`*@L.H&`&W[8:-DQ@0,'&S\``*#180`+`7PDY!B"
MH<B+"P\>,"B@3H>)"Q*2_V"Q9X^$$"QH(,HC`&@?'0EDY#%K(`PG'1=T\-,A
M!8(=3B]B#**#+,$>.PX*%'C_7D:?/7WLI,&P9Y(/!3?8E4<"+@Q`0!H&2%$`
M-@8(X((891B`01522"$'%6N8004$,@#0!!5=F`'``0)D=0(BL^#AT(H1^8)'
M'\&$P>(N@O21S#+-^6%'`@7XH<,?=)SG1QX&++%%&)?X404=/B"@0&,R`">`
M7T"]L,#_&@LH4$8C=MCQARH'T:$/(OW\$]!`#FPD"2?T].'01@K-^(>;]^%#
M3T1WO@EG+5-)L<(0$U0P@@=]`!##'BX8"D`IH'`!P``W)##`!R,DDX(/2RSX
MP!D?,'"8.I[Y<`,)!'Q0@@X"[#%!$0F8P)8/4W$R)QUS<F('%3F8L9F,?I`P
M0IHN/)#`#@;L(<4'=NP```$8R""&>3<(((,@9RA0!02^]0$%!@L<^D(5#P3`
MA1]:D*##8798@$&F.DS0@`Y%+/%(%1<L(4-G,H2APQDZ!*!`#BGD\8`%Z55F
MP1(N:-&'#&]T(`$B5H:P@\-:\-`!$.-8\(``9*DV@F1O`''`_\A%#'%`$0>\
MT0`;0VQP0!UOQ/Q&$C"_$4``=3QQ\Q-/O*$SSCG744<2%`1`@=`44$!T'4DW
M[;331#?-=,Y)3YTTS4D8S3/,3]0QQ,T!Z#S$$`WTS,8**\"P`1`!B*`!BK/(
MJ9&+,/(@H]RSZD"`,MXQ*QL!.H0Q":U_V!%I`FD0TL<`7+BPETL3+(#`#7O,
MI(,,A</71QYE,.`%%V4,@%\^^Y0)D$`);810FZ#L:=#<DCA"R)Q_-+1>FW$N
MM*=4#I"PPMH!>"#!60)H\<$9="3`P!F@^/#`"`*\8(</#!S`'W@C'!"5#IF5
M\!T"DOD0GP!%H+;'!0((X,/ZL;HY>_\U?^S!1![G`8E=`W;L,0``#6"@+Z)O
MV($?7B"#(@!A>R5(`7'6D8(WR"`68A#`"#H0.%0M0$=%8LST`'`I'WV@`1-P
MB0],T``7Z&`/!@#`!9CAD@TL01M["\`2*K>'!32@<G9((7,X(`$$O&$!'*!!
M'E;0`'4,4`"72D`5N)"`)J;@`1V((@(6D``2=(`!&"`!=`S0``1<X`8&V!8V
ML.$"`Y0`"3?`P`U*0(`"8``*)0@#`3CU`B2\(`P&0,`+)F(`*KG$<7;041D`
M@"0'A`$!:9#>'PJ`@'J("CZ&7,*6\&$`@@$E#@:83W-DX#TWL<`"/=B`"$[D
M(A7A31>]F$7_W>XF-TGHC6]](``$(,`%`MS13;5#3S8$YP`HG`$EQ3'B8=X#
M%`@(H`H"8$`>%D>%S"0@#Z%PP)CX@0@SH8X@#(D5G]JG.F+$#A%=LH/HF$`/
M5<0J3[J#$^]P@!48O,$"/V!/"4SP@/7)$@`)V.,"H"<&`W%!"Q@H@3H,D((%
M[,$'9^@`%`HP@!(LH`JC\4$"1'`M=1C.!`FX`:QB-:<TQ<X1:VH$>R[`A@<0
MX`8`T,(2+M#&S+!*$'M``!0(L+YHN8``"%B"%+2`#2XHP`4![1*J=G"&$B0@
M!UY8GP(4\`$(%,``(TC!"&X@/1\L8`D&.(,/PK`$!)P!I3$800P*_["`;D'%
M!T!Q`59#T($0M$`!)TB`!5C@`1P08`$BB`$&"M"E,SQ@"0Q80BRN@X&64"L!
MQT!`/H_!!N8)P@4N.`R3:N`#'?6A!MH0#Q<,RIX!I*!&AFO)=0QP@?R(QPN3
M(*<2.Y('T`DIC:TC@!0\F@<@)*`C!$6)#GY``A94R04=>(\=Z.J*44J@E*=$
M)=UB=$I7GJ$*2]"70TVP@!N<$!\==<``""2%,SB`<P08P"-?8(`!N$0=UWF!
M`O*PASWZ80\)4(`4)O<"-DW3=&=*'4?HP5_6:9,AL/MHD'J!B$FTKB,K<ETO
M.M*[!FQ@8Q:H0+%H&@.]FL`'%\@2!AA@%?\/>,$++DCC4%"R!Q-,0(T^@,`#
MN%!846'1!;]D``3T98<2Q&`!G9Q*1!9<.WYT"3W8.0`7EK`$!81AH@#8@0O\
MD,(;?.JJ3('4!P3P`0(8#ID%8A94\F<9`"SA!LR*`0-N2H`8R(9^"MB!#/!S
MN25,S`<E@,8#%O`"'V#`4%15G@S2H0,/K"8!#BA!!40``!Q(@*ZR<<`+DEP*
MERA`"P+HY`L8<%M.$`"QG#`',?L`!`($B0Z-LXX/7%#9^NKQN@O`P&'N4P50
MG*L<U]&!&,2P#:!\`"B-*,,A>F$')O:G#V0ETZ7[88<#=,`.?."#&```S#/T
M%BA[4$!X\I,%#UC_X`W&16YR6Z1*YN+-N=#5UPV6RH`2X$<>K6O&%-,@#3LL
M=,QE\8$,"G!2`N"G%P4H@Q@*\+8\*(!CJ>!$+^Y;S=.A24WICEW[TEV0`$ME
M<"!=L%0:0@P%2X4/O@M)#O8@@@,0`'`O6,((?(N=(@#@7,03`5!TH&)^N60(
M/[E.`C:PD_S=@"44>0$;*H.2%)>6HZV31RC238<]Q.\"6D"Z`!I=`C842!`=
M$("5]Q"M`\C@,`;80$L&R(4#*&``Z/@KR/>0@P_`R@<CB\IA7)!4F5>AT6'@
M7WCVM8&3(P8*3>G2$@Z0SSJ/8`=6IH$'#M"#`3A``E<`0`;.,VKUG6NG_R-@
MU!Z:Y=S*"$(&4ZBOCQK+'AW4``(&?@$"*AO(";#9.`:5Q!Y:S0D'G$"T?>CC
M"06!`:`@HB:JH(._S\&)-(*3`#C(0Q@:TP)+Y"$/4K#)'66;`!^(5P'="<.1
M*X`"$_$C1=OF]HN\+;=0[$L$T06/!'.``#]X=!*U>($40MR=/L3@`1^(0;PO
M@``7(,`[G-C#4_ZZ`+`GX`%0(`8^T`B24`']@%^H@P@%P6![D09I0&\'(A\/
M&%X#P7#%L`TG50!IT$;R06]BX(!61A5MHA&NPSL)X&`J<``GL`?"054X<2UA
M,&HC\`%(@'(L,!QP5@`?H$>&HU(,50(N,`(+X/\#P!0#)L!&-.4%\V%G7A`5
MVH1^VS0GO3`)<Y(`!V`!X`!C7;(`.R`I*P1B6_50(C"$8O!$VB,(+Y`HF70&
M+_`!4E`"Y0!=%W`&,B`"`L`%YO4"8^`!%^`#?10#*<"&$+`NY19G(S`"BW46
M*9`O)^`#7A`#`1(#!U`!#,`".-`#`.`@+_`PL<$"5[!4'Z``<*A62\`C2%!F
M+@"'-T!_"X($"@`!:U0")7``%W!&S[!0!8!&"V!&IXACLG@"##`<LE@`4H<-
M!4`@'#A+@R&+IL)&!>`"4M>!"R`%-["!",``,S`#8H`#+I"-,Y`%+<`%(9`%
M9"4`490`&=`$7"`#)`#_`3M@`4XR`0```P=@?0Z`?=DG<"\27ZPD)[VP+\H2
M!H$F;;`H"(33"SIR:0D0@O'U`E^E:#*``'F462X!`=)S1V%@!P60`5>%`;`R
M"0#P(M0$(T"P`EEP?=BU38-@``_@!1OC!<&X`W.0`@``8C;0$13G$%+``'.P
M`WKU`%40C#&0`U#P`7@H<'1R2K;`.R3P-2VP`A6P!PY@`3&@&.:`10]P83+0
M$U4B!<*!`4AP!AXP2_UW`Q]@`6-V!BZP`"<@"(7``,*Q,$SA`AZ``(,U%7!2
M#.#1``P0!@4`!1<V/1BP`PMP&G;&`#\EBUSP`%UX/J-Q'C&U!`#`!7M0`AZ6
M_QD^0``F\`%+((L+4"#HX`,`\`$`X%48\`$8L%<ZP'8/4'L%4)I<]G\?4$\L
M%W\,,``G8`$B(`(%P`&L@`/2\1P5L`->((M+P)D*@``S&`->L``'D`(N&0,?
MX),MN0/$R0`>``5OL`3,N3$"``6/&`,"\`#O-R&/"`50D`-:(&;=P@9P29X?
M4`48\(BR$8P,L`!LL`#!Z`4IT#\5Q@`<$XQ0L`,Y8`%-T`,5``#ZV0-<X`85
MH`)<8`(C0ET\T`4H``8*,`$3`!@90`49L`-)``)940#WB(_;1A5X\`@3T(\S
M\H]G$)!VH)8R``$#.'&<`"D7,`,4L0=44$4)@`![</\&$R`#-R`#:-41-\`\
M"HA'2X4`7I4F#A"2@S"E.%"2)^D+*2EQ#J!8>?`"/E4`?R`%`%.-W863N:,+
M?5`A#Z!'M=`$_/"7>W",VD`5M(,W2RD5)(`5()`$'F`#?L`"(J`%HE4J`N`>
M#M`A"'`8`^`"5:``OY0`6L`&$)`?(1<#L;`',N!K?;!L0%`98<`%;+`#!L(\
M_P5@WA06%]`E*68!YD8`7L`&7#"`!J">5W="K6E=.O":$'`&`U`357!J"9`"
M.G48=_4`3F95L7H?_P:)&R1D:*4#CI(`73(`>D4Y-I8#,6!>85`%2:<#$A`&
M"E!HHL,"3&$##E!)(C!CO_'_G/0'`-YS0H65/W9``!>`$H^0``)Y'T4`.&/0
M!TM%@*('*X*PHBAG`I:D`WF0`H=Q0B5``BB10Y41:Q8`6J8!'[H'(&1R`U"P
M#W&U#WR@!1W@`'R`!QVP`WR`"*,P`P\C`0HP`V1"`B@C2B=P7"::7"C:!QTP
M`0.@E-?QHH2D%RS01]K@)71@$5\B!D]1!M*30P-@`0L@!OI3`B>PBD<*%.$E
M%7F@`4VD;_B!"%(ZDE5JDBBY8PPF!?DD7@FP!@[0.#&P!52`2&:Z(GV@6$4F
MD'1P*%;Q`-<@*4A9I]VGDH/0`0T``FI3`1[P`B;`8L)R&&<``55V*F>P`!`P
M`#(0_P.7P04%8`$N``&'>T*CMA@W(`:5)`,R@`$38`"2VR$*D&H)D&,3UTV[
M$'M```48IE%,Y;CK.)NN"@$(X`5ZU`?_`14Q@&&I>0$```$),)8R-0$*D`*6
M%P92@%$7@+K+@P!,U"T1"07!DJAZ<0&A6`+"&QA<,#FKVR2?604N(`$<\`,(
MT`,D0`(6\P`\<`(B,`$L()VBX0)S86;OJ@.20PAV<`*&5DTD,'R(4`2G<A[Z
M>Q[;,`$$\(]-<4)V@`$]L*-Y4`7#`Q2,%$C@,6WY01<$=E1LHEXNFR8%$`Z#
M<`(D,!`<``0XX``<@+,FRP\#8`19P`>#T+(=P0*&*TI7</]]<9./J82S*\JS
M`$E(X\"\J9@?"B<)!?"VAD<(B!,#+B`%[24J^BFPNB5@>?`LB>*1].`'7TNE
M5CJVM2-Q?I``7%`"5+`93J*W?A64I-HZ<HL`8A"*%)$\_)`&7O`"D3*GO>"W
M_@BX_K`";]`#`H``+1!8#(4!'L`H8?`4ZI&KQQD#X6$`'Y`"+I"1CM(<?<`I
M06E=*#4"I#9<RM`4!&"=/X>7L(M*!G"%HYFH`[`$*A4+/D!E#X`.7/"KE/IH
M6H!6!9`"!Y"M,54\>A1MGR4]D7P`BW(&`%`%(I"1?K``6@``E)-3YG(N"L#,
MMS9"R>1=)5`%$&5N"S`$,\`!#A#_;2*0`PS@FP*0`SW`!S66`JNA/RZ0`CO@
M/8<AN2(K`2<0LA*P!S@`G+G!!QXG`8[P4U)I2'8);1-``^\A`08[?!)``P"P
M'830L.=!$ZFZ<E!@'8^0`K1%!23*#S>P`"NK`0Z#"!R0`RO]"`!`35>``P60
M'!(P`2?R,"S0"J)$`'!C2B<ZQ#G+HBSBH@&I-Q90E)L@<+/R!V>0`,42)-&F
M/+PK?`F``4_$KR<$*:*;"D3"!0-ZE"`IDF0LMEA*MFRB1#N``0-`!P,@``MP
M"9A23W'K$'1`!6)09)>P2+U``)Y2I("<E'8*N'V0IRLP`3E``SQ@//P"A"[0
MECN2`P*`_RY0P,SW(7I>UR4$$!=)\0(38#R`XP,[P'?2XP=0(`("A1T?4&FL
M;*JQ*P8C``$P)P7C``6#PCQ^\"]<T"4E0)54=60-$(@:"0!`L``^G1[D=T=V
MT%1G4!35TYEVP`!L4`7J4)G0;&]^/1JB,XM`$![JI06TBQ(04`6F@@P>T`/1
M40@Y(&1Q*@!L8`+P80<1Q`![9+P'`(N99"A9T%898`(ST`$X`$I6%$4KD`%-
MA`,H4`$X0`(+7@$*T`$,_@$D@``+GF0(,`$_*@#OBP!2P`4?(`,5\GZ\R^$C
M,%].Z@4'8+9.N@2%Q>%0H'@(D`$J4)=.*@5%8`$9(`4XD((DD/\!",`#*&`!
M$TX"`&`".$#A%J`,V'8B)0K4-BO416RG/1N0]S$`9_!Q.A(*Z$8'!N`%OM0F
M7L5&+[`')W6:FVQ:)\10!2`&]$``'YA5@R/&9,T/87NE*8K6G)``2_"(R!,-
MB"F5H7&7.>E-$%`D5+!,?Z``B(`3=""G?8M+?RMQ@X`#AMP#+;`'-!!GCX(`
M$$`")F``)^VDT9/*%S`!.]`E+U`"B[NKD)H`$(!/7&`!NZP@#.!DYS(L(29_
M3MC:KW.J;(!/"H`!"0!B2(``#W`N=F"\4#!N?KP$7)!,)2`#*?!/1'J?^M)0
MDED^,;6#746O#S#MXZ8%WA4&`P`!7@#_`916`OA$4#SB($&9N2ZP'8%#`O*Y
M!"^``Q706Q[0`2P@.1Y``B<``!4@#D%J[@#P`!"`K1N&V$O``RK``PC*`R9@
M`BB``CR@H3@``RK`X$2.3^?X[VP5`@S`[]GX`!4`'2<0`B*0C0405T<HBYR^
MC`0@6"7@@(;P<0_(`%(`@O_7\O^,TR=P`D1P`!EP`AJ@`22P="T_`Q,`\"UO
M`1T0]">0`2B@`B;""37;7%"^LU)^Q/BWL$(U=&LB!I/3M7-+A"C7JX-1H[@F
M"3JR&>219'<XIW0PQG1>QF=]Q@SVHSY@N51P"$IT6P4@!8)^IKG@!Q))%A"1
MRWV0!@\0IWQ+_Z>0/LB2WCLK``(;L`')T0?H(\QBD(;/L\EA<`#B#+5($`/!
M=1WN"%$GQ``F)P;C,'@/X!T*T,>@,`!2<$Q,1&NEVNLT(@9%T,>BR09F=T)=
MY1)[``%L,`+AD>PJ96[+/00&=18[P``H`6Q:<)0^\$$[H"\O8-N^]0)WZ",I
M$0-\Z1VY+P#F<1;K:64H95"'P54'4!DT0`*2W1I\T`%7*#I7``AL)#HZ=@5:
M*2QB2P8^!#Y0.%=7/RR2E!D3)S\V-BTL-`,#)B8T-!P_&1JA?`@V?!Q["@LT
M$A(<``X2#CHE4GM].HHZ=(06A'YT!E4.#G0."C?-?V<,?,T:.+:W!_\=#C0.
M)P)[?!(V."Q[ZA,S>Q)\+!4+`3LG$GCX>'_[_/W^_7W\],'3I\.$,/\2[A/8
MY\P.`"]TW$C@HX./%WX8"J1S@XN",'T<]`EC9T\8`GU>$+#CAY>./GWL^)"B
MP(N"/@.D2$E0)D0>!WG\+-G(4,:!%6+HT($9,&.?8CH2)`AS9D$#&7WR((@A
MY884E#`S+LQ(5B"""Q]<A.'EX66!!R^\#A"H46'"?$QARF@0H$(#$A+Z$/A0
M),6+/@D$:)&VIX"'$6'V&&)P(>(R-C'"T#$*`$FP"P`>#.CC0T%G/W&KY+C!
M.B]3LF'%_NMS`0@#.Q(_,/!!R````&%>0"C_4B6!C@%<!``H`*Q$B@\%=)1^
M8/Q%C!0B$MAAL4-$/3MV3O18\(.##"!:6N3(L2)`@Q8MM&S8`*3%@1ST[0.9
M7P3(@18-O($>$#`$X!X0#?"U`0Q``.$>&VPT^,8*]T'(Q@$'N+%"`VQ88<4*
M_JE`@BN!<3#'#'S0P`</)I3C``<*7-%,'P<UXX`)30S0C`18[`)4"0C8T8P!
M'=CAXP-[T)%,`CG`](P+4@RP%`%>,.6+C0ZPD8`#P+`@@$@C22$&+S<F$)`#
M(2RAPAM8%!"077#R0Q9!661@0YP`P73&;YJ5<$)--^@`#&R")6!`4'WLP44.
M<^0`%QUV*$7`80XP_]''#4MP(<89+=U@AA<Q4.%#I']L01`=?^BE!5)*#=34
M1B])(<-A):#EP!D#+`(`%6`U-5999EWP@`D1Z6#!'CH@$<,>7OF0*D-X]I,/
M/F0E,,00"+0P`@$Z+%`%!"E@<(,%7+CP0`F"#L#`#@-``$4".RSP@A<07.#%
M`"5HP0(46ER@PPLEN`"!#PO<4$`*=B0P`I0[>!$H(4O!M%!8=OEQ00X`,!",
M#TM@<,8'4``)P`U5B,$"`"Z8P,`),HP0C!T$),!`&"X@<`,`"C``00DW"!!#
M#AV<,($)/]A!`P$3Y"#`%6_D`(*!&QS`EX$!/$TUU&]<7?767(/PM-=67__M
M]1-4/_&&`&X8^,3:;"=A-0@`D`#!:'B8R(*-"ZC`!TQYQ(A/'SR`TXP*'HS6
M!P<"<+#CG]<XT`$.0HK40V#/E"'`,Y"Z4,9A=!#00UAGE/&44D`DL)0?).^1
MZDQB!$2'`F4HY<`,'O!P=@'1YB[0#`C\D'NJ,/GPVV@$R)#`!"4XN<]3?PQP
M!JI<]O%''G2\L%08-%$QMQ_\I(&``E)L/@`52WRPA`L^2%_JJ<`G(%_K$K_Z
M5&]:</&"`R_(\``4/@!5ON&^^@.PG'*6!W`A#(2X@#I*P("X(,!9`9'8[Z:%
M![)<H`%#F(``"'```7S@!2\(PP-&@`!U)"`%!B#_C1]<T`"(<,D%6I"!'?I@
M`"VP(20ZN$`59`B,&`P!`P/PP1FT``"4]&(!9LH+(018%KOD\``E6`(`1N.'
M#W2P!'L0RA!8H(,PW`!#-TC4`+2`D7_-8PF3$L,0#F`<8-1/%P.P@``FL`L"
M`*`%)UC!TW(`H`!LH`4B$(``UB.`%@0`"$UK`83>LX$B"&`((OCC!D`4`/PT
MH#XB`,!#=A"`M26!;&2;@VT.`[QGZ((&/6A`!60P,)C88`XG>)$$2)`!#L""
M!AFXPC7XD$O%\6$""Q@`!VA@@RG2(`\VF(&=KF"#,EPB#1K8P@QF``<XD&$.
M<"A#-<$@!"-X\PM!D$H9_]Q5!JDD``A0H$(":)(#*2```3QXP`,@\,X=,.![
M$*C``3A9!0U(\'<*V5WO?D<(Z6AR5`6(P0=R0`+9"#!194B!``R@@WT,P`4"
M$%T>!O`'+@'#&=S[`ZJJ%Y,\>/$,4X&4`TS%/)BX[PUB^-NSG%(,.UQ``9@)
MH1^24`8AT6$!.X!?``>8D0(>\"6\Z84'O"@%"$)K@M/*B`.L%8`.".`'&WB#
M"V[@!V8)8`=[>($=N%"%C(0A!4](@0_\4((/K$`*A$C)"%+XDK8F`#4I.,`'
MUGJ!`'PP&+2Y`&P*P9(F5NP&.1"#NJ`@*``,`0IGL,,+&N"");RL6PU\@1@(
M\/^$]/7L`SNXP1FJX(4=8L0/=A`!#X9Y@@14@`1Y4&4'J@8"$=!@!B)(0A&V
MA"4'#$`$'?@``5C@`A=@X`<`2,`+*A"&`PQ@!P((@0!HP``&).`$D6O&<FZ0
MAC048`!AV*A(4*4Z`1+$`2K8``B20('V4B``[HVO?-U;A_E2@+T4`$%^VYL$
M]@;`;76H`]C>0($5I,T-!%8#@JWP!C=X2`U6J.1ZI+:>'.S@"?=1F@!6L(0J
M5&$'<SC`AY<`A"H\X#<[*(((`M!/@,9)H+[+W4L,JM9@R""Y+!F5D!9"@`+D
M07H_R8/F=H``/X2!"EQ-`P$@]8*.2H\.P-B##\(P`$/_[$$DZVLI8K0`T^7-
M%%9]D('-`"#8&X@P#R]P`1N$^YJ0$M4/"`CN41%#B+>\H``R<.H_HT5!LAB`
M#6_0)P!,T`<4%L(/"0``!!+`!>%-P&)#B&*_1H#&'11`)'X@P1`,@($EO,##
M!("`%]Z"@`$(X`P82,&,68.;B+G&H0F1"!O(*`4BJ]D%17B`'P*P@`+L,"P%
MR,$%#@"`'*9@``A8@AUB<#XN,*L!"LB(1.KA`0308`$,4($*?,`!"]3A#45`
M!0"2`(,M^0B.;`#-&6Z``2B(I@H(>($`)DL``0!AV#J09P*BHX,\Z*"*+?%I
M,ZHL4NE)3R`.N(8*5O"!"^S,_Z0V:)-D$R8%._!A+0DXPUKP\)4?YX$FX<U#
M'ACP$SSP@0#>&(@&3C"0P&1``I&B@Q@`8*FG)(``6`X#&1P`'A_<X!DQJ4((
MF#<`A#TC#R&0AC/D4`(!TH%V"T^L^ER<$!C_#B;268((T@<D&7!!.R%-U5+.
MX,[1B"0-9N`"%PQ`AS!T``+%73+W'&"`)8@A`0AXQI6S@FF8L!15+N6R`;PL
MOYI*!6`Q`$`*E"'%&(@!`6Z*S:^`%></!/,E;:$#$AIX`Q+H>>I\CFI&9#"$
M``!@`\5&W0,P$!'$"*`()`!/%0Z@!4*$`0("4$MX'A`#?KL`")Y.U`+8((`2
MV.&B!_]P`6F2;8`])*`#+\%Z29SQ)B96?=B!VK(6T*4#!3S!!'5>P@-6$A4V
M`,#X#HA!$7(@5N$(0`%B+<$#@ND`&_2`^#9P0!@JT(+FOT.]0(`#27-(.*`+
MY?`.$K!;&\1N#/``/K`#$+`'*1`&;)`",4!"6F`'#^`%,G!I!>4',L`#'Q42
MX@4F#B!2)N@`%O`&R34!Z9-PPB82#N`"M,`W$'`&#H`/"C!>>0`%,4`W>;`#
MG&,'OC!#=)<`'[4'#P`2SK`,,P1E"F``,^0'`Z!KST``*100=E`$4M`JP>8D
MV",&W/,Z6[(D!S`'`2``!0!K5"<G?<`[,18M6#<`%2`"9Y#_$A"``1,@"H4G
M&'"'@S"A`$NP3US0#"IQ>,X`*6D``.Z&`720!]QU!@9P`S_V#'_7/EH0`(.7
M*E\V/SK0`?%V!BXP!,KG``3```9@`!`01I+'1`-4>9?G!P]`""5@`6'``DWU
M+'N&)WV6$1?T!BBP`FIX9PF%/NT"`%J@`#Y0`CN@!2)0`"'T`A[P`#=0`CZ`
M!`(`!7>F>,E5`B4`!2-@6L&!`0Q```2`+]1X%DH$0D)2?6RX$+51:CZ``>LQ
M-R0!?`50``F0!V+@`B7P,1YP``O@`V@!`%5P`Y+Q`@A@`@5P`1=0`I15`"2P
M,@P0(SC``(/&`C9``P$"`ANP-4"`_P`[LB-]4#H;)`;DZ(`B`'\I0`!OT``(
MT$Y:H(0/T('1]V\^(`#QU@=,L!0_(8,%YP<$$1)K`@`RL``E((-SD!0P08-)
MTE4*P"F!>!A/L0"B`1-[,`XP`3,(0`AC8`#:00SY]A*\H#!75@PNL(_7HVL!
M$3-,X0"E(R1VD`:7`V4O8"A*0H:HX@<\X!X!@`4L!WIM.#%P>'7!,``?8(>"
M(3<(4`)^\&\25"C-IQ1TD`!RX!%F$@8(($^]]@P8<5)VH!EYD`!40`4TD3X"
M]'<,X3Z:Z!2ZZ"0)%`T8\!%I&1,#@`$/8`:L.%0#U`=2$%Q`I`-WP`"TR'IX
MME81))AQTO^+8<8&M+4#%0`%NU$`2Q`#4.`!-W"*5ND"^?,!)71\"O`0L_("
MV/8`"K`',P<`'Z",!F!=AQ$&ID&-AO``2S`(3`$5S:`D="$6=/$L-Z`%'V`!
M[L8:(@`%`Y!%G;:>='";YN,"C4&?[Z<#;S$K_P(!5:"&.O`Q`.`!!6`'/_``
MT!D"/V`!`(`#-K`AM!4`%$("S1`Y'-`';-`!(D``-[``35`X5<"29\""[F.6
M#_`!-JD#T>,`"[`$YVD'3.!;)]@JDN$J1/D&.R`#+A@2?(`%%%4(+L`%(F<'
M?;,27(H`!+`'(J<`,7`&)O4"`""F+S``-Z``HC``ZQ0'/C!E>Q7_!V<0!U*0
M`P1PIW'``%20!F=P!M3973'#!27072=0!`I0`#UF`'-0`$K6IDC&&J%2`*S!
M`PUP`!N0`S/P9MQ3%KOX3PS!.V=P=83@`XG)+<*!D!B!*O^0#'D9$U*!D#&!
M`%4``#&`<S92!HHF%<\@!3@3!@6@&0&Q!`_%$!<@>`0Q%JXA#",P`KL1$0TP
M*O@#HI''F\`29@D0`\'I!Q,0$0P4%Q!``'2AG,LI>F'&%R/P!CY@`D\P-_^2
M5UBA`P3@2&$A`P)P`<&@`S%0!;PA64]0;(5``.6#+#J``"AT?"\`!#%04#<0
M+GGAFDHA=DPA=F.H`[Z1&/T2#)^&`&'P_YAY=1@2,0('H*^$4&*XL0=2H`45
MA['AR!Q=Q`8*``X2T`$',*/E$`(50`/J%0!O,`1>LUM@(BC-T`#P<@(L8`$6
MX`'(Y:8B,`$@8`DM@`,M0`,?\``D<`(N<DITX&NBDB0SHCQ["1/H]08M<&("
M@P!",`<Z`W<[L`/E0@;A:09=H`"FL0#%15;9B`'M)I!<``5FL`5H8`9KT`0`
M@`9;``9;T`1SL`1;$`1H@`5N@`9H$`0`,`>46[E8H`8>!EU:4`4ID`(`\`9:
M(``>)@!G8[HDFV%5T`!S(`"T!P04\I>1-R?YX!1DJY]T`2ENZ`<G0`($8*H.
M@*HS^A*M]V\5-?\;//<4>5``#%`%2/03*+5H+_`3*E4&"(`!5``I^CBKU-,,
MQEJNM*&LZH.[3"$1,9![Z0.GUK4'%[`$2W"MLD%4VLJM`R"<W!>N!0"FY>IB
MO6@Q;)!!+4`"`+``2.1S]'F#P:``WCFG^<@`,G`#QJ4;@2J(,7"#_V(`#R"/
MU>`%%S"/,6`!$&``!3`!#]"%0AHQ%24Q&O&I_&E3\U8""X``9W`!Z[:>R/$!
M'S"N/F"=+E".ZN!K"E`"%I$`'GP!UD4"+G`!QJ4`*#`!/Y!P64`N6<L')#`/
M`:`%*.><0"`#4($;B%$$)M`""UD!%1`W.>`!.)`#%;`!/&`!0*`",?K_MA:@
M`!K``;N0?VV7;+,9A3?GJB+U4(/SDB-0&!<:!&XP`H+4C/M4!6@``&QPJX>;
M`RD@18,(!+\A?F[P`"@``%L``#FP!ENP!F@@``^P!FNP`'/0!%R`REO0`%W`
M!69@!EBP!5U`!F1@!CE@MWFX!%3P3E+0`-[Y3L.A$U)`!6N``>:4*5)A`.&)
M`F<31F4Q+??I:LDP0UYVK+\;O+DS/\3++06%&P*A$)#"O`5@MZDH<F5`CLJ8
MGZB3JZ$3&0A`!:$#IDOA`.&;G,GZ!@:PK$S4K!=@*!,`?R9`!U)@G9FR=FTV
M>65A//;[;Q`P!GV@O_P;0?Z+KAW0'H^T`RB1_P`>\`%&*3/P1P@W``4[\`#,
M80`D"@4&`)]2Q`5V@&H,8'POP&E>X`5BX'R)N0`.$##EXRY8P0OGV\+)Z1I/
M(0;L`C#KXH`YU*\Q<`/(404?$"4#(`,8$*9')``6<+\W`P`&L*8RL`3MZQ@H
MH`&[<`(6(`(A(`$T@`,&L@)_\@9/``2#0`PIFP,"0A\-L"&9N@%]W1X'`&A\
M(34-``,P8`$VL`O@\!2WPFA2_7[4LQ`/]:0[P,3)\PQDAAL'"P&1\A0/-#H0
MH!D]^;>48@=+D$4A00`5MQ03\81]0`;4\Q0W@`4U]SJ',G!K,#H^@(3Y.0==
MN!1[D`,.(!"C:0#CU?\52_$',X`"MB,`/S?-^6#-HT.9(9'<V@R\AKF@#Y`"
M9Q#.,U1]50=T+W`!+8T1Z#G/#Q0Q'Q<#%P!R"8,!$*``7(`2J)+/R$J^S*I$
M%Q!O@_$;S8-K!SG""^V*P.+0P=D'RT('X7H#X]J_`,6<UO($'UD!+X$].:`%
MO,$"Y&A\W1<AO.$#7*`%$!`1`S![+I`N.N,#R`(!&*(=9R``#<#9I.$"(Y,`
M)AM]@&74.AX,!:"3_V(!YC<J.@`%*P``O&%'^E((+V`"7R<H"S`"%L`MOK$#
MRC42$V!=W$;`%O`#$H#6.Z`"5[`')&`@;X`!%;`"3\"%T8<;82#78%,';N/_
M-E[37[2U7G%.-EZS0=E%MBWQ`ESP``W@!??S*V2;7I6-`<GS$VAP`4(=WS_!
MDS5PATJA`+K:!ZTL)4("$4I!A#60)'T@!A4W.JPGI#DT!Y$B$FEY/ZCE!6*W
MV^/5!P?0A5>V!W.P%)`B%>.%`$G!/3-0`0BP`57@)M"-#V#R%$TZ(RTQ#=?-
MS7(($U7(W>>[K^:ZNSR7B&%1/6>PI^V8$F?@`\8EZS(`!>`C!D\H%,<*$_O<
MS^7+$.=K`"0PWE<+`(B6*1@0`]$PX&_V?-S*&WW0%KW``,Q2T>/\X.B:`.TA
M`L+,13`3UD.<`#(0P@0@!NM977B6%O,4$3>PF6PZ_ZX,[!4QL``6$$S%!0%8
M*QG()D_05U!0L>-/X201(P8'<,$/_\,/<`80$`/9:UE=9+<\TQ43\(P[L*@C
M3QWVHES@H0`8\'4X<`(F,`$7:0(XH`(`T`,>\`8@\`:*+`"'A!58%Q-:,`0`
M8A_]`0,;U@(PO@/".`)@OP(BX!\Y,`(U+R@0TPS)+@5FT``Q\&/+DQ'G9>@7
ML``H\1-&&5>.+H.B,I0(@`3CI0!KL&3.X&E*L0?%`QX2,04&VRW%@K$"4%`Z
MX`+-]V]VP`#)T-A@0@<LBSEY\"68DXJV;C-@4@`H@`#".`.Q(93YX`R2KP!0
M$"74!W@GN.R&.1)>T)*%$/]7WYT089&?*;$1$4/=,3'<89`I,<`%*5$&-P`>
M9_D'>V#?Z([?_^P:F))LRB4#,]>A9[`$.Y"%V`HL^HX!0NX!8Z#@##``!?`5
M#@Y5M^N+'YD`+0`(-PU2+P,Z)0!%#V<O,3$"!79[544B-WL%&#)]=CH%;RD=
M.@,F`@`)HU`',04.)4-B?3HO"`)<?;BY?0YT=`Z\O'UT?7Z]?GX%*1,"`B1[
M/@`C+1<Z=E4+G2\/`CLN+W:?+CXZ/EQO+@-[-U40>R]]854")WDT%2L5/Q(_
M%0<G#2`:M.`6H`@"';(0^C$P@H2`&Q<L,/!0(@6"`4M.C+AP840"+7L>/+A0
M@!'_G6JXZ/Q)B0!#@QCO_*P\AF>7B@T[+K@@X(`#GRTR]M@)4\,%HT)DX!`8
M$&8!DC,$SC!X<(,``21HQ!2X(0;!FC)@N7BI(86*G"H*Y%"A`L;*6C)DL(#I
M8J;N'"Y0,"P1X(6!WP!\/XA\\V")82TYE@!8PB;'CBI56JP0$"!'+&(T\6BV
MDV!)8@8`M.PPX("3RC]__!`[08(`ZM>P8Z\D%L9+"@(Z<B/4X4>'[-3"AO'R
MI3KE,6.X\A2(D8`+-DP)I$A)\*[7$N#%+VAY8Z`FZF.Z9+$`PH;!N#!+&`!+
MP.`RYN_'XA]+<"$&!A]V^B`8LX<`EQ<%2$&`:JK]9B!J_YHE>(P#%S00@`PY
M###!$A"D\X('14"QAPX3C"!`;@XL!\``DAC`@`%[]$%`$5J$T<<+4FCQ00&Y
M560>/`D\(,,+.A@@@@""/?#!D%X\$,,:(L50I$A>+.G%8FCE(,!!G@```&YV
M5`3!+`IH(<`F`[@P0@HDCE&`%S$8,,`9,L2PXR$`[("#'?SD```+>?!!``,]
M@/!$`R(!\`0;4B`D3!]"'2!#"B5D`L4B2WBS!`%:)&!`%3*,8`<#7LA0@@Z_
MR%+<,,(@`$5Y+QR3&DTV;7!`-`],U(45.V``10PI"+"&DE#PM49=57S``!0,
M5#'"`UY``441R?ZZ1!5U+;`$&O^_KL%%#M::T<465FC;11=H-/$M73F0P84+
M#"RQP+D+%+$$%_`NP,:Z"G!A&+Q<5/$`%QBXX($I&\QQ67P)XG&#&0I4-0`!
M8BC@0BNXR(0=:ZX=&%LN8?1010GA$=.'@006-Y-,!18''A,O^``5`;T,4,!6
M"(2A&AT`J.8`'J5=T,(;(>P2,7BYA/B!`C.6EL8:*F-0!@(WY*+J'PH!W0='
MSI'8QSAV^.!-"0AP?"AO$K]67,=D.]"!@Q8<4`$-)7@AQ1D+?-!FUS&TM(0?
M//J``20,N%#"`[A!40`"!XBQ@``)/(I;?P\D@,0.G(D0PPT`*)``<R-@<(,6
MGMY0@AC_,<0Y&A<,2#%"&05`,&4*%\@``!<Z[''&$B8X\.4%'WA!0-T*F"<`
MX!<`L%L8""P`Q0(^%"#`!`V*88`'"RPP00'H$F"'`P.0D$0`0TCYP:`(X));
M0HH"8$`!"S#P`0&TAW%;,PD(H%T8,>AX"3`(E>;`'A)(,($'+PD#V/J@&3_@
MC`>3J0$`+E""&UP!"PQH%!(P,+E&E8`!#"1`";B0``WN;@EB*,%5!/"4`I1@
M"@N("@&DH(`"6,4'7O!<'`8@A2K$X88#,$,"!L##`3R`AP""@`]ZJ`4J`)$`
M<^!A&,(@!3F$P097R$`6:&`##I!@!6\(0`M88(?\Y*(7=*""_QA>X(!B\&(`
M!GA``?Y@!_D<XPQ2T(#%8E.<,#!``&D8V]/F.$>3S6P8>>!A'_)@``QXP9"M
M6`D`:J*_/H1@#CSSV<=6I8L;7&0!$+B>'ZB0F"4,KFD_0\W/QG8!$A!K''Z0
M02<(H(`@$L!CHW2C+-U8DUQT8`,!:,`&!""!/G1I;Y&`0`J*P`"7-4!X723`
M!]@`@!O8P9`[B$'L$B&_/91@`0>1Q0T$4`28[`$!B$&'#Q:@!0`4X`4-,D`U
MDF<*`]CA#``0@`ATD(<7"*`!#'`'%ZB2GP+$DPTD0D`#KN$#;93S!M.4@AWH
M8(<7,.``L-/!HE8P@88J@`U:(,`+?O\`@`FX0P<TV``(AJ"%`U#&(!L27WZ^
ME`(6W&`!%EA?!=`!`!\<@#Z(&X%#/9``&@T'%T+A@P,DX(`)]*`(/0A#?H8Q
M#,TXP`0;J(*)SK`+/&QA2QN2`01X-`8.E:"K.H``QTKC@ACX0'P`2%6-%)`?
M';!`!GE(R`)(I)I+[8%4"]CA0AWP@8CY(`%>]`,0J)"B%\VA-+M(0!FRD`,@
MN*$!5FC`"E8`@@!HL0-[0&QXV#J<ZSE@*#L0@R_H$!_4^$`.:>"CV'!A1SSJ
M,6RJ!1DQ@-,+!*PE`7OX0X"D@(,$Y(&A>5BDSTH3@IV%H#3>H63$;L"%`>BM
M"F<8"A2JD`#_XB7`:1)33>Q>P-T>7:!>)-+!!QR@`R0LX`4W:&%NNK@AVI(6
M.&3KF`,0L((ZV'<#0&C`"!8PA`8<0`%A+4*A[&``%Z3@&"^`P+'&48(#-,`%
MO?&#`JBB&@((B<$"&(&&='"#!U3A('X8P`>T$`L"&&`')O#!'F3`#'3X@9P?
M2)6*3&"!+A+/`R<8QQ)>XH<]7&`)15"`'[K(`"Z$P1T$2$$5FM:!9UF``!)@
M06A8\(.A%L`"'7#`"3J``A,,@`,*`,$;WO"!>R1A$-7H8ESM<%-(L&`!&%A$
MY<ZPO@9TP``Y6`;]'H"`"V364'FHQE!M0`,>M"``#W!1-?R`W)HH_V"@4X#"
M&8;!!PJ5A@XR4("+A@&!2>]"`6GX6!\@$(-7.B`/._"!`U;"2CNLY`9P]<6F
M!H!8,:0@#$RE`AQ2]`<'/(`73$A#4'C!YAJX>M4'R`.C\Y"`$(1`I"#`)2YW
MYJH<=$`"0OU%,/03/R4?X``[4%<5N'":TO[AM*F-;7$<ZEKLQM9BYDY):DY=
M##'HI6YY>(UP&QF"'`2@`[C`&7QRD:6>4N$$!=C!'S`P&B"X0`%E</>J9&D`
M&2B.-Q]`"`&\/+@!Z1&^LPT.&$?N"VT[(`0-<%`.8&#9)U"@#@%X`P->L(<!
M5($$2Y@%%(0G`RT8(`6WF=$+D*EB%PR!:/\8T`$&Y@H`&?CA2S)8Q0U&8-99
MW,`#X&SH$ES*B@2\"@#BB$$^>4._W\$$`D400V'VL&`/&#D%,>B$'4:@*0H4
MP`](^(`/&+"C"GR`!"W(@`8"P$5:GZ`"5B*!#2IA@C=LH`YLP,$$WE"'(2"@
MBZ3JPP\:(@(#7`"F'B!`1P?@@0*(@`27PH$(!D!!^H0A#X5%%`TXX`"A3J`?
M.`;;S6J";1XT(`4&X,(9\L`$/C0!`:7A#`1P/8R+"&,/;].V%+C@`P)YX7I_
MH`,-'<`$)A1`#*L^A@M<?;TT?,"S=I""#[K_"RX`9P"B[;4=@#^,%_Q!`"G2
M3!82,`$L1CN+`>#_`3```Q,P`5QD<K/U!Q`0('20!RXP?AH0'4N0!Y]E;NCV
M;O'!;@6@"WOT;K*Q1Z."'71P!LVA`"CR"W^P;S[#6/^&7*NF7,)P`TL`4?E&
M!6+A`&&`$2`D<3\C"Y)P`<UQ'\>P`$H5!CLR."4`-+R!"ZLU22`3'WQ@(BJP
M`B1``Y;%.0>P`6\@3;,`3BEP-=H@`%5P3B_`!2.08NBD!3?0&V?0`5JP`-4@
M7@UP7N^08:B`1EYP$#P2`PV`4"\@!@=0!#L2!I1C"3PB`#.'!#[@`Q^@*'L0
M!A?`3$/D`TH6`V'@`\NP"-S%`$/@3@O#``$P(U]6`3LP`3:@90"@`?U#_P,`
ML`%K4T4BT`)\<``ML`,T<`([4(LD\`,_,`,LH`$.<`4F<`(3H`$_T`$X0`*D
MT`$T,`'$V`$S8`(SH`(V0`(D<`(G,``VH`$O\P.X,0!70`-\4``L8`$R<`(B
MY`,$D`9G8`,#P`<30!XC\`9BB`9+L`)J@`95@`9:H`;[B`8`X`8"@`9H(`!`
M((9BV``""1F"(@\YD"L-H(]5H`5%`!G["!C[6`5S\`0$29`-@)!5$)#[F`):
M\)$,F00'@`8I\)`!@`(BD`,B\&V4$0"595F5$0`K8`(]0`(<P`$V\)-,L40(
M0``(4`P&<`-_D`8*H```4&Y/<X'J=@QY<$<;*/]Q'LA'3"@,P!%(5C$`O;!J
M*E@:+)AE!/2"4M,')Z`%0"`%SQ`&*T`=N%`&#Q!QH00UXE-S9Q`&)I1I0X0$
M58$$)0`!!/!Y"7`&ZOA"B]A#SD4`&M"8COF8)8"-)T``!6`")&`!(7`"**!?
M,7`K.Z`%@N,#2_`(-Y"#[3("Y],HBE$`/H`$8:`%8I4,(X!BR1,G-^<#5;$#
M,U(`:&0E)N8%8D(`6F,*2U`"Z6``!X`!#>105;`F,;`*K%`1.W``+J`B??``
MY[6(+Q`W6O,J*<":%R`""N!@&[`!E+4!#N(@20`"-4F3VP,"2;`](@4#)K``
M!Y!+?$8""&"-/``#[,G_GNZYGO'YGW40G_%9!_"9!`4*!!5@`A.@`CRP``_`
M<)61`QM``2."&4.F;7S`!;MT`^+P60[0!5)P:@0F!WF`>51P!MS';&>`$M/G
ME2GZ`13(!`YP!LC'!.!0!L27'PJ0HGW`!'"P!-W7"S50`,1'!TP`!:,U`%/P
M6PN%!H0`1@*0HD35`1U``ED$@+BT`_UU`#F`6W?5"[H@1`F0>2\B!DN``*2U
M!Q:(6A@H$WG0*P60>1UXE0>2E66$"]KF"[C@:F'9!V+@;PG@@@.7$@3@`E0`
M!6IB9!A0`'<U`#P@!1(7-0GA8PFP`*76&SSR#,N'!%TC/N-#<F0Z2_(1-#A0
M_Q`!@`$A0`%/\*KV]2<?<`%2\``E(`6C00!5(`4N(`*J-@N5<P(7\`(04D@[
ML"=-YP7(`P5BA1`?X0%B0`*?PV?8B1$N(`8,H$$+M"$ZH``4X@TZD`(WT!DL
ML#MB9PD0P`#1%2+,<0&B4``?8`)%X`(Z@!8=8`$+X``64)("NI[PR9X#JJ#V
M9:``&P`$"[#VE;`*^@;_V;`-2Y,.2Y.69:`)6Z`6BZ"5M0/=)$`$0D`V`U4"
M8"*FY@!@<`N](`<(D"+#0`4L@P=T(`5>(V%F)6LC`APXJA)]4`#4@5<O0"HW
M@`:(Y0`8\*0?LP=+8!JG%5<G(0`U\%O"<`#?<#T=</\!!L`&6CA9;+`"$`L"
M+=`!<54<>!`?A9D?V]8':;`$2!E^3PFG4>D'<YH#5:FA\"%+>/H='S,JN8`:
MP[`2*<A(*TBH07NJN7`#ZG<!#P``#-`'[$$:/D`%UQ5+HR0^$&$"MHH+A:H#
M9Z```P"J7J,;DV1N?10??6``DQ5S0*"%;%`%K\H&7"`#$SE&2@<`4O4,#H,E
ME#,"7J`:A)-6B`(!)C4.C/@!'.,)#T"=XX``;"``'/,"P]1*Q*M*N1$#)25`
M84!WMW`(SW("U>"ML9!@)H4*=@`!*V!6>,,%+2`">[`'#[H#`"JQ-0F@"0J?
MEE59(F6PE06_^!MM-KF_#WO_O^U[OS;YK_/[!.WIB@U0`0,`2QX[5"8P&0;P
M`6(`*GT`!@O@IPF``+]EI$B`7$S317W@`H"#6$MP5KU``#7`&W1`N#%!!Q@@
M,_EQ*0MU/7D5!OK35Z4!1^^P"P+PHW>U!UJP&SHPM6$2`R*P!!;0`Q@``##@
M(`+``KW4,72``,)'@5\Y`,UQ5O8''L?P5^D66\20!PN0`VLX2J+4,;`%;[/T
M;DM02[6$9P%``C=3&K-$!VD@!0E\`RM0HF$@!H)3`BZ0`*8J2WT`:Q#@2;'S
M`.G+-<D#`4VS7KV!IZ?*`NFI11;`+^UR`(S:`0*0`KC5"3XPACPD!A\`!020
M!_#T_Q(O`(EC<@,JY@,>4`47<(DOD,2,<`)=,I1:LP,CT$I^T!1>4`*%@``,
MD``^4`(QX`$'0`W*DYS1I0-B``!"9)@,H`6\B0`C(`(RL#``D`(CX`T"!``H
MP*(N8`'LN[42N[7Q^Y[MV;X0Z[[_:;\1Z[\!C,[P>\[[.[]O4`$';`@I04",
M]&@",`4?<((<``8ND`>P)P,7(0EV<*0(O0<U,`7<]0(@3(88L12IC#Y,\0)3
M4`/&60B/ZEP#P&*+N(A0X"DE#0`SY`-BX-&+>`95@`'".0!Q<``E<`90@0`(
M8)AGX`(UH(YG0`([<!-=^\38A3?39P!ID`;KN)14M5#*U?_+/>6!;7HM8UR7
MIOH;LQ1?:LQ(M<2")>HS<YP&%ID"B;`#<R``6M`8.R`%@>Q&'`8`!S`$FUP%
M0%`%.Y`"!R`/,W(HQ.`;5WFJ(:"U)G``"`!VC9,ZA\L`WV<\)=!%QIP[-X"C
MZL.H1@AT1G$",?`!SG0(,;`$&'`&>Y``7N`!"B`#6O,!`(``*<,%,28+,K`$
M*4!]S+4$7H!94J$%:1(&$_`!A4(.1+,$J(`$.R<.`\`%9DT"X*``5;`A-!`"
MQYP##[`#6[L".P``B&>0.[#=.R`"<7*0%1#>I,@&`0`#V(UX/W+>Y_V2.U`!
M*/#>'@`$;^`!/2#>VXT"B.?>V`W_`Q[@`2C``/K<GDJ,P`A!*IKQ:2DG`*E[
MW3M@!>5D&"/PX`#P`.4D)-&0`D)"X44``$,2`^7Q`?6S!%1G)+(;*WEQ`*/I
M"``P!([@%^5D'QB``5I@!LKB83%@!AAP4=<`!?#"!@[#!1/V`0_(E&OZ@![0
M`A[P!ET;*D=-!WM\P=(Q'38@'&P$-%*]1N]6&F`\!P8@MZ]!-F<\MV[4MFX$
M`'SZU?Y&`KTDQX),/X^1`HK!X%8"`*3\UO)!#A8@NZ)C&!R^&$N@N0GQUY`L
MNAU`61/0`C30>#'F#NV2=/V1`^/71H#8W)WP:)G410#0`-EP!OVR(0T=@$/D
M!QAP`&$P_]$,AU"'P`ZX,```$`!<2``Y,'.?]0)LL`39P`7F)`LO@!B?$KYO
M`)?KL`.=W0<Y$`-"P8@!``0]0-WWVP+`2&@9(`#NW0,]\-X5D`,9P`$2X!,%
M<&@`4&4]@0.(]]XHL!@[@`*JR`?:S@'WQ`=\T`=\<`4+P-US#@`B4`0TL#][
MP`(M4)-OD`@>8`A`<^`.\&AL,$SAM@5;`*9&$@-\K206P!=PQ@`B\`$Q?CBZ
MS2^%[0+]H@!)O)2]\P`3H-.+8@((``$3,.H3``$0<-C8E``RX#IED`#1,<P&
M8`"#FB8WL!74K$%<(U8:Y-,J<P8XT%$;L.2:I:$>0W*\4`PRT?]&)A,&4YWE
M@[0`7.[E>DNJ&BH?6DTV6CU+`*`_:!X`"+#F6R^ZHZ7E,_,+0K%0=BZZG*`;
MA870ERH4<<\;@.V!D0P0/=`"$\`#B/C;F:"<R</Q?N;''O`!0L0"N+X`HGTU
M$[H5GE,ZN&DO,7`!!)8N+F``-%P")B`.%T``G4$-"*#:`UU($TX"`I2SL'P&
M!K!!"U``MKP86V(`]3/,0H$^WD`""7`#*;!\]9'7'I`"`?`$*P`#(O#>UWUH
MYPR@=0`$[;T#%N!U(*`VB@$`AV:@3R"@@!$G2]`!')`#*S`#YRX/CU>Q%IL$
M]BX"%?``*'``E!4``Y[`"^+/"!ZR4%#_`L+1!50`"`X.="$)+PYV#E)G?8)2
M!7:)"!B,=GD/879T?6<9B0X%"6&"#@IG#GMV,P"'#A(3+)DZ>PRD9Z)]?78`
M$QP.C3F^KF4A='YT,E)]?@XL`"0;+1V"N;E^U[J_QW1T@W[9QM_+80D%?^?H
MZ>I_QGLN.6*;U?/TUM?W^/CU]OG]UP"DJF7)`0(!GT;+^O61-R@7MU]V%H;S
MEZ^/#AW5+MK9\^*&`AEG[&#$N$S'NI/J]+%H``+&"@`\""A8`LE."2XQ`"@8
MD.!!C`\(2MSX&2/!#0PQ"EQ$8B$%`P,Z$C#X\""!CP1+/EBX4`+I!0<ZN@*H
M4."%#`!+H!3P_R%CR1(N-[!V>-%GCXP/`A:$.>-BB0<70C%\6"+EA0(`&$26
M6/!A!X0^-P9[L1J#P8X`3W9,(/%FA0`1(@2(%AU:1(L=`G8T8(.@18#.!T0`
M0)UB-@``6V[/WJ&E29@<*ZB`F"-`=X4/NAOO`"`[P($3'02```&`S0Y&)?O@
MP=-(00,!-Q[<:(2G21,'?!S@H$+C5ZDK>/C@^9(%(14P&G+Q`6"#>Y\K//S2
M1P%?."$('UP0T4=Z(0A``QZ"<-'!*'A(4($$C9R`P`"_Y+$##^T)T@('$O#!
M!PX=+.,``E30\8<=SG`F#375W-/(+W]4(\^-X5A#CCDHG91+&%`4@?\!BQ`D
MJ:0"3#;IY)-<1"GEE%0N8.656&8)$(U]#%20,'CXDTM$?NRQ8R[>4"0F29&,
M%`8&(VBAQ0<WD'2/24&BI-(*;Z`0&P<ZA"'%!Q?,<@,`*[B0"@!`"'#1"R54
M\0$!=H21$P+?&%"$`"78\<("6J0`B0X7"."!'R_X8,`'AN@@A18"B)%J#@(P
MD(D=$#P31D=+`'"&#B\`H44,/AB60Q4$Y'(&`$7XL$<!%RPA0R0(-!!#"3K8
ML<0!R#H@`Q<I//$$!F$0`((`8=@P``TOL$M#'KN^(,$>-/3`!@E%//$&$`KL
MH=%()&V""!T8<!&&``TH\$2_N9!D$4:16&3_1P!%2$###B`$($`1%?CP\#?;
M=?>=`5X@45<?3:B`GGH9&-@(%5<LV`=]*PL!1AJD;&'#C5<(<2`1!9(BA(*"
MS+`#!S<J,(.!@C3!1XD:X$"#B?N!*`@-+83(00@A4(W#%]KUP0(*$ZR00PA<
M)F3C(`\MT\TY-HY33I[J))0'%T#$H``55"B9I!2`!R[XX`D4;G@"91B@^.(&
MW.#XXY!'OB6&VWF)`)AB+N1'CM;H$E&-:NK3\$46^1%&!^6((4,!&9%$]TGZ
MS-!``!/D<%L?)I20@`@(Z`"!!5@5L``"-W#QP`O`ED#5)(Y_$,8%;!C@@@`*
M//"!`1,P<$8J)2R1_Z3S8J3@`@37R_!`"2+<4(`'*?A+3A5>5(&`\#'L(;\8
M\4,`Q;<CW)#(50"XP1+"<"@(1`8!;K&#%N"B`"^XHPB8J0,#4I4$`3Q,))$8
M1$,T88<>-``!!PA``-B@@(N0SAY]^(,X^F"E`52A`2YX0N\^YI"Z`.L;.@@`
M$"3``1%,9SH>\`%&N*$=[I1B9%!``A/LP($F=,$)''!"!H1P!0[8X`HJR,(5
MKF"#+GQABU=H0A",0`0BS``+1L@"'&:0`3"$P`A?Z,(6A/"%#'P!"TWX@A"Z
M``8K=*$+/!`"%L"@@BZ89PY-Z$$/'H"%'C3!`SQH%`H\T`04;``%%1@+%O]R
M4('ES&$.`,""`%H0C0!((V*@^X8#Q$'$A-00&W(#TNMR=`X[*&`.4@B#+E_`
M2U[FX9>_I($PV=5+7D;BF,<T(3)-R$RP/(04`/C&)B["@A$$@&%JLL8Y4GB-
MAG0N=*(#W3@@\0T"$"!NUY@EW.+6"-D%@`<BZ,!+EL`1!7R``4NX@!UB4`41
MA"%0.8@!\L*RA`8L`'D3$(T4=."##PSA`TH9```,X"\[W&`(L7K!`!0@FA*&
MP0L">(!%0/B!%WA*!@*HP@WV,(`<>&$$O+S``8J@@!<<C`$>\U<*JF`!?RU`
M`"[=PPU2`%0"Z*``2YB`"8"P`1`DH0<T&,"Y'*+_`SI<Y$S58,`*2'"`C"6L
MAFK[ACX68(&##0$"3X#`"E>X$,WEPCGH\:%SWM"Q9>0B3.+PC@CU%8`58(:O
M>WV#8#>0A#<,P;"O&8)B1:C8(<RN`6]@`QL@6X0&-$"Q!V!#$;0PP@/,-%]:
M.(`61C`$T8[@M!@530XV%1H`-*`%H!%`"C;`'"R((`>V6TX+1O"!VHC@`!5X
M@Q8Z<!'_5`0=_(!;6*_Q@KFI,X4OHL(<##"/=*YS<WV0@';K03=\,+.ZU]C.
M=I:@PFGJX`;6[-?F0H<(A^1($]O@!S@I@@J/T:$C!%"GGF")I@+,K@(Y^$%U
M/N"Q%V!`"[;2P1EBL`2/_^G```MPP:.@0,(7[.$,#0!"MABZ``\0P,()```"
MD#<`6!'`60D@J@PN<B@,E*FY'^`"\L('GHNDX``6$$ES4U#"`3T``P/(U@<.
M0`+D(4`+_')6"7*PA&S9(<0M8$X`GAK5J>[#E0F!PE:[&H"O@I<B9#4K`@(`
M`?&:^<S;^0-<]R!7$0`!!018I5A5F`L%E)8!`L``!!2`@!2D0$D_&1\$$/`!
M%\@``3+P`@9DP&@OB"\99Y$!!*8P!0AX@=)3<`$4,#V%)=3``!>80@VJ,`4#
ML(`%,4!`XVX0+18X+@$+N$`!"H`$$<3``"4H0`FT,(,"G.`$22J!.<?G`V&3
M8/\%&S!EH5*XG?5N3K_KS(-S9PE=6[:`NJ`[1YKA)EYGWQ7-SZX;/?)A9O(>
MXV$W$,`U\^!LA70#NIF@\YSG"TYV9,(/!$A`?J&=$O[FPK\92T(T=)"5`1#@
M`558`E3"X(,88,(/%R#``E(@T2400%1^$(`?$I"$BNK`T=A"W@ZXX(<J(`$"
M*[B``7(P@01\`%NZ2($)\,U2#"Q!`3G`@`!UIP4='("Z.O###;2@$XKZQ0>E
M*H!*!3@!`\0*57[0P@3"0((?T,`#R4Y"':`JU1PL]Q[K/(>6N>K5`'W9'PL@
MEP"&,.8)H/GMVW$.#T60A.E0H`+_;$0Z\]J`$9R%!0O_^4,BJR&#G9!"`5?H
MY@0Z((X,/*``#LB#`P20!PA)0.(2B`0+)L"ANIC@!F`AE0""?!$7L&`,U6AR
M+@@``0*XZ`]5B$$8V$$'KZ,I`1?8A!^2D8L7=$"$;[CV&$S2;!6&6[_7D+8L
M7\=-6\ZA#.#5-A[0X8=N&__;9SX^<L>-CW*7%]WJ=@&[<Z2F<Q0@!@?(@8M6
M:'QZ4V0/=4E#*,[)[WZSU0$A:`!AI_,#.UQ`"PK@`?1D`BYP#TCP!AZP5`10
M`"DP`D6P4`@@`%JP!'21`D"`/';@`U?"*3+%/JC"``$@<]F2)+Q4;$\`!3E0
M3CDP!/7S`A\`!$F`$1?P!I#P_RLR<`!OT"]A4`4%0`$AX1T,4#]^,!,^<`U[
MH`48P`8X@#LPT%1;%P8#\`0C4'[&)W8KD`%<U@`F("#RU0\+``4#L'9H569P
MAV9O<`#SXD,@T`(PT`-G\`+X0&=]8&<CX'(WL`E_@!-TD`=/!@&C\`M<<`;7
MP`<MYPH.,`&/MS(Y\""N<`4F,"][,`,(0`,2X`I*DP<LE@(8J`,+(`,^$!$$
M)P^L9U3<```RA@YSX`N-D``&<`Z^TV,#4@$3$`V%0GQA4H7\EGS3QGPJ9$O#
MM2/6=8MY4H9P%WW=)U[F9EX%$'[C]W5BU0=Y``$[<``"(`6:X$H3X7[Y\`<^
MX`5%P/\&`H``#E!_Z<!._\82,-`G$L!BHY4'%^8%2U`"`E($0Y`L?:`I"O!B
M2[`!4%`2"T!/R),`E54G+P""&#!04G``V*)@>`$5>[`#3V`!@?("2Z`%BB)T
M&^,Q0Z@%F+('!E`%0$!1?2`%3P``O0<!6I``3M9A9>$'#[`!,<!$.#`!/O2$
M43B%%!%V@G>%6>@"7*@V^[``.+6""I./Q&AFPH4>&`,"%7```/`#"0&'<N@=
M(U```%``J")X/1`R'3`!_;$=B$<Y.#`#@B`!&>`!1$`U%:`!4^,``"(,,R`U
M!\(#1(`A$G`"'D`B@J``6=`>$*("/E(&`R`P,4`%9_`'3,#_!$O@!$R`"#-0
M!GO@`$Q@`)#I`'@0`A[0`3#@=ZCW!\5G7="FB\O772JT!PJ0D@X3C-IW79YY
ME&=FC/?@?>=V$<L8`"8@E=EX#T3D!VEP"GT`!9J0F]K8#X)P!CY@<`,`7>38
M?O/@`#-0!"!@6#!``I3R`N&3%#=``"Z``5PA&D%8`.;#!0!`+,@3!N*A.CY@
M`EJ@<C$``1C``&*@``<%`)X(+*4R/V(P`(GF`C'0CPL0`V(0A!>0`@.$B1]I
M`,1S`CHA!2F``09P`-Q94E[P<A=1`E#0`3<`GQ@`'@J0`A9J`2$@&P```EM7
M95[W=L]F70S0`!G0`AG#!F:72D$Y_Y1#X`))H`"N*5YGB!XC&@`54`0`X`-T
M\#GK56=#`(!_)@47X'(5T`$X(`4J\`!\E@%2`!,9H``D4`$]P`,3P`.HT0,J
MP`,\T`)@R@,J``98H`(I4P&#A`*.-`<[@`*8M`,K(*</\``'L`,5D$D5P`:W
ML00@606V\09%D`,[@`67@098L*B>)0#$\8UQDEDZY!PRT)F?N9JO(YK(5YJG
MF0!<J)HG47S;EA)O!SO^D(P/4P`B8)NXF4U]D)\OP@!NHSG#Z0]_D`<W4`8)
M@`.0L)S7U9P`-P$M0`+%40*_<@8?8#LW$`80T"L0<!$/@!80X`!\X0(#Y0.B
MY0%],``N4/\%50`!+Y`'+K`#7E`"?>`#WVI2N)(".8<\+G``3>8`!,``@KH1
MB^$"86`17M`H`_`"!9`#`(@\X<$&4N`O&(`!!+`'5R$"PV)3,M``!R!$R)I^
M'N!#5"95%H2BVO9L4,"B+CI",<H/^\`%%A"&0Z``23`!VGB&)=*C.^"G'K,0
M03>5#0`#`'``/@$!])H#%M`$#,`<'F`!"V`"6`!)%L`%.U!H7+``.Q!0+J``
M$W``7$`%"I`!70``=90!9K`%5)L!<@``9D`%@,,%N%0X'?`64F`X.Z`X8B`%
M,2`%!L"*(<6*!E``<Y`%6=!K/.`"NJ:=4'`#2!`7`&`"KW4!_M+_FLY6?YJJ
M3O?@#@?@J:^D2C*J#\8E7_XQ#[2$#6H23;-Y5.IV4-<@G-@PI`908%"P2L;@
MC*%##ZF[!VG@`SY0``.0DXS+3L[)!@&@`B)P`GM`%0L7`VP@4`HV`@>@`ZA@
M%TL0$G9P<`@`?SZ0`VP`"?X*`#R($11)++I`<`FP!T+%L$7&B:(!BB]``L(+
M*5)'%U"P`2.0"@D@``>@*!@Q="Z0"Q+5+P\&O35E!P@@+)]H!V>P!&0*`%/F
M`0-PDR1QN<M`?AS;`"3PL3!Z(P(RNF@2(26+,!.0LE>F>[K7!_NR!QS@LD`*
ME<MEI"UP`0&$$7_@`CV0!XW0`;G4"'8@_P4GD%TK8@#'$,,Q`'J(``"S*WDR
MP03_)@6=5PII`"$.(`8`D*^-P`5E,`I^8`<?P`UT<`8($&?+L`,,$&2K)``<
MP`>)@'L-(0,29A%&`PW#A<*7BGSXD`=E,)IYX@<8X;C3\B\/(WDF0@U<8ID6
M,0;#9U4)7`]EDB."H'O]P+FC4YL6\`+LH+IM-0`%(`9B0+N9"L.-`']T,`!<
MT`.]]1BVFHLV<@*SXP$"8`(TT`<`$'$(=!NK8P'LDP"_8@<#@!2L5@(7\!3:
MN0,3=P%#\1G)6U$?T'HJ.0$C`+>Z$4`&(!Y_MI`EP`"JE@"T_`%2,'0%=`$/
MD`*,D0`#(!+_6/\`-[`Z=%("L\$`.B=32```4"`+!0`$MS'`/S``2=!SG;,)
MX1#!?L`%6_6Q6KB.8`$6:((A*^,`"]`#`R`")UL'"[`0#2'%UY@(S+`OJ#"B
MU`$#U]%6TD1G$U"X`:0+*1P#5?5@$$!Z=.`"KF=5B&95.H``XJ$10:H+=%`"
M"A`1='`#"!`&QD`'7"`&?W`12#Q0G"@#V6P12_`PK(<$)K0$%B!$&)$#'&()
M,E"+.D`""V!"J\`9!U"IS':+H)FIQU!+=:M?%E$7"E#5=+QA&\&])J)=_ZS'
MP*),J7E_QQ"9O]!L^&#(J:INB<PYY;<B!?,`DDPWX*`+FK,'4N"M"I#_!J*K
MN)_,$@?@&32@`RR`%PM@KG@I``;C`QA`GQ?A`PI0!>=#*BF@!:![S"E@%2]`
M:(6Q!P00`T/0C])V8_69;@)0*&'PLRJI`P2P`R,`KJ5-C^-A8#OP`*EP`1_0
M+Q'A`FRP`L7"`E7`D;RDW`J7S7>!`)%@`A6K=2@P`#;PSO`'2\8[1-E+!PJP
M`<3J55P@$J1C0I4(P1)@`3U@`Q:<!#.'$*W$TIM@!WY`J#R:,2B@SMCQU>O7
M!Q<]`B;,`CB"`,)[7O5IO#6PD+XSQSH@`PRP4A=1`91R$:RG$>`I"SJ@`'7"
M8JQ@0BYP`<AC$1R=V=1Y$7NP!`M`>GVP`P-0_XD/5BA\+&E\K`,SX`$D4%HK
M=M6)6[NO9P==_5QQK`!`0`)L33H^P#4AP`)+/@,SH.1DZ0!C<&&N5@*Y5@!I
MD.7R5P`$L.58SB%R?0]T39OJ-D%XK1"YD`=B<`-G<$Z=_#H.8`!0@`%0`)_?
MD`=4@,5EH)']@-C=Y%^F%!LD(%34:P(G@!%(3`DGX`,0\``B_@(3``!><`$#
M0#Y5,$%UH3P0P,T>D4]A8``8D`-<4`!\X0$ZH11V``6LPA-[(-R4;@`Y$0-+
M^H\`L`"?6-H?(`,G<`,D(*6Q:W-5L!/D`P"M-PL*P`4CYCBJ3E$FT`,[D`1W
M9W`@4`0R4+<.9D*;8/^='4#-&Y!0&3,$SU#MOS(23R,!&D`"Z!ZG5V#!(+`#
M4M#4AX#MF]#-@$,Q/-2C/[K203=$%MT`1H*$@0,``@!HA08!-=!G"S!HY//+
M"$!H(F`!$P`!7&4"$X``$\"T)#`!V<,+&B^-#*`D4'``"L^@#%`#@X92"$`"
MA8<8#2\#(Z`3)P\$'8_2#Y`D,L!@DE8#/^4!9VCD/(Z+LQ2Z7.W&0?+5IED$
MO8-!+'41"44:H!%;.=`"*'`KL;P#6=$K6Y#U61\$:)`;7?\`:R`&EHE78L[=
MGAL`$R16_D!$#C``<>'F?3Y+<3[G==Z*Y[JA1*4,;Z[&UP`CLX,:'B"`[0G_
MZPPP*J#^$_^4`%Y@`23``!W00"I^`B70%V#1$5`PGBO5$U!0%"\``57@`5S0
M..*L%"]P`0P6`W!\%TL@ZP;`!4M0\P/0<%5`8@AP&Q"`='=JS1UQ&T41!A;P
M`&(@$KT>`REP`\WUGSEP`#"0!$F``C9``-_QGA_/TRA^`RY@`M4C`M[N'"C@
M`E8R(=9;B1S0`2I`\3U@`AH@`@T0M18``29@`I322CH@KBX@!1`0&C3PP4[E
M5PT&"'T.=GY]='^%$PUL%B-<4E((#RDR$!!0#RX0+@@`F@@U'A\0)`@?(A83
M$R0MJ@@3"SLDJA85$Y:=J9886A`("#(`&+@(`KXR_Q-+"[\R6CL3OR1`J[\/
M#Z\R#P`R-1`J`A\!121CAWAX?HCI?^SM[NY^?H=_=@8%[_CN?3I]=A!L$%[8
MN\%@QP`='C8H7,@P`!8.="3@:,'FP($Y&#.JV;C1BIH#.1+T.1>O)(!X??;I
M0"(@`(,7A=251-DG7AX;!'S,G)FO9QY"?APX$/1"!@,N&&[L+-FSJ<R@!=@$
MZ`&`10<@'_;L&;#$Q0L=>PH<$*!#A[\J.R[XV:-`2P(=?@CTZF>GA(@/8730
M6;!B`0$_+QZ(^*JCQ`,N+^S8<?$&@A\=+QB\^6`V3(P/!/J\.,-&@1W(DB>4
M+<&F"A([>PP4P;#O!H`/9__\U-O`90]JQ@U@!``!HL6#"D,$`$BAY<"#&`\8
M,/`@6(L(`"):"%@!(@",'"($:!D!8,F''166[,B18T?V'!5T"X"Q`X#V%.T!
MR-]1I;3[Z3NF)TFR(4"%'_O8D=(AB32@Q04?%$"'(`:P5M8-%PS@P!XZR.`#
M/SHDD`"%=B1@P0VVV>'!`'LXH`,!".@PR`DDA&&B'1,4H*(=!51`PU`.*,!"
M&'8XD$</9>G@`P($E&4'`%`,4(@.!N%H@`%!3@&!#F/H,`,#$PQQ@`SE_$&2
M.DZ]$\\\]=P39CLJ[?$/!#XLX=P(`KQ0@@D*K0##"AO@J1`,//3Q!Q];6`'$
M1AG_%<K1'&I@!$8:(Z$STTF%J,222V'$M%2D4)7!1167KG-F&`@D\`(=0Q5"
MP`(`[+!$&71<>B8^,_510`,!1%?`'@0L$=`>%\3`0)$*((?`01"D.J5F,BQP
M@PX#^/`!!B\0X$$,PLAI@1<`7$#A'@P\L*P/!L0`11@%Q+!`%3(BL`04,<CP
MU0!>8.##`'(*,X`+`#"70`D??`#``I6^D,`U9\C)A04^[+'`=S+>\(`"`E2P
MPVX-'*!%`P(<,,(!,(@P0@O%M2#"Q2.,4%P#;P1@W<<;']!""R-4U$(.+@O0
M`L<-]+<"$-JU7!P;#6RLA99`'"!5$0=LD`0(`!RPPQF&_P!F"")]*'+`!0#<
M4%,?4@"`XPPD7"%(CAK@&,F"="3@A1@X+I&9/&EX)L@-$`Q0DP-<B!&4`UGL
MX(10#G21@`U\],$'"@,2H``26R\1@Y)P"6`#CB$80*H#,K@`^`PB`%<$`BEY
MB0Z8KZI#ICVE_Q&DF@U,X,,#!PP1P!LD6F`=#'7JN4$%&DBPAPTTJ^$11\0C
M:OP<6)1A!QTD/4I369,R4*F?G8Y)!1N3=5IZ'J'F06I0?0P@A894B%'34JFW
M,Q.-,("0,@\29+B$`@MX40`47'@10PD$""#`#2FXP0T6\)8^A,$%,6B0#WP`
M@1&8ZPPE0%4*I."##N2`!?PXP_\$JJ```$CA#`QHF@(&4(`A(*<$)&2`2/H`
M0@!HX01]($`*V/"`'25@!UK@PAD*```#4.@%%]".`G00!@6XX`!0*(%K$M##
M'Y@`"&_@C<H"\`3935$`&#`!`"K@@@FD8`A#>$/*`K"!(50G96+4P@(,T$`5
MX$`*6$!CGE*V@3?D+(QO<(L!/K"$"PA0"V)$V>SZ(T6FG6`H99E:@:Z6M7[T
M`0$5<(`$))`&'%QA*'W@@=@$@0`JI*0/:C,`$PRQA#C\@4($@``=Z&`')$B!
M1"E1@`$`%P(L_$TH/"`"'P"'`N;Y80!44%!*EN"%`?SA!7@0P-\$H2%^@%(!
M`^K`&_K_,P0,[,%/7XI'ZL;$CC)M,T`(Z,P>$F`"!9C`!&#)T@;NI+L```$'
M-AA#"=!P@$%YY`")PD@^]3D'*^1`F.>C"0"V%JD35"$`#P@#'ORDEY3$HRQT
MH%"YN""#3^XD'Y?2@0(2X`,`,.`,<#G#N;IC@(#RI'3G:)X\2M""W02@!5^Q
M`P*`H`4HB:$^$-C#"PJP@!&\Q0YB:-=7?+"#(N#EER-(069T8(`JY&!984B`
M``RPEC!@``A<.$@'BM``4?E!`6Q8@%XRU*YKMJ4!)4A)#-ZP!)B\8`%:4(!M
M;B"`)>0A#P00P0HLL`"*1)$-0&C!&U8@#B`TX&:[`<%^DN#2_R>\@0$+Y-\+
MBLB&)#SA"2"X+!4SJ]DJ0$E.8<C#%7K@TMF)\;2SFUT5).2#,RS/#DM801*B
M*,;$@D`+,*C"(6DP$D-\$@$5P\$.0L`!&NP!DC88``VR((49A"$,`U!``:X`
M71,@X`<T^`$$'O#*'Q#@`3/0P!4(T`$NE*`$!9`"%RY0``(@(08(*$`!9I`!
M+"1@!C/(P@,RT($L9*$#PPU!"$B``AX(N`-8P$(&*H>#`TR@`QT@01,LD``<
MX$`;.-#0%J8X!`M@\I/GVV8A"E&/&Z3O,6,(YP@WD=01^(`.+AC"0NZDD!:H
M@'`Z@``^=_P1-0QJ4(0"`AO8,`<R7/_3H6CJ@]=&7!,-8"$`*!C`0O^0$M3T
MXP6$T8$%PA@`BWH*HTNQPPU*`%P1+*%$#B"`%,10@##,(WWN2&GS^G"#`^RF
M#D-HP`"^^X$<Q$!-E_E`"<PR`#[:(0PL,,`2,-`A8>S`10)(00P$,.@]E``#
M\B(``6Z@!1:\H($`&($,[*``""@`75\10PI<4)<"8(T!-\``"2`@@CZ4(*X,
MT()K074`!(RS5Q5H(0E:4@?%UN'8^RGV?D"@D.KL(`,6MMT*UF``NWE9(`DH
M@X:VO6UM)R`-=J`'E4GE`PT]Z4F5._>3RJ"@5;)R#W10<\H.8&$<M`0$.S!:
M"!S`AW,`3BC_BB"C^^JH,A"@;`5B5,@B0+""!C2@X4.`06[J6#&+@,!B%L%>
MR[BZ'3@-H0@CR($`YN`0\^R`#0)(<'L:`!T1B.``6%@"`%!@D254X#<LK\#-
M18`%4:"@"E7`@!>\``8@Y$!+"!`*B$-<NE@YP``FWB:55/SI+-H1+!BPCN[Z
MLX/>K>0`=8C"$\0>!<N2?>QCYRP6-FG1E)1ER03-*Y2E[*>\E,`%,B#!&HDX
M@.V&T,M.Z=0)%"#C%)A@#W\8``*DX(LTP!D?<G947!KP!.BP8`=U>,`.[/!=
M"PA55[%1TI`9$*<"8%H`!?##!5H'A-;"U0>*T0$'4Z"M$CS!`@V8_](#@`Z`
M$E@F!B4A?`@[(*08!"`&+W#`$JH@@+^<00`YT(D=@G&`&!RZ!1800'9Q`(0-
M](`#:.X#!S@PR1\`P*4@&-&-.E`'-VBM1X)87DW0E`]#N%LQ5%M'(1:T]-!%
M:I4R<4S[@07\Q@<[L#0`(%@=X``+A0>8)!0*L`('<`(H4``T,$D%H`(<(!0S
M$`(7R(#P-!1Z`&&V(0$%$"/\E@<F,#DIX0,D<#[E!A-E@0!*(10%X`$W8C@9
MH`%\,$D<8`&[A`<T$%\2(!0F8`$V<`Y\``!)B`<2$`)9T`]A4`8(L#Q_H`%-
M@`!#T`+[]F$.]65AXG10=V)3UQDP$D8.!/][,<80"@$$1C!^U_0";7!7=G!7
M;<`$3+!*>+A*=L`$=\A*\+<U*@%W(T8`6``"%4!WB&`')%!/6@`$2W`#A'`"
M$"`#%P!X37$IX:,`$T``+T`".I`'KR,`;#!!8`AGD1</.]4`28`"`/`#)T!3
M)P`3,H`5MI$K"Q`/=:$%;.")I%8$"W`0BM<`+T`4!J``8:`9-_`&2@477-``
MQ*<8$&`,8+$'#[`$_+`'7!```%`6`^`!;'`!B:$#`%`$^Q`&"F,!4/,"5?`$
MM>$'$[`!"C`A`U`!4`8X*5&$NT0#`G!&[I0=-A,`*U`&#O!F[K8@/4)E_3=_
M[^``:+(@VA,I5./_4`+B!XRU`4"0D1M0'0``12&0!PXH""D!<`TP#CWD(Z"T
M!`OE``5`)$*1!PIP!@O%!Z]0A$_H`0G@;Q8P`[MT(J*A&"7`)K_U%D4X`XDX
M21(P`3.P@0Z(.(+P`PHP`Y+$`3W`.Y+D`&O'`7S`!R2``P+2!SBP!DK2!T0`
M!B0@@20@`?VG34U7$@P2=4U7A@KP`A:@!280`$/P`GL@`V2T)WB2`Y-#`%`@
M##I7F#HW',.1`BD@'S%WC6@```3)D`I)B#5AB/ZAB+(!&66!*6'P`6]P;)C8
M$YWB`G.I`R:`07^0!P60!@\03&_V>**34B7!&;OC`1X0``M@`4"P#T"4_P(*
MX`?M]0R/@7(84`2IX2M+4`(CM@`!,"\4-!ST4@4WL`,(H'H!P`6/A2$N4`4%
M8P"=>1)>4`0R\`$*0`!`IVJC%@8O\"PLD``6`GT&<`"C(`)^<`)L$`('L&\$
M,#$HX`#D]TG\)@'`4W"\L32\L0%L8#E5YI!_,`A^$FZE0SU3XU`+N2#CYB=]
M,$K>XP",E0044`>+50?Y%@#[9@@X`C@(``-`0`(BT`%VH)83``!;R0<:$%_[
M:`(P)$D(X!F^TP$H@`.[)`$,D`4,N`>#UU!G``$@51:K8`<]R`(V,A(.P`-9
M<(%.J)(.:`-1*0@28`$H()/GL`,V8),=4*)X4/\&+_$'=#`#8&`U.+"0;/DJ
M8@B7<BJ75L4QPD$L;+@!+8`#_KD`15!'IS6H8A1&=01&;^`&;I"H5B`W,[%*
ME!D7AYB(_K<'/B`#!&`'9W`#>5$8'7`!)?6%@;<4?<`%*9``=","\])W:>`#
M&^4GL,D.J5@(2,`&CK4!13`!.M5!F5HA?.0V+S`9*<`%0H(!'F,!+R`%'X``
M":,#"W``54`98<`%'U`%$_`")Y`"SWHA"=`+MI%C,7``7G$&0Z`%`'`08B``
MD.@#?>`"#\,/85`QJ*<#9[`$S`@U#."9FH,#;&`"5W!^#X"//CB5.^`^#R=Q
M@+61;E!2)6)1%MH/I\C_#N?SL&/B`)A2/311"`69#G:0,H>%'2JG`#G@!AV0
M$N<P-D(A!450!!F0`Q-P`NB%`#O07@1``@H0`B>@:1;0`31[A#!;L_MU`D);
M`0EP!1I``!>``9J&M`L@!@10`"7``"ZPM%*P`UEP`AIP`CV``T*;LP#0M5G0
M`U(@M`0@,1U``#DK`#B;M1.0`020!C.``+^B:5^``BHP!"NJ="`6IV<RIV28
M8IWQ`@AD`1Z#9?&X`GAB'3V@`1P`!RX$,AMA$?64D3WF8XEB$45C'(QBLN<`
MJ18;=Y/*@JJ3(5KP`0:@K%,R?3(W4**:B4M1(0N@`!\@`.CT2[*[!%R0!A&;
M_SJS:FM2D1U#4"DDA`$?P`*<=W+C\FE#$'UY(4,!9`<^P`5=`18%H`4I(`98
MUA95,&@Z<`/E$8H[M`0)D!<=,!8)H*FA!@"P5Q2>X`-AX`,NL`,R`!D`P'*9
M*@8/D`,?((EV\`'W^0(L0`(5(+,@$+"3-)*`PP%-4`0M8',6@`$6H`(5`*V9
MP4JM$CKL\#T]`9&A$U`*B;'R0#WQH+=TL`1S```6T`0JP``]T`,*P`!+()4.
MB<!"D:(-4`$MX%$8\``>,`<FH`(+(#$]H`(JP`,[H,*Y"1T6P%<5@!Y<P`,\
MH`4/L`!-P`4QL&I0``75&@,6(+61A@%<P`4/``1#'/_!Z-$$*LP#!T#%W2(`
M*$#%?74`'A#!3^0!:8P"%<`%30##(^`">KP%)^Q.)*"WH=FW;OET='HF^S`&
M)-`9&3(!)>`#-W`'=P`!,E8G%<"3<H`&%5$<P\,1GTP\!V`%<W`1!R`%>3!*
M(.:Y\A`I>86(+"@UWKL#DS8"$"`@/B`&-R`&_`?"G=(/!3!4/C`&,20`EM4`
MT!2KLBIG)4$`1?`$*(`",*``)R`#,A`&%I`U"L`%G6#-;'`#7@`%P=P'JK:_
M,C```_``9RL`,6`"(R`&"N`%1H$!W-L'M"<%+C``=*4`-^`"/"6^,O<",>`%
MDJ@#7#`"RW#-/C`"-W!J-^#_+PF0`@]P!O*)!)!1`@)``@QP!07P`"T``A\@
M%`T["#U2ARS"`GG@.Q0B20LB%!(+JZ^RL>W@D'$:*0M)->H0-6L1%'XP25LI
M21J0!390D0[9(_\63D!P`CL@PP[``BB`E%>0`)DA2?`4I"20EI(T`PO0A7R@
M`@6`2#6+(2AR(880*BK"!P70`U<0I-3<@_S6`S@R`$H)."KP`&4C%%8I`1P@
M8&HI`6+0!'F0$AK0`R9P6(.\EKL+9BB!R.GC=C+0`%YA`28P`1@``)\!`0)9
M8SQ`.%[P$1:1`\03VJ)-/`)P29_[26]GL6@3;T^V`S_@D*QT(C&P/Q-POA0"
M`4L`_Q)6Z,L8-0#5EF,N<$UJ4@7KPLO*')MS5@*T4@$`0`+YM@0GH%-<``X8
ME`!+D`-YL9Z1:!;1JP5>T;T'D`(I$@8R\!PE]58Q$-U]X`-:(`!OH0,7L`-]
M_!E24%=P81@?(`9F80`I<`!B\!GA=`!?00`?,`+69`?P\@#!;)I%\`![(`'2
M``+]R:5CXW8^@@`D@!HJ`A8Z<-P>KM@[483_U@$QB4D$\F\.$$XP,`-3!3@X
MX#63=`4D4`!C$Y-],$DDX&&#,`-;*TE\T`11:")G@$XIH3@7,H-)QX$5,#F2
M9`(%T(,]N`0V.0!4"CA-X#9X4#A==Y46!CABP`#>0Y9MNO].AUT3CA*K(SR&
MJ>/8D#U.ZP$#+I9CUJ$0*O`#-)H#(%=/`I`HH]WGB6(&;6"R();:(;Q*<K<#
MEZ2F8&$`._`!GY%()T(`25$J7N8J^$#.Y)D`'F`"_;"?"B`%;@/3L#FK+"D5
M.D?BI9@8`F.]14)G,9"IMI$`JKH'!W0`I1D&*5`$@X9E'2TCG_$:ZY@#(U"%
M-.)"<C4A"O``,$$A"5`%15("N3UJ,%($K6<'Q6@!'T#6"[T$_?!$2_#:&%W`
M.**6>JLB>]`!)@!['$('+_#A[JX^ER(!A:/7>:`"/1#86X,(**[B'="B/2(1
M`$!^$J`!.%`V/:@`5X"4>B?B68#_`J`C%"I`I'AP(B8@((41D\X$#"/9T38P
MDCRPE$(A`:SK``-@`ETH`4U0`5.M9&5SXPG@HD(Q,,OC`!H`!CQ0DDGG4&<.
MFVF>R&'"YBX@)!]@`2QP`U_!ES7&DWEP`\8SRAIA/(?"YX>2`V8P/<PC>?&P
M9*M]!2+`C9-#96`A!5)<`#L2)&-&+P5YD-53?ULA"1\P`2F1K%20``;0\<<]
MJX51!`$`?2*P`S>`''X4`T9$T)`QGI#,K`@D!9AV`5"P1EQ0:M29W<1K`$CK
M`PL0`W\?`\6"`5)@+@H@OL6H`P\`!0:@+8K3SA_@`@MP#>I"`,'@%79P`D*G
M+$+R`!B`_R]74`LF4`&$%=(A[W9N5X<_(,8S8!L.^N[OWBF[M$MBP%<)("'\
MQPXHG@%LD*L``$_)]>)7D%Q9@`!"O?TF,`/410-'2``V\`,"/`&P.-@D<`+>
MU2!+>P$$=`,G@`084)[RQ419D+4G``@>)"$S,R<[A3,A'A,S63,5.SA9CU@9
M(5D=7%Q9(08\`#<&8CQ8*$-`)`X.?7YX?GY_LK.TM;6P#@8WMKRS?7TZ,@TN
M8WL^/B\W#GX0;QM`/#02?&=D9`H*/%W60F3=WM;AUE3D!JM^?7B_ZWT`RW1]
M='17.P$`-GU_P#H&'P8*`*!<T*'C`H8)"_(X@/<+EL.'O/;MV?]#P,>>/CZ:
M`/BP1$R^7B!IX1DY$E>)(@$$%#E00`>!&%5V)`CC0T&5"W9>N,!0!8%+$RD>
MW-!Q8\>!&`1E8%"@H\\+*3L`('A!@,&!!R_V7'B00\8`HCL6#+#S$L@".RZ7
M:,$P5H:6`T-?*/B@`&V))444[+%SX\T;!!).>`!B80<(%*L<2&`7STZ>/`1<
MF/#19X\#.R$S:]YLZ^%#Q7RN-%E08,#%5K'\)%Z%@,T;$2L$`(B:H\&2';=S
M8`$``,4!`!50H!#1PH.'#R(."$`!X,&!'<(_`#CZX,&.$4L>>(DQH@H&#STJ
ML/%@H8F%'"AZ]/#`Y<!Z\#D`6.BAHL7_`0]-S%]MHJ+'CAT6,+"`!U4HP``&
M8.0@PA`P3+!**Z_$PMDMJNDRH3[`".."#C[(8,$'%;P0S#,]:""!#Z*4H4@(
M(1AQP8LPOCA%C!?,>($8!B10`!TCL4.'`^[X`8\\5XA@CPT.8+C'#1C(4(46
M`D"APPLL+-%""B_808=#?WC&I2W`Y*3#'EGU,8`4"4@!`0$?72@221'V<5(`
M!RBW@$4%J'7!'F&<\<$#);S000P'(#!`&!#LX,4%+_2!0!4,^&!'"08LH8`/
M85Q0Q0%24&5"#AX$ND<!#[A0@@X#<`$`!#Z4@($`&!B@PQD/`!##0"_`Y%.K
M%ZQ*@`P?5/%!_PE[D+!#"BC\$)@'#[0`0@42K+(88U.B]<($+D#`Q0U[N.FM
MFU["$H(*"RB001AT#)`'/.CHLYH#&;"Q`0`KB""<!R(`T<,''E0@`@#,GH=?
M$^$)L,`"&%30P@XJ6,"#``]P88(+#`B`C0LQI+`4!!``L(04&610'P]2(&"L
M"0B4G(``))``,@`J)(!#!P!8DD`''5B"B2:<&/#)$@6((<87<\#P!@P(/.@*
M+-]V6>$N$_X2S#!]7##"`2T`H(,#,@SA@08._.!""E5@L8,``NB&]MILMRT`
M%G!C(0`5>:3C(QU!#DD'`4;N\$.2^]A1P%R2^421`*\IA%JX7][R4O\*:%\P
MAIDR%+`7*TW+`F>$?LP90``M6)!""0.4,($'"B!PPPL0?.`%!BXDL,02+CP@
M`\:X^C`V`E"<<4%V&#Q@\@,D*(#!&38A,>49,4!1;A@&#`B[[CLPP`4$!KC@
M10EV+%G%!!;<$`:P52R!P`4Q/,"`%\AX```!#H2A`!O/VB'M.N@0E-68!#P`
MA``RT$'F!@@2QB5`!&P``-@<<`9TM2(?JEE-:V#0@1V$8`_1"L$2^!`M#>#@
M!(J1P`0(P(=5X,`$69(`"P21&$[PX1<^@,`ZSK"FIN@``0%4#*G^IA@3B"$,
MT7(`8E8Q`!ZPX!<2L``*KO`@!;*"#QT(06+_.L"`7SA@!FH(``A2H;0(-0T7
M%HI:AH;!(0N8X`,FJ%L-8(`#5MQ@.G.P`A#D:(4ZJL$*:LBC'O>8QSG<<0X"
M@`,KXK2.O,5C;U@`@=^21`>"D.56-YB)B"#`!@AH`37Q6)R7>*&#!32`#0T8
M`@/&\(?QV4`>6QK@YF"A@Q(`08M)V`$-&,"`K]C!!`?XP`#Z8`<,:*$$P'CC
M"`K0/0BP3W]>8`,Q*?*`%.#$46Y(`0%$)(4E-*4/88B!%B#P@C'<H`$/T)\"
M@```$=E!`2EHB9Q2(J(]=*`!'IC("Y;0`!F^X`4`HX$#./"!`%3`?@\"!CH<
MH(,PA*$I"\AE"?(@_T`".I06C'/`%;A@L74U\"-TD,6[6M.`+%3!'-%BP0XD
M0-(KD.`$5N3!%?I`4@18@*0J9.$J+)"%57!(`?LXPP1\L+4;^F05D$#2*A;0
M@2OP01WNZ(,#!F""$`2Q"16X`AZ.N@.P10L';5R%&!:`2@V`000-0!HK(,2T
M;X$1:IO)I`,2,`R^I.``10#`15P@`(OXX`-^W&,<@<#'.>25CVH``E_5@(8T
M\$@=J/Q%4E=S!2S8@XFKT%)-%@```>Q`!EDB`*,,<)&!,H1Q7G+`!3IP@Z"=
MX0Y.*4`"+L!3339.,R1AS!E0HB"5#H`!'J`*@3Y0@#Y0,2K`7-('8F"'`?_<
MP`0+.`-8<H"5%R2@"B)P@8@&D*@;3.H%&/""=:40+`^$80"UJX(8+H(H?R1#
M#`]8`@%Z604!&,`.!A#`[*@0!@?X8`D?\,,>=+$$#PS@`EIXP@>N2>!]<&@`
MJ3(?,@CBBL4U9).<`2V$:Z%4!^?/N#'XP`5*(*E6L(L58VT-$+(@@BQ$JP\)
MV`$')>!!$#J`#SP`&P<D(#(^<+`#%<@`3'L@Q1E?@0>*<8`&5)J8D$FK`,E:
M!1\4,(,!E)`&*%#J4KD@199RX0$GP(-B4%"`%SN@`PE8C`1FP`6%"-D\,!`K
M*Y8F(7!Y.(QIY1$=V,J%%UP@!2M@PQ)^80`R3&3_"G/LHQ_G^-<Y#/8`:O"C
M7_U:!+^BP0AYL!\>4'G8Q2:FL?;X@92_<H,/8*`!6@``4V[XR@`,8!D/EK!G
M^D"`,-BO#V?X0_=D((`&N->U9=V,0]AAAQ.4&@@KT("<1"?J`D`A?%!(0`EB
MT("6O*``S5N"6+S@`@-XH0`E@,((8K`#,<C@`769TJ,Z((`]E("BM=(%`P""
M`0(8H`$+:-0+$%!9`=R@?P#06-#FD&\I$.`&#*!"'R`3L0+Q!2_.$?`#=8`+
M=NQA`#$`P'NGU!1U6'&LFQO)A#+.<8UWYH$9E8<-=8`$!,2@SM<D:(5#S`8V
M($`$4M#`":XP`400@0@X_^#!(`C1`QS,``?CJD`(@&X"``T=!SG&ZA=X4`$<
MA$P%`.`!#TR0@?_P0`7].8`9L;Z<'EB@8>ZIS@,L^X`*>,#0O4%!!>):`8^U
M8&%FJ\W9<C`'-[3@:$E;LQ>]U2XZP%DS#9ES`[B`*@,PZP%A()-I2@"`-`O6
MKW7"HZ'K!(0#S('NB1XT7_T(AC@TTFZH'(FE5X%I`&C:IB\(@PF&H(4JC&`J
M!9E=%<:"&EFH^B$#1\`FG+>7$@3X``GX2K@FM.MUA`T((-!"`$1``QW`5PM+
MV"4!`/"&.K]@`+PAR!Y8$&I@WB`';&``.@8@@!&LKE@/D-64+!``+Z!E``L`
M@O_Z;\#Z@73R#:OC$`"V*:(;L&$%/K`02_`&2[`0YR1Q>T`'!>`,`Y`E!I`#
M&18`'[!PL+`.VF<`,2`K:.%\35%\H$5\MY=KM;`0\=`E!$40^K,`7B`B!&%\
M%>8H;!``;)`$;]``-:A%;.`&*[`";K`!.T@_#1"$#>`&(%`$+;<"`?`&0/!)
M`;"$13!';V!H<^0&<U`G<_`&*[!H(Q"%.3`"M28`51"&51`;:2,`0`!(E@5*
MNH$%""0"(O`?5;@#;&B&D2"'5M`"&X`T^+-W;O8'?H=6L)4/*#9X@G,"!7`"
M\?8'8Z([#-(`&[`!?N$7;N`&S@")&V`%/#B)5D").QC_`&Z`!D00#SK`(^P@
M>B!V:8YE>E+V"^,C*\]V!O%S`S?@!UM3@;&0:K<G!@H0!C>``+R$*B0P`'X@
M)L,7817(#B?0`)_#!D"P4C>0`DM0!2XP%@/@!4N`!':`!'Y@`E6@/!>0`P83
M!@GP`;C!2C[@!1]P!C[@.RF``$A@`$&1`IVS``+`+,3T`F<@C4SE!]AW!GV`
M!*X'`"Q0`AX`!2*P9ULR`U60!@-```0``3EP*2I8!2E@!PG@A3LP!!)(@>C0
M2,O`.@E`<<"P!TOS"^K@`!VW<1V7<9F1416(@EEQ`Z3!<!NH&B\H8CB``B'`
M!PJ1!6M0-R1G`,JE)<''!#J`_P=E(`5,0`=Y``<N(`9T8`=]4`-(\`MYD`9R
M0()G0@!;X@!28`#ZP`1I``4#,"0U4`"NU@=,``6L(`$VD`$UA0<28`(/H`$C
M(40S(`T.T`D<%`8=8`$TH`XVT`46L`)ZV!!\>"%]]W>`YX=TAGU/4`=/$``%
MX`IYL`<G0'5?L)E?(`1R\`5R8`1?8`2D29JC"0>D"0=$D`5$8`1$$`=XX'PF
MF7&C)U&I>'JLX!(/X`9(L`?I19(%8`*S:'OR@"$AB`[^I@`ZR`5=\HRS`P`7
MP#@@B`[&1P`QB`+@$0`A,`(3@!$QX!-C$C$I``%2^0`-0"AA4`(,@%\M\0#Q
MAA8$L/\#*S`"7A`&+W!9`A"2,D`!#%`%U\<`[_,++Y`"+J`%7R$#;W`VIP(%
M6O`&#/`"?C`"(R`/\_8&\4%,!+`I#&`9*7`UNY2/"I<_QVB5!(``'7!0C-$M
M[2*"#P42'*>63&"2><`$I_%Y*()@=B"5S@=BO\!1*R,&))$S*-D':8``*#5P
M+I!E**E[)&$`6R`%@^0!"=`C5V`"070"72!5(Y$!5%!"5[0$-D`27)``-L`!
MHB=E-F`"'<`!*$E966:F`(!2JY``8<8*'8`"-B`!-$`$8&`"8:4*B,FB$98/
M?W@AA$IG>X``PBD#'M`*#I`'-^`^`!`$E!H$9!`';6`$:%#_J95:4V'0!9Q*
MJ;`YDA5'FZ=(>K<I9;#@`U70`!:@!6SP`5E2`!"@`,KP"\7I-"$(&070`'.`
M(V=`BW;@`PP@%`PW89I1?.LP`*]D"C-@`T&1HWYP`[3S?D%8@2^P`&P@!;\@
M!CD@7<!0!0\P4#[`&R+B*$^`>+!P`R-0`K3(.@P0*#H@!D.07_RX`!*8)7)1
M!;TE(K?AAP,`!6_@`KA0#V76)2/P`+P4!@^PD2)JD[PT`560`SMP'!X3'B+`
M6[;7"BT*6QWW('8``.`H`I;%&V^X`R)@71=WDZ"4!3F0!6RZEP`P<#2!`UTV
M<%Q@EP[`!`C0!`^"7MRJ90Q@`.G`_V(J,`U\<`(J`%D.@`U>E@5^PU)\H`([
M>51`HAAXP%0F%BT6$*=X$)AQ*F4XD`"K@`<=\`"!R6)]^J=[**BZ1JB,F1GY
M,#5BT;5(4`!W,@;RD`9H$`51<`2`>P1*(`1Q(`=/X+>!&P5!$`=\@`9NX+>(
M&P1$X`![4:J;4YNEAYM38@P0T(!C@8+9)`"G1IW'N6M2X`8?A3UTD'H84'^-
M4HRZ-J)*99V@DP-MI`,Q8`+CPP61(1;F\R&480%58`):T!*3`IWGA+<'8`",
M5P6S00`%L`/1JP`BD@=24$EWA0T`@"*A,)[4E1<QL*'`X`*I.Q5>(`"#HP4V
MT3M5P+M50/\`ID$`?Y(`0!$`>_:PC40'82`"(``"25`'29`$3_`$(/`$;N"+
MQ]BQF?&B`#5P;U#`_1L`!)R$21``'9"C>[`U+,L&'2`"3C4-%40#',`!1`"7
M(DP#/#`#'$`#;ZD"-L#"'=`#)&`#+TRU-G`%-C`#/#``/_`#.IP%5Q#$)C`!
M0:P!6:"3)R!S5"MS28P")_#$(=`$$W"(@B$)AG@"`"`%B8`-A9`%$X`"A<`"
M7R`<895W9-5FB@FW@)@9Z$"+;+4`>V`!`C`!%T`"%^%\;2`$2O"W@7L$09`&
M!*`%?`RX41`!0N`$76`%2J`$@+O(7<`!>S$&0[H.IBAEJ/I84K;_@1E,8&CA
M`UP02J>&2;@H8;"F`&4`R'D@(B60`D!@`A`P%`M7>ROZ6K.@K+]@`T!`@P&0
M`7QP0X4"``R@`PD0`QE&`"7@J@90!?&&`'?"4`L`!1W#4S'A!570*NOS`6*1
MS(S2!]"F!5"0`K*B`%R`S=##!BZ@86`A!1D<!KP!!''1:#U!!UP0$W-0!O+\
M41/!5FNQ!!)(8+B@)?<)P0(LP4_P!@'0``D@))2LJ[JZ24PCB/J0&A"4:Q"D
M219WJI]3P9^ST0)P=PF@)3G*HS#8`#R0`TW`(N.2`R2`53S0!#R``RM=`3I'
M`AF``CNPTAG0`R+@`1GPTB+0`SVM`(61_P$F8`(ZC1]<]]--\``]T`(5P-0]
MD`/!H78]<!]EMP1S8`I+4`%+^"^SP08E*[)S@+(B('<YT`)ST``'<-`.PBZ)
M&;N+N<8AD1HZT`%#@`$Z\:H-T`)9@B(ZD`9!,,B`:\AC<`&,W,=*@`5?$`=@
M$`&#K`1!8`24NV:EB`>8ZU@[P$31PH'.EWK'0!`W\#HO``^HMB5H'!)T0+X"
M<'D[PB=I,@$(X(\VM!?4J51.\PL%Q`X2M0(@8#8"<`)D`@&_<5"Y<IY?(;^%
MTLD9AA/D-P1:,R97(P9H<0$"H`76M0?/I0#Z%9\'(`,9?`,'P`8R@!;T]P$;
MR%T[90<N4`0C8/\1=*``19`#E*'>0$"]O`0%$>E-```$+@``]MN!J!%$'.#?
M6@0"#!+>6@`"#5`&2B4D"]'&('<W6\*Q(>>'QL<0#U2"$)L.[^)E()"$.0".
MRKA%1?`&.(!!)_9B2M4:&X`"Y+0>%L#57,``2[T#$=,$%,4>*J`J`L`%*D"7
MLK$)"F`*+J``-0`%4E$#$$!99(``3@X`6Y`RNC<"7)`R"0``5$"G4E`&52`S
M"4`"2T"U-[,$E@!T"8`%$\`"+)`%"Z`"CI`%H.`(,_`%6]`#9=RVIPUX&24+
M?1"W+MHE==T`>$UK10`B'"(#7K`'<6`$$2"XA!P%:C`#;=`%A]W'<[#_Z&IP
M!!%PV)`]`!)@&;6=#I9]JA+5-RNU"IOL;@NPGER0P</Z`C[`E8S1)BV9`27^
M!FZ0`,!P`;<^`@.!%AFL>"2)/VZ[L>QP!<@GU4!0`:HUST#`6AVP*!\@!5^A
M`^!6`-C.>``@!F,S%XPBW+QA.4M"H*UBG_96`C8A'1=```K0,4LP$`RT!`9`
M``VT`%JP`!B(@1_@`VE0/K,#/PP+0&=P!B_`!/D9`^[E!0?P!-;T0+BP"AQ0
M#P5>`7_#!R'@B;J.X9FD5%UIVL`@#P\6T16(DG2P%PUQ#JZP&I;<!WP0LY]S
M`*=&`PT+`AOP.2:@Y@:@YI20"3W`!D40`@*`_P,<M)<[H"4.0``)P"8[JP!L
MP@1>:08_P@1`:T5D<`/J,"EUH27L?@8_8@<I(T#<O`2P&`\N8#GKL&>K$`8\
MX%2LH`)+`$**U65S*O2KD`5-,&,.0`2S`0,'H`IZ5^P@48)\[N>]@`==0@?O
MA`%CX`,)X(X,0``Z``'F]P)Y(`1J(-A1D`-7P`1HT,>-W`5$$-B/'0%@`#80
M<KFD3@^8G)O#:@+ARP`Q0`*=7`+4;5VK8-IYW@N\E`<(8``%4`9H<0(,``48
M8`&].27*)@5A^-&91)VY;7S('@`^N`,9(`+.M`=G`*`Q@*$[X7P#@`'DJ!?.
M)0`QP%,E0,T+`+\R$/\#'VT'\L,;!M`Y!JD`'`8L2P`!KI9B0R$X#P`(50`%
M.@0?6@EV+Q."!@X#+@^.+PD`.5Q]=C<-`"\Z8@(!2SI]I7Y^$@X.>RH"!P$@
M.P4:`QT!*P@T?*JJ?*D#/V%79V<^!#X#/L4$871]?J6J'`4$)P4G&AH%U"?6
M)S1]$KX.J30A;R!L(08L.[`[.2`!`6\;\_?S("M9.2$.NUG0.*"CXXR<$J?L
MN"#PAXX?*5"@]2G@18JS/0RF-.QSQ@4ICB[.1)L`@0Z>/C.6#!C8AXN!,`[P
MX`'01Y4-+AUX60!P0E6?)3U5)<C9!T^6'AQBSK#R)@`0$BS]X#GUIZK5JUC_
MJ_:A8[6/@1M9PVH]1:=#@P4OV/GPP:7`"QE#(+R@$R>(DBA'\N85XD!(!+QZ
MCP0A\F5.%,!W(V09*/5DT9D.:O*ZX@[`CYIX=!1"X$.SG3V>"2PY$`::,S]B
M4^^ALV>/`3&12WQHT,"+CU(OI,C`\,$+%#M;GY5*+3':#RQL@`#904*+B`LZ
M-`E8XJG/BP]B=*354J2S#BD"'IS)4PC(#=`Z"CRX84<'@@95;NAPX$$+!.UV
M9%19\/F%BQV:O8#!&U5X4L(21;C@B0[U.:/*`DL4\$@H"S0$P0@`R*?#`P%\
M\-$SJ*@B`0X\`!!`$BMH<8``+8#PQ@$`="#!C#/R_W&"!W/DT$(./!Z0HP`Y
MS#$'`V=$]@\?-&30PI('--G"`4#H.,<!.5AP!0TT<,!!&#9TT>(\!R2W@3P`
MM/#&&RO``,0;#:S`Q@H;L-$`%C,`P`(Y$M09&4<):+"5`PB<`0T>,KCP9P%0
M)$"'`W8H(`8==-AQ!0*,.G!&H'9\1@(.>Y!S0@\_[.*``@4DI0H*Y#@0Q@2+
MJ<+#`U>D0I\&>X;@3RH%F,!+%D#0<P`)I3PS%6JIA;555U\5BU51?I1UU@L+
MC)""`%H4L`=<*=SP`A-&J!%87A'$$4<7=P46@1EQ^!6%$GE%$8$1>3@DDRE^
M`&#D9)5=4=,SBMRPS0TLL/^G@P\0:,$``:HX9(JR5SEH!P%V-+1'`E6D8(!F
MI"#A`@`Q6*!`3*<-)U9QI?P@`AM-PH#"`UQ\H*$4#!A0P@5AB%'1!1_L\``&
M%R`0@P(,+.#6'@@\H,`-4H2!`10W&``%;USXD$`*&.S`A2=AM'S#!3<,L`0&
M!4```,<0R,```U``<,$>+_CQ@4ME$'##`P]0P1L62]Q020*\39"'%QU^I,,I
MO$B`@`DF)E$'!774`8(\C[>P!``53&[)&XTSGH3B23S^.(I8C#UV!3L`T3D(
MBM?!.>J;)[&!"#O$OH,`(C2`.BP@-"Y/`#L<`$,.`NP```PB5+$#%CD`L(,'
M7&C_T0,")"#00PY24)$!%SMGH``"2W"1@112++$#%0IDT,3R4GP/``/?3X!!
M!0A,D($)%9@PP?T5H"!_!CP(P$,&`-R!"OXW`1((0'O:VT$/HH<``/A/`5*8
M0`Z:`,`,K`P!Y>L!%M)G/BLT8`,P((%CI$(5AEWE6%I)E@G_$"PZE.$L.KA`
M[*A%@#U`8`A#2`$+F)`N;WT+"T2P`1C*I9<YP"$.8/!ANX)@!":03";VDHPJ
MKB`"WNE+%9JQSK_\]0*.0$`!)4A$9(JSPHF5X061X0K&]I"']F`L+1CP@@5N
MX(`_D(PXP2K%%1H0`"NLX``XL`,D8G`>.Q0@!E6(VG=B_Y`#"!QC`0(`0`+"
M4`(,J.TS$'C`$A#P,`6,S0`#.`$4!##'%RC@9^W)31668(`7^(`!!FME`2;G
M@A)<"P`8\$0:'E`%+TBH`!^80PS2X`,I%"$'"=A#"5P`A0L`[@/.Z,/@:B*K
M#*B@`K"`P0XJ\#G(X8YUW43=XV"1C]U]SG'=Q$<=8%$'>S0%':?S'#J;DH]W
MPJ),.5"!_"18P04\``$(D(("#M`#`"+``G.0`D"QAP$$4*&!7`"H%'*&@`P@
M``,I>(!"I;`^\"%@`0!0Z.$`8`*`-O`#%44`#W+``Y.*0)\9D%\.8II`#Y#`
MHO#@PO8FT`+V`1`%*(A?!CP@@/^;9J`+H8,!#!`0+!(2:X4LY$H*P;+":+KP
M+`1A8QY*,``=P&4(&_A`'IC0AB]$X%M1,(,3X*`&P!SA,(-I@U_R<A<E!,$)
M3X2,%!UP!2Q8,572U,$-8I``#P!`!ET]4`H2F<;3/%59="!``B"@TY441`9A
M*$@!,JN#/<2@"$#X0!I-4\*PD*P//V`#[Y;0@A#TP0=BD$$*%`3,$5A@``/X
MP`=BP(#.O"`&(N`D5S.9G:D)8`$E(``7=E`%!&0V#`M(P6;]%8,8%"`_(A"!
M"<)P`<-^X`(.2(\F7U*`!,3`"SH8@`.7((87B,T2"FBC%"X1!@,H8PFJ_8!P
MIHDG"5C_TT0@J,`/;``#BV:@`C!H`1:P(((%"R!T/+BI"E`0CP`<H`E2(($)
MD%<!+.R@P3Q"P?]XL(.5!@`%!YP`B7,@NP^/[0`>()$%6K`I$3Q.!`<0@09F
M1`,/2*`F5TA`9'PA`-BH(@M+@!0=!A"W:%#!!W^(3`(6T"PZ%(`!%MD*%\1`
MEC,HX"->OLVB(("`CZBG&<YP@;5.HU]5#,`$_H@,2&F5B@J<8$8.&(I/0N`!
M&D3F"ETP@5(I-<9A054K4F6A"DWXXYHD`(9A>,$8`F1#L&Y@`SS@`!/2\)>S
MZB4"@U%78)2`A38XP:Q'8%>J@\`!M@%'%?;BA2H(X`X1($P5_W[0S@58\(!&
M7N`,`T-``2X0@X%D2@?1-,4>Z'6*9F\E#\901A[Z<`,!8$`&8G#!Q73@!0"X
M``'C:Y8#FOU8J\C$,<$B``P"(`(4"!H"'Y#!'L1@-!,(C0'POD$)PL"`%$#,
M!S+0Y`/<\N@8"*``-_#"`:H0`[D!H`0!D@$G!GX&3>H6X?\\^``&:JB!<<$2
M$`B##W0;TA(4+`<>,,`99""`!&BF`%7X`'7L8(`J!.`!^S6-9$:*NQ6@X$SH
M"(``.G"%HFN@Z"0X@(LL/`%NTB,`&V`3*T5^AJ(7H`=NN/0;6E```+R!!"!H
M4XJX<`8;$.,*-IB!%XJ0G#?`P`9[P/\F"$30@AW44`=Y`,!'"""%97=6``;H
MPP"H31/-`+P`P8*`#Z#A50QD43TED>8"#'`*D(#(!R8@0'`4,`%26/D#MT'V
M`BXP`.#T0>^ER%H'@@6%*A3`#ZOA"2_T_`QZ+YL.5S"!H)>Z)Z<>FH7.]HH!
MH)H*1Z]@`6$HE`QD,(4^7"L`.-R`G?DP`#4DX5NI%@(<K.#6=GW!`4SXBUZB
M`,07[.$S_XAU*F9$ZP!4X=;A?:T4;C""^%S@!6$X0PIR\`$AOV!!&#-&'T%N
MSK8GBL`28@``1=,`6G`!G\$%:Z,#LE$*=D!N87%N\U(3J14+*$`")-``*L$V
M"+!P\E$"(R#_`-KA!R40`U"0"2]@`D6``*"!$0T`'78@&P_W`G807=J2"1\P
M`M=5"!\@`#*@&0@0%P/@!]!R`"Z77KU&1X4P!#N`?_YQ`%_V?^)S#-0V!%`0
M'2_P`&^`<XQ'%G[@`+EA`DMP(IL3"AM@`A!`!1)B"LJ6`%0@!1B`:16P3@VP
M`V0F!;0"*0,Q$&>@&QQE=UXG`T_0`@D@!640!B`2'.FUB!>P`4"@"R@@#Z,A
M`!`G30#0'G:`!/(F33Y`A)^A`S4''`61`"50$SH`1A]Q49XX-V6F&29`>?/A
M98OB`'$`1JWA`%0P`7ZW@ITA34=3>JK09CH0!B[@@';@`"X`%)G`_R`GL`=\
M,#$N5PH)!QITH`$JH`)*10+->&ZEM4)]8$<280##MT*D@`=YM@*YA`%#0!M#
M0`@7`'67IC(GP`%"T%;?8E=M8`;B-WY!X$1;<%:>%@%@X`1\D"DUH7YXTGX"
M`'^.N`?J(0`*<`&(!1H&D`(I,'A9E$6!10H$2&Z1PAJK\`?DX0,(,`!SHP`Z
M.#&WX0=YT`.EX"#E>($8&`U7H%HB8`$\T`-%L`0LD"D($#QB8!T7\`"^]178
MXTH+D`,+4$-A4`73X0.>,$L0L`=AX#,Q@!`$4`4Y``6>D(`CP`!=Q19+D%D$
M4`(D`#8O,#=5H"!V0`(GN%D#$T<%<`8W</\#2Y`"GX$!`O`!$%=M'9)S5:8*
M!^4.(-`"#5!%&P`<P`$-J`$-1E(*!C`$32</&V`!]\(H>00I'P$!2U`"`+`!
M)/`$-!$L[6%'->$0!/$'3_(#$O``\E`%+5`%.'`,-\`3")<`8$0`2&``%GD#
M<@,!\;&7RG<#8C`W,K"7-]`R",<"\&8"8H".'S`!6U,&".`R95`&4N`%92,#
M./-="N4"`@`!NB$#)#4!"2`#!H1!7Y0"'H!!"I`"6O`S"``!.=`#/.`""C`Y
M"L`%+J!P7(`!+M`#+2`"($0ICV%HAU:.E2=\4`4B>38$%O`")!`#&*(`=R`!
M]0A6,+`"(M`!26'_5JK6+A'P!41@&&@5!'G`5MVG!D3`!Z7`!'_@D.SG#N_'
M"W[0'GM``+#W?YVE@TH86)G0'A(A$4@ZD@,@`'7P!$_P!GGP!YX8;!`X.#(P
ME/Y!!0H##:F!@>AV!3"0.R"08WXP@GOY`2RPG000(!0@`PB@!;:T&TOP`6'P
M`0LP`%70HQ?P!FC4!P3P`$'C`@.@GP.P`S=0<6^P``=`>MCA`Q6X`&]`,='Q
M7EK`'\UEGM(4``"P!WXP<F&B`.W!!6_`/<K5(0"07Q]20LT"`0W0.$F`8"+0
M%']Z0L]0%3Y!``U``DX7ALNV+UI11V7(**T(``1PB$\@`A'#FE$E+$51_PI`
MT`!W1IL@\`1/&@!0:JU`AZUGL@%#0`%O@$-#T!0'0!L-$*ZT\0J@Q09R$@!:
MD!Q\Q(!:D`-O$"4G.`<Y)``",`=L(`(I(#Q%4`1CPUPK,#9+\`!:```?P``>
M$`-L$`,/4%T8P@4Z99\QX`(0X`(BL``>F`!G@Y$7$#XW,`4&@`,HT`/?&(XR
M,8XF!*'GF(XFY!!EF`!<^%OZ.H3`>`%#`"?V$``"!GY#E&J?)@3<PJ)OM6H#
MP"T1H`1GA1=S0`1]D`=0)"(/Z0X1R0N#\P)0@*U0R@:"(IFGP#:@P7C1(4W,
M1H`.X`5NX`;S<`.9D&N>,``1=0I6:1T&H'G.H/\L8!HL`\!'.?!!?-"C">`*
M"Y!>%;.)F]``;?H"!,`&(P!Q/E`$0_``DFD"51!8"?"NCN``)M*I$C@@B6"*
M-3A&*4`!!F`'(N$"11`#YG>9;W`"IR`%#1"*+R`\?N<#WYH`?1`&6QL#'R`*
M(@DBYT<'N8%BZ```*R``X3H`K#D0#J$5M_H'!#`$O"H/0X`!T0`<T`LIQ-('
M_ZE_D_H$*9"+S[L1B`8IOB.;*`"E'U8!;7H*#(`>`\`"+^DU&C(1,1`=`R,S
MG:4#)#``Y^<'!E!FP+%,#@@:4G`"@T,'/D`"#A(',E!#DZ8;Y[=5#6=Z$V!+
MFN$'#!!8B^`(FJ$`@IG_:W;P`/FX;!=P`9FP!S>``3*;>[N'`*D@CN7&,"YK
MF3#+,#)+!S2+`=>2P3_@`=3X59=F#RL@Q'9@!$W;+E&0`T30!MTBM'J1`R]P
M!4%P&$K`+E%P5T7!N52;H^X'?]H1!H$J`"D``%``;,\9<T1("F4;1BS@J=HQ
M.",9M700+SZQP4JH`,DDDJ<P.*PYF7F;%7L;M2=@)C#0`"V``Y`Z6$4@'X+G
M!3'@`_7%!@)P!L!1`,R%%GZ0N4O@!Y%V!H9%`"^``%6@!2Q`"@Q0!"D`&ODQ
M6PMB3'F:`"/P`9VPNX?@`80`74#@<IEU`9=4GPD+J0:P(DO@J2_``+;\!*,@
M_QS-MB@/T0.*"0!`@$T-L!HWF:1;\6IV\$)-=P\/D"ECQ$(L5$<L)$TND`(G
M4)HD4`<B<"SBIC!;,<A```,#(`$H,`^NL`,0EVNH)X&810HO4`6!-S@;2<<`
MMXK1H0!W=Z;\00HW@%)E""V)``UGT'D-$0<0L(E]@`!%>`H$8!O/H`,80+\!
MG)J[BQ.#HP.M=P.P%W=W%E[+Y\8)9P>0<@4J8`$-``,0$!DT_'LW+*%5118T
MNP![,`$C`#L',(WU>&DKD"8;<``%P`=M(`<!V2Y@$`=EM;12'`5=$`=P@`99
MS+1*H`9?0!YT@*,2`)'PY\&YE0++UQD^,`*TP09?EO]>'=`!.S`$3+BJ(ZF,
MX`7-N3:D/F!P]Q$-&-,07"&98E'(?:`!0)`.(L`#,``%G9$?WX4`\K$`%8`!
M16`'/F`?(LQ5"J``7:4#,;``8B!=_J$%2V!=QUHT"S`JFFAXPI,`"4#*``!)
MG1$M%[``N;0Q[.%\(R`#4I"_%U`$]TG*#_`!8M,>DU,"[;&U28!Z8*LP<UD$
MGE,Z[K`!(AG(@4P6?R`&#9"9:,*9>U*.=238X76F#W>(L;H5DLF]]#(<B?P#
M#I#/\Y"LP):,."=-)2!O`9("T(%&!O#/!"`#2!`=C0)QFK$;2$H1929Y%V`:
M!.`16]$1#DX'G#=I$JB4@:7_9NU1"AY""G)[C72P,8BG&2;<C#$$':6`!`S@
M1AI@`18P!#`P`3Z]LC6L+$&-CE!U&E>%%BQ@`F?\LQ\:HD6\F3:P:4'@+8"Q
M+F!P!4X`!G^A:N[2!4Z0!D(0!&``!EYN!$Y0"K$F(FM=:VT=6(KP`@4@`SHX
M`#)3`%+01=J1``^P`[O5IEE$;NF&`3=PQP2@,&Z\*@S@TJ4@DG5TD\'1V#FI
M1T7`;A[0`3;0,6VZ!PJ0L"60!TW*!JOH`,!4!?=A2!%E?B^@!4`@JB\P`(SZ
M97U0"0\G3280`W'\HQ]0!.&L`P7SSB)8,</8`>S5'C?P(IX`+;8.<78`!6PP
MVYVE_[!M&@8`@)H?(;.5=Z8,H)BE(P+C.A<M%'PUZ0<WL`(DX`&/LYE[H@H-
MT:PUZ;V&^`8=D`0I(-_))M]5L2BP"0/XK=\[T`("P`*XY0,`$`8`?P,DL!8^
M4`+-A0P#(`,[@`P^8``08%]G0``,<`$$$/$NX`$5?P8)@*<%4`(K2`)K20#$
MEEP$4`8Q(`/;D`8,8%U(T.8[@/)I.@$7P`XW$!]B(`8)\#4I;`!#>)$&<`$;
M2P*X#=SMF0`N4`4RD`!3X$D`@.,3,!4_/3(CZ:41"N3DR`LAT``^#!<\37HQ
M=(\;`-5AGP%\,%9H<!BC1K1.@`9<+;3O0E9,P`2R%BQE+O\9/U!K5U"9'XDQ
M;DP`4%!=!X`Q@A0#'R2#D*D#51&A-1$&%>@U'GGH-!<H4_][57%N#D!@%@8`
M5N('2\``D18#6O`!"SX!9@P`P`:H7N`"=B!R(S>4FQ"8^,<%^LK/I4!KT$'*
ML,0>Z@DC8>!9%Z`%%W-^LZ0MQS`Y;6H!0#`"R20#J[L#7L!9D[-LB3H[!&``
M6L#,@G,*4U$44L`%<E<Z`I#MZ-Y4PE$*!4"]3N>.Z4V2\=X'8D.:;S`%2;`#
M4U]:S=8"]IS?\K`#(P`(0!\Q2P\C#%Z$50]>'Q]%``\?7E5%DDLI`BE+``!%
M(BF=`EJ<``('.3N:19HI:)4IKCG_;","(Y4-(@(Y(T-:(\`-!UH'(UINQ`<'
M#6P'10=O`6S-16\K;$4-*T,-;@T-`=D-&P$@(#`3?7UX['Y^?_#Q\>[T]/#N
M\&)B\OS]#O\.0C3`,`#""`@^(,CH<^'-!A@/-ZS8L*'"#`=TTD2(<J1C%"5H
MC#C9HD1)QR-1(IAQXL`.$X`.U/4!`+#/OQ\[`H@@$#.FCCXO2O@8L*>/CA<Z
M]I2(P45'F*0^"MR8^F+/3SOW_,A\42`-@0$?"M#YF?2%41WU[/5;RX\='@<_
M6KP!D00&#S\&!,A0\,'`!!<&/MP@`*G$T0Y5#"!`X,.%`BD,,!!H``&"@`4#
M,&#PD50!_Y0.&&Z4V`%`1A4&!194GE`@P8$$`V+'^,`7PAX`+F0("(-``(0/
M.UXL`"`%J1T`!BX\T"&%C0@1`9XL^6G4'1ZM>*1PJ5`.``P!0]X4U4J>O+IW
M?<0TX,$]P`H&$FK*M$</PHX"`#;(J)."CG^9Z\BC51\M`#&``P\$$```T``Q
MC18!**-%$4,H`\0(3VB1`RI:O)$",!,>($`55:PP(HDCL-&)*6QH`<`.2Q11
MQ1)+;`&`%I(\`,`(%<3P``.V,/"`!Q]HX04&#%A0A1<+<.$"%P=5I@``7E0F
MPQ("<`&!%#+L,`$+!G1@@@(LB"8#``648``.!Y0#`PGQN84/6_]IJ36G/FRM
M!9-`%KQP09DE+#"&#A=(!,,*B%(D404$V&&'$1&<A%(46%R!0P0@H.11!%^<
MI4Y,,M'TCTUPY;23!#;I8(<.`UQP`0*1<3;``BGDX$)21\5`##$R[#%>5C+1
MX<,-"22PA*,Z^#`!`B0@8,`+=;Z39YYN.6`##`%L<`X-?@P@PX0%]!&&#`=@
M$`90$Z"I`Z%:B'"#'03P4H51/D"10P*J-K9$`B^\`,`0`JA:P`YL</&"`P3$
M`(04JMZP``-VB`M``S$016X1+OBA0P(`5(&4#C<LP8`/>Q@P1``R)+O$&R*,
M$,!TZJ#EQW7K:,<="!5\1U%1`/;Q!QW_?6A%QQ]^W-#`!"B8LX$*/0.(SX!3
MEK#$$!T\(<!_0;/3M$T'P/"#!`F"L,,(.Y&U7+X7K.O`"R*($33(TZWK0P*&
M.9#'!)S]A``&9!40`P+KVJ&``6H3,($._@V@@&&((S#!&$;Y30!9)HC!F5$?
MK'N4"QTXL*X+'Q"@L1\H%"#!'@ZXBI$.)7PP`%I7]#`Q.@[,W(ZTT>:>53[[
M3"N/3`$-]`+H,1!R!J%#K`#11!1-!$0&I].!1A0<=:1$!$(0`480W`>!!AI@
M$.&`5=0!*&I/I>I$`*J>D[4'O"Y`<7P8&%3)MQU[A.'"`U!X`,`-[_,#5H@V
MH#[0@0`8X((4_Z2PNAM400"[B$$)HN4[MKBE#S]@0P!@`(06F(``,A#2`Q1P
M!OQQ80$WN,`9^O`;&9P!`DOP@`P*,($E0(`!"EA5O3X@@P08P`<F8$`'+K"$
M&`!``3?`0"3V%08[M`X*8I!!53X``18DP(A4_,T)`2`&59W@1S*X``BKL``#
M!/$#_YL2`#S`!NE01V8TR\YVRI$SZ+P!6C(AF@'500=0W6`%$Z@`"++5@XAM
MC1Y\C!H`WB`#J]6D':0:%==@8`,$F6,'+1!!"0RY!*.\`(1D"8,`"-<P`&AN
M;B50QQY<,#FT0"`&FBO`!PZ7E`6D[2<$N)56%(>$=?4A`2[XF.1D`O^8X_TD
M;G88'KY^X@(`B,X.?J@`"UKB@"&N:P\WV,%3^F`#'O0`!K2SW75PE[LZ[>X/
M>*H@/`!D`.%-``,0<$$-7E>HARB/>8H2P`GV0`<CJ*$D)Z$4$3C`!SXPP0E,
M.*@#^$"^H)FO)C<QU?IB1A;C("M9'RC&$JR"/P3\"#@`O`JPU,$;&@&``7_0
MX7"`L`02^(""ZFR+6VR@P0-4P`,>R,$'I.`#'UA``:V4`AI]8!07&!$#9R@`
M%T1V`CN<(08*@`H&/O"`"^SA!;T!``+\<`$CNN`&87BE#!SE`P6<Y@5V"(P(
MO"`&;P'`AF'(`P)&D+:@>$$`#"!`R1Z@!0S_K$I)2WA6"03@QIA9!SLV*X<(
MBI"3#7`+:$$;D!_D8[1T#7(#,3!DS^IA0`=````G6"0"GB`"2?9,D@L]@($0
M%!U,:I(L'[#)'LZ`K[&\(`5=+"5U?"#&F"%$<S+@V[J0P`#`&06),CG#X?X1
M!PA,#G4)F(!5^E""S<1L<1S5@1<T]P(NX$L=?"%`'U;E@6F.+SD1LX,L(Z:#
M*YC``D4(IYRDM;7(IN6<Z51GL-J)@1=`@`0G*,$$SI"Z;$'DP(JBB`5HX``G
M"&$C'8E4!+K`DG\PP0X.>(D$^+`JAX8*HND3@08,J:IU/455Y/,!7P4`@%6M
M:P(->,*"-AFSD?:!_P`(((`"N/```SHEA5`H`0%>:LZ8RJ-:-`5!#BPP`1M4
M80>ORP,+EL"%IPQ`M1KS%0**P#`=%"`'$#C*;/6IPP>DP`>KND`#1G`"C1%`
M`(9!"@*6<(%5=6`@[WL!"5:0`D-"H`HW"-Q=S;('"&!6<PQX@PM</".K["$&
M+WOC86LV1Q",0P`!&`(-[$"'\M`#:)-U0`$VP)Y!#L$#`PB#JOO5+U6K.C8^
MX,(.D+`R$ECM![B^@JZO@&L"$(#7!#A!`PS$`10HR!0"(($!#'"#%"3G`E*P
MI:N^M8`$N(H+`D@`"?82@]S(0`I+4``"I$""&*1@,3)80!4^L!@I[,`#"O]0
M`!46L(-X*\`,*6``%S#@@AV(P`4+6(`7C(0D!NB4`<5CP`%\)`DM"`"-AE#1
MBSS!XD[P8N(I4%$L!,`&(#QD`A(0YYSJ"],[]4Z=[C`@?_=P`@'`X!,T>,$-
M*+*\!%/$/1WH`Q\T$`23!#0"66B?VA;J@/C\!`]8.Q^I<**3$Z#***LJ0!64
MP88JH)E5[\LA^080702\3G,^(Z!,\N#N)GA%=*SBUQX(`%:8&AD>2`8""$PT
M@98L(70R<,$%+`"!X2V@F43=GX\"#3(,/$L!P\*-`>[N@1BDZ0$36(#C7PR`
M!10@W!X]0\(0,(B2FB`&"R#J'C`0@PL8O@_#Z8#_68<3@QL,HDN$<^(#EB"%
M.4?:L#-#[!P#T(`66&`#=9B$%,+@'XP`[0\.N(&/=@!(%"1!0=E"E/01]8UO
M;,,-;QA!"1:9`!E+WPT4<<@&'+("ZV\PV#L8Y-2+,(@8,*"OD?$?`^8/!2``
MP`)-8E#`>4PE+OA?!//G)*:@&5SP`3F`&QA@`B+P`0G4!0R0`DW"!6N0`C%@
M`G\'`"G@`BZ`)'CE)"9P4AJ(`.KF&`I@`2GP`218*PS@`@A@5@RP+`I0//'V
M2E4@3S5@`A4@`!]7._.U3H=49"9G9)#E`.T$!>/#`C(P0QCA)R'0A$Z(`R$`
MA3C0`95D!WE`!%^0A4*0_X4B@1'T$$=X(!-A^&$PD3X"H`&C<DUGD(3%<@-Y
MD`<@(P40``7GP4=C48=!DQ7T,#P(8`(NA11[X"TZD`<&P!-N)R!Y>`]A1T#N
M`!=%8&E%@`*H,@,+T`+Z)',/``0>0`!A,`%`X`*:!$(F<`:^TFP"X`5645T"
M,`%"A@$?,@$O,``PEDI^\@%`P``G\`()0`S!5``>``0/4``]A4-H-0`NP`9+
M0%3&R`H%,`"R!`1<T%07P`8/@%8%``4-(`,)<BRX!Q!V@`!MHB!T\08'8`*M
M(04'\@_X8X4#(`5B<`(&H`"!9&D,0`+%H@`-D`1)(&/0]P8/@`,]5`!Y4`4!
M8/\`"=`!"9`!6`!]@P1]`;`&'8`#";E(XJ@@`M`!0D$`KG,&`W`#0-537X:.
M83``92``L=&1$-`!/949-Y!JBO,`)WD!*'B2&/"''<D%J18&J=&2`^!??3(`
M-"`&#W`"-$`#8<`%,U"4$D`#,,F."R`%[R,X2P!`_]`#,Q`?=E`LG.8`2/`!
MQD$`*N`!#8`.3U</1--I9+<#P@`%AMA'6G%.!G!R%32$1=AI?80105-\1"<!
M?!D?,#$@&9903,!AQK>(_)`[`/`I`,%T9Q@387A*+$"*Y+,'0-(QM?,/`Q)3
M9Y!C53`"`'`Y89``<[89TE)!:B%VP5)\`R!WJ0``.,#_`1R``&R0`S^0/[_H
M`3_@`#0P`5H@14=A`:61+"+`!K#4!WN040SP.OAQ`&)@%8WA3!B%,:MR`RFB
M`,IY`%Y@!V.P!Q<``#&@5RY`(H&&>JR0`$9!+EY`5#K@`BF@`"^0%P*@1`OR
M$^41'QP@`1E0`2T@CG60!"M0`16`)2@0`XV'`DN``@@J`#^"@3F@!2``!$!U
M!DFU`UHP!\,P!Q@J`%1``)I'`!J@E@A0`!Y:`$V`H2::`RBZ,"<P`S.0`2U@
M#@I2("E``)WV`K&5800`E>HP``)0!CU1`"EP2@E0`)KC`A.D%3(`2^M2``\0
M9OZA`'5F%"7`!>Q%``MP`M1!_P(+X`>HH@&X"1`+,`-AP`$+50&=U@=Y@`%2
M`&I4<!_T\`!P0"H)4`;_L7W;1`#OI3S0\P^094!T8`=B8`;=A@`0L&](-5XI
MU0]Q*81:080-``6=)EGOD#L71!\IUS2G>9C1DI@VL70YT9CKP&F#>`;,!IJS
M50!Y<2[CQ03'ITY<P05#P`E$A3`YX`9S$`*U\W;]P%F+600Z80$5<``3D`&C
M9`$?8`-[,P,>@``G,#X)`&@O1"PQ$&T(()1(X`>;<`$,``!$40)"50*B80<0
M4`2F41H`P):/T9VYM11PE@`*<'F1P`#)$3`&D`(7X`+D:@<Z&9]XJEY5$`->
M8`"7-_\$3V!*!:0#_\`'?8`#/8`%T2".@V0.26`.%#NQ@V2Q=:`T,*H@;S`7
M#/FP`4!^B*)!2:`H#E$.#LF0$V$-Y,"0+5!UFW047F!`:Y<`,>$'HH0O6B$&
M5=!AM)5*/P$!*^0.(40^3!IF_S`X9%$"MZ(.L4:D&H,`7``0)\``5P`07%``
M88`JQ88>8?"4U*$`]^%08)`%G](!/AH3Z_6G5P"LX*0`?JD.--,'BT<%/H!6
M+W`&:?`D`T`'+Y`'BBJ7ON-0#J`>&-!IAVED3J.KN;,$8>@`8\B8:+@.26&<
M""`",8`!8^4.`Q`TG'8P/AA3J#<$)B`<+S`&?V``0-","4#_?**[-?.0<GM@
M`X\(`#PP`2?0<7I%`#T@`A5@GC\`!"90E'U@`@V0`@?P/@B0`PL09P%@B\78
M@M#T`D2B%P/@!Q/P!MNU,2)PO&BE`"E0`'X0%``0`%50`&;Q`0UP`T&#`6^@
M!5BJ`R3`93;Q`CM0!$@UO@$0I"\0!CM0L.V#2/8IFQL+L11+%P8<L701L2@K
MCOH(`F_P?.5PP`?,D`GLD`6LP)?EP"E@&#AKA#;1D2UAA5SD`/#@>E?E5(5X
M%!OS.D9QK^232V,5,1!`>,F"`&<Q+B70+]R)`!B6!V=@`E_#EPA@`W[I`%%5
M%6'@CF(F`SV@5XZ2`04P*ED0`AS`_V"IT2\#T`$'8`XK8`+Q<1Z3Z@=4L&A_
MZA]`LP<"$`,_LQ:+*KI_8$"&"VKQH`Z*"[LH%RV.:Q.1^ZF3>QT_X0,80`U5
M8!@#\"]O4`1I\#-A8,)&=DT]21WX4Q1[D`>.G,<%Q%F1Y(@3W`(`L`(Y@`,+
M\`#0L0,V0`,2<`+E%30WL",WT"UB.Z-)<0('<`-KTP<^\`$F@&8RP`8"(#K$
M!0F<2"AKC!;KR0#0HC\-8))V<`,/4#"<X0?'B&(Z(`,>4%<38P%^L`<)``0[
M8)YV$`-O$%NCDS78@0,6L`-SL;$46Y$8/,$:'+$36Y%UT,`-.<$IR[$)?,_Y
MS,ZFT`"_,/\BQXN!`B`C#_2_MW`+!S`$`)`#$#0,!PW*3S9U;[`#*:`*#?`)
M`*"^6I`"3P8>'5,%.=``.4`BR#L$*?`<`K`"3_8<&^#0`B`".[`!NO!`PX:!
M!!,`FK`#)3('.X`%.P`$0``==%'/$WO4&Z0`96A\=``!:8`!$UW25<`%4P(/
M0\,/;ZQ?<4P'<TS'0J,[TW*I\Q'6F_JX?:S3?]QADXPKOM2Y.'N60S,G%00@
MJS(`J`L!25`'=;`$9J&K=$(/$I!DYI"Q`9#7"I($!W!$/S`!/V`#;S`!=M``
M7J``14``"6`!!L``H;<'?H`$`1`&+%`%"7`&#-!W@`9YW34"A[S_`OV;MUYP
M`4"D8FR@`Q_`!B7@!2E`G4MP`G0E+GZ@`#F`0#N@70)P`0<`!3RJ#K,-`6\`
M!3KP`&XT64<Q,Z22`5,"L>Z<LOR,SQ9<D0<<#=O=P.^,LN$-SR'+D"#0T%4@
M.GY`!S-++W6&8F'!3]3%`'20!T`A!D#;!XP1UQW@`F>A8VD#-`A`>'Z0$*IB
M!PEA3#I@`!!@!Z=S!CQ@`PPE`3Q`E'Q@-SV@.8KS77V0I.*US2IP$075A%=@
M!9>%P&MT`,_!`ZARJ?$``<9IA>)VWUQP!LSLQH(;UF=I-(>;B'ID9.4DUW]=
M)YP*$Y+KF$`1!C?@`JWK2T<A;D/A'T)S_]7J%`87()JB^3H'A"4'X`*<'5-5
MCC5H7'1\B3")K3RFX)\MT+)>\B+W(0$LL&8`KHL?TB<^4`7(0:0E,`0[X`7]
M@@!54#!A<`8X4@3O8XS.I&539P)/L="?^0(G4-L[0(H0H`4+$(MVH`6^C`17
M)<X"\"X&,03!Y`-2H`6!,<ZI9A9(83?O(\HS/7X*L@+N87.V?NO-,WVY+A',
MT['-0P[B-PX3L;+B-^SEMP':H`TKZUK"&`;^XBOPTBLZ,`9YKG;8)`!Y@&$X
M]B[OPTI]](T/<%781!LNYN1H!2\*(.X^@$+K@E5]P@%[H*Q$F0<28`$LT)-[
MP`$5@+>9T7?]HO\`@06(#V``;^@`.(`#,[`"!1P`'L`=RTH"YU[)[_,22GW?
M=-"">4`'"I`&.T#?@2OD,N'CD3KDF1H/6#/6F)P6Y[.8?CPJJX+E-:FU/V$5
M9^!Z/BPT0*ZI:4$`?`4$RC#M$4.(2S`%,1%3W^XHCN(`KC:2L9$'-B``QKL"
MG1``OL=\8M,!]^L!)V`#"E`!58!X8:!B.Z"2/G`"2Q7V9Y)L/H!C'>,"Z$L`
M;^4#X&H`H.-")&`+L$@`2]#1@\%U5'4!.FD?'A`&8J`KR#$N,4`:BY,9A^!K
M!&``?#4$%K"2"CX`^AH;$,`#*+`#&6#=7)`!*M#YP]KY&;!`I-_Y)$#_^LQ"
M`@??^JG?^A'Y!:V?``=/^Q))`@A)^R$0D5/8`4W8`1V0!0?O^\`?`B;``Y:H
MD@-P!BEP!G=;`A#@[&'P9E)``$+QK"/)Y$[>4S[``&*0!\M/`LGX%=V)W&C%
M@C[@_$FT_'(?`\\2]OL3!C]``RS@`3-@`T`I1"?P%30`"!4^+P,^#`IG9SX+
M(@F#+VL&<5=A4B0:5@$@#0(M&SL5GR@F-'DT80,#86$O+GVO?3X^?GD)-SMA
M=`Y_?WY^O`9BO,/$Q;P.?7XW;!@.OL_0T;_&TK[&U]A_``[<?0X2-@!O`AK<
M#CIVZ#</&#(EZ70("V\)=/9]=,G7U79G"#(W_RZ\T.$@#`$?-P;8Z9.M&#Y[
M$.GLF;@GCT5P,`1L.%#A38`B`#2"$.#!!`$`"$@4(:!CA`L?.@8P`)``PAD[
M"BPD*))2``0$#`R\>"!%H1T`#"``*!'FPPXN,0J<^"!OAXX8.PH,O%$%)8(!
M.M@D>,!`I@`I2%]X`&!@CPX=0*0PN+`'RILG.P:^[:,#7Q\[4A8L\7"%CP,^
M?#C@J<:XL>/'U5Y-^X-/`C<[B'&8:"%"ZYX72UZ(1B*%U0L?`A*\*/'"0(H!
M+\*D06#`8I@%-_*$R8,@!JH7-RIP@3W`A8+386XLD(4P:*H!"F+X^/&#18\0
M5WX0Z$&"!8$S/P`D.O]SX]#W,Q@$R#A3@,`6.01*E(``08Z;)"!`:`+1XL"&
M!BU,T`TLSU#QPBL.Y..'`P74`(!$#/4RC1C"-$2,/GT8T,`"$5KH(3%^P"(B
M8R+"LH0WEKTR```!Y'"".6_IX(,+6HPPP@XEZ$"'"Q\8@,P>=B#SRC[2O``%
M&P(((,)$=-R0`&UG`/EA+R56"9$#-JS0P`8!"*#)&P<`\81^(IRPQPP/B$"#
M!#H4H$!90,J@Q0)A.+#'"D5T`.0-,="$C@$+?"5:%0<HH,,>MS00PT`=A/06
M`7W*T-<`'QR0@$(D@&G':31BH!>/"1R:P!``V/'9$D\`L,<K?1&4CP-E+`#_
M`!8FX'#%-VOBH>NNO/;JZZ_`!ONK9,.$>&@>#@P00@4>'%"$!RZXP(467$@[
M$Q?8'KG$`@I@4"D7&)B!P1(/2.N"`%Z8"\`(7'#+@``I1.O"#@`H@"T#56#K
MPKOL8(`!`#DPH((*'N3@01,,6)##`QXPT,-F&"3\`+P,Q(!!"D5\$$,,+N0`
M@!=KK($&`$NPP48#`1S00`,P:!)``R;L(:1DODCAP@"OW-,D52_\L0<OUOQ!
MX91_".G`#4`LX`QD(5:9C#1./QU-U#L@PXT$X+#HHC?GO+6'`8<@``%8.LBP
M``,,Y!&B+D-2(\T`$&@E15L5#?"`RB[0030VS^`A_^(`!^2WR48ME$1H%14D
M8-@`*'203`(&_"N:"U4\0,`>"HP`Q0$Y[N%##`JX=4$)#R`0"Q`YI"#+#CLL
ML=1`9PB0XPUAN':!#A<L4004/A`@``9:N/#6"PH`T`$!")Q!>5].I2"#'2ZL
MD.I"?/%%F3VRB6$`%SGLD``WB@DK_OCD]SH9,7V]D,`.+8O0`@P`//!`#%J@
M'0,*:*!=\0$?,,"%%W=;`!08L`9RN8!;*?`?%\BP!`%$ZTU=H<\$'N`%""@`
M`BY8`@(0((7BN2`!"9"!!Y:0@`XD0`%+R$`'0I`%%&0@`2S(0A:R4H`2&,`+
M7"A`&M+`!>\1@`!VDT,<PO_@CP0`Z04%\$(8@,0"C00`!A.0`/5HYH<S<$$!
M`VA:'V2BFJ+M0D*\&-J4\H&/&S0``%+8H!K7R,8VNG&#4HBC'.,(PCJ"<(YS
M%``'C(:E';3H!%QKU5L64H*7O"4&*4A2&+SA!WN<KUA%ND$)+L`%!.QA#'T0
M0Q5R\`$?Z&U*)(*%.9(%`_V\S'@D")0%+%``$L1@!GG80P=0L``(<*$$-UB"
M`J"``3&88`$N>,`9PA"_&Z!#+E*0`1=\(`,,*,`$2Y!!"KRP@`]<P`<0P,`[
M=.""=#$@-@IX`!<^L``9]*]B?8"`"!;`FC/T26,^V(,XN;`4"#QE!VQXPA+Z
MX@?_'?03'W:P1QY>$*1EH2`$-G!`^1;*T%]-(VA_&$,8%,`L$6P@!RW8P0D6
M\@(O(,@&63`',;,0)`?,8`FKVF(9T@`1*?C`&WU(``;2X8`2)*55%^B`CF2$
M`(+$Q`4Y>DLSN78%+A#@:CR8`0W,@0)OT"$/"Y!#SA``@`(4[0]KR((NZ)"`
M,B3##B4``,YT0``/B(!E$ZC2,QR0!A<@(`%2`"$"AF,U.P!M0A7ZD,[,N`,\
M^G6.;_RK8`?K5Q%8QFI;]&,+`,F-M_C!#@900`DZ((#;Z8`+%[A!&?)!1GVX
M+1H^,,`%!%`%!1!@#'Y(0P((8"ID@#)J54I6$4"`I`VP_X`/`Z#J#FYK`ZJ2
M@`9VF,`.1F#9`@A@!%+PW`*T8(%^A@$#,6"-^I(DE#WL1`!`*D$,!"`&4WTN
M!;<[@Q:&`(7AQ0`(7C@#[@``!)B\@`0:2P=7&J`:.Q#@#6\07FZWY84``("?
MR<@9,OP@F@3U(0R-V@$-F,;@!CO8%\3[0`(XH((-K*!+1W6`'3Z@JSY<`0=,
M\$88<O`])^`A"UA8"!WBD(`T^(()9"#`'YA`!QD\H"]]@-0$6D4"!%#O#(9Z
MRP#8>:BRQ:`/$O!P$]+`M2[`LALG<@`3\M`$*9!1`56`PQ_TUH20\@$/.,"!
MD,Z@NG[^@`<].``4!T3%OQ3@CO]Q+4.4\/$'NX)1:'G]4,[$P(R9P?;/@`ZT
MTRK@MU$.0+&,149?[""&6G9,4CI`P`48THV`MJT8U0@M`[2@`!84`!T#N($!
MWKJ0UU8)DK[`T@$"L`(!',`")W@!`2@:`@X,@``6\$`6?G"V%&#Q!3)8P@<@
MP!*9+*H/-RC`_Q#@`P3L(`4)",.,7`<!.]C!!]2\`2$*\+$37*`K7E#-&1Y`
MLN1"%@`3^(RG`;``-P&@"AXP@!UDD(,E+"&H-_#""/R[D!#Y^QX'7J2U7Y$!
M=`OZX`A/N#>J:;H]6.`-,-B``#;:ASUL@QL:P(%A'.`$`93!`7O,`@!"G*P6
M)\,!B)C_<4QCH`-9)P`I!8CY`6-^`REXX`8X3\`'I'`#,=P@F#?@QA6ZH`%8
M4($(3C#'%O#A@#QTH1Y_H4)5)=.$&9BC`QTP3(X_L$@=_&`"'H`!#!00I!'Y
M`J8)`GC%Z=!(2(8QSQ8:4H8:``4_`SHR3JL&D:0!@,-RS09^U$(!1-2JBOO@
M`C((PZ%.(S.V=7;OT,`=`Z)M@+<\50QS<(,8/.NA4.;,'@Z@`1!``(0*<,>V
M-+`!"U;I`03DP;@Y($%\8C`"@,E"`72:R`T.@`$VG.$%'=@T!GS@3@@\0`8O
M\,<"#A4&""RA"DL8A`P.L`26B(&]`)"!#PH0E4DM(`=G2;X+_]A0_0&\?&$O
M%8,66/"6&X@@5:ORMR\4M,4!C%*A`ZB`PO>O<*P930)\<`!:86U-\`;OTP(F
M@``3,`$"D`%"(`1-L`4/*`1=,`=@H`(0"`8'0`9=8`8SL05<8`9=(`!@8`9F
M0$]:X"TI``"LXSJN`P`?0"X?```Q(#\Q6#$58P%+4'MHD`-N,`<Y,`<"T`!!
M.`<'@`4_J`8'8`5NT`!J\(1N$`!JT(1JP&HK<(4;8&%N8&%/P`8>\0:F!`,\
M8'?/\!`0X1>PP%EW]79$0R!B0'=LQV"0]QAS^`P58!B[X@<KDC(%("1[P2I]
MP`+0%B/]5':[0"R?!0UT@`JK$@;&<O\&2^`&4/`"W%"'$'4AL<4!;,`?*F`"
M'#!!;F$'"'``./(6%G``,J,#);`$!V!,8(42$X$3`4`"!U(VW/46!4!^+'%@
M'Q!48;`Y"V`J+\`&*4`'AW(!6I`">H$`56!,?7`&8+)$=&``;_``YR!/&[!C
M0+(6K>4!_&8UR'!8AL$'=H`UB($U'%`!UO8-?R$S,(5D>,!FYH`'R#(`)V`F
M*06.W1"/$A"/\:B/W&`8EH$U63")?T$'/8!?(/`&1:`R7L@&10`$;+`"0'``
M6J`%(-"0<U`$;-`B%WD`$%DC5=``(W!<KK8!5;`#"I!L4A%S);!#[?%#9_!#
MW\$<!Y$&`K#_!#M`*`#0DQ^@!?8V@UYP``\@@_`2`PR``54`!!2$`5P@`"C0
M`PO`!084+>]B,PK0!")P5FOV"KH"#532-/(G(4$3-&+T(6>G#'"H=WO3EJ@6
M#2C`!WVP&+ZPAP(X8!6'#H<7$`+@8R\@!OWS``J0!X\W)03P`$*8`U5@!R%B
M""9P`020!QT"(FR):6<G(C30D0>@`JQT%+X1!N\"`,:$```$`$A0<3<``)XR
M`.2Q!/(F!@\P`@_P&3(``!Z``1NU!R0P=3Z`!`BP!!``;._F&SI@`0R@,6"A
M/MXS`!<`-M'U`A80$A.0!R20`RBP`Q;@`P[P`UVA83AP`BC@`2S0_P$Y``*E
M<EC?,)`2P`&VU@$F8`(6,#`J(`#IT')\P4_\9%>200?UB0Z'P@!#L`(^,`;Y
MT&RJH2"0E0!_T#,.<`4(H`'H.0-<@`(H$#\[L(M],0]:<``^`4(&4`47$*(0
ML``7X'/(R`4&T'.9$PQB8#8(@',%,'D%D&S0Q`(RP!)=8WEG&#6_0$;B84,,
M<`.*L`@&4`*R0"FH8!"!D@H3556BL0<QH&T3,0530!$W\`'U>0438`$PT``0
MD`R+<6=M:99PUQ!I:490$(?1X)9LRAAQ.9?/0$Q\.&`Q8BJ14P4;0':1U@`-
M&1H/,9D6$@8),)70I3=@Q4ZX$5"6^$AWI?]%WG`%J_8&5K`".-`F7)!(7G`#
M;Y(`,>`()K`2Z5```Y0"BV)<LI(`)X!EW",&!6`!&!`E=L`55ZH5%_`!59`"
M/&<!")`"4%`"D*@%L&$'+R<`HDD`4!`_5<4"6L`9"&`#(0``)O`"$G"8#U`!
M%I`'+'`W.[!JI6(.*+*>$L`"$U`!6\(E;Y"%&W`&`_`9K%`(ES$DNN`,#N`#
MA6!#2,`B3R`I(3(#<U`%!<"?.38'<[!E?S``3<`&/(">)K`E*[`!;*`%??$9
M>P`!#5`%R8BA`,`J!!`J^/`"E74HRI`"?4$'/I``)8`/.J``IVF,,A`#>W`"
M,*$C$;&C:O4+3W/_8SG&`$'%3=J&8TN0=CZ``3[V"@Z2(P<BGG;``7:``]_C
M%@2`4OUT!0K0+#```=P0II=(-&2JM?Z&IFH*EFPZIM7PIG2IARQRE\GP`A.!
M8S)2`&XA(\F@`%2`((T$J-F@"X-:`@6P$+'*C*EA9XD(MI;IJ`>VB0T0)LX0
MJUH`!%V'``W`!0?B!R4P`JO@`'R6`HKW`C$0`$M`8+@C`"SA!\\U`LBG`PO@
M7WR!344`N7WP`E7`!E*0#GY0FRUG!^>U``-1`$/P!`3P"@10`=M``S0P`P;#
M`C3``@$0`,:[M##P`"CP!G?X"C2`((?A`"3``P`@.()3!R#P!$]``>!;_P=U
M0`%<QPOY0"5Y@`%)(+[LFP2[*P,5UP=I`'X&<+YFQ`8,J@$"L`D=8`X6``2>
MB`<TX#>.]5@(H`#P4@(2X0/[Q!<$(`6#Y+&3-@L&\%\3P4S&9(S$UDCQ\`$#
M4`!D(S60@2&\\`"^J[->0Z(^D`X6=P\3-07^M",I@`3/@`(LT`TF9&VQ"@"+
MY&$[T``0-P&^@+6,BI9XQ;7)X+65&;:@-+9R6;9RBK;]9"SHL#9_P4\#0`%5
MH#8/T99L-P##T0L)\`9#P'-LMZA[)R*VMFH@@!]Y40`I`!0C$"76M02T@P$$
M-@0W\#EW(P`#`$#8=@$A,E%LT)LW0``%T!GG\O\"6G`"E'(`R/@!JZ*Y'W`&
MW^0',5`$,Y(""_`L8>":=A``"\(!)W$`-F`"$T`#T#L``H"M!S``#\<".^#&
M2P4+MW4U&9`!%9"\^-'&^C$"+2"^WBN^#]`S^/`+5I,`3Y`$WIN\;!`#%+`D
MWI`&*8D`E%A3J2,,9Z`!.1``0%!K2_4`T/L#]%BV?^$`">`"15`%-^$+'\`-
M>W`&"5"?-+`#8D`0R*:.*F(`O7L.)`"K?2`#+A`&)0`6(OP8Q,(0?G`BL3`!
M9&,'LA<&=A!+7(`.=D`#,E`;L20##!!K.B`!$S`#'+">+,`"(RT!/V`"$K`F
M"7``'E&U7OD+6=O$;-C_Q$F\EM+`Q'OCID_\#';9AU]E+*S2<H?"47J8("\0
MAWMC)PSA`T6S*0EP$RO,-TN,:B42!BB3O.<*`*2J`V$0`]76<L#4/X^%`=0'
ML4@@3B)P`\HP!&=0EP`P!-UC*O,C``7@!]3X``VPK@D`G&[1!P(P`6S@3S<@
M`&]0B@BL!1]``,2D!=,+T2L`/R?``9`:`#TPO3G0`V72!_5LGJ8BES2@$?C%
M)5#9`&T<`/CQ!A@E`K-YC`;P"J4&--YP63ZV*3(@`C%0!Z]<<670/0L@8YDT
M`OTS`']``"B0'R@PP'C0!`V``@.`!RE"/6]Q0O"2``70.TO@:>/9:3?``B0P
M_P(F`$)F$WL;Y`(>L``3<$$[`$PFL)LBH``*L+<'_0S7<,R4@0\L6`4C(->D
MA:?+>ES=/`(',.!OL`(M4)%OX+Y#<#+Z@:X-;DH4L`'X$0!UD+Q52Q!$W*9'
M;--JF:95K=-FZL1PZ@M1#-2/Y36C"`05"0$380!)4@6OC2!S.24:]A<5YS-]
M,%H`$[M?-+AK^EDE,@`=280]P`'C$D^Q>ILG.[D'0%!^4`!+D`.)MP<%4`4+
M<!.M(9CI@&W-B`Y<4'N6Y7X"$1,=8`&AHP,)H-@$50`3@R.?05G6[`#H`0`$
M8&M<D#&7\ZP'X`')X@`B4`%AP`$_@`(!4`%7T[J%@_\"SBN8[@D#1"D`^%0!
MP)P"N50!N,$V5Y4S%=<#P`D%@3$"J.("(F!));`#SK0M!.#B'1!.$"!R#<`#
M$X`"%C`#:;8$)Y`'\;@7,9(`T\(_O$1[&#"5:Q&?"V`";#`*Q8X"!S`![VD!
MS,(#"I`!ZWW`$_`!?8D;;V%WEP8B3T-&V1T"!8<`(1`"V?I"X\X"(L`"Y-X!
M#V`"!3`#+,``(M`=)U``+G0"&G`"$\`#&J`!/[`L&D``-C`#"Q!V,$`"0RS3
M1=QY&V[$-^WA.0WB1BP-9.O39VOB?#$1LU9+MD!0\MQ+]I=V]D`TWLJ8QN@#
M';!!:8`L:`SDHL0!@0,$#^/_#!OC`R4`0S&P?!;@!1JCMB$!`2/P:3H`B95G
M`#<*N^Y$K+V8.Z3C!6H[L5K0`2_`!1``-JP13<CU`C,8M)WT%B;`%AU`B^26
MJL^R`QZ``VPP`5<@`#<L`2=@]B$@7&^@*D:#`B4E`7M@`\,K`!_0`0LX`NZ3
M`EI`>V`B`WG0;[N`#`N1!P]0!2X``1LC`BPB%%:.`2.0`'D@`]"G``=0>0^P
M`@#0`BN@`'PP`460`R(@``_P`QR0EPL1(Q<P`5JP`^KU%UC*`7QP`ATPTK@E
M`AW@?[(L,RC]G5@C`0H`2%C#T>IC3#AV:MG02.[,#02@`AGF`"[``C^P)A)@
MZ-RP_P@D(/P\D!4PY0%9AQA8MYZY#P`VX`VGS``P4`0DT!<9OM-W=I8,__!?
M2]\2'[85#PA^?@,``2TG?71_.GTZ=F%<2RX)!2\Z81@-&`5^?0Z)BG^BHZ2E
M?X)]J78O'1@0`Y^FIX*T@K*TJ:D.'$`@`0<]#GXW.PH/2V$)'R0`-R]L$Q`B
M!"\R7#Y[?1@+,LTZ,E4Q6@DE%A]54G8E.0H^?3X/`@HY7-\*"QYG"452``-]
M!#ZT<[3D0X,;.F@``0#``P<+.8!X\,'!A(`$'#@@6"$"@X<``/8X&/GPAL@]
M=GZ<0>G`D0X=`+0("/!F`H`<%W+Y&>7)@9UX-AL`J%)HP?\W+0V`+!B@PT"1
M!FS:V3'0X,V*"F'L%`"PHL5%&GP<T+&3ZF4"%UJFN5PB020!'&0=T!`08M>>
M$")&.B!`8H8=GRH02>@CP\*+"V)>UJIU"]5./S$D[+5`P*<=#!VNA.ECI\)(
M"0,6D$`I8<(.1&$]L)`@@0.)#GIG[/CGX`H/#T5@0*#3!\_CG;*"_^E3RH`8
MX:8<WV@`A<YB6\BC2X^.@D]O6H0,(5+TTI$,`2*J:+F@X\49`#*@$*##GM9T
M4JA2O3"PA&$"]HV?Y\^5BE<`(#N<5MX-(QQ00'D,%`'`&6%`I@4!.NP1Q@(,
M&+#'&3LTL`19.G@`!!<OV$'`$BG_0-A'"4MX$>(92QS@PAXZK#,$%YM=($`,
M*#7U00PW].'"`0T4D,H$;.1`0!XT9+`#`C]P0`,*+3!)```'8/#`&P#\)0%9
M+`"`0!@HK9*''8R0V4<%,KUQ@``I+)%3*L`-)\P>'^P00PI5+*%%#$D,40()
M)=RPQ`HQ)(#``#<``(T8$!1@P08;()!``E,.@>4))OP0(9F,7&!0"F=P9L<'
M#J!$0`)_.3!`%2&D.H,(>4CV`PXG2.:``I7])8,)U9"GPW/0E9(*;ZC$,!(!
M*E3FDPDG</#7'@_T1(,+.-C*S`D.\"&!!2'8V@&J/@FZF1\VW`:#;JGX-LM[
M/!5WW'O*_S'GG'[LUCM===<)DMTAB2P288P)^""#`B60=<8"&#"0QDB@Q`EO
M)V49``$"4HB11W#`.CP*+KG(U4L+*@B``@0=+.#"`ES<0(('%T"!`35^(`"%
M##<$#$$,$+C@Q<T$8R#0$@.]@,`"-9>@@P(Q*,#%`PP\(`4+"B!PPP(*=!<#
M!E)<4$`!#PC$0`D)H)=`!14LL$,&-MC1P0XN=-"!'5?L8$$/#\Q@00L@I9I'
MJ2$`T,,%)5#3$F^,G"G3$ETJD+5.HPC3QQXQX!S#"1",P*<`,@%0@`('5"&`
M``P<#(`+`@#![9HJB-""!Q[`4,0"``A0`2,OI7+!#D.,0/4$,O^,`,$$"+CP
MP>\(3'"`!1,HH,#=,@!OP@<6(``!"2)P`<'$'NP@`P,0P#CO8M)YLL3U)HC@
M0O$D[&!"-`B0((`4Q9OV@?12/-`"%P@@(,,.W$,@PP?#\Y\+1B"#B?$``"DX
MUVZNLZYZ$8<4QF%7O)H#+'M9$#GX\HV^"L$O[NA@#'T80`'^AP$#,.4&\2":
M'3K!&PO&)Q4%6((`EF"Q4)0B8_OI6!AZ<0`>]``',0"`%%[P@GX`P$($H)`E
M]C"!#P```B%*P`S/8`<66*2$>R"``B#@@P@E($\&*`\$M+"`$APF!DNXAAVF
MI@`_Z.`&&`#`!PJ012@T0`8OV,,%4B#_@@Z$P0?&P`$?JO@!`:B``PX(00-$
M$`8:L&`'()',XQP@@3R<0`$?:,$1_U*65%3@`"(0P!XD]!K&B6(D>\C#!YKS
M$@@(X`-/^!$2H)<`A.%J"3=P`0$8D(`;5*`'.?"`!7#0`0M48"$]F,`)=D``
M3C7B`@S0@A:@H`#@"2!_)%"`!ZXGO>--;`(+("#PM"D:_0'`!!-#P)U(X`I.
M5=`4C//$%O+G`A$H@`3^&]W$9.`^$D@/`@!X0/$0\``MX(\$^V,`^@!(/RX0
ML`8(.&"&8#`!WJ@K6.]YX"@B^+`^#$->[[R@2$F10>QP<#O#8<08?#``!GS@
M#`4X80(,8("%__FAA2Z$&&=\<(&HO0`_R0DI?%Z8B@$`X3\JX($&!%`%5.W!
M!TM@)B,&`#1').H`"-&!%)=`C1<,H`@(<,0['N`",-V`#0*X`9E^M`.CV>$"
M58!"F$I0A6;:`0)LJ,(H?;"``S`@#"]!0`M^(!([V"0!>^###MY@@HS@``C7
MY``?+!"`'7!`,IC5@0\P``0L%<!,;O2HGE(@`#NL(@%O\N@HQF(':"V@5'9`
M`.B>8!'1D8!"UP"`&!8P)4:@X&[08X$=F+&!'52`!',IF$OV\)T`B."S?AA5
M(S1K`#.%80=A[$0)=A`B.O#4:(Q`@`\XU0$3#"`!,NB.4'D")U'0(?]:.CB#
M"[KX$H)9P@\O\`(==."`,+@@O1&2P1+`JP,+K(9,;F,$'4H0`S*1RURZL>AO
M[*5147!T.A/\'F-&RN$_E'2#VND7C")4``RD``,W,(D."K``H:W'$[FPUPMU
M0(`"B,$%8G!.?L`75)UZXJL@$,H.>@``I!UHQ5Q0@`&DP--BM.P!7C"!`=0)
M3A,X(QE+R!JEI,#+!#`@<BX8817,!@63[$%F!:#I"UR`-77N8'CJQ(`,O'"-
M;*@`!?[L``%B@((,+``%'D`!"QZ)``N((%,,J"P-$#D8"0!R1U*HA)D:D0H]
MB4!S4)!>:N-$K#S$@*P,@)H`/)"$`=X@!9/_P,#5!K`#%DR@`!4HP!@LT($1
M((\$/[`)$'B`@`K0H`5G\.H+'A>V(92H<!^8[JFL6P7RI`()52!+'_0!WC[4
MX`S[)0P#6`$!'1"+7C=TSTWAF\3UO(1H`R#+"Y;@T1!"H=MN1,`.A)0*`^NE
M`R'H3@PMT0?;M(ZBZ9JP`]TEP4Y\E(+@[O`%/SR(DXJ8,YI57HJ90F,N(&$'
M/;HIQ&2L4QT,H'):,$`L>LSC</M8+E8(`%K9L8<!(``#%R`3`:!@.1_DX0)>
M(&`)2J"`'2Q!!@,H`01^;HD$/*`*"%A)EP3`Q3-,X-(7R*(+&.`#!\Q'!#_/
M@\`$`(`+A`&%_%,K_]C3S8$'Y&`';[M"#`[P@1G0P'T'R``'KJ``/"=Z!X.D
M9!\XL(08&.T=XZU=X5HD`#:D`($IZ(`IA^-1R%7ARP'-006><,P8P*`"003`
M$F3K,XO@3`0[@($(1%`!$^R@0`#`G0`VD`/,%6,"2V!`#D3P]SY$RSGZ*-P+
M!'"!;!<@!=Y^1P*0H&`N$$#C,GC`8;H-IX1O#&+%\O;!"-`3HH6H$:22#Q<`
M3!@`$'^%%IC!9]SV%SJ<8`G#UH$-7/!O"`2\@>RJ\!\N'#Y4B$$3'G6^PNOE
M&4_@H:B%8"`C(0AD00=B4`55D`-SH``AL@<645>)D'\%QS&I4`91Q0`OMO]C
M&U8*>-"!_!%"'^,!!\`K)2`#R?<*!O``<A133G0,)W`)"N`E+U`"9R`&*+8'
M+D`4'W`"/B`\#U!&K94^.R<%!.`I"$``-O$!+H`HC[<$$_`/2/``*1`P@!.#
M9R`;`%`V-A"#0$$#>8`7#_`#'6``9U`!10`2(B%))H`K+R$BN?(9(T$E(@`"
M15`!+7``.$!)8:$7/J$J'E`%+M`#FM0"%@`"3P`"B.@+OA```8"(C)@$CY@$
MB"B)C2B)(%`'24`!=;")FIB(6"``+6`"DR)%!C`I$``%DS)E!^`%"8`#4H`!
M!T`%"1`"QH`!&9`!,;@`&3`!)&!V$.`*T_6!J2#_"SVA6@ZP`UQ@)0+P`!;0
M!$VPC`_`!1;P`'/``%``!0455U`0`U7`!IK'`%Z@20_@`0P0(%_6-4``!1_P
M`"B0`P<P!$,P`2/1@1HD8PTD!N\R'0_4!_>'`?E7<OMG+^SF?YY@`P$H?@[P
M?Z9E!SY@!C&P`%0P1"\A='2T!TS`0O(G'#@T`&(0!V&0!ZHU4O3H@47%!H9@
M`88&!!]@`"\`1TLP/CY@`)@#*`0``2G``D_%`ES0$,WD`U6@.RE&<Z-V!BUE
M`6=`8MZH?(?Q`"/P`3MW,B-P`SYP`QZ@%F?0#>-`1`J`5C-P`BQ0`6R``CA`
M`"S`*JUQ,$#@:WQ0`")0_UEA0182P%W=L0=$)!*[0`/9L@,','M/UP,\$`)\
MP`%[(`':PH=Y0&0,\$HFH`4/$`"MAP6?B`4[D'J0*9D[8)D!DIF9>6E9F'H,
M85QD4P%8T(XPT)D>L@1;X`4R]`$%\0$K4`5>H'DM0C?LN`,HH`(J8`%8X`&X
MR0-+4`4^@T?#)HP9>0K\,1Q+D`4A(`4>(`4A$`(ST`/..0,SL!4%D`9I,#54
M<)T%P`5H(`<W0`!I@&<%<`(G@(MBL#5A0P!((`8X@#<!,`0*D"X=B%$%)PKX
M&'^BP(_XMUX!^1Y+\`D)^6,!*"0#Z@ED,C5?4C!/I3]5D`9TX!/N@6'`,BS#
M0?\6'3:2_Y<*.X2(;Y`#65`$2S``EB`#![`#760''I!6;A0&,<@I":`%$$`F
MHS($`P`C9Q!$;N63"K`9+S!&850>!34:=G`"EH-?*T9-9&$'=W(@[_`$`D!)
M82"3"S`F#L`#0)`%?)!%*_``E+0M;[`#6M('>;`#_@0\"&``-\`"!1`";%H`
M7^D5(O`#,\`7'<`:DK%H#*,JOT665T`]I#8!5T`$5W`%&J`!!5"HBJJH-G`%
M-O`#C[JHAMJH-M"H)_`#`S``-I`!)M!Z"8"H)S`-!'`&$I,&!%!CUW2J!'`#
M(J`!IYH%&9`9C<H%,W`%F#H!,>`#"*``DR:,Q,@;P_C_!UX0F"?``R?`!]K"
M`VYG*RCP"62Z`%+@K/(F)(J@`@C)!_CFK.?W`G]`!S/0`KY`48-!C_;Y,/B9
MC^&SG_WXCQOXG^PRD`/J``89`%H@)!*`!P+Z"?-14V5@"6$@A2D0=1&(4]*1
M,6+1$YS$81J:"SO$B"```SW`=1A`1%#P9A>0!V]T,NZ@/QX1!@/0<U2G`PC`
M`!:@.63"8$_8%,G7`4]U>`R@-1[Q`5\36!_015*P!PPF`V$@8"D0.C[P`0M0
M`4T@F!P0@PB0!4?H`0!@`P[``"A0`2Y@`R1P``&P(:;E"0N`,%#```'U`$!2
M!"U0!!L`!#G0`GJ)`P70`2I@_P(LT`$D8`(`,'H,0`(AD#X`0`(X8``>('D@
M((HD0`)2@`,X0`*3(KAXFP&NF`%X^[>+>[@X`#PDD`$\<(L\P`,5X`$M(`)7
MD"T.\``0<P9EL$)D*@!EX`!_("([,!CR2@F8Q0--,A(RX`%V(`,N0#O$>0MP
M`JQL41N"VA,*D`4$8!T2\`#LX0!Y@#5C00<),&]T<#$]D`5Z2$P]P2+K\0=$
ML'KQ^5J]49\:8ZY_D)\9I:[]J7_N&AT!2I"JXG#W:IRZ,`I_80DOX`=AH`A^
M,'(/4Z&D$*PBM;`<>H8!4`<!T`.:E0!+T``?\$8`\#:<(0-/D`-5X`@(D`)-
M60V>X_\%_]`'`B`#G($)7-MB>]"4!X`2",`&6A!6.B`%7E`"3#$`(,$`9/("
M#]``6I!>XM``)9`*(A`D(W$".;`"W>(`+``"HW87`O`&#Q`#5Z$EGS``@A`A
MA08`;[")=4`!B0B*B*B)4ZR)DI@$DIC%FHC%FM@"/"#%4XR)9`P"26#&:(S&
MF<C%7%P'DYC%;LS&((`%K2=^>!"7GD`':2`%>1"A>2``!D`<TX8%B)0'`]`!
MV.()"O`#?("O<S:["R!MMXL<H>`%^$H`/%``XZH"'8"7'2@"P]&\4"`%.]$'
M5)!6HV"M].@V`[H58="M2?))#6`"X\J]%P0=X*N/XNN/_EG_OL@!K_^7O@$P
M!X*!KWBPG^P18^6A!4/0``F0"*9;KACS3C=UL-U;+_S;!S8``X8@`BM@'6\T
M`EJ0?BR`:H"E`TO`!@?R`CYP``=@`()P`0<``?*K#L,SSUK`!L0'$!N@!2OT
M1AX@!I:@`]$4<_#`!@V6"B[`!DO@`R'R`0?`Q*!1CE>P!\O4`)^\!QS`!B"`
M`=E"`!XP`7>W-\9;%C#B`&+0<V\``AO0TO\+`F_POW"\QF^,Q9CHB(F(B92(
MB#7ML(D(B9:HB)<(B47-Q3$=`&F\B6^<!%YQ&@GI`"@`,3&Y!Q%J![CT":B+
MEWQP!1U0`-K"!PA@`Y<E`6(`!=50_S6*0;X1V`FB$*!=C0#-XB0*<`(V0`,V
M,``6X+$#P%=?,@`$D(,)0)3(@@/46:R;+`:EV`QI4`!&T`,YK!N^0:[97+#`
ML<OI.ASK^LO`'!SG&Z_9D0,GD,?)S+Z,YU$MT0<]8@=RPG@3N!@V!`K%R2[\
MRP<#0+6^<``@`+\^605KU@XI4`!A@"4E<!`_J@#UE`!$I`,?P!3Q>`$C(``#
MP`5+T]SOG$TO!2-2H`5,%@/"G58(M`>;QUS8M0-Z]0(.L$=V8`$"P`&)]D@`
M$`(!8`**50`.4`1T1`,_`*Y)(`)VR1IET0E))``-T(@@<``HX`LH@`'+0XXH
M:0$F$.$1U?\#%L`#`G")#3"W"K`^O$BW0.#1&["B0]!ZEBL`>HD")SH"K,,Z
M%8`"M@8`/,`"'G`"!5"=-&X\5+P";_`&G;7C#;`"3_#2;^`&%/"(3_`$==#2
M73R)F0C'75SD;Z``HX1#R.$)89`#8,R)%/#%6^[%%+#44YP$3T`!8PZ)<-R(
M_RO4`;`"=;`!C.CF,QV/84'9N7S9Z!H=^<>?ODR^G2T+_>>LQ"S:?7"OT(>1
MPU(>VN,&"5"_K-U>ZR*!L^`8T$?(TF9#(CF2N4`#5%L$PZ0";)!58;!VWB`&
M3`4`("D#6E!((>("%L`4\R&.+U$`A=3<.O``"N`%&JP#.2`#@9?_@VS76A#0
M>B]!(%S``"9`EU$#)G;P9CF`2&%`615P!=AZN1[`M!WP((2)`U0+`%LBH(-1
M%EUR`".`.TDP&RL0``.``Q6@.:3D`0C``B_P`^S]:BH09.K#`C3`&M:A`?=0
M`0&@T0#`>@(@XRTP*%0"3!">`#0P`14``W/3`3#AK)+4`8J2`[:(`!EP3?F#
M-!0#/W-0*&60`%R0`\Z9!5)`-="9!9Y<`%E0`"Z`2\I3.,2)"J-0GQ$H"J3"
M!QHP`1H@&7R@`!H0%LC:!,/RL0G`!)Z``)KC."8P`WLX`X#)&;L4"S8P`;A1
MR\X:']2,'+I\YUP/,??'`);>Y_6"`I*Q_Z$A5`B"OKT:B@O1%08(\`&*K0NX
M`*R"@,T^IEKX,?;E.Y*:;@@+,`$2<`,?0![3/0(#UG(QX2M-L8R?X`/)Z`X^
M($UTI%D+P'26`%4"<&1,"@55)P8WT3U]()-U]1(CXMNM-4M0]`(DL$@#(`$_
ML``YD,`T$%M%P``CL?`HT`%YP`(S$1)Z!V.4)@:\F!E'!0`_$``;$*-%\`8,
MT/L`D!1I90'/K`46P``/RP-PBP,TD.\_@`$54`*3MP+9%!Y?LP`B8!I58`&]
M4WJRU@$/,`27E@`PT6ZY$`+1M`-GH!=3#0A^=`1E=(9A`@F&>P0B$@X.`PDS
MCWP*!'V/"4M["?\*.GVAHJ-]=G2AAGU^=J)>#GQ7EY`."S-A$GA\%89T>0M2
MAG\(505_?706(;,X"7V09SMV?WXV/!4P,!.0I'Y^?]_@X>+C!F+CY]_=H6(-
M#'3H\/'R\]\HCWBB`P`!.2>A>``#XE'G()2^(0G$0#H5RL&+@J)8G:(CZ)2W
M8]WH:3PGD,:!``<L]&"A8X$6)!`>7'#AXL6"#Q`.W!!UX4`)'R4&?)C@PX4%
M"%K.#("2@\N'"SH<A%F"H$^!IP*6%*CR`0,`'P,\&(BAA<`>'6<>(#C3X0:!
M)1=*'/`C0,$/!0T0[!!0(,^>#@(&\$D0A@$0!/M``-CC0$)#4*!8("#_0>+$
MQQU7`KPI`$!$BP5A#'@0(.`#BP4C+(BPX"'`"AY\.E1@8><'``"M'SS9<,'N
MK!,LG/71<4-`!0@%!DSXT$"$!P5A`*@:%2)'``$$9BD_1B"!Q!>)Z.RQT^B1
M`QH="D"R=*(PG@L>.GTB-6HB85."0JVRLZ3P%1/E"ZH0;QB/<D$#_,+0,#<8
MTT</6>#A``<D=.``12=4,<`QU7R`S03LJ>+-1N*4LY$Z?;#C#H<DEOB'/0[@
M8]`^_3@C4$!^H+(;;P;<X$,I,3K#T"D&YG&&`^KD>%$H)FX$(PU`@-#`#@<H
M-]0..2"@0P(Q*`!``3I\,$()=NSQP@4/+/&`_P\&=*:<#@!\P,4(,N@`@04G
M?"5#%0@L(<4+8E21@P@EZ(```@Q@X,,+#0!`@!UV;.*%`%SLP<4#`C#@AP9:
MF%"!!0X4\``#/_`A@0<J*"`"=SLT@,(^@Q5VV#%]S("``B9TD*0(!+P1``X[
MK+`!`RRH-D0.)!2`P`A#B#!!#THBL,<>%K@0`@9%T$##&1^89AU$MC6T!PL"
M6*#``A`LX,$;`DQ0P045+(=*"`"PL4-Y"J(0"G<)Y$'1'E48P-`957``R0`=
MS%"8`SA<,4L'Z27`A1TZ@)(A*\<@:H@?V_SQ@02P\*`!QA)PP8*_?#@`VS$^
M<"&%'9`@D,(-="#:1/\6?/!!`PXXT/#"'F(`D(9=]P%PX3:C9%2DAQJ!*.([
M128=#XHJ]J$//_X4].)`Q^A`APY[>!`#!OI:%)^.W9@B!A<OZ.@,?-/TH?0\
M,/Y01`!PK_"##B7O4(4,#!OP&@$O^($$`RWI4,!<&+QPUA*P@2(#`"YLEQD4
M,@P01@I:C.#'"S=4%D,)3G.A!=E?(?#`#2\@44412_B@`P9+?.`"RC/T`!T'
M-!3`Q0X=T(``$%HPD`<+.XA0P0@!I&J8;C.RH(`%#\!5QPXV!`#"!!"XP(4"
M$$`PP0(N(.""%!.X,,$$.R21C5TT6-"`!S3X:\,23S10!JLQ&E*00V(4P0;_
M!`A8D,`#*PA`"F0P@0(PY!AT*(,"JG``+RP``RX8`10P``4O[(`!/6```]RP
M@P?T($P-^.`#4+"##HII#@!`004J((`B?"`%C3-%AGA!AS04(`$,4,"/6.$`
M`900"VS``@!*"(0<M$``+6A7"0%P.BT```T`R,$;<E"%(;*A!2(0`0!:X$0?
M[H`-0ZP,$&`PA&P`311",Q'1Z&&T=B!M;7`$!]/RL8,`M"!J?9A:CKZ!*!/4
MY5"\0*`H]I`&*4B!"W220@'"\"`'H"V.\0B(`W[`!A"L(`<',('WH'`#+C"@
M`%_Q`086P`4?[`$)`%"``ER0`$"M$@)A@&"?7D""_QA\SP!VN,$"9."")=Q@
M"2Z`@!=B8(#FW8@.7(B!)VZF`#4M``H+6`*X-C>`)2B`!A(X@P>.HP`6N,8"
MI)E!!T1@@@\:P`1%$`QAC@>14-P@>S@@0`N2L(,?P.T%B-(!P[HT(SOXX2MV
MH($*E#0!">0A=AU$``WVX`/XR>]K%1%%'@IP@!9<X)`*V,$;5O"Z%UA-%(8H
M@PMR`$;$/8`-2T`<E,*XA"FFX`,[0,,**O":N0@@C&S0X@X`H(5"52&&&6)5
M#15@%,3Q16UV$(`(L"``-OA0!#L``F>PD(-V#=%N0)C#$G::`S?X<*M%+&$%
M<I`#$GY@"4`($^(P648%G/]1/AM2HSF*EJ.C01*2<S1('5L@'DCH$8T-4X`/
MPN`#(.DFHC>8H!2J)X`_&84+9W!&.^_*$8`XP`;I/``/>D""!WP`"3>K90+T
MV5`MW(`56Q$`WNP@AAU\0'4!^H"7,L.`)>#23TX$98```(&;$<`%"^B3#BZ@
MA0?T+2Q#J((I"U#;&^PA1`Q0@2,)T(,</(!+/]"H"1[1@1W$X!8#0$'QUKFJ
MAAG`!2:P``\J"8`K@``$`VA8P[Y2"L3(]SL6L*0")!""XYR@?SQ@Z!:>X(8$
M/$@^1))/`2*%@!A`0`H`A$[+/HJ*!"Y``%4HPQD(0`#E;M@`$.`P`=(@@!"_
MP`?_8A#`%6Q@@P*0(`1A",,`3#`#&H2!`U)('0(:U;"@/L@`&,```WX[EH+0
MH3X<((`"3N`I"?"@`-CTE`=X$0:3'7@3!?"G`TP`,T^%0!DH.\$2!@"D`2"@
M`@>``0_:B<:XEFB-\VCCB"B[MKPZK8YSZ&N*7I0C^V*@!%68R0'I\*!?[B`!
M+WA!&KR`*`,P8`<+>,$!U4;G<`@D#$`(0*50,SCGZF``,;@NW2@'@8:58`EM
M`<4>ZG0HK`$@!F7S`0,"W3`,5+$`?=@.6N9[@P\PP*,U>4`H2B"``Z0@RX(3
M@12^,@`""&!C-%C`^O2"`"0^P#L3`,`/]O"#'FS`>.5U_\`-FID#`;Q!,!HX
M-SZ=(=_ZZO.Y24D?"(J``+RHP`:$(4`.;/$`$!2X(#$"."MB5(`YY.#0IZ#"
MDGRPB@-7N`Q<$$`*,/$'.@!@7P9V1AYRH(@]_($`6*B$#:20A?$H0`,*PD,"
M/I`HLE&8%`_RPQEB("8(+($*$T*9L!UP!2[DAQ8S&("_'(`"AN0!"DWI1K6+
M88IDZ"8!&>_#&5(PH3_,6``-@($+V`S7I,%9'H+P`Q[8T8-V#@0@E=X("OB@
MBH`\[0"X%KL>042'%U#!!5!H!I`64H`8Q$`*`UC%'PK`"5$HF0%B>*XSQ+%'
M.'9#'0-X&TCLX:</2($E!``4"_^@8`(QH'H"7N#"!;R`E(:-7@$,L-$.FO5J
M"`0Y!@L@@`RJA+5>?Z"8,BA!,&7@@01````R^,`E@D\2'<Q^`0P@@1\,L$(+
M`(`$#'B-"$C0[240@'8*P`(*%.#M:$@6>8[T00&D$.H5/`$+"K#5=A@BI!QI
MZ#M-","24*`"&A3F$23HP>\#\.\<6<0BF0($&\`#>5`8"+`"[^(=QU`0$K`'
M(<`#>Q(GH?`!#D,`RS9?`G`!=2=ST=`E85`6!6$'+D``J]`'"0``8Y``+N`P
M,V0,!)`"5;`$#"`%A041PM8'/J``)0`1+G`#8;`'AO``D+`'>8`!3>$,)%`%
M,]`'8=#_!RK@()!`,P_"'0#0A#J@`2(`-PV`(?_0?EXW5QKQ#F,70L<C'VB7
M=O2P=GGT>$\#!$N8#H_W>!/3#<C4`#<@!?:R#9V$`%R"0(.W!!#C#&?06CBW
M1^WG9DD3AWU``S#P7F\``\_U`@F0`CMP!CH0!@C0`)AA.!<P`J3S`B4@?`UC
M!P5`B65S!BZ0+V<@B2)@?5U2`"+P":`800D07P-P.E)P!GM0$[#4!R_@`K>G
M`U_"!BD0!B_`7Q;0#WQ```^`.R]``\P8`#8@`3:@`$6P/&^P`WQ@60KB3\=@
M`%3P`$7@!F]`C@U0!P'`!``'A^<@`1S``W`C`KGC'97`+D50_P=O8``+&(>/
MYP`LL`)O@`/8Q@86$`8TP';W!0D=8`)*51XQQ@"(X0,7P#!8DP*EIP,$,!B[
M,0`&(%Q^PG"@0"5[(`,FH'@9DB-Y(`4"L`)C<D!_\``Q=@(N(`8^4)-<0P`#
M4)/6=P*X@0(64``LP`(FT`((,`,AP`+TUP%0UP3^(P,D,`%$B0`0P`4'8"O9
M<`=BYPUI-#1@2`]B2'9EV'9X@(9IR'8#T0UM^(;3P(_NMPV2P!T']%N]&!_O
M4``LUQYY(!=B@`J/)TAQI(B,&`!#T`(PT`.#0CXI<"=G,&M2L0>K$&H%4`+4
MTSQA<`.>%0,=P!T?<%,7X"4R\``&X/\#-]"12U!J)1`#`A`#2)!+E2$H8:`#
MCA8GPK(`*=`H+O```"`%.L`!%K`#E](I)]`#.\`"NG,%'K`#DF!=#^`<VLB-
M$%$0"I0"`?`$_/<$3Y`$;G!@&[*5X+`@7/!>`0`$!U`$5F`%;``#!Y!IUOD&
M4@`1;$EP<S`'&@!P"H!24J``"2%?RW(%I"$"0```#[`I!_``H08``A"@`?H&
M*?``'O`!Q!$#'^!9E'B93L2@,>"?M<4%B.%C#Q(&6U`%S>@"9T`1?P``&O0!
M3N0%!#H"$<H`'H`!!X!!I(%%(B&<0P``/0!.!]<#/7"<%X1!'@`$"V`!"R`[
M,+`!0S`!IS#_$&NY-E\G#U])AD%SAF2Y-&;Y>,D1GFKYGJR""@7Q!Z``"3X`
M>TWH2*K@`(-WEZ/@F0K@F*F@#CSB>'TY`#`0GA:@0C$::#>0?-Y3`BIS`_IT
M!@HP`ITQ`"5P/7]W$XWU.0702S.Q!R7```C@!3-1BC$P`BY@EZ!I`@9``,_D
MC1!PH%!``&?P/P-:`AWFE"@@!C/@`2BP4#T#!!Y`C0IP`!50!E>``$5`3V:9
M(F<*)&=P`0``!"E`13`X!P+PIH@H#@O"`RV@`#S`!5R@`M2J`DV@`CR@2F90
M!09&$>^I%!/0GK-``@*``DW``$T@`+M!:!PP`0*X`2T0+"=0BI%9_P`7``$W
M4``WT!OX>@)B<`&!]A0@ID@W@`0+$!XE4`+-)`8FH``4^3`:YP`,H`4',`=X
MZ`!YX`?710".E@!/40`8<`$W4`*1>5TG4`(LT`,NP),G,`&-50"DZ@$9H`%7
M0``D@``:<`8G8`#O4I,SL``^DPU`R*3<^69=.0]1V@-A*7=5*@]J>)9^D*5N
M2&GON2$5PPKR97PF@`D]%@J@<`,5\!4]UK4?0"3I8+9_V9<<D$X-8`$3\`,3
MRS"26`2>^)I><"7=X`,0D`.[X13&QG`3$@!+,".S5S9](`4KX`4E<#EV4`3-
M``H/$`!>X%$OH`6CY4\7L`$>@$]V8&O.A?^#3_`&#)@5%M`'>9!4?(6Q#M`"
M.^`,?&`!;R`"')!'OIH.WIIHI:`A4I``_!A)11@`;+`"#<`&#5"\;'"\Q]L`
M;_`&S:`A7(JFK%)Q]J(V+V!]SD`8)K`!,-```G`"26$'$&EJ,N!16),(H.`'
MSN:84=N18>,"BZL#?E`G4[(`CAE4=0>$"$"\$(`1X```H.`#)H`$JJ`#/>A1
MN[$$IR",MF0*=E!M-[`*=*`"(8`/#@!U$#%U$[('83`<:::D6=FD2O.D\9"T
M2TNE37L.3_MX-+`/!["E;,DC#K`'3,!'^N11"8`48_!1^N1.8=MN78(U)""+
M[U`_E":GZD`#;U/_!";``Q-`C%XP*#WQ`=;1,%S@`A?0!TLP`EE,`,8'H*C*
M"BZ0@9\F:QY``&$0H!_`-VA20A!@!P,P`)ZU+(F6`LJ7`)T1`P.02S&PH%CB
M-R)P`C0P`+53`5R0/DTE;'G0`U@`58RD`@$@N_<#$/7[("]`9@5A+W^0"&OY
M>/!0@#-0!4!0!`>@!3DP!Q4K`*5\`*I<B?S$I811$>)`:5.A.G8Q`3``50!P
M`H9A!P"@#C8+;]B!%!/B`REP,Y5<%O!K!USPOLOGOP:@`#.2(6%0<<QU)QG1
M,GE,!J#@J5@2"C-I2O!+@5CS`EX`S=T@`W01(WY@`0XB`1)``CA`A!@I_R&^
M2`/F4@0-8`+P2[3+2B(B#`\D/*5C><+HD,+=0`-+`!("4[7=H!1#C*9?X25C
MT`$3N1MCD,,]!K9BJT^LD,<#,`1]PP3K1VAOI#2*:`-UBH`',`1^0'B-XI@7
M\`$E```&H`.4DP*,UM(,`%/V>@!B<(E^H`-`4`4-8`![@`$Q4`6PMCA[``#Z
M;,>EQC#^TVL/+$"^U`DB\`!:("@[_<!V<`+9L$67Y0$KP`8WX`#3]P-SX`!G
M(`(-(%!O@`7^XB)CF6M`*#%()74R<;:J``_Q\:7J_`?;`-BB`'!<R@1%/`Y(
M`P0NX`.$I@`KD`1)T`\%D34%`18=(+;X@A0Q\O^"]9L97-PE.H@U=O"9I=TH
M0;4<4U@*A/&EW_``H!`&,F")=O`".AC1=N`!7OL"7(``%#D%*],E=,`#(>`I
M#I`%>UD*/P"3^VDN!]``+M!V6MG/'/+/Z$`18ZBT`FW2[[D1%7"E!YW0+;P<
MB@A2`V`O=+@LH00<>Y##[=TP8]`'EDF^68LU.C`"$-`)#$"@!BH%W<TA(.(,
MF!8`MPP#(?`5I_D!6/("4/"?EMB)GL@*+Q`#,6J,S`61;HP!47%:"5`%(Y``
M0'@!J)8'6$,`4*!#K#4"#:``B3:HJ5,*21@#JO.+=*)/'@`#.U!8!8`"+?``
M!-`^=50O''`%.`0`L3O_U[YZ"H8E8T8V`,W$!50;V.@0O8)]8.!P#(+M#.[G
MO'$(#D)"-3SR#J?)%#\P`0U`5D5P*=MT`#'``!"JU'X7`QO@71@0H$6`U'[W
M&J'&`#G@:VV^`T60H0[0M3/2,'VY'-Z::]W@7:$6%9[E!<7E=P\`HS'@!0P`
MZ9$R3``P!#+HYE7%HQZ013'0H!7`!CMM`6,%!%DW`5;#STYZM/*P'.S@`6R'
M1B9<(E7KW>#]!RL,$G&G(6I#,2&X`+B$Y5Z2:,IS$\:8:,S^)4=Q`RRPK_DJ
M[0H`!'?M-$-4`/_](:,0"4FB63`@`"/;D2D``*5Z75Z`KPWP`3>0`S7-"B<X
M_P$=$%\Q@`!+L0,WX`4I0"40$-/(U@<Y<`$^@``^T&%_M@"=M01^R@9]87W"
MN"8+,)J&HP4%8``'T*,QD)$BP`(MX`'3F`<X,`<_T`$PEM`@(-<IIR`8$0I,
M3@<#L`;U`80?LNWAX'[?`%<,G?-!_0(64`0BP;TBD`,3@`-E(0`&$.TJ6"/Y
M6BXE<`:C604<Y@-((`.Y1P`]40`GY@.?Z0,DL#"DD+6Y#E=]X`4Q,@`R@`F[
M<0GX)`@Q,!'*#`&\<`/XGL`*(#"%0?*0@)$5P#"+>&8ML(5=",)?R"&ROCZU
M;H8#722YKA'?O8;>T.MPIR[J[/(CYJDCB#*[80!4__\2$$#UGN_Y'0`M2#3*
M(U#ZIB\`=5`(>7`#O;27-,]&HQ!0WYY__FFB->EK1@B;5:#4I2`:<8(H@`$`
M?8($ILX&7'P&5"G\.N!@A^('"9`#&(#O+]`!+S0F#M`\(W`H2'"@>>PF59`"
M"U!8%!Z+?(`#PK,#),`!/^`!$[!0:*U"6<`!"Q8`*+]G1M;087`&-H1(4@`(
M?P5]?X6&AXA]BHM]>(B%?GY]D9*,EI>8?2\Z+P@Y#1LB.SLG=GTZ2SH.?3X=
M+Z=Y50FJFE5V.IHL)3JW$R5^JAVI"0N;C#K(.I3+?G^*D7U>BCX*@Z?5/B_`
M#[A]=BX(WCH&53>J?CPA#A+_$@D=?0X.)P(^IS09%0=#+HIXS9&/`@HL9$#,
MP("3^HAIX($/(S]X'!T\Q*SBLHF'*CCTUXS&D@`'"CB"IBA/!RYKH#Q@D,;!
M'P<O9$R`P`#``@4N<KI0P%.!A0,5EBRI$+3"AP=+4KPIHV%!E0<W!NRQB!%1
M)44.:!P(4&3"!`1:JES8HT/!`5)V[(A)@<!.F)A0R29(L:2`CC-+&B#89,?'
MCF)]'W@8M.>G&&0%'@C`\.(%D@\?]KSHNX#+KA(?1LC8A(#-`0(<:,P0T2.,
MG1\=*B#(LR=$@QUY'-CP\`8+!SP.(CKP0X=.'P()7"!U46`5O*J%,$5<OER1
M[ZL6_Z-;U+$'GHW4%42(*&!*QP<'R`C(&*#(S@@IU/L,J))L0`)SUVY`D['#
M3H<%>4PM2J:,ZC-)TK"BP`V*Z$!<-L!\@`L=>4"A0#(7C&".,CS@@!4.%CI`
MQP]5D#<&#1,`4$0#"DCBSQ\`(2=002HZ(\E"#3T4D8K25:2B1HT`%,9'(8UD
MB20.V$%`&0/8\0<=O-SB`P*[(&.)'04P\,HIN.C@FPX[N/`'``T``$`*.R1`
M58M7P4,#$"`T8($`+2`@0PH)E/"`"0PL8)H./N2PA`\`)"#&$C?(\($!7.QP
M@04+^#!",:?XL(`+)2A0@@D?#(!`%0I@:D`*"X@1@P%IZ?\`0`PO0.`#-0Q(
M`8`'PI5P@0!A(-`""7OP<4(%'IC0PQDV5!""!CEDX64"'@`1@&VXZ>:,;P9`
M4443=M`1;1^]U<A,)LPM=Q&*UG9K2CSKL*""=J78\8*"R)R1P";452'%*YQ4
M8<P>!MQPBPX0E$!E`DL,((,+R>R73'3.3`(@,F'(T&19!+Q0G0X>5/D"`P\B
M0XX8J^B03CP2=-"!!'N<!D"1.M#`@P`P[-///\VT^`B+*B8$HT.+0"1159F,
M616.'/WA$4@G2$0'-+Y1ZT`9#Q30&SR]42<%@?^U+,@'83RTB!U%E.!``@IP
M@0$&"Q2@,W)E2O##`2`$`,0&)I3_<((+`%3AP0T0`.""`018"D0*LMR@0`H"
M0"5#%6'=0(`)F)900*0IC`#`#214(<`.,K"@&``?Q`DW`C<4((,6`"QQP0US
M"9#"@$L`(``#);#0P@X(G-"!!SD`X4$',\0P@@``A/!3#@!@4=MMN>$F";/.
M,K#*M'1PVZT?X$:?R3,/693M]<PELXX#(:C`I@D(0(#`>6Y2"H'X"!3Q@0)2
M*`#!`>$CH$`,#)P/`:<DG/^!%C1A<*_`R"#8?Z*!`/E]``,%?),+SD>"!(R@
M@.$;@0@0\)4>,&0"4IC`#GH@!01DX`$/H"`"7'``",Q$`0(8PA`:X(+>G"A%
M+CL$S)`C_S.&T.P9,Z(A)L8V$9[IJ`)`$]H_$J*A3"4@9"ZB0SP28("B&<P0
M!?A`'JA'"$FDH0I*U-`>I+4*'F*D3'L8@`!`L8(``,`H*=`"&^@"@!%H80=5
M.$H5AK"#FE2A""-(R@=2@,<EQ&!_.4"*EP[0@!%`AD<>6$(5#G"`#PCE`3DX
MP*B@H`\`/"!TC1O!#KRPR!'$(`9G%($`2`-)+5B``2@0T0&6(`(+`*`%5=C!
M\))E/*,E@`$[X$)OBJ:?Z5F"'<`,IC`E8`=PI25(>TBF,O?`@68Z\YG0'(`T
MS_"#`>!@30>P`$\0((#S(6`!2]C)5]CP@:_,I`CQFQ\#()A+&?^<[P%:D`+8
M=G.,@?G'8-&00@8_L``$-#`%"U2`FT;@E:],3GX(L$`1>O`5!.S``QG(P`0$
MTT$$F*"$$"#!`K;RAB$\B`XOE%H,"6*0F+W(AC*Z&49R9B/D^+`C%7A#"X)F
MB"I2*P\#R`,$,'"#V!2L$@:X0"\I48@T/&"*!7-.'Q"0`&\4,UII(1B9&.$`
M#J!L!3``P09<@($E=!,#H(R!"V(`A/5!H`H84``#1(`!"'!A=2Y0U4Y0*%8,
M","L.X@!3[PT/]!Q00&0@8`,\@@!!;`AA#1)00<%T,UP5C0').C``]A``A((
MI@,DJ$D'#,"#%B0`!PCHP0-6@*SBT1/_'F7`I0"$(I0/A&X+L(VM;&?KI=K:
M]K:A8ZUN<<O;WGX)<%703@NT(X(0O"4,I`I9"1!P!H>]0`!2((L.PE`%LFC"
M`,6Q4KZ`88<++*&[`.M&@>QIHP%ZP4HOB%,R%-!<LMCA`<2T`P>T"3('L$`$
M+*AO!G`@`3[PP6,."!D!=N"#\`#@#6]@X<JX-5(9EA1GE+C!"CP@`>,83*03
MX0T1T\`=:@UM-T?:PY$T-+2*5(`#EL@#"MYP@*`!I,34*D`9SH"``2B1$""6
MA`^@0`5PP:-E::":31<1!BZ0F%I(OC`S7$8216@E`#!`@0@.X(T\]%0'!."<
M'WR0`/+XX0.2_]A#"7Q`AP%`H3A[((P?,&``7MR@22XX`W4*0(`^%"!,WB``
M`7SS@#)P0@H^2,L9PAM4'4S`%7ZPPPWH0*\<F,('-EA%")JPBC`4(`]T4!<5
M&E"%/.!A$9_FC0XN4`4VO.$)`7A"$I[P!!`D`01I@W7:`D#K`,C:U;!^]:UW
M#6M;U_K6`4A"$NK`ZUWKVM7"AG4==-V"XC@@#Q5PTI(*C(P<2.$6=A`C+QPV
MNBHI@`#<30``7G`!$_!"O-6[EH<IT8/\N(=`R(CS_RIPBF0R@!_@N4$1+M"'
MZDR`!/'8`PXZ$(\RYX`\?0`1REB("VT1E4PM$\.#5VH("<,W'L^(8?^0J)4&
M+NW@#*MXA4MNX*YB1FT9)RX3!X`8DB<"*1*D.\,$R'-D21SO7_5(2-&,FH=*
M]*807.NB%T>ZC(1O!0@\0,$!CF2',_B&QF*`1TZ;]X&KF>(%/-60-L##9O`T
M!A<+(`#"XE&`/@5\BE^6`J;S4"4"<`$77T>``9*9;6\8(`>*"%FT_`8/;RAQ
M2`I80:=)LBQ)&$``&PCVL)?-^&6#8-G"]G4`B!WL7%N>UKWN=0`2+_DW;'X#
ML_9\VMZP`<]S/@!E)'WI/[^!%K0``"<`%[W-M=R<.Z";['KNO71P`_B4)?;(
MZ```1FV!_UU".AF/!C+>G0PN("$,N+`#`![_]H('+.!>)1C!84SQ;SX$&$-[
M"/`9!%"D/M@``0#0QP+"KRT&0[P0$H]9Q5?P@&(:!\-?I%8D"%`%(%0A!RXP
M`##A#05@.FU1'1:1<HP0!BPW""B2'-]R`V50>T5#3R7F!^F5`,CD''Y```]0
M'<6T-%$D!2>W+0UF"$7W9$A7`3`@"6%0!B@"=?W69;OQ`.5!`%63!UQ0''T`
M!R^A`SS%"6^&"Y9A)08`<F67`+UQ*LT00B_P!TQR"B7P=G005'8``7/'"PA@
M>#F`(GIF"@6@`$M(!;X!'!`@>#U7"<X0@C>0&9D10JPR%R3@01.P`!E``C@0
M(CU06:`E``K`APN@_P*110(F\&\XD`#>TT`8<D88@B%[^%D3H`(X$`(AT`$,
MY3$X8`(B@`-9T`$3@`(*D``A4``>,'.LT0?1)AD^8`#LD@>PPW:LL`,#L'SU
M$G<ET!A]P`(5X"]OYR3'1Q640"U;\`(^4`(RD``^H&<8(`8LH&>806<$<`-^
M=`,G0#HCH`!B0&<6H`(LP`(%P`,\,`/=V`$"P`(W8`#7)`#ZH`)[(`'M!T-D
M$W$3-Q$W,P/TYWWWYS+5830#L`1>D`8*,`=<D`=,8#32.`<8EX`<4"8_TW(U
M97,OD`8X&!7/@63-@V1E]P!DAFF]<0-'Q1M,H"'D@`$"N!M#%T,I>'03P/^"
MDN!VBD!C!*(!'Y`&BF"#ZB$%2O,"83,)"F!R%D`@`\`%LV`@3<(%,M`'-Q`F
MO%$&!D`M,1!=#I`#"(`,4X@,4!`Q$'`!4X0*DU`&6M"52D@'8L`%IC!@NT$`
M[=,``I"&DW`DBQ`A`3`$7-$"6N!&,C4".9`#;*`%KM<""08$#<`&QL)(10`$
M*]``0%`$19!@BED$902810`#",8&@<D&:1*89=0`F@D*&[`!*T!Z2?"9")8$
MI$=ZH[<"&S`$(%":IU9Z"48!'?4$"/8$910`GF>;"4::;I":J::8%N`#5;-#
M8P,/>:&9":8%!Z`%;Z`%0'``0#`"RUF7RBEX.:#_!5H0`+"4`R,``S"0ER+0
MG#L@`@`@2U\R2BV0,FQC"N^(?QDFCRIR,V+@!BB`CQG'9,XQ8"/S!S?P!FY`
M`(40&PEP``BGD`P)`"`Q`X10"*MP)%)P9@X@!3%P`QIR))+@#!BW!U2P`PJ0
M!VZ9!@QP!J;@!V&P`!^@-#[@(B?)9,'(`<;2%170`)-``%!0"#[P-.JQ!&E@
M"EXP-&$@!32)=8OF!PI0"';`!7-G!PH@`\BP@[A@`A<@"'VB"&50!KWA!0@@
M8@)``BWI`I'@`@N@`W*G#7[P`,Z0`'/@#,?X!W9@`%KB`&>0`KQ!``8@!6J9
MABWC&W:P!VW8`A\@`"[`_P(=X">/TSELRD2]AU8%X`-(8```4"]T)@.<LSA9
MZ38%,`$YP`(:<`4$@`(><`69J@$6<`4G0``SP`,_8`,V<`\L0`,T<!TM,``<
M8`,L8`$L\`.LZ@$DP*K5Y`&3\0)G<`$^0!9A\`&T$@D^T"'`,``7<`)^$#(R
M$&C*<`$5\`+W$3"_>"TB10</\&P#X(UYX#`30``_,!EVP`"\0`<<@`$N0*XE
ML`,=P`M+U0%YX%\&$`+)A&4/P"X<@`,5T`)#8&Z-$!$LHZ+P-X]?A`=BL`'S
MB7%M:9\TN@0+,`EAI)<_-P`?8`O58F(+N8`-F*"0P&@,D`-<8!H/``$B)F(H
MDO^@C'!%.6``')H&C)(&&#`"7-`,16.G2W:"*+BB604#*]D`O)$&4.`;-2H?
M'8<$\!`@EJ(T87!FO"&&**(`;89U4]D'WX8,"P`!@J!8+Y$`91`)#)``=I`'
M<U"U@R8)H+0'6=D=`.`2=^<,$$`%DC`#;5H`:%`(ZA)X`J`-#VBA*'(#&)`"
M#"``,F`'+;,&WO`")P`!($<=```!81`).B``R&`N4G`!D6`'<C<5?H`#`E!A
M$L`!G+H]-&`!X'(XX2<!>4`",^!]',`".4`#9%<!W%%5#S!SJY`''E`@/O"L
M<`<`[%4U8;`#;P$>YH@,:KL+?7`'':`@%X`!^RB<ZM;_L,JW!]<!'PZP`#<0
M:/U6'Z:P!S%P?<5$``+0E,54(1S3`3BPC_PW`)%``R20?D-P?0$;4@3[!_$W
M50E[8@S+G@?!"$+B1U.T"GO@>3B)`$"PHQ?(#`JX""O'8D1015+C!U3@!1]@
MK@M0N"\!"8I0,'DP10/@!1L@;&Z`>G7P!'.@`&^Q2T8B53KK/)+``5G5`#_[
M$@2PKG2P)#<@"#CZ$E[@#`.`DV6V`&GP!WD074/C`D`IE,J@``6&I%I+<E+P
M$F40=7[``&7@``20`IMQ%URJ`S&P!"_@`D?D#?7W!P8P![Z1`%*P"@6P`,P"
M`&'P!VB)`&K)MRUS''20`!:0_P*!V\6^@;C*X!XVAB15$(#2\@+LH0IT<`$7
M`!YT(`-*TQMB(``T,*\<(!C;8P,HP#$G8`$2L`@D$'NF<0(P6AVW$GOK(``\
M\`(YU0<B<"_3%GTYH`"<&P8CH`W]AEW0P%R4<`&Q_+S6^B/WU`S10$QAL%EZ
M]VU2`1X/("V2X0'0BPL$<``:J`AWN`X=TP%I<1KD=POP^TH-8`+L)[#N1R/N
MB<X*L0'\6S/PF&%)9F9DV'=^4``QH(ZU7#0+3`D-K`@/W'(=3`A]D`=,E09<
M@!1U%KTI.V)(9G.,A@!U,52)IL<NK+-%]P(SO)(P\!(O4`:-4*-BP"QAL$5K
M0&)20?\'+\`%07H&3+<`+,`+85`U.K``RMLP#M!Q3=4'85#((21B:9!S!!"Q
M>%)@$&`OV@!N5=@"BB!-L5$`7.!A!L`;&I``"+`">]N6-@LD!L``*6`!(M`!
M8P`/#L`-J]"[!88D`%"XT),'TW<*Y+9HU"(#2.`D"2``]K<''A`#QY0'RD,#
M$G##%986.%"[$G`"+4`#_G4"'G`"[<@'%3!S>E<!YM(7)/#$>U`%-986EST9
M>Q`&M=@82OP";_$F_O*EZ)9N2U8S??``/Y",_G0&9T``%K!9)?`#,P``9U`"
MBK,$'J#;)V``!S`!BW,")F`!,S`#!6`")G`")U``!B`AO>?_.P)0!/]:SO;[
M?OAKL/_[(ANP!#<T"3E4%1K&-$H5+3#F87VG9)2``C2@82[X$4`P`Q9&$GG@
M`P-``&D0!M72/(]`,'"``<'Y<R\,<=!P)E`V`1ZPT7T1#F6&DYK@`MFPVKZA
MIV0VHDJC$/JGO=31;42)##)09W?FT710`(/P7@DP10P`-6Z').'3"3<@71``
M#R&0`[XA!DWI`$ZM(2&<9PD``0V0`R_@&\[`+=2RU>*Y&`64``G@+@D@`S40
M`S6``!UD2()50`\D`S+0H*DBY5[03S4@!0]P`!DD/P+@+@4$`2(@`PHP`5P`
M`.$C/M8GY6Q^`#WA/19@`FLN`!5@_P([(2L0X`(FP`4?X"!_ODI0\.<N4`3J
M6MR0`59<D`)>``48``5M1.DN8'R6$!!$-31]L`0@U*<B4`%>\CH[8$DBP`85
M4.HB4`1G,0H[T'JC(`*NQUC?>1:B@'B2(P"1E)IL8]T#VV`SA#,H(@8K@",U
M$]Y5H2%7X0`C71[38C!!\AP5P=[NK=,\(M]8@15[O`!@_@%<L&?\W=_1865%
M\\X#WIX%#@,'[@%#P!L%,+29IF4=5P!'\@`NZ.!`"@\FZPQ<P`*:@`'H8;5R
MM@<N`'`XK2%,"3U/B6EEBPLE(-067!9'Q`D?X!MEH-1]H$^)5@"7[@=I(`#.
MD`8)L&E`+O_D-L4;AR("#9`$*J1"#1``FJE"<3D$;\`&LDGS,/\$#8!@.$_S
M0X!J/O\&H2F;OI9XI$<!.T_S+$]KM]E1MDD!<FF;6N5Y*Y`VJU?U".;T'34$
M15`'0\`&0^`&.^^8*S0$J;D"!_`$7\\&8/\$C.0"R90)FMZ6)>95H@0#6J`=
M.P`#C+4#HMX`J>0EK/X!1!%3`N`!#U`!C.4!'M`#H\0`#&`!'M``]!,#KL2=
M_]IPYFSN*A+L%(<'$H8"H7SL*H41QE%IMS0#Q10&/$`%?I(W'%J"D4#M%<F`
M!VH<;BD9::637F6R%2KN%8&G-L?YYRX012?#,-\#+*@(-["C?0#_DZSP.,Y@
M@V4F`S29!PO01'30DT8\()R0P;@09]>```[0KB38!TKN&^O$H27D\!@P"0QP
M7@K0`=*U!&M\IADO!7Z0!V$("`Y]!`)_@V4(#3DO='V&AG1^#A<8(AX`$`0#
M+SY+86$O)3($H"]>+B5]`V%+/ILO%P9V+P,R-WLO.B0C879A>1X/>30O+QA[
M>7L$$W;)=C(E#KDG6CIV>R46!7D2>PP3/Q(.$B@Z.JH)!'O7`%)V?;Y5>WTZ
M>P8WYWU2/G[6%P!V;KBPHT-0GX,(_RA<:*B/GS]T%"X11R-$`7$2>)P@P*$;
M"C[B^/18,(X/H0Y\'#@@04("R`X=""JK_\)/E8D#,!J8V.,`C\^'?AXR'$IT
MJ`$Q19,^PC-CQ4>$#GTJ+6JG$9TP"JH`.)/'P9D517)4V0&@B<&@:(.BH.&G
MD9\^K`(<F&'0;1\'"#!`B%'F@8$];8NF3=N'CN&S4Q,K%HS6`8<#`4"L:+#B
M8(%C='Q(N4&'P(<;AAZ\';"9SHL%-^XJ>+?'A`$=+Q3(T$''Q1EZ"B#02;-#
M2A\F"<K0<>!%"L\<$'*=,6%N00P["#J\H+>$B9\R6@PG\$VG`!>'!78T*I``
MPHI%C1ZA[7,CA@`&*1#L,4>'@;D^FL_0!^#B!<$7*?`$3P(&%&:'%`72DT`*
M80CRP@,,.&!.'O\,O*,#`29(:$X"^!!4`!#^.7""!P7880<-*/!``S+DT',A
M"0.XF`($Z[PEP'3UW'..#A.D0L\%.[S`0G+O#!9440<]%-$?$SE``PXLB./`
M`B=H0$-*%:@$D@<52B`!`2V$,,Y*"(R)`PX2%#2``/S8<04*&[PQQ$X]_?3'
MD8L5=52>"CF"QPU.20"5'U+E.9Q!:2R@P`!T=$4'%RFD<0,".U11521&KM66
M0W!5(!==!PFB$AUG2$$%`@4L0$!$#C!FY!^"#)<DG[0JE98#>4`F5PL-M$7:
M.Z2E=H8"/A0F6A][W'#&50L44%@"#D2R0(%[=(!/'RX08$X'8O21!@#_"0Q7
M``%M/6"<`U#<8L<9+A24``+0=9`'/%0T8L`<XW'FAW<*^:"`2FF4IP@CCA2\
MZ04B-/`!)KD4]`%M^"%``$$Z[*#`.CH,D$+#.ACP&CTR&!"4'?_DTL<+,4!A
M#FQ06$B`"QKV(4,!UNAP0Q'6V#'B#!(T\PT-$G"#@HL$R.`#07:(0*,.?@`X
M';(WE"@A`B4TTL<%#`[IGT.O$C7KDDW2T$&4XU!IPQY>5F"'`W9(P*5*#A"0
M0P<N.7"F`R`ED`!!#MA`4STT3#`"#$-8,)]/>``E5*T*[<FG(WZ(L4(%?`Q:
MZ&(.M-5(&@C<P'9A="2P`A.F+5#%79EGRI9=_W'-9=!!P\U3D#[@`F:'JX,]
M<M>LC/>N$&$<`!&`3AXT8-@>:2@4;&$%K-/'`X7!\TX>7'B.GR%VN(!/QF&\
MQ44)YQS]!P%+2-$(,I$\@$`>X^/([CDO]`*!+.;$4=B];^7A:!HNW(D?'7LX
M@PRDP`;T%*PAC>B``(;P``#(IT@/>XL/1K$C`"R*:78``&W,<8$+1$L'!'*1
M`0)4LP5@(!_&.$=G5G,0'5"0(&(XP#KBQH`3C$,"%I@`#3@@B`KLZ`P)\,%\
M,BB#K87A1B:R!SYPH8#FX0)(/K@`!.Z3I[<H*2A+N,(5"C`!$IS@BST8VPQ.
M,(,=G(`%+,@"`"H0@O\0L(`$0##!##J0!0M8H`,)Z``#&(#'!$S@`!`8X`0\
M,`(@;,`"[T"<XGSW!\?EB5-9<`/E+(<'/AEF.)W9(P'8UHPEY$`EU,L!Z(SD
M!TVQSE.N2U+!>#*``@P@`0H00QX,@[NTW,E_;W$$(QE'&!H(#P:#--Y5Q""(
MY>7!``WR`_14LHI&H48E$X.'`CQGAQ+H1P<FT)8.D."#/WS+-P[P@0\$49Q9
M)@`)YB#`=W10@!O880(7V,,\#&"O[/CA#&>(ECKMT#0IL(T`[RH@P=232Q8\
MH`4`:,$'%*``!$!``+E1``:6H*B&CF`)7(!`;K0`@8Y"P`M>Z"@"/L``!.3_
MQ@M`,&E'=S`CCPI`!AI=P`X\^E$,1)0!;&BH`BP@@`5,X*<BJ(`)%/!3`?Q4
M`0OX@`L<*@4MG$(V$``"0W.S1Y4"@`L.54`,6@`!F^9B<8E!"T3>LH0)\,`$
M%4"!"=8J@A[8D0<J:($)[*B"'`C``FXM7@5X8`$5B```;K7`#G9@@3U^H`@Q
M2.P#=I"3#2R`)XJ\$UAKY4C%Y-(/@/K`.Q!"J$H^#G5[:*H;!`"`'+AA!3Z(
M1!Z@@"_#D!(%8=C=06BPA```H0"BLF*H;A!+45FMEF)=Y$%VR<OUY$%X19@`
M"H8`S=78P0:VL`/Y;N"'/1PK#*7)`VH:4:_,<:%`_Z=!@#E,<!L=0$`^)5@"
M`N`1BX-X03XZ$,!W!L$%[ZD,`A=XV@<.8@`M'"0!<H@$`19PNS-401!I*`,!
M;S3<A]1%@6\004]9<()V`N`&&$X`!A)0@`*48`<+$`.&;Y`#,13@!#?@01--
M;`(2S$#$"LA!ARN,`A1TN``SJ``!.IR`'MSX!#S`P8E/,`$VD'$&)*@`"5AP
M8@]8(`1CG`$`9D#E!"R@`Q4N@!8L((8OGD#&5"X`%3(0YAZ,0@-$%@"2>=`5
M48W##_S\'>@6@I#,/8``/Q"S%,YPA3,\X`($N((-SI"",_S`T!^(@0_P>0-`
M#N`,`U``#WQ@@P%T=`#B)/^QL@9PA0R(H`4K4($XHO*0X=[ELHT01$,6@B<Q
M(*6*A?$#'-SP@-3ESE!MB548#/```0A`"P(H4_XF92*N#>8!`U`)0F@``-OB
M%@^MVIUA2F4`9?..N-BN8F,>$P`8H'4('.##"50PCF6P(&-+H*XI')('#CLS
M-7Y0P%O"X`(Q7&,!Z\56><^K@Q(XD+^OT8$'X"O?MZC3(<[!BP'8UX</M"4!
M!XB$W@JC@?GFX71]T,!VV,!@7?[A'`1AP0X:@((=D(`G#MC#P\SA`XDY1`=+
M4$`O8+,#M/$A#SCHP#CLL.242"`$6*#!#9M@%I5PH`D2@#:0I62W30HB"T`8
M$P'_+'""M8G$!`/@0!\D```I_0`!5U")!+`P`0Y`FP\"2(ECH`RW#-A0$!U8
MP@"RH`"?PXT/>,![+@T"*X=$XB!;.$@8Y-"MH#3+!XSPPQ+HD#,O8,"U`QB!
MR`@E!_-I)P&P.^(`F$8#$F!A#AM004JBTJ?"=&5D*J3#._[^.Z&XFD]OB<2L
M:TW*S]J!"6P;3A@(D`8Q;))K=WF!($BIS&2_CMD!*`)=H-V(S=Z@"@U@`QOD
MSL\E9?OZ4P$>#$``!!+T8`5>*D`/5/)U,5P(`&+HQP<:\0(IP"'E&$@-'2[V
M\0G@XP4,F*(.;(,;\7X+`OT@`PE0#PN0`*#P;UZQ&O,'_P6A96^P$@."8`"?
MU`?;`1Y04!ARDSEGH&!A,1V+0P\\,0,>(``F(`(G9R$>L",#(#%,HP,6]#0O
M(`+A)D\Y!S<($`+O(`$*)'3CX`'C=Q<TT`-XYP`%8`*"HA(DX'1],`-1-PXC
M<A%\P`$5H`!"MW4[8!`V`':B4@498';CD`-:UP=\D`4%`&UX<0(<H'4GD`'B
M%@)7<D-;IQ)F^#F2,'SC`&U#XP!.D`!B0`=XT`?50PHZ,`9+@!!VX`5F8!!G
M,`=E$"M?@`-P4P8Z!V=K8C(<0`(BH`4KP`7*1BBE-TOP0`#6D@>;-0\0T7H*
M\7JP)GNT9FNV!&NODWNC`F>2@/\ZAA%K1H)LUM8'R,<&RR<H5F0'#.!`L)0#
MZS,OV)>,24$8>5`$(``#".`!&Z`2)\``?/!<)&!OZ05OBW<RI;$'\3<<4G!Z
M+@!>^6<.Q$(/$R`#U:1>J@<!2^`!,:`%5;`$`*`(#[`$.W``2[`$!U`$2S`'
M`K`$'[`$*[`$4/`!6A`MVQ$)!1`#AH$$5X@?&Y<#L2440>$B+-`#=V6"/`0/
M'M!"82`#RV(-2P`!85`080``+]`S.A@"4K)D@L('."`"/"@23;`[?"!J*G$%
M$P`W#I``82<.5_!)XW`%5*<2-#"%-L`':),E*F$#4G`%7N(`(H``5Y('?+`#
M5^(25,;_!V`I,6G8!QW@`3;``5?`0UHB=G'H9F('$HZ!!S3@`:`$![BE$CR@
M"4,4DH*0!TW`!6OC%0*P<"J!`XVH$EF0!5)"`R+`(C2Y`RT0>F?A6;`3$%``
M!`>`F57@3@X0!G]P.Y*5BJ^V&+$G:ZU8>X\4$:&X!$50!;+`$Q#1'3O``+!2
M)+EH?,M66[[8$Q*P.`[``)SH$.JU!YZIC,;)$+?"!Y!1!-&X`2XQ`#KG`#Z9
M(`FP>3JP!J.R"9V)`<[B!QJ@$-GC3A="+GZ0+>>`!//A&>+E![R&`3*0&PCP
MG@@@!?,I&RH%2PB0G]LA!0JP`Z*D"LGF+0MPBF6`@?2I"-V#_Y'WT0=9X`$Y
M(`)`L`,CL58'P`48@`%0D`+`R0`FP`95``4,L``+``,]4*(,0!8JT%>DA0%V
M!``K0'0FP`4YT`)-X`%-8`%L@%=-<%`]8*,6(`+QV*,H$`!-4`$>4`%%```/
M8*1`@%`H8*1%$`PHD%!+\``HT`,@,`<5``!<&@`50!85X&L`0!9L@`5<Z@$H
M,`=7B@)%$`"1D00@D`04$*=U4`<44*=U2@%)8*=S2@$!@`58L(\'L`,BL`,K
M@`4"4*@`\`;^Z6N3L0,",%AUT`*#M0-68`65BIE8\*!8D`0`(`(B@`6@Q@8K
ML`"<19E0\P`*,$M-(P8NL`]_P#ZH^/\'JDB:L39[KBA6560UTN!)`A``<A>K
MCD```#`'4-`JQ*>+KR.%`;";T/8.T?('"9`#!R``;U`$!?`"Q[FMK9>1>X!<
MP91R-'`"%,$M$B(%F]<'V#D<I-`'><"=#@DKY9D:@T``]+``J>`'2)`+ZLE/
M"1`#%V`.\D00AM`J=Q*MAK`I"L$$!9`"<W`0^"0(`Z8D.("!V]$`<Y"@?9)+
M.A`"(R@`.5`!%F`""P4$7O`!*)L#\?@`7."AB<6B1=!7*J`"%2!4BK(#'J``
M:X4";,`#/)`!$Y"H)C6?`B`%&6!2#C0!"$`"'J`"#94!7-``4I!S%@``$]`!
M!M`!%?``2];_`3BP`UD0`AU``DV``VVD`3F@`%Y6E%^D`5?`$H%F`SPP`S9P
M!0/@:6E)`U?0`UQ0E5>``&G(!U>`$N+``2H0`AQP)39PA6#)`5`&EGR@`'9+
M`U=";AC!`Q,@`3S$`2*0!1V!!SA@!)#;1DY"`W(+$IJ+`UK0`!M@%DF"JA)8
M(%7Q.050!0J@$-H:FK0ZFI9UJZ?9-8^D$K.0:"_@`@+P`03P!_[Q!WNP``<P
M2YAR;+AY$,SJBSX1;8V0#'M`'A)EK[3`K<9Y*QS0`F[*!ANP`20PLBKP`#ED
M?\KP&<+)?E+@+*M5`(;A3X"Q87"!`>*E;ZHQ127P`>)E!Q@```40_Q3Y$!16
MDTNP`Q6Q:6`+&92^X0=I\'B-!`"MX@,*AK$:F[#T8`<>*P(KL*=PN@$$8!\$
M$09!5#,Q4$1,PPI`,PX&P`*!F0`V=!=?"S02$(3DUK@+@!$:\"]@Z0`A@(;C
M4`"?Y+AL``)QRGV1>A$2,`!0*;@X8`..00-5`+B(DP-"!VTSD`5PF0&;!)8X
ML`2)JPI.)B4GP`5:YP!!##<<X`%9D'=N?`"(PP%E,`/7RP-7$,-NDW1YM[4I
M@0=7H`4)`,AWHQ(P80-8``,K,#P-X,@;4`>2H0*G6GIY080(X`(,534WL`-#
MT6J\&U96!"@HD*MXLABL=T]+X`6`<0-`\/\&2#&["L`&ZA"]::&L"%&],Q`J
MT8,IH',#$'`+U@>^MD)\K\AJ&2F&1?`&(!``0]#$#7``3/P&@]D'9W!A!_$`
M\FN_+Y`NA3$0RJL`U+(`,D`/V700$P"`2(`)S;$#-%PS#?S+L<<I0?$Y!O:?
M4B`%DL`_T7(&(W`0`&4><Q`C0$$/'VP`'B#"3`P"3_`$+[`$^;""]DH/_#$`
M$B2#UX!S(8`ZT7&$(;`#\\(V-BHJ09AT$C`#G`@W4O!V2QAU=M`!;P"GSZP%
M$G:7#@``H?(#&7`%?0!MMMO&')!V7L(';#<.300W"2``&"$!*A"<?7`%/"`H
M@Y`A7A+'D`@2!##_!Y7CKGF,.CR0!2<@=!(`E2Z!`D4GG0<@)GW``1F0`7"#
M`R3P`\(3`&\0&2`0J2O0`CTU>HF3.`<A,0O0`"S+!0LP!XNR%;`RJ[5J60M1
M`"OP`:@\6=FG>G?B`TK*3WV``$"PF956``^0`XR"RVBAR]2KFUG`649B&`;`
M``D`F\:<?48".E8#%;`S'';`!S!PCPUP`L_\!DWJI@T``+)P`BEP"SI0:R?3
M.2>3+E7!!?/0O*_Q`A:@?^;)(PK0!^FU&CH@4]?"P,M\&+5MVZ12!3EPOV5B
M!QK@`L4R`*T%4`A00&=P*7=A#6B3!2B0`PT0&6X:`'GP,!+2<JMB#0O%_P\Z
MX`,:[1()(";C0`(,[@`=L`,-$H4,D-8TT`0@P0?>`91)B#<B<@`<D`<A\,AO
M$"<A*P#NU#-=%Y53J90B8`(-XA@"`#1M34<N268^)P5!I[DVT+1PJ0$Z=(T%
MX`+&EP<Q\-KKH`%:$`;R%`9E(`;RM`=D8`"N5`Q+D`QY$`8?@&QY\`)I``3H
M2IP,-0"4BP-2H`'"4^)Q$@``8`(;L`,F,-5`>4ET,,Q+4`;(D#EI$`-I``7.
MXG$+45F)86P%X`9+,-F6=(MT,```\`&D^`YI(`!L@++FC0'V?)N[R`&HC3JD
M9!@#(`8Q8K"QO8Q&PDDF$IBGO@<AG@>)JP4J4/\$;$`#D0$$H`IJ0.`7`W`#
M'G`#_```7=%NN.4#,0#ET%$C)G`!=F!I"+`)W$F*\=D'!1!SQ>`"Z78.#`PZ
M0'D-41[EA9'/AB$&!I@L&#``=E``#!`_`)4`6K`#`]#ECA(&E"8V%=`"!\"Z
M#;#?+E`%`@A3,:``"2`#,C"0+B"?+=!%)(``534!"E`!):6T'J`%"@"T$X`%
M5ZGP$R`".&`"4F`"[8``0(L"*C`!&<!0;.#Q*%#B!]`",-`"(G``%D!4)M`"
M1*6S#\`#"&!6_,@%;ZT`+<`%)J#P/8`"/M^?3;!6"H`"!\!0)K``@!KG$R!8
M1V4&#J0`+D`%5:"J7$#_!2[P!A#0!0O0!0^@JCR0[R)JH2XP`B[`!2[`6CE@
M0ES`!2L``%"0]FBP`V:0H@"P!"90UXSZCY3Z!EAP5CRD/X]N(@IPPARV+*$5
M`V?@!:M2S(TSRE-ASX5^Z*BY&*>&*YW``,19%=*5`F_P!FP0`S&2))B^K)MN
M^H-A-9L%^:..G*M]ZG-^*&WC)0-P`!XP&33PS`T`!)C9`"T0`P90#-DZ'0\@
M3XO."`.0+M&2!G[`!(`8L,J@+8!8(H/P`GYP`C$W'V*`&M:.$)<$E.(/-]UN
MWH:1#..Q`!'A![&U+MO1V0/`!+AWB^9@-SG`W_V=!$7P!-$'"`TK`4-L#6Q)
M_P%O;P$-(!LK*XN*`0%U3QL!&V\@;IJ<((MO*W5`DW6;E96CC122;TD@LB"5
MCZJTBYDK#9!UHF^ZE:F5*TF3P(UO#8P!D6QN25:&G@>";,I%16Q:=7-`5D"1
M!P=:;R/G6CD!.5IS![LY.54I`0<I:%@'<V@[.P<Y.YC1B@5C1P`!%9IP<,#0
M`9V'="`4X'+@0X(\"00H\+&$0!\Z?T**-"!&I,F3(OOXZ=.GP)LE#OS(G.D'
MI<V4?_HP)$!@#TL[+%\,*'#&01\[=%32E/E@`$.6?3@L"<`FB\Z82V6R7)GT
MIM>O8&]F70F5YI^94!WL*=)B0P,2E9)L@"%K"``6.O_"&/#11X>7JV?"],G#
M1<S'H@\57-!9H(2./BX<][E!0$>))1!87H!RXS%9J*"WCNUSIDJ.I&<(&"7`
M)>D+`ZL32&&3(TQ-KCKLZ#90X4"`68HN>.%YI@"$&SX(G`$0.4QJ`3]LV/B!
M@(1T&Q,ZT)">0<"`/`-L/'A`H[R-'N5I%.#!H3P'$B?:TYAQ@,\>$D-F@2@B
M0@0.&GW84($#$O!A`PE7$"A!!1G8@`<>$F"Q$(0SS-`0`AI((`$>(>S`08%Y
MJ&#"4S]DT)`/4AA%AQT+&`:4#W/8L1(?,Q3`D@,9$!#&'GO8$0-0@\701!X,
MV9!#&0[@X4`"1O#A`!\AA&#_`QNR_"9+"UB\`4,+*DB0Y(,T):!`&&4\D,`>
M"=P0AA0[V.&`'2B1%%9*9!7@!DQCS1F2'TE]I-)5#D&4!TMT."3:4DT]Q9)4
M5%EUZ%(?D963GI16.E96(FG5$($P#%(/""L\$NHC=]EQ@@<&^*'#%A_E448:
M@V%P0Q]HOJ`3`A?0L8<",@"U$4LD]$K`!PKTY0(`G?WY*%JA;46::2R5D8!1
M9RBPVA(R$B`;&P+8]EE?#'6P0P-6!O!$`#YXH(-//D!0F0XZ8/;"'CJ\L`,-
M;^;100=..H!`!RSQD0`6?+C)00\6-$2#!QPHJ0$7#>'1P0E>.C"#%@1VD!]P
M0[20_X4$;@+@P$(_3)"@DU@HL-"3`GPH`0<A6$B@`@1`:$<"(E1,0Q,+-*3!
MB'CT08`"@_IA!P-(`G7&`41&5<8,5_$07\45>,G'@@]4/.6T2N)@8K@)<```
M$"VL<``0!V!!5S,)&]4L`0N4T<>\*][,10)_`!5G27HJY8>=>&*J9Z$J]C&`
M`EZ<H5,8&"RP``()B,%74F,EZG944U5UU:5;X53IYV"-!II,>VIU(Q^.:)*)
M"CL(<(``(E1@`0MT$+"$&*K&4&@8,A1`!^,%&$W%"W_L`<$%]5H`P6,TPXL`
M`CH,JP"\"^R0[+=^EX[ILSFPE$`"#[$6$P$",.&'M@@T,/_'`%K5]-A'.*^P
MR0J=MK#'!WWY,8"[?>D```0OD%$>1(`O!^B+7V]"``X8(H$."*!B?&"`"IYR
ML)6=H&<-2<`)&C*#.;RI``*8"Q#0M@(!J`8H(G.2#3)P,@=H9"%7$P`--$2#
MF'E)`C3K0\$Z((*&<,`"$_32PY+D``*PAX$]2,#+''`%('#`23"S4(&DQH$G
M+NAJ3ZP`"OAPM0$``0=.XH,13%0@'/"+"#C(0@LZ@`,6S,`##5A&#Q05&CL4
MX'%2D)847,"``ABJ#WNC5$U"4H`5?``K2Z'41Y+R)BX(8`D^8$@8<K``+RS!
M-`]`BM]H8CFH,$ISRS+=9R8%NE+_VD1TA])>6O(``[E4((0.&(`!T#,``I``
M+\LIP&.\8)072,%W85B`C>A@+3KH``(&6!<#,@.9=T$@,R7XP/+ZP`7K>08J
M$`FE6;CG/?#1(0U<4,D`!/"0,R0@?>O[4TAT8!0=A*`"+0"``'KP/`,<K2]]
MX-T9DA(O`*IJ#P#8`T/XT`'8%.B6#0D!P1C8A"8T)$0-.8$"^N4`'%SA1@4X
M@)=H0`(`**`#"6"!!Q;P'0(]H"$V0$""&+*##-``#TYZX$"S(#,^T$P"+^T0
M##F@@@E^Z&%\J.()3#``\_2`!-NYP@R`<!T-?,&B&M!`$SI0H1-<`0`GT,`)
M9K`#`%2(_P@A`((**A0"%?0@2AWH@0I"@(.VMB`$),`!"3P`!#9LH&UC,:`8
MJ*``#'`!`52X@0/^X+9`?NYOABR<63)ENLZ5[B<$B,$"PJ`;G?Q5EHZ<PQXH
MEQ4PV"`M(ZM`HXR"2)JH)"<L,:5J47(ITIV$63K)`Q!`\)8*;(`A!7@`D7@G
M!@>4P'H..:0?PH"`6>5!F!^APIO\H)B\,&!ZD%&<#A"@@-I)TYC5NP'E%IG-
M38ZF--WK@VSH<#XN\.D,`CA,&:2@O@&HD[",%"GL@`"`\<3@`5IH0@\\@`(1
MH*`'*/``#!""@@IX@`T`J(""12"``L,S=CNH0`Y6L(0$CXV^`/_HAQ7Z"P`1
M'```(`9`#K#052P`X`W]V$$.&@`[V,'@=5@0@`!@(((=,/AU.ZC"#MR@!0&T
M+@5OJ`(6=!R/UNV`6U5(\H1S7`4!L`$(0MX!%A`L@!BS(<8R9L,<JBSC#6#A
MRR)H`99D;(5XP$X$*X@Q%E8,!!'DH,H!:+,`<G"`,K]YA'.><P!4'`\@;.#/
M$`M-T'3R$0,60#5D273I0B(&OEFJ``WX`%"V"TB3,&LE-0%)G\A[AKM!9;,)
M*()#]N""\'I7)CVX0M!(2P/1-B`+1%RMK&?M%=.NY1$D"$A,!B`%\J[)`$>A
M@@^`PH"'..`,[-L#%,20%&#3:@(L.,K_#6S4!Q,XA@X^\`$=SO`!Y=(A`0S0
M;DT6699!BH6;I"E*$1D`E)OI2EOL75]70M*'56>A!R,^0`54P(4,F*`%/)@`
M#U2P;QX8O`4[4('!30`$@QL<!2C(@,$-//`)H.```5<`#ZH\`1((O*4*4(`*
M/)J!#$Q@WQH?^`JXX/$>"*`)/-"X``"@@I#S(`<00$`&N/`!+N0<`G/`C!2>
M=P`%4.%Y#(""%*@@A0=P00JR>4`.F+[T*@!`"E`GPQ+D@``I*.`#7<=Z%1@`
M]00LH`AAEX(9N(`#.21@"7_-8P*J("T#S'T'";"[%`Z`@;R7`0,,2$`(#,"%
M!0P^!%+(@10&_X^#)K2@"&]8@`[H,.AZ-VMT@G-MHT'WMTC+B'1^*K<HH0*G
MA^C$#F=80@R<\I`\0$$+23EN"\A[:C^D>M4Z:?5HE43KWOO>M'R8[1`R`(#;
M.N`U*^'U#?B$@`$PH0]KX,H`V)<'!C#;#P98IP*`K8,3E&`ED7E,MH6VA.KZ
MX0(Q$'=.3"^:KZP$O"PY@^+635XZ(.`HYHRW8"K-$GM[(`</T%)%A5,`0`-5
MI`$9,`/FD7`_\$0V(`(VP$7O`49!10(A\$0"XQT2Z`$>0`-<M#,>R`=#A8%\
M0`(9<C4S4`1<)`$%T`,%@$4>P`,V4#$H4"B&@P#[Q"<>M0=YX`=[4/\;+.$J
MVM4'3"`1ZV<``&`K*\(%K4$MUO(1!``!2/$F@;<5/B!J01@Y$.$"E+$'A/4!
M*^$F2W!221$&19``I7=.4%$&<K,2+R``LS(8.',`;V`!_0<5E7=Y>7(6@[1Y
MAP5IDN9:?L(YH@%(F!9;+C`'.1`##"!U.2!8#A`&"I`"DS86MT=H#J![;&`A
M0>-[GBAK-/$D!P`"0W!R&V`T9P`!>4`'RD<:'P`K??`!.?$:@N5ZLV)_2.$'
M)B`#]:(`4F`'.J``BG,S]T<``$`%?N``U:1^Y-9^M89NWQ-_YE5$Y-0'/G!.
M#0"$IW45+/%&.=`$`$`"=B`!+($"*$4"JD'_(`#``R%(`_?R)!R0`!V@(7R0
M`1V0)'T0`@+`14_2`SU0(/W(!RQ!`"-2,0F@`816`#"`!PLA52?0!R_C`5Q@
M`PS!`15`*]B&@RM"!VC@`GF0!W]`!U7@A493`&F0%$R@``40DG1@`&V2%"S2
M&D`Q`"[P)V>@7':P!TQ@!K"1DWE0!+2'$<!6*"Y0`#?@A2_P%W3P`G3P`%Z@
M*W20!VQP$7PB`U1`*-_C-GDP![Y#!QSP!1[V!AAPAV1Y>;6W:'_@AX_F><IB
MEJ#A-F]2>J`Q`#>``=JPB`4`)-LF-T%CB:J&B2\@6IN(CY]8F*5D6G9P`')A
M<6\0DG<$%+]F.`!0_Q(.`!._DR8.P`2%P1(0X!/'E`#K\E?PP@4>H0,)X`+;
MM@7(Z`!04`7,R'Y*X7[0"#[Z$TX.D`8ID!0$L%[9N'_C]A06@P+?N`,3L!`Z
M88Z41UPU@P=T``!<$$`&5`6#PA`)(#<ZD28/(C$YH"$F98Y&<3`;(H)-P)T.
M8(*$=@(-0"`.<`(](#,+P@7NQ1``0!8^@"&D505<,)TN9&P.,&TR87]ID!-^
M(`95P!"%XCB$1@#%=A8^\(2%L@;.9HUL$!-'80!QV`=FP!,@Z0!@N$ACV"<#
M<`!EX!-^,%Y\PH8QH195,`!(P0$XH&)#('F4AX?:="EHJ9:"!(@^L4A\HO^7
M_)D4/K&4]/80?+)9\&4T/J&?(:$6Y)45ETA:%DD54-.)AEFE>F):$E`$25"*
M%3`$25$`&#!8Q%4&?N`#.U`21^,FO.8[>X`!S$9,Q#-='>`'+[!,*\$%)=`7
M8B(TS%$H#.":Y+5^?1*;SPA_XB4%*D$`9I",9Q!>:6!WM+%_]/8@.C$#4F<"
M/8!`#%$L@)0'!C``(>D`9,>#2<$``C581KE(!@`K#I$%2X!3065P1,0'/*`3
M'%`B3T(@(4``'W@%+1,T5\`%&I`D$J`"2!54$L`#Y!5+>\$0]X.&A/4',.&L
M!8`$-F@`GP5(;\<GK(@!+F!`V%9=D5@MTQ<&`_#_`%)``"_@`V60`SQ1``6`
M=6F0!C>P!=]3!@;0(09@H0G057JG``?``,^3``]0?L\T'H7'``S0`%S``!C0
M!./""V/I!Y4W:*>TAYKG:#D::3MZ6JBW`RF0`DFF9',VLD=)2B?A)H`$)SE!
MH:)'$T]JJX(YI95FI39;:VBQ![/U!@P&`ZNA`)`I!261!@`0H`ZP!CD1!FFR
ME%`0/`Y`!6[B!RX@`W,#!<O#7,.8`!#P!P6`!@J0-V9@/8':C(1Z;H8Z=`.Y
M`(35J"M!``8P&^E4LXHR`RC0`CD``G(V8F\@L@(P!T4@#U;W!E`F8P+P!O(@
M8^,PL@U0!$F6`BVP9SH6_[&$BP5>!A`KUCI5IH@^-F<@T#IN]@8M(`)5(`)/
M-F8Y0!OQX+=OE@-+\`:O,P]5$``Z)D_QD&1'!A`Z5K@Y!@!5P`9L8+N]*T\9
M5@2\>P]%,',5!F1+@`8@-@(YD&$`$'1+\`$?,#9+<+T`\`_5&P,Q\`8`L`8/
ML`8BFW10T%50L`90L+`\LP!@,`>T,`3F1;$T6K.6AK%]J+%7JJ/T&P8WL`F_
MH`B#P`S91UAO,EB%TA4,L7Y:L8J%XI>X%UI2:GDW.\$7*Q.9J`4!D`B:\!"O
MP1)*>P-(40;F*JU0\0)AD#=<8"-_4SPO@`!BH!L\`2_"""]GX`/G@ZX?80"<
M,?^VL.E:9@LM^;0COX,!<&('D51+<A!O`S!O!/P@'3`'>_8`'?`A2I(P?#(`
M94``KB&PH$I8```4#H&OIE<&S`9("D613J("%H`O.N122G(""/!2WG,%7H('
M6:`%'\)$)C"L2J(`_T%$'B`22KM/?Y`'`O"+@.0`:,"#'^&?R2@%9Y`W:0D`
MWD('C3-N!)`B1T$`"+`'*[$'30!LJW@#.3!8^50&U$8'5.`[++L$BV0'/4#$
M,K$T!E`H=@!U@-0'^VIZ/H`L#T$#8%`77/`8%9M:K&6_C(:_<])Y@6A:?\(5
M?8!US6C!ID.DRG(;H3&HYL8237!1@+('KA9MQDS!$PS_6P&#P=Z;`UYJ.+!A
M.$)+*PD0!D;Q`"OA`..W!PLP*P[@.VJ!*WTQ;2KA`J5)`"6`>N6W$@D0`]<G
MJ.46.O!W/K#B!V<`!2%I!U=)&KPY!_O'?U<Q`Q6@!18```A@G`Y@CAJ24G1,
MCNLX`!M"`R*0QP(3`J1E@3I!4-)Y>@Q@APQ1IT!"`#6I$W2``XI#L>B):9%%
M;7;P`2X@SRP!`$G!B@B@Q3KQ/TSY)@(P:0Y@H2I!3,%3H2G@$TRP!VMW(]6R
M2&<P`7WB(\#F$#[`!E#AJ8;!$@J0!F?P`BOAU(4VAE`1HME7*+)!6O@*U).D
M&G3`!S@09O!;EA9K*??+>?I;_\V7<\!8!Q$&2EA\P@3L]T?.`A&-M<U]T,TW
MXJSA#!7D3,'FK$.SU0`3X`$;0%@3(1AH(E@WL`0V\@?T;#A+^P(8$#Q[(`5Y
M`!00T`%YL0#3-,-[(`/593O(:`<8(+;8C'D.#2TEB@`Q,=$LX0,ML!J0JM&D
MW<1],`-+``0>$(X"^3(PH2$EDHX+H@``,C+W<D,A,(]/@@,RS1`&T"UDP0`]
M\-8.U;:UNA4)D(Y]H`$3&G]-\)!'T0-CTA"NK!,#@(,WL@-4X)NU`1$W,"M\
MLLI0X9*#,A@,L`!]X@.U^GX30*%',RV%<@9:L%ESLZ]NX@`;P>*5:13).(::
M]`)SX/]LV)<`9+&O;UT%3*E#.%,.8VEY9'E8C?V'GJ<53SVH*O(\3T$G'W$6
M?V)Z*](CSG$#9:`F*NO9H/W-HSW.I6VEYJP6&/P6'O`&*G$&/\UKAA$&M#U8
M#U"&2YL'9G"+F;$B")!,+^`"T*,#+B!=':"*!/``$/`0QX+A?(A:92L6#RTM
MUVT&,%R@0B,;ZK/12WHC.*`.6"`")C`#6U4``*`!!*`!66`"(:!5)R`"39`%
M&E``62``,T!3,Q!S)W#K_?;J$I4#!7`":5``U_OK)R#JMUX`"8`"\'KK+I``
M\#H#!M``\&KL2X`#R8X";CKLHA[M.LSL\)H##&``\$H`.7[_`V)0`,\SKVD0
M`PGPZVF``'!HDC<P'M%^[.A>!@SPZ_#Z``IP`VD`!V)P`";YZT,7[EZ0)D9)
MM$8)KTNP!=&>4<4%KPI`FB89<N@^`[S>[!O7%A@P><5,O\N<Y&LI:>M'XYO]
MR#S^U(,5$T1J@Y],EU)0>!E&9RDPHHZ%6E_>$.#<".+L\6->F&7.!X^[`B?W
M!KJY`(?APK&4`D?9!R<U7'4N*TE1++JRYW:@VYD!Z)5Q'R:P;5Y`W<IH/:<U
M2`WM?@\=C=C6&M@F`*N!=9?>W3?2!UF``G.`9@+P`/ME`4#0`TW@`0^`$!Z@
M5MF(`GMO`0VP]QSX91:@]S-G5CT`_P`-8`8>H%^*V(AZ7P10$`,8\`%`H-\*
M6P4/P`#ZQ0`@4$D,H/E+P`!KT`3_(/@*"P1KD'1>P+H,$`-0\`8"X`5."04K
MD+Z?#[(QX`4,$'2-&`,`L`*`QP!>T`ZS7_I\Q[U+T`*-^``QH`4[X`6X'P,!
MX`).Z04Y-AX,``33^P`?``5L$`,?,!Y/AOP,8`91+/VF<?E0,+Y0@`%K$'D*
M"P9'!GE&;^1&#@A_@H.$A8)^?H)B8H:-A7X%#1][?7YT='U[/CM+2SN?.7.?
M.P([!9A]F'0.!0HQ`FQO`2M:`A@)!'9_J96#?7U-5[\.Q'L5`0TLOWV.S<[/
MT-'0B'[+O_][!P%L)#U#?ZP8#G1Y"3=]/@`%?0X/E>0W="]0Z@XNQ'X3!GTO
M"Q`Z?BX(Z+"30($?`A\@K..RPUPB1+M^073FYTR5')42)*AVQ@P=/P/F$#LC
M1PJ;.6&6"2+FH,\,#SEZ`)!B@\8`&CUHY`ES1LJ),&'R?%!`($\>.SM\A+%C
M1XP!IGP2%'!PU,"2/"WM8.#B8`\Q+JOH^*!"[!(N8GG.B+SD@\N92WF@9!C@
MP$Z>)JD<#$C@(^^2!%@_[LB3BDZ!4^*DO+5#Q\`'QG3"+%#`<H!"<0.DK"*V
MP,`E.B'MI-IS6%P?%VG"B*/C1:*=&!@PV0F3XRDFC;QN&&@9><?_'M%,0@#(
ML0&#CCYXEB5G)NU0HC^+F@^")"D/G8A]\J1I4*1(@P9LV'P/[Z;([E^8_(3Q
MLN+-B@-5'O!MN2Z]1%_`A*TK=BR92ND`!B@@(=18DTDV#4R`@C=B:19/.>,H
MX(,=?CR`B0X$])7'`F+\8H`E=D!@@`XO7##B:27HH`,2-SAPQ@,(I))`#/`\
M9.!$S51T425II&')&0NL\P)E=IR1@!0-H/0?,1(XD`4*.32Q!`X<.-!D#Y7T
M$89BB/2QA`(#8!(&`%CYX8`!%[3D0`(=8F)`%7N$A8%'F.P!A9H$N'#)+[@@
M0D<:17S4!P$,I/%1'@\HD-(J6U3C@`\(_YR!B!TI*/#"(0+D`:(!YJ1"A:%N
MDOE+'@PLP-L9>E;C`P2\V<&`/JF<<4"7+Q@@!GUD%'"&:'0LD:4=#S"`B8L'
ME$&-%%(PXX<!"?`V@``^./!'5"*,L$&0R"GW"X`31<=M))-4(HXE+Y1A0!D:
M)7!N&66(H=%OJJ22APL"M'#`'#GDL`,#5(@1IGV]"/)+,,/PAXPRVPZH\,+/
M%&B-!-FLH.`&J;PP0\7EU"7&47U82,P``V3262H$@"CB0`0(=)I`.IR1"T(Q
MG@F%&!_MLJ=$S^5H$485$8`)D.OLD2P=!!B`I)()K\.'`R$\D(,%,U5)#`J6
M@*98*GXL40-A?_^$@88=Q]DQA3Y^X,&FP&548=TJ#$!1B1]V2DLT%^CUD<`9
MQ/2A00/55%3H+\`JP/4?2Z@R``(^]V%'%8+OXH``<8IS@T-]?/J')0:D0$E7
M4"PP+*JHK"JH`S.OTL<`!Z"2!Z=[*I#&&7L(XFLU=`2;91@')'")'T>*FT`9
M>[Z00PG2YB&'""T,L<!QRV7+7'/=,B(-1-1=A1XF?[Q0P`S<=S]#`5EP'P('
M=C"QC)@%&+````+,@2\G#,0`1<@X=YF?@7N@<#!]#/?O_W3V&P;$0"`Q%+R!
M+1!8Q0LR1H`%$.`7[8B'`=21!PQ<;$WW4,`%=+`'&:1I92JZ@`SZD(;_)2"`
M#G90``#$<)Q?J$A%>7$A4R9GAY9P9$=].!<F"("!79QA!Z(I6@).DI)>5&,=
M?1##*YKP`1SL05-V\$!A]N*#2SC@2T?)W@["()L+W"H57J30'BZP`[HPI0D8
M8$IV7*":09&E+@XH`P&>V(<;S"$/7B'45+KR`"X,X#<.V`(>]W`&!!0`*YL`
MTV_"`*T7Y*%$!G@!4!0@AC"\P`=22,$<?>"#&#1A`)R\P0(XZ8,;!(23!/!`
MI,[@@PMHH01G.$,)I""#E/%0707P00$`4`("E*``2_A``5)V`RVXX#`^4``7
M2E`"4RJ@`&*`9@YD<(,2A,`$(P#"M9B'LX1!_^\YWHH&'O#P!SS,8`5+J-+Y
MPB"#`+@3!`$`@3SA*<\`\,"&CG(`-58A`0)80``K>$(=*/`&6%'CH`0+F`3T
MMX(LV/!_$%V8PX;!`03AX!B5(%0UMM0A'RRA`-^PT#[*H(X]<*@2"?P%!"Z0
M"0PHI`]<>*#=8D0`&!U'A2VZ$`R7<9P76&`).5@"``XPD!MBQ&X;<0`!N/"'
MV>1`-&DX$AMR$(:)'/$7-_#`"!J0A#=L8`@->$-7W>"&-SSA#6A]0QW.ZH8`
MF'4(LI!%`.!J5G>B-9[M>:=;-R"+)*S`K6\`05KC.E@*L*&L:D6K&]CP!&0<
MM@%/6($;-M!6-XRGJ_\K$,\*DO"=%="5#47(!AL.``3Q/`&T0`#"&X9P@`-H
MH0@!&,$(<G"`#6A!MEH8P@@$((`J".`)%\F!`%I;A2JD@`VUJ`(`JK""40``
M/,'T1``$\`$`+$$`(_#"!SZ0K^I^X`$-6,(#EE`!$7QG"":HX3CQ\)"<30^<
MTA,G.<V)3AI(0`+,Z(,.Q%"!_OIW"2CH+PI0L`02..^(C[K`!^;P5WFN8`Y+
M<($!L*+/@R(BH<]9Z"P<&K"(>E@Z$UT'#0X`@@T@H`(KJ,8-A'4Z*3#BAXRH
MW2_V`@^MW,`2$(B=#CR8"0LHQ`\QU:\,7("AA.B7(3G5KXI6\\(2?,`+.Y#_
M`@L$0+F=_0)9)&/JHP3P"P*4P214M:H+S^2%4HS@`QAP@0)<P#@(*/,!DZ&"
M`JK@!2X@0`$0R($+((``!&`@!GR&`)S=C(`>M(`$")B``D0@@@PD>@(B(,$$
M[CR3/B,@!OWH,Q6*H``I9(`,`%```J20``!X@0I2X'.EI4`%0"-+"@)8`P(2
M,.L#\!D!,N#"`F@I`R\@0(2Y%L$%+M`!&3P@!AU(P`4N;0`TD2`&3D%3A"=G
M`!(`03>+@``$)K=B*7#J!L`\#+B#>9@2N%(!ORS!FG]9`#6S^P8"$`,!"G""
M"=1+><P;9WNY!=_FC+.<YTRG#;<5!AH8W.`@L\$5_\(P`(9S@`857D=-\94"
M\7K`!"20]PN&Q1@+7U@_&68HAS],\F]>5<1%`$$#2%"!-_S!,%Q@#(WI<(8E
MU.@!N]C+K4AE#@<@0%,[WN"0I'`<M]!AQPK000F6``$_Z(`+`$CR"W4@CN.T
M;+S3%$,57K`'H_))#I4`TBYN`$0[^,!H4ZWJ<ZH!PQO$(`<,`(`,7O#"#XAC
M#P200N+L$.J^*`Y.8+/#L%NB`Q+H0T59$`$?JF2''O1@:59"@5<&Y;;5X&(_
M!"@";PB5AKS$0%&F6<(1,5G%O^<8;GX80>`%SX+C=+`OQR&CU>5!MU_X0`:!
M)X`_5.0JLND`=;/G%-7MX/^"$]!]#SIHQT!T(#\8^D`++.53`E[8;/TZX`4"
M*%D?.)"!%L!@`Q80S7KW#>)^2^/?]%V"??6YCJY=X?WPOX(&3J`!^:M#`M?I
MT@`8T(``-/8`%>!09B(.:E)A%H9A@F`'(M<2)=>`#1-`HP($\E0$0+`"+Q<&
ML!(&Y;`.4C``&Q=!D1$F<=$B?:`.1_=K^G48F.`"9Z`BL(0A-J4#%P`%4O="
MC+$,=K!4HU4%4H!\7M<'L<06+K`+0K,*1H(D8;9VUM`!`A``````"7!\?O`!
M2)09>$,,2T`%ES(`?#=U:,)[)-!ZE(`#(B`!>6!PCN<51O$`5D)S"E!#XG`W
M-73_#@UP.14!!25S"?Q"&"T1`X71$V$B#CQH!Y1@!Y!C!R]@!^#F>I%R1`D`
M)RJR!QBP//I5`A`@&BWSAL,`!:T'-B_`!KRG<RU4?'1W'!\P=5[``/H%A+G3
M)7WV0L.V#,*#!$YG`\?@5N'G`.-GA_RF"/$%#>@7<!R`!_2!B#>P`<B8C,JX
M`2"0!!,@+7W`!,3P<I=0`#C``Q506VB%7`!0,A[W<??15,?04!WF@.9((!"8
M'3#05_`$-R_0)AHX%7U0!@Q7(:@`%/LP#RT!4A0R`1ND=#+%@L=!`&$`@P@`
M-@9@`36H(J7X&_I%``@``07P#U4%A#@$,JO0%HG@`)J!_W=2E82'H&20\`!:
MP``I<)"BX0=2=!U;<@;#L`,N`$5Y4`4#`38=\"%.5P[4(!P_0`DTX`$6L#1]
M(`$]0!@5\5+,<#=T8#X%P`:[\`=G$`,E\'+`X@(;UQ*BIRJ*,2Q5@`!4)PA4
M=0W-)AIV(`4ED"47D`(OH%]VL`"4V`?J]@).=P8YQI9-T"&5J`4#L0<OP`(3
MJ2(*<`,#P'L/0"&*`QN)>`Y5L$&5@":IH`/5ISCH4)![8`/Z,U<FD&_LQ8OE
MYXO^-E_"2!7/HXOCM!\L@0,M0$`G@`>B(0BK8`DML5[$F#T)L`0ID";?Z`<(
M*(X;]CSG^)MV>'(.4%'QA`Q\D_^#7.$`\:A4'R4([:`E+A8/\V`FE*%/&D0B
MG>85`ME!3;=T"J$#"]`0IO%"?;,,?G`!!P`+`5!&76)E2-5E4)`(!+`$TG(&
MZ))V8L9!.E``3N,"#X![7=<'06()/L`7?O(`$&`4V0,`:WE]'E2*'M1U+\"$
M54(#'(`!#&"A#D`#%J`!$J"(8&$7>R`5X\`$"3`'#:<]'V``(#.?9G`#!#``
M%F%+8L`%4C$`!I`#,=`NX`8$%\`":-(/-Y``))`H)*!L7#`"$"`#??:$?39D
M`*!H+K``2Z!H:U9Q#)"E'L`&&/``7BH"5;!='Z`%`/``7A`#'\`&`+!=2P!:
MU;4#*?#_!F&:`BF@!0<``'#:6BG06U7P!J0P6S`0`,A(B;N((^_EF><'FNC$
M`1*!!]>!'.NU'S:P`Q0``CTP`'B`1TAD#;M@%Q*`!Q)P*6;2=;OC<;MI!^.8
M!;X)G.888@<"`C`P`2HP!#P2`XBP)3?P!SZ0`KFZ!X5I-07@!W;`!7AI$'^@
M`PKP(7O```I0"6ZA(@A`-U'IE4#&J^,9B;RB3Y2R=3IP`WPCEQ9Y5+W#"@MP
M.02@!5#UD6H7DF^#G@-%`?`:K_(ZK_#ZKO1ZK_-JK_BZK_QZKTG0K_(Z4`);
M!P/[KP0K4/Z7!`*EL(UUL$]P5@%0!W(E"^UQ5ZOU'9`U!.+!_P9\U1T',`1`
M<`"C];&N9:=@)5S8%0#IN5NOY5O#I04I4%PY,`3%A:<"T``P@&^0NIF&&@W1
MTQS*4H*+^J'(D0A,02(LP!#Y4@$W$">8:!\HY`+YT@+YPEM4&PJB(%/?>*HB
MAS6LRJH'I3@2.`0(@`(;\!$$X(>G@P#Z,``-80FBIR4;:%*GT`=D`"*_QD%V
MIE\!H2(RX`]+EW3@R:O'<7+_H&0W``!<H"(#D`ZZH",\HQ&J0C=$4P5=]F5)
M4D3,80UN)P`/D`(0`#M<5YA&<094@`1`80=9&!1MX`!J^0*P.VQ[,+O;-@;'
MP80TL`=\((D+\`(2L`<#X`'#B7=TP_\$Y9,`2#`&Y>,#0&`)![$&N\(4'X``
M7.0'B&*\<EM%3G>2<;(..4`)*:@.J0`!9_D+%P``R$<B"^`";$D`S?J0EZAD
M4/"/2C<",#1&K<>W)<"%*O(`QX%"F&9U8:`%3Y&37GD<&K%\8U**'(`#`)`\
M"^`5A>I>/FM^T1"T!;"HI-D+#C`#-S`!.?`&6H``&[=\E&`=67(Z`.`>&,M5
MW.$>DD4S'V&J()>`75LS7_N;86L'0#!7)&"V&96<[Z`)#W`*4W@)&/A`\G`#
MTJ@9=+=2=F`9TU</`D$07HD0E[@'+A!UA<M3AWL<`R!4$Y(`!S"8EV-E?H`N
M+>$#X<`*;$C_<YB+-)N[#)T+920`OO;8$EM"`&4!DX2A)2D`-OK5;"\D(F"C
M`QV@>,70`PS`!W8@`1SP`!*P-$NU&720`)VW"DT9$03@!7OW)5QH)@#0-X?S
M%IE0!6S$&`[P5#7)`IWB`.2K(N>Y`VM)(IW#>TM%=1@2O_K%``G`ESKP?+]!
M(L*G(L=$`'0'+.G+?,NSQ@=P`:@@`R.D7QW0`:L8!E4`>S3@P!"LF>3W38AZ
MP9<CM.GT-EE"`"E06B/``"30SC(@!20@S?1#._OP`:I(C%:R`WP0%F4P!WNT
MM37<5#=,P3E<<CO<PT/PPQN@QPFP#AH(#QP9)O:8"CX0,ANB#I#P_P>4<#(O
M4$WZI0`NZ0?,=!#3"S87P``WT,7#\`\#H5^609`88!#*@L:<5$,^$"14T9$$
M<"29^Q_6P`*O$`,`<,<Z\!%4B`F'\T#BP'0<0RD-:2(M)&4OE`4"L'Z(P@`L
ML0<>\,B#0@;Q<GF54`!%8"9T<`)>L$?`HH45!@"\0)=\;`D[``$;5PF0\T(L
MT'I'1P+1NRSHJU\55'OG0&3PBXDZ@`'TZP/VJU\=7;?(FB%A$P,OY*L8@$3G
M*@,PY$&\E\!@G'TJTL`/K#SJI6^<"<[0\8O/@,'H))02D0<7\`1@958$FP1U
M(-MK-0'1.,Y:L@0Q4(`.<`"96@T&``2[D?^;7-N;.%S0#ABV$#,+"MT2M5(-
MF=$F]%@)(O4H%KT`P3HHS("LUJP#)U"^(/T+9Q`R3L8J=D,C*ET)5B?(+E2*
MU7#&.Z(>=$$T/90)#0V$M-;328,*8N`!`L``2S!WPTR?OT&7:0!',,)UREE&
ML[M`%Y"(=D`"%\"7"R0"-L`!86`##]`#+]!P`X`"-N`#>2!*EF1)4L%P(WX`
M>=!P8O``!F!)`_``J'$&EK0$##<`K7`#%3T`C$,`L?0L)<!)1E)+*<,%!H`$
MN00!55``O50`'L``MN1V/N!+ZL-,2%`"@-9,!8">S%0`-X``),!N,3!LA[%+
M7GX#Y_L!-R`&:&[_3&>^`,3**;KF%&VN;!>``Q8P`A^K`K\QP;U8VD`[SAF\
M!$*9-T03`P_P`<$DIM%E71-ISOL0+/ID)7P@`&J20]=6/P@5T`IHW`2-W!ZF
MW`BBT+O@OM)R./IP!@R@#G_@!9=0*R5%@V8"&,<*`=.W!PI``H#9@CJ0`)9=
M4[L7GBF=PH!SR%/7WL(*WSR#+LQ``%#P<@60`I=@)`B@WYM[=$GDWP`P`E^B
M`)TF`'@&`5RP!#&M`%2@!3N@:U3`!0?`!6KF`M_E[0H03&OFGP?``]X.:2*@
M`"9@`ES0`F[I`C%0!>[.!>,.!2[`!0K@!6Z@`'#^"G7FE@*0`K`!!5PP_P=<
ML!50L"\+L!4K4`636"H-P``8@*&=8`$D?V;Q$YX-``4DSP"SE:4,0)(N8`%0
M\``C\&=G.@(`$#\Q$`,!\/,>$`,[T/-G>@"*[J4,4`3:A:9`H`5H^EUO(`(/
MX`$?<!';]0J>&UUO4%WD)0`PD+.9J0-^WIF`+@VH3>BZ6!]-=>R1O0>VNY;@
MNPPQ?B>.(@$9(`ZB80!%T"S$S>D##>K)72#+O7(>L`&64`!WLK8?,I\WU@>V
MFAT3I#@8<&-TT#@Z8.L#T0^`"7N2!H1#H2(+0+C$?NPRY$(OI.P9H1GGP`5F
M<@9<1D+Y+<<"HU]TH$2]Q?,ACP&VL`#QH]LEC_\!<Y`",K\&!Q`L4``%3_CS
M&+"F"R`_#_SD*O!/_SWS_AT#0_\`5>#S1+\$,I^F]@S@076F)KD%"(`NC\@L
MS,(`4L`N.1H#Y?`[6L`F:.[MW^8!4J`;IB0`S08(-Q<?7F(W-PD/)3<%"0P%
MAV(?"B<E!1=`-T@G-Q`()9L>%P8%!24`)25G-P`?)02<(PHW9R40+D@%!!`0
M/F<$-P(G!#Y7&3LM0R82#GC.?G]^T'_4U=;7T=-B8MC=U'W1?04K2WP.#GY]
M=`YA"NX*$Q/N)@LN7"X^8^K2=&$N"@[Z]#G'(2`=.@08I`DHK:&T)E<$3K.#
M(L"*+/N\:=S(L:/'C]G_I/61<"!``Q(H-J0KP$!=&"EB^O@`4."/@R;I\ABX
M02</@QM]_)"AXT<'!`,Z="R`T$>'`A]!$R#046*)BZ0+=MS0$51@'SM-DP9-
M2E9LM#-5<D1-(-#'@H-G!-#IDZ:,E`9SPGBEEBZI@1@"M#0XH&4$X09:<AQ8
MK*7QG#=LM!P`\AB(Y0-L(@/14N2`8BTP!B\^T*`!$,QL5ECN/+B(ZP9%5A^`
M#*0(&\B9@;`!D.:@G0\#^PR00B"@@R40!MBT4R4,USV&N.I`0"#L!0![D@Y@
ML("LCZM-"4S80T?''@87R!(882?IBPLL=)1W<<+''H$?DMJQLR0&V3!:)*!#
M_U$R3-6>#&SIX(`/(U1G!PTD(#/$`LPX@P<TTH#$ES;<?`3.2N28@XY`#L#!
MA@`CC""``(NEF&(#%ZC3U4`$G&''.>?@<8XZ['CE4$,]:."C'Q19A!%1&B:I
MY)+7-'2A5PZ4=%)*?XBS@`-TO""#&`@M40"1,;B4`$]A_'20`G_,!4$'YKD@
MA7P*G.$''0E`8$=5"NA@!P8I;#7C/@)QE<Z</GZ(EEI^))``43Y`X<`?!%1Q
M$`$&R,!&7GNE$^@-#P@P1!(!))$$!77402JII:)*P:FHFKIJJ:;"FD0=HB8!
MPJRTRIHJK*W"*FNOO#[Q1@L\%06`5SY0-^`>.R@P@/\Z=`CP@GX[R><`!"58
ME\)]=)R'`5<R<0$N`0KL(8T.4!C0E$Q:%-7''@;$QY4+-]B7SA)-3?N!?UP-
M<$`'Z=A18%!T)BA3#G+N`2$`+6RPP(U_/)--DAG^L0U('XI#3D$$]X%'`CD4
MD$8):=P`Q0*EW"`&$.K.E<Y<+S"PPQESY9'F#0?,P8`=!P7UHQ]!]AQP11<)
MQ.312'MDH3->V0&$21-4L`+/80#E1Q@)S/!5&6&`U<-!_831$Q<%!%23`W9(
M88`?#M1XD`O5"3?`"P0\`$%2%Z0KZ,\_>N/'H4&%,0!<"["M@P$]$9"`%&SD
MH%=0508T4`=:!/!&`"!0\,;_"@UP7EIIF84N.ANNE6YZ;*.E+MEDEF'^!A!6
M6&99[)>U<(#M+>0.PVFC`;%!``?XN4>8`6'M0T!V`(#`"TTQ]\)<#I3B`%<R
M^$`'SQ<L`=:[_\PE'%/J^"!%0`IBD-Y79VBAH`YY'$+6!`1,"Z98.L0`!;@#
M"'#^X8L.9$!,T@B#]@3"@1``(`<.,UK2*G8Q#X5C'$LHB.32`;)':0H!4M!4
ME`QPCH#M(0Q<F`,`SH"C`@B`,E40P`/$1I2?!<UE7R$:1L"1M!K:L!I+PP.)
M.``$$*P```)801^8L(<T2.,%"2C`0+AFAS\P8"YT&(!>]D"V@*3!)G0X"HWB
MI@`"_\S%!V'8PQGLQA4#8$`,>^-;0_P&N*N)K0]G6(!-_B"%KRB.<8Z32)4\
M-A!6`*$"(\!<#U@P`Q9DX9`S2&0B2\'(1CK2D6F(Y`P*<()*GJ`4+&@`"`X@
M!2GP(`.@#*4HI4""4)(@'O'@@0(>T((&M&()7CA`#!X0@R6,H#_[>L,(/O`!
M6@XA!H2`PA)2\``O,$`+L/P`%%+PRP<PP`N%B4$,&/"!`T!AFDO0PC6EJ04`
MV,]^`=BF%U)0!0],4PL?6,*^8E`$"SB3`82Q@#2]$(`=3/,#5:C"-#T@@"IX
MP7X,:,`"BHD"`;QA`VZX$@V1QL`.>21C$)2@S^A0ACD(9/\N?T``!.C`!($$
M[RN1ZT/=,%`<KU1A!0L@``$0<(!%M?!'+^Q*D8JVT!O:E$DY]`H/;770`/QA
M#RLE#Q)OT+8'I$$@7D@'UGB2!R@4X'I2((\?%("X%T!@?'UXRKL6)](/,$4'
M+@!`?&:DQFE@XV]I"8H!%N4'`D"A2CZ0E$@7U[C'08-$YV!!!0Y@`1&```0D
M",Z.O#(0'!F6;X3UF1^8T0P=]H$/-%A!'4#P.\L==`-OR&P`+&?9S09@`Y7=
M0`Y$L)@)I(PFC+@`%RX`B0)480&&8(0`#L&(`C&B!`M@[0U*H(`40`()8K`?
M(_]BB1)<``.I*$4,(("$1=Q`"Z;_6(1&2X$$*%S@MC?PTFX+T$M&/A<"IK@!
M%:@@,O&"-Y(&$``DTI`%%/SU#5R`W`(YA+$';FQ'56*"`=JE*3M@L&G!VR-1
MQ$'5@8#%!RO`0!Z($BD(=-"%&A!:#(VDP)M:.$DY)2`0;+6!S@6$7%0;4Q27
M<(-H;.$@`Q#Q'A8`E#YLE&T(T)H=7("`@Y!!3@Y(0)X(X%6L:$4^0^(;&].:
M*!D,Y`SQM<,-=H"E,]BEKGH,SN1R4$^_)H$$#I"`CB1'6,/BJ!L_PZO'F"8!
M&CP-!+2ZU5]O5:LVUXI6LQ)5;`)0A!;KP`MB&8`,""`?.^P``LQ+BK22`B^B
M"@0!9VB*_Q^NPZT78(`+Y/.!`@ZB@S/8B2P80%Q3?*"^?!G``.T!:PE>@([?
MT,\#]VO+"!(`%CN4`0<X&@44"2``FN&!#U+00FKB6U,F-;2^((I@E!UPBA>`
M)2<#L$-./O!4&=DA#SZ`91[`<8,1S($:`\AQ#A20!S7&=&@4[O6%Q[V1##N`
MAR!H``]4`(.YI`$#51K.V@:0`FXXX`'I&"K:7!"3/Z#))@@HL1V@`(%HP&U.
M.JZT%\:CE!_/)8T_&S*B%/73,RA`('$1R!VA##DQ%\`#+>B!E1'0V!R:?&F)
M33FTUH$CPH8!"ZDQS1L:(+K/E68%GOO<!E:`.2`<4+W[\<,2%/\DDT^`Y055
MF$#7!I0"2NO`$&-1P)>:<H,4,*\I4,``P9`\()&6ZUQ0$(,=G.,#('@%B1?`
M4A_H18`!2`,X.IB6,]?%Z0L$3"H6"D$(@H*'/.P@##KB``Z0\09XV_#7#@PV
MQZ`!LS\<>QWI(")8PA"-)LX);0QX@Q9*P`!A[2$/"TX`9+"$#@A+>*8S)+?J
M.6)N/A0A"0W`@0=\2H<;M.0/84``EPBP@YK8X0%5PIH8'$#%FF01;?Y.@!^:
MRI0_)&>K5/!#"3Y@H*QL13J*C3B8VZBH\'&!&GG00IH:@0".WU6'63:`!T:@
M`BMG@`^WWE!#5"YNC9S<&1+(?S.,T_+_^]_Z'"'P!B#0`@P`1'[B!_G1+S)P
M!L\A`@KP`D6Q!UH`@7WP`M6B)]BB)SH@`SM@+CHP`!Z``:%V!E?!%<D"+@Y@
M76-!`.HS/2_``M<G:F'D!WOP`:6G`[34=>DC`_>A`XN3!\^F*$QP#F?P=P0Q
M>#F04%A20XCW4/:U!#3`$%62)F<0`V6P'SP#*0]0!1C@`U.XA(4E!EB060#0
M;XZW"WG`$'SS;1-&4ZOWAMV088_50RN0`0"P`E@R'.J`1`5P'PD@17_P`$1A
M!P5P!G_@$SPA#LL!$TQ@!RJ%)1/P+`@A)S?P`3*0%(YP?>M25A(7%&>0:'XP
M`+R&1$>V.`V0_T<=9R$.P`(BAP$"<"M8ID,AH2EF90V(Y2/54%A>)B*/Y0`B
MLB-,,V:J*`'FD`6ALAO(H``7(`,7D`(7D``7@``Q@`#+V`$C,(TDP(Q:4"#9
M2`\R@"!+H``(0(T,,`(%(@,3L`/*@P`DT%M2@0`F```%P@OV)(X*``%#@$H*
M$`->\`ZO90+SH`4FP`!<P`4CD`,%N0`8\`9+4`]0L`,[8`$8T`-5L`--P`!-
MX`$KX`(QL`8H(`*9L0'?=WCTE7@:$T$[<A#2EP15H$0',3QO(``[<"+/\S(,
MT3,R`B7KT#X+5HO5$"02D0[W9A)9<"$^"8=(&3'/L%,;@`!4TA,G@/]B(D:(
MT\8?ZY`E:>AH+38X/$,%B&,'<W,F<3,``Z`#!(`<TV,`+%8>7+$]0<D1<)06
M1"$XZT``218]D[)6C7-U&))EY]`!_.0!?@4""*!_%^:+S,!87B80S.`Q;.,5
M)^>7+/`[!X`"`-``*I("EZF.`)`"6E"1K3`$W52``#`$FOD`2R`"*9!.#]!-
MZ20S18`!M/0`*O(`SO0!`J"0SR0`%@`%#!`#.;`$%K``O3D$C[8`7,!+"9D"
MCZ8`&*``6O`/"N`",BF="P`$#)``W]@#'H`#.)``*F`!.-`!"8`#.?"=(9`%
M"D!:*\`%%<-0)>F$BJ=V!',7B78]#B`&58#_!@.P!P4`!%%%*"^S!VY)6$32
M!S>0`QQ4?T#I,R,A0XZ5E!)*#4O#`251AQ6P`0*1!BZP8$M%%T8U)_B6)4G4
M$QA0$WL@!<_C8NJ2!U20`.A`!5!A!U+155^U``#`$V)1H._9B8DB!7-AEQBW
M`V#1"'C$E]$@.:O(3WUU*P@0H18V$`.0GH<4`AV@=WJ7!7HG!M,V6)&95Y19
M`2D@`C,@'1Z@@0/0`<_2%```:,J6/-F1%*:@#AL8-WU@`!\0:E2D`*$65%]Q
M@N>@%,,W/6A!%B_`"&0!`6W7:F'B'MRQ/@,P`AW0'GU``N.3?WHG.0.P`P,0
M>"%0`3G0`/%UE$K2_X0=`5'WY2,S!A#7(U);X"4DL@154"@%FG++UP=E4`3J
MPJ!"XJ`SQ0)[,:%):2%]@&X-X)0;4*2W-QPQ<09E"`XM0:)*M"=?0@=4L`>'
M"!/=P@5U-%4^P#92898/,!5*T2=L^14&2JK7<"C0P%6$R&N1,B=GL#A%D`-(
MRC8XP@+\%`.#"6L24'])4ZP9D!J@E5D[MP([YP8K,`?#]R3"N#3Y2ID>D`+J
M%2@`H">AB&C2(0#C\:UVD`,*DATL,'S=,@%:,Q()L`-IN`<<,$U[<`Z\Q0'J
M8'%8>!XL8`>D5@('$&H6&(,NH`L06(,:6#\QL!\Z$`9`$"/7@P/CPP>"U_\!
MC?D#`G`%>$`#@L>>H\J$\7FJ3QB%T#)$4E`%9[`'+Q!M<T`%QN$#*1`#!S$B
M6`(,M!6WAZ"66D!4=-`-#2H2?$`TP%IAPOJ&Q,H'E7.L/=``8)$0<\&LPI&C
M`<$`6)('2?0N&-!B5%`SNH<VW"H0<0*N=U,"#_`F.L`%6G&N/*JNUG`&*9`#
M[:I\=I`&D/8W3;<@]&JO>L0V(J*O`B!R?T4"-$`#>'!A`X$`EJ59G>59;'`#
MFL)W)A>QP.,!.R`"!=!U0Z>`!$`>.B`"$$"V1"(`V6$'T'$#-[('"*!$[Q("
M2Y"&#A`S#U,>XI&&=G`&$W`CQ!<#(;`^!<`>31'_!M<E'1-0`F49=\`A$+\7
M`W'*@NF1%-Z)(UG0`>;`!S:P`U>098*W`UJ`4A@U7]300/)YDA+5,P/P`3D@
M`&@P!W.``.Z;!P"`"GNT#_Z00BORPBN23R-PO`";M^G`!Q5@$7T+L']K8:IH
MK"3@`1M@$Y*V'Q\Z`%[@10[P1-U2!D_U`DYU$$#:1`7F7VRUN0XP!0C@!]SU
M)G:@`"1&NNG*$7[@`VB@NGX@!KLJBDT4!H(X5PE0K_>Z(PY@`'MU`!OP!(3Y
M919V#A.0!$50`2;``UP`D#Q@`ER``D_0`$#A/:2JP)1)6D#0`_"``"UPCPJP
M`!_PG/)0!*_E#B[`!@O@_PY<\``>0`\NL`,><,@N4`%`8`(J8`(6T`(YL`#(
M^0`YP``6P`"=T@,,P,LML`0>8,H>\`8>L`3JE$_I]`$CH(X?X$V[`0#JV!G2
MG,)#(`!+D,(YT`(0R3#<#)%+L`$`@`4B@`6MU`"%Q\,:8JIP^8029!SQ!@";
M!00($`8X,F,%L!]0Q#/1HRC^_,^*@@$'`&IWBPTVW`=YD,,KP`)&V<-P2*QY
MH$E%$,0:FKXQX0`I!A1U_`+3%@-H0P=@9*+%<D7K<!23$C<'!T<,.'TDX!>3
M*\9#LA'I@+IJ(3?7@V0&`11VX`-E$,>T"SELHR-[T`&>@CF8DP$#P0>'R0<*
M`/\".1`"-U(A`<$'69`$*R`&@]*CU:!_(4"9R?`&HU4%`!"3^71"`B`"8OTZ
M^50%*;`!.U`%(B`"VQS7,YD#S[L#"%0!SRL",%`$W2P`KB3-`@`#ZOB\,""3
MG`D"`)!/*3`"6D!..W``_;38'S`$;]U/L/'6ZJA+FFT[$+D#<\#-6+`#%?`&
MXUS.<\`Y":7.(,'.&X&J*)F2:2(3SLE!:$-\MTV@=XL'*HF3*7<.%470>-NK
M(I'0.OR[#OW03,,!16`Y0-0``G&H`R%\[]*'V.H%UV,'-L`\*Q83=$`S;$,%
M9:`.-:*Y8UF6TS<5=?S2.SK&&H%QJ:L.-G`\#H!DZJ#_9&AS!GKYTWV9KP!P
M`$/P!D,P!##*#(?)`1/@U#-P#HW9#!*``["WJYK2#5PM@`<``",`!`O@SP+`
MCC(``0^@`-]HC5[@SQ?0`CA``MX9RQUPI1Z0`2P0`@9`G2P0XQV``AY0XS-`
M`CTP`Y74`19@22=0`?"C4AUP`"<P`#Y0`B20`#Y`EB:P6V#D`Q_P`B\0!CX0
M`PN0!\:6/E(01CJ0`23``7S`!WI7YAQ@`P!@`[X8!BH`!)WC`JS]$:[]WD\X
M;0*A0W/2,V#C/2^K#N9R'^&`(4(V%P9P`./M#3T0$8[Y+@K=MZ:;W#9$K!S0
M,`'`!ATVLR3'#F."T5Q`,X%X_Q!Y(`9>!,6-#*.'9G<TBCA3Q8!U?`%=`@%%
M`0$?T&)CD:YEI2D^@-?J8`!E$*3N"4<>$!`:<`%X]#A\-!#K4`#_+0(6X`[/
MT@Q+304*SN`!H64.@`.+O#8B(1'J\`W$*`$!"`)`0%HA$Q![\``[HF=0\5A)
MMP?W80?2<@YYD`7@>R,D4!UHTP$[($$<8`&0=@[D(B($P`-HX[T6P`*W?0(M
MP#SLT`'#)Q`N4`)AP`=$8H/H/G=IZ"\Q<@[LB".92HP<(`(1S`=7(,\6X0(!
M\0R$3C%;V\[24``-H#VW2'^)!45MZS(_XS)8@^?=`!$6(@U[P+?J@-R2/FZ4
M?D)`(/\`F2Y29!`4S)J^7L(V7A`4D*M$B*@F?8$`ZK('-*:YB;:!&Y7E"``6
M8&PU+91]N=X09W#&`B$%6XP07'`04GL.Y-<``F#/`Z%#`]8'8C`'3P``=PM#
MX^:+"3X'"PZ,6L8'VLX&WJWSTO`H:>*+9HXYMQ,`0*#P#D`#2X`C5X``$?Q8
M'&L.`V&O<V$'<-!L?4`=54('_/ZOY]8$"U!8!;]_5P`0:,,!/<!!-S(#+6`<
M-)``66`</'`%$B0!*+`C>]L$#'X"_Q(<4@!K`!@"#$X#ZL4'?:`!*.\P8!'T
M$[/.+__:V2#S-!]F-I]8K7_^%_45ZZ#L/T^U+#_T.EST1T__;C]<$N2^<W-2
M`!@`"'1]`S@W?F$`-W]T7H(#4C=]>0PW#@X*=GTZ"I%V"Q`Z=@H^FB00#AH/
M"`Y]7(E]?8*P?[2UMK>"!"DYL%)2?@X$+@Y^5P)]P0D(#0)AK`YXL,A]-TM`
M,71^?7[:M][?X+=]$A,@!S.6K'C0'`D@;&+($JRP#G:L$O<.!@%)!Q4"1,S8
MXX"#!V0.KN"P84G"#@0<)$C<84?;GAM(Z`A"0$"CGQ``./!Q,,`"#P?SKF20
M*.'*A#UV[.0QP8+//0(".#C@0R/+#)89?MC@(%+%R#X<FIBPQ.'*C@XT).#!
M$4*B@Q`=1N:Q@6*`)1H\#C38@$%"_Q\\:/W\X18.'-L_8L2T%;?63X$&2RIR
MVZM-FM^_LP31XDMX+RQ9>+XUN8(6#[<]*`*L8!$K\=S+F#-KQMP8Z0')%D3`
M`%9@@1TZC\38(;!DAB`OE@:4*4#G!8,"]A#D836!A8XP7$#I@.!#QQX$".BD
M68(@EJL"VV0!EE98FY\SNV`ED'+/AXM[67;PD7"F`PDV`KPBBW;8+H,<#(AM
M^]-GLV8)?*B`R#&C'D(\?&0!`A`=F)6.5?2,AU\'&P1PP`,[`%&!!QY8``0*
M*#P`0`M+//!`#V_D@"$`%;SAQ0-++"&`````L`0;52SAH@`!++$#`#LTT,`.
M-V*QP@Y8[/^0PPHK"I!#`RTDF4,.=>1PP),Z:G&`%@X6\:06YK"Q0A$!!,#&
M!BL`40>8&VSPAF1@!O!&`V^`6<=8;08`0@`;+*!.6G79]U9<FM7'S5UY52=H
M=?1M@XQ@W]"3C5J*,9:6'Y!)1AD=EMEGZ:68UM+8.I_!0(('#2`S0`*PA"&%
M`78<-\`>?O10SQD#]+$'!K@IAXP?"!A@W`TW"$*<)C>4$(PJL1C`10%J&3K=
M-H/ZD%T?!!#`"@%<Q)+'!`[D<44")##CS'JR(O/'#>_%(%^RF;95$`\@O'%`
M#D8NV8*10,PY[Y)+"H#%OO'&VT*7;[!X@`<+J*!`"UPLP(,%`*C_P(,)$TBH
M``\.-\#%Q5P\\,'%5%0!A0)<4.$!$!DHO$"0$V?`A0@*0+S`#A/$S,,.#_"`
MG`D-F*#`SCWT,,'.._#`!0(9*"#`!`A(0<*^&2!`@@)`J)*!%"AXD,'4/5A-
M-!=:+)!T!F"TP,802YV%YUN:[2E79G[:A9=>A.DY"]NL--K88Y%-5EFZ?/?=
M5F,\Y1!``Q-4T,`B+XC!31X)&/)'&C#]X84T883A1Q[';J/!'W;H@,`%L+SP
M@G$N$+#-`"^LQAPM!2B`+'U];7;=LS%M4P`4M."1!3($X+!,>L]$4XL?!D"1
M`A3$L%6?W[<4=-X*(,S99?1OG,FFG-%'_S\]]5:`D$02:F[P!!``Y%`@,@>A
MI!!#^`&`0%3X5?'"-@X4D,;R4IBN%@D`Y#&2#1[@`1XD0H`,H*4/-B"!'22P
M!QHP@`4%L<,,6@`+"=`@!#^QA`)F<((\`.@!X\@#!U3`A3S,XP3F6X<#<-`!
M#I@P"UG0"1Z<<H6".`$'.]#""I8"C;,Q*FV,XA/;Z@(HN/$%B'.K'6#"L"CK
M@&,Q=X-4WB95*>99D6]WXT,1DK""#%1@`]D@`!D$\0(9H,H'7"!`3):`C!?<
M(`VU64`:_K`'"-#!`<-)@!T&@``]]@$"9S!.`A+PN-4Y8`$`@$XL8N&`;_3E
M+_=(0Q7FH!W=0/]K`9S+0D@D0(`._.Y;T/`3+,3``(\E3RW9N"(MD,*%)-3A
ME;!\Y?=<28%:RO*5MGQE`"A0!UNZL@@5$`%ND`&`AIQ@`AJ8AP-$,`$^\`%`
M.<@#+/)@`-7$PG6P\(,4L.!!/(3A`2KH`Q\X,`,32(4/)S`G2O80@ZH09`9`
MD$H?:-`!=*#%!%DX`0W0\H#&2``%33#;%5K0`4O@`0$X,!M6^"!.#>3`*S;@
M0P<VM$-8W"U/L@OBVC#3MB(2BFW`($88$@`%+YCTI%[(V`.V@($S_/`64'Q4
MI/1&*57:%%.=X<-GV.#%%<R/7!HY`R3\D`8`&(!S#Z!/&"[0JSUP(1[_#J""
MGR!@`#_886C:((X?=&"*/Q3@`=SY`Q=V4`DZW",F:$VK6M'Z@CP40`!S$,0@
M:9$&+M#"!@)8QPDZ(`5FJ">4?A`$'0P0@RJ8@1BU2*4J)6*".@"!!R$(`0P[
M(-G)5C8$+.2!!S#D@3D$H`X\8($&6'""&4P`0@+XB5DJ,`\$2L$&R."#`#)@
M!PZLHPKZ<,`-:`,+",P1&&78P3PDP`$+V`D6!#`!!WC'A73,JJ"P.($(4.(`
M>F8!)7RPP`QL$!4\H(`H*/%`$_##AX%F821\(($4TC%(E/A/`([B`/]:,`05
MF.6B:,N,VC:SO`*L(%"%25L?]#*`*M#)3-4#_T$#W%"]-1D`4;?H@:/8$ZD&
M]*>F-\VP9CHC`2`$``:%:X`V"+"`6`Q`#KTZ0R(<P`ABO$`*T'E!YOK@`FFX
MX`*DDX(.'."",V@"`LTIJA2V004V!,`-1WX#DM7$X"14KTMN>,(;5L"F)ZQ@
M#DLX@#8&B5PNV.$/5\B!)4Z`@PRL(`<T,.@!8T$',4"A"AB@Q_)>:BE!B9-=
M_+G3IA+3%V`,P`L"0)&,JE>`W=C#`3,(C0!(4(`3G&`'C2Y`"!20A0)86@3'
MLO0)1E```J3A!DG[=%T38+\T9&`''#Q!%CY4@!D4(`$6</1>8WT"2ZNBT2<(
M@0`<78`L3`#&C6X"!O\M/0,`U+JT`,4U#HY&@!E0:P*X_IFK9Y`%+#2[URH0
M`!`VH`(]JR6_F-EOG]3B7P#'+3."D,\W&9"'/0Q@`&?8`2G"\(($Y$`,+/Z&
MA#LCJ\A8>&\:#OA<&E.0SQ2!!!58@48*@($O/\(09UA"`>C#@-#!N`\R3D-6
M64$'+AB@#V'``"C\T.-0*"`YRR%5'PR0`#KD`0H0R$,>4I``)M"!`$/NPP(8
M0`<IB$$'LL)`'@8;5S]L)QMG&(97ES">;9D9S6J.!AWVL'(S8"$^TAA,N@1E
M#P4$0``%V/.FUN(162$`WZ?KM#Z460`+Y`"8%#+!`9J@@@7T``L/:()XWR#_
M`@9@J`<68P`#H.`B*#S@/4M@0`P@Q(8>Y!T%+<A!SYH`@`/TH`D,J$`++)`U
M#[2@`CV(00]0\`8+>"!K50!`UIH@(A1<'O`,.'T3#M""V#<A,CM0084"8H$F
MA&8'7.B9!U:@@I[U($)CX2%^Z7P9<8/4J_\UXEXTDVYNA.$#&,@&LRAI53^(
MX0!BJ*(M]KWF"E]8_`)/OZ8:8X<#O`,'*%A!+,Z``*H__!`*(,`?'``;F1B@
M(WG@`LC2!V(@"#K@`A]G!Q<`'7Z@`#ZV<OI'`!\@`T'5$70`!;K1<9'0!ZV#
M#%+0<A!P`_>@3<B0``<@"&D`1W1P`BZ@#32``Y9P_P9EQ@QII@ZQH`UT<`-5
M\`9+(&=:ERE<)PH!D`/0(79H07:"L7()X`R"E0XV@1(L4`4;D`,GL`<C47&6
M8`,XX!66(`(%@A)]L`/I8`>[90E]D``#``QVD```H$QA8!+I<`4(,!(.\`,D
MT!!.%4-6^&@$@10=<`+I(`57$`92P0$]0%Y)80+C)`$_@`4Q%!$D`(.6$%GB
M5%T`$%%X\((`H`4Y0Q#+IR<:Q5_D%GT?A1G5!W(?T`0<IQ%:P`K:8`#@1P?@
M0'X4YF_GIWZX:`LYU0(*%F+<L!K`X`.-LPV0LW_8P&*H`RDN$`E_<`9KL0FZ
MH@/OM@VE@UPZ8!?,049,1/\'&"`%EK,JL'`&"@`+`Q`&>8``-S`_?>`#M6%O
MHC(_=%``7'!']6,)O6-F`E"#9R$?V7(#@M.#6;<66U<=`()GZ&`V>[86U/$'
M!/``94`0#O`"(36&,R`";]`"N&$)%8`0<L@0EC`'4K!<EB``F8`,8J!(=$`%
M]V,)X9$.2;$`PZ4!$[`;J]%,*/$"/1`"Z2!=Z1`&)(`.&G0"8<!0'+"1L>4!
MW88,/Y`#UP4+&7"'EM`!93`.#H!7-500."`"![!#WH910$0+0H1N]5%NT@=N
M;5$/CI!X&H$0=D0/97``CJ-O$P8+Y@=PN8B+=\,!]5($/(`"HT$'/B`%>X`:
MC>/_`&&``,[(?V:U!P5`"C(6"3EX1S2&8R/E&PT82#H@`X;0D#EG:6KA!8)I
M!P[)8DG7"ZL``67P`ISC`G=D`#G`#6+P<7Y0`ER@#?(X'AJ0`/A(`P@Q#1YQ
M`P]P`%@W-\R7485Q9U^704:X*7N!!U*P!AG@8[FU0);``@\P+P5@%G8``!Q)
M`ESH``(@!0PE$57`!+%`ABC)$7VA23W9`SPD`1J0`<\4#`H@30ZP!Q;``L3E
M`"=P#*Q`3X!H"3R@`>#E``_@A#W07"AQ`G,0`BKTE"@A`0E04);P`R(@37PP
M`$W0`"NP`L?UB1D%EAMEBK;S7ZP28-0WF'_@`P\PCX(E_PF%0@U5P(!RR6]U
MB6%WJ7X$QP<>=I$M``.Y\!U^\'#0L@2*T`<Q$`OU!AUAL`#0X0"TQ0HF\'$O
MX`(R<(VCH`D3(`/0XI"!5093V0</H$<.D`/C>!T*H`T8$!]44`EKM`T&0$D]
M)P4+MP"RR)Y]<`4=L)N]R6*"8`>N62,^*)!`6!W5Q04!@`79V4-[)@UK)@%A
MD`$BL`,>H``X,%PL,0,TH@49*0$?$%L*P85V,%LBR0=5L`=K@9YF10<)<`;T
MJ$D,51`6P`42P0<$,(<H00`V25P68`#*1`!BB`STM*@.,`$_8%`.X"K1D!0G
M@0PG@`4Z*14D`%T.D`55$1O]8_\)5P``T;,!RN=#H"BBFR$(=F&BI6B*ST!-
MO?*BBR!8(S4`$#9^<]EO@W.+.:JC:+$3GQ$]5-9E&G%_`R!Q@H`-?O!B,39C
MK"D(")ACW."`/T8"'+@$4SE8526F"9`'?Y`#"(`'-S>.W-@#EZ`:@_D`VE`&
MK^D`'SA@!<":?J`!6(`,"H&/(ID.Z;:&.<"#@UJ<0%08">$!()!:>K8I$9H.
M.\$'/]"76-``5B!X/1![F9<#0'``)D`"")4#D?@T#S`!ZB4%%Z(T2G,`@^0+
M"\`%VY$`#Z``@Y0`K*=>948B.(`#":``%0"W.%`XYN$T`,`%))``==L"=$L"
M2O&V.+#_!$C#0DM3MB2P`TN``U*``PHP=[IIMDWPMFH[N5X[!]M!`CR`!6WB
MH5UIEG/A?"1:KDM`==DT?4-$'X,Y`)WF:?83+9UF:=(2K[4@87[`'N)4`8.S
M.W5SK[DH*UPR!"(@`#"`#`P'$SZ@F=#R`06@`W1PH'1@*K31I-!!!PH`=#2F
M*S)&`D#G@,9Q<O$(`!V@"1=P`=D0`Q=+!UK0'#I```J@$0SP`,-Q`>KX`*?1
M`5J@'3I6/S4&+540@W5[9O-#M,@@C@#P`.@K'=R`?K+#+(O"C4W0`SE@!C^`
MD(T:==&`#U`J)PW6)6HR`@`P`E;:1^')MZ>5`3@0B0>`OKZ`_P-:L!U]=#&#
M5`9+@+9@V@0"4+:GM@0SK```D`!EH)L5T`$R$(E+P`,LY+@O/$@(D*!\RX8*
M,#6#E,.^D``W4K8\P`8JH`P)L`5@P+@XT#/;(049<`#J130]T`)`0'QR]BC=
M0!_D:BA[\66#$8KC!GVE2QTZ&PZ'T48*P",IP"."'"-"`@"FLSP1QAA^P0=+
ML+OUX+N_NP=%\`1L\"DP`'0$(!S)&PD#D']`YP%TH`-N%$@A!QTZ@&.:8`*1
ML`<)\'-],`HZH`.DI@,EL`0=$,L%<`-`%P,R$`8ZP`"@T[[CF)D04$<&,,`0
M<!H7<`!`QRO.*X^E@@&Q?`9Q.P0YH/^.>Q#+>1`"+N`!#)``!""1"]P86X=Q
M:WD#$!`#RU@`3(3(ER$-@B`%10`$#<`&.C($*V#-`"``)1#*2$H/HR*1LE(%
M@ID-#I`"&G$/EJ81=*">&B$&2R"9+U<MN?"^]#$`$R`-#L`%O1(+!;`#[DIJ
M:YE_89#-?O"I`^8`#$#1=I$#D-D'&4`JDZB3VBH"-=1`_+.5S>6HFZ(LTC%U
MS$+'&!66'#6*>7RZ]L$JAN(`)5!-3FT`U50&#Q!E.:`_-3H-N:M@O-M(D*Q^
MDC#)A%,!0[!5+_!Q.K#)L%`">S`_7A#+9STZI0QT+A587`!!ZT@*?6`"!`!T
M)5`1)?`!./;_&[&B`QZ0`!)9`O.S&AY[!C[P`A!P`JE"R^2;OW[@`\5!RRX`
M='Z@RWMP!A<``4/0#-L@D2\@`#M@`+LA.DTT=IGB<A!)!6,:!M826+W+468E
M*P:0!I;&`KN%SH4E`!FQ#1&M#?07*U:EL:=Q.6)F$65@"&8%`1U!#%;<AR_@
M!1@@#<+02'0@CBP6D92P%Y)4DB/%6Z_<::SB`'DA"'F04H)U`R/P8&L1T^D`
M0^E@H9!=7?-543Q-<-;!#8?RIZM4Q^)ZQ^5FNLQB'[)H&(>R?X)P$1\0`$6@
M`!I`=;.HR-+`R(XL+EV=?E8%U@@@UL9!?Z$P`)JIV&<@D?(KR@80_T@#0"NQ
MK,NPL`#:*P.N7#JQ/(P%L`2![<PZ,*:I\@"1H`/B&,L0P`4O@(Z[\<K9;``C
M`'1B<`'97`(FT#EG@`'93``)`-H"H([W@`%8H!J60&_,<FXXE0F,`[:6H`V*
M(HMBF6]?)@\2$`IBP#!5((*A_`':)XSM?-`)0'4N=ZKUX0`GN7\HZP/V\`=L
M>`\8M]*+=`92M0@^(%5MY*2"!:RG$;TB[2N,31`Z8"Z6\`(+0`4:43\"@"K[
M]P5E,!(2`$/#90.&'!4_,`$41:OTL&=WQ-"+0`PQD0VL(N!P,:+O;-0&#KIS
M`1/T<^GV<#LY,`=5X'%I&)")G,&PP`<5H/_5"+'A'*X#0/`$GH("#8#+%A#+
M)/YS.:[+A$V.","D&!#D$#`_!T@93<JEKTP*P\&E)P``\EZ^NZP;.B``H-`'
M21?+\6L'5$5U/9X)3*Z_0'<""\#7@%X"6>X&S1#+FI`"&M!NR)`'85"2?[&<
M'B]V]L?#I.#?9E7K']\9'&<'[$&T]L`"#!#""R`#,I``58`<",`#'P!D$"`%
M#X*V0'8`"#`!$$`%:\``"*``$`!\$'!R#P`$1W_T`E`%(*,`.+ST9/`>5'`Q
M&#`'&\,%&/``*Z``"]`%38`%>;L`"S`''B)X"\`&.X=Y[[)S#/#@`,``7Z\O
M=%?V.V!\#[`!#X#_`A,B`'"RTQ8EM"6YUO:0;G]*QZ(;['@\['L<#K+@IV8E
M!512!`A(`+$BF7,3[8O<R`VP.QJ.[1HV8-M>R1_P[=0P.6>-CM"2"-HP.:B1
M[ACG<;%\O3^FRS+&I0?H4O7>!R4``-SK!_K>!Q8@`U17!1`0COV[`.$.`5`>
MRTL`=!<P`K`@`^R[LMN@8D#G`P;P2=*PG<_`"F=P!G+F%R=_\I:P%1Y@"8IN
M#P.F\NF?%LSBBL!0#PK-`"E0!```"#$?#P</#UX?`EY>#U`-.UY<7AA%7`Q0
M"Q\?7"Y4.UP0+@J$""X0"E4`4A!2"@`)4@D0``8R4E(`+F5B90@Y!F)P_V5F
M5#=B!3$7!C<%)0`%T`4?#!H%:08Y4C=I!5U4:=P*$R<G!2PB-S-9(2HB!RLF
M#GWS>/7U?0X$7`)L;%54`^C0F=?GSQ\_?@R*$6.PH<.'!OLD++!BR1Z"""%J
M?-AGX,`$58#,X>)CWA\[=/+DF2=/8X\K>/#-XU,!1(,L^!QLW,FSI\^?0#GN
M*0*"#8(/#2XBZV.'`(0+>P@`$+-'QP<=.@;(**'C!1<Q.OQ(D=@'@@$[>Q3(
MT-&'"P&L$-:66+)61X(+71\@&/!BQ`4_?<XHF+>`P1X(-R[ZN:KCP@@_.J20
MP%I"0=@;2W38\9%`@1LM`26>J'+C1IDR"<ZH)/_(VI[KU[!?YW%0YD$&'&(2
MH)83!F'LWPY>./`3TX$="7DDH)7`P@2*%#=T[-F#P8X#!P/*S+9C9T<9[G3L
MH+$^O`02[GVDG`E/)P$`XP["0''A8$]3*M?I^*`BL#X#`W0D1,`.*/611QEI
M=$0'%R6$80=6%H5GAQ<+.$#''VG\8H=!&2204P@A](&'!%=4<04^'.!000LK
MJ,"'/"*ZED<"&'"1AG$%,.#%=W:\T%!&?RP4U!\2_4&111@E-&2`@,57Q1-O
ML.'&&PVX$<`;3U!`P1L&%.023*SQL40`-[$TY)EHIND39$`$``,)2&&E#U8O
M)'"#'P,P\)8?'B!49PG_?KRP0`%^.)#`'@B9T.4+"OS5APMG("3#7\[(()$Q
M8<4@@QU^+(&7#CXH\"`"$)1U`W=^*`#8!5JPQ0(+@)7`!:(ZQ"`1`0D@,(0`
M+\SS0@QU:"DL"%44P-)U\ORF[&O)4I&EL!34D<02-ERW[&\RX>$`'Q(@.X,(
M`6S0)6!+!!B8%`,41(<64H1W4@Y$7K?,0'\@D`:](,D3'@-<'-1'&BY<^(</
M]!ED1PQB=-3'#0+\$9,3"13@$1=GR(,0`$W:@0(4`M%10`XW-,2#%#'U`6*W
M>(0AP`E]2#!`!CL`L8$))<=HCQA+2/%'?\.!!,%!.AVDI)!`%038D1?-`^20
M_W9T-/"32=0A]=13)_%&`@)#9,$)\ES7!Q\H!.`&"UZK:?;9#@&V-)%X_#C/
M'B.0:<$'1=S1!U98:64`WGWTR@!D+T#6XZ`/2H2G#'MK%I8."I24!V1^B,$`
M!-+A+>BA8?4**@*],J4#!"6D*]&#%PAPMP-L^>%4I/9!5L(%$#0@P`!-]X'`
M"$4`(5(`22310`5+[%`!#PYT*V+QW.$QFX$2:.M`'LYSP$%,?&3Q@``B[*#]
M'"#DD(4#([[X&C[-;UL\^-:.>`(`0+1P``PK;``"!B]H]@%!!"!0DD$YR$!'
M&`;1`J>8<HR.V&$"!"#2'\I`('R\``I<,%=E-M0'`O\HH&MY:,(-F!*8AEUG
M`'(@U#PH%@:L^.$!"GO!`S#@KP)H@2$ZH8*'YB$&`SB@'#@`0`AF$`(<M``$
M('A#/,!7#X=(`0HKT0D=AD,'5/S!!@IT"#""8K0^("U)9[J0'Y:X1'TE1&%,
M8@JR-+*UKLD#;`%8`=E:@K8V`@4AK(GC/`;"&CI@I0B\`T$``I"[`VCA`'Y,
MP1(`4`4!;.(#57@``);`R!A<3P`K3*0',*"%'>AHD(BH0@H>P```#$(``MAD
M)PGY@!VDX`-0$``A&?"`*B`B!0(8Y`Z@$(,4:($!G3Q`#`"0@Q0(8I`*&,$(
MJK"$!VBB"@'@%6#8PA9\[*'_"3G(P1M`T+LZ!```*/"`!U"0S1[T``4]:`(X
MO8F""G"S!X;P0`4>L,U%/J"<2\@!F;")@G>6LP+XQ.<2\`F`"@```-K[)T`!
MT((\`A$(`@A`!2[0#`"4I@`)X((!H)&&.9@!&,L0@`&`408%4&&C-XB!%&IX
M`Q=4@:0)*"8P;B"%#^C&``A80@)FFE(NS'05!Z"I%-9@TU@L0103D(4`,H``
M!"A`>PJ``!464(@$$/4!8*!"!C+`S@6\H0[4#`!6@0B"#11!!3"2HQ3*(`<H
M&+.8#)""`0#@(Y-(D2%%:V%%DF:X,VVQ(/@@`$;%4)J%+`08!5`,&;F6DZ^%
M38UE_W.C8GD"&`71$2&0)9+"#*>#(AS@#<EL@37W&(`GO-`N'U@"$MX6AE#(
MH"0Z.,$";C"``FB&40LH@1V8$948&*"$!;C`"_Y3OQ?X@#,*:%!7()``%]Q6
M.GNXP`<@,`"\^6`)!=!<5ACA@ZKT(0PER($"I*N`!E0A#'>SCP["&H,&L&&/
M>DP"!:+6._924UK4C"]\N4I?:B8!B/?58WWUR]7>T3>_]@UP>_6XQPTT(`DM
M@.4._%&%'53A``T6)!]S\&!I5B&:6F`#$*)9A3<<@,-:2":$Y^"&%6AA#CDX
M0```^4<^%J$(YVV`C%<`A#H<0,9L>(,;&K""!I"I`53:P/\3IG0E$$`)LU>-
M$F;W^(8WR&_(6-WC"IJ\@14$0`0>,,&+D,5E"&P1)050CWWZL(0[L;$A4XSK
MT>:*Q3/-!C!YB(%E^W@`W0'AQ6R8@QCHT#:M$=9K:$3LF1=+Z+0IR#C3L0^R
M[*"2%[P@#U79@Q8L`(0&#``!3VA`#D8PA"<<`"IV<`$#+C"`/;P@#!9<0!A>
MP)<$6,`%!#A#TTJ``1>0VM%[0$`,$A"&ZMH!`55PRZD'X`,,R)35K$[`)GS@
M:&(S`-;-[D`,(.!H1QN`EA=@=A@.$X/$^"`,4LC!$@CP@@>]8`]+G`T*V""`
M.1Q@`U9H@!6``(,ZZPZ0YJ4Q(`__X#[W`8'&;&C`A_<-!'P7G`W\UH+[YM`"
M+31`)`+?M\178(7+(OQ]]_YW"^0)@`F0``$"N$6N8H``6"1@#FD5@QS$((`R
M3-0`+K#I,DAN@#+<0`$I,$`"X)#2;D,C`0Q8R`T,@($":.`,9_`"%0@P@&L(
MH``$($`:$%`&I)_!!5`_PPL*\(#I^#8&&#A#&`9P@QT@(`P7RH`4;.`$#G0@
M`38X`!!7X#XV5,`"&Q"!"3*`/"9PV0$0Z!@>Q`"!]0#F`25Q*YKA^I,J7E%I
M2@J*'ZR#CSRT\A0*\"@5/,H#!7S@`-_QTD/*6-A`KU'TA4X]8/KC6Q\,(`RK
M?D'4"5""_Q)$?=4M6$`#0'`#$@3``Q>00D(%<`/?AN&H8BA!:93O!2GXX`9G
M\,$")@U]4/D``"-@P0U8H'47T.(&!-A#&%BP`Y^7X-NLO$$)"H#JLNO)M\1>
M`@+6SW09].\$O_5!"0[@J1OXX"T8``"N1P`R```+$'6OMVIY,'9VT`,"8`'J
ME`-8T`(MT$\5L`.#!%`Y(``M(``[@`47J#T[(``(Y3Y8<()8(`#1A`7MHP4(
M=8(BL($JB'`"H&D;)X/1I&$MT``,1X$Y0($[*`(`H%`$$!\5X&AYH`$(0``J
M80<I(`6QEP=5T#1TL`<;!6EYH`!I@!:T81'6D0<U@BQIH`"SX?\`9X``Y+$'
MJZ4@!%`%'1,&$3,Q!.`##V(5X8$/2\``>$`'3'`&<]`E':$`"/`A'4`#!P9$
MTE('*&`"`=`"**`"QF,S]<`Y!C(C"D``*!$&`DA'#Y%FC2=72`)Y9S)'\S``
MTS`<2G,0?R`/8G``>[81I`=HAW5ZJ5>+0D,07200<80'Q($0P7$`-1@`'V`!
M3\!'<?,$18"&]?,Y"^`A7:$#!+``^M,CC8$!:U$_FZ$`)E`"=Z,9"K!K3>,@
M)Y!69S`==\,%!VA'#W("MK6,"\,%LX(5>U``'C`!O<(=!/!J7'$W/G`)'9!K
M#3`";X$W88$/>$`(6+`![!4U&Q``^&7_4.G%.PZY55S%6?EE-6G48QNP`6\0
M-4$D/^RE)<%"->LUDL$2+5CE7S914"IP;A+@`7-T!LY'$%4@!<;1$7,@#];!
M#/-@!Q!``&J3``0B$';``!B`/Q"@$Q44>/A@!QAP`TM403DI$74"!Q;2%FE`
M.YRR!/6!#XV@,&=P``!B'%0P%M>1`!WP`P<FD0[9`B+@83D`5@KB6'1P"P;0
M"E"P"0BP"DLP`#N#>G_@B3[A>&PFBJ/($GO`2&C76(V5$C+`!O<2>0X1BV<T
MBXEEBX4&68TE1ZG8F#IP`$.`60W0:1/V!-;T#)K1-RX@4WAC!P:P`)<X'3IP
M`P\P0P]2;&Z!_Q78$5-K\2![$%*PIC@#,`$/@!5,80<LL`")(QUB8`*6X9L7
M$`,*8!_<40`+4!UW8P<%X`+=!@$KD`/2U9@!XH`B(#\5J0(JT`0B\`@B4$[:
M\P;9@P(64!$BT`,5H$H`T`3"$X,\P`,3,%4FP`4`(#]`H`(\8`5)$`!8(($I
M)@`IB`7`N`,YL`,L`DH.R5\(%0`J(#UVT"<=P1GILD0U62!TX(8*`@WXP`1+
M*!-EL`76<1(09"%TD#^U<X8=<1T214=GD`);]#QE4``%LG1H`1D/T#%[P`"#
MT1$$(`!8<R%?X"':`B(<@`4K\`X\MG&[ET9RR9DW\&PT-5-E``5>@/^&!-&)
MC#>8<%0`#1"*AK,V/<$:QO$`.8`U5TF%@1$#X.FF!J$"QL(:&I-&WZ-XF#FH
M/\*8<.1,>`1$>U0$;Y`##S!E<P``%X1N`2(#58"-=U,"32`%?D"I'<"5!*$#
M)3!MJ3D04E`%JX$Z-]!\\$$'+[`$"W`1Z"$%!W@=W/$"O&(AU0D`>*&+4B$&
MDR<0A]$)FM8YFZDP38`%.\`[U;0!,U`\'2`":/D#+.!4.5`!$_`##M`")X``
M'"`&%H`#A=@!,R`%".`UQ?,B),`&(-`"/T`#19`$&\`%VF@!2V`"^,H##]`$
M/*`"7-`#6L`#*+`"\-4["'=EXB`%(P`!#,O_!1]@"@Q;!!\@#N)0!)FG`-SI
M!2ZP`"85`S&WFEI0&%S0!`)0!=?YKP)0&+0D``P0`RX[H=-@"`WP`(RT!`T6
M6A^0`P+U`0!P``"5`@]620U6!3P(M#$#8=JC!5JPGE02`$,0`!HFD1M0(9+8
M6"]@5!6C+P,@B(%SE68Z)$JBIA:AF9$%%.;2).%6D^#W?ZA&J\$&(QJA`C.`
M#XWUIRL0(E%$J'IK$)`%IWO0)GQT`"9PJFN0/R[`"URP=L>BL6?1,6+`!07`
M!#TI"GV*$J])!6%@(=>Q``M0$E=9!AB0`.#A``4@`%R0+O*@#[:U;19"!5!@
M+!:2!PCP'TTS&[B`_[EW>`9<D`*-^@+T4D7SX`IH\&$;.`=+\`-_,)LI``MG
MP`(R,`&=-&X.4`0%H``#8`"[)@/@!E-=TDPY00(P``(P4``=T)%OX`4>(`@C
MT+(NNT@QP`@?L`$,@$C_)DS#E#N^U`A%$`/I:[,/P+\,T``B,`B&,`2.1+.:
M1+.$X$F?U`":0+-*.T@\>P`\RTB1ND@]VV"R]`;_!+0;.%#`F`H`D`(PD`+:
MPP]%4`6:)``K,$P36G"AM`,CH`4E*P(",`0C:,(Y``-L,+5*XQJZ&2JQ$`NY
M<HD#43M?*WD&(;:(0K:2V1->U!\$P`!-5L7%^`8AMQV`N:=SBXI,<5AXN__%
M>VN+?<L:+U!0#2"PIE8`9D"F]0$P;@%>?9`6M4EY#N`##T`5X)4'UMFD?*@!
M+F`&/B`0>&(`B(<HX:$/8@`>??!\#W`=#D)VKYL2X5$`#G4157@#"V"63%$`
M7+`$<\QH>?*=OHM71!(@"Q0#KC0``X"%?Y`'=B`&(M`!2PA3)M`!':`%-A`&
M17`#/WD#4'`!"7!I!J``@&A'.8$`X;L!'4""9/)_U\L`9_!ZPVD`Q#8`%P`$
M8A<&AGQ;LK<$;@'-2S!VK04ZL.<#`N`"S'9J(Y!_V&P`CA8&)G`#O?8"4I`"
MI89JC5!MUHEK%@1IXL<`"7!NVCD">V`<6G$J:#'_S^N\!XPA'?][$:FE!;H5
M%A#0`7@S4ZES!E5``!U!`R2P`^^V`#]L#UB1!W306K,WAVAWHX(:F&>Z)DN\
MIDU,ME2T1%MTT"DM!3S``$LP"-()I$R!RA`AMW3;DV!LRF.LMV6,F"&V`18P
M`320TI@A*L@2!H51CBGQ`K4ANN1!FS_YEV40`V4P$!_$``?H(P)!!:^`=DMT
M!C_U>@AA!ZX`!XPV$&(``-\!7I'S``J`=BB1`'F<'W8P`````>!!!PA0K+\;
M+X#1I57``"A!E#M#NCL0`B30O"0P`0;0AC^0!T5@`#6@5YJBO=J@`-&Q3$VI
MS&E$H0E5!)`AJ@M0.'V0_P`>[2H'H`.5'`,G0"<`P`7+J`,H]"!GB%I.2&W"
MT0<Y((\ZP%?SP#C<V#1KQ4QYP@5X<P)<,$`69*LO@`&?8@<E8-`!,B-]VD3J
M)U[%B1:UP@!880=GH`7P'"AJ@3=2(`."HS*WS0%2(-(^+!%`G#I5R!(!@BP2
M02]O!;8S/;9.+'E''59,L8#G-ANZJ#!QV\5UF]1YN]28V=3D@T=)L`(5H!QV
M$`:UX0*4>L>8(!"!8P?*!KO6D09>0(9SO59>T"L(O090X`,[\P<#@`M-.L=E
M]]?!T0=;VW+I]@)B\`!<8Q!T\+C3*0]Y(`9S@(8!#M<N(!$.@`!L`)Z-W1%;
MY/_)2U`J,D%'#C`#.[#9U+K9A:@").``0'!SU^L!.(`#88``Q5Q\E4,^K"TS
MY10`0%!NT'CEQID`7"'=N?T@)?``QH(5?ET_D&$K;.$#,I`N6%$%$&"..K#<
MV<D,S!1<DZ<#S5R'>P!VW5@"+O`@[GU!XU64>X85/I#;`U$G-P`CL54_50'*
M[?V5E#$"8($5"(`7=Z/16*$R2&`A*1(S;T#2_FW2;.$16]1%95JF!Z[$1D+3
M3OS$/%'@"@-'OB@PP[%Z0E/A1_W%:13&&DZH'%X\;;(!.R`"!YW3!O`!!@`8
MOCL@M+-$3""[VS40*"T5?EF%+)['36,A:5";@/'*N?;_`*$Q$+^J,*WL"JO7
M$5SP`&=PHRR^`QN$Y1!`\8^54B6P$HO-Y:;<MV<``0Q0!MK^[*0+`"2``VFN
M`"1``PH@`!Q0!#.P708@T(5(`@9``@4@#^-U.B30)C6HKU02Q(-HG!<PD'V`
M!`)`J3[`!2=@79L,Z(*2F@,PS.U]YDW3J2D`Z#J`!$`Z$/KSZ1<``*+NG-WH
M`Y0C'9?&'6C!!=%A'P-0!91JA:YE1Y?86V/``(^&'?PB?B]@``)P6@1P?#_Y
M?T6%!%%7`%4P4030`1:0`XR*`;I-',PNGAU#1UY^\-/^1@E>TYH9%!9R$)M_
MDPUQ(6:=']C^!T;MQ79K[N>^_^&'RA)V``0V`;XY,`#7@=))GI2C,P`4#$5;
M%&>/7Q#3<08Y$`+UH^-XW*0&P=&V0B3<`6RB:Q!-9W8&HQ)LG4"S\0<00'P[
MXP.&D@,N@'8](P!B<`9_<&Y4H`4?<&F,K=0'3P"J?$&;:1!\@`,Y``@>/3PJ
M%CTF)"@-/$`6%0H,``P]$PQ<'BH2?7TZ?0Y])$`!#1L>%0%O`@)5(T,B5;`'
M50"K(W4/(ZH-(SDY56]L(CL`2V^O53EL`J\``5H"N2EOM*M:6BE5.T,CV"E:
M;SLI.P(-;%7+W]AH.0VPNB,``+!OV.$'6CM5*4`YW#LB#;`)V,&&S8Z#TD94
M65+%&O^Q);D^B`.P(AXQ`4!@##&QR0^>CWATZ/CCB<Z?/W12^OETTD^?DS`-
MB(%)LR9-/R<+-%BRQX_/GSAM"CU)YV7+H"?[F$0)<]-0%3,\N>QC!T6`%2%>
M&AW*M:O7KV"[_MQ$U@X0$!LF6.@08("=,'U>(%B2P,\+DW2\8-AC9Y.#N0E,
M>OHSY\\>JG0*,*C+L@\`+W]<^DQ`U\\>.I8%#"BJM`\7+GS_]-V3(VG*$HLY
M^RFPXX\#UWU\0)&"H$&.NUJ3]DV0(\`'!TA=_ZA0)PF%.LB3)$%.87F=X\N5
M.Z\#@@0-39[ZX#B[`06_#4#Z^-$Q(`%?'782E+#S8@^!*B__.J$NP6F/@@0O
M[.CP8T'DG@$%["'2"Q_@Y],+.\0W7@'T"7B!#W;LM@1<>X2Q@`OHZ>`#!)W0
M<48"P*''Q0TZT*%#"0"\(%X>993@DAT0$(!>'WOTYT!\%W:B0P$YD+B?#`GH
MIX,!!G3BQPTIG.&''7QT4$$+&RS0$4@AC328`Y]@B1A.+M4D4U@MO93&3CT!
MY1.8:(8%54=^6;5!"*]ME>:<=,XY%ED.[-$""$/T8($$!4!Q@QUX)>!%`70X
MD)(##"B0QTIV^%'&`VE0Y<D`.2B@Z&%BQ"!%HJ,Q@(:B>:!41H%^Y)'2&0<P
M@.4G83!0A0%T[('E#0?,U%D!,2CP_\*FO-U@*1T^//#-;9B1=)0?8@#`QA(1
MOC3`22?LD`0(`8!P+0C<=NLMM@&$&ZZV+4B@Y2>AH.(D#`$`,9X.!"@PGH`R
ME*"#@`04,14!#]!'XP<0#+"?#@^0Y8,,/FRB@P`DL,=)%0(Z8(<8)'*B`!(^
MZ7!!"H>AQP`&9)5@PGYTQ`L<50R(,49\);3021]A2"'&)G:XP&!\>U30\1X/
M8#">'25H8=Y^$R!`HPX)!-F7#P*<(5(8'FSP1@,+=%*34VB>^8<8,X'9Y9@\
MF:EUG62?M*9X;0;P9IQEM^VV37?ZQ<$!V=:QP6$([$#K)T<*P$48B_8AJXN;
MT"'&!XB6^O^2)7W9X0`!'RA@ZR=]2.&!BGO8*L82PGZ2Z!*N*L6$`Y1IH%2B
M>\R!*&)G+$`%<(06P`8"F"4:Q@-O((O32SYM<H,7"G$AA0$$H#Z`!^(FK_95
M&R01[AMO/#\$*FI[P%>6.J1[@`8LL)%$`V01,#)9ZHFWXP$BP<N`C%0!X*M^
M?2S!";P(*UP%!'EPTH<`\:%W@[T.T`$"",")]`!`0.QA0-5$4@(7$"HV$"@*
M'>R`@0N4R`X%@%A1]F"``IP.`B4@P&5T$`/]V4&!.CI##F;F$B"1Q0`6%(D/
M=I`_'5P!!=$;`H;D1!(>?D5K7,N:F,@DMN"\#4UGFXH#W`0G91W_\8EDBYLG
MYA8N\-`@0F5@0`$<EQ(#8,``>U"1'P:``"X,0$MY^,R@LI,&*"1@,Q(;`!3*
ML(?\%<4+"3A#'_+P*"F,""XO\`E=?'`91='F#!/T21FJ0`!"*0H!*5.1XWP`
M@!LP(25]D`$;=*<LH_3A!`O8P1S8L((Y)*!4=.`##EI0`4F8H@(>,`$*>*``
M(#"@`B[````\P(`)]&`!#S`!7`+H"0>D*P<:V,,!GK"",SA3#`SPP1E\L*$'
M2=,`!QA`"4YP@25<@`#;3($%;L"@,^P`G`0P@`M80`!GYF`!-R!``9`P`G(6
MX`8(D,$)"G""Q92`G!.H0@E*<,\'>(&@_R4PU$#38*@"./0&#U#`#9!P@PN,
M@`4/A0`"]ED`+\B@`S<X`8KN><\E'/2?V(3`">3)!9O-TP4*^.<-#)`#!MU@
M!DW("!L48#6:8,UK00FBUX88-K%!,4U)3-O:G'C4IH9%BGV0`-W>P$H)I"0,
M$.!<7Y0B!@P$9JL^H((9W(*E,'"!+J])E`%B8$;QV"$-#)""JE+E@P\\@(">
M>,$"`!`DRB4``#'0HQTJQ``O$'!1$RA0G@R9`BK<!8LQN`&H$L"/N^PN,C]Q
MP``(Z8<PG(`+YMD#'V8``!S@X`<%Z``)0C``$OR`!BU@P03.<`,+).`"`P`I
M!%C`B3QT`DLD*/]"`%HP`1P<X`T;B0$48I`I#%C``COX``:FRX``0"`&#/@`
M$'K&``O((@88@,("M,``*'`A!E7P@@6@X((A[,`"P(1"`[B``09$0A(?TX)T
M%;@$-BP@!MCM1W@QL(0#3!<*!8:"?6,`#P;$P`.X6\""Q:'@G"Z!E[R$078!
M7(0#_-<+,0C`#L`;`U4`N,15@,(#[/L&^PH"`$!@PT9ZVA0?>@6(77LJ4<MD
M)J>J*2IH\P03V>;C(G,%JA(0Q1N``(`KWL@!8GC`#?+W"0-0ZC(T&@`&7'!&
M+-E!"DL@0);H$`8$2`&.=B#`8NSPA[L,0`%CY4M1$O``\Z#M#!]SBR?_3LB%
M`@12*0;@G*JH(@8OE"$/2G)``980H,K9QK*==$FB^%B43Q!@#@C@RPUV0((!
MWD`&$.A`&";P@Q>PX08U&,`-8I"T%R3@!@HPP$K&4TP2P(!;XP(!$"X@`U`O
MP0!)DT&C$M"!!-3F!LB6`0!D@&P6I&`Q+&#!#1B]4A:X0`S;/$,*8A0&`@R`
MD=,<``O$\()R*\#/\:%,>\ACB0S%2R1]&(`4E"*Q!<1P1_Q3RA[(26\%$`!G
M>\#`O>YUH0B%L9(]T4$'+A"A(1F`/?<"@,`<P(<LH"`'0Z@:#W_ZU*#F&"Q?
M(Z)1C=R5I`I9;4VT,<F++$4'P/8J$_C'#?AR_T;%4,&.?2A!*`^3D@&XX`-2
M^-4$(7I*0NW!!PB@0AJ*\I:LJF@3,7N`7"76AQLP``&4<X!9^WR9MU`!CWMV
M0!JF6ZG+W,`%+IBU'=;Z`#(^.EDOP<SI\N`6S)!*HW:X@0A(0`+:DJ"X+YB`
MP(H`:Q]TJM<OD$$!(""LOOSV+[=N0"M;$``V_)D`.]S$-\V'!"VDKP0QL!>-
MW)<?\7Q`*1J2P0#F=[_^T0%B+M$!LM,W`7_UP0``",,8:/0Q>+][$QOBC!V@
M((:!EV`$8RA*'CJH,)N)\%X/V/V2'@`%QQ-@!!;T`QWRR0DZ7"!(G6":C/S`
M`2GLH`4;*<K55'YDC_\+\0]@XS%05LX5DR\1Y42F_\I;3@-1-``!'H`"`@`A
M`X`'?5`&,6``B$$'-U`%()(HC[,&#X`H$Y1W51`&BJ(H9\`%M`.!`[`#"E`X
MM0),-R`Q?4$`FK%G=N`#7B`Y*5$K!E`%A.(X:?8`M"-G!9![BD(CBV8`"+!)
MD,8[DD8'>8"!H*(H)R1[5=!K?@<!,O`""@`A0+!X/N!%0"(78L!XF/1X"'!K
M.6`#'&`!&]``OH<A\)8`!"0?X<%`!S4@2Z``89`^\B,29R`%";,)`I!I?4$'
M_*,CY*0C%Y,Q"<`Q]5%>)G(B)K!59S`!<J<##%`D`G(&(W`9J?)J+N$`"B#_
M4BJB`Q^@(W80`POT.".@@)M@9E2A,0GP,DSC-#I0?N>7<326%.PW%#B6-3ZA
M$T758_IG$R:0!6Q"(T/6);M(<C]A@&1!`W2S`23@`32P!#%R%W/&=8O"+P:0
M!UE"1CR`2)38`UP@!IM"!V6``0-4*PZ`9_A1.W)A,Q.D*%RP&/E#*%Y$!05`
M.2<$!95"=>&8`("3)Q``=)PA>V=E&YM!%F11%#KP`F$P@]WW`EZ@:)R&`R5@
M`#*``/HX0,JT>`1P`UZ%6\P&`;1RB5@B`1G0`""0`S_@`!;P!@<@`?I1`A.0
M/DA#0`)R`P(@(">"`?9R+S$0,`%D!P^@(^7!/GNP_P,R$"%+<H$2LP<8U0EV
M(`-(H#!_!1?L80$8H!]Y]SYIAC\F\@)K$49[4`":44<'8P#E%@8250)G<'0?
M4);\8@$^$`9A(`8YH'K_I@"SU4X(,$!G8`,L(`(&<`*HQ0,B<`!1$HL]E":U
MZ#4D(3NY.'_#2!,\X(MXT#M[P$1]8("/27]`07$'``(-X$M\X0):M(XO4`:_
MEB43TS.#U@=G0`4*<`824RLN,$<T(C'01`5A4$@%X`()$!F;,``08$:39@>0
MD`!S9P`?XP-TX&9GI2HIL7RI@24O@&`08)-[<`$[$``C(#"<\"X9,@`FL`0/
M`&"%%0,/4`0$,`$P,`P0!O\`!Q$#.U`!8K@$`K`$`*`%\>`!Q%`%'Q"'424!
M$L`'ME:2&L`'/1`N%3`,55`$%G&?`F`1(R!B!R$`YG`0SB(+X;`#`9$"*8`1
M"C$/!S`0#VH,Y\`*"B$"(@`$(Q`.WC`$J]"A;%`$^I`"(U`$'8H-1<"B5<`&
M*WH052!BXK`#.?"@PW``(N">'^`L\6"?,;H$]KD#;U`%#^">O5`!%2"`58`"
M*&`*;&"E`2@"14`*)F`N("&+B.E^BMD'C/DH(Y>9?Q"9ETF9EHF9;FIDFYED
M(/`&.,",<8$`4``X7'0X(1`A:@4%"I`HF_`",8``@X8E5E8`(!D&!<)'P)$'
M#Z#_@!.4!R_@`G:8$B0!.<)";V'@55A"95R0@NU!!W]E`%H7*05P`#X`C3H`
M`=O@`SKBG9P0@RH)8!X`8,MU`A[`+=N"+=M"'2#P!,7Q!$GP!,S:K$.`!'!!
M`P.P!S20`9UY``7P`RBP`@&@`B:P`!@@`KF$`0L@G@N@`!+6`&@'3",0`R;@
M`J<*`%L&4P*@`#!5KA>B``J@7YS*J46@`!!@EPH&L%+P`2Z@4<*F!7DI!5)`
M#%(``5*@`$`'L`JP!*`&L0"P`%(@`P][``D@!4G34L`F!3;8:[W&5Q>0LL/P
M?4GC8<5V`860!2R0!2:@`#/``B&``P(@;1T0`BH@``>P_Q%D^A%F:HLG(51/
M%1EK6D1U^J:229D/@'*7.8M-VS9`0164%P`5H`)\L#1<\`$$Q$4)T`,S`RJ*
ML0"8I&@+8`9Z!'QSP064TP=BX$9AD"I^L%8N(&>:Y6!@Y!JJN@1MA25G$#GY
M\0=AD`=>\&NU8@=Y@`!`AX&`@P#]PI2U47D%T0`'4`1L<`!`<`"[0*%#@%Q2
M,P0-T``!`!W.@6O:PBW*VJRNRZQ)``0KP`8-L`*:NP+0\P8K8+H!4`0T8`-?
MN0#EUAX)@`0(5`)`4&Y?^0&#$D8/P&5"`BTB00`(P(HZ,`((("1V(`#^P4$^
M,JMG($9BD`+Y<2_DJC_B(R1GH/\`VLL`+*`C/N!Y^F8`G1-XX7LO>^`!"D-"
M#"`D`R``J2@2IH4E3=(!YB(!`R`"`O,"'/!7Z#>F#E"FAVFT6_-Q-\8EL@,`
M;*J+;@JGD^D2/(,*64&G5=M45XNGJ0``FJ!9P/D`<4`6+T``4'`82H%!(V(9
M>;`'=<@%;)8G9V``"Z"`/I$'@>*-B?("!:"OA9-F"+```[!Z?_##LY$YM<(O
M09(2=B!O2Z"<F)$'FT,`UFBX)#L`\0$!ILNL`="L=1``R_H$J("LQ?$<Q3$=
M<TP=R[H<V@*[RJ'&KIL<Q)H<RK&Z;[`'$@`O[)L^]6*5^3(_H)>3.H`!$!"'
M8:2_TXO_,/!6!0A`(0N3FR)Q3X#H-.-Q`0?4%].Y0*SI0,#'4^F#`15#'B/0
M(6MW`Y<84_VC`Q6@(P03`Y3C`]AG/@A``ED2`B'0M0@L`#)B!^67HE$RM'A0
MM$!UM!8L%KR#!&R@P4Q;IQ[<.U6A+A&\%"5\5%?K`-QA`0(P`7M6A"VU&5A&
M9]58.`4`3WG@.$QP!L%)CTB\&(J2$E:'`ZMG:1I[%XKR`F00`W"Q)"_P.U=,
M(P;P`3'P*%!'!2D@!L_)04M0!L;#!5*W=B-@#D,*!`T@`OV@!9@K#N2P2:HP
M`BLP`KEP`&S0`BJ-<3R:"U7@HOH`M+(P$`>@$"F0`RWPT2*@_PIL``0HJ@HB
MX`"%_'N;@(8Z$$!(<`#ZXP-<D(:*.@&;N`>GQPEG8,DBT7KO4I.=\`(7("SC
M$5,^L0?C^RLB0:[I0\_I@W0!E-:A"B^OK!1Y<`$2S0DN4`*9(R"W3#->X"J=
M0`!:H("K1P(X$,$.D`6#FB<?^`/ZP0$9@!$;\0D2S'$@AZ9@X11^D`;5'$AM
MFIG9_"(/@"T=T,W?;,(_P0$OIS8"T-/$HIP4M`1M^PEY,`>LI7T.T(`/P&8G
MX0![Y3C:MP=P,!N8Y!H9BV6.8Y\00G4)L`-8QA<OT`18]T";*C\D069GX#YG
M$A=5H!26X0`QF``LL`0C,QX^&(?E!O^Q`I)X;Q0I`S`!+^(#?L8);T8""VP'
M'^`T5#%1Z/$"]#L_(=`#)RD!'+``"\`!GV`#`S2M9U>6=O!-.I"0!C"`N1EH
M"/,"`_``(U(`9)P"`W4"ZJ0>!$``(G!N>70"`G`#+$"_&*``*WX!,<";*>L%
M`"R1"G"D3GA=.P`!`6L!5?`9$J9?#+`$&(`\P`1@XO``'_`!^&F?2YZC^@!C
M,@H+VE"?]-D"!X`%6"``'38.*!H`/(WE&X`M&P#!E4VU<(/97Z'9G)TBU]S!
M3_LB5A$`I8T'WGS:1W2U>\`N9"X!>3A!/(=V-$,5=E`:1+@):M:!A_$'.:"`
MCD,C"@`%9R3_'CC!2"41SUR@`+#1%WG(VR0!225PW3AQ`$M'%2B12W_6%V7P
M!I%RB3<`!0:@!10PZ[0^Z\]1Z[B>Z[J>Z[>^Z[[>Z[Q^'+Y.Z\P![,9AZ\PA
M[+<N'77P!LVQK.+2K&\<+FX<`&N,"M'CQJ0;NFPPAJ:KN450!$,P!`?@N6S@
M#!TV2OS0"RV="X,Y!"4J`$-0H>/@#/D``'/0`L0``+U@G_'`H!70`R)P[JA0
M-1%,M!/\S!6,)I2N$SM0MY_]F#R``T'F"<@3`"/<S'C^1)OI`)1W+1L@`7^P
M!%(P.9H%!6:`@4KQ!P20`L:)%S<`3XLR1G.P`(022/81T:^Q!W_P_[^-YPEJ
MY@+`L1((DH)(J`!58/-[5#)L0`6,ZQ(#D+AB%G=4,-@B$2$Q4!`+$`;EUDWM
M$0:H@0##^P$(0,:9$P/#ZP-2@`1CL'N`&ZMC$`8I`!=C<)VDB#1%(A+-XA:#
M]:WEQ@%[P``(1``0P`EC$),%]`).;2($P`6L:`=>``'Y,1X>D#X$4#_HL0,E
M?QA^0(B[YU#X.T#S@WN10B,Y\C00\#-G`,SH$?A"[`?QVQD3<P,DH0,F\&\Z
MTHD#@ET^P1Y:<`%ED@`D@`=8T@&E':`_L`,VH`,T0`,\0$I"*P%G?J;0S/!*
MVP`/_^:9*004/Q46'RX9O_$</Q;*!`(P@/\#?Z+#$55WCJ-@!6"-@JNQSLF:
M"W!*<?<'"!!8J/,XBP$(87TO?PY>4@-]='0."(AV?8H$2P60#@X^"@B)C'U5
M"96,?@E>!CYV#G9[``4^.GDZ"2,8.CI]%P!TM6<Q"*IV#S)V.GY^'[HZ`PA(
MD3I+7()^>RE[?;4R%[4Z4@DZJ1<B`XQV%@QV='UV'GNU)2Z0UC($D7T^#7T.
M.B4Q)[4O2RY>$.NSI(^?/F<0S$N7`H+`2`($#A-SPYH#*0MO[1"H8P^&!;9T
M^'!1JYZO9A@,[!$81@LQ.GMN5#SHH@`!=F,>6.L8@T$M.B]&7)#F(`$)!_@Z
M=$#E@(:`?G8X=!#_<6"#A3T.\&C]\R<2UZ]@PWXMQE6,&+%HO_;YXR<-&P`O
MBLDEF[:NW;MB>>`P2,^!AP`!0O39BK>PX<.(T<Y-=R#`AA[K%)V!LN`,TDM4
MFA0HA.[,`@AY\#FXX47!`#^APU#QH-(!'3L)'DA9R3;!$B@^8.X9P``#`4A_
M["#8@2`/)#H%&)A^P2A/%09ICK]`D$)!'D)]"#P0,ZS/C1T+[`@TD$+',!\,
M$.P)\^*#,%L$Z859%HG.!Q>"^NRI\F)G@FR18-.,&"*$H<T"%L"SQSKMN,!.
M+0G,T]D0]!#`0`F1`*/`0P2A@Q`$)81$7'^1\+<3"Q75(D6(M5RP0S7Z_WT$
MWTC:$+!A/G9`D4TM/HQ@BP-[%'`#.CHH@,1-^CTPABUV]`1C&#DDX$=<'9#`
MAP,2*'6)`P,\I8,$'&0!0`M623`885XA1I=9B*W5UEMQS4578G2F)<1>!T7B
M%V""$5;GGX"J*5<J0`0`P@H[2("4'00`P(!Q=D#BP@,PY7')&0\D@-4>=!@@
M`!=Z#L)%%989-]H2-R#E!QT#<&$.'OC\$\,`=OCQQP`0?/*:<0,LD8`JL2K`
M0!B,($5%"JD6H@,N2]DA1@H+T&,``/2@)X4V'FBZ1Z1>*#)(A-;0P8!#M>RQ
M@X&U&&!`+0[(L*YY"833T0M-7!6I'0SLL6T)"O^HHF\")>B[ASWBY5&"!06L
M]$(,"ISQPL,?//P"`1`4\$(8`U1WQ@`#A)$"`6%@?,$%&+]0,<8^2)&"#P/X
M8*$%/K!<`&X$^,#"`@2<00`!O=1<P@U:E$!`&@4DH-#.#(Q<0`DE5(!$`5!_
M\`#4)8BAA0LE&%`"#US,,$,!$RA0P`PL>(HB"UDHD,,!0RR`E%9X<)7F86N>
M=9B;;L$EYYR!_JD77WK^%=B9?1=NN%B+.5#5!B(`<`(^/N1A80)AV)$'3`N4
MD8BEV7%A\3EM+9%&:%B%,8$+XN@7A@(0<$>'I6DPD,``J=!QQ@?JH>,';`]8
MEJ&KFB)%QPU+*.`#IP;_,;#`#5V],(`+.R3P@@%5>''#T@A4<4()!1CP@.=+
M`Z"`3#)]@,3U8G"1P-.38'`#]P4(<,$-%"D@MDP+3$!_`0H()8:Z2_B`N@SP
MG1NH2PI3&YD!%H```XSL`D,00P(2`($=*$`&,N@``'!W`1G$2P8(D,$$[@-"
M&1S@`Q!```(2``030``"PHI!V!````S`T`4>*(("N&`"$U1!`!C`@*M&X`(&
M6.`!(U@``WHR`@#$``I>8$``8O``J?WP`0^(P0&6`(`*9+$(#UA"`(%P0BXN
M(0`Y^,`&6]`"%"P!!0+(`0!VT+@W`$`$(MA!"]ZP@3>HX&UH6HN@RF(WP[BI
M_P`-T-O>#E>G.P$.'X+K4]P82<E`+88/+7`,"7)0`2^DP@<(X0+.,I005.$C
M4C?XC&46P1LJI,)2>^#"=E[C@#`D@`%2@,0Y8L<%`AR$2U)80"$4L0<#,,``
MJ\*'&*#`@$5$*@VNX@Y2]@"!!Q#``5,*@P&X((/O[."%,L#``4`(PRHL`9PY
M>$`*I0`!`4C!$358P@)`F``!6!"$"!A!"%78$WPNH1<0D,$"#I!"$LA@!SN0
M@@P4.@(9D$`*7`!``MXI@QBX8((*?4,",*B`%+@`@QKDX'\^X4$$?$`!'1B9
M%AY`@@LDP``-O8`#7>`"!]Z@%_\S@`M&,$!<+(&`-_](P`>Z=P,9,$!(-V#!
M29?&@@L400Q0NP$")@"_!TP!J"4`P/M*@`0`+(%I0CJ`V&S"`Q-HH``GL-_.
M3C`#`73@!`0X008$4)7P9"60B:E;FXJ!R'/MS5:5/,S?\@1)/A$NL(@55#'P
MT0(0O`$'%2!!"J9PCDM`TS27Z`\"8E""VM$A#9H(@VNR\P`J]"=2!,#`4?.`
M%3O<0#:UPH>-7#"/2^#+!6=8!".D$(,$7&X180"`"RZ'S3RXZ@:HB`0"U*F?
M\W`A!EJ``GQ<!`F18``!+QB&[++;$9^@(PQ28$8MH&`\:]@!`((PCTRUX:YA
M^&%:`RC7`L)3"WP-0Q\*T,;_LE@D$C8,`Q-<*,%],3`!YA##`]I01C]><TY0
MV@*](4'13A!P`DCXX0(IZ,]K@H@4D9#$&A2KQGAW))(#(,^U-UB5#K`V@`<]
M0!O`>+$BP@"$;A##:+9-0`=2(8$PB*``'>%#"$30@B&8`)"3G)MA]$JW@_0U
M$9&82V(+DX$O/%(=AH75E+><%KG@@;"*"\`;$*`""5AH`9PZ1R88@"0'_"$V
M"'`-.FRD*7B(P0MHQH<?SD"%!T3G,L:4`CKHL&<%!*08=AC``@"0FQE+H7A8
MP689&,``;W%)`3%(%3[VX`+Q\2$=>1##`X#``%7=0`3Y$,FX7L`.!LC@(6-`
M<"UP_W6#D#"`"Z"TQKE.J25\D&`ID1@R*+&$@2;`:`\Q,-4)WD$/@"$%(2O8
MTADP4(E46``_JJK`)?HP@`D48)K"M8$?D%(%&ER&(N-N1"6*03T2Z<`"M(B$
M#[A`#!W8B"/X6I>EPE`$53E+#`?108!9;8T*F"</>?C`!SCW@B)T`Q\AR,"6
M="R:%WB)`QPP`I';IJAB?+DK@FPR(?/:![?L`,H&`2R7[9*!#,`M0Y$<#!U6
M3G.NP$TK>@IS`$C0@T\G8`=#VG:C%$`LW48T#=ZB`\\J4=DS`*`,25<T!@2!
M3:4_X`55YY(+Q+`H5-RZ&,Z$```(\)K70.G;Z>`V%*"@BO^JEZ$%-I"`!*Z4
M!1%80%$2F,$.4NT#&^IK#/-\P9+V8`$=C&$W,BC`&!9O`1.XHA8`H)T$[!""
M$"C*`3BP_"6RL`,;7$(""U#!E2YA`2PY@``3N$P?$G`"N4O@"BL8_0\\MR4%
M9(`&BNI##[8=!A*<X!)\J(`":(`'">!A![C?/`NV1`(-`)H:Z;##?$ORO'PX
M("%7DCL&0L!C&_3;O$EEE_',$XEU`$D"#_#`Z&G0@@1,7@(L(($$MJ4E+-%`
M!)[G@Y!WD`.KH,+C*I=7@,4F:E)R;'!R],`W-1<6+?=RZ1!S>#!S"\AE-P<K
M>G(`CC4!=P<DI(%=JW)]7.`"D9/_#@Z0/@G`%PZ0!E[`!;3C9OR#`7DP;JK@
M`C'@`Y=P$`I0/.?`!,@1`UQP!HJ0"K($,EM2!M'#<`D``%`@#JDP,ZAR"7]`
M!U+@`3/0!V!R`G'4`UJ(`AN@`@S0!&N@!0+0!#W0!$`@``_0!`RP!D!`AFNP
M!@+@*&LP4'.P!5C4`ROP`)#Q``(@`I`1`SD@`AZ@ASNP`4W0!'K8`EK@`3U@
M1&R@`EI8`0=`AEHH`BA@`4V``AZ0!%S`B"B@!4O0`VG(1BAPB$W`!I#!`"@@
M1Y"A`@W0`GJHARM0AF4(``!`AA;0`@"@`DW@`0#0`**H`@\P!SFP!F4X:J+8
M`TLP!Y38_P-SL`-:"`9-``*\N`8,,$<,4(9UN`9-8`:GR`",V`-DA(G@N`'@
MD88[(`"4U@15X(?E8`&&J(5-@`8-T`!OD"#8Y`<?5R=,1C<&B(!1%H`3^!4-
MB'-6*#@=(',#N645F"%\``0@X%@H0`.G9``?P`4PPFTAF`==@17>4P#>,@!I
M``7OD&C7!P4GIRK@%0/S4`S3PP7]P@A[<`9<@`%(%PFX,G8>$A.HHEMV4`8+
M@)'ZPB5<L`37]`=YP`<9L`/+9P=Z]P`S<`(GD``Y<`(:H`$SL`9<D`9IH`$/
MP`,SP)4S``9<F08SH!<G4``:``9FD`50DP8B$`)I"3;>AE8F@/\`8W,"$R``
M6>`U,^`!5(A6&K`$9W4"'=`$4BF5"H`#5NDU#0`U!1`"/8`#>5F&;@DUE!"5
M(;``E#D#C;(`48E6(A"54DD">`E7*M`!!'!6"(`&1&.699@&5@D'8*`!7%D&
M9B";1$`$/4`%NYD%66`%8ED`7T`%8Y,&35`&!F`31+`$7L-67H56)Y`%.:``
M&L`"<F4"4)-6WL96;?4U)T`$<Z4%C\$.`/@G_;AD_XAR"KB0!6F!$H"0"KF0
MB=60^/"0(!``C<,'?[`'EN(]!J`?V,0;!$`(J;`',@`!Q")T,0"$ER`Y4%`&
M;O9*Z>$:A;`'"3`KBX`/`_`!7+<6?9#_!WWF(4`!!0_@`ZO2GT8H!:,U"!;$
M'(Q@`P^0`\LW`UBP>Y%0`%BP)3;`0'S``:"'`\G'!TWP>0-``C/`8Q;``YZ'
M)0BX>=QW"0F0!=NF=TWJ`%P@>EM2>HIR!0IP&9CW>_A@`RO``?AP!;2')3`9
M!I?G`:9WI*WG`'Q0/,1G?,BW)5XC=XT0IQ(0`CO``5@">@N@IP/``WB'>AQ@
M!W)G`3MV"3_0;\!'-ELR`2=@`U@1G[EG!YIX&6$P!SAP)7T0`G&&%)6'%$Q`
M`UAP37W``4*P`AM@%;5PGOPX@(6DGB;'G@+IGBYGD#H@.">H9?2)6/89%8T!
M`GW4`R!I!Y6S_UF^I1]T4`:4<1H.D`>M0FW`44R4@'7,D0:]Q3G#\P`W,JUG
M@&EE<`XY^@#(%!QV8`-D0`7G`!,W,"H@Z0`/0T,L.&Y],"T*T`DT<`(HL`-I
M"0"EAPKQ4WP.8`,JH!XTP`<60`+FAB4/L"7*P`)XUP,J\`,/BGRBT0'<YVL)
MD!4.D`58X'F*@B!F@@\]=PD%8`*75Q0$`"8.H`%OL&VS]VURNJ04&0DHL&W*
M@'9\L`,F0'Q\@`<B@'N*TI>BD0$%8"8.,!66Z@`<8$2C9P,LBR6(^GD,L!39
M-0#W<`D<4*I88@(L\`/FM@<5@`]Y(`&:B`]]\)`?BP="I@!LVP$GZ/^U`E``
ML.($*F`H&V!7LDHGZ5D8!W&K"9BK`_F>>M(#@/&K(1>LE&2?C.580)`#,Q``
M%O,:?5``W2J!?+8&,'(0!E`*PT0(<R`>'T@\"#`(KR,<`G`K7$$'&?JQKJ`?
M=\N176$'(=@5J^*?![`6E[$'RG$)A&8''O4'@,H!>%``33`5/3`83=L"GW<%
M%C`!',`'$J`")#``5\(!%J!_?&`#",`"?+`'--!X&N"]`O"R^&``93!ZF;<E
M65`%UX0'#G"(H^<`7!JS"M"R'7`%9S(`;,"T/Z`"-DND)F`#WHL"<W>POF>]
MP4>]]'M\YD:_,Y`%>MI\2)$E`@"DU:L"5V'_O3;``];K`#^0`<8Q?Y-I"03`
M!FD+)A4L=WPP`5&)P#2@?EKA`';X::N:`T:0%7T`!U\@IPY0!A(*M4X@`$0P
MM$XP`Q4@`&_0`[;PMP(X<@5(N`'IN%R!N"B[N'>%Q95DGY?0&&_0`3W``;$S
M`*?E6K.$"ES1!*""#UUA`)G6"0B1`^\@@06P!/F"%!RI1;^`#V5P3J^S"&>@
M!6C`*5B'*:P`''_@`BM0`,DT&BFP!J)U#GM`5QQ@;DG)!6SP!A50>3-``@=`
M-BS0`9?(`BS`Q!:``Z@<`I\<`BP0`M,;RRQ0`9&%`SC0`3GP:TK!!5R@%&2\
M`'3;`2IP`%+P3B1@_XL/]6MN10()D`$5,,R':0(X\,P(\`8DD,T9```\8)HD
ML`,`,`$XD,T"0`(9(`4YN`#FC`.ZJ`F:H`49@``M=XCR_,W8BP`*T`,M,`$\
MD`$\T#@\P`,38`(YP,\:*`(#O0`F$(<6T-`F\`088`(JH`(5L(L3S4D5X`$6
MX`$'T`-@H(4'T-%@\`!;\`9HH`)+L`58D`-;T-(YP-)B!`9O@%!;L`-SL`)L
M$`#X*,6#]`<$6!ANX@<$``0G]U>.^YZ+)44!D)#`ZL6!!3?ZF`-BYL]N)@4'
M(`:Z]5ELP&QN]@?#.*^*\%I(!Q-<T0-<8"NLE`(P^!K!D80SAP]*%P-PL/\6
MIT$'".`%MSMS"H!>P"$.1;`'7<''#P`%A&9;-]`"%/EL;=4`9%2/`<`&5M``
M5@`85F`%:A``;E#95@`$#:`&0$!&;C"Y!S`'?#0'Q`@$;W``+[TV;-`".2``
M;,`&<]`".]`8.=`"*UV/J^W$`H`%(I`#;"``<90#1=`"(B#<`@`"QQU'P8U'
M6,`&0(`%6"``2]``50#..\`&<H10;G``E@C.#2`"%0T`OHT"`#"C.U`!*(`"
M6&`%6Q`$8!`$+RV-\9T#8'#?8(`%9K#?78`%6]`$7=`%0N`&0E#@0B"-7R`$
M7Q`$!?X%1F`$:)`%1D#$:+`#(="71,",1)`&XJG_`%>0!E<@!1F0!DY@`S8@
M`#9``T[@!#BPTOY'#/IHN()+JW?#%D)-U*>Q2,&*U`>AU$S=N$[-2'"#)9ET
MCQ6P+;QS!J%Q$(JV"?TI#4!9$8O0"!`P.ZPRD^E!.Y$2!N0E#AZR`]3&"0Y@
M`%`@`U2W*@P`!=7&"!-%.VLA'#N0,'!]`BCDY;52`2;P>Q(@.4M09E=2`")@
M*0[@!`H.?%3P!6Y.I&_C!%]`!%OBSRWH`$L0=T=+I7)7JHIBI=O&!:4WPG*K
M*"5\>:%Z!=G'!PT`J`YP!1.@`:(1-I&^LQSJ>UO2`Q.PL'F`!Q5`L@Z0IY>`
M`P0`MR&+!OGG`%U@!DQP_R6$OB57\`5.(!IFT,-,,.@-$.W'3@0]+*="0`1.
M,'I!\&G66P%+L"5.8`7M*Z<%D`%6.,0=RP1.D`-70+_[)P!=&*LQCIXT;D@V
M/M1%K>/TR>.Z!Q@_'N1/K14'(=4@D(Y\T!\^4$T($`U*)SMKL0AYD`!0<$TP
M80=R$`,&,``76@`?<1.IX#VF<:$^$$9BP"FO@P#%DQ\__``,D"JL)$2YI3JY
M@@"$!A-IX$1D%QR2CC!84@`[4*2*,F1L:P--(''ZQP-?8*;T"P;/9@,*0*5R
MJ@)@X+^7@`66(G>Y/!@2(`4XH!5,(`8[<`5;`HES-W>[!Z@$P`76JR@-[+4@
M`/_L!+``ELX']B-:G^8!>E+"20HK%:`"83#"*5GI&>QM5H@',P``^2<!`2[$
M3E"DEW`%&6`#:-L$.+`E3-``(YR"W#=WV>X$'!#M6P"H?$`#MORC<@H$':!_
M?9`%+K`EU;PE'#`'2;JJ\=)_A9>/^PBX]P[4^8[C1KWCN_IE?J`#BAL`;RN!
M`B_D!.\`6A``*Y`!(M`!HH5P4N`%OL7'P%L`87`YJ"`&"U``D&([6Q=IVU(&
M#=,)>1`,83!N,!$;!'`Y."D;0!*B&,H`6(<*QH4`#@,(#GT.:0!B+PYT=G0?
M5&=^`PX_/3TG?"<[/0Z"62*;#@-<&9MV"E(T$H--$IO_3ADSFQ)<35>"#@!A
M@Q()(8(27SA]?1(A.U>Z"Q:L#GS*FU<*?)\D)ZQ]/QMVFS83L,P*/#:?'K'<
M+*P2'ER1$A(BM0YV65GH"`6;?658\!)-39\T>/`92$"*DT]-0MCA`,K-GGA\
M"F3Y1&7&%6U,MCAH)Z%"!6D2PLPIPV=0EE&;0G08R($#EAE.)#C!L4/`!@MV
M)/CQ@\?/GY]`@PH5NO.G&#%#D_[L\V<G`2`[!NR<6E2IU:M8AV;(@*?K3AT]
M`@1(X``/G:QHTZI=:[4KGD$'`FS`T:*"ES`.\M`QP"!!I#YTSL2(\9".@Q<(
MO"3(LZB/@052_.390^<%%Q=G_^P`)L`EQ@L_FO,@>)"`,I,^8AX8`#PHC`M'
MK`4O*#.HSQX$`A2<2=3GS`,&=/PP/(&BPHD3(@#,"#$CPX$38@PD>-"#!0LQ
M'BQTN%'``(`"+&X\1A#^QH,/)"Z(Q_(ERXPL/'C,F\%%Q?LL7`Z04)GE0840
M68000@5E+(=`#P`&:`("`C:W`H,=2,$`#PET@(,''F1@(0Y8=)!``E(\P$4"
M..````H9E.%A#B;@0`("]4DA10<,*%!B`@R,``$",D#@$8\(3%`!`CLJ\`"1
M$T``@`<N(#F$"1!$:<("1"(`@`D+OB@"`E0HD($`(DPP@9=%/,!#!B1X4$$&
M8F*(`/\""DQP`#@3"`$&$$"\88$.#NS4$UM`57646DPY!9545%4%Z*):<>65
M'V")1999C%9JZ5IN;=("""#@T`,'#&"PR"(%0"$%'<+$\YLPVCB`8QF&;3)`
M"FGLT8<V+RBPCF%]Y-'$`W[41@<"2]"FR"!5K-;4K0HH,$"L>RT1QA]T!#?`
MD;96:P<4#^01BQW3D;!#$54(8&X`-6%1A17D"E`%&T!@@04:[V+A[KAST`L`
MGECD8*\;\LI[P!SR`C#'`0!@L4-<]H*)YPXB*+S"#A3GT(`($0N@A;P"4%Q'
MNB(<X&_'!P"10\0[K)"P`%BPH47$`+#!!LL1KP`FRRUL+`#_``=TC(4(+;R1
MPM`I``&#`"F4.X0(5=0$`\9@%M'"SCN#((*Y5X^0M`A%I)#<#@!<K+``#;`!
ML0@[O-$"`#OG`!7:6JQ-,0!O5'#U$E@T`$,`>_;)DT^+"HI46H7Z\514B2IZ
MZ:);N;63`V&-5=99BU=N.5"..W``"`&0@`(K,2`P`&![+9``(K>&L89?AM&Q
M1P(+$/")'PA`L=@@A.A:`JI[,/&!"WKY04<>,L101CRW)K`$%;;TD087#!B@
MS2!<+)"&,(,DH%@NMQ(@``-7+!-&$P!HL0,)"9#`PP$XR)'`%P!L(<<7<FRQ
MAAQEE"$'&A_J#T87^<O"%N27/WTD_V`>(3!#%P*4!3.8@8$FR`$.$%@<!LY`
M.3.8`0D>((8`L:!%`6).`.:3A29DH``95$$/.G""`A0``!IP8194D('C7`$%
M'IA!`7YPA1U8A``V^-`5?C``!<P@##^P00>J4((7#.`%&&#``*9XA@6$X8DG
MF,`/6D(#"^"``WNP`PU@,``=[&$/)6#!'G0P!@2<X`QKW$,,)+`'#MCA`0_8
MPPORP($<)(`&S"@`"<[(AQ`88!-YL`$`?F"'@61A!SEX`P-TT`<_`0Y0@B-4
M4PQ7!,0E[G*`DL($L!<LR(D%!SIQ`"A762FJ#$,+`7@#"2S``>=!00&:L8T8
M&(``O+S@#_\$B*)4$O&",NAF$W]P@!P4@(!2!@9&`Z",`X+)/-(AQ@N9&<0`
MI(`!*0S"#PZXP0)BX`-6Y>H!B7"`'J>#@.`HH@`86`)OIHF!`S"@#V^900YL
M,8`N4"$/WJ*"%/!RJS4(@PYA0(`8>$,%,SRK3[BP10=ZL0D2V8(%6-#`)Q;0
M@W9LH@=X8`4T-L**!-2B#WR00`#P80,%3.0;X=B('5``$`50U`%-L,``M"$!
M```RI0#ZQ`EK<P,1^"`>=$C&1@Z#`>P10`%AT);IPKB)%32&#B6X`*KHH(`;
M--$..OC`)_:PA"4H0IU`(,&M'#`#!0#&51T0A&VP\(-;%5(`!WC_@P<TPY,_
M"8,MF23<)@G0-1\D[I*LS`H)%-"\03#@E!+`@RH32]FT4&4CFPH``$1``U2E
M@0%4"(,=F+`7#/12$79(0PQJ$(E/P$D,>Q`>(2`356'L00$UD)VM\O``*:2A
M=2^```-@:P?-7$L*HT,D!!1``$4DDY<W:)4=I/"!!,!Q>'WX`%0-8P<"+($!
MP:*#&.9`!U:$004*X``@)]#+LC@`!>$-PP3$@#T%0&%T9XE*+"KT"1<M8P8[
MD!WU5F$+#^#NJ=+8!`YDMPD.@.`M#K!!!B:"4@680!R2E:<V>1#735A`!0.`
ML`ALP)%YI-0!KUAJ)_"RB06L8A`T^,<@_YZJ%\!P00Z:480;>,.$`B2@6EPU
MP`V\18<M`-D!2P#`:83!!F^B"@Y4")9CCI<J`9Q!$7F80`,V<!-*"N6O:PDL
M6@I'V!08]I.5Q<IB&^N`QP8`E9)-LYRMXDH)"*`%#=@R'4%#`"IX00.HZL,`
M8L`%:J$J#%2HP@NPMX<;+*&9Z4R#`@#@+4$,X`8,:*YFSL`%`1`@#R]P70*`
MP(5?!J<`2YA#5`\]&CA2ZS9+D!Y@NKL#*)SA5G^X+0`.O`0HX$,#.=`&'G(E
MA7C8`0$#%80=>E!)/^Q!"C?P21^HL"MA/("@#G!/JE3TB1?NAB$3<$$M!X&!
M/MGA#!-(L`,Z\/\#/B`B#RNP11@2<`\',$$*&1`M*YH`X80NM)$N<)8=@H4"
M&_"!`WS(H$<[<(Q-B`$`)=$&.#0CV5$`9@"E$017RU#<X0$A#V\]0P&JY0`J
MI.$%=OA#'Q@06]>=9P\@=X`6.N"#T4EG,GF(CK<&<`8`I.$,3$C#`\2R@05X
M.2A@5HN8LT+FPAYVSE99<VT<"]DX0_WJ/ZFSVS8`@R'0H%=VV,,`3$4*0>_@
MRI^A0RC:*2P#>*&<SJ:##[H9]N(ZX#(Q#PP#Y*EL.T"`5BH'3`&\L`#AH8H`
M#P@M(E_W`42I,PW)>HB@S_#=PU=A#G@\3P"\@,<EM&`.'D#!`[20@R7_/`"'
M;/C`!\ZC!0%\8`E>.$`1`+`$U4\,`+3/00YPOP0M:"')`*C"&VA?5MF#C?8;
MP'WP&Z#\'<RA"LH'``6"'S$V'`!BXVJ`N02`AC=<S5PK*((`<E"%#30@!R)K
M00!:T((#M``&,$!_T!HP!RV4+`!`8,/!W/"&LA4!""`@,_D7`%8@,VS`?V43
M``U``0W@!BNP`F\0`"O@!FX02['4@`KX!A'X!$\`@1J8!!E8@4]`@148`"38
M`'4`!&(1@1002WO"%$@'@TH'.(,B6$[A=&B&=4$A=7+59E4W63HX9U01=K`$
M`G&!`C^6!P3@&+:#.@-0``)`!8;Q$)Q!!>5$_QEA(`6Q<RL@QQF+D0ABMP`8
MD!EY00"W-#K%90=<``#/`@ET<`/5I0W5(@8?@$VL80,NX`4&D"W#`@#%!DZO
M8WI*N`15L`!<``50T`!<L(@,4`554#TND`(`8(@+H``"L(B+F`)+4#T*4"Z(
M6#US``4+L``ND&2+Z`*XYP*&^`#V=!E<X(A0L(@*,`<N$'!0(``NX(I+0&@\
ML(@!,(H+``4[L(F&N`-5@`'(R`5SH`"UR`6:"(D=LXC+E0,J$!\\0`D9P`,3
M```QT"P*$'O,R(Q#PP7>6`6O008+L(EDT"P[X`54X$\*X`9=0@40L`8,``%=
MD@*$Y@)20`4Y(`5OXO\"Y?(F,L(&A"8C4+`%,B(%]B@'#DD%<R!0R-8#\"=)
M1P<426=9-#@X8S98.)@H0;B#C#5U/OAFD06$(5E9ER4!<1$`/```(7``!0!0
MC%$`D#$(=A`&!K")Q^(`!?`;N_$085``'Z`9MG`#(W)D9Y``,9`J+T!Y2_`L
MMK%-59!.PU,`?7$KAL%I#[!HF_`"";`&:<`8?1`&<```.W$K>T``R]5SC?<"
M83!>/A`&0QF+4U1$N35%<="5<'D&+G`Z+_`"+H`!:3``=+D$!7"7"2`#3S0`
M;V*8+V``.W`#=/D"P7@&81"8#!`&>1`&)0!5>X088D"788`$;O!$8<"64]#_
MF+I"`*'9E3#':8O1F:'R:0X0!@!P`BTQ`.YA!P`%;6>4!][AFKZYB*)E!Z'@
M+6N)7-I@!TV``&'4&Q_W$#DG!DS@FU)@`(?0!SX`!;>R4S'0E8(0!O^8<N&$
M`-AC`(<D"'E`*\$B`1V0`RVP`0R@&5\F@QII%!S)=!YI9D^7DG_`@ZGB9G"&
MD@#*2J[D`)F%`Q:P!ZFA3MDB!?>5"*=Q`_MT+'90`%QP/,'1*Q]0;%HI&AA`
M`!UW*P"0A*YC`*'3.GGA1[:A&:6P`#ZP",%R!CD@E:ZCA@I0::ZC`#E020>%
M:JAH8)5T`W,@#)``!<Q#6LBV:(#A!1T:!@JP&H#A_P(,<&6H@@8^@"H.4`:K
M(3P)(`=]\@<W@`9+6$F':"O@%`-<2@`U<%4R<*:]$@!`NDTWX$X0X`*CTQ1>
MD)92JBP.$`-7ZA.WD%PY5V\.`&UT0%HW(`!2V0<8$`.Y!$6JU!L(`'*#``4X
M`%9EZ0;88P?BD2I==0:,@61&20>X%T:0P`8)\`>Y<`,00#H&H%6&D0<Y@`34
M(@&=(`!#\(+W"5@;J4DWZ)\Y&)("2G4F:74'FEB7Q0&9E2:L``%+8%C5T@<)
M4`6ED4MG4`54P!K.XP5B,#SF658O<$;4D@``<*>SAJJ0)EJ.5ETW(`4)H`!O
MP*H?D@`(D`-%X`4R@*]E`/\!2:`8UH6<#'"E@]"C;Q"N:9D`.;`"4%`MAB,`
M1OD"9``!`-4'-4`%.P48Z.03>0`!!H`J?@`!ZP!.?T!IFT`'4Q"R3#$%"8`'
M?V`'#W=K3.``9,`%=/`G,1!X3T5:B3`%301D3\`KCAFN\4`D*%<M'P`83)!0
MTG,6Q@D4;,@8>!`=]FD/*O<'WC&CBK"(!\L$+H`'QH4`OFDK7"`%(-<4;P!.
M@.$#(:L9$$``1Z5*&I$+#L!YFA%J0%`&TV(',W`J@*&>9X$JGL84#L`"-=%E
M^!EXP*J?2N>157!K2(I8*8D#+C`,^(!3`0`""6`-RTI9KM0'+>DY$@!RYF$K
MI#/_`!^0!J"1<FG@!0H0>'YP!EZPA'[P2UT*+*"A2@XPF8.03'_P`3>@3I+Q
M`:5'?+P'?,2W!`/4O`.T!M#7L71P&3WX!WFP`4N1"-<"'()```"P!]1R!@B0
M`&!%!Q=P`5(I&H;A;`D078H`(E+I``\`=V\(!TQ0LS<`!^KTAEMP94VA*SH`
M&DP@!UP:!EI%6G1@75RZ!P>0"W;@`^UKGP90`VF@2MO2!TP`<PF`!!CL`!E+
M`."+!QYP`G*8!O<0'&(0">`K!FC@E1CK`G;G`&[%&$L96\&RH?:F"%H0<]-T
M`TM!!6)0`BSV`-P5J%Z@G&%P`,BE=O-*`&>`<0A``%),_P`[T+X$,`,FD#-Z
M<I%+L;A9L718X1,W&+FD1+DA:;F8:PM-L+FH)`B?RZQ3,0PPD`0@4`$[D`IA
MX`,\D`*R`TY[404($+.(,`.O,0B,D0`I(`4^D&M_$`H[(`;@E`ABX`7'<P;4
M4@!58`8IYP-_R:+V*665I')`-LIY`$P88&BJBP%["!3Y>@]A,+L"P`:75P4I
MD`0[,`+E4C95D`,"X`;GYX@"\`:.6"[A5R[!_`:M=R[E,@(Y8'UHX"XR8\P'
M\`3ETC,'Z"[G@LUS\`;;)P#B-WXC(`#3A\TNDP+F$LWE(GS&'$DSPWW]9\PC
ML`'87`4'<`".F`+T5RXIH`7"C/\T[](NCO@&S\PVLCS,1?!\`+![(/#,38-7
MQE@%#8`&P2<`6]``-;%\S">)2_`$<\`V#Q#+QF@P.;`%^O(&>#2,+5,$6TPY
M&.G%81RLE@6YDMMLGXO&RS`(%L#&GOO&J^1*=K`I2<#+'-`ZC8:8K-(K4%``
M.[$(!-#)L_8"D[@(B;`7`C"\!Q4&JC$\PO-L?,E,,!C*AQ76??`"NQ1J@<8`
MV$0*?U`&`"`[@=%KE=1=`H"D4@H![B0%4Q!&IX&SW$5ON(,`F($\'R!:@A`=
M@::>!W4#;<VE-UNM=.!K-0H!I%6S!I`&N40';K!J=AIH^!I5U`(<MJ506W49
M!-4'#P#_#WW@0M6:``0@64QP`RGP4'V@*P[`)WF`L\9U.H&V``:@`];2`$8Y
M3>$*&%10`)[-")2A&7A$50Q\.PX@!K$J#((K#"]0!04P:R$`-'J2D8P;9C"-
M%F+,260\N35]N3?M`#D-`E*PTSQ].:[$P)QC`@+0`89I;%+`!;8I#!`0`P70
M&+W!!8<`L6=076?!&P6@`%NZ5E+055P:&*:CH=$M9<*#/0<5:!2^5@8@`,@E
M5WZP//0[``N0`F6PE@#``+9```?`5V%`BK8@4(R!*C%@"WM`!51*!U1@:\)S
MLK5%!V5`%MDC!3X+VZUM8[ZF<5Z08R>@`-+D*M<C#'FP4L+@_Y@WD"KX>-Q$
M3-TT7N!>($6*P`1+T'#/?=V`(04%H'*N4@7)Q03!V"=C;>+"(+ZC`TX8L!B4
M-`!LH'&!05_"`,0ED`?"LP6WHAD>\`"-D0<'$,C2K0!TX-L=T`$=^@("T-]\
MU`$B,`)#@`&H\JO>[;@Q/<8SK3B5:]Z9F][KK:SM73D)JGX!T`$P4`&P^2Q/
M!06U,CU<L`3>I`VW]6CE6BT$\`$AZ^<.X`/,*&"=206J#!@/(4[<@IZ!MKZ)
M0SJC?!;=!0`/@."*H'<NP)X^N0!M3<7UV2<^<`!T[0(\@!',M&AO0<3!D@=D
M0!O@9*6/P!2XP!,.$`*0+%DNXC=B4/\%2[@'LE!N<N7F#I#DN62MC[`)81``
M@29A]`4:NF(#.>L`2]L:4QH<;=8$K=4',+0,8B#F=$#F@5<&:![)+F8+>5!N
M?:`#!"`ZM:T#%K`8FN$#P!WH!'!(J`+$KCD('\!=IDWHU<+`IQ(LT(T]YTM)
MMU(%Y30,`#8"%KFXW/W%W_W%,EW&Y9W&@Z`"FXL`)WGJ[AW'?;`I()`F-)`"
M$!!-U9('U.;6AU8%:5!.]^MV$&#6YQ9KMA(:<')4AI<'/H<\@H8!V!HLTG86
MH`SJ0($J/M!+"V"%GT`'X&K)\>`J7&``*=!X3W0!10"73SB*9W`&>*@`&D`#
M-*"ZAIF:9B#_.F%P!AC`05-4W6)@`P/P`S+B^C;0)9R/<560PC9@`TW@`3]P
M!E?@&[]_!08PAIL_^V*P^;X?`#:P^07@`CCP`S]```O``#,`_927^S]P`F?;
M^S_@`3T@!F]T!3!Y`AIP!26"_"/B`V?@`U(@`&*@`?`?GBU4`$)W!B>055S`
M'4A0`EX`"!,E@S=#!6F'"50$!&DQ"08W!00[AY,[``62!0T*8@4%"%`E)R4*
M+@4EF@=BJ@52`BUO##I]?[>W?;:XO+V\?GZW8F*^Q;?!P`1%56>Z?<#&T=+3
MT3@N?1(.#GT.%F\@"!)X#M3EYN?HQL#`VBT!(```?'T04&)[='1A_PE+9=K;
M!+@P../`#IV`"`;TR4<`P@,?#O*]2.#%@!U\=M*XD)*/(0,$>'0!L^5G(9UG
MZU+ZL=,GH!T?"!B(T>7@Q8(J!;8YV),`0(,<#+Q@6!*`00\/*`0(.-I$`)8'
M%IHT:<$@!A0&`G8P6(,UQX<'#!9H>2"U!X`=4BV(V&&A1Q,`0#RX;2K`@HHF
M%N:HL.LAQUVI.U#T:&LBB0FW/40LB=I$!!:[%KCD6+"`"Y<J`/::R"&@B0H>
M*G(TX;'`!(H'/+CPT*J`"Q4/0'C(YN%8MH().:0H0+``@`((P%,\@(!@]Q`(
M$ZCP?B`%`8(=KHDGR(U`BI0J`II;=_,``?\$*5P^."<1(T;UWPU(0%!`9<F;
M#6\PU.JE*QVT/\/.I53&3*6TA<_\$8Q^*A6X3@<F<*-@-]]D($%]Z40HX82X
MI,1-#B"`\`8,>_0Q``;RT:$#'7NXT$,)#@S@AP-G,,"%00`M<8,VMMCQ@0(G
MY;,'`C$00,=*#H3A11C<Z,,%!,X\\V.2R!BH2QH8;/,"%QC8X<=)?3``P$D&
MT8$`$%58EP`7#4@A@Q03++&$=3A\A8`,,N"P@YA2+,&`F`_X)J8`$"3@YP(8
M)-#!!2!V("@/`F2`PP4=+`%`!P:4<<$.(5Q@``(?,#HH!A.$D$4'8@0@A@$&
MD,>%`5FPT,0#"8C_<8,8*=PPPPQB].#",#,L@4('!9QQ`@`S7,$(#C@P<@87
M9?A`@`\)"%#"`%=\&,,//OCP0P\#A#'`#0J<\<*W%LCPPAY[A,'&N.26D,`_
M$!0PP!XE?;`02P\\$)$=#FA1!A-_V%&`#`7I<,,%^.QA1PH^&$2#!R`$4-1\
MO#@CH$@34RS@,0/F9TY)`O)'P#D`CC1@.0:6;`07VY2D@P,8-/@@'A3&+#,Z
M?>B0PQ,@)+%!ASJ4P`4"S?BA@PXN*(#$"R,Z4`(&4N1!1T3%)>##27D4X$4"
M[^:31]$STEAT`AV&\3-*MFPCTLC%E!2023>XL``!^'#C!01(#WV&G3K8_Z$#
M$B,,75/1`4,@KD%]Q#!T'R],<$$M.D"`@0\UZ[!$W3I8JDOE">C=QPT`$#`T
MT19HK@,M0INB]]`7Y)3W'@'4TD<8,MS`.`0UA)'T!Z>_H,#B0U<V@.L5T$#C
M##/F@T`!5](!ZPN1NU#ET&$LH,.*!"!`9,T+R'#Z'BM\K@,!%T3>K@\OE+3$
MO7VH>5)!!R20S^8*:%/Y!??J,`**^EBPP0JS3%\,22))4H`X)J",$6-C*"$`
MF`A0L@:61&(SZP4.NA#`E7D#!`[J`\PBR,$.XJ)F(\C0$%J@@PZ]H&TNN%Y+
M9""?$?7!#C=8@`&<D8<R*$`!"\D#3[C@A0'DP_\!S,+`NP`R)BG49&PC^8/9
M4"(-EIQA`>O;0QJ@8`8"O$")/H"""^"E@S,`P'![T$$!#N"Z#RG@<S5``-)T
M\8'/^<`%"6"<"SQP!J'U`0"42T#X:I8`&82Q#P:H0@F&1H<%Q$!S=F!`^<2X
MQ<\EH`"Y"P#APB`%V9'H%`D[">Z@MSO&6>!QC`/`#_BPC1L4CPY2*$!'`ND#
MQF&``2S1@=@^5[W?B0@*)-B#E-C@O1(80$0Z0``+;A`&H7V@(-IXP`<ZY(<!
M:`$!*[+#"<Y8LPOPCD0CF`D=7H"#'+1@"!;PGR_(!HQ\0.-L&!/&`<V1P"((
M(`T"C*<`@W&2BWGP#U__H*`#'L@REVGPG@"5F2Y&X#`/",`#87R)[EPPR+I=
M@#DZ>8F+ZAB1%TAA`82CPP!VX\.GV8$B/F)'&G@@!0*X``%D4Z(S[F.,;18@
M!RX@"$T0X`5BB.B-'RB!'0@``%H,K0!]&U$83IJW8(KK<PR(7!@0(`;708`!
M)1":'Y8P`,V-JA9T8%08_<`YS^G"!2]J'I&Z"($PHHY\2`O#&_"A@P'$[EX(
MJ(%"2F*XF@T``3>HV1XP$%,KZ>`!5]#&"USUO@L@@25_N,$.?J<WYS'N!2C5
M&[,H=ZIOR9(-!C/8"6Y@!SM`=A!A'$`,\!$1+SS`8"MIGP^N=`,2O"`,@[W`
M_[BJ584;0&0`'1"!+&BQ"_J,I"-,7,C([J.QC5V)``=(`0'DR=R3).\/6&*N
M`#M"W>IVQ`@\4!!-+IC!#0;TN^G0A3L"0`(1Y&`$E_.0`A;0T+:*05\EL4,>
M;N"%!<AT``.HP0-T@:\\7`5R6KM!#O+:H9UNP4XH3>(265J,@A2@7@P@DM->
M8(`8Y"%R`W!!%:HE@@.HR5$!^$`\`'``+3AJ"24&P(?9<&*XC.#$!RA""M0$
M@!6,&`!:,'$\M'"`LRQA!&^H0@J&S(8&"*`*5=C!$%(`@!0(H`%#WD$*#L"9
M%(Q@!Q0`@%($P(8#;+G((\B!%H`<9@'D8`AL&`&5W__PAB*D60!OH'(.#E!D
M('0Y`&YP<Y$#4(0A'*`!;&:#FQN0A"*LH`%#>`(;%LT&-J/Y#0V@0)\?'0!$
M)WH(;(;T$]X0`/X]X0ENX/0;ZA``2)?Z"9@>@L/8W``VU('-`=C`!D"`:?GT
M]A</#.#[RDF.`JK3/@<Y0!48Z,"4F+,^/RKV.J0;SR]DUVQ":QD&7P;>:NNG
M#P0%`0D\<`$VR$"60_,!!B!PNJ$])T@>O0$4$+"^FL2*1GTH`!3<YX>"R>%\
M'K6#`98@@`1S;,%H&^<>"(`!`S#`'P7I[`.@8$=9[L8'*9#Q#H0<@"8?N0@R
M3L$.BB#L%`B9#5(^2Q&T,''_$@-A+4V&<I-3D..SX/@`):]"`T(^Y>1J?`D-
M6(*(X1(/1XT@*Q^HP@>2<..?CU@`6E!Q/#S\@:]HH0IJ@L*8'14#!K2@`G@Q
MBW"$`G4,K,$+`&`#E2R`%0&`B`%0R`$7/("!&$"',BY(P0<6X`(3*"``-_S-
MJM8S`0!89CT0$``7%*";(R.`"LHI0@Q.*@43>.`["`#1;MZD!1DX!P$6T`(0
M'G;K"CUM2<[X?$GHD$[\K),:^$C&H<'"@-:[_O6NA\(#[-1Z*%@%"KC/O>YU
M#_O>OWX+*'A02?:0!^Y2V]K(EP8=[)!M!51`WS?J;`EO\!'+OE`*/7)`'B(B
M!BX4_\]*90!`0K:A[P50P6GXTMT#B*1]!_3$WV5;:<!]<1`H.``!:V*)+GZU
M@^76(@P8\``BD%,$4``)H`6I<`,5%@.IX#,N8`"@8#6@4`(W@`$*``K'X@47
MH`HE``"M0``EX!S&XAV#<`92L`.\`H+E`8($<`8Y=09G<`-<4`(M>`:[4P)G
M`((!4`#5TC92<`8^4`(N8`$&4"T$\!!&Z`(R4"T^\``,Z`,#X`,`D`798@,=
M4`8#\`)Y4`,&4"X3(0!P`UNV!ULOD&&O%08AB%9[)2YA]`(-H#>>=0-Q-#0*
M8``Z54+GLQ,.T'0KLQ!L8$3<<`,3$$O69%8#`(:ZL`<AH/]ELQ`@](<E\J5+
MT;4.I5=<[!1L`E``S)8D=.`#!=`ANZ!LE&@.&?!L**$#TM9=R;>*:>,'-Q,`
M.%`!M5```K``+^0Z*=!#=E!,^@8$8K`BY+"',Z`DMK``4)`/=O`'>_``&$`D
M5_('`^`%5_0'B(-$_R9_RJ<\7+`0/M`#.,(ET'4`0H,TA30$,;`2/0,$KC,E
MUS`T$P`!M@,,'S`2NM,!KL,%2\!`Y8-'EP,IM>`'EC<].B`&PU8S?K``'H`O
M->,!T],2"@"*?O!(S#0``?!`80`!>:4+NO$[0@,`(O$"2F@E?H`!4-!*P%`!
M-D!*#F``8H`E[4*-^($PC&.,H&C_$US4$)!3$B<51N3"!M+W/0D@-':@`(,4
M.?*R$'M@6@GG``?`$>10`+881GY2;TBC!4BP$MQD7K.P#<5P$F%`!6R0!'7`
M!O8`+^]3B:='#<_0$D#P3L`8#`,`@PH1$1V1!F4`+\'0>;TP$O6QEDQ"-MQ0
M!BJ0:S5C?/7$BC'#EXZHEM@6`$D@`PC%/`8@`.637A4Q-,FH/#'P`B)I46MP
M`Z3766D``#>P!]"U?$N`!,]P17W0':-G$]#T(S\"D^7P#`'A4=@W`-38!WGP
M!Q^P!+&D`U(8`PIR`D50$G\C/>8F+@995WZ@.W$D-"[P`0PT/0"0DY4S0S6C
M&_\H!IGH_PP8X`4\HP,>L$8EL``F:0?'HP-U4P</!%DS!`SK$0;[I`.X(S3'
MD@")B'8J,C15\`-X,`X7\(M]P`00``>X(`8[`#E?)3W<,$LEX0,0L%K8$T=2
M,@2/50`&,#1^@)$$8"6M>1$O])N$DP=->0MT8``*,!)]U%D[T0+#R`%[P`(C
M`&08(%UYD`=<4`0(D`<6A1UIL!*X]FL@HS9M60)TX#31.`<QE@(1E@M]8)=X
M29OJD&ND%U_)IB`C(YB$V0<JX$]ZB9CHH)CR%%T"I`,MT#!:-CVPM0`CP#L_
MM00KFHRPQ06'M!.>I0`0=0MV<`%5P`55M1"*=0-7A"]GL`-HH/^D"P`!!>0,
M$6$261I/?Z`!`T`%+Z`->R`%.5!6MP`O51!.G'DW5?)")3`"S&,'&S4!A^,=
MY<,2%G"++T`"&SHT"1!3G/E7'UHSP_"/`V-'#Y8PXR(%944N.F`"1>56FK,Y
M14DN#:`0;14[8;14+I`P[,D`?Y0')"`&(CH!M@HO/9"2VZ`)Q$<'97`&)))5
M,LF918.9ZEDS94@PG^,"LI56YU)&!5!"=B`%-&@E+\``3T,DK1<1[X(&"?`Q
MFY,YY/,JIS,`.S",?4`#N94#;Q`ZO=8+*\D%RZ=_J*0`'W,&%6)`-),,PJ9*
M@JH`Q;0Y#&`#=!FE=WE.TD"F6OHT.B3_7-3H`%PJ0%\Z;?\DIA-"IJ)X)3I0
M!>_P!#!``A<`"06@88"Z.G;PA#3A+_;U#Q[B?2):$`F@``-`?GL0`U1PL@61
M!EZ0!BVRHGSY>;JP:P9B)3>@7,@$1`]`!1[[#$U8"6%P!ERV%@(@`D_`;VM!
M9P<0`$^0!#E3!R"@9`"`9!&7="D@`HWV<XL[!%4@`B)0!4`@;$=69%7`&0?P
M!#^G%$,P!#D0NGJK%&KV!@)0HSE0!#5:!3]'`2G0`G];!W5``110!RO`9RU0
M!+*@9B6V`B/G90YS`'9V`"``!,8+!&ZP`C&F!6_092/7`'RFO(V&9H)V`(76
M:M`[:(#V'D70_V9UT&>MM@$!4&1L4&F9Q@9/<&ANYC#D6P2OE@,-4`2`%F,'
ML`(K``2S"P*$2[N$2VIO$`-FFB0)L`6D8@`$4!#Z`!;;0'J^9GHAZP?(59#;
M4*DQH!NO=,#.(*4N&PV*V2&/>A(%>&S!<+-)L@#^Y%T\:Q^$^3Z;F#<"H&I)
MT``:4@=#``!)@&J*%`8LX0-+$`,^U"$E4A$^&B-2L")>61D$P`2"NG9YP!*H
MRB,)L``XY)>'^4`PFR0"!@"9LR)]D`!ONWPO-``+\`$W0``Z-PE(<`$'<`,Y
MR`(6<!9`,&LX`P)/H`(5$(0@>%+&H@`,X"[:0IH$$(7-$<@PH0`^</\&;K4#
M!@"$!$!VA!P&'^`#VB*#4%@M$&``2`"$/C`$@4P",`"X./,&#U`%KA4&-E`!
M80!;)B4NXP(B<,.9%7`"-,`!>3`,.9JOD+1]%R`"O\.97+``/%,BI^,#S"E?
M"P"O)819)R&<LF-N)4"M+^`!'D4'#[`%J6<'.5`&[X,$:G01ED(#6I`A&9($
M`0"ZY7P`#`D@`I0`#``!<@I).4(`59`'*X*6#QS!RZ4@4^!IM4433]*R>?FR
MN48D6&(P9:"?SY`R).P,.3L!\X#"*4P@3#**N_F7.I`5#;`!'5`!@6NZG_8$
M!X``%U%".E!U+'$2%B43-$)\8*@C>3``6I3_!TIL,%4``?E0LPJ`9%3P/K-)
M-BQ<,G_@`^:7"1F;(DN@G8[T`"P``&VD"S=0!/CB`#0P`2BP`_6;,TD@N#S@
M4Z^S$9SI`!`0`V>0-U.5,#5C`!=`B"3@.C=0!2<@(@[`!5"@?UD"B@3PD*YS
M`9Z#F4]@!Q+``D6`U3K3`P+0`=D@`1Y9,S[`!=^V$E511T-3`5F[#<.P)'B%
MH@:0`LTP-!@0.C43/:X#$PHA(C^3.PW`.'M0`+(51G58`M?S`<L7$6I2$-S0
M/@M<`!#P.8Q"`X'=,`Y3<20`NA;@`B-B75Y2!ES`@P1P`HR0,`?76\25EM.P
M"V<@;&F0#SJ\38Q`_P!.4R1TH,$!S<&YY@=A0"JF!`<;`2`TLM"ZL`#OH`!\
M0`<0'=$DDVMMR\*=E=_YG0<Y8`&![5EOD`1#`&>5)@`Q8`#?@BX[(`99JTL[
MH@!IX*.=!0&=HTLY6@9>P+&<*=.*'`8&DZ-<<``XLL#L\$,NFG#ZC2\'808V
MT00%$`:2?'\"4`;L:3L#\`%6=EI(@P0^R0$<,``\4`%6O0(Y(\X3\`#C\A*,
MC9D.\>*_LP0^D%"68C`?)=(7X9V0Q)F&Q)GDTD,&4P`FD"V<F0"R8S`OD`0Z
M\->]_0X;X`$MT`$T0`-V4`'DL@<^T$EYX\CR90>=$P8<X``AT(6=50--Q?^>
M?GH&>]#*/JPW-O$M=G`&$&!%870DB>ZC.Y/@&GHZ+L#&.FR?E1X&RI3*\M64
M*D('W%*&>]`!.#``?]LP,!#'(B`#;Y`#$Z``/EKG.9JC"$``:_`!55<5&7X&
M8M"CH0BR(',+U3UL3],'&@`'?3`4,0#,"O('X$VEK1AZ)E49E,$<+Q0@?<#>
M7OH./,`!\DW?*NRH.G3B**[?Y#("%1#.+_`#G&9DY=L)/8$*>_`N-N@%[E(0
M`Q#%MI6%*<H%4K"+X](V&$!,.Y$&F!0&37R$+O"HH7>V_[#N^>U@-WH&5,`<
M<>GP4M!Z597O0J@%/92%8^3A-/`#)E`OYG6[#2#_PPC@`=H2!JO<62]0#R_^
M+:2IPR]@3;#E5A`0A126`I]8IPP@R5GX`-F2VBZ0+1XN`]IZZT\P`!#;O3!@
M:"*>`U@3YY*=A6\D!=\2!JWGY'-.`!S`!S6$-0Y?`V60HQ0F`$B@+2_0=E'N
M60LP\TA`E+"U5W1#+F<P!-F"7W)(AO+*Z0,``(B<+5(FEZS.L5'(0JE``!,P
M`2?0Z@$``QDM`!/P!BTP&)R9XIUU/(-E2@7@*I#4QYQISP@DLLK^#`8@!7N@
MR`CP``QD3@8(BO94I4GR#QD;*68+71WPJM&E`RH@[AP`(>9N7,N&3GNY#BOC
M341.+`%0!YO6T=+CQ0D1_T8:U1KYO!*ZX2X#D@8$[T,YA`%<$.4_8@=0(`5A
M(!$6Z%Q,4C$H04\B<1(,KR-Z.B-.;`=+``@(/GTZ?3X`.U0("BX-5!,*7``Y
M.6QO24D@`4D,`@@U5#4`7@A45$LI7#6E`ERF5&L/KUY+GP@,6@N*5(@*"E12
M.0BE7&A4OE0/JE1D4D^**AL@TYHY#3V^&0(0OBX['XP0*2DN"C4U`B89$QE-
M#+\D`#T9B@P'"A##```0^0A5,B!(4;!D`H)^HQ1(&?8F7SXNI/+M6,#%%X0<
MO@92<N'"X(HE&3IZ$&$"4H4/)E90"S!MR($`,'(PL-.GILV:";@,\-/'@8,^
M=/_HW-AQ!NB?/W[\'!4CYJC3IU"1ZDA*X$"5`CJRGL%0@$&?&PH(^*'C@$Z!
M!'MJ1HV:U*8=.C7).O!QAF9/N!TL]"24U<(F'G;^]%E+N+#APX@3$T[:UD&+
M%2QA#+GT9,BF-RZR7OB`@.8?.P,00`D#MT\8*5X2?/ZSIP"7!0.`TB&@`,,9
MN$*AQ!A`)\P""#S'*E6+E+$?FF3[C!U`P(6=L@,N2LD#U`Z!&!C*&@)0)1\5
M%VX@9%"@8D>.E]0T@>@A()0I`+(4+:GB"D$P,J6H>(F/8,V64OT=H,LP.U1Q
M3#["$%.%.:9LX4H-OSR!0`86N*$>"$D$L,$#"DPPP1S_G]3@0@H/0'!.%:VL
MHD`."V20`0)--,%.//.\&$,1^.B30C_#"!`0!"8`H``"$T"P@P<"#1.`?0*Y
M$(,44`+@@GWV"4#"BP@(X`D)"."P@@<DD("#!17((`,)%EA`@C4';`!#`PV@
M%\`*,_UD$V/-&8!<4`ZX!H%=1R6U5%.*^3&5'U5=E556,>S`A@!8N+`';GVB
M19QA;=6T!P$?+.'I$C'<L"=9>>VUJ%\@`":88JRVZFJKQCE@1PMO3!-`"Q;L
M0&(5;*0@JAUVD/!`&(.%`1H7"?P4U!X0,/#"GCZ8D6Q/=KRP!!5_.,"$61PZ
MX!MPRM$QG%*,_1'46WT$]E88_P0P(%<?>0"00AIDV9''#0!(D=8A#."IA1\2
M.#"`"3U4@2$%=20<P)A!^9%'#=,Z``L!0?6Q1!P],5%&&4$Q88`<VWZ%!@%`
M^>%"$S3AP00#>0A&`!DOV)0`$LGM\00==F2A!368O'%`%@[@P0<*@YE6PP7*
MV<$%%$7YX0``5_@D0199\.&3%#-(($$?%U3A0U9T+&W7"Q@48L<9"`RPZ`(R
MV%'("PW0Y!,!8MB$0!HOP.6`%[):C0(*6_?!!Q!2X.'3#"9D)4$''7!PP00=
MM-`A"1U4L,$;;_0@@5TU,6;'#1#XX%-/8;@2QD\.!*K4'TRQ:BA55I7@-B$^
M7!!)`O\[X?S366D-=EBF-1G`Q@-+Y$`\`LK]9&ZI/RVJPE^!^?[J]-1/;UQ/
M`FA2`0P`^+#']R\X*:K:.EP@I;T[E8Y!&NC2D0`#!=3DTP!<I-V3`VDPL`1U
M>3A@`R,%^$UPQ"48<BE',)-*"LYP8X`J,*`NU%+`#@R@MS`88`G#(@``&%"6
MV<SA.1*@`45.0(()`*`"/+`/#5!`EMXHH`Q%@X`7*$:3)9#F)QMCH!Q*,Y0"
M[*$L+EB``Y+B`"BTK`\$J$$>GM,'`\#!)[)*`EDX$`(/<`$'4B`!#RSP@X`Y
MX`$V"4,-RK`M!W!A#6?PB1U0,``)6"T$6?"B%`H`13&DX&O_65E`V>B@`[)E
MQ1"AJXD.ZO>"/>C`#FS006D(0$&X*$`,`[#+%JBCM;\YP&I\T$(''$`#/)Q`
MB)MCG`,DP`$[Y*"+=MA#"`3P$@_\\":,H<,+Q+``!BR"`5Y0P""2H[I!N>Y0
MB?)A5@@`A>^1Q9C:Z@/O+E48X/TA`2,(@QC@)X4R\(2`?F`>7W2`*E5)KWK@
M#&<S&=,3$6B"!$<ZP-?RH`/Z/>`&?6QG`5*1KK+X@`H,N`&\<':!)=`A+=[R
M@0(2<)<\^``!`&"-+`>`@0]\`%S"*2!2#B@8<<&K)Y])PP/T%QN<O2`!.WB!
MTYY#@$6<`0`QL$D!BE`O&O!@`9NS_P,.2'`%)@)`.V%P0;($4X,'G"$X`/@I
M60Q@@'"5`0%T0,I02F`G+LPD:2P;2PD4D!:X)*`$0.G)$_H0L-#$T2=9X,$/
M4`>`TH1!`5/0&Q=B,`B@+"%JHZ3:3R0P1SS41`Q5B$U-,!`#.[V``870@0](
M0*R:L$T'/[3#$#IG%H[51`$%R$/%'C!*GU0``$R4P`%(T!,)%$`!4F.<UO;`
M`1&<8&L2F($(<O`&#MJI<T3LPZ8,P``7I.$&O&E94GO).D(EYG6(LLH)"K$I
M+F1E#V-)CG*6^<W%\$0M"<C!'GP@A0%`*:L\<8`VG0>]58GSN^!575OXD`.6
MD*`"/]""`O\(\0(=A`$#7'`;'U]0@CG$YB>@4<@>[,5'+T"A6GU@0AX2``6.
M\62_&YP47`JPA#E`E("P;<P`SN""#\P@9H(Y`Q<(\(!DH<X.#[BI_&:SA`5X
M80'/<<`9<B`X._P`$C_D0)AL,$H)N.LG>T``!6LB!=@DYP$4D]4-;L!`&>!F
M!DO00(HCD0<OHG@L:..3^PCP/5FY02XTP`$=?1*"">BU#P^HV`L04+>:0,`%
M8;AF$Z+FQ@(4(&!T/8'A)("O,"S*!<;-R@L6<%P?R,!8^U7`!?:P1$1JBPEV
M.$$9@&4'R`[@!87T@@VNP($K+`$`-@B##0:@A0Q,^@=C(@`!3N#_H1N<X`<L
MR$$(3M`!%DR@!;2RP.CNU)9K[N$,Q!(76<RU6T'U]I>PJP)6]<R;M]"!.G8R
MBZ6:NQ;@.:`YZ?(>`>IB49ILMR\L\69XMQW.6-E!`)M`@`=H4(('+,`'J>Q#
M"6J+;K?I``%+2!9UZ)`&*-S``83^`P$PP(`!(/LT#"A#L?^0AB5T8+\]*0,_
M!C@<XJ0+GP)X@!F60`#J(-$%="@#9RR>!P)480[THLX+I+"#!FCA`;IAP!L6
M4`$/5`#6+O=`#B+^`!18X`!><.@'M""`&'@`"JS$H`<8P(8/^!P**:A"#&+`
M@!0(0#<Q`$`#,,B`&(R@!1YX@`>:4(0>__0@!A\8`10\X(48I(#J7L``!1CP
M@!YX0```:(('>H"%%J#``RAH`AN@L`9<CJ`*/?#O'$[.]!@<H`(U[\$.CM0#
M"^0``"KH08@;P``&\'L$(XA!V1D`!`QX8`%OQP[3!2`"T6/@"?QFP`(>L`,,
M-&$!<UB"%RJ_`#9L?0%-``(0FN#V!01`'LI`03I4D*L=J(`!*C`!##R0?#+!
MX`"9"Q@LR3G$TB1-;CSA;>L*!<S8/;<`5;!#4GR0`&(-T0_,18PS(4"!]K<_
M`%"HF%+H<&T=/"\)VN:V_E\5*\>8MP);4P(+P&?`DA4>$%1^@%R(,A&J0P</
ML&.!\0<%0%G$L?\W]'(<1P$`"W`_[_5@JQ,41W%L2U<%1!8#A$('`E@="Z``
MO/0'>;`!RC(6<;`$7I&`-S`'7#4``S`!+J`U$H``)$`#>Z`U%I`5"8@`%Q!8
M)&`"!'`H7N`#?*0#0V8H.E``!F"$-U`!::0##C`!)O!#A[0`:;$'4T4LQR$%
M)5`(A!``+V`U618"-'!).*``-E`3$M`#%3,`5$!!"8AG1?$9*`!7#C`#5>,3
M.'`"]R,&`!`S61$)A6`H+I`4@D580*$#+C!HRO$"!S"&H!$_0($`!'!#>]`$
MH\0!#N`!'F`'>"`T!U`XJS@#$^!&?-`!.-`_'#```D``?-`''(`#J[7_`A@@
M?;3F-!4E&PKE71'H:]OW6SRA`V=P``*`B(7@`Y>6+*&A5V1Q%GFP.D_Q7,_E
M%()R',>AARFP!B03%TA1?PL@#1F0.LRV?_`X3IE27JF"`H:D`V+@4&EQ2':P
M`#'P4WN0+6?`(19G"!@428(Q9DM@`/LE&&GP`0F@6]91(&>0!PRU7D>1.M<$
M%TC!+5J0`U405-FB8F0@%QRV`$615'N0`%H@!=[R!P,`']I!`'/09*9A`@K`
M!S1``QX2!EKC`!6P*#F5`('5+"23%4N`1SJ0`$FH&1!@-JIU`OCF`"9@`4,8
M,)JS.65H2%R#%89D!W7@!WR`!S20`4#C1B]E_P-CZ0!$PQ,#,%!EL0<+``4=
MY8!MQ`$2`$=01`(S,#HWX#5@PP5EDQ5A4(2$0!M*N0`)\"Q]U`"*9"X%`$-D
M005B4`)YXX`<P`?]<UE\`&=`0`)V10,LP`-0E``XX$8^(0`AH#4TT`$B(`(!
MT`,T81S4HXR^I7[-^(P"("I^\`*,])?3!@5B8'W:R(T^P9&R<2>"X0!YXYLI
M<``1(R[*HX[2$(O>%8_8*8_/18\!,`(2,!52J"LQHQQ[L`0>(%)%@R]ED#I'
MT0<Q8`;+"2]B(``%X#2RT@>^LA,CB0-5@&\5,19&432=TQ,)D'8Q4$N1-!CM
MDCH>93S&0@!'@0`Y(/]4'O<`!90&!S"2`R,I2\0E-&`3E)44X2,#@>4"0,88
M2:D<7-,!4]%$G)44,[`#4MD3)L``>#E*#V`U@*2`7).&26$'3_!<-(``0.,3
M/*`"/]`'>"`!2U`T9P5#YH*@%04`!!`T>#`#,V!7$I`!+!`P>"`&(K`3/%%+
MA_(">I$4H3&>?8`!"+"/83`$,<,3!'`#@M$'$R`&!!`8=+`$5NH`GA(T@@,$
M"."E)Y`!/8$'(1`"AN,`')`#+!`T?,`"(B``;R!KRE$NUK,ZRXB;A*";6%$(
M!"`%.G`";O`1LL$3Q=F-#>.-$994`^`"19`#95``H:@=04%_>M$\>52=$G#_
MG=GYJ]W(&)<D`!L0``+0`B=0+8=$3.<63R]@@D4!++E1`,^B-QBPF*8AIU10
MD?:B3$L06;<:'5PP3=A2%M_X7-7Q`0TP!VP`?0D@%V5P``Q`,3TQ`$N@``/`
M&GLP`#%0!6*PKP"P!&<@:@:@3J(V`UYW`B=``%R@`EEP!01P!0#P`V=P!B=@
M`0HPL"?```#0`25P`AI0!1ZK`1K@"Z)6`A/`!24P;5ERB`HK>0L;L3N@`:+6
M`?`C:@0`.1J@L"<``F=`LC/0(@I+`!;@`2%`LR>P`S-0`"=@`#'``PK+8``0
M`FZ6!AU;`%CJ(2!+`"I``B2K`1"PFR5P`UWQ3FZ&_R\G4``E<`'V]K$%X`4N
M<`,EX&9#<`8%0+8)``$$4`#Y4TVT>@8RBJ4SL`\G0(@:``0*L+0:@"9N=@(=
MDK98V@(A0(BNU@*M-)N8RG^:>IN_DYO0B!6$L*]]\`(^0!=[`12IVI[7=!.P
MU#`%2Q\!RP4WL$0<B:NFLJL@D).^"JS`>CT.`&X@T`*_EQFII`/KA@%?4Q,O
M```?0#&Z@P`/%1MO,9!<(%D]\0(0P`4%8"\_<0/Q)EDX<QTA!AQPX33`DUT/
M$`,YU173LBE5D`+P\T.;P@#&U4&ON@,)X'%S8`8N@`$+X`:N9P%-D`,MH`)-
M8`%:\GI-P`4"X@X,D`,38?\!7%`%!Q`#`EQ[RC"`.P``7-`$&+`#6&#`9-(`
M#T!\*B``.2#`%F`"#4!\%H`".<!OKP<?,=($)D`!7-`#O"<`.\![)]P"#Q`C
M%@`$52=W$.P."V"YJ+A10/``%N!UBQ<C"Y`#)68!^C,$#``%4+```J`%,9"^
M#%`$G@<%.X<=E:<%*3!T]%L'+L``?8<*_`8%L0?&7&![B-<#0%`$15O"(-##
MO+<#+2#$KWG`#-`$E=H$?P-NE\-!E^IKFNM+A>*YT5@3P'(&-S!M=YM5V1B1
MW%B^]_,NWGA@!.`]<,%$RDF=J<('N\N[V1DK$@!N&C($)L`&+/`"=6&\]-M>
MA3#_54O`&V7Q`F7``%2`'"T#`+C#O0X@!;:U7W+Q`-2*7W*9`\#A!TR0+A6%
MG&$3`P@@"Q]@`*<S&VB&'4&6!^5)!7KE$P;P``B0`@`@!G=;L`:`I5D`!F!0
M`'!`!%W0!3.@`05P!5O`SUC:!`K`SPR+`JL&LE-+`"3+#E?0T#@P`0U]!5^P
M`T>;!B=@P!$=!A4P:5>0!5P0T38@!0_;T&'P!E?P`P-P!0C0`9-6EB:@`0-@
M`S8P;F$0!B\6`K<X,`OP`SLI`2A0`!R0F523F1)PB(S*`4-!98001*D$+.OE
M-M:ERXUV`;JL`P?P%L_A`_%#!TR@MV'P0W3@6ER5=9D9_]0M<)J,6@`D`$54
M@UH<@&D!0P,F\`8!$)L^09N9"LG,V*F?^T<^T'11MP084&BHR\G@&!?6-U&W
MJAP$H$?V1AK'H2PU47\64"L\H,KOR,KPZ+N4&@`5(`)T!I$#,"E2>*!I")X*
MX`5%M1?LVS\]<1T8(+VCBP"A@EQA(($`@%OUU"Y4T!-UD6S87``8P+S$4S%Y
MD`8L>`,;A8ATH(.QQQOID@<8D`-%T"]`40('(#4VT`67'3!?D`$#,#I@H*1X
MP`%4X&%\H``]<(Y]$(BH4P:;-$HA(`4Z.K@:(#5':C4^X0'Z31NF.$H)T)=V
MQ0<!H-\T0`)=ZA,(P`,TQJ@H(/\U5\`#F[2DN">(%7#?-4&(4H,`61,P!I`"
M9Q!8<^EN?D0["&!G82@#^_@";)`W<U,WDUD`I&$N2^!%?+`$`-@3@X,`D#H#
M&?"3(=`!G<FHJL8!>+`''4#`&\```8/7C_QKD<S7]+DH:KT'+@``:8``=%0:
MJ=N1I>$#!I``8BX&$(0;S%($(8D6%1,7]:<"M6("+<.-FMW*POK*_V=(7=,V
MBW)24*"4C58%'(,N9["0/O$"LB(:VZ@[$[B]/3$6VIPW>^`;ZV5=TKNZV279
MJ(,Z##L_M-`_W3K!>])$,O%<V)T<3M`%H.43+N($-@$&=L(!/#`M$D`%8'`%
M]_-6I;G_G@G7CH:3!5A`!%"4P__M`&"@WU=`!::($ULF.'6P%T-:I%UH`@TN
M`0`X/['^''R@`AX@B"@P5F`5`E#$X5[40(D)!<KR`E``GCX``>2C`VQSCW#3
M.PYP`X[5!Q!P`V?0.P^P-3YQ:3JJ66O]$S,`6@$C2@%#7JO9!S00`I,:FUOC
MY*YBFZRBHK/QN3,)7_!;2TI=$VE@V$Z1+D!!6_,1L/@J%PXP8/1K%5L]H)3]
MYD8NYW,>C]?3!\![69/R40\@!6]1%B7@OTWX%B^`3WHBG5+`IO?5!VE0#@70
M0G2P"&+P'&.1`#%0O;*T@K)$K>D"/%E5IWIC+L_&!;)Q03%0_W$+E$MI`/+V
MV@1W40`?]!Q7P`4NL$3)+`7&TA.4)2L'%0(TD0<9P`!2R:@4IYF]F`!68P<A
M0`*F2$4[0$=-UL%-Q@<<L`!\`/F%.@"9:0<)`-1QR`$@0`.F:`,9`(<[J0!,
M2`,ZN02>WW$3D`">3P/:?@)A,``T4`$%0`,O,`",LY,<L-([.0`RD`+4&OM6
M[`.Q+X"E.P".6P`ZZ`,],`$K&P8WT``E<`9TT0$D@+,*(`,&<`(#6P&B]@,_
M@`@Q.P,"PK0$P+@*ZR(D6[@"<(@[.P$$''WG)RC,Q(QZC1@JBD06#RQ[``@R
M7"X)"E)[='Y]?6D)+WY_D8MVBP0)4O\,"@P+`WUTE`,?;`\+$P1T?7X.?GXA
M37T.?3JS"V])+AQX?9&\O;Z_P,'"P\3%OHH"`2`5.X]T+U(/$'N>#FD*+GMV
MJ`.8!73@#E(Q"GM_?7L$7%RGL"\)&&F)='LS7`@.+Q@*#O-TJZP"L@*&*DV,
M10[LW%CBY<PG!P,8,-A&QT<*-E5RH,D1H(H``2*`L/E8Y0"0'`)25&FP0X0(
M`0>TJ$QQH(&`'1X;Y,`I(N:.EBT.N!21XXV`C%6*L%%99673'0**#-W10@34
MCW5>?@1R`*4`($!`NESA$BH0+2UWP+`)$L`0D$!'`$@!X(#<%"E&;!`!H"\0
M&'0!["C2=Z[_T,)V^U8`$.`#@`H51,A]_/&Q!P\P(%?X`*,(B@\?*KS)\>!!
MY!85+KM$T:.'AP:76^]H`..-!PE]\.B6M,L8KX%_Q(CQ?4Y1'P('!!1P(,&.
MC@)^[*Q*9=Q/HT>\4E6SLV?/C3@&I)PY1R>,@B55$`P`QV27@TBN8,F:I<(6
M#SYXWA/?S[\_\47)!*"``":\X,D>"3Q0!B*+A+&.'7\XX(`-4G!10![]6,.`
M%)_`THT"!'37#P1<&$`/.`-PD4`!4"@`CB>H""0007W<(``$`_1SW!(Q%-`'
M)6ED(D8>!%SD448=>00`6!_!=-)1`K`A0A4I[.!3%3MH,1)>58R4_U907QZ0
ME@`K--644CC]M()*+0'QTT\C_/22""!<!5-55FD!!%\_%;%#7U9.5E<150*P
MA)2&+O'1!TLLH4452^Q0015#+/%!:5H<<*D'%1P00PP/+(%::1Z,(,`##,0`
M10`6,-!J9*E:`.D#&)B@0`L+Y+I`3"8LX((";RRA@`)<>"""`A-,`)D"""`P
M`1LN-)M!#T4`\48/.N2VVSF]$0><</\9AYQR_3P#`25^,)$0+(E<!\EOJ/R(
M"(9A#`"A@>^$2,``W4VB7WRQS*+#`@$DP8,=>$C@W\(,-ZQ(%4^`0(((SX9A
MAP\.%+##$F&@8D<83121([T(5.%"/Y3XP/\`%.`D@B`9-_21!SUG+''R'OT,
MH,`#`-3@B2<RR@B,'7Z<P4"HZW'CP@YA1.=`&#)\8``!53R0QS8#-`"+#BFZ
M8,<+>R@`@<6P/"#P"R[(D.T>$,1``"Q[`/"#`]UUT$%S#N#`CX0:+P>+"QB$
MX0"&2ZC"!P$\Y)A0`@30((&$%-CQ^``3="!Y'CPL,#=S`&RCPPL*J-V'/C&4
MX(D.7I0`C@XWW*`#'3I(8>(L8E3APR=V0!'#V0LX=S$"+]CAG(K=Z;!'`P+;
M0<`4L]A1`Q(A<N>%#I30T6BV_1R00"QTE*!`MG1<<$&VL@C@@R(2S`"2;3CK
MA@=O_'T[G&_:'9?_G(_YV#&`\3K6SX@C[_J#'_ZABC(P8`T/N%0"PO`'<-Q@
M!0%X@P0/P(]%I"(,`)O/P`IVL(0U[(,@-(8B1/"$.I```&&(`17RD",ZR&`)
M"7C&*L(0J83,;``+V(*)V'6&*OA($<\8%H,H08`=Y"$//QO``[0`@9_U)FC`
M\87,?*"`$WR`"K'8PP`&D(($4`,1"%H``0#P@&WXX08'H$0?PH"!!6A#!\VR
MUX\6H`CCA2Y;</P`$D:G`Q1<(2$2L-L>'A<"$L@G!%C0@(0DP`,5\($#$I#`
M;6!Q!1?0@#L.Z,`)<.8`&@2`7WR@`0D,(#D.3(`'F^.`![21#Q.00`*#_]0$
M`1S``0=X($2."X$!F+,'$K#`#K4T@`A"-,@%]&`/D`R#!0;I@#,HP`;"<P`&
M2#"`6O)A"#20T![.T(%%*F`&)\"0'3P@(5I^Q@&/=``;$(`;&IS@9+`09$(X
M,()-[H$/ZA/!M6+A/OCM1W[AJL3]'K<''1"@!E"XAX\L^#_L\&8>".#1T1YP
M@3P(T`]Y2$"SEG"`*HA!/JEP0`8%1C"#(4P_(4RI2B/A!QWH4V(`^!P#N+`>
MNB7(`$B$4$2X(,X]A($*#+C!-A:1@!1(80!`)(`F^!6+/R3H#)38AAB6T$3M
ML!2*P.@'`1@@4F%A:`]Y*$-3;J>(`<2@)`=!Q?\-YN``'?@!;5[K#@2`MS8O
MU!%T,G".#B:P!-,1K0*SY$X'0B"Y3.)#0EG`PG(D9,Q(HK,)$LC/"13P`L>&
MX`1TZV0`<*8_!(3@<0Z8``9F2;<*<$<"-E`!"08I`16@8)8TV`,*?B`!/D@@
M!"&PK01PP`)89G('5XAD:RW@6`[PP+$_F(`-(LD'"^"`F5GKC@0X0(`.=&</
M$V#!"1RWA]M(B`^0X0-S''``!/"A#Q(XP01`BUOI[($&`M@DWUQB&WYN:Q'Q
M>Q>XZ">N^_6#:PS@D1<`$(,\J*(@`/P-?OU@@`1L<0!G>$'+T-&'`:RA"E0(
M47'H`)]7!(P^;P`!#_+_D)^5FCB$+4T&3'5`)`5`01';3$`.:D`-#I_A`3NP
ME_#"4`,,V.L]&?M``F"A"@(@@`L8>T\>"G"S?["1"HLP#G6"!HP?I8$+%C-`
M#'#P(PDE@`$I>!HX?.`"+7`U%LB9CP\@``'CV0$!)`C#'EIJ-NJMV8O&@P`#
M2@#C'83S!7G`@77IUH$)X(P#(?`S'ZJI@B8,()1\Z,$C^7`"!-!`O+LMP`!H
M\`(.@&"ZJ$5`!V@P`!N8@!TVH`$-Y);J$Y@@`S^P06H]$((?Q+H"+)"U!@2M
M`0W\@`<3N,(/-)`!$6AR!C-``:Z1S8(>S(`%+.B`!3KP[!!40`4XP,$,<+"!
M_VQGFP<6((&X4:"""8B;!`+``0\R0((6``'8/.#!"BH0[PF@0`0FB#=D5&`!
M%9@`!CWH=Q,J``,@!&"2_>16?B.Q7V/4;UPS$)[RO@>)(/DM%>[*#BR\;**F
M2@<6`B3`5Z##"DHTL($CI84M3)"+]YWXY0M31`XBEH`*T.`/>Q`#`$@)(0<D
MP`O?^,,+_N`#+C"`PW2C0R9F%J$_S&`)\E!C&+Q0AE5P^`\,0,-#!K`/ZBPB
M$5@-!@$PH(@_D`$-;SLB+`X@A8OFP0<`H(#<YT[WNMO][GBG0!WFOO>\X[WO
M?K\["/(.>+D7GNY[KT,2$)\$$"2A#G4`0>0C[_B"4?\@"8V7O.*5,?@-!"``
M&P`!Z#^OC`"L``0;2,(&5M"`%7C>]1!<_>H/8'K66\'T)@&"%4#`%1@<``8;
M.$`+6@`#&`R_!0+8P/`%D(,#K#X`/;"OR_'[3_W.S^&RZ,,9M""`&;25:UQ0
M78VXH($%NVL7[_H1'09@,40(T!P<-D`1V"*`)2P(_1'*`CF90]+/\Z#E,!>`
M\=,'(Q!B&P`$V4()-U`%"B`X[^$"`"`&X'`.*O,!V[`--U8%!O`',V,'"2``
M&(!^1;,$#.`0$>(@2W`#^;``"J`=B@!%4>0+UM""7Z<`0"`%=!,)9W``380B
M2[`&;8!$9P`$;;`'+^`#;63_A"^```H08=WQ`2\@9R]0`PF0!SXE`SVB`W<@
M6P3``>+5`<_5'8446R*U`S/@A7S``US`!^+E`-$72<D56V)X`K`420&0![!$
M`QW``IR$`Q-`6Y%4`;;%!S;``QV@!PZ`!Q.@`G^4'SV@2(E8`-XG(20P`X^#
M!UF08\PA`2:@`N7D`#R0'Q+P`R1``Z)H`AW``=E$`VP0"\QQ`EE03A,P`]6$
M3CV`&^*%`EN0B+$`!`F`'WU0`"U84.+S.NA0!2KH!Z;D>F_``)=X7]WB&P!%
M/]FW?<H!5MFR!"5$`4_P`/T0'7MP?A=%-V4E`','`&>@?>X1!P/00/DP=`W$
M!*B@_W^+U'\B!H`"F(_%0#=1L@$P,`0G($!VD`<OL"$1$@L1]1[MB'-4T((3
MN`?C0`#900!>@`#4P`IHDP:J$"%V(`9>`&@MXH)31F7`X`=;E0@'>08[`!T2
M%AS=]PD#``!>P`L%4`1_,`MP93Q[(`-CHU<>8$%L,V2R(`5+`!W9,EN6M4M]
MP`<),`'GU0<SL`.0"(I-4$L2XET20``F`(B9-EY\``)X.(JB-DA\,`$6\$>+
M``"H\#2$H!TN4(*LX``/4`!VP`=YD`4Q`PM2,(EGE`(V(!\NT#L2H@^1U`<_
MD`'G`POA!A!\T`#BM&26(QT((`8_8&`.P`"P0`F-\@^KX/^+NI`')="#=&``
MX^,<>U`%;_,"-&`!("!Z%K`("4=]WF)]_Y%]5\!]B_4".'D#:2!AGQ`0XCA`
M*-,'4B!&84``4$`%#/2-0/,/8F``VA`.?4"/_*=R(B9>+J>/VEF2!#@$`0`#
M(.`!7/`"3[-D+9(T#F``#W`S=,-U0(=)"!(#$H@*%<$`RBD=89`&4`!TVO`C
M!H0`#]""+SB20O,+`U0&]9<`:D0''0``+1@+=G`!=#$`/K`$4#"0=+"#\Q$&
M+N`"`B,#"!`&;C5.9^,")/!Q+^17?;`$I!5(A"4AA91%,R`"!9!./%"5KH@"
MN&&8B1,+?=`!!"`!CD,#(."*HA3_`M_E+#:`3!)0`49J`CA03B;@`>67'Z^E
M&PZ`;.6$`)88"UD@`C8@I9ZX"'RP`.5T!K!63@N``VS820U03NF%I,RA`%FP
M7'C``2CP70Z``MXX"6R7,.F%`!=H`#Q'/0+@.K2D`!O@>5RE+=,7C2)$F]28
M+=9(E]KD(SK`+$=5'<&I"._1!PE0!C$B!O$`1$L&!VE0`,(H!0&$6/LG`0)C
M`B%F`MBYG;9Z#'U`>R```"W``BO@172C?5```=SC'6^P/8)3-'TQ'HC@`!"0
M`F`E/,%8D48(#A#9.6#3'66@*`+J@C!890Z@5%2`C(L@86.D.(L0$3[V`:^@
M"`0P![#S_S'8X!R@JAX)>!"OLP<(D`"S\*,>4`+&HP,5H`&/$TB6PQP=P$Y>
MN@,M"FZ0=)6@=083\&.9)%\)L5D2HH<\9P<=`"+2`5[,$4H*\(OBI0!-H`%M
MZ`%TR(8AD`5LR`=<6EM\T`'`]4@<H`(JP`$Z2P..I+,:H``:H&H\FP&I1@,V
MT``V$`9*FP4X0&HVP`5`:@.E5@%74+57L`14:[4M\$Q5VP$F0`!78&0(H`$$
M4+8YH$E5VVXML`&KE(C0N'#!<7W%L`C9<IO=)P'_$)H5D00!4`0&`#0-578#
M]`]$I:`_D@`ND(YT4P".$2DX@0!2I@C4":NS(*L@0*N)>*N:2_\>!Q`Q"N`!
M.F``']";#V$`)1(&7X<#.Y`&'_,/05(.7^<`2Z`>KD@'4@`%8C`OPK,$>;4'
M/O`C/#`'W?J"W_H+Z*`S+P`%)4@1=N`"*?B):>`%SUJ4!%``97``&E`"K;,`
M/5(`)1"8+."]C%L"!7`"!;`/Y%L"?+4B!7`#`-`!Y:M>$W`"](L`)D"_E99N
MJCH#/3"7Y7L&`*`!)S`#'1`#68!LPH@`T'8#)Y`$DC@#!@!LS\8".\.ET`8`
M69`%N/4`*H!;,^`!`$`"(8!L%2#"'9`%\9;!'_Q-&<P%+8`#N-4!BX$#))!M
M.Q`"V98!*)`!-(P#CS$!&<!N`4`"0)S_`1:PP\DB`AZ`L^O6`C@K!"IP`'/`
M`UW0!#S@!CO02"I0`3G`;Q;0$A;@&A:P`J[1&A70``;G`900FY!:#-.(?93*
M?9.X!R6P`!>P``R0``O@(_$2G`E!0&7P`%Q`(DL@!>*T1@V)`%2``#&``)G)
M/9,;JZ&'N=FYN=H).YT+`A/P`=2P,Q?2#R]`!4*&(8]`E%X4G?IIR#8T`%ZP
MQP_Q9H6,N@9&``_@"/)A`UXPO`0Z([^`"@1@ICZ@.VF`#MH`%3@U0';`!3FP
M`F8F$5X@(+K#``)@9C$@S3G@`:G"`$`0S3'`?1(!!5T"`!(1`YYA`1:``3\1
MQA@``")@3![P_P$KL`0]T`08D`-S(!$SU0`+T`1'TP(>T!H6\!@2T0-<0`$F
M$,;&(@(,(!NG@@'_?`"-UAIS@`46T`0FD`-`@`)-@+,'0&X68`)]P6\JD`,`
M(-(HT``JP`7QQGPXF]):H``F8`(]@`4I[6]8``"V`FP!D`'(D@$#Q],3(`(]
M4&\(D`-4D`%?0`4YD`-(S<-6@`+>I@(`0,,D<!DU7,-``,0=0`)1O+;.Z*C^
M-)L,)[?$0+=]8+?+H0W-2R4$\`)BD)B+$)STB0H_!1/ID2.($`[Q0@>M0Y^[
M,)VO*C`N8`MK&%F6;*NRH*L3$%/_4`"-G#3'D9SD&1T&0%5)\PS[L/\O,8(`
M&-!QJ.`#N5Q3$N("$!`S=)`'+"B2,!A`O:`*WF,@^NH%-W`U%N4#.X"#_T`'
M:;`#F.D)!*`%&XH-U*,#%X``4/4Y&%"B4O"A'U```:NRS7%;N86PAB8A[GL"
MX&`'"N!&$M('1T<'HSBQH+6'#VL'`6"5-`##DM-+7RL==E`!+0,ZVX,*".40
MG[`&[5`C*@@.4O`-:@4`E[W=0[4'"_!U/J`>QL$%<H`(&,4&!@(.!#"?SOK6
M'1@#\B@AI:$NX)`#0DD'3(80%]`!_?H"6K!+.L`'7YI\Q.6VCPJW#3>W46:-
MDQ@+85`"Y^-3_I,&4F`@D``CG!D&$%`%W.?_1;GM1-.Q1?]%'2S@C>.E`XP4
M>A:`(95\V"<F$++0`@63'.2#(!_@`KXY?APB,SH0)$M03HP`@2IH0Q`@R!CB
M"3?`@K?C"53$`'^;!U#@`HG@@NZSYZP-+P3@`A8T`.-JRT@D!C$@`VM)0S%`
MN#Y0!$,%5PGA<SCB5@YP$)[P`ERPW."0HBWE!Q]`6@X@/JYX`17D`#>PDO&B
M`!C@HWBPZ*K@3#D""PG`AY0@`2`@'9T$PXNTB)NSIU^'-H@N"R[0$,B,WQ9T
M`WQ,G!*X"+7SNZF`Q].1!R$X0&<``;^K")DNK78P!-RC`R5P`2T#`090`K#]
M``@ANV5>3MKCBM]+_[<)L#VO0^)(X`>#Q`(?T8PFUPNR*8V2:@QX4'8^,`?=
MQU!^H!L,Q5`$(`6HV^-^[8$E,0=S0*[=+3`43Z]X!)4H``N4RXFAQP"",^54
MOE("(2%8#@)200,P,@`&``!ED)G'L08=`Z$&D`(W\")]X`,/X`79?=KC.I^?
MD`8?4'4($0;CT!T)E><!L>?NT^>\H-M0<.XOL`0`\`UM+@,`4`+.,0`,(3`#
MD$;@\`(0H`!,H`U3(`<2Y@E/#S<CVS)EX`4$\#I_L`9Q$"_"\75B4`/<X[Y(
MT#(U0`;RB`K?[0`^H)P(4081%PM,$`!U24LM6TY2P`-A:EL]`#M!Q*^S4/\#
M,9".L\``;[,(!0`'W9T`<$"?[NL#_4HL`K,'7$"W`X``IC\+:5,\.M``>N7M
MX]-6"%``!$`).A`#CP,+E[%($C`'./#[U4[YI-E6/U(%FL\Z]QX#1`-";UP,
M_[X+`3_P%E3PNG#PE:#PJ4`>VX$`9G`#QYD)P;,*!66:>-2OV9=L&C\+$N`"
M'9]-(!_R*67E#J`%RG`K%@`(!'0.80Y24&5Y=GUT"5P)+WUV#C=<8B]T='T#
M+EQY?PYV>5(+!8L.#@D8"G9^J`,*"`48+GU^MWY]>+N\>'Y_P,'`=@555&=V
MF@-F#P1_3'X^&!\(>P,``A,*"A-#,A`0-0`I"#7_-1\`+E)2$"-2Y1!52^P(
M7B-0+N$C7.#U7N_UT"`8"*4(%`A4$(PS5T.*EG<UN%11$.X<E!I4:B"H$R[<
M@P?@('S8D:]&.RH)%<A#207;@H14!$!!`*Y'#(0(EC`8B*#)@5CK=J3HAT"`
MC($N`)B@"6''!PCOI+Q),!""A0<T%2[(AT!*C@S<$.3(,3"#E`85<$Q`L&!'
MR(\A(;"!4&Z"A2):`L30\4N8W[^`_]P")D9,8,"^^OSQ,4?`C#Z0;>V*3+D/
M`2EA;/WIXP"R@T9E4-$1LR9-,ATZ["Q"O4='93\S4'"6@%J"@@T@&-!P@.>P
M[]_`@PL_C,O5G@,!`F38_X&@P1EK?5X8F#F(CAT"5,C0L>:@#(`'F3_[D`)@
M0"X_3*8G8.0@#P$&2_98I_-"R@,!"@8+UM5K5U^_C!#P`!=+%!!9'-Z9=X8.
M85S`@!0O/%!@`3?<<,`)!2!QPP)>(`%'`61`80`22!2P!(D%%.`%%R606,,2
M,HR(Q`=3E(A$."0B@0`4.<J1@@PV<EAA`26@T6(!%T`!1XD%U"###7`L&8"-
M8IB38I.(%""&B1^F01H9!7QHQA9E%)!&`0_(<.5`%*;!A1172I&"`406P$`,
M*9:01C,8&K``G2DRX((89Q901!HEE%!``A#DB4$"%]Q`9($SS%```$M4*L8,
M+?]PH4$6,\@`Q94U*%`G$@(`>L,$.8R@%U_#$==78<,EMEACCT7FAW_%W6(9
M9II!E@LJI*2QQWL*F&>'#BQ4,4X**<"XQ[)\]1';;+7=EMMNO<7J[;?@`E8<
M9RT$`(()*-"@@!<WY"&?`P;\$PD=T6!`A1U[3"L&%%2\L,@D&'B1!B%T#)#`
M/YUU=H894)S!V0#UI:"`,+GTYY^X3!"0;"<$)&,=%2E(0>T+!<2`@0`/](&:
M#T6X1D<8V3$Q"56%<+:&)M:1(0=D=)2QA2"0K1&')GV($1HC<%"!\Z4%X*P`
M%\D$K0D39]00!Q,.,%$&'!X[\`03FN1A@!@\RT'&T*C_W!PV%0DD3$43#D/&
M``&148A:'T]VUL<-.YR1"1TN+#!)>PO\/0`"/F3B`!?5?$9'`WLX@%H)%Z"F
M`P(WG(")'1[P(8$#?*"``A^H2-`"#I\[4$(-EE^0P"*2C&"`:W:P(((``7C@
M6K@4SVJ8<+8RYAAEN_K2:RZ79?:+8@[XL=VE*P3P!@`%H**R`;*S8$`E"-Q-
M^[4.T(::MKKQQOOYZ`-7G!T<Y)7$!`!\OD`.[89BQPTY>.*'?`-`L4,>@W``
M`9;0-LXX8``QZ=@DQ+8#&33/.@/@@@+R,(#.#,`+^>G+>8[W'[]<APQ]",,#
M`)`&1FQ"`0VXP1Y4M@<#5"$`_U[0P0MTX(,&<":$V1'%'N1`A0$P`0]TV(+>
M\M`%*=`!#WV0PQ(T@`=4;"$.HBG#T>!%!M[0H0!H@`/1R&"&'R(1##^DPQG(
M,("_&0`.8,M$$C+1AS8DP`"ZZ`,5S#"`R&R!,W1PPIMXXP`R;.$*3<1#,RQ7
M(1,BX`*MV%L5XN8'+C"@,_3!`+TV@3A;T.%-^*+7&U3FFA(DP'(0V%X>5/:!
M\#F``Z(KG0.`D``^X$$")5!`9%QW-SO0CX4&$(``AL"`W:%//[0"7BYN-3Q=
M[4)<R0L6*/+`A.@40`JKZ%@N6B.&*M1Q65*0@<KZL$(=@$]\.M!6$VB@B_29
M\YS!*/].^`X`@B2@H`6?ZQ\`]C!*ZR#@`09ZP1_HH($F0`"2E%A""5'AASPP
M`&J1V8,4/G`#ZW#&!S&X02;W0`M;X,*BQPN,95S@BO>X8!"0R0,4!)`:U$AG
M!"ES#0'8X(H#*L`$JI$`#A!00<YX0`*<X0`/I*"W!%2@`*E[P`]0X8`0M!(5
M+)A`ZK*P@QF4C@L6X$-D/)"P,R2+J&400QY0P8<GY.%S84A`"(@J!15<(7P2
M0($=)&`'&O"`!&S=@P(\0(#PV<$+)=!!)FX@!FI)X0+R&4T*SL`$K'%A`9"T
M`Q?X,P`IU-%YF-1,`Y8EN1)TP'((8$$!7N`''7B``Y\+'0K_.B,!"1R`!*13
MG0)*ZKIE;2<''9@A#9JS@0`\P)?G`^;O@A,\7!'OF'_Q0S*7MQE-P`L*#/#"
M1Q(0.4W<8$XJLP-=:GF+;UI.`4,`@07(V2UT>I=WXS)=<@*P`7(ZX`P?\8%%
M[2"%)81@.Y\A`!>H\"XZ0("`*XPO`Z"@WDSDX9ZF<)X<=9(,D7)ADAPL#F#V
M(%S$#D(,'X#"`!:1!X/&P`<RE.$2J)>A&S2@`)7*@@504*D9F*`)'3B!!F8`
M`$N!&`46P-`,>+`#$F0!Q`#`08EY8((29Z`'/OX*"RKE`10,>08G$$&*9M"!
M!W2`!4->2@A8D(4L@&`&66!!!TQ@_X(LF_@!.A[R#J:L91BS(`0&\```2#!E
M`P```F(PP`44,*BQQ<`%8[L!&7(@AZP:8`L$+(,!W&RT,DAA"PB08AF6\`\#
M)*`,;RA#`A(@`Q-`@=()6,("^"&#!`B`!`,AP5@R@`"SK"`M$\A`6R`P`0C`
MA<YRV4K@1)`$$.1N$>G3;:P2XX,6%%-8O#K>&:@0!F`HQMC-&X"CH8"#!0"@
M8YO100*&,((7`J$`KKF%:V:PA-255@<3J.TX4?'=<L?JHI1Q0%[("\]]%HP*
M53"0+:95!6!\X@]Y`$<KDC&`(K@`WP[(UP(:0#<3WF`)-Q!,'5_@ZH`?](;M
M`8:`/]-21O\,HA5_L,,9%DL'8#B@"H/M>/-4HNT!I.`-0RA"`X90AP8T``9#
M",`3AD#S-Z!\"&]HP!M@[G*;TQP&#0@`S0]0!*'#`"\Z7WD18*Z%H^,<Z%HH
MPL^+4`3D-*#J,`C`TJD^A*/#0`L'>(+783Z$%HQ@!#`_P`@.T`)J'^#M76_!
MUU>N!2W<[@T'P((`L'``(&#A[VR8`QKV/H<G5.'P`"@"&PX/\@T`0"A5*$(*
M'K^#(LQ!'@!`0QTV#(!QC*#S'S@``*KP@!1X@`U-Z$$%>@!V#[A>!6\0`%B:
M\(&)F$`!'UB""\+2`"Y,(`$DL`#;7]7!=&:BN,<6EF`Z+AC?[3K_%[W^M62,
M)VQB&SOCQMW?"TZ```*400%G<,`?6(.`L.=@=CIHC2WLP&VB?CO<(!BW^,U-
M_]^@.S(.P%T`3`"`'Q2B@G8`!0I@'2M$!^1A!W_P`OZ2!E!05YM0856@3_BF
M&E(P,435!Q\`-;]01R:2!GFP#9RQ0@GX!P,0#/D2#""U3WG@!S<0@9(P"7V`
M!CS%"'YP*0HP+0/P`3'@6F$@`&.0?C[P#:QQ`3+@`ZU!4:@Q!C[@)$=X`1B0
M5S*$`020?M)Q`V.P!R]P`S+0&CIP`Q605_D"`2[`A7O@`C.T!R4@`S.$&A=`
M`-;P`C[P!OFR!SYP`1?P`OER`1-0`D=H_P&TL0?JLH5KA0`60`!_R`5QL"M_
MD`8E!!ETP@A_`&%A8%S@$%AR95QAE1F#``$)`$"Y<`":@!IGP`*:8`=MB!K[
M@P&[(0&H=%.O)`$B@`/M(0%G``%WHSVN@1I50`"W4#LB(`)OL!?%=WW.,XS!
MY7RU`GV^EBO`1GV],FS%MAD2=T,),$)5,`<YL``E:`=X*&<QXCHEX`?XT@JP
MT6VE0QOP5S[S5W_L>(RY@']\(`#M-`$KD`,,8$)V`&$,4(*;$09KH`6&X3QV
MH!(0L`A^,`!BD`-IL$_]2&`F*"&\.`QB@$&"0B]]T0<VT`>*L%7ML55-Q!M8
MXP`%D`-5(#+6<?\_`E`#".@:-S`"'_`"8;`$'T`?-/0&>I4O7(`!J=$'C#*)
M@O$!MX`'BF6+P"`#'^`,S?,`ZA5P4R`&=]!9!K!:MU```G`!G!%.&#`&H0B4
M@U``+A!^JI$`&O`O#E`'=_`Y-(`#+(!6)&`"0P49%8!$A",%D\$#%7`&>`!`
M:^`PFO`AQO9&S.="#H,:"V`!V;8')L`7.E"+4Z@R&"`R7/@&N=!)5HD:"*"&
MG/4"G\4;?5`!`,`!GN,`!Y``KX0'!.`""3-I>M,'.7`"W"0!+*!+;]`#L"(N
MBN$\]*()OS`(Z82,PM0'T<>,TY=@T'A](-49:6``DT@`FZ48UB$#.O?_!LG!
M!A@`.]SD34O@?NCX!B#0`X6PCNT8GLWWCIYA6N9"`AY@`P+@`@/@`Q3&!0WH
M+AWG`U4@!F'@/`[@`Q)$5.>5`NW"!/+Q`D\3?GC4@@1089.0!@R@!0S0)I)R
M)1IP`C*&9!):`!(Z`XR8``I@`#$@!0#T&2^P`PG@`Y&0&@D040!PCY!Q!FQ@
M<1_(!0'7'9C1/'T0`YYA!V3P3[90C0/E!UX@"*@P:`\D!E30/"()`&+@*Q`@
M.)]A!RG#&3:``!F)"B%0`!Q`5`%`5&&``UG0&7P@!3Q@`Z7E`++!&7G@`FTS
M"53P`'AI!W@@,#A3(:Z1"F(@.2RX2):S``RP_X8O`%,JXP.(DZ=;:%(-,`:0
MH0-(@ED&P(>N\0"@PP>BI4H'P%-XP`<GX`*6DP`X(!][$`8M8``$>`$C4"ZZ
M<VP`HBO%A6Z]0QB[Q5O**'W%0YS6)XW%U1FJ87'T4EP^$`8#@0P,,D/4`AG<
MYFW;V9W?*9[(>G]](`%[4"X@,%>1PP`*0``3=I!0L``'"HGMY0EXE`9_X@.=
MX0?5.$$GR0FEH3CBN@9E$()T0```,`=>$`,Q``50D`)`L'HHX`$]L`,'(`"I
MUP,J@`)SD`(QX`400`<&L!,^``W'(@!HX)XS]`(+D`)%\&PEX`,=<``$D`8V
M4`!FT`0;2P`(0`9P</\&<4``6W`&9["Q8-`%5Z"R5$`F+WL&9'(&5T``7_`%
M,RL'V*JR"(`%<K"R_;0%1,"(:;`%:7`&!1`"*A`"::`!!)`!9:`!&G`%1/`&
M5+MB/)`!5)L&/-`#4_NT2%L"!'`#TDHD!``%2U`&9#M`"(`$B4("$#`D+D`"
M%%("$%"5DG(#'O``DE(B'M`B-W`!%A`I%>(!"V"X+,`&';"W"#`H<8:X4'$4
M`-`5"9`%G1<"64`""0`$31`"E3(!'Q`"(2`&7-`#;&8`'9`#$]`!!H`#=Y%U
M>V&JPK":QK5"N4`TQZ9KR0B<R_A;SE@<Q2F-+05);&0]9@J<4#`"*7`!$U;_
M4BK36>UWCN#&G=YI/L@:GLHJ";C3G3O``F%@(COH.'2P!$^T'9!1!E70.,V#
M7DU#HV&0`T8$&:+0!/MH<?"R!I,80&&@`'5Z"F>@!6-E0"RV!`/`B@Y``QD`
M`)DA'W90C6TS2?$+`&LH0S&@=4O@+#LP!"FP`QL&=N.P`W-P`)/7>6R`!CN`
M!FB`%TNP`P"0`PW@+"8L`"G@+`+P>9@B`$#`>3FP`@)P>"GP=C7L+&R0>54@
M``WPPX>'C8>W`SM0!P"`!8=W`%H@%$&\>*,'`"M0PT)1!)\'+6SP!B-`PRE`
M;=`"`*,*`"*0`E]7PP"0%S=\.RXW`K\(C+]XP]2F_TM([,6ZE`)U<,,Y(`!:
MP`8C$'5U4`=#\`040`&*7`<@$#T!T`#1\P9UL`$KL`*2'``K,`1!5VL;,`0;
MD`32N0'2"0*V9J.T&PPWM`D4XIZ3Q!X2YYNNZKNP&FS/.*N*01G)P`0#$`;3
M(@DFQ$U<$``YX+_J93G":HYHI0,0@!L]P%W9J[V^@G]VL`/FDG4-L`3$\`%E
M,"WRT0=844>?00D/(`;3,@@4<0.:""]'&0;)4%`=ZLN:\`=>0`4$@(>94`9<
M8``%Z`=EH`(S\#FE%0)-D`!7VAEYD`,C"E)]P!8%,(G)0`!:4`!UI#(O$`,-
MH`5C+`(CD`-OL'AG-P)81_]M9R<`8AS20\`&-YP"6B#&T%+&8TS#:_?2(\`&
M+[U+U08M1'?$`@``'`QR-0W$*7!VT8(I4$S3(\!Y(ATMT3($G`<`:I=[']!T
MT5(!'U"Q'_`!'@`M,>!ZON8!6BT"CE<!#S#5!Z#5?0L#6AT#']`"'V`!\DK'
M,7`G)O`$%H`!M,```+``4*`%3_`&01QTV=5.M4;8AUQK2>#(B9T$B&W*C/W8
MA5W8,+0L@,%-`W`#_E,%B5L`HP2)L<RJL6)1-A#(N7(>QF-1MK"BN+Q\CB,&
M,?``JE!"""@YUG$!.X`!0+`#!@*#FG`I/*,#DH,`B>R=PQ3-[%@<O``ZUFS*
M`9#_!$_`36:KC:%`0PNP`)P%"BV$"`'W,@;@`@B`@)QQ`Q_A+\@)`0R`#,V3
M!B[PF.[VP%S@`CYP"ZG``$W`D:K3`R[@SI(P``NP!*#Z&6(#`!Y:4']P!G?F
M&3(D`PN`88LP!F((`3^8AH-;A'LP!F,`!>F'A?GP@SIP`1]0`!:N`U!0`B$N
M9Q4^!C<`X15^`P"`?F-0`QBPAF,0`UR(MT;X@Y'2&E<8`'QJAZPQ!2Y``%<X
M!C%$A=[-X0K0#'?0&@P`AGO``BJ$&C)0.>EW`2DPA3_8"61H`D<(J!B&&MY]
MACH`.<RJ`Y:%"A_`!C@P`#3`!S2``@'`3NUDRG1>Y^8R_U[,;2[M=.=/H.=]
M/KN50;\&\`"YG0!EFP!2P`!IX%"?'8FM"ARI/=HY,`-()&"9,$R6+D:K3329
M@`!'_`!%@"?OHAH)FP.YU\WTHC>+"`#[$1G"'0![2JO&'9Z\P!DF$#T@``,@
MT`"I<2PQH``8MAT#L`HW0+][8"<XX,N+L'%E<)_0/0\UM1U\74<7Y]I]151G
M("A[L$_=04!LM#</D"P@!0L/8`#A2@?UT(D(R()+``%U-0E[<%A-(PF(&@-J
M.`#?"`$#8#E>P$D498N==0'48SDQ`(4=7CDJ<P.KA1K/!4?C$^.6\P`<3@`0
M@&&A$"D<K@-/8#DOD`!3P!H)L/_@N?@!A_H"C*-7X;0$X;@L'G`""0/EEA,C
M/%--)<!).;DLDE"=*D,`$[`@A(D`P*H#0Q`YJ'`"'1`^/=``/?`I)(`#(M``
M.X`;&_!R0-<`;,`&10`$0)#U0-!W6L\&6F_U;!!U6D]U<Z"C@=X'=E(0.Z``
MZ_`A7L``,-CHP20<J=UKDWY#G+Y!NCN\SKF:4H#$<P`$Y9XO`?+>+J#..",L
MBI$&K$Z>#>T&`;`&G)7*LTY_O+`K5V#2(,!.-OD"^WX#,<`%==0:!<`%`F`:
MH:!0'Q#DBE,`"D`%!B1`'V#=XM@'5K4#0,--BP8!'[H';B)+&><`:1`+G7T_
M(X2`D2/_H#M@E>*(L/-@7!T?`P"PL,DP;.4ACNDG!M+J`PE0(22@/#K02ZX1
M[]TC"0;P`>&H,H4XF8.6BP5@BZYA(DA04A#`!5PX_B5U!C0%"#J"!B4Z=CI[
M`3I].B\7%X)V%RX^?8PQ?0Z-"C*".@@QA79]*B<2FC<W.G0Z"6)TE@8`9XQV
M"ERC?78+GCX(/H)C+C)[>SIC;&,.#G8G!J<H`3`D.S`P#0$"T2@3)"0(X%(D
M4N0D..?>YCCD"@DD"?`)995]?_;W?P8Q9PI4X09A?`AXX<>!/3]^[(D1@Z^A
MPS]]_/0Y,R='%@>68/VA`S%B'SH@SU`)8Z]>05A];BPIHJ7!_Q(#Q38.,'#&
M0((T>4!&E/@G#8`_$BWU03#D28PP>.H]7,JTJ=.G4)?BF;K,08XW(!HD27+#
MCC$=-V(@B&0GS)('+W0M2[`D@9UE=M+LR(,1I)RV*+WN>(#1#IT]7):\6M;'
M1Y4"?_:`O/'@QL=E!G(@2#S*1XP/!#Y:@@``HP,_=`H`D`*K:HP8=/P<VL,8
M@8L%#)8HD()`2A4($&0@2`$`'`(H(Q8@^%8%0[@8'F20PS`:@0P,P1%`0+`D
MQ?#:(Q),YP+`A710#!!,`/>$G'0O'W!#\"#"A'0((R"XD+\CO0+J.:"XF"^`
MP00%"CSP`(`U`/!`#0I`X$41#.SGPO\.52S`Q81:*(#!`E!4X0$&$PJ0@@4,
M2/B$"3TP$)L(#/0`!`@@Y+!"'5LE,<T*)/!Q2E48":6C)3@Z<`4?.7X$"QU!
MZI@``GE<4(`=3-`QB@.S.'E00G\L%%5)$EVA10M99"(!D1TYD)-F$XU44D="
M]C$`.%H\(,4`NO2QAQ0[++'%#C$0(%%J'_D$E(X(K/"$%P,D=>6AB"8*U51)
M9=+"&])`^D$"+[QP2%@N#""(:B86`)(==ACPDE]]O'`#`!",N8<^+NQAB6I0
M`!"&D',N@0"1:J91Q1*:2;)$II;DX<,24)!JQPL!WC!D'PGTYD=:>VC@Q0)I
M^.5''@HL\4+_(X-\(,`#'U3!`!<8N#`"N;=4`<`M7,1P@!?ENB#`!Q<J\,&O
M^WE1A0(+N.!!FQ@HX$(*`ICPF@M`3%`N`\7M%^`2$KJ@0``2"_Q!=Q(^((`%
M+I1[[@(3<"'"KUPH`,`(,5PH[P,FM%S!$B:4;*`+);O;H,``I.""P0H(@``&
M0*?0`X<N5%$%%"4K\`84"YC`0P\5F*""``%L``,0&P0`P@Y`=-!`!AS88`,-
M''"0!Q^@YI''"V&$H7:/!83AP`MJA_$67*#F;0<5`Q3P@11"O@`2/&E-J1!#
M5WI$40XS.`"DG';X$,8>>7Q$JD@D0004,ZXZ&<8`-PPP`!.5_*&2_P)GU+1`
M`J"A1(>?05F"@!M//%`H'HKFKKNBC!;D0`LL`B""`+9U8(@N)0`0`YP$#<#%
M84YZ5<`22\9I@!<*1/_"]`GX\,(>?PR0P`.9,-%''F7DF8D=?Q0P[E_G&[`#
M`P-\*D8*:V3BI/-+*)O)"V700@*8`)I0`6`)!'@+'<(@!0#LP2ME$0,79)``
M!<1M`#X@E`\&4`(&*&``G^L``"[@O1<P('0@A$?;9L(%T3EB!]T#X0)B(#G)
MH66#!7!!"5Q(01]LT`=O(`#;?)``&8CN#"2P0.A\:+LPO,`'&)C``"KE@@_<
MH%(OB$$';-`V`UP`A"^0P07:]H($"(`%+_\`(0:6Y\0!8&`//CA#`100NL\M
M0`$$\-X`V)`&T0U@!@D0731@T`,1K"`)`9@`##*P@1KM@0\V.H50>D08'!6`
M+B`A4HXTV2,(?(\`9\@#'O(``4\A8(#W0,CA#N41&U2D<7U!P!H`@(8U*,`'
ML</<F3;I@`(0@'\I*$,8=%"Y!.2@<L4@!V@\T@?8Z0@"M+/=5'9'S6HVA5&9
M<(``6"2"`S2@!"8S0$0,48"8@;`8`W`!`Q*H0`2X:0\.&)P7I%"YCQ3@`0@0
MW!^\L@`O^,!)?Y'"`\0`*I*$@5Z"R\0-N"!,OSB``+^"9QCHX(,%/""4?J&#
M+-*0"3D58`$+D)O_+G3`!2\4`!'-0,`-+@`!>NR!?)9X010788=FB4$0?0B%
M)73PB$6LJE6+*(`(#(!3=6Y+$#$PA`/.T-)%].$"JO#I$])2JIXRP@"4$(H7
M<O0""TQ@$0[(5@G\L`@/L`!(#DC%(NB0`,=$Y`95*`$C^L"%8EEB#QA8JP\@
M0(N/<(&>QK"#&[ZB@P)T8`\20$$2MK:"-R2AD2W@00-P4+8@40E-.MD)0@I#
M!SQ\)B-30HAH_7`DR\2`"CZ`J*<^L"2#`(5*5DH<0@:0`\9E,PP0*$,!"I``
M+MP@2+K4'(\P8@";8$`,,OA`&D#B!P.P@0L7>(L4$O`JS3E3*`C80.UN_V?-
M[GKW#XQ*"A]RH#48@"`)QX*`%J2`TSZ(Q@2"@(7SJ@`GD.3!``)00$&*(8L4
ML,^>`H"`8BQQ!H9QU$DOH((`[9"'Q)Q*`!-U$@%R(&#PO2X'.[`;7<+`@`,X
MIL&O$\`%_@(+'SR`"X+#2!@P(``"&,(7*T4`G`3A`4T8XHZ+X"D`5'&(/#FU
MN#EF@0MP6H`=B%,3$%B`JRSQ@%'H`)PNCH@!6.#D/CSA$*7JP`48H0,6?-`3
M2_#$'EP`.$&`X@Q^<)4%"``7`ZCB(S(P`$+``H!",$)@6+8#!D;AAS7!R1)D
M0("K,/(&+/>A!!T`U0Y8U`*M+78#(%C!!B;@@/]3X&&S0AJMIB72YX24YB.M
M>T@"=M`W`T`A!TLXC!3F0"K#50EQBP(*'FC+.$O[H`8#L,<+$$`%\"WC#)GB
M240\TP<Q&$`*"B@C%PAP#S$T@`(-(``=J,`%CD0$(C[Q"$JD4)0MS$HIWPUW
M[GHG`0D`+PD4..\`C"$%`<@9$3H8U@`2$D\[(&`!E</('\(``!#7XPR3@D5"
M!E`%`_SA!1!),`!4&<\"I``Q]J!<@*+WAS/LN![@NX$6&/`8@^P``+A$>$H`
MD!&)O,#(Y^/('F2`%C^<0:4W0$`"BV$"5C0"`@F@Z0TP4`(LN^`$$@&+*L@:
M<QU(I`!00`).90"!80K_P@5''0`)@''5!$8""&DY5@E.*H@;0*`$G[%##$!5
M*@A`@A&3.(,=R#J!&=``;26X@3$T*M?/,`:7B`#0W,,JD;E1*B,*,$#E_I`'
M+>1D$2_H^1X8$(`*A"`'+=K`5D`0`!QD4Y5.N;8E;`#NAFQZMBZ@`L+I0(`J
MO$LR]7`MYF,;:S_,NK87*54>H'``+;#A``!`.*A<'NQZ^%Y_;!%`$8"0`Q2K
MQ@9T$#D\054,<&=[3Y;@]A.\;0EQ6S]1O4M*"Y+0@!44`>A[<+$,8A!='6A*
M!@*`PF?F%H8'"$;V=+A!$:IU/CM`U"W+O-]DWL+@P*3A!0:Q)IA!>'^05@Q`
M_P4&`0MLP3K[]`<$```,$&&I$1B(P1$#H`!5@"2?05ISX`(&@1$^$!@^Y`4C
M4`0-(`!5,`)5\`8I4`4$\P9#8#154`1/H`4MF`)#H`40TDT'`"$IT!(MF((!
M<``I\'%L$(,`D(0!4(0`(``-D`-&(WPC$(0[0`$MB(('4`15(`#"QP8NZ"$L
MB().B'M&@PTH^(('(`([L`,'<``RV`!:*(8U>(9'R(5&LX0HF`-N,`=<Z(1%
M`(4YD`(4```R:'M<*`(;@'LM@'LKH!6(A`.5MA-/H7E]P'E+\7F@@72VXD-2
ML`0,0$]T`">NQGI/@3NN1VL7(28@X0#%)3B=\VN]!_\1_V40^O-$KG)P]G`#
M#0`C3X!("^`D\+1/ST<F4B`HU-=YUY>,UT05IT!>)K`#%5!H1Q4&4.!NW))&
M6N`"01&*#[`#!5`8#&8#`K`,&[$J#Y``??$Y`7`#!1A/`[`$I!8G^9`#LI@3
M:;`$5!`1BE$`;&``9&<'!=`F9.<``P`A$N$7]Y4#F:$1>7``<O8'@I!.5;!2
M!<`")#``7D%7AO!`$$`"\!868W4("J!X:753@H`$Q!!47J`L@L!T7]$'O'`(
M`V!$GI`*>7`(8]``3F4'-\`"*#$)+B81#``J>9=S@M`!"P`,$L$#;,8()Z!T
MBP!5CU$`A+)9TN%4?@`!9/7_+!>04'X@!2WU%WZ0`Y508F*P4Q`0`E?``0[`
M`3V0`)#V!B2`95%!B:+X$)BX$3X0&;VH!0@@-_J62K`%:Z4H:[0&2Y!!"SGA
M-J,0$K&H"WV7"P#U*CD2!@I@!EN(`5L``1A1$$`QC-O6;=^FC*2YC$FQ#`*0
M!`J``C3P`5!0`MZS"1Y0`E_Q+#`$F&K"!2&E/W;```]P`O!$),AV`_F6!WN0
M`P;P&;`0!B`%)_`$)72D$PZ0`%`02-9"<`2E26>P!"CF`(KA`),B;7U1`!A0
M`(.F)@5GG)Y``C%@`BMU2TX%4T\'`3]&/61%!Q[PC;$076^E`'L@$:<B3H+`
M+U6&_PF"P%1GX%07X(\Y%@!+M@<78#R,0`)<4`F&X`4YAE=?)1$0\`%VU@<,
M8`K,L!!.E0#B!!H&D`(GL%.O\1:-D%<ZX`![50D2P04(@&4ZH),QV@<$``DQ
MB@`LX'9]P`$>0`+G-03HN`AUF1"6$`?(*)B;QB<?\4!UD0E]-XJ$Z12F^'H6
MX3AY\(Y>4`(+)`7L2!C`-F^^!Q$"YSL1(7#KLU0(L(94$!Z91&^@&7W&.)JE
MN:<-T3N9(`(@,`$5P`<O\``>H`I.Y`/98@"5$E0/D)1O,1$V"H"D]P<84)T\
ML@<)\`%E,&":^@!;5A=G@"&8A)$7PU%D548[P`5GX!D)D/^!="$18O``P.*=
M9P`ADJ,+V&(K@^8`95`%.9<6,LH``"`&+*4IFO``.:9G"F!TS+(#8D!6.J!3
M@T!0BV``7/"?A94"1#4*$/!&.^4%L*`#!*!#GM!6./4"`9!G0#:A684(XKJ1
M)@`X9-6A<L4(%G`"\916;T8'8H02<+6BB\`O3F5"1D=1?`42.H`!`G8(+S`$
MA[`(/>H)"M`!+``G#O``$\`B&R`#`K>D'>&DE_AY.@%/V50JG7EMK[5*4;&E
MJ"@!EF`'$%`#7D``$H0`;4H'9RILZS,DJ[@,R[)O#W(];W``M_(7?7&G?2!]
MQ\BG3FL/V+0,(A``"U`!-'!H]%+_`I9R+!_P`6(P!H$E&BVT>X4J<Y53$`;`
M6AB;!P5@!@"Q@=OY?[I0%NU@-^?#M@^00,L0?E`@!50JHSE0`+0@)LVB`&I3
M%G2P*\(Z-U3P$L99*F=P&)IB#'LE`S)@`@50*0?E1$\4(B`T`'1"*1L4`P#A
M0Q0$0F$@`PR@1Q<@`@D0$"^@3F?P.0/P`9][`PL@!J@K!1VP00$1``3P.6=@
MN:*#6PR@NY\C*TY48!_T.2X``#211A[0`3]@`T040XHJ!1LD/NZ&06ZT#QA4
M`K8K.KC+`CY$`!Y@`04P``1``&QP`S[D`V+P"SYDHP8@N`]H`EKS!F.ALI/(
MI'T@LGA)_[+@HQK+EQID5WTK^VI7XK*P5Q4^4`9V4`,/L"L$H!BPL+.^MZ:M
M4T"=Z9T\"@4<M0=BX"E\XA4]07+0M[1YJL!/NZ>,0AC;U`(``+/Q=AH7')')
M)4X=-:H,@$D`^0`,X"F?D6!+(&!`VP$,`!.64P9'7$^A\0!0P&;UQ`5;@``.
MP`08<2H)0#D%*%#Y5$]E\*A39!`O`"^_]!@)$`,%8#[@(RH8,$QV`&PQT(0Q
M0#,ND(W[@0%0:`(@M00'<&)W]"UXO`0`8#!5)``.\@%%0*L2TX+]TB]:T#+D
M(BY<8`+V0B\THP!)P"$+@`&&K)N!(0+Z43(ML,E<(``[X,<FD/\"@>Q!"I`#
M%=`T)M"U,3,P).,"#\`&,0!2"["%%G`A"W``'6,"%H`BK"P`**(P)O`&%O#)
M)04`0+,`O($<0`,$```"3[`!U.6_F0?``NP0F,AI0O$60>&92K%Z6=H4HJ4F
MM24&=6%_$C$`93"X.>(#E$#.!_%[U8=IF2`:_4.I:>*9&K`#0N$),C`$(&"[
M+OS"?&H)$D!>`M`"-,`*D1,#",0*FM")HAA/!-"WS#`*V/(!EF-/*(".&34]
M<A:ST\,%0+M`4)#1]68;.$LDI#<:[+,,85%M^J9QR_-9=(`>@N-0:7M@$E$"
M%<``KN(\`B+-"H#)`78?"O!Q_S$!#-#_`DV0(`@``,)1&S&`3]/!'.\!'5`0
M#H8\'1#0;K2!;+(!`0F2,@F2UD]0&[0Q0^0@!<1*9K4A`"2`U@;R#0*ER%*@
M'`#`!?"`E*M#03'`!5,`#UR0`Q,`#S*P!$M@N1T@/\=V`:HK1@OZ`%I4`,4U
M!&YV`[SE`JEP`TW@`O=+`">P`PN@-4,@`X=P64XA6O+ES5"*B2A173NE.0M,
MBK4==+0U`F<Y4HGWGQBI/Y80@FCFVTSASWW`0$:#<\293?'T!QH@`LO@"3H@
M`Y"&`C9@*`[MM#LU`@'P`#!@`EOF%5#D`FRV"I;)!=%:%1\M!6>PBF$0>CX0
MST@GP3P"`0S0_ZG[A+>OFQ&+!P54Q0P&T!B-R59W#(#Q%!:!E$EW<4L%T4P?
M(-]"8@LN4`9Y,0,?H``V\`,DP`(L@`!7L+<]4!5[,!ZG(`$L4`$%L+<+(*:P
M4%P>@039LQ'3PY*?D*T9@0D2$0<REDGWF\6Z\`8/>@,&H!-B\$%"P7'_,T$9
MP7)Z@A%<H)\.(`;^PRQGB1!BL`-@MPP\H`*1Z@`J<.%A(`<VD",\H('+L`)5
MT0=7$'L.D`%9X`1\T`=XT`,D`-N=$)A/L5FW3=O?I<Y7LEGFEP,CP`*"8`P*
MD`+R+0!>,"LHP=Q,&MR3I`L(4`3NM`.D83G[E-W;C="05@$VP!/CS?^GTDHU
M,!``%E!GQ_(Z2%,(RY!.:)`&.#(^+70^+Y`&L$%X1%)3"]#DR\!`.R`'3K(V
MH@)UNJ"S".`%$I$3>2`%&.`8\53M'[``'\$$88"["S``\:11W+E/SR(&4+`#
MF9$)/B`#.Z`!GY$'--`!/6`",T`",]`!$_`#GE$!=\,'*J``=],!.S`#7M(#
MIB`!=M`!B59I<P2S`+D#+%`5$V`!'.`E-;8,/P`!_+X,'9`%_QX`@,D!6=`!
M"K_P"Y#BEO`!RR`!-"`<<($`%2!7KG+MJR!T:R5&/R8`)V4,7*#4,957$;$F
MK6H)$S20<EYI?$`$9>`9"*"6:-4#&QMI*?G_I".K&7!BZ-Z%Z%&AZ,.M"L:P
M!S$0*U4P!RGP"IF$Z<Y]]3&K&IVNRZ.!$@9A!Z1N8RUYZC^0":O.ZH(PM57C
M`U1P[3<9?TPC4LQ`!FS<*^@.=5[!-@\``3?@P0GPB0`X"@K@!660$V_A3I32
M%WO`U?N-$:1T0F]QDZ(!`=$3Q!\4/1TP()ETT2YP!HKA%P#^C31@!QQP3PO`
M`_D^`38@22@`3WS``2!3%2$``!._#/E:#'O`\)"T!RS``X@E`3.`_)4F`1.@
M`AQ0;A+0`]QO`RA^"GQ@L=L/22OP^RY?\H\T_BJ@`9$4_.5&`RHP`=-/`BA@
MGHAEVL&0"F,`"#HZ_U,L.F-C!BD%8X8N+GN">PJ,=CX(/CI]?0H)D'9V!SX2
M=AP%61(.#@A95WP.?$T*`2!#)'L.?7^ZN[R\?GY]='T#?7Z]Q[Z_RK_(NLQ_
M8F+-R+]].@,Y(S?6?2\8855/'Q\(#G:X/EQGQKG3?]6:?3<[<PPW9R\.PIIT
M=!HBJ00)DK$!1(4??1RX6\BPH<.'R#3I$/#&`P`?=!(`,&!G#YTP"P04T/3'
M`0$!7OH%\X&!RPLZ>UZ\2%#E!K`^>](LX9+'CJ8"2Z3\LO."P+@\P#Y"*%+`
M`;$\-+WXU%0&`YJ$^L(\6'("EYT"`@[H\[@'RAPJ^NCXN9$C@00:`QR<0/\!
M)$<.(#L``*BP0J_>(@<J[-A!,<<.P0U:^&VA>+``&'YS!!"P0X2(`S`$6`80
M`(!E$0T,5VZA>3.%RI9;9!8@H$4#S3E$K!"03<`0&")R"`#RYD"+V"M@,,X!
M`TCK%AN$^X8!`H;R!L&+'P"!N060`$"`.-\0?44+"D!6K&#3X`WT!B"XKTB>
M9$B2-QMDQ'-831@Q8P[QZ-^/!S\U_-$\5,TUV=P@B#4`L#$$%Z$10(=/?J2S
MSA_M3`,/3CZX(,4+>^P1S#YTY-''/P$)1)!!-B0$T8HLML@0,'N($(`%%7@$
M%0-A]&/'&2DP<$8>7E&1@P$PH;.#&`G180X9#`#_F0H=-P!0P(/]$`"`D^84
M\$$!0_5A!P8/.-E''A`LX6!'E<Q!@!]*TD$`"BZDDLH-#;CP4I4?[#!E0@/<
M(,`H?'0X0P6T`2%"90`T`$!>.P"AQ:*+-B`"``\`<(`(%63*6J:"!9:I;`+L
M!0!C%>SEP0H]9&KI89KF5:H'2>Q5`0H[Y*!7!9<!@,)>0*#P:@LBI$HH9!5X
MX`&PQEI0F04>]$"9!RAX4`$,'EA@K676FF!""R98H$(/(GBK@@J'6F"""AEL
MH*T*/*A0@;8*`%"MMA-,&D``&R1P('U)#5/,0_$$7.$QSP3(KS78C&!`)B_H
M<`,&')510$=82<C.0A>Z_\G``P_$$`,7(_%CQQ\D.B"0#B=68`,P+K;L<HL2
M50'"8'OX-(`"##AXRQD,+$"`EV,F``61^N111@P*Y*C0&1@PD(8Y-2/P0`(B
M>DE%4!X&<\,2$/1D3!X,Q)"&EP[L(<423='QQQX&5,&%'50:P``7`_0#915E
M^&0?%SAZA`O.!>3!P1XTD(``"2:$<,()!#Q`P`D:%&`!%XL3@,,.))SP`P$6
MR%!""3\8OGD),EA0PAD$=+`#`B7X0,`".?_P@PT?#'#&&3.8<,_M)'@N^P]#
MW."#ZQT@\,,9/LC0@P$^R+Y$\ZA;H,#P/[@```O##]!#![/_@`,)-MA`PP0X
MT/\@?@<BL"`^#2I8\`,-\%M`P_L:3'""^!RP:P,''-#0P/XT*$7Y`H6`!,R`
M!GR@@0=(,(LAR.`%=O`/QOIU'X`)C"3-*)@T#D8@;5A#$$1Y@0(0<(9@I*(/
M%J/0!.-A#@(4X`92R,$*N)"0^93L9"="@0WP,+"7^?"'!--$%0)P*0YHPBE4
M<%PPAO$`,X2AAF:3$MP<\(("`.!MPF!".G9PAGXX(`]B0!N;^G`&*4R-'PXH
MPQP@L`=@F,0+`M`9%:6V#A'1X6P*`(8?[$``M]V)#FFH@A1$E!4&-($8YG@!
M#]+7(1N0@`4AF,`/Y(2"5$@@#^9RA0/0=P,'H"(&)=C_`R,N<`&!W,`%D;#B
M#?:A``Q,10=>$$@)%$"`3,CC!G80Q!@"<"`[&.`"$I'!`GQ0C#XL@1$Z\`8$
M!(*`"I0@F3J`@H%TL`<6%,)D).A`)AR6`B0(Q`48Z%#9H&`(.O@``F?003\4
M4(.&Z<`.0WB!!$91`!Q\0@((Z(`&@,2'!<YB!2385T/JXR\)+N2"_\H@@#;8
MD(`-8`1:$$,F3`*!%P``#2GX`))TT8<X+&!"+[I)+O9P!@#,80Y0:(HN'D0A
M#0C@A"8JB,I4!,2:VI0;`@C`!!I0@2?N(0Q0X8(/SI&0C?DA#VJ#T@-6V0\V
M/4`!?^B'B`K0A"X&PP]E$$`"_R(8AC\4H`H&,$96O""%J/HA%0GX0`EK"($4
M&$!.?2#`$I8`09^\(`8+&`#+K`@!#/;A`3W@DBXDT#@2V,$&"#``"Z:'"@>@
M`!5C,L$$&MN!Z\7#:2LM0UA+4H`XZ>(&8%6&`J"0-1W$0)UT.`,52D@A`W2B
M&'1X@AV8\,4RE(&'?:!"%^+`!!YN81=[6(!0HHJ`):2!HU!`$IMN(`8'`$,&
M9<C%6@20AA#1@6\^^4,>R!F,`4CA#!PE@PQT@`L=-"`>$BA``CC@`#QDX`L<
MV*$#P)``$`1@",M\!D/^I8D4K6B,95,(4I$:U5UHT(*:>*@62IF),.3Q`R&2
M0M>2XO]1D*[PB'E8P`&0%`^/Z-$!+H7I0&2:(H78],0^3(H`0#`!`51@`[<@
M1AB6D((N$F!DDCE'W?K`A0,HP`%*H\,*7-F/ERQ!`,1,BP-`D``*T:$H<UB`
M/G11@`9(P[E[Y$(5PO`).Y`I`/GH!A_G4(4SI.(/89B#%[I*##&L(`=^J%E'
M!%"$/[S@#Y><`!",1X(0L``!Q)BG!0(E`3Z,<`_]8T$/3B"!/M!``5-2T@VV
M00<F$*`<PBB!%UC`H3W(@(T'PH`?R.O='?>A`$TA21&8`),\$,``7,Y#'$CX
M$1[+Z04(*`,36&T`=6B""5)PD##2,+9^E&&5^B#`&LSL)03_U""72H)J+EY0
MAARM<Y!]P`,3YA"71@^@`'S@@P1PH`$;%-H)8)C`!I*0+VN8>+_LZ(-_(1)G
M`P@@"75@@Q+_,#+\'-@A#H6H`;R4S`44@"=GX$1:.OI1@RIT/E]<0`.J4%VU
MX*(=(2[OB%%$4Q1['&;O'.($+,"6'X<!%P/``!68D&T@">`![\A%'IH@I2<_
MV0Y:4%M2[,`%#"#5)U0$@AVC2H483"FJPZ@SFPCI!0QX24D.,,`<*'23-```
MTS[)0PYTX5P')&`.!N"%UADPV%=,```)\$`.M+`!+;1`"Q1IC6[P=1P@@*`N
M8=F`%>PB`"OL'0@'0,\!!G^```B'_S'KR8YOZI"#P5\'\(!?00,`[QL*6$$-
ME[>"&RX_!S>`0`UJ:(`50&`%T:/G#:6W0@#JP!TKK"`)`1!/`^[5`.[`?CTK
M"``%-K"!>X$`]O?:P.Y[#P(*V!<$OP=!'98O_'77`=\46'X=*)"$XD<_"=7'
M%P**X?!F\%?>/5Q(S3!0!S.5X`,-&$$)<K0V9RP4P<,0N"<<]@`!I```;$R2
M`RK<?8*)E`X#@``8\`%H<``Y@`!>I#9\D'$?A#*]=Q#!\'$2N"(2D5,TPP=-
M0PR?8`,JL``G(")Y@`<;@TNW`!5>(`:I!3<&L`,+D".W0`!<L`2==`X.(`9H
MUW5V4`8/@/\`G_`@;.$%'G)6!``%-Z@/JI`#8G`.YV``#T`WJ9`'!9`#2S``
M>>`11J$`9T!4=,```&!F?)`'-M`#D+(H.!`"'<`"&]$!9K@$#V"&(:```N`"
M9]@!6\`#(9`%6<`#/("'69`!*,"'/"``/*"&.``M?A8"!2`"!1`",]`!/8`#
M>#@#/#`!'9`%(1`"`0")66`$/-`%&0`&3=`%:+`%34`$(0``,\"'8*`"J2B)
M`/`%K8@"&4`$M)@!LTB+/'"+1)`!.4!N&D`$8(`"M/B+*'`%&J`!6:`"(7`%
M5V`#3:`"1$`#Q@@#,^`$UI@&"6"-')`!1I`&-N`$?+`%$Q``2;#_`C)0,_UW
M#-\W;PXQ$X^02YJP!Q!@='WP1.ZG"P;34/&@8!Q!%)&0$!ZA$DK"?P,E4GLP
M``R0`G-%*<#T)"7!@#$5`!`8?A-8D1'Q3B.0'D.``S.@`"*@`#-P`@,@`6'`
M@B?'7G8```*P#N)T-B6@"3^W`PKP(&5C!];C(":D$UT4D!#`14NT%FQ05EZR
M!SZP!%L&05T%`0*`5%_4!V$$`5\D#'8`!``P)B(R`0<0`STA(G:0%Z1P:>@!
M`F\0`%K0%*A0`?/T%@LP6:B`AC,@`7L@`2I0`(UUB>+&!UG`!:[`!RRP`R%0
M:'PP`2K``8#9`X'B`#\P`1H@;A)PB0C$_P<<$``VL)<SD`$5$`!OP`,-D`16
MX`2.Y4G\TP03("<9``!$\`H.8`99D`H<@(>-)0<A("=90%T)@0<FT`3LU0?Y
M<T)70$+[(5D<$&Y\L`*>E`K82%N-8W`=\#U8X`'D&!^YE(Z]L(X4.0TWP``)
M`$$QP2$#\`$/\`)'=8_0P%#[M8\"ETPU4P"AI"3#HQ8#V7`%&0_G(`PA\B1*
MH@G``)$#,00!@`((@0<6&:#3X&XC\`:_=P!`0!X;P`9:P`.N<`4+9`.>Y"8[
ML6-Q]@`N@).<M24OH0E:`6@P40Q08%Q,Z0=40$)3<6I2@A0H!P4(`%2X0`<?
M0`4XB1,*L%0>,?\F>S`'8G!C7\0%J].#'2(`!C`_*'!]T[<"+$"#%7!K*C!9
MJ1`">M('KM`$79$0EX@*$I",C28!,R``'2`G/,``[.5)'C!/#G`%"L!H4=H!
M9<H'($`#J<`'DI@#=0`"/;`"=?`&[+4$<\H!/<`#)S0!4]IH!@<C-\`ESQ5=
MQ2`&%-<F"O`VQ5`6%Y=P+VD-7,!&>9`);Q"7J:`!"9`*%0![6+!ZS_<$`=``
M0X``+X!!\$8AX`<1&E$`,F``,D`""2`#+R0``W`-XIF/Y9E@$%5*"<8%'Z``
M1"$%99`6=$"0(14/7L1R4$<E5^4/+Z5Q*)-[!Z$?`MJMO3!J$R$",##_!)Q1
M?:]G$)IT`AZ0`#2`!TCA`VN`(\#P`@/0!!_02102!E)P1?F`"P7@!5Q@;7[`
M,P_P5OK0G1_P5JQV1U6P`%/A!P2P`P&;$'XP`#O@!3\S%@H@2'6C%C>`!C<0
M%\&0`$NP53I2`"PX`PN`;]+'!@;P`H3Y`">481/@J0:`BG+B`B'C,!)E#:>D
M`\"`!!MA2Q`03OP0`Q)Q3K5D#;\$"8;P!+?0#VF@E/@V!^3X!N3U`2"T!QBP
M3,(@`Q_PDIG@`JOT3I-&!P/!$>HD!HI(7@[0+1Z13!90,SI@";4D"`M04;K4
M`/*$"@00FPX`*TG0`F_P?!()&0U@"YD`</'&_XX-T0$N8``*$`,CP`8`X`(0
M0``8VZJ_2IX'99XCP`(2X240\``9,+DD@`NI<`:^Y@<\M`S+X'[+X%SQ<!,<
MI39]<`4Y$`^Z)`/:^@,JY*TM`KN_\$4=,I\/TF5=M@>;F@(DL`0C(`LK<```
MD'NU0P,=<@(8H``_$`;>.P!<D*$O$`8^,`"ENU6?0*]S4P`#$`:VPP`8L%5.
MT2=3XP/N2P=2DP#M6[X:D31?-``$$`/2E`<^X&I4``6=\!$#0+(@0Z]1MP0*
M`&MY$`8DFP$#$!-A<`(/P``Y-9;8-P0,H``3@``"@``*``%4<'\0D`$(T`-:
MP``(@``0``!0(&'S&/\#,HP`#+`#$.!L&#`"+@H!92*30@P!52#$"&`]72O$
M7H`T1?P$-0`!"C"YT'LO5?`&3^`&(SP"-7#""K`#7'/"]9>W$+"O73O"'I/#
M%1`#4C!"37``"Y##`)`"2*R4.<P%`)"W)PP`2^`(/3P$(CQ"%B"++78O.5`0
ML/<!1<`"`K`A+Y`'CRQGJ:"\E/PD6=@AF(S)-"@GJ>"_`U`&"_`!#"`%O7H!
M?65B_]80MA1_6C!PZF0-,8$#-"<%?!`//Z`"5X`+>'!Q"'5!Q/O+O_`#+0`,
MAL`(.#![!Q&\POM?Q&L'0%4S:9')F%R%=%`%&G$`2_`$;\`&+<"?#9!7A$/_
M`P]39NT+@",*:%0(%3MP`1]Q<@,@P.P[``-P`EPP),,0!G$@!@^``03P$G:@
M$5+@OA-\`P^05Q-L!]=9!6(@S[9S-@@`R7%1!I22!P-`%$RX`R$+5`FP`P]`
M%)OZ.FP0>[,@ED[<8@A`!4*LPC',`#E0PS$,`*,<PU[@!3&,`#'`PS(,!3F`
MPSV<)RA]TE5PHE0`I%"`Q#'``"<JQ`'@Q3>Z`UH0`$\P>V+I`@C0`E(LQ6!,
M!5J]!#E@!C^]`](S0AX#`1,PPQ\@`U3-``<`PR]-QSV,`$<\0G@<QR@-QE,L
MPVX@PCR``(,\`1.0`\A7'K\7`!\`!`:0`U+`O#)1_X70;`Z4W!%5Z!-#Q=C2
M+&>4G%AEL`0+(`9G8``8X`(9DH3^]GX.L<K\&#`"$5<X`&Z0=05-D,NIT!_$
MV\L(!<PVD`/F@$PZ@`._J\S++""SC9_^`<QG-0=?G`(SL&X!4`1U\`0KL`,=
M8`>C0`<_(`(NP`]Y<`)Z<0+TZ0#6`T%840"C?`M942D=U@=IE0#9YA,;"UM$
M(=$)()5[(%</L$=Y<-\*L`0HF+PRL`,I4D,:$`-4("(EH0!:D`"[W$([\'S5
MEP16UFH]<)\\!Y7",`-H(PQX0+8\1`=B0"3`<$H8;N'QK0E2P!/"L`=KX"&5
MP#HJ(09EP)0.X`9<YB4L8/\"(H!\U<MN^="DPA`&7(``+.<`9U-=":$[)N,`
MD]9E,J#>'C$/([%.;V.$#JMCP;9$/$`%69,'!Q`&A28!&M`!\U0!R%<!1;!Z
M`9``6H``*R`4`:-?O_PA/7Y5P7U!"<``+K`E\?BO5N0UG?L0!T(@"V9+J5W+
M<N(*>/`##Z`!<H);OCSGM!T/5_!2N200":"M5^#;OUV0;RXP;\XF.:``*;`#
M#K`"R+=B(```$^`!G&8.\?4!9=`_^7`"38`!(@MDHDP`FM0'1Y,!$IH08?`!
M+O`C7I('-ITW9Y4'^XPDN+`'5-`#U>8`[%52+@%T-L`W8L"\^`T`4F`.(C(7
M/)#_L79`!0#PXN8`OBR+?44P`S6)`E@A`0M`!5<E!E/J7&:`)$I2!B$0#^*M
M;2JJWIJ```N`)7Z*"S9`!2=P5GW@6F("`C3HI81J7PH``^]1-@`P%6'0`S.9
M$#@``-R]RPO``DJB`RS02>9``B00#Z!U\)W<!%@2`ZI[,R>`%5S``ZV:$`UP
M<F5S`C@P3QY@7RK`&^F1``<@`PT0JFKS#B)%VQ1RL/'6Z+!+T*3,#[=@`%?3
M54>?RL&J`P0P`@JC3B`T40X00)P\`![P,[5Y,JE=VXX>,+<M(LF42Y7>&9<N
MG9GN?[#;R\`L1"Y0!0)`!SA0+R@`^#_`R!DP.$YA`QZP_P3L)6[C8P$2"NTT
ML/%O20-4RCDF$`;!&?8(T`2HP%XT(.NKF0I7(`98@`/0'O99P-'[(_H9L`/\
MXPH#8)DX0)BZ*:4/T.5TV@,>0)<),0-M$6Z(_QHY8!$Y\)>!X@%`!Z@F8.BI
MWQ3MQ0,SH`D2H(9=.@,]@`=&-!<=@!49H)>J^P":P`=7D`$QGPHSL%Z&'@!R
M^@HGP`.-$EBT4@3BAI:XD`=<D`&-M?%=L<L*``@L#A(.+"PT?!(=.(1[!3M9
M@WP**AQ]$A)-?(,#"!I]?0X*$Y:$0!P.=AQ7(9@Q&QXS(1,=.PE`"`U2='U_
M?W[`?J##Q,-T#F>\P<O%PWL)&/\)?L>A"@@$#@Y^OL"^8F*^X>+COSI].CX"
M(Q?F?73*EMGR#C]<&H28S><Z_/WM^LUF8''@3L<8'0E6!`#PXQ>YAQ`C2IP8
M<5FP8=TJOJNB`,`!!20RH,AA0D"+#!-VB#`Q@42'+#UV5`"9@82"'#U"DD@P
M0Z4"'`A(X"C9(P2.##A("%B2(4.'!#AZ".""=(:4"CL0)'`J4H"*#E(2D##!
M1D4"*4(58-E1$P&.#A78F.B@($,(+B(`*$"KP(.6EA,$'$`!H`<`(#F/"J@9
M$@N`#&Z;M+"008&")180()C@P4-+!!9$X)@@144.#R&E/`#`PW+@"995`*#<
MM$D%+@O_>$P(0'D"C]`P8/3P(*)"`Q4\<O!HS6,':Q,\*K1H8L(R@`<F%IA`
M44%%[@H53&3OH>4V#RX[!%C@HD)%"Q4F5#3!@F*!?2PBFLCGLL&"?P8>S&;!
M`0&H]T`/)@!1!1`)%"%%+Q2%TP<PH`S`RT,6791'&;@ED(`+9BA``!U^Y`%A
M1M]$R,T>Y@R@Q1L-O/'&!FYL(*.,&ZRPP@8\!I!$`#GR:..0,]YHY!M#)*GD
M$&X<*>,!!X`RQCX)+=20BEAFF66&PC33I9=]5,%%"DF4^>,&=9SY1@!L;L#F
MC&_R>",(`>"XYALKS.@FFWPJ%`"=0-HI8P`*R4CGGH."H&>=_W3B.22?/3+J
MIHU`\KGFGI6^`2B;C>88*)R5_EE'H'R6VJ:;($SZ9YVDKLFJJYJ^">F;%+C*
M9Q**@D!G$FL"VJNBK%;J:;!MXGDJG(/:6B20.KJII[-#-I"JG)>BNM`!&Z3Z
M1@X)'(``B0#IDY$?-DPH+D1]Y)&&&`QP<4,:8:3B#AW<;/-'BBKZT4XZ;,2@
MF10R2(%`71,$M1ED""#\KV8,-^SPPQ`SK((`#M!AT$$=2,N0EAQW#!&7(',)
MRA\"4&$`%U#$QP,)%N0`0AUU@&"FKC+KBNN?+\^,*\TRE_ERFK@FD2;/0>]<
M=,\YV]QSS$`3[7/0-OOL=,Q$(VVUT/\^[MRSF5+3R?.?17>M-,U&UZPUSV2/
M"K290*\-M=,VXXRVT%]S2K/<5?\X-MJ`WLRWK@6Z4,`BFB5P02X/*L/,A"#_
MX0XVC(>\N`-,V.&##W;0D0<OZ9YH+[X18A2&8!?HD\<>A*!"2"CR@,+/,/[$
M_D^XPPR0`^S\5+E#0Q!Z[/OO6@*3!P)+``!`%7FA8!@;6W/MO/-*-Y!#"].S
MX2,%,&>?_?-<!]#``3GD`(2/,`OM-O<S2Q]^#@V@CWZ:,+]Q0`LFO9$$]MKG
MCS[]*K6@$/I_`]P*<F`\$5CO;&0K4_F&%K,54"\]:!);`$NU`@&`9P<Y\).I
M-FBJ#;0``"C_0,$._(<C.0W)1D["4PM$4`7C@<=X'U!`&NR0I0DYK@_EJJ&7
M*O(Y<*A(=*0#B`/VX(!-A`(3F&C='I;X@C$X47:SHUT?;(<[A`P!!+MS'/"V
MR$6)C,P!+]B#X_C``504D0-\2*,:TXC$-A(B&VG,QALE@8DUJM&-22SB)N:A
MQWDD`H]XC&,>!P#(0IJ1`XU`'1^(*$=`_M&-?+PC'ODH1S;*8Q-Q',0\))#&
M,DH@#_CXXQ6(2`,:Y#&2F;SD'AM)R59JDI-F5.4J6ZF/)6K.#GFP@QW\,,1=
M:LF&H,@AEL[UL1X.$Q1^&-T!2M<,"9!`!-`4@0`$$,UJLC`O2[@!_Q1?)\5A
MV.!VKLN=0K+8NRZ:LXO'L)>$]A!&%H4+#_",)SQ#T0=X2@"-B6!C/>7)3W["
M<8^<W$0_!SK02R2"(`1-*$%@EX<PKNX<>TAH/X]XT'U*=*!%E$`?T$B0;%AT
MGOI(A0-\\`(ZV,%U&/UCZP:!"7S.<1XA=0`_.:G1>'93'R_@IC#>8:YR>G$;
MP?3I1(B)(6/^$)G*9&8Q'&"!`'[M"5!]0@!<$$6,2&X95`PG0L;)NW-ZE8L4
M`L4[')<*'3A@F]Q<JB816D_6R10/;H5I2#\*5[C*<:$W;89'\QK.4)CU'/,P
MJRLIJ597=G.A,KW$2PFK`UV:(QL#*&D[3O^J5SZ"8K"$C>E>FR'1D-IA#S;(
MI3LJ%KF,4`28.!2J1!I73&_X,'1(#6(S35"L(*&01WF:T0H:\*W2!N.B\OQF
M%777U:\:UV-BK=@V@&&QJA8C9"#U`SR%<1'I]O.JP+#I0O&`W0S%51O=W:FY
M=/`"RH:5KZS#"'?U,5!AX#44%&+K>ZN[#]>1%)G9O:Y%0'J,UN75O7)-+W>M
MR\^0]2&GYM"!O;ITH=`!-;5;XA(/77O,"275=!8(P!#"4S#8N$`W!8/`!"8`
M`0CX8*R^R^H^K(C%XA[WQ5CJQC)X8;',`3:OO)AGC@E\6;J"5(K"@.N.-RO%
M'--SO7E-:V-MC+O_]K)7GN<M1GO3.5UZYA@/1#;&>%_'(NI.R,G$`(8.+$:0
MM'8SR%6F;CR[U%[O@B*G)%*PA!U\0V$:%T6O/6ULEZD/'608!AW8@QV6K$L)
M\&,:_>7I[X2K5>)J$<:0UO.7YO6.=O#42]XE43!\X=OP2M@=D],T=M\15NJ&
M5\NLZ^\_/&T1JUIDPCLE+84:W&IE[(,..44FB8HZZ7/LH]?/!1GCW$'L3?]"
M9,VH=!@&/6S\VI#.07TQGBN<3,&401]VH"V@[2`!70;6#E5^QZZ/O>F==ND7
MS_8%!UJ`.T6L`(M7X&6DYSV1G>[ZLB4M=H96:UITXW?.Y.C2@B^2[E\6__RT
MXF6=P!>^[X`+_'?JY`8RT:6X8?A@#\@\.+^]W&G)/3<<QA:VN.@0!D%'[M\1
M]R(Q!I#R<T[[F-4^0!D>8@<5!(`-)+##2N6A4?\^6[K#.&E_Y_LE/LQAGO+(
M&`BP<(50T/OI#AXB1J!.]1JB6Q@Z!WC58\PE`NQ!QELW9Q_"P`11:UWEQ&:Y
MM(UZU)C/G!P.L'D#&($)G0_B=)9M\"_@"HK,9<.D?^<&YXR.]%`H?0=-=T#8
M%^\X7F)\XHR/O(2NWH>L-USR&[?(&7:YC7%CGF-C+[OD\N5>.OA`XUU\>=N5
M^?9Q.&`"&RA"".3(;0GL`927300]0<[W4-"!`/]>J,(20F#KD?V!`W-H:T=#
MT(``(![+GX?ZA*0.^>B'O1=>MORKK<]KS=.P\RWGOA?);O;+USO6R0@_6-D.
M6[<_I`\_R$(!3#G$-W+[KMG@);VXT7LZ&&":2R`87+!+RO`'#N`$<Y!8"\5\
M2W<%<"5^D39]CX=Z$`AIV&<NVK<,%2@.($,`G.<0&WA:Y#=Z[2<,<4"!6Z1Z
M[<=Z#^$`''`")S`(2R0!!(`#%@`>#X`""7`"83`O"]9[#H``#W`#+U``#,``
M:<`X)&('3A`E/=8'#,AT#QB"QB6!4T>%\W:!6`=>VQ>"(N-U*(B%$C*"(:,B
MQ7<&JI5Z["=I+`AW"M#_``W0`?)0`#EP)Y+"!DN@`8C&?\,P/&60"J:'``8`
M(=K0!S1P`(@%"@Q8!0Z8AF+H.U98?8]X7%I8>5RH@538@1BW7)/X?F3(6GH6
M"GN0!HIW7"K(AM;V$#;0/BU0`$,T`Q7@(ZQ"*;SR`!9R(OVG``^P.2_``P]0
M`%VB>'30A(GH`%%(`%/8B5L4B6&HC+]3B1EH;%[()9O7#<T8@J%7?EUX?IH3
M!C?P=::XAN<7<PGP$#.@*$O``>SD`9I2!!9@."&0!3S0/FX``>H$=)?U"`TP
M!]^#`'M@:P;(`4!P6?(0`N\F`(WHC+]T(<+8!PI0!57P`3>P4O>FD%P'<J-%
M_Q![(`8`(``?(`4FQTOJ%W8@HVG'0`<WL`,I4`5F$`=_D`<C&7W[!V`O\`!`
M<`!`P`8`8`#OD'_2R(&]0&SO4`!+P`9S,`=O(``W(`PWU&\><XKC&`95<`#E
M2`X%H"@[0$0<``!85`![4$I]0$8*P"88X$M[-PS9,#Q+P``%\'/T0@=\``1V
M59`'F9`6F27Y]@<%\`1S8#(?P`9F\);@XHAW.0ZFM5..DP8Y\`1;P"'?`XP#
M\&B?5Y(O\`M2T"08\`Q5L`*1N7_86(@5DP9S``!B\%FJ\0:5J3E-V8()YP=I
M4`0"4``T9`</L`,$X'NZM'X4QG7)-)55.0X$P"8H8/]['.`!('``,R!'&]4'
M64`C"^"9^-@+4K`$.U`%*0``7-"9O1.7<YD-!E"7\%28I\4+D%4\+U"(??`(
M2X`YE.69XCEA$D=R'`D!Z?4'4I`"!G!NT0<R)I('1$D%)<=+?4``&)0'6&AE
M?7`&+H``+Q"4?W`&`R``",!I.@<1!'$A?9`&#R`&FL,+9_`'")`"7-`-*`9Q
MXKAQ4DF5[\<#;&*;-,`?*\`#--!1>'`".T`G&-`[T>E_`)`>.2!\-T!L?W`,
MW!E7WPD""%E/[[E:%T*;"N!MO*AS4K`+!+&D%'&8[I``#2`&`_!WF],'"+``
M?V`AUF=@`XH`N=1X`V`'9V#_`"D@AI5'+^@A!@>F#;XP`#>@`+QP4JLE5G3`
M`%[`IV.5"E(``*<W#"EXHCS4FRH*=QW`/$D@/1T),T`P`6)``NR#*P<0I+P7
M=+PP``R0`&&0`(-8I>]0I/-@`-+"=$IJI47%"WEP`"7@`BL0!ALB!65``&>A
M.$[IJO6"D70`!5[P#ACPB_$""@NPIC%9=27I`#<``!]0!2Z@.=KPH7ZP!%@H
M7F?P`,6C`!;B``D0`U)``%!@(M-0I0%';`X0!@RP`'EP.6%@`S>0`"_@`PHP
MD>@*/%")HK[9@C2@%$,0`#'#)KCB*;HB/S%@8WR87+@F!07@`PF0!@;(.'^`
MJO*0_P7-)P"WB0>^ZG`$@0``0`55T)9IL`0F*P4&@`/G*58=ZW#`6@4)L`=A
MP`4`X`6A&D9E\`"$N74@([-<(``Q0*]V(`;?.*)T```'JGA]$*X+P`48P`4&
M<`8^0`5>0``N(%K9P+'IJ@UV0`!:(04NX`(*``$/4`0%,``&(`45XYZ^LZ^+
MFJ*_*0Y#Y``#@*DZ(BMO(CT\,`-=6C$+VPMH2[0&,+@^,`T39['9(`89VW1:
MV[*<9BX+\`!2P`5I,`!EH`!G4`9ED+9K"FK+*IY82@=S$`9I@`!'F`'LDP`.
M4`!5D*^8)VP^X`(/<`T$0`#?0P4*$`HQD+2@D`#M`@&@:O\+NLH`9Y"=)D(-
M[T=/#N"U":``,7"$#/``[J(#-T`&(K6S$>*VQ42.#Y%$H4`#)V``"R`"*B$`
ML4``5W!2#@"3,L9WO%"H`I`#`E`%7I"$G`,,<?E=BEL@&^NXX2!DOR<`!F"R
M7/`!"V`'!5``98`#G..@_GMLP*H7-\`%Q8,;"B`&+X``$\FVD2=L#E`&6N`%
M-AL#.:``6\``CH.T5`@*90=\##`%#5H`&/"\9%"\>PI>[]?`H$H%7ZIXA0BQ
M<&!+',PQVHLA%B8`#/(0_]`/CL`""'80`'&/!7$.9X`!%S``,A"DKJ,O<;ES
M66`]&BM3#WQ#$V('.4``?^`#$##_(CWI(58VQK\:GPJ0`CHW`'VKD7I:HAN8
M.0I:`#:@%31&0T>+A>^U`!_@@6NK7`1`G_KV?K'F`#W``)ES;J!P`TN`#4QP
MC5>JJ!]SQ(WJ>I0T`+6)#=DP@1\7GWT7!A!P`P.0`#?`.=H`ET#@Q=9SQF+\
MP-6U`*M,6IGS`@:@`#P)+G`,P?%I``"0`%U*1.]P!@G`!:.%A;AD!Y=[F_0T
M10+#!=!L#`FP!@:0R,<0!B[P(&'V$(-)$`D`!:3(8'[`+K:8!V6'O9N\F_EB
M8?T*=Y1D`U@`!,GI<Z>,;H"72QIP!DY0`&AX6?#4Q1Z5#5_,O[?LO].`!SK'
MS`_@!2<X_T12L`!2X`-[];F@*\5T,`!20`8?8`",E`8,X`)T:B)8J#E]X`,Q
M\`$Q^X]GH`!K@``?2H6#^=$)\`#`>PRMO`004`(\I6AP)Y1CIQI0<`,G90-D
M.ZZ`Z+I/R<D.-R$O4,^NAY:0M0/(B5=E&)]Y,`.X(1\J\`57L#J)A=`=Y0`S
M4,O8T+B.*Z#RHLHA>Q:F2Z\]Z;EC'+J:4P#2*S`0@#(%<`QINL+OL`<&T`,Q
M0`4(<-'H#-40^%S@_`#6H!D+L`3J6XAZ)PYB9;@'5L!<H-A"F+OI1-0F*L]7
M.C)5_<F:?1$6XP-360!CIB]=[<\X-`-94`99D`5$X`0)'0IHS?\Z:\W0;NVX
M>``N:QL&9U``-T``9]"@C0S/=QFZL;P'/I#`S+VF>]"E0\Q]Y$DBI$L`8I`&
M!.`#0UJ9A+U3=C<`:5``XKVF[^R#X2=PQ!`&`Q`'RCT`R^9WB,;1YV?:]8;:
M5BT.4/0"+A`#/M`/8U!4P,K;5]`#!X`%9:!1!`D*OTT0P9T#&N#8OLI30N=1
MY'G9RD6B>>W1=/"/[I"FA2UU!DK8[V!W.N=[^D?(X)5J-$9D[]VK0XJ>P`"(
M1#0RF_/AQE?:]Y)G_]T+5:T%<1L.LN-$`W!Q_'`0"AZ?$J`!6P`$<V`%.8`#
M>[50%=X'%WX/T&V1Q#9:(JD,UVOF;SG_XL"JKG]':FE-0SB-EB:'$2P;YZS=
M7UK6P.9&SN#".26>.6;.!`D7Y&TKU89)(7G@FUS24H@D28PN`8XSF!1[7J+`
M6P60``*P`X?J7I<PRW$U`\V'X4XWXA3B$"=76C;$WQ9YF./B;!3R)0>Z.!H(
M5-E:+P1G+^:R7$`7W\LU8(:[:2/#E,0LY*`SSWF`Q-*0(8@@`300`EK=`BT`
M!-(^/^"#`"7GI_5"#`(#6(O,#A8S#!+@Z?,`Z@$P!QH`?<.<[NJ^[F]MZ.EZ
M[`S")0Y``SP``_>C-69"L$_`6\D`G9.&`8/87(/+"V-V#N&>UME`[BUP`NC.
M[@[_\!#_B$5L_\3PGNP600,:X#(4H"LQ`P/^`P+8([!/\`8,T(.>0PPEMCGD
M1:K]0/`''U<%T'P+W_`17_,V?_.+-_'OCNQ<\@(>P"8"4!T*<`'GZ0,7,&)4
ML`-N\`0'`#G9_F8%4`-$A,`)<*@]]?+S4`#6L_#9@/->__5@'X[^?=H5SR4W
M\`9,KTU+?A!T,--L`@5F2>D%L!<\H-AE4"X<A_5S:#US$(.E&/:`'_B"3WIC
M_]]EGR$#4"=+P$L+Q5/F1@<)P"9<@*Y1M@4!X`:R.`>1L%EZGPU:7^ZN^/>#
M/_JD/_@Z#W+H5M7QCOAL4@5KFFB7E5T$L``ST@3U%&6AD`%@$`(+`/\`(4`%
MJEO-G8[PJ\OWH5_ZR)_\7W_ZW,!I4KGZ%K$'*1"P(_`!,?`3.]$!)$`"T2$`
MNE($6DYTPG`6#B`&$#"T2]G`?Q#N/9=8)]!\6SW<RC__]#_,S`^"8U<%16#Q
MS``(2`\!22`!#3`P14",&X1);!DT?`Y]EGU^F7\%:0YY`WT#`W]T?7]^?0Y`
M?*F5#B<-`0<S#GA_M[BYNKN\O;Z_P,'"P\3%QL?(R<K+S,W.S]#1Q9I_8F+$
MF9DO544)V=]].B4?!TF%(.CI=4E``!D<$I27F-EV#@YTI?BH?K=TJJSNI8(E
MJT`E:0@3*ES(L*'#AQ`C2NQ%S1JV;'FX2?G_EDV'I3T&`.S(`:1($1AL#H@0
M,8/&/0D"+WW[DVH>/U26`.:\=X)-P7L3@PH=2K2HT:-(C56\-@RGGSTIBFSD
MB.H%'1WW[/PH4.#$B1D:*-W#<R^F)7"5;EJB^<^/*@ZN[FE@`P((+0=)\^K=
MR[>OW[Q+L:V%*I6JGQ<>L?9Q<2!'CPXT['"PX8"26)@V-?'K0Z<?IDMXWU9J
M18`NF[M_4ZM>S;JUZUN!FPY.P68J1QUV+-FQ,RA`@`T`3L3C`_/E:)F9,.5+
M3B\MWCY`X.Z\8@7$Z52OLVO?SKT[L]C"_'3^LZ=*;<,Z/*;2P2"`H3H@<F2I
M+$%Z*\/,^U'#1),F_Y`PQ_5Q!1#6T6**=P@FJ.""K($G#!VWV%%%`[;=M@=N
M>7CP1@-`;`!"'8?@P`%9Q?F!QXG(]'$`9?/\`,0A\]G"X(PTUFBC0PX&`^$?
M=J30``+XX;9>>RW\0(.&%'P(P`"UQ-/'B3(:H^(5`=KP8@,LU'+CEEQVZ64P
M.0*SHQT[_(B>D+LQ\(86)]QS10\MN/=&"QD4!R4R>+1`Y8F6#'!``"O$^.6@
MA!8Z8YB_T$-F`Q`8UH<!6C30P!#N`;K!$(@<L()[Z#S`P9,H'I-GF_.$\6>@
M6AJJZJJLJH:H+_3H4&:CADD10!U/K.->'1284P=\YH"0!``NW2EJ#@:UXO\`
M#7]ND(4$4;8J[;343O1J+\T!T``5CAIP0`-LL/&&(2N$N\(*,)S+QKD]T`!J
MM,3@D8.!93$;P!O/PEOMOOSV^UT_U3`5'FC:<DO5;@#FD<<#;P`1`@T<1$R#
M#0-P0`/$8T&I,4<:=^R'`'>5Q8$6]SZ+GXD=ZSO-R2QG@Q!^O,"LC,RZM&RS
M82_?#'`T.O>\,S(TYW)R4SCO$K1$+7\FQ@W$[,0!`"N@$,+45$]MA!%EE!$"
M&%;D\$4(1H20!0Y55YW%V6BG/0/:,[3M=ML&Y&!`*9;0\4(.OG%A0`%ON]T5
M$7]WQ=7@7*5A^.&&$Z#XXHPW[OCCD$<N^>2*GV'_^>5G0([YYIM3[OGGH(?N
MN0:DEZ[!"82GKOKJK+?N^NNP<W6#-3?4;OOMM8MAP.Z\]^Y[UL!GG4`"P9<Q
M_/'()Z_\\5(T[_SST$<O_?345P\]`LU3@0`"4$S1]&AY(+"$!QB4;SX&"[@`
M1?DN+!`#%`M`P0#Z\Y]O__T+Y)__^6:8`<7_4````>C!F3TL``L'>(`7S-"$
M!CKP@1!D@`0G*$$`6I""%+2@!C?(P1AX\(,@#*$(1TC"$GKAA"A,H0I7R,(3
M?N"%,/R``E=8PAJ"$(,2'"$.=\C#'C:A!T`,8@]Z2,0B<G!]]TNB$O7'Q//E
MCPM<8*+^H$A%*KK@BEAT_X$"MLC%+G*1"E2H`03&2,8REG%[:$RC&M>(1NNY
MD8UN=![VI+`]&4"@`,30P1C2LX<]^*`$N+,=$@QP`T(BH7872.0%$*G(1CHR
MD;3+G>YZI\BEV8%NG.G#"PBP.RD8;WF@#&7RXDA*.;+QE*A4HQE7R4HSUN"5
ML(RE+%GIQ2U2H96XS.48YW@].):2E*(,IC"'J;SB&3-XOO/=T@)Y.]9ICG.B
MB*8HPO"":EKSFM?<0UFV.8]N>O.;X`RG.,=9"E30[6?`"$=Z<I.>=KKS0GO4
MP1[&T$=WRM.>^'2G3,99-R:<Y9]]L,,>3D$5<#J*GPCEI\\6"HZ$.M2@!?TF
M0_\GBDXI>;.B!*4H1O'ST(M&]"R)DJC.SN(RG\7LHQU-Z3?Q8)A2_`$/G#G(
M,,(1SWCF$S28>5)-8!H@A3:4,_G(!V[$TQG^[),)#M#HR2!*T::I%#E*C2I'
MG@K5F4@#G">5JLV^Z=1N_BP;#CVH.*F158Z4M67+B"I/=?HD8I0E)^&40&YJ
M0M>==+1C8S4G)O&!R8M0Y:PN4T98E?J0H\%&HP_5JEF-IMC`UJRQCLVH2!%+
MTE\8EB:3M6HRU-H'"4#+6,*8QVA2QJ=\A/,>/K,$E"X!4Z]^)JE`A2M.,AM9
M7%R6&50-)V#)"C3"SDRLF=%HS$B;5N`&=Z*\0(YMC4MXTK_N@AX[F^UQ-2NT
MD5(UJG$ABTR%T5K6DI:E)`7H9Z![,]7R2;4>3<XI^$,3ANX6H_^"['N+Z]S'
MUA<:M_WM?9_1,_KREK'[M2PZ\ZO?I@JVM0B.UW=3!ME,+#AE_HJPA"?LC.]V
4E9\/SO""^TOA#GOXP[T@;B```#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
